| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIsotretinoin Entityteratogenicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNiacin Entitymaculopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAllopurinol Entityhypersensitivity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTamoxifen Entityretinopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetronidazole Entityneuropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCyclophosphamide Entitypneumonitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGold Entitynephropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOcular ethambutol toxicity Entityethambutol toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClozapine induced Entitypolyserositis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySulfadiazine Entitycrystalluria revisited. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityPulmonary gold toxicity Entitygold toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylaxis to Entitycalcitonin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDermatitis to Entitycaptopril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe Entitydapsone Entityhypersensitivity syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnisocoria from transdermal Entityscopolamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPriapism associated with Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylaxis to intrathecal Entitydiamorphine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDiclofenac - associated Entityhepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCarbamazepine - induced Entityhyperammonemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityImidazoline EntityImidazoline intoxication in children. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGold - induced Entitypneumonitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCarbamazepine - induced Entitytics . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPriapism associated with Entityzuclopenthixol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDelayed hypersensitivity to Entityflurbiprofen . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMorphea after Entitybromocriptine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmpicillin - associated Entityseizures . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAtenolol - induced Entitypseudolymphoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLosartan - induced Entityangioedema . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDisulfiram - induced Entityhepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetoclopramide - induced Entityparkinsonism . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPhenylpropanolamine - induced Entitypsychosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClofazimine induced Entitynail changes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCiprofloxacin - induced Entitypsychosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityJaundice induced by Entitystreptokinase . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAgranulocytosis during Entityclozapine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHeparin - induced Entityhyperkalemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityStupor from Entitylamotrigine toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCimetidine - induced Entityfever . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVancomycin - induced Entityvasculitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGigantomastia induced by Entitybucillamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIsoniazid - induced Entityanaphylaxis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVincristine induced Entitycranial polyneuropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBromocriptine - induced Entityschizophrenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatic reactions to Entitycyclofenil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityQuetiapine - induced Entitymyoclonus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEnalaprilat induced Entityacute parotitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTemsirolimus - induced Entityglomerulopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRhabdomyolysis following Entityclarithromycin monotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTaxane - induced Entityglaucoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFurosemide - associated Entityfever . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThalidomide Entityneuropathy in childhood. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatitis following Entitycimetidine administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLansoprazole - induced Entitythrombocytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityColchicine - induced Entityrhabdomyolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityKeratitis in Entitymethamphetamine abusers. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLocalized purpura associated with Entitylamotrigine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCiprofloxacin - induced Entityhemorrhagic vasculitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityCodeine EntityCodeine intoxication in the neonate. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRosaceiform eruption induced by Entityerlotinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethyldopa - induced Entityliver injury . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcetazolamide - accelerated anticonvulsant Entityosteomalacia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityCephalexin EntityCephalexin rash in infectious mononucleosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityScleritis complicating Entityzoledronic acid infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySeizures associated with Entityfluoxetine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary fibrosis associated with Entitynabumetone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetabolic acidosis induced by Entityacetazolamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Probable Entityenoxaparin - induced Entityhepatotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary toxicity associated with Entityerlotinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFixed drug eruption to Entityrofecoxib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEnoxaparin - induced Entitygeneralized exanthem . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Biomicroscopy revealed Entityamiodarone Entitycorneal deposits . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAlbendazole - induced Entitypseudomembranous colitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCatatonia associated with Entitydisulfiram therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropylthiouracil - induced Entitycutaneous vasculitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNodular scleritis following Entityalendronate therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute dystonia induced by Entitylamivudine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Occult Entityquinine - induced Entitythrombocytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProtamine - induced Entityfatal anaphylaxis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityChlorpropamide - induced Entityhemolytic anemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityParaplegia following intrathecal Entitycytosine arabinoside . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySarcoma complicating therapy with Entitycyclophosphamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityQuinine - induced Entityhearing loss . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGold - induced Entityaplastic anemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTardive dyskinesia induced by Entitysulpiride . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intravenous Entitydiazepam exacerbated the Entityseizures . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEzetimibe - induced Entityacute pancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCefuroxime - induced Entityimmune hemolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | EntityLamotrigine toxicity secondary to Entitysertraline . |
| 0.9992 | Adverse-Effect | EntityLamotrigine EntityLamotrigine toxicity secondary to sertraline. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAzathioprine can cause severe Entitymyelosuppression . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute leukaemia during Entitytamoxifen therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVortex keratopathy associated with Entityatovaquone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Paradoxical Entityseizures in Entityphenytoin toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatic damage after Entitydanazol treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInsulin - induced Entitycardiac failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNail staining from Entityhydroquinone cream. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDelusional parasitosis associated with Entityphenelzine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPiritrexim - induced Entitypulmonary toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropecia - associated Entitybilateral cataract . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTerlipressin - induced Entityventricular arrhythmia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAsterixis induced by Entitycarbamazepine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCardiorespiratory toxicity due to Entitymiconazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNabumetone - associated Entityinterstitial nephritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHuman insulin - induced Entitylipoatrophy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySulfasalazine - induced Entitylupus erythematosus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLichenoid drug eruption to Entitysalsalate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Uncontrolled Entityheadache induced by Entityoxcarbazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intravenous Entityazithromycin - induced Entityototoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFulminant hepatitis associated with Entitydisulfiram . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary toxicity secondary to Entityprocarbazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMesalamine - induced Entityhypersensitivity pneumonitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPsychotic disorder associated with Entityisoniazid . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityMagnesium EntityMagnesium toxicosis in two horses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySeizures associated with Entityofloxacin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPemphigus foliaceus induced by Entityrifampicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylactic reaction to Entitybacitracin ointment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRifampicin - induced Entityrenal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intranasal Entitydesmopressin - induced Entityhyponatremia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityChloroquine - induced Entitybilateral ptosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDisopyramide - induced Entityheart block . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCarbamazepine - induced EntityDiabetes mellitus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEtoposide - related Entitymyocardial infarction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMyoclonic spasms following intrathecal Entitymorphine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate - induced Entityliver cirrhosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCefoxitin - associated Entityrenal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute psychosis associated with Entitylevetiracetam . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetastatic osteomyelitis following EntityBCG vaccination. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAtrial fibrillation after Entityvardenafil therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVisual hallucinations associated with Entityzonisamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGliclazide - induced Entityacute hepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRisperidone - induced Entitytardive dyskinesia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAllergic contact dermatitis from Entity4 - chloro - 7 - nitrobenzofurazan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNitrendipine - induced Entitygingival hyperplasia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAdenosine - induced Entityventricular fibrillation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEdema associated with Entityibuprofen therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTegaserod - associated Entityischemic colitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProgressive hypokalemia developed during Entityphosphate treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProgressive pulmonary fibrosis complicating Entitycyclophosphamide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCardiopulmonary arrest following intravenous Entityphenytoin loading. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityQuetiapine - induced Entityleucopenia and thrombocytopenia. |
| 0.9999 | Adverse-Effect | EntityQuetiapine - induced leucopenia and Entitythrombocytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entityparadoxical ocular effect of Entitybrimonidine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe Entityvancomycin - induced Entityanaphylactic reaction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFulminant hepatic failure associated with Entitybicalutamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTuberculous uveitis after treatment with Entityetanercept . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCardiac arrest following use of Entitysumatriptan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Early Entityritonavir - induced Entitymaculopapular eruption . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCarbamazepine - induced Entitysystemic lupus erythematosus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySalicylate - induced Entityhepatotoxicity is reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | An unusual case of EntityEcstasy EntityEcstasy poisoning . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOculomotor disturbances associated with Entity5 - fluorouracil chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Does Entityacyclovir Entityincrease serum lithium levels ? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Exacerbation of Entityschizophrenia associated with Entityamantadine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Diagnosis : Entitypractolol induced Entitysclerosing peritonitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityErythema multiforme bullosum due to Entityrifampicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Suspected Entityciprofloxacin - induced Entityinterstitial nephritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Widespread Entitycutaneous vasculitis associated with Entitydiltiazem . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute interstitial nephritis due to Entitypantoprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAllergic contact angioedema to Entitybenzoyl peroxide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9985 | Adverse-Effect | EntityDapsone EntityDapsone syndrome in cutaneous lupus erythematosus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNonconvulsive status epilepticus due to Entityifosfamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPersisent ocular hypertension following intravitreal Entityranibizumab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTrichiasis associated with Entityprostaglandin analog use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPersistent light reactivity from systemic Entityquinine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterstitial granulomatous dermatitis associated with Entitydarifenacin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIfosfamide - induced Entitynonconvulsive status epilepticus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNephrotic syndrome associated with Entitylithium therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Aminophylline Entityhypersensitivity apparently due to Entityethylenediamine . |
| 0.9999 | Adverse-Effect | EntityAminophylline Entityhypersensitivity apparently due to ethylenediamine. |
| Adverse-Effect | EntityAminophylline hypersensitivity apparently due to Entityethylenediamine . | |
| Adverse-Effect | EntityAminophylline EntityAminophylline hypersensitivity apparently due to ethylenediamine. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | The 3 - week Entitysulphasalazine Entitysulphasalazine syndrome strikes again. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDoxycycline - induced Entityphoto - onycholysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBleomycin Entitypneumonitis potentiated by oxygen administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute Entityvalproate ingestion induces Entitysymptomatic methemoglobinemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate induced Entitysprue - like syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPolymyositis after Entitypropylthiouracil treatment for hyperthyroidism. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAtrial fibrillation following Entitymethylprednisolone pulse therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOesophageal ulceration due to Entityemepronium bromide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTroglitazone - induced Entityfulminant hepatic failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityToxic epidermal necrolysis associated with Entityinterleukin - 2 . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCaptopril - associated " Entitypseudocholangitis '. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFulminant liver failure associated with Entityclarithromycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCefuroxime - induced Entityacute renal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNail - changes induced by Entitypenicillamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPsoriasis induced by Entityinterferon - alpha . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGentamicin - associated Entityacute renal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRadiation recall pneumonitis induced by Entitygemcitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Can Entitymagnesium sulfate therapy impact Entitylactogenesis ? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySalicylate Entityhepato toxicity in rheumatic fever. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPemphigus vulgaris precipitated by Entityglibenclamide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFlurbiprofen - associated Entityacute tubulointerstitial nephritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Fluorouracil for Entityallergic reactions to Entitycapecitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Chronic Entityfentanyl application induces Entityadrenocortical insufficiency . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Agranulocytosis and Entitygranulocytopenia associated with Entityquetiapine . |
| 0.9999 | Adverse-Effect | EntityAgranulocytosis and granulocytopenia associated with Entityquetiapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Treatment of Entitylithium Entitytremor with metoprolol. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBarbiturate - induced Entitysubmassive hepatic necrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityUlcerating enteritis associated with Entityflucytosine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityExfoliative dermatitis secondary to Entitytobramycin sulfate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Protease inhibitor - induced Entitycarbamazepine Entitycarbamazepine toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere hepatitis caused by Entitycyproterone acetate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGabapentin withdrawal presenting as Entitystatus epilepticus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySuxamethonium Entityapnoea terminated with commercial serumcholinesterase. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTransient hemiparesis caused by Entityphenytoin toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | Systemic corticosteroids in the Entityphenytoin Entityphenytoin hypersensitivity syndrome . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeurotoxicity of intrathecal administration of Entityamphotericin B . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySustained monomorphic ventricular tachycardia after Entityadenosine infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere hepatocellular dysfunction following Entitycyproterone acetate therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBleomycin induced Entityhyperpigmentation with yolk sac tumor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Atypical Entityneuroleptic malignant syndrome associated with Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFocal renal cortical necrosis associated with Entityzomepirac . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCapecitabine - induced Entityheadache responding to diltiazem. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute coronary syndrome induced by Entitycapecitabine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute Entityisoniazid Entityneurotoxicity in an urban hospital. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInappropriate antidiuretic hormone following Entityadenine arabinoside administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Skin rash and Entitysplinter hemorrhages from Entityganciclovir . |
| 0.9998 | Adverse-Effect | EntitySkin rash and splinter hemorrhages from Entityganciclovir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPriapism as a complication of Entityheparin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThrombocytosis under Entityciprofloxacin and tazobactam / piperacillin. |
| 0.9999 | Adverse-Effect | EntityThrombocytosis under ciprofloxacin and Entitytazobactam / piperacillin. |
| 0.9999 | Adverse-Effect | EntityThrombocytosis under ciprofloxacin and tazobactam / Entitypiperacillin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNonoliguric acute renal failure after Entitycaptopril therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCaptopril - induced Entityacute reversible renal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGastro - oesophageal reflux associated with Entitynifedipine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIsoniazid associated, painful, Entitybilateral gynaecomastia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPiloerection induced by replacing Entityfluvoxamine with milnacipran. |
| 0.9999 | Adverse-Effect | EntityPiloerection induced by replacing fluvoxamine with Entitymilnacipran . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Allergic and Entityirritant contact dermatitis to Entitycalcipotriol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case studies in Entityheparin - induced Entitythrombocytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitybleeding resolved on discontinuation of EntityAPV . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DIAGNOSIS : EntityInterferon alpha - 2b - induced Entitycardiomyopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case study : Entityadverse response to Entityclonidine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySyncope induced by Entitypropranolol in hypertrophic cardiomyopathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prolonged Entitysevere cholestasis induced by Entityoxacillin derivatives. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLithium - induced EntityCreutzfeldt - Jakob syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEctropion secondary to bolus injection of Entity5 - fluorouracil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCarbamazepine - related Entityhyponatremia following cardiopulmonary bypass. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinical and morphological features of Entitygold Entityneuropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySporadic rippling muscle disease unmasked by Entitysimvastatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRefractory hypoglycemia from Entityciprofloxacin and glyburide interaction. |
| 0.9999 | Adverse-Effect | EntityRefractory hypoglycemia from ciprofloxacin and Entityglyburide interaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients had Entityampicillin - associated Entityseizures . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAngioimmunoblastic lymphadenopathy with dysproteinemia following Entitydoxycycline administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethadone - induced Entitymyoclonus in advanced cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityParadoxical cerebral cortical hyperexcitability following Entityflupirtine overdose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTorsade de pointes during loading with Entityamiodarone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe Entityabdominal pain in low dosage Entityclofazimine . |
| 1.0000 | Adverse-Effect | EntitySevere abdominal pain in low dosage Entityclofazimine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIschaemic colitis in a patient taking Entitymeloxicam . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Probable Entitypropafenone - induced Entitytransient global amnesia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute myocardial necrosis during administration of Entityamsacrine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGeneralized argyria after habitual use of EntityAgNO3 . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityCorneal endothelial dysfunction associated with Entityamantadine toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reversible Entitynonthrombocytopenic palpable purpura associated with Entitymetoclopramide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Methylphenidate and Entitydextroamphetamine - induced Entityperipheral vasculopathy . |
| 0.9998 | Adverse-Effect | EntityMethylphenidate and dextroamphetamine - induced Entityperipheral vasculopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPure red cell aplasia associated with Entityfenoprofen . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCicatricial entropion associated with chronic Entitydipivefrin application. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLeflunomide - associated Entityinfections in rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A possible case of Entitycarbamazepine induced Entitypancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Lichen planus and Entityacne provoked by Entitygold . |
| 0.9999 | Adverse-Effect | EntityLichen planus and acne provoked by Entitygold . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCutaneous mycobacterial infection post intravesical EntityBCG installation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An Entityamiodarone Entityoptic neuropathy has been described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Regression of Entitythyrotoxic ophthalmopathy following Entitylithium withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute leukopenia associated with Entitysilver sulfadiazine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTrimethoprim - sulfamethoxazole - induced Entityaseptic meningitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Unique Entitybehavioral change with Entitycinepazide in parkinsonism. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIsoniazid induced Entitygynaecomastia : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Rapidly developing Entityhyperglycemia during treatment with Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The disease predisposes to severe Entityvincristine Entityneurotoxicity . |
| Adverse-Effect | The disease predisposes to severe Entityvincristine Entityvincristine neurotoxicity . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intrahepatic cholestasis and Entitysicca complex after Entitythiabendazole . |
| 0.9999 | Adverse-Effect | EntityIntrahepatic cholestasis and sicca complex after Entitythiabendazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNaproxen - associated Entitysudden sensorineural hearing loss . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Neonatal Entitymydriasis : intravenous Entitylidocaine adverse reaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLinear IgA bullous dermatosis occurring after Entitycarbamazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBilateral anterior uveitis associated with Entityclomiphene citrate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityEthambutol toxicity manifesting as Entityacute onset psychosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entitydrug interaction between Entityzafirlukast and theophylline. |
| 0.9998 | Adverse-Effect | A Entitydrug interaction between zafirlukast and Entitytheophylline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRecurrent hyponatremia associated with Entitycitalopram and mirtazapine. |
| 0.9999 | Adverse-Effect | EntityRecurrent hyponatremia associated with citalopram and Entitymirtazapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySeizures associated with Entityfluoxetine therapy are uncommon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySpontaneous splenic infarction associated with Entitysumatriptan use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNicotinic acid - induced Entityfulminant hepatic failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTriazolam - induced Entitynocturnal bingeing with amnesia. |
| 1.0000 | Adverse-Effect | EntityTriazolam - induced nocturnal bingeing with Entityamnesia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Asthma and Entityurticaria during Entitydisodium cromoglycate treatment. |
| 0.9997 | Adverse-Effect | EntityAsthma and urticaria during Entitydisodium cromoglycate treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCerebral and ocular toxicity induced by Entitydesferrioxamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute drug induced Entityhepatitis due to Entityerlotinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPanic anxiety after abrupt discontinuation of Entitymianserin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient on Entityouabain also developed Entitycardiomyopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySotalol - induced Entitybradycardia reversed by glucagon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityPilocarpine EntityPilocarpine toxicity and the treatment of xerostomia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Probable early Entityacute hepatitis with parenteral Entityamiodarone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute respiratory distress syndrome after Entityrituximab infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBromide intoxication secondary to Entitypyridostigmine bromide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute generalized exanthematous pustulosis induced by Entitynimesulide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | EntityPhenytoin EntityPhenytoin toxicity due to concomitant antituberculosis therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Unusual Entitypigmentary changes associated with Entity5 - fluorouracil therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityJuvenile absence epilepsy exacerbated by Entityvalproic acid . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterstitial pneumopathy and low - dosage Entityamiodarone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLevofloxacin - induced Entitydelirium with psychotic features . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMultifocal inflammatory leukoencephalopathy associated with Entitylevamisole therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProthipendylhydrochloride - induced Entitypriapism : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPravastatin is associated with Entitymyotonia in animals. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHemodynamic collapse following Entitylabetalol administration in preeclampsia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe Entityserotonin syndrome induced by Entitymirtazapine monotherapy. |
| 1.0000 | Adverse-Effect | EntitySevere serotonin syndrome induced by Entitymirtazapine monotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGemcitabine - induced Entityrectus abdominus radiation recall . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Life - threatening Entityhyponatremia caused by Entityvinblastine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Long lasting Entityrespiratory depression induced by Entitymorphine - 6 - glucuronide ? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGlaucoma secondary to epithelial downgrowth and Entity5 - fluorouracil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Drug - induced Entityfever due to Entitydiltiazem . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitymania associated with Entityfluoxetine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityColchicine - induced Entitymyopathy in renal failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Life - threatening Entityhyperkalemia induced by Entityarginine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDepressive symptoms disappeared after Entityinterferon therapy was stopped. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEruptive epidermoid cysts resulting from treatment with Entityimiquimod . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDeepening of lid sulcus from topical Entitybimatoprost therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We diagnosed this case as Entitydanazol induced Entitythrombocytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAliskiren - associated Entityacute renal failure with hyperkalemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCiprofloxacin - induced Entityrenal insufficiency in cystic fibrosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Fixed drug Entityeruption in hands caused by Entityomeprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReversible cardiomyopathy caused by administration of Entityinterferon alpha . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAlprazolam - induced Entitymania : two clinical cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityFulminant hepatitis and lymphocyte sensitization due to Entitypropylthiouracil . |
| 1.0000 | Adverse-Effect | Fulminant hepatitis and Entitylymphocyte sensitization due to Entitypropylthiouracil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9989 | Adverse-Effect | EntityTheophylline intoxication following Entityviloxazine induced decrease in clearance. |
| 0.9959 | Adverse-Effect | EntityTheophylline EntityTheophylline intoxication following viloxazine induced decrease in clearance. |
| Adverse-Effect | Theophylline intoxication following Entityviloxazine induced Entitydecrease in clearance . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMycophenolate mofetil - induced Entityneutropenia in liver transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAllergic contact dermatitis to compound tincture of Entitybenzoin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pulmonary infiltrates and Entityskin pigmentation associated with Entitysulfasalazine . |
| 1.0000 | Adverse-Effect | EntityPulmonary infiltrates and skin pigmentation associated with Entitysulfasalazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySpindle coma in Entitybenzodiazepine toxicity : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTiclopidine - induced Entitymarrow aplasia treated with cyclosporine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPriapism associated with Entitytrazodone therapy : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | MR findings in Entitymethotrexate - induced EntityCNS abnormalities . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reversible findings of restricted diffusion in Entity5 - fluorouracil Entityneurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : EntityBudesonide use can cause Entitycontact dermatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRestless legs syndrome due to Entityinterferon - alpha . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entitylethal complication of peripheral vein Entityvasopressin infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Allergic reaction to Entitygemfibrozil manifesting as Entityeosinophilic gastroenteritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProgressive interstitial lung disease from prolonged Entitymethotrexate therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Angioedema and Entitymaculopapular eruptions associated with Entitycarbamazepine administration. |
| 0.9999 | Adverse-Effect | EntityAngioedema and maculopapular eruptions associated with Entitycarbamazepine administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal toxic epidermal necrolysis related to Entitylamotrigine administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNitrofurantoin - induced Entityacute liver damage in pregnancy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCyclophosphamide can rarely cause Entityinterstitial pneumonitis and fibrosis. |
| 1.0000 | Adverse-Effect | EntityCyclophosphamide can rarely cause interstitial pneumonitis and Entityfibrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute bilateral phrenic neuropathy following treatment with Entityadalimumab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmpicillin may aggravate clinical and experimental Entitymyasthenia gravis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityincreased libido disappeared after Entityfluvoxamine was discontinued. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmiodarone was discontinued, and Entitythyrotoxicosis gradually abated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVisceral herpesvirus infections in leukemic patients receiving Entitycytarabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBowel perforation associated with intraperitoneal Entitychromic phosphate instillation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCo - trimoxazole Entityred cell aplasia in leukaemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Recurrent hypotension immediately after Entityseizures in Entitynortriptyline overdose. |
| 0.9999 | Adverse-Effect | EntityRecurrent hypotension immediately after seizures in Entitynortriptyline overdose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNephropathy caused by Entitymethicillin therapy for staphylococcal septicemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDapsone - induced Entityerythroderma with Beau's lines. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEsophageal spasm following Entitypropranolol overdose relieved by glucagon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetformin - associated Entitylactic acidosis precipitated by diarrhea. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmoxapine - induced Entitycognitive impairment in two patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | First case of Entityivermectin - induced Entitysevere hepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute sensorineural hearing loss following intravenous Entityketoralac administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLeishmania infantum leishmaniasis in Entitycorticosteroid - - treated patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethemoglobinemia : an occupational hazard of Entityphenylpropanolamine production. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPentazocine - induced Entityfibrous myopathy and localized neuropathy. |
| 0.9997 | Adverse-Effect | EntityPentazocine - induced fibrous myopathy and localized Entityneuropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylactoid reaction to 50 % solution of Entitydextrose . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLeflunomide - associated Entityweight loss in rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnterior ischemic optic neuropathy secondary to Entityinterferon alfa . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPhenobarbital Entityhepatotoxicity in an 8 - month - old infant. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We conclude Entityperipheral neuropathy with Entity5 - FU is rare. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PET scintigraphy of Entityetoposide - induced Entitypulmonary toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He had Entitypriapism following the use of Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylaxis to Entitycisplatin following nine previous uncomplicated cycles. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : EntityHypersensitivity reactions to Entitycyclosporine are rare. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary oedema after Entityhexoprenaline administration in preterm labour. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After abstinence from Entityoolong tea his Entitydelirium resolved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityQuinine induced Entitycoagulopathy - - a near fatal experience. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitypulmonary toxicity is probably induced by Entitypiritrexim . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | MR findings in Entitymethotrexate - induced EntityCNS abnormalities . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOsteomyelitis occurring during Entityinfliximab treatment of severe psoriasis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She was thus diagnosed as having EntityAZ EntityAZ intoxication . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal failure associated with the use of Entitydextran - 40 . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAripiprazole - induced Entityhiccups : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRhabdomyolysis associated with the use of intravenous Entityvasopressin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Other Entityupper tract neoplasms after Entitycyclophosphamide are reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBisphosphonate - related Entityosteonecrosis of the skull base . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute asthma associated with sustained - release Entityverapamil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityErosion of psoriatic plaques after chronic Entitymethotrexate administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | We suspect that nefazodone Entityinhibits metabolism of tacrolimus Entitytacrolimus . | |
| Adverse-Effect | We suspect that Entitynefazodone Entityinhibits metabolism of tacrolimus . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHyponatraemia developed after rechallenge with controlled release Entitycarbamazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTriiodothyronine - induced Entitythyrotoxicosis in ophthalmic Graves disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInsulin - induced Entitylipoatrophy in type I diabetes. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOptic neuropathy in Entityethambutol - treated renal tuberculosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Localized dyskeratotic plaque with Entitymilia associated with Entitysorafenib . |
| 0.9999 | Adverse-Effect | EntityLocalized dyskeratotic plaque with milia associated with Entitysorafenib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityChoroidal hemorrhage associated with systemic Entitytissue plasminogen activator . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere acute encephalopathy following inadvertent intrathecal Entitydoxorubicin administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary lymphohistiocytic reactions temporally related to Entityetanercept therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of EntitySIADH induced by Entitymizoribin administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPhoto - onycholysis caused by Entityolanzapine and aripiprazole. |
| 0.9999 | Adverse-Effect | EntityPhoto - onycholysis caused by olanzapine and Entityaripiprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A woman developed Entitydelusional parasitosis when taking Entityphenelzine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityEosinophilic cystitis after bladder instillation with Entitydimethyl sulfoxide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTransient asymptomatic bradycardia in patients on infusional Entity5 - fluorouracil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Easily reversible hypoxemia and Entityhypotension induced by Entitynimodipine . |
| 0.9999 | Adverse-Effect | Easily reversible Entityhypoxemia and hypotension induced by Entitynimodipine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityGelofusine EntityGelofusine allergy - - the need for identification jewellery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDisseminated salmonellosis in a patient treated with Entitytemozolomide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEpoprostenol may be associated rarely with severe Entityerythroderma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityChromosome abnormalities after Entitychlorambucil therapy of polycythaemia vera. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute acoustic nerve palsy associated with Entityvincristine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case report of withdrawal Entitydyskinesia associated with Entityamoxapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInsulin - dependent diabetes mellitus associated with Entitydanazol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute dystonic reaction with low - dose Entitypimozide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFalling backward in two elderly patients taking Entitybupropion . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reversible Entitysirolimus - associated Entitypneumonitis after heart transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRifampin - associated Entitythrombocytopenia secondary to poor compliance. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInappropriate antidiuretic hormone secretion after high dose Entityvinblastine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClozapine - induced Entityakathisia in children with schizophrenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entityfatal case of pancytopenia due to Entitylevomepromazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Near fatal acute Entitycolchicine Entitycolchicine intoxication in a child. |
| 0.9999 | Adverse-Effect | EntityNear fatal acute Entitycolchicine intoxication in a child. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAtenolol induced Entitymemory impairment : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After discontinuation of Entitydanazol the Entitydiabetes completely resolved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate Entitypneumonitis in nonsurgical treatment of ectopic pregnancy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTardive dyskinesia in 2 patients treated with Entityziprasidone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Encephalopathy and Entityseizures induced by intravesical Entityalum irrigations. |
| 0.9999 | Adverse-Effect | EntityEncephalopathy and seizures induced by intravesical Entityalum irrigations. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Life - threatening Entitycranial dystonia following Entitytrihexyphenidyl withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFlaccid quadriparesis was noted after discontinuation of Entityvecuronium . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityTheophylline EntityTheophylline intoxication mimicking diabetic ketoacidosis in a child. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intraventricular Entitynafcillin - induced Entityseizures in a neonate. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLinear immunoglobulin A bullous dermatosis induced by Entitygemcitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal failure associated with Entityacetazolamide therapy for glaucoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGangrene of the fingertips after Entitybleomycin and methotrexate. |
| 1.0000 | Adverse-Effect | EntityGangrene of the fingertips after bleomycin and Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFlucloxacillin - induced Entityaplastic anaemia and liver failure. |
| 0.9999 | Adverse-Effect | EntityFlucloxacillin - induced aplastic anaemia and Entityliver failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The course of Entitydelirium due to Entitylithium intoxication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere neurotoxicity with Entitymethyl G : CALGB experience. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Spontaneous Entitybacterial peritonitis induced by intraarterial Entityvasopressin therapy. |
| 1.0000 | Adverse-Effect | EntitySpontaneous bacterial peritonitis induced by intraarterial Entityvasopressin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Their Entityparkinsonism improved on discontinuation of Entitymetoclopramide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLinezolid - induced Entitydyserythropoiesis : chloramphenicol toxicity revisited. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRifampin - induced Entityhypothyroidism without underlying thyroid disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere acidosis from Entityacetazolamide in a diabetic patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute pancreatitis associated with Entitydanazol treatment for endometriosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySirolimus - associated Entityhepatotoxicity in the kidney graft recipient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Transient Entityphenytoin induced EntityIgA deficiency and permanent IgE increase. |
| 0.9998 | Adverse-Effect | Transient Entityphenytoin induced IgA deficiency and permanent EntityIgE increase . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMefloquine - associated Entityhypoglycaemia in a cachectic AIDS patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLansoprazole - associated Entitycollagenous colitis : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEnalapril - induced Entityanemia in two kidney transplant recipients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Transient leucopenia and Entitythrombocytopenia associated with Entitysodium nitroprusside infusion. |
| 0.9990 | Adverse-Effect | Transient Entityleucopenia and thrombocytopenia associated with Entitysodium nitroprusside infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitycolchicine - induced Entityrhabdomyolysis is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A diagnosis of Entitytrastuzumab - induced Entitypneumonitis was made. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAlprazolam withdrawal Entitydelirium unresponsive to diazepam : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAbnormal retinal function associated with Entityisotretinoin therapy for acne. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRupture of a cerebral aneurysm associated with Entitynifedipine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Phantom limb pain as a manifestation of Entitypaclitaxel Entityneurotoxicity . |
| 1.0000 | Adverse-Effect | EntityPhantom limb pain as a manifestation of Entitypaclitaxel neurotoxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPapillary necrosis associated with the HIV protease inhibitor Entityindinavir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmpicillin - induced Entityinterstitial nephritis with generalised exfoliative dermatitis. |
| 0.9999 | Adverse-Effect | EntityAmpicillin - induced interstitial nephritis with Entitygeneralised exfoliative dermatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Traumatic late flap dehiscence and EntityEnterobacter keratitis following EntityLASIK . |
| 0.9999 | Adverse-Effect | EntityTraumatic late flap dehiscence and Enterobacter keratitis following EntityLASIK . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOfloxacin : a probable cause of Entitytoxic epidermal necrolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBisphosphonate induced Entityosteochemonecrosis of the jaw mimicking a tumour. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case report illustrates the Entityneurotoxicity unique to EntityHDARAC . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three cases of Entitygold - related Entityneuropathy are reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropranolol - induced Entityhypertension in treatment of cocaine intoxication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySerotonin syndrome caused by interaction between Entitycitalopram and fentanyl. |
| 1.0000 | Adverse-Effect | EntitySerotonin syndrome caused by interaction between citalopram and Entityfentanyl . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxicity after high - dose Entitymethylprednisolone for demyelinating disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAccelerated nodulosis during Entitymethotrexate therapy for juvenile rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThrombotic thrombocytopenic purpura during Entitypenicillamine therapy in rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute respiratory depression as a complication of nebulised Entitymorphine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCeftriaxone - induced Entityfixed drug eruption : first report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityComeoscleral perforation after pterygium excision and intraoperative Entitymitomycin C . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIfosfamide is a known nephrotoxic drug with demonstrated Entitytubulopathies . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxicity associated with Entity6 - thioguanine therapy for Crohn's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxicity of Entityhycanthone in patients with metastatic breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDisulfiram Entityencephalopathy as a cause of the catatonia syndrome. |
| 0.9999 | Adverse-Effect | EntityDisulfiram encephalopathy as a cause of the Entitycatatonia syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySensorimotor polyneuropathy with Entity5 - aminosalicylic acid : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Delayed Entityneurotoxicity of intraventricular Entityinterleukin - 2 : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Unusual Entityhypersensitivity to Entitywarfarin in a critically ill patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVasomotor reactions after Entitygold sodium thiomalate are well recognized. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intrahepatic cholestasis and Entitycutaneous bullae associated with Entityglibenclamide therapy. |
| 0.9999 | Adverse-Effect | EntityIntrahepatic cholestasis and cutaneous bullae associated with Entityglibenclamide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTrazodone - induced Entitytransient hypomanic symptoms and their management. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Some patients develop Entityhypersensitivity rash in response to EntityHCQ . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Possible recurrence of Entityamiodarone Entitypulmonary toxicity following corticosteroid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxicity related to Entityitraconazole : report of three cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySeptic knee arthritis after intra - articular Entityhyaluronate injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMultiple sclerosis - like disease secondary to Entityalpha interferon . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The literature of Entityvincristine Entityoptic nerve toxicity is reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An Entityintertrigo - like eruption from pegylated liposomal Entitydoxorubicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hypotension and Entitysinus arrest with Entitynifedipine in pulmonary hypertension. |
| 0.9999 | Adverse-Effect | EntityHypotension and sinus arrest with Entitynifedipine in pulmonary hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Liver transplantation for Entityfulminant hepatitis related to Entitynevirapine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDiabetes Mellitus was observed in a patient given Entitycarbamazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate - induced Entitypapular eruption following treatment of psoriasis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary hypertension during Entitylithium therapy : clinical case study. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClofazimine Entityenteropathy in a pediatric bone marrow transplant recipient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCardiac arrest associated with Entitysulprostone use during caesarean section. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropafenone - induced Entityataxia : report of three cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Disseminated muscular cysticercosis with Entitymyositis induced by Entitypraziquantel therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitymyoclonus induced by Entityquetiapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatopathy subsided after the cessation of Entitycarbamazepine and lynestrenol. |
| 1.0000 | Adverse-Effect | EntityHepatopathy subsided after the cessation of carbamazepine and Entitylynestrenol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Large dose of Entitymethylphenidate may cause Entitycataract and glaucoma. |
| 1.0000 | Adverse-Effect | Large dose of Entitymethylphenidate may cause cataract and Entityglaucoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySyndrome of inappropriate antidiuretic hormone associated with Entityvinorelbine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute pancreatitis after long - term Entity5 - aminosalicylic acid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFoscarnet - induced Entitysevere hypomagnesemia and other electrolyte disorders. |
| 0.9999 | Adverse-Effect | EntityFoscarnet - induced severe hypomagnesemia and other Entityelectrolyte disorders . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylactoid reaction to Entitymethylprednisolone pulsed therapy for multiple sclerosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Simvastatin - induced Entityrhabdomyolysis following Entitycyclosporine treatment for uveitis. |
| 1.0000 | Adverse-Effect | EntitySimvastatin - induced Entityrhabdomyolysis following cyclosporine treatment for uveitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The spectrum of Entitynitrofurantoin Entitylung injury continues to widen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Paradoxical ventricular tachycardia and Entityfibrillation after intravenous Entitybretylium therapy. |
| 0.9999 | Adverse-Effect | EntityParadoxical ventricular tachycardia and fibrillation after intravenous Entitybretylium therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient developed grade 3 Entitycapecitabine - induced Entityheadache . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEmbolia cutis medicamentosa following subcutaneous injection of Entityglatiramer acetate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These results indicate that Entitylithium may cause Entitybiochemical hyperparathyroidism . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A new type of Entityminocycline - induced Entitycutaneous hyperpigmentation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReversible corneal keratinization following trabeculectomy and treatment with Entity5 - fluorouracil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute endophthalmitis following intravitreal Entitybevacizumab ( Avastin ) injection. |
| 1.0000 | Adverse-Effect | EntityAcute endophthalmitis following intravitreal bevacizumab ( EntityAvastin ) injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCamptocormia , a new side effect of Entitysodium valproate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Histopathology of the thyroid in Entityamiodarone - induced Entityhypothyroidism . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMultiple seizures after Entitybupropion overdose in a small child. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Successful challenge with Entityclozapine in a history of Entityeosinophilia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitypyridoxine - dependent Entityseizures is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySystemic lupus erythematosus during Entitypenicillamine therapy for rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two Entityfatal cases of poisoning by Entityparacetamol are described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNephrotic range pseudoproteinuria in a Entitytolmetin - treated patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCaptopril - related ( and - induced? ) Entityasthma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitynoncardiogenic pulmonary edema by Entityethanolamine oleate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypercalcemia in an AIDS patient treated with Entitygrowth hormone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySystemic vasculitis complicating hairy cell leukaemia treatment with Entitycladribine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCephalosporins are most likely associated with EntityVitamin K deficiency . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reversible cholestasis with Entitybile duct injury following Entityazathioprine therapy. |
| 0.9999 | Adverse-Effect | Reversible Entitycholestasis with bile duct injury following Entityazathioprine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityUveitis associated with Entityrifabutin therapy : a clinical alert. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmiodarone - induced Entitythyrotoxicosis associated with thyrotropin receptor antibody. |
| 0.9999 | Adverse-Effect | EntityAmiodarone - induced thyrotoxicosis associated with Entitythyrotropin receptor antibody . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Peripheral neuropathy and Entitycerebellar syndrome associated with Entityamiodarone therapy. |
| 0.9999 | Adverse-Effect | EntityPeripheral neuropathy and cerebellar syndrome associated with Entityamiodarone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitypriapism associated with Entitytrazodone is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : EntityElectrolyte disorders associated with Entityfoscarnet are reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMyocardial ischemia associated with high - dose Entitycarmustine infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethylphenidate - associated Entityenuresis in attention deficit hyperactivity disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Development of Entityporphyria cutanea tarda after treatment with Entitycyclophosphamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute reversible ataxo - myoclonic encephalopathy with Entityflecainide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus cabergoline may cause similar Entitypleuropulmonary abnormalities to Entitybromocriptine . |
| 1.0000 | Adverse-Effect | Thus Entitycabergoline may cause similar Entitypleuropulmonary abnormalities to bromocriptine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHigh - grade atrioventricular block during Entitydipyridamole stress testing. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDisulfiram - like reactions with newer cephalosporins : Entitycefmenoxime . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We suggest discontinuing Entitygemcitabine if Entityradiation recall is observed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFluoxetine - induced Entityakathisia : clinical and theoretical implications. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityharlequin color change and association with Entityprostaglandin E1 . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Management and successful desensitization in Entitymethotrexate - induced Entityanaphylaxis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Response of a Entitypromethazine - induced Entitycoma to flumazenil. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Multifocal electroretinographic abnormalities in Entityethambutol - induced Entityvisual loss . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute renal failure in a child associated with Entityacyclovir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Withdrawal of EntityDepakote resulted in resolution of the Entityeffusion . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDipyrone - induced Entitygranulocytopenia : a case for awareness. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The second patient exhibited sudden EntityPLMS following Entityolanzapine injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFixed drug eruption of the scrotum due to Entitymethylphenidate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxic effects in a child receiving Entityvalproate and carnitine. |
| 0.9999 | Adverse-Effect | EntityHepatotoxic effects in a child receiving valproate and Entitycarnitine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Isoniazid and Entityethambutol as a cause of Entityoptic neuropathy . |
| 0.9999 | Adverse-Effect | EntityIsoniazid and ethambutol as a cause of Entityoptic neuropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityAmphotericin B Entitynephrotoxicity in humans decreased by salt repletion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLevofloxacin induced Entitypolymorphic ventricular tachycardia with normal QT interval. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary edema as a delayed complication of Entityritodrine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityToxicity related to Entitychloroquine treatment of resistant vivax malaria. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityCarbamazepine toxicity induced by Entityclarithromycin coadministration in psychiatric patients. |
| 0.9994 | Adverse-Effect | EntityCarbamazepine EntityCarbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Circulating anticoagulant in the Entityprocainamide - induced Entitylupus syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMyotonia associated with sarcoidosis : marked exacerbation with Entitypravastatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Gold Entitynephropathy due to Entityauranofin obscured by tolmetin pseudoproteinuria. |
| 0.9998 | Adverse-Effect | EntityGold Entitynephropathy due to auranofin obscured by tolmetin pseudoproteinuria. |
| 0.9742 | Adverse-Effect | Gold Entitynephropathy due to auranofin obscured by Entitytolmetin pseudoproteinuria. |
| Adverse-Effect | EntityGold nephropathy due to Entityauranofin obscured by tolmetin pseudoproteinuria. | |
| Adverse-Effect | Gold nephropathy due to auranofin obscured by Entitytolmetin Entitypseudoproteinuria . | |
| Adverse-Effect | EntityGold nephropathy due to auranofin obscured by Entitytolmetin pseudoproteinuria. | |
| Adverse-Effect | EntityGold EntityGold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDoxycycline - induced Entityhypoglycemia in a nondiabetic young man. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTetany in a child with AIDS receiving intravenous Entitytobramycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case report : Entityacute renal failure after administering intravenous Entityimmunoglobulin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDyspnea possibly associated with controlled - release Entitymorphine sulfate tablets. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute kidney injury caused by Entityzonisamide - induced Entityhypersensitivity syndrome . |
| 0.9999 | Adverse-Effect | EntityAcute kidney injury caused by Entityzonisamide - induced hypersensitivity syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The renal consequences of Entityindinavir - associated Entitynephrotoxicity are uncertain. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Occurrence of EntityIDDM during Entityinterferon therapy for chronic viral hepatitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A further case of Entityanaphylactoid reaction to Entitymethylprednisolone is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBull's - eye maculopathy associated with Entityquinacrine therapy for malaria. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Can Entitypropofol precipitate Entitypancreatitis in patients with Cushing's syndrome? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClonidine - induced Entitybradycardia in patients with spinal cord injury. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLymphoma developing in a patient with rheumatoid arthritis taking Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmphotericin B overdose in pediatric patients with associated Entitycardiac arrest . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIsoniazid causing Entitybreast tissue enlargement has been very rarely reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityParadoxical pulmonary vasoconstriction induced by Entitynitroglycerin in idiopathic pulmonary hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, recurrent Entitystaphylococcus aureus sepsis developed during EntityCyA therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNoncardiogenic pulmonary edema during intrabiliary infusion of Entitymono - octanoin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMoxalactam is more likely to be associated with Entityplatelet dysfunction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere Raynaud's phenomenon with Entityyohimbine therapy for erectile dysfunction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere systemic hypersensitivity reaction to Entityibuprofen occurring after prolonged therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Fatal Entitygemcitabine - induced Entitypulmonary toxicity in metastatic gallbladder adenocarcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Massive plasmocytosis due to Entitymethimazole - induced Entitybone marrow toxicity . |
| 0.9999 | Adverse-Effect | EntityMassive plasmocytosis due to Entitymethimazole - induced bone marrow toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Ketanserin in the treatment of Entityprotamine - induced Entitypulmonary hypertension . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Bradycardia and Entitycongestive heart failure associated with ocular Entitytimolol maleate . |
| 0.9996 | Adverse-Effect | EntityBradycardia and congestive heart failure associated with ocular Entitytimolol maleate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityUlcerative proctitis in juvenile systemic lupus erythematosus after Entityibuprofen treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient developed Entitycholestatic hepatitis while being treated with Entitynitrofurantoin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDorzolamide - induced Entitychoroidal detachment in a surgically untreated eye. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMitomycin C - related Entityhemolytic uremic syndrome in cancer patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Possible Entityserotonin syndrome associated with Entityclomipramine after withdrawal of clozapine. |
| 0.9996 | Adverse-Effect | Possible Entityserotonin syndrome associated with clomipramine after withdrawal of Entityclozapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityrecall pneumonitis induced by Entitygemcitabine is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Myoglobinuria and Entityacute renal failure associated with intravenous Entityvasopressin infusion. |
| 1.0000 | Adverse-Effect | EntityMyoglobinuria and acute renal failure associated with intravenous Entityvasopressin infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmphotericin B - induced Entityseizures in a patient with AIDS. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityallopurinol Entityhypersensitivity syndrome is a rare adverse drug reaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : We report an unusual Entityparadoxical effect of Entitybrimonidine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The most likely cause of such Entityhyponatremic episode is Entityvinblastine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCefoxitin therapy for Mycobacterium fortuitum bacteremia with associated Entitygranulomatous hepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcceleration of ventricular response to atrial flutter after intravenous Entityadenosine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entityhypereosinophilia related to Entityzafirlukast therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal damage associated with long term use of Entitylithium carbonate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reversible Entityvalproic acid - induced Entitydementia : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere hypo - alpha - lipoproteinemia during treatment with Entityrosiglitazone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Excluding other causes, EntityPentasa - associated Entitypancytopenia was considered. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThrombo - embolic complication after Entitystreptokinase therapy of pulmonary emboli. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Development of Entitypersistent late onset asthma following treatment with Entitycaptopril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmphotericin B - induced Entitycutaneous leucocytoclastic vasculitis : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropranolol - related Entitybronchospasm in patients without history of asthma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTrimethoprim - sulfamethoxazole - induced Entityhepatotoxicity in a pediatric patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBronchiolitis obliterans organising pneumonia associated with the use of Entitynitrofurantoin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCerebral edema associated with EntityGliadel wafers : two case studies. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAgranulocytosis induced by Entityvancomycin in an ESRD patient on CAPD. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityZidovudine induced Entitypure red cell aplasia : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Various case reports concerning Entitydapsone - induced Entityagranulocytosis are reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeurotoxicity of Entityvalacyclovir in peritoneal dialysis : a pharmacokinetic study. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Recently, EntityCD20 - negative tumors have been described after EntityRituximab therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCutaneous ulceration : an unusual complication of intravenous Entitypentamidine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Aplastic anemia and Entityagranulocytosis in patients using Entitymethazolamide for glaucoma. |
| 0.9999 | Adverse-Effect | EntityAplastic anemia and agranulocytosis in patients using Entitymethazolamide for glaucoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityLethargy in a newborn : Entitylithium toxicity or lab error? |
| Adverse-Effect | Lethargy in a newborn : Entitylithium Entitylithium toxicity or lab error? | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLevofloxacin - induced Entitytoxic epidermal necrolysis in an elderly patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMental nerve neuropathy as a result of Entityhepatitis B vaccination . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMuzolimine - induced Entitysevere neuromyeloencephalopathy : report of seven cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After Entity5 - ASA was discontinued, the Entitypolyneuropathy symptoms recovered gradually. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCimetidine is a rare cause of drug - induced Entityfever . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He was later skin tested to confirm Entityallergy to EntityMTX . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Secondary Entityacute myeloid leukemia after Entityetoposide therapy for haemophagocytic lymphohistiocytosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMinocycline as a cause of drug - induced Entityautoimmune hepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMacular infarction after endophthalmitis treated with vitrectomy and intravitreal Entitygentamicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 57 - year - old man developed Entitymorphea while taking Entitybromocriptine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | EntityMethotrexate is an effective but Entitypotentially toxic treatment for psoriasis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIsonicotinic acid hydrazide induced Entityanagen effluvium and associated lichenoid eruption. |
| 0.9994 | Adverse-Effect | EntityIsonicotinic acid hydrazide induced anagen effluvium and associated Entitylichenoid eruption . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLovastatin - induced Entityrhabdomyolysis possibly associated with clarithromycin and azithromycin. |
| 1.0000 | Adverse-Effect | Lovastatin - induced Entityrhabdomyolysis possibly associated with Entityclarithromycin and azithromycin. |
| 0.9992 | Adverse-Effect | Lovastatin - induced Entityrhabdomyolysis possibly associated with clarithromycin and Entityazithromycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The occurrence of Entityacute hepatitis is best known for Entityketoconazole . |
| Adverse-Effect | The occurrence of acute Entityhepatitis is best known for Entityketoconazole . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Our experience supports hemodialysis for ESRF patients with Entityatenolol Entityatenolol toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityStevens - Johnson syndrome caused by the antiretroviral drug Entitynevirapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDasatinib - induced Entitypleural effusions : a lymphatic network disorder? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Increasing the Entityolanzapine dosage severely aggravated the symptoms of EntityRLS . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hemodialysis was also shown to reverse Entityifosfamide - related Entityneurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeurologic toxicity associated with hepatic artery infusion HAI of EntityFUdR . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityPapilledema without peripheral neuropathy in a patient taking Entityperhexiline maleate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Sudden cardiac death due to Entityhypersensitivity myocarditis during Entityclozapine treatment. |
| 0.9999 | Adverse-Effect | EntitySudden cardiac death due to hypersensitivity myocarditis during Entityclozapine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Marked Entityelevation of serum creatine kinase associated with Entityolanzapine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDoxorubicin Entitycardiotoxicity : possible role of digoxin in its prevention. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityParoxysmal supraventricular tachycardia during treatment with Entitycisplatin and etoposide combination. |
| 0.9999 | Adverse-Effect | EntityParoxysmal supraventricular tachycardia during treatment with cisplatin and Entityetoposide combination. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal acute encephalomyelitis after a single dose of intrathecal Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Oxygen potentiation of Entitybleomycin - induced Entitypulmonary toxicity is discussed. |
| 0.9978 | Adverse-Effect | EntityOxygen potentiation of bleomycin - induced Entitypulmonary toxicity is discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAllergy to Entitycloxacillin with normal tolerance to amoxicillin and cefuroxime. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMagnesium tocolysis as the cause of Entityurinary calculus during pregnancy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHemorrhagic cystitis is a significant toxic effect of Entitycyclophosphamide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypokalemia after normal doses of neubulized Entityalbuterol ( salbutamol ). |
| 1.0000 | Adverse-Effect | EntityHypokalemia after normal doses of neubulized albuterol ( Entitysalbutamol ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityToxic hepatitis induced by Entitydisulfiram in a non - alcoholic. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute renal failure during Entitylisinopril and losartan therapy for proteinuria. |
| 0.9999 | Adverse-Effect | EntityAcute renal failure during lisinopril and Entitylosartan therapy for proteinuria. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHair loss associated with Entityparoxetine treatment : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere diffuse interstitial pneumonitis induced by Entitycarmustine ( BCNU ). |
| 0.9999 | Adverse-Effect | EntitySevere diffuse interstitial pneumonitis induced by carmustine ( EntityBCNU ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitycough continued for the duration of therapy with Entityquinapril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMulticentric hepatocellular carcinoma following Entityphosphate diethylstilbestrol therapy for prostatic cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCough induced by Entityquinapril with resolution after changing to fosinopril. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityLipoid pneumonia : a silent complication of Entitymineral oil aspiration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCorneal edema recurred when the administration of Entityamantadine was resumed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFluphenazine - induced Entityneuroleptic malignant syndrome in a schizophrenic patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After stopping Entityindapamide , Entityglucose tolerance impairing may be reversed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTransient acute myopia resulting from Entityisotretinoin ( accutane ) therapy. |
| 1.0000 | Adverse-Effect | EntityTransient acute myopia resulting from isotretinoin ( Entityaccutane ) therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCardiac decompensation following Entityverapamil therapy in infants with supraventricular tachycardia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three patients developed Entityproteinuria following Entitygold therapy for rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nephrotic syndrome related to Entitysystemic lupus erythematosus after Entitygriseofulvin therapy. |
| 0.9999 | Adverse-Effect | EntityNephrotic syndrome related to systemic lupus erythematosus after Entitygriseofulvin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Colitis as a manifestation of Entityinfliximab - associated Entitydisseminated cryptococcosis . |
| 1.0000 | Adverse-Effect | EntityColitis as a manifestation of Entityinfliximab - associated disseminated cryptococcosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGabapentin - induced Entitymood changes with hypomanic features in adults. |
| 0.9999 | Adverse-Effect | EntityGabapentin - induced mood changes with Entityhypomanic features in adults. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Discontinuation of the Entityitraconazole caused resolution of the Entitydrug eruption . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Tacrolimus ( EntityFK506 ) - induced Entitymutism after liver transplant. |
| 0.9999 | Adverse-Effect | EntityTacrolimus ( FK506 ) - induced Entitymutism after liver transplant. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCarbamazepine induced Entityright bundle branch block in a Greenlandic patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Angioedema and Entitydysphagia caused by contact allergy to inhaled Entitybudesonide . |
| 1.0000 | Adverse-Effect | EntityAngioedema and dysphagia caused by contact allergy to inhaled Entitybudesonide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Apparent Entitycyclophosphamide ( cytoxan ) Entityembryopathy : a distinct phenotype? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient had MRI T2 abnormalities compatible with Entitycyclosporin Entityneurotoxicity . |
| 0.9997 | Adverse-Effect | One patient had EntityMRI T2 abnormalities compatible with Entitycyclosporin neurotoxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute renal failure in a patient receiving treatment with Entitysuramin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityCarboplatin hypersensitivity presenting as Entitycoronary vasospasm - a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere symptomatic hyponatremia during Entitysibutramine therapy : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPhenytoin toxicity : an easily missed cause of Entitycerebellar syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This pattern is suggestive of Entityrenal toxicity due to Entitytobramycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDelay of corneal wound healing in patients treated with Entitycolchicine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityWarfarin - associated Entitythoracic aortic dissection in an elderly woman. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypersensitivity to Entityzonisamide was confirmed by the skin patch test. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPseudoephedrine - induced Entityhemorrhage associated with a cerebral vascular malformation. |
| 0.9997 | Adverse-Effect | EntityPseudoephedrine - induced hemorrhage associated with a Entitycerebral vascular malformation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of acute cardiomyopathy and Entitypericarditis associated with Entitymethylphenidate . |
| 0.9999 | Adverse-Effect | A case of Entityacute cardiomyopathy and pericarditis associated with Entitymethylphenidate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySyncope in a 65 - year - old woman after Entitynitrate ingestion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DIAGNOSIS : EntitySustained ventricular tachycardia possibly owing to Entitythalidomide treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute lung injury associated with Entity5 - fluorouracil and oxaliplatinum combined chemotherapy. |
| 0.9999 | Adverse-Effect | EntityAcute lung injury associated with 5 - fluorouracil and Entityoxaliplatinum combined chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCardiac toxicity related to EntityBCNU has not been described well. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCiprofloxacin - induced Entityhemorrhagic vasculitis is a rare side effect. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An immediate Entityhemolytic reaction induced by repeated administration of Entityoxaliplatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcyclovir Entityneurotoxicity : clinical experience and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute syphilitic posterior placoid chorioretinitis following intravitreal Entitytriamcinolone acetonide injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRisperidone - induced Entityobsessive - compulsive symptoms in two children. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFibrosis of corpus cavernosum after intracavernous injection of Entityphentolamine / papaverine. |
| 1.0000 | Adverse-Effect | EntityFibrosis of corpus cavernosum after intracavernous injection of phentolamine / Entitypapaverine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | This Entityeruption appears to be a distinct cutaneous toxicity of EntityPLD . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityErosion of psoriatic plaques : an early sign of Entitymethotrexate toxicity. |
| Adverse-Effect | Erosion of psoriatic plaques : an early sign of Entitymethotrexate Entitymethotrexate toxicity . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After nine previous uncomplicated cycles she developed severe Entityanaphylaxis to Entitycisplatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityColchicine - induced Entitymyopathy in a teenager with familial Mediterranean fever. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIbopamine - induced reversible Entityleukopenia during treatment for congestive heart failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We also describe a case of Entitytimolol - induced Entityocular pemphigoid . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute aluminum toxicity after continuous intravesical Entityalum irrigation for hemorrhagic cystitis. |
| Adverse-Effect | Acute Entityaluminum toxicity after continuous intravesical Entityalum irrigation for hemorrhagic cystitis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Only a few reports of overt Entityjaundice are associated with Entitystreptokinase . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Sensory neuropathy revealing Entitynecrotizing vasculitis during Entityinfliximab therapy for rheumatoid arthritis. |
| 0.9999 | Adverse-Effect | EntitySensory neuropathy revealing necrotizing vasculitis during Entityinfliximab therapy for rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityElectrical proarrhythmia with Entityprocainamide : a new ICD - drug interaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLivedo reticularis associated with Entityinterferon alpha therapy in two melanoma patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The association of Entityphenothiazine overdose and Entityrespiratory distress syndrome merits consideration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethemoglobinemia associated with dermal application of Entitybenzocaine cream in a cat. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When the Entitytrazodone was reduced, the Entityinvoluntary movements promptly ceased. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnastrozole - associated Entitysclerosing glomerulonephritis in a patient with breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTransfusion haemosiderosis inspite of regular use of Entitydesferrioxamine : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This concerns 2 male patients who experienced Entityincontinence while taking Entityvenlafaxine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient had Entitysevere temporary weakness after an Entityampicillin sodium challenge. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityArterial hypertension associated with topical ocular use of Entityphenylephrine in dogs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTigecycline - induced Entityacute pancreatitis : case report and literature review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAntineutrophil cytoplasmic antibody - positive crescentic glomerulonephritis associated with Entitypropylthiouracil therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Chronic Entityhydroxychloroquine use associated with EntityQT prolongation and refractory ventricular arrhythmia. |
| 1.0000 | Adverse-Effect | Chronic Entityhydroxychloroquine use associated with QT prolongation and Entityrefractory ventricular arrhythmia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report here a rare case of Entitypleuropericarditis due to Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Inadvertent and accidental Entityepinephrine overdose might result in potentially Entitylethal complications . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReversible heart failure in a patient receiving Entityetanercept for ankylosing spondylitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityExtensive forearm deep venous thrombosis following a severe Entityinfliximab infusion reaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of Entitytuberculous uveitis due to Entityetanercept . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Five months after initiating Entitymirtazapine therapy, she developed Entitysymptomatic hyponatremia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : A case of Entitycarbamazepine - induced Entityhyperammonemia is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pneumonitis with pleural and pericardial effusion and Entityneuropathy during Entityamiodarone therapy. |
| 0.9999 | Adverse-Effect | EntityPneumonitis with pleural and pericardial effusion and neuropathy during Entityamiodarone therapy. |
| 0.9999 | Adverse-Effect | Pneumonitis with Entitypleural and pericardial effusion and neuropathy during Entityamiodarone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal hepatitis after long - term pulse Entityitraconazole treatment for onychomycosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is a rare case of EntityARDS associated with Entitylithium intoxication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypersensitivity reactions due to Entitychloramphenicol are rarely reported in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIschaemia following selfadministered intra - arterial injection of Entitymethylphenidate and diamorphine. |
| 1.0000 | Adverse-Effect | EntityIschaemia following selfadministered intra - arterial injection of methylphenidate and Entitydiamorphine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Unaccountable severe Entityhypercalcemia in a patient treated for hypoparathyroidism with Entitydihydrotachysterol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAllopurinol - associated Entityhand and foot deformities in chronic tophaceous gout. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of EntityRitalin - associated Entitycataract and glaucoma. |
| 1.0000 | Adverse-Effect | We report a case of EntityRitalin - associated cataract and Entityglaucoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nephrogenic diabetes insipidus and Entityrenal tubular acidosis secondary to Entityfoscarnet therapy. |
| 0.9999 | Adverse-Effect | EntityNephrogenic diabetes insipidus and renal tubular acidosis secondary to Entityfoscarnet therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report here a case of EntityTEN after administration of Entityciprofloxacin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : EntityAnaphylactoid reactions have been described previously with Entitycisplatin administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCentral nervous system toxicity associated with Entitymeperidine use in hepatic disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Drug - induced Entityagranulocytosis during treatment with Entityinfliximab in enteropathic spondyloarthropathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One other patient on Entitydigoxin stopped taking it and developed Entitycardiomyopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAdrenaline Entitydacryolith : detection by ultrasound examination of the nasolacrimal duct. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGabapentin toxicity in Entityrenal failure : the importance of dose adjustment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe steroid - induced Entityglaucoma following intravitreal injection of Entitytriamcinolone acetonide . |
| 1.0000 | Adverse-Effect | Severe Entitysteroid - induced Entityglaucoma following intravitreal injection of triamcinolone acetonide. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A short review on Entityimatinib - related Entityhepatotoxicity is also presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInteraction between Entitytacrolimus and nefazodone in a stable renal transplant recipient. |
| 1.0000 | Adverse-Effect | EntityInteraction between tacrolimus and Entitynefazodone in a stable renal transplant recipient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere apnea in an infant exposed to Entitylamotrigine in breast milk. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHalothane Entityhepatitis and prompt resolution with methionine therapy : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The elicitation of a Entitymovement disorder by Entitytrazodone : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPrimary central nervous system lymphoma in a patient treated with Entitynatalizumab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report three cases of Entityamiodarone - induced Entitytorsades de pointe . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prominent Entitypositive U waves appearing with high - dose intravenous Entityphenylephrine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCentral nervous system manifestations of an Entityibuprofen overdose reversed by naloxone. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Development of EntityPeyronie's disease during long - term Entitycolchicine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcne provoked by Entitygold seems not to have been described elsewhere. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe Entitysulfadiazine Entityhypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Sustained - release Entityprocainamide - induced Entityreversible granulocytopenia after myocardial infarction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Carbamyl phosphate synthetase - 1 deficiency discovered after Entityvalproic acid - induced Entitycoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatobiliary disorders associated with orally administered Entityterbinafine have rarely been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Diffusion - weighted MRI correlates of subacute Entitymethotrexate - related Entityneurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityWithdrawal emergent syndrome in an infant associated with maternal Entityhaloperidol therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient suffered a Entitylife - threatening anaphylactoid reaction to Entityamifostine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three senile patients developed Entityfatal acute encephalopathy while receiving Entitycalcium hopantenate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatocellular damage following therapeutic intravenous Entityiron sucrose infusion in a child. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9991 | Adverse-Effect | This paper reports a case of Entityfatal perhexiline maleate liver injury Entityperhexiline maleate liver injury. |
| 0.9991 | Adverse-Effect | This paper reports a case of Entityfatal perhexiline maleate liver injury Entitymaleate liver injury. |
| 0.9981 | Adverse-Effect | This paper reports a case of fatal Entityperhexiline maleate Entityperhexiline maleate liver injury . |
| 0.9980 | Adverse-Effect | This paper reports a case of fatal Entityperhexiline maleate liver injury Entitymaleate liver injury. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Proton MRS examination demonstrated a persistent Entitylactate elevation during Entitymetronidazole treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A typical case of Entitydextran - 40 associated Entityacute renal failure is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMycobacterium marinum infection complicating Crohn's disease, treated with Entityinfliximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CONCLUSION : EntityAcetic acid is corrosive and may cause Entityvagina bleeding . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient who became Entityhypothyroid while taking Entityferrous sulfate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCaptopril - induced Entitylichen planus pemphigoides with pemphigus - like features. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThrombocytosis associated with Entityenoxaparin : A very rare cause in newborns. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypersensitivity reaction following Entitychloramphenicol administration in a patient with typhoid fever. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylactic reaction to Entityrecombinant insulin - like growth factor - I . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two reports of Entityspindle coma are noted with alcohol and Entityimipramine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This therapy was also complicated by EntityWarfarin - induced Entityskin necrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetipranolol associated Entitygranulomatous anterior uveitis : not so uncommon as thought. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Choanal atresia and athelia : Entitymethimazole Entityteratogenicity or a new syndrome? |
| 1.0000 | Adverse-Effect | Choanal atresia and Entityathelia : Entitymethimazole teratogenicity or a new syndrome? |
| 0.9996 | Adverse-Effect | EntityChoanal atresia and athelia : Entitymethimazole teratogenicity or a new syndrome? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Erythropoietin is beneficial in Entitymitomycin - induced Entityhemolytic - uremic syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report four cases of Entitysevere corneal ulceration in Entitymethamphetamine abusers. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPneumocystis carinii pneumonia as a complication of Entitymethotrexate treatment of asthma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClofazimine Entityenteropathy caused by crystal deposition can be life - threatening. |
| 0.9994 | Adverse-Effect | EntityClofazimine enteropathy caused by crystal deposition can be Entitylife - threatening . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterference with the cortisol axis by the microtubule antagonist, EntityCPH82 . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDisulfiram - induced Entityfulminant hepatic failure in an active duty soldier. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | High - dose Entityphosphate treatment leads to Entityhypokalemia in hypophosphatemic osteomalacia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Possible mechanisms for Entitydamage to the urothelium by Entityketamine are suggested. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxicity induced by Entitycyproterone acetate : a report of three cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Caution with use of cimetidine in Entitytolazoline induced Entityupper gastrointestinal bleeding . |
| 0.9998 | Adverse-Effect | Caution with use of Entitycimetidine in tolazoline induced Entityupper gastrointestinal bleeding . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypersensitivity pneumonitis - like syndrome associated with the use of Entitylenalidomide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The medical examiner's report indicated Entitydeath caused by Entityfluoxetine toxicity. |
| 0.9999 | Adverse-Effect | The medical examiner's report indicated death caused by Entityfluoxetine Entityfluoxetine toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | In all the patients, Entitypellagra symptoms appeared during Entityisoniazid therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We hypothesize that Entitycapecitabine - induced Entityheadache is vascular in nature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDesipramine - associated EntitySIADH in an elderly woman : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMitomycin - C induced Entityhemolytic uremic syndrome : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEsophageal candidiasis following Entityomeprazole therapy : a report of two cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The syndrome of irreversible Entitylithium - effectuated Entityneurotoxicity ( SILENT ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thrombotic microangiopathy with Entityrenal failure in two patients undergoing Entitygemcitabine chemotherapy. |
| 0.9999 | Adverse-Effect | EntityThrombotic microangiopathy with renal failure in two patients undergoing Entitygemcitabine chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe heparin associated Entitythrombocytopenia is a rare complication of Entityheparin therapy. |
| 1.0000 | Adverse-Effect | Severe Entityheparin associated Entitythrombocytopenia is a rare complication of heparin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMammary gigantism is a rare complication of EntityD - penicillamine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Zolpidem tissue concentrations in a multiple drug related Entitydeath involving EntityAmbien . |
| Adverse-Effect | EntityZolpidem tissue concentrations in a multiple drug related Entitydeath involving Ambien. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Patient 1 presented Entitybilateral ballism 1 week after intravenous Entityheroin injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It occasionally accompanies the Entityheparin - associated Entitythrombocytopenia and thrombosis syndrome. |
| 0.9999 | Adverse-Effect | It occasionally accompanies the Entityheparin - associated thrombocytopenia and Entitythrombosis syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Selective estrogen receptor modulator Entityraloxifene - associated Entityaggravation of nonalcoholic steatohepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHemolytic uremic syndrome following the infusion of Entityoxaliplatin : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Dose - dependent Entityolanzapine - associated Entityleukopenia : three case reports. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPellagra encephalopathy among tuberculous patients : its relation to Entityisoniazid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of EntityIHA associated with Entitycefuroxime administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The HIV protease inhibitor Entityindinavir may cause Entitynephrolithiasis and interstitial nephritis. |
| 0.9999 | Adverse-Effect | The HIV protease inhibitor Entityindinavir may cause nephrolithiasis and Entityinterstitial nephritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians should be aware that Entityindinavir Entitynephrolithiasis may cause papillary necrosis. |
| 0.9998 | Adverse-Effect | Physicians should be aware that Entityindinavir nephrolithiasis may cause Entitypapillary necrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTenofovir - associated Entitynephrotoxicity in two HIV - infected adolescent males. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityCarbamazepine toxicity following EntityOxybutynin and Dantrolene administration : a case report. |
| 0.9997 | Adverse-Effect | EntityCarbamazepine EntityCarbamazepine toxicity following Oxybutynin and Dantrolene administration : a case report. |
| 0.9972 | Adverse-Effect | EntityCarbamazepine toxicity following Oxybutynin and EntityDantrolene administration : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When Entityco - trimoxazole was stopped the Entityred cell aplasia resolved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGemcitabine - induced Entitypericardial effusion and tamponade after unblocked cardiac irradiation. |
| 0.9999 | Adverse-Effect | EntityGemcitabine - induced pericardial effusion and Entitytamponade after unblocked cardiac irradiation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCytarabine - induced Entitycerebellar syndrome : case report and literature review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGemcitabine - related Entityradiation recall preferentially involves internal tissue and organs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Can roxithromycin and Entitybetamethasone induce Entityacute pancreatitis ? A case report. |
| 0.9999 | Adverse-Effect | Can Entityroxithromycin and betamethasone induce Entityacute pancreatitis ? A case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient who developed Entityacute pancreatitis during Entityamiodarone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes a case of Entitybilateral ptosis induced by Entitychloroquine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySorafenib induced Entitytumor lysis syndrome in an advanced hepatocellular carcinoma patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityToxic optic neuropathy associated with Entityethambutol : implications for current therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityLeukaemoid monocytosis in M4 AML following chemotherapy and EntityG - CSF . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Heparin - dependent antibodies and thrombosis without Entityheparin - induced Entitythrombocytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, an association of EntityRitalin with Entityglaucoma has been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNonconvulsive status epilepticus : the role of Entitymorphine and its antagonist. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with Entitysevere cholestatic jaundice induced by Entitycaptopril is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterstitial pneumonitis associated with Entitysirolimus : a dilemma for lung transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Complete remission of the Entitynephrosis occurred after discontinuation of Entityhydroxychloroquine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGold Entitynephropathy : tissue analysis by X - ray fluorescent spectroscopy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The role of EntityAdriamycin in the production of Entitycardiotoxicity is reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHyponatremia in patients treated with Entitylorcainide , a new antiarrhythmic drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySpontaneous hemothorax following anticoagulation with low - molecular - weight Entityheparin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitypsychotic behavior resolved completely soon after the discontinuation of Entitylevetiracetam . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRetinoic acid may increase the risk of Entitybone marrow transplant nephropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The relationship between Entityinfliximab treatment and Entitylymphoma in Crohn's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Therefore, Entityamantadine was permanently discontinued and the Entitycornea cleared again. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first reported case of Entityhepatolithiasis during Entityoctreotide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The literature search revealed 22 cases of Entityhypersensitivity reaction to Entitycyclosporine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Seizure with Entityhyponatremia in a child prescribed Entitydesmopressin for nocturnal enuresis. |
| 1.0000 | Adverse-Effect | EntitySeizure with hyponatremia in a child prescribed Entitydesmopressin for nocturnal enuresis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Rebound Entityhyperglycemia following overdosing of Entityinsulin in cats with diabetes mellitus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVocal cord paralysis as a consequence of peritonsillar infiltration with Entitybupivacaine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGemcitabine - related Entityradiation recall in a patient with pancreatic cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropylthiouracil - induced Entitysensorineural hearing loss associated with antineutrophil cytoplasmic antibodies. |
| 0.9999 | Adverse-Effect | EntityPropylthiouracil - induced sensorineural hearing loss associated with Entityantineutrophil cytoplasmic antibodies . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxicity associated with use of EntityD - penicillamine in rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMesalamine may cause Entityhypersensitivity pneumonitis in patients with Crohn's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, Entitycyclosporine dependency is associated with the risk of Entitynephrotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCapecitabine - induced Entitymultifocal leukoencephalopathy : a report of five cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the third child, the Entitytics ceased after EntityCBZ discontinuation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Can Entityketamine prescribed for pain cause Entitydamage to the urinary tract ? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There have been only two reports of Entitycimetidine - induced Entityhepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | Lower extremity Entityarterial insufficiency after long - term Entitymethysergide maleate therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityElevated serum triglycerides with Entityclozapine resolved with risperidone in four patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityUlcer became worse after Entitytobramycin and gentamycin treatment for 2 days. |
| 1.0000 | Adverse-Effect | EntityUlcer became worse after tobramycin and Entitygentamycin treatment for 2 days. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In some cases this seems to happen because Entityspironolactone causes Entitydiarrhoea . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Secondary hyperparathyroidism in certain patients with Entitylithium Entitynephrotoxicity is also possible. |
| 0.9999 | Adverse-Effect | EntitySecondary hyperparathyroidism in certain patients with Entitylithium nephrotoxicity is also possible. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There have been several reported cases of Entityomeprazole - induced EntityAIN . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Stroke - like syndrome after Entitygold sodium thiomalate induced Entityvasomotor reaction . |
| 0.9999 | Adverse-Effect | EntityStroke - like syndrome after Entitygold sodium thiomalate induced vasomotor reaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTorsade de pointes represents a potential complication of chronic Entityamiodarone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intraventricular Entityvancomycin - induced Entitycerebrospinal fluid eosinophilia : report of two patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | The Entityampicillin Entityampicillin rash occurring in cases of infectious mononucleosis is well documented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report an unusual pattern of Entitysupravenous hyperpigmentation occurring after EntityCHOP chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHydroxyurea - induced Entityacute interstitial pneumonitis in a patient with essential thrombocythemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGraft versus host - like illness in a child with Entityphenobarbital hypersensitivity. |
| 1.0000 | Adverse-Effect | Graft versus host - like illness in a child with Entityphenobarbital Entityhypersensitivity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Neutropenia and Entityagranulocytosis are risks known to occur with Entityphenothiazines and clozapine. |
| 1.0000 | Adverse-Effect | Neutropenia and Entityagranulocytosis are risks known to occur with phenothiazines and Entityclozapine . |
| 0.9999 | Adverse-Effect | EntityNeutropenia and agranulocytosis are risks known to occur with Entityphenothiazines and clozapine. |
| 0.9998 | Adverse-Effect | EntityNeutropenia and agranulocytosis are risks known to occur with phenothiazines and Entityclozapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMilk - alkali syndrome induced by Entity1, 25 ( OH ) 2D in a patient with hypoparathyroidism. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPregabalin - induced Entitycortical negative myoclonus in a patient with neuropathic pain. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Arthritis and Entitybursitis in multiple sclerosis patients treated with Entityinterferon - beta . |
| 0.9997 | Adverse-Effect | EntityArthritis and bursitis in multiple sclerosis patients treated with Entityinterferon - beta . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 53 - year - old man developed EntityNMS without rigidity while taking Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Accordingly, Entitycamptocormia is a dose - dependent side effect of Entityvalproate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient who experienced EntityLABD shortly after starting Entitycarbamazepine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTiclopidine - induced Entityaplastic anemia ( TIAA ) is considered very uncommon. |
| 1.0000 | Adverse-Effect | EntityTiclopidine - induced aplastic anemia ( EntityTIAA ) is considered very uncommon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDystonia associated with Entitycarbamazepine administration : experience in brain - damaged children. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a patient who developed Entityacute rhabdomyolysis after taking Entitycerivastatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient with systemic lupus erythematosus developed Entityerythema multiforme after taking Entitygriseofulvin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Listeria brain abscess, Pneumocystis pneumonia and EntityKaposi's sarcoma after Entitytemozolomide . |
| 0.9999 | Adverse-Effect | Listeria brain abscess, EntityPneumocystis pneumonia and Kaposi's sarcoma after Entitytemozolomide . |
| 0.9999 | Adverse-Effect | EntityListeria brain abscess , Pneumocystis pneumonia and Kaposi's sarcoma after Entitytemozolomide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In these patients, long - acting Entityoctreotide may trigger Entityserious hypoglycemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAlbuterol - induced Entityhypokalemia and its potential cardiac toxicity are discussed briefly. |
| 0.9997 | Adverse-Effect | EntityAlbuterol - induced hypokalemia and its potential Entitycardiac toxicity are discussed briefly. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityInfectious endophthalmitis is a potential complication of intravitreal Entitybevacizumab injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHeat stroke in schizophrenia during Entityclozapine treatment : rapid recognition and management. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCutaneous reactions to Entitypropylthiouracil and methimazole occur in 3 % - 5 % of adults. |
| 0.9999 | Adverse-Effect | EntityCutaneous reactions to propylthiouracil and Entitymethimazole occur in 3 % - 5 % of adults. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes a probable case of Entityinfliximab - induced Entitymembranous nephropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTemozolomide - induced Entitydesquamative skin rash in a patient with metastatic melanoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This represents the first report of Entitynonconvulsive status epilepticus induced by Entityifosfamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entitysotalol - induced Entitybradycardia reversed by glucagon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEye movement disorders in bone marrow transplant patients on Entitycyclosporin and ganciclovir. |
| 0.9999 | Adverse-Effect | EntityEye movement disorders in bone marrow transplant patients on cyclosporin and Entityganciclovir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityphotosensitivity is still present 3 years after the withdrawal of Entityquinine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The clinical picture was identical to that of chloroquine and Entityhydroxychloroquine Entitymaculopathy . |
| 0.9993 | Adverse-Effect | The clinical picture was identical to that of Entitychloroquine and hydroxychloroquine Entitymaculopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Life - threatening Entityinterstitial lung disease associated with Entitytrastuzumab : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Combining Entitymethylephedrine and Chinese herbal drugs might carry a risk of Entitystroke . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians should be aware of the potentially Entitylethal side effects of Entitydapsone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9987 | Adverse-Effect | The use of pamidronate for hypercalcemia secondary to acute Entityvitamin D Entityvitamin D intoxication . |
| 0.9998 | Adverse-Effect | The use of Entitypamidronate for Entityhypercalcemia secondary to acute vitamin D intoxication. |
| 0.9966 | Adverse-Effect | The use of pamidronate for Entityhypercalcemia secondary to acute Entityvitamin D intoxication. |
| 0.9677 | Adverse-Effect | The use of Entitypamidronate for hypercalcemia secondary to acute Entityvitamin D intoxication . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Both patients suddenly became Entityhypotensive after injection of Entitychymopapain into a disk. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : A case of probable Entityenoxaparin - induced Entityhepatotoxicity is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLithium - associated Entitytransient thyrotoxicosis in 4 Chinese women with autoimmune thyroiditis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The literature search found 12 cases of Entityradiation recall caused by Entitygemcitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients on long - term Entitylithium therapy developed the Entitynephrotic syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFulminant hepatic failure is a rare complication of Entitydisulfiram treatment for alcoholism. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Incidence of Entityseizures in pediatric cancer patients treated with Entityimipenem / cilastatin. |
| 1.0000 | Adverse-Effect | Incidence of Entityseizures in pediatric cancer patients treated with imipenem / Entitycilastatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIncomplete posterior hyaloid detachment after intravitreal Entitypegaptanib injection in diabetic macular edema. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere corneal toxicity after topical Entityfluoroquinolone therapy : report of two cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTardive oculogyric crisis during treatment with Entityclozapine : report of three cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intravenous Entityvalproate associated with significant Entityhypotension in the treatment of status epilepticus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnterior spinal artery syndrome - - a complication of cervical intrathecal Entityphenol injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPericardial hemorrhage due to Entityacetylsalicylic acid in a patient with essential thrombocythemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He developed a late Entitysecondary infection in some sites treated with Entityimiquimod . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To report a case of Entitynodular scleritis following Entityalendronate sodium . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityToxic hepatitis due to combination therapy with Entitymethotrexate and etretinate in psoriasis. |
| 0.9999 | Adverse-Effect | EntityToxic hepatitis due to combination therapy with methotrexate and Entityetretinate in psoriasis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySuccinylcholine - induced Entityhyperkalemia in a patient with mucositis secondary to chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNonsustained polymorphous ventricular tachycardia during Entityamiodarone therapy for atrial fibrillation complicating cardiomyopathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityAmphotericin B overdose can be Entityfatal in children and infants. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityStupor and fast activity on electroencephalography in a child treated with Entityvalproate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeurological side effects in two patients receiving Entitygold injections for rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIncreased libido in a woman treated with Entityfluvoxamine : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Marked Entitysinus tachycardia resulting from the synergistic effects of marijuana and Entitynortriptyline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityexophthalmos improved dramatically within 72 hours of the withdrawal of Entitylithium . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hyperglycemia and Entitydiabetic coma : possible relationship to diuretic - Entitypropranolol therapy. |
| 1.0000 | Adverse-Effect | EntityHyperglycemia and diabetic coma : possible relationship to diuretic - Entitypropranolol therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDisseminated cellulitic cryptococcosis in the setting of Entityprednisone monotherapy for pemphigus vulgaris. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of prolonged Entityterbinafine - induced Entitycholestatic liver disease . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, 1 eye had Entityvitreous hemorrhage after repeated injections of EntitytPA . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityStuttering priapism complicating Entitywarfarin therapy in a patient with protein C deficiency. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Delayed Entitybowel injury is an infrequently observed complication of Entitychromic phosphate administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMalignant mixed mullerian tumor of the uterus in a patient taking Entityraloxifene . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Entity5 - Fluorouracil Entitycardiotoxicity complicating treatment of stage IIB cervical cancer - - case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians should be aware that EntityPLP can occur after initiation of Entitypaclitaxel . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGynaecomastia is a rarely reported adverse drug reaction due to Entityisoniazid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Autopsy findings were consistent with bleomycin and Entityoxygen - induced Entitypulmonary damage . |
| 0.9999 | Adverse-Effect | Autopsy findings were consistent with Entitybleomycin and oxygen - induced Entitypulmonary damage . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPolymyoclonus seizure resulting from accidental injection of Entitytranexamic acid in spinal anesthesia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pediatric Entityheparin - induced Entitythrombocytopenia : management with Danaparoid ( orgaran ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitysustained hypotension after administration of parenteral Entityverapamil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The clinical course suggests that the Entityinterstitial pneumonitis was induced by Entityhydroxyurea . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | 5 - fluorouracil ( Entity5 - FU ) - associated Entityperipheral neuropathy is an uncommon event. |
| 0.9999 | Adverse-Effect | Entity5 - fluorouracil ( 5 - FU ) - associated Entityperipheral neuropathy is an uncommon event. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Abdominal wall ulceration and Entitymucinosis secondary to Entityrecombinant human interferon - beta - 1b . |
| 0.9992 | Adverse-Effect | EntityAbdominal wall ulceration and mucinosis secondary to Entityrecombinant human interferon - beta - 1b . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityToxic epidermal necrolysis after the use of high - dose Entitycytosine arabinoside . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySymptomatic hypoglycemia secondary to a Entityglipizide - trimethoprim / sulfamethoxazole drug interaction. |
| 0.9998 | Adverse-Effect | EntitySymptomatic hypoglycemia secondary to a glipizide - Entitytrimethoprim / sulfamethoxazole drug interaction. |
| 0.9998 | Adverse-Effect | EntitySymptomatic hypoglycemia secondary to a glipizide - trimethoprim / Entitysulfamethoxazole drug interaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAngio - oedema as an unusual tolerable side effect of Entityvoriconazole therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Life - threatening Entityacute hyponatraemia induced by low dose Entitycyclophosphamide and indomethacin. |
| 0.9999 | Adverse-Effect | Life - threatening Entityacute hyponatraemia induced by low dose cyclophosphamide and Entityindomethacin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report five additional cases of Entitycapecitabine - induced Entitymultifocal leukoencephalopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityChlormadinone acetate Entitywithdrawal syndrome under combined androgen blockade for advanced prostate cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary fibrosis subsequent to high doses of EntityCCNU for chronic myeloid leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three distinct types of Entityminocycline - induced Entitycutaneous pigmentation have been described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDocetaxel - induced EntityMeibomian duct inflammation and blockage leading to chalazion formation. |
| 0.9999 | Adverse-Effect | EntityDocetaxel - induced Meibomian duct inflammation and blockage leading to Entitychalazion formation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmikacin - induced Entitytype 5 Bartter - like syndrome with severe hypocalcemia. |
| 0.9999 | Adverse-Effect | EntityAmikacin - induced type 5 Bartter - like syndrome with Entitysevere hypocalcemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal outcome of intravesical Entityformalin instillation, with changes mimicking renal tuberculosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The use of Entityrituximab has been uncommonly associated with Entitydelayed pulmonary toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeuroleptic malignant syndrome in an adolescent receiving Entityolanzapine - lithium combination therapy. |
| 0.9999 | Adverse-Effect | EntityNeuroleptic malignant syndrome in an adolescent receiving olanzapine - Entitylithium combination therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Therapy with Entityindapamide may induce Entitydiabetes in essential hypertension patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAdriamycin - induced Entitycardiomyopathy aggravated by cis - platinum nephrotoxicity requiring dialysis. |
| Adverse-Effect | Adriamycin - induced cardiomyopathy aggravated by Entitycis - platinum Entitynephrotoxicity requiring dialysis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReversible MR imaging and MR spectroscopy abnormalities in association with Entitymetronidazole therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityCefazolin was a probable cause of this patient's Entityleukopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Evaluation revealed Entityelevated serum LTG levels EntityLTG levels and no other etiology for encephalopathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three diabetic cases of Entityacute dizziness due to initial administration of Entityvoglibose . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hemodialysis should be performed for rapid reversal of Entitymannitol - induced EntityARF . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 54 - year - old man, treated with Entityamiodarone , developed Entitythyrotoxicosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityMetoclopramide may cause reversible Entitynonthrombocytopenic vascular - type palpable purpura . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | EntityFatal pulmonary fibrosis following 1, 3 - bis ( 2 - chloroethyl ) - 1 - nitrosourea ( EntityBCNU ) therapy. |
| Adverse-Effect | EntityFatal pulmonary fibrosis following Entity1, 3 - bis ( 2 - chloroethyl ) - 1 - nitrosourea ( BCNU ) therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report presents a potential case of Entityrisperidone - induced Entitytardive dyskinesia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entityangioedema associated with Entitylosartan administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient developed Entityoptic neuropathy while being treated with Entityisoniazid and ethambutol. |
| 1.0000 | Adverse-Effect | A patient developed Entityoptic neuropathy while being treated with isoniazid and Entityethambutol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPeripheral nervous system disturbances caused by Entitycytosine arabinoside have rarely been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These cases demonstrate that EntityCBZ can induce simple Entitymotor tics in children. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : EntityAnterior ischemic optic neuropathy may complicate treatment with Entityinterferon alfa . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOptic neuropathy associated with Entitypenicillamine therapy in a patient with rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDiffuse alveolar hemorrhage after Entityleflunomide therapy in a patient with rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first reported case of suspected EntityDIAN due to Entitycefuroxime . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityGeneralized lichen nitidus with involvement of the palms following Entityinterferon alpha treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHigh - grade endometrial stromal sarcoma after Entitytamoxifen therapy for breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Correction of serum electrolyte imbalance prevents Entitycardiac arrhythmia during Entityamphotericin B administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOphthalmologic and neurologic findings in two children exposed to Entityvigabatrin in utero. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The exact mechanism of EntityIVIG - associated Entityacute renal failure remains unclear. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Due to the severity of the Entityrash , Entitytemozolomide was permanently discontinued. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Possible interaction between lopinavir / ritonavir and Entityvalproic Acid exacerbates Entitybipolar disorder . |
| 0.9999 | Adverse-Effect | Possible interaction between Entitylopinavir / ritonavir and valproic Acid exacerbates Entitybipolar disorder . |
| 0.9999 | Adverse-Effect | Possible interaction between lopinavir / Entityritonavir and valproic Acid exacerbates Entitybipolar disorder . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Retinal dysfunction and Entityanterior segment deposits in a patient treated with Entityrifabutin . |
| 1.0000 | Adverse-Effect | EntityRetinal dysfunction and anterior segment deposits in a patient treated with Entityrifabutin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of EntityEGE manifested as an allergy to Entitygemfibrozil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Myasthenic patients receiving Entityampicillin should be closely monitored for possible Entityacute exacerbations . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHyperpigmentation during Entityinterferon - alpha therapy for chronic hepatitis C virus infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Primary cutaneous coccidioidomycosis and subsequent Entitydrug eruption to Entityitraconazole in a dog. |
| 0.9999 | Adverse-Effect | EntityPrimary cutaneous coccidioidomycosis and subsequent drug eruption to Entityitraconazole in a dog. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOtotoxicity as a result of Entitycis - platinum administration is well documented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of pediatric Entitybupropion ingestion resulting in Entitymultiple seizures . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityNephrotic syndrome in a multiple sclerosis patient treated with Entityinterferon beta 1a . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmifostine - induced Entityfever : case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal intravascular autoimmune hemolytic anemia after Entityfludarabine treatment for chronic lymphocytic leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report three cases of patients who developed Entityleukopenia during Entityolanzapine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He became Entityhyperkalemic on rechallenge with Entitytimolol and normokalemic following its withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySerious adverse events experienced by patients with chronic heart failure taking Entityspironolactone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAminoglutethimide was discontinued until completion of radiotherapy, and the Entityrash resolved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLeflunomide - induced Entitytoxic epidermal necrolysis in a patient with rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Abnormalities of the pupil and visual - evoked potential in Entityquinine Entityamblyopia . |
| 0.9999 | Adverse-Effect | EntityAbnormalities of the pupil and visual - evoked potential in Entityquinine amblyopia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute myocardial ischemia following accidental intravenous administration of Entityepinephrine in high concentration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepato - biliary abnormalities secondary to Entityceftriaxone use : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetabolic acidosis induced by Entitycetrimide - chlorhexidine solution in hydatid cyst surgery. |
| 0.9997 | Adverse-Effect | EntityMetabolic acidosis induced by cetrimide - Entitychlorhexidine solution in hydatid cyst surgery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityBone formation induced in an infant by systemic Entityprostaglandin - E2 administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInfliximab - induced Entitylupus in Crohn's disease : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProtamine allergy as a complication of Entityinsulin hypersensitivity : A case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Additionally, Entitydanazol produces Entityhepatocellular damage in approximately 10 % of women. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThymic enlargement in a patient with juvenile idiopathic arthritis during Entityetanercept therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEsophageal candidiasis was diagnosed at endoscopy in two patients receiving Entityomeprazole therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Symptoms and Entityendoscopic lesions quickly regressed within 1 week of Entitymeloxicam withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 61 year - old male patient developed Entitygynecomastia after starting Entitytheophylline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Papilloedema and Entityhepatic dysfunction apparently induced by Entityperhexiline maleate ( Pexid ). |
| 0.9997 | Adverse-Effect | EntityPapilloedema and hepatic dysfunction apparently induced by Entityperhexiline maleate ( Pexid ). |
| 0.9997 | Adverse-Effect | Papilloedema and Entityhepatic dysfunction apparently induced by perhexiline maleate ( EntityPexid ). |
| 0.9995 | Adverse-Effect | EntityPapilloedema and hepatic dysfunction apparently induced by perhexiline maleate ( EntityPexid ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Managing Entitycardiovascular collapse in severe Entityflecainide overdose without recourse to extracorporeal therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These Entitynail changes gradually disappeared when the dose of Entityclofazimine was reduced. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReflex sympathetic dystrophy syndrome in renal transplanted patients under immunosuppression with Entitytacrolimus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Severe and Entitysustained ocular hypertension may occur after intravitreal Entityranibizumab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOxcarbazepine - induced Drug Reaction with Eosinophilia and Systemic Symptoms ( EntityDRESS ). |
| 1.0000 | Adverse-Effect | EntityOxcarbazepine - induced EntityDrug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ). |
| Adverse-Effect | EntityOxcarbazepine - induced EntityDrug Reaction with Eosinophilia and Systemic Symptoms ( DRESS ). | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySerotonin syndrome induced by transitioning from Entityphenelzine to venlafaxine : four patient reports. |
| 1.0000 | Adverse-Effect | EntitySerotonin syndrome induced by transitioning from phenelzine to Entityvenlafaxine : four patient reports. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRadiation recall related to Entitygemcitabine has been reported in lung and breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHeparin - induced Entitythrombocytopenia is a rare and serious complication of anticoagulation therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient developed papilloedema and Entityhepatic dysfunction while being treated with Entityperhexiline maleate . |
| 0.9997 | Adverse-Effect | A patient developed Entitypapilloedema and hepatic dysfunction while being treated with Entityperhexiline maleate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRestless legs syndrome may thus be an adverse effect of EntityIFN alpha treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The responsibility of EntityCCNU in the pathogenesis of Entitypulmonary fibrosis seems very likely. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Indolent Entityaspergillus arthritis complicating Entityfludarabine - based non - myeloablative stem cell transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report suggests that Entitybleomycin Entitylung toxicity may be reversible if treated aggressively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three days after intravitreal injection of Entitybevacizumab , Entityacute ocular ischemic syndrome occurred. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To report two cases of Entityacute endophthalmitis following intravitreal Entitybevacizumab injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityAmphotericin B seems to be the probable cause of the Entityseizures . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute myocardial infarction due to Entitycoronary spasm associated with EntityL - thyroxine therapy. |
| 0.9983 | Adverse-Effect | EntityAcute myocardial infarction due to coronary spasm associated with EntityL - thyroxine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxicity of Entityparacetamol enhanced by ingestion of alcohol : report of two cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Early Entityoveranticoagulation with Entityacenocoumarol due to a genetic polymorphism of cytochrome P450 CYP2C9. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute pancreatitis is a known, although rare, complication of Entitymesalamine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : The occurrence of Entitypriapism in our patient was related to Entityzuclopenthixol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9986 | Adverse-Effect | Neurointensive care management of Entityraised intracranial pressure caused by severe Entityvalproic acid intoxication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitynormotensive scleroderma renal crisis after high - dose Entitymethylprednisolone treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRhabdomyolysis has been recognized as a complication of tocolytic therapy with Entityritodrine hydrochloride . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIbuprofen - induced Entitymeningitis : detection of intrathecal IgG synthesis and immune complexes. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Transtentorial herniation caused by an Entityintracranial mass lesion following high - dose Entitymethotrexate . |
| 0.9999 | Adverse-Effect | EntityTranstentorial herniation caused by an intracranial mass lesion following high - dose Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeuroleptic malignant syndrome due to Entityrisperidone treatment in a child with Joubert syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntitySkin necrosis after extravasation of low - dose Entityvasopressin administered for septic shock. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Histological examination of the Entitydacryolith suggested its derivation from breakdown products of Entityadrenaline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9994 | Adverse-Effect | Itraconazole - related increased Entityvincristine Entityneurotoxicity : case report and review of literature. |
| 0.9821 | Adverse-Effect | EntityItraconazole - related increased vincristine Entityneurotoxicity : case report and review of literature. |
| Adverse-Effect | EntityItraconazole - related increased Entityvincristine neurotoxicity : case report and review of literature. | |
| Adverse-Effect | Itraconazole - related increased Entityvincristine Entityvincristine neurotoxicity : case report and review of literature. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPara - aminosalicylic acid - induced Entityhypoglycaemia in a patient with diabetic nephropathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prolonged severe Entity5 - fluorouracil - associated Entityneurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : reports on Entitydelated cutaneous reactions to Entitycaptopril have been seldom reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe leukopenia associated with Entitymild hepatotoxicity in an HIV carrier treated with Entitynevirapine . |
| 0.9999 | Adverse-Effect | EntitySevere leukopenia associated with mild hepatotoxicity in an HIV carrier treated with Entitynevirapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Adverse reaction in a patient with Entityaspirin - induced Entityasthma treated with zafirlukast. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal complication of intravesical Entityformalin during control of intractable hemorrhage from radiation cystitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCerebral infarcts in a pediatric patient secondary to Entityphenylpropanolamine , a recalled medication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 45 - year - old woman with thyrotoxicosis developed Entityagranulocytosis after treatment with Entitypropylthiouracil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal interstitial lung disease after Entityerlotinib administration in a patient with radiation fibrosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute renal failure following intravenous Entityimmunoglobulin therapy in a HIV - infected patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Restless legs syndrome and Entityperiodic limb movements during sleep probably associated with Entityolanzapine . |
| 1.0000 | Adverse-Effect | EntityRestless legs syndrome and periodic limb movements during sleep probably associated with Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPancytopenia associated with Entity5 - aminosalicylic acid use in a patient with Crohn's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report the first case of Entitybucillamine - induced Entitygiant mammary hyperplasia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute myeloid leukemia evolving from essential thrombocythemia in two patients treated with Entityhydroxyurea . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There is no consensus on the treatment of Entityticlopidine - induced Entitymarrow aplasia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRisperidone - induced Entitypsychosis and depression in a child with a mitochondrial disorder. |
| 0.9999 | Adverse-Effect | EntityRisperidone - induced psychosis and Entitydepression in a child with a mitochondrial disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityStevens - Johnson syndrome in a boy with nephrotic syndrome during Entityprednisolone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcyclovir - induced Entityneurotoxicity : concentration - side effect relationship in acyclovir overdose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : EntityAlendronate led to Entitynodular scleritis and rechallenge caused recurrence of scleritis. |
| 0.9999 | Adverse-Effect | CONCLUSION : EntityAlendronate led to nodular scleritis and rechallenge caused recurrence of Entityscleritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDeposits of plasma proteins in the skin during treatment with Entitycarbamazepine and diphenylhydantoin. |
| 1.0000 | Adverse-Effect | EntityDeposits of plasma proteins in the skin during treatment with carbamazepine and Entitydiphenylhydantoin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityL - asparaginase - provoked Entityseizures as singular expression of central nervous toxicity. |
| 0.9984 | Adverse-Effect | EntityL - asparaginase - provoked seizures as singular expression of Entitycentral nervous toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Provocation of Entitynon - convulsive status epilepticus by Entitytiagabine in three adolescent patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nineteen cases of Entityallergic contact dermatitis to compound tincture of Entitybenzoin are described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case extends the spectrum of Entityfludarabine Entitypulmonary toxicity to include pulmonary nodules. |
| 0.9998 | Adverse-Effect | This case extends the spectrum of Entityfludarabine pulmonary toxicity to include Entitypulmonary nodules . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityoculogyric crisis induced by Entitymetoclopramide is described in this paper. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClostridium difficile toxin - induced colitis after use of Entityclindamycin phosphate vaginal cream. |
| 1.0000 | Adverse-Effect | Clostridium difficile toxin - induced Entitycolitis after use of Entityclindamycin phosphate vaginal cream. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARIES : Two patients who received Entityifosfamide - containing chemotherapy developed EntityNCSE . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors describe a case of the Entitycatatonia syndrome associated with Entitydisulfiram therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | EntityProlonged prostate - specific antigen response in Entityflutamide withdrawal syndrome despite disease progression. |
| Adverse-Effect | Prolonged prostate - specific antigen response in Entityflutamide Entityflutamide withdrawal syndrome despite disease progression. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnticonvulsant hypersensitivity syndrome associated with EntityBellamine S , a therapy for menopausal symptoms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two weeks following rechallenge with Entityalendronate sodium resulted in recurrence of his Entityscleritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient developed Entitylarge intramural esophageal hematoma as a complication of Entityheparin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | The patient was diagnosed with Entitycarbamazepine toxicity related to the introduction of Entityritonavir . |
| 0.9997 | Adverse-Effect | The patient was diagnosed with Entitycarbamazepine Entitycarbamazepine toxicity related to the introduction of ritonavir. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityL - asparaginase - induced Entitysevere necrotizing pancreatitis successfully treated with percutaneous drainage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of a Entitysustained monomorphic ventricular tachycardia following Entityadenosine infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTremor : a newly described adverse event with long - term Entityitraconazole therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 2 patients who developed Entitypolyarteritis nodosa following Entityvaccination against hepatitis B . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three patients receiving Entitygold salt treatment for rheumatoid arthritis developed severe Entityaplastic anemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHemorrhage from a falx meningioma after internal use of low - dose Entityaspirin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTemozolomide was restarted 2 months later ; the patient again developed a Entityfever . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal injury due to Entityanastrozole has not been published in the English literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Mechanism of Entitytopiramate - induced Entityacute - onset myopia and angle closure glaucoma. |
| 0.9999 | Adverse-Effect | Mechanism of Entitytopiramate - induced acute - onset myopia and Entityangle closure glaucoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There is a putative role of Entityliothyronine administration in precipitating or activating Entityhyperthyroidism . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She was treated with Entityacyclovir and subsequently developed EntityVZV antigen - positive zoster . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClostridium difficile colitis associated with Entitycisplatin - based chemotherapy in ovarian cancer patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Polysomnographic and pharmacokinetic findings in Entitylevodopa - induced augmentation of Entityrestless legs syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPemphigus foliaceus was seen in a patient with pulmonary tuberculosis during Entityrifampicin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Intrathecal Entitybaclofen can Entityimpair sexual function and ejaculation in some patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute Entityrenal failure should be recognized as a potential complication of Entitysuramin treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | Lower extremity Entityarterial thrombosis following sonographically guided Entitythrombin injection of a femoral pseudoaneurysm. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEEG abnormalities were observed in two of the nine children during Entitychlorambucil therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySchneiderian first - rank symptoms associated with Entityfluvoxamine treatment : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Progression of chronic myeloid leukemia to Entityblast crisis during treatment with Entityimatinib mesylate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylaxis from Entityisoniazid is a possible side effect to this commonly prescribed antibiotic. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and Entity5 - FU - induced Entityectropion . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitybaclofen Entitywithdrawal syndrome resulting from oral baclofen underdosing. |
| 0.9999 | Adverse-Effect | We report a case of baclofen Entitywithdrawal syndrome resulting from oral Entitybaclofen underdosing. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReversible posterior leukoencephalopathy syndrome in systemic lupus erythematosus with thrombocytopenia treated with Entitycyclosporine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A MEDLINE search identified all the reported cases of Entityhypersensitivity reactions to Entitycyclosporine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The mechanism of EntityRTA induced by EntityFK506 has not yet been clearly elucidated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethysergide - induced Entityretroperitoneal fibrosis : successful outcome and two new laboratory features. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two renal transplant patients developed Entityanemia during treatment of hypertension with Entityenalapril medication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus, the Entityeosinophilia myalgia syndrome can be associated with parenteral Entitytryptophan administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | When measured, the Entityserum lithium level had increased 4 - fold during Entityacyclovir therapy. | |
| Adverse-Effect | When measured, the Entityserum lithium level had increased Entitylithium level had increased 4 - fold during acyclovir therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitypapillary necrosis in a patient treated with Entityindinavir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFluoxetine - related Entitydeath in a child with cytochrome P - 450 2D6 genetic deficiency. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVisual loss after a single small dose of Entityvincristine has never been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLaryngeal dyspnea in relation to an interaction between Entityacenocoumarol and topical econazole lotion. |
| 0.9999 | Adverse-Effect | EntityLaryngeal dyspnea in relation to an interaction between acenocoumarol and topical Entityeconazole lotion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To report that acute Entitylamotrigine poisoning may result in severe Entityencephalopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Extensive Entitysquamous metaplasia was found in endometrial glands following Entityprogestin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | They continued to rise for five more days before Entitysalicylate Entityhepatotoxicity was suspected. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a patient with Entityifosfamide - induced Entitynonconvulsive status epilepticus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After four months, while receiving EntityRH , he developed painful Entitybilateral gynaecomastia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Five cases of Entityclindamycin - associated Entitypseudomembranous colitis in leukaemic patients are reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTrimethoprim - sulfamethoxazole - induced Entityhypersensitivity syndrome associated with reactivation of human herpesvirus - 6. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, several case reports have suggested that Entityclozapine could also cause EntityTD . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAtrial fibrillation occurring in a patient taking Entityetanercept plus methotrexate for rheumatoid arthritis. |
| 0.9999 | Adverse-Effect | EntityAtrial fibrillation occurring in a patient taking etanercept plus Entitymethotrexate for rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : All cases developed Entitycorneal endothelial deposits after previous use of Entityrifabutin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of EntityRTA secondary to EntityFK506 administration in liver transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An adverse reaction to EntityIFN was strongly suspected as the cause of EntityCHF . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Both PAN and Entitymethotrexate have been independently demonstrated to cause Entitysensorineural hearing loss . |
| 0.9999 | Adverse-Effect | Both EntityPAN and methotrexate have been independently demonstrated to cause Entitysensorineural hearing loss . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityAnastrozole may be the causative factor in patients with Entitysclerosing glomerulonephritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThrombotic thrombocytopenic purpura induced by Entitytrimethoprim - sulfamethoxazole in a Jehovah's Witness. |
| 0.9996 | Adverse-Effect | EntityThrombotic thrombocytopenic purpura induced by trimethoprim - Entitysulfamethoxazole in a Jehovah's Witness. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySubacute cholestatic hepatitis likely related to the use of Entitysenna for chronic constipation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute myocardial infarction during high - dose Entitymethylprednisolone therapy for Graves'ophthalmopathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Only 3 cases of Entityimatinib - induced Entitytumor lysis syndrome have been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCiprofloxacin - induced Entitytoxic epidermal necrolysis in a patient with systemic lupus erythematosus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report two cases of Entityfixed drug eruption induced by Entitymethylphenidate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Concomitant administration of lithium with Entityolanzapine may place patients at risk for EntityNMS . |
| 0.9999 | Adverse-Effect | Concomitant administration of Entitylithium with olanzapine may place patients at risk for EntityNMS . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : Three patients with apparent Entityitraconazole - induced Entityliver injury were studied. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinical profile of Entityoxcarbazepine - related Entityangioneurotic edema : case report and review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our series of 3 patients supports a causal connection between Entitybleomycin and Entityscleroderma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is concluded that EntitySIADH is an important side effect of Entitylorcainide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Treatment - related Entitymyelodysplastic syndrome after Entitytemozolomide for recurrent high - grade glioma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySustained hypothyroidism induced by Entityrecombinant alpha interferon in patients with chronic hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLeukopenia due to parvovirus B19 in a Crohn's disease patient using Entityazathioprine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Bleomycin and Entitycyclophosphamide toxicity simulating Entitymetastatic nodules to the lungs in childhood cancer. |
| 0.9998 | Adverse-Effect | EntityBleomycin and cyclophosphamide toxicity simulating Entitymetastatic nodules to the lungs in childhood cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVerapamil in effort - induced Entityangina pectoris in patients with normal coronary arteries. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report of EntityUFT - induced Entityscleroderma - like reaction . |
| Adverse-Effect | This is the first report of EntityUFT EntityUFT - induced scleroderma - like reaction . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySelf - limited edema is a well - recognized complication of Entityinsulin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCeliac disease onset after Entitypegylated interferon and ribavirin treatment of chronic hepatitis C. |
| 0.9999 | Adverse-Effect | EntityCeliac disease onset after pegylated interferon and Entityribavirin treatment of chronic hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySexual dysfunction associated with intrathecal Entitybaclofen use : a report of two cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityScleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on Entityinterferon beta - 1a . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The cases of EntityCBZ - induced EntitySLE reported in the literature were reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Treatment of Entitycarbimazole - induced Entityagranulocytosis and sepsis with granulocyte colony stimulating factor. |
| 1.0000 | Adverse-Effect | Treatment of Entitycarbimazole - induced agranulocytosis and Entitysepsis with granulocyte colony stimulating factor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Early peritoneal dialysis has not previously been reported for Entitylisinopril induced Entitymultiorgan failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCyclosporine - induced Entitypain syndrome in a child undergoing hematopoietic stem cell transplant. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBaclofen withdrawal : a cause of prolonged Entityfever in the intensive care unit. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGeneralised cutaneous rash associated with Entityganciclovir therapy has rarely been reported in literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityValproate Entityembryopathy in three sets of siblings : further proof of hereditary susceptibility. |
| Adverse-Effect | EntityValproate EntityValproate embryopathy in three sets of siblings : further proof of hereditary susceptibility. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Granulocytopenia and Entityagranulocytosis are considered among the most dangerous adverse effects of Entityclozapine . |
| 1.0000 | Adverse-Effect | EntityGranulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of Entityclozapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The observations suggest that testicular swelling and Entitypain are side effects of Entitydesipramine . |
| 1.0000 | Adverse-Effect | The observations suggest that Entitytesticular swelling and pain are side effects of Entitydesipramine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeurologic degeneration associated with Entitynitrous oxide anesthesia in patients with vitamin B12 deficiency. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report of a Entitydisulfiram - like reaction with Entitycefmenoxime . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : We report two cases of Entitypseudoporphyria caused by Entitynaproxen and oxaprozin. |
| 1.0000 | Adverse-Effect | METHODS : We report two cases of Entitypseudoporphyria caused by naproxen and Entityoxaprozin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitycontact dermatitis due to Entitysodium bisulfite in an ophthalmic solution. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report 2 cases of Entityrenal damage associated with Entitylithium carbonate treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Cutaneous rashes and Entityeruptions can be caused by many medications, including Entitycarbamazepine . |
| 1.0000 | Adverse-Effect | EntityCutaneous rashes and eruptions can be caused by many medications, including Entitycarbamazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute generalized exanthematous pustulosis induced by Entitysalazosulfapyridine in a patient with ulcerative colitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Possible linkage of Entityamprenavir with Entityintracranial bleeding in an HIV - infected hemophiliac. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTamoxifen is suggested to be Entitycarcinogenic both through direct genotoxic and epigenetic mechanisms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clearance rates of cerivastatin metabolites in a patient with Entitycerivastatin - induced Entityrhabdomyolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two cases of Entitysirolimus - associated Entitypneumonitis have been reported after cardiac transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Seizures and Entitytransient blindness following intravenous pulse Entitymethylprednisolone in children with primary glomerulonephritis. |
| 1.0000 | Adverse-Effect | EntitySeizures and transient blindness following intravenous pulse Entitymethylprednisolone in children with primary glomerulonephritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We conclude that MB is an effective treatment for Entityifosfamide - induced Entityencephalopathy . |
| Adverse-Effect | We conclude that MB is an effective treatment for Entityifosfamide Entityifosfamide - induced encephalopathy . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Possible Entityheart failure exacerbation associated with Entityrosiglitazone : case report and literature review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute interstitial pneumonia induced by EntityONO - 1078 ( pranlukast ), a leukotriene receptor antagonist. |
| 0.9999 | Adverse-Effect | EntityAcute interstitial pneumonia induced by ONO - 1078 ( Entitypranlukast ), a leukotriene receptor antagonist. |
| Adverse-Effect | Acute Entityinterstitial pneumonia induced by EntityONO - 1078 ( pranlukast ), a leukotriene receptor antagonist. | |
| Adverse-Effect | Acute Entityinterstitial pneumonia induced by ONO - 1078 ( Entitypranlukast ), a leukotriene receptor antagonist. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 48 - year - old woman who was treated for thyrotoxicosis with Entitymethimazole developed Entityagranulocytosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Rapid resolution of topiramate - induced Entityangle - closure glaucoma with Entitymethylprednisolone and mannitol. |
| 1.0000 | Adverse-Effect | Rapid resolution of Entitytopiramate - induced Entityangle - closure glaucoma with methylprednisolone and mannitol. |
| 0.9998 | Adverse-Effect | Rapid resolution of topiramate - induced Entityangle - closure glaucoma with methylprednisolone and Entitymannitol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityRetinopathy in hepatitis C patients due to combination therapy with Entitypegylated interferon and ribavirin. |
| 0.9998 | Adverse-Effect | EntityRetinopathy in hepatitis C patients due to combination therapy with pegylated interferon and Entityribavirin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, EntityEO - induced Entitynoncardiogenic pulmonary edema has not been reported in human. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case is reported of a child with Entityfatal pulmonary fibrosis following EntityBCNU therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal interstitial pneumonitis following high - dose intermittent Entitychlorambucil therapy for chronic lymphocyte leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylactic reaction to oral Entityprednisone : a case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The following is a report of 2 cases of Entityrifampicin - induced Entityrenal insufficiency . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | High - dose Entitymethotrexate - associated Entityacute renal failure may be an avoidable complication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityFixed drug rash induced by Entitymethylphenidate is a possible but rare phenomenon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here, we report a case of Entityangio - oedema associated with EntityVRC therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate - induced Entityhepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityScleroderma in association with the use of Entitybleomycin : a report of 3 cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Voriconazole ( EntityVRC ) has not previously been reported to cause Entityangio - oedema . |
| 0.9999 | Adverse-Effect | EntityVoriconazole ( VRC ) has not previously been reported to cause Entityangio - oedema . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Five days after the fourth dose of Entityvincristine , she presented with Entitybilateral ptosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, repeated intracameral EntitytPA injections may cause unwanted complications such as Entityvitreous hemorrhage . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Oral Entity25 - hydroxyvitain D3 in treatment of osteomalacia associated with Entityileal resection and cholestyramine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySideroblastic anemia due to Entitylinezolid in a patient with a left ventricular assist device. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIdiosyncratic pulmonary reactions to Entitynitrofurantoin are not unusual, often presenting as eosinophilic pneumonia. |
| 1.0000 | Adverse-Effect | Idiosyncratic pulmonary reactions to Entitynitrofurantoin are not unusual, often presenting as Entityeosinophilic pneumonia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatotoxicity resolved once Entityerlotinib was discontinued and serum transaminases returned to baseline normal values. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with acute changes suggesting Entityacute hepatitis after parenteral Entityamiodarone administration is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCardiomyopathy after widely separated courses of Entityadriamycin exacerbated by actinomycin - D and mithramycin. |
| 0.9984 | Adverse-Effect | EntityCardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin - D and Entitymithramycin . |
| 0.9980 | Adverse-Effect | EntityCardiomyopathy after widely separated courses of adriamycin exacerbated by Entityactinomycin - D and mithramycin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Because Entitynephrotic syndrome may be induced by EntityIFN therapy, the IFN was stopped. |
| 0.9963 | Adverse-Effect | Because Entitynephrotic syndrome may be induced by IFN therapy, the EntityIFN was stopped. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDecreased plasma cortisol level during Entityalprazolam treatment of panic disorder : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Neurological improvement and rehabilitation potential following Entitytoxic myelopathy due to intrathecal injection of Entitydoxorubicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPersistent hypoglycemia in a patient with diabetes taking Entityetanercept for the treatment of psoriasis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.6311 | Adverse-Effect | An unusual cause of Entityburn injury : unsupervised use of drugs that contain Entitypsoralens . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intravenous Entityhaloperidol is generally well tolerated, but Entitymultiform ventricular tachycardia has been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When EntityDSCG was withdrawn, Entityurticaria vanished and the child remained symptom - free. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGrowth and adrenal suppression in asthmatic children treated with high - dose Entityfluticasone propionate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Development of EntityCrohn's disease in a patient with multiple sclerosis treated with Entitycopaxone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A young woman developed Entitygalactorrhea during treatment with a new Entitydibenzoxazepine antidepressant, amoxapine. |
| 0.9999 | Adverse-Effect | A young woman developed Entitygalactorrhea during treatment with a new dibenzoxazepine antidepressant, Entityamoxapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Central pontine myelinolysis manifested by Entitytemporary blindness : a possible complication of Entitylithium toxicity. |
| Adverse-Effect | EntityCentral pontine myelinolysis manifested by temporary blindness : a possible complication of Entitylithium toxicity. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Skin manifestations of a case of Entityphenylbutazone - induced Entityserum sickness - like reactions . |
| 0.9999 | Adverse-Effect | EntitySkin manifestations of a case of Entityphenylbutazone - induced serum sickness - like reactions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCardiac arrest after Entityesmolol administration : a review of acute beta - blocker toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitynephrotic syndrome developed in a patient receiving therapy with Entitygold for rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVitiligo associated with Entityalpha - interferon in a patient with chronic active hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAll - trans retinoic acid - induced Entityfocal myositis , synovitis, and mononeuritis. |
| 0.9995 | Adverse-Effect | EntityAll - trans retinoic acid - induced focal myositis, Entitysynovitis , and mononeuritis. |
| 0.9993 | Adverse-Effect | EntityAll - trans retinoic acid - induced focal myositis, synovitis, and Entitymononeuritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | Subcutaneous EntityIL - 2 is safe and well tolerated, with a Entitymortality rate < 3 %. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of EntityIDDM which occurred during Entityinterferon therapy for chronic hepatitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere autoimmune hemolytic anemia following Entityrituximab therapy in a patient with a lymphoproliferative disorder. |
| Adverse-Effect | Severe Entityautoimmune hemolytic anemia following Entityrituximab therapy in a patient with a lymphoproliferative disorder. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CCBs should be considered in the treatment of 5 - FU or Entitycapecitabine - induced Entityheadaches . |
| 0.9999 | Adverse-Effect | CCBs should be considered in the treatment of Entity5 - FU or capecitabine - induced Entityheadaches . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She developed a Entitysevere urticarial rash 3 weeks following initiation of therapy with EntityEnoxaparin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three months after starting Entitycitalopram , she experienced episodes of Entitychest tightness and dizziness. |
| 1.0000 | Adverse-Effect | Three months after starting Entitycitalopram , she experienced episodes of chest tightness and Entitydizziness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterstitial pneumonia probably associated with Entitysorafenib treatment : An alert of an adverse event. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Detection of activated eosinophils in nasal polyps of an Entityaspirin - induced Entityasthma patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityToxic epidermal necrolysis resulted after 19 days of treatment with Entity5 - fluorocytosine and amphotericin B. |
| 0.9998 | Adverse-Effect | EntityToxic epidermal necrolysis resulted after 19 days of treatment with 5 - fluorocytosine and Entityamphotericin B . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitysevere aplastic anemia secondary to treatment with Entitylenalidomide for multiple myeloma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatic angiosarcoma occurring after Entitycyclophosphamide therapy : case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report three cases of Entitysevere hepatotoxicity related to Entitybenzarone , a benzofuran derivative. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two infants developed Entityhyperkalemia shortly after cessation of prolonged EntityACTH therapy for infantile spasms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, acute cardiomyopathy and Entitypericarditis secondary to Entitymethylphenidate use has been rarely reported. |
| 0.9999 | Adverse-Effect | However, Entityacute cardiomyopathy and pericarditis secondary to Entitymethylphenidate use has been rarely reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We now present four cases of EntityRSDS in kidney transplant recipients treated with Entitytacrolimus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This sulfonamide like nephropathy should be differentiated from Entityacetazolamide - related Entitycalcium phosphate nephrolithiasis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAlveolar - interstitial pneumopathy after Entitygold - salts compounds administration, requiring mechanical ventilation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The epivodes of EntityNMS occured under treatment with Entityclozapine , risperidone, and amisulpride. |
| 1.0000 | Adverse-Effect | The epivodes of EntityNMS occured under treatment with clozapine, Entityrisperidone , and amisulpride. |
| 1.0000 | Adverse-Effect | The epivodes of EntityNMS occured under treatment with clozapine, risperidone, and Entityamisulpride . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Cardiac hypersensitivity and Entitymyopericarditis have been reported during long - term treatment with Entitymesalazine . |
| 0.9999 | Adverse-Effect | EntityCardiac hypersensitivity and myopericarditis have been reported during long - term treatment with Entitymesalazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterstitial fibrosis of the lung is a potential complication of Entitymethotrexate therapy for psoriasis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The events of Entitynon - convulsive status epilepticus subsided following reduction in Entitytiagabine dosages. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : This case illustrates a potential link between Entitydermatologic and ocular 5 - FU toxicities Entity5 - FU toxicities. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVisual hallucinations after intravitreal injection of Entitybevacizumab in vascular age - related macular degeneration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Symptoms and pathologic changes of Entitycolitis are associated with exposure to Entityrofecoxib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityReye - like syndrome following treatment with the pantothenic acid antagonist, Entitycalcium hopantenate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Presented is a case of Entityacute renal failure induced by Entityacetazolamide therapy for glaucoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Such anagen effluvium with Entitylichenoid eruption following EntityINH therapy has not been observed previously. |
| 0.9999 | Adverse-Effect | Such Entityanagen effluvium with lichenoid eruption following EntityINH therapy has not been observed previously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The mean time from starting EntityMMF to the development of Entityneutropenia was 4 months. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPsoriasis - like skin reaction in a patient with rheumatoid arthritis after Entitysulphasalazine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | Severe rhabdomyolysis following massive ingestion of Entityoolong tea : Entitycaffeine intoxication with coexisting hyponatremia. |
| 0.9990 | Adverse-Effect | Severe rhabdomyolysis following massive ingestion of oolong tea : Entitycaffeine Entitycaffeine intoxication with coexisting hyponatremia. |
| 1.0000 | Adverse-Effect | EntitySevere rhabdomyolysis following massive ingestion of Entityoolong tea : caffeine intoxication with coexisting hyponatremia. |
| 0.9991 | Adverse-Effect | EntitySevere rhabdomyolysis following massive ingestion of oolong tea : Entitycaffeine intoxication with coexisting hyponatremia. |
| Adverse-Effect | Severe Entityrhabdomyolysis following massive ingestion of Entityoolong tea : caffeine intoxication with coexisting hyponatremia. | |
| Adverse-Effect | Severe Entityrhabdomyolysis following massive ingestion of oolong tea : Entitycaffeine intoxication with coexisting hyponatremia. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIbuprofen overdose is usually characterized by EntityGI upset , dizziness, and mild sedation. |
| 1.0000 | Adverse-Effect | EntityIbuprofen overdose is usually characterized by GI upset, Entitydizziness , and mild sedation. |
| 0.9999 | Adverse-Effect | EntityIbuprofen overdose is usually characterized by GI upset, dizziness, and Entitymild sedation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Administration of cisplatin in three patients with Entitycarboplatin Entityhypersensitivity : is skin testing useful? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere hepatotoxicity related to Entitybenzarone : a report of three cases with two fatalities. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of reversible Entitynonthrombocytopenic palpable purpura associated with Entitymetoclopramide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityActinomycin D associated Entityhepatic veno - occlusive disease - - a report of 2 cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient developed typical EntityECM after subcutaneous selfinjection of Entityglatiramer acetate for multiple sclerosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients are described who developed testicular swelling and Entitypain during treatment with Entitydesipramine . |
| 1.0000 | Adverse-Effect | Two patients are described who developed Entitytesticular swelling and pain during treatment with Entitydesipramine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Putaminal infarct in Entitymethanol Entitymethanol intoxication : case report and role of brain imaging studies. |
| 0.9966 | Adverse-Effect | EntityPutaminal infarct in Entitymethanol intoxication : case report and role of brain imaging studies. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityWorsening of neurologic syndrome in patients with Wilson's disease with initial Entitypenicillamine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first histologically confirmed case of EntityNASH that was aggravated by Entityraloxifene . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This was accepted as evidence for Entitypropranolol being the cause of this Entityconduction disorder . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPeripheral nerve dysfunction is a potentially serious complication of high - dose Entitycytosine arabinoside . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTorsade de pointes associated with Entitymoxifloxacin : a rare but potentially fatal adverse event. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHyperammonemia secondary to Entityvalproic acid as a cause of lethargy in a postictal patient. |
| 0.9997 | Adverse-Effect | Hyperammonemia secondary to Entityvalproic acid as a cause of Entitylethargy in a postictal patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A small number of Entityoxaliplatin - related Entityhemolytic and / or thrombocytopenic reactions have been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinical signs of Entityhypermagnesemia are an uncommon complication following oral administration of Entitymagnesium sulfate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | EntityAcute hemorrhagic gastritis associated with Entityacetazolamide intoxication in a patient with chronic renal failure. |
| Adverse-Effect | Acute hemorrhagic gastritis associated with Entityacetazolamide Entityacetazolamide intoxication in a patient with chronic renal failure. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMyasthenia gravis during low - dose EntityIFN - alpha therapy for chronic hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | His fever resolved, but he developed symptoms consistent with those of Entitychloroquine Entitychloroquine toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLupus - like syndrome caused by Entity5 - aminosalicylic acid in patients with inflammatory bowel disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intensive high - flux hemodiafiltration is often used in the management of Entityvancomycin Entityvancomycin toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She developed Entityneurotoxicity with an adjustment dosage of Entityvalacyclovir for a cutaneous zoster infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThalidomide was withdrawn from world markets in 1961 following recognition of its Entityteratogenic effects . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Itch and Entityskin rash from chocolate during Entityfluoxetine and sertraline treatment : case report. |
| 1.0000 | Adverse-Effect | EntityItch and skin rash from chocolate during Entityfluoxetine and sertraline treatment : case report. |
| 0.9999 | Adverse-Effect | EntityItch and skin rash from chocolate during fluoxetine and Entitysertraline treatment : case report. |
| 0.9998 | Adverse-Effect | Itch and Entityskin rash from chocolate during fluoxetine and Entitysertraline treatment : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a case of Entitythrombocytopenia associated with the administration of Entitylansoprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Special care should be taken when Entitypulmonary symptoms appear in association with Entityticlopidine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is well - recognized that Entityflucloxacillin may occasionally result in Entityfatal hepatic injury . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is the first case of Entityciprofloxacin - induced EntityVBDS successfully treated with tacrolimus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We attribute the clinical and radiographic findings to Entitycytotoxic edema secondary to intrathecal Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBenzocaine - induced Entitymethemoglobinemia has been reported in man, dogs, and cats. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySquamous - cell carcinoma arising in a basal - cell epithelioma treated with Entity5 - fluorouracil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRisperidone withdrawal - related Entityrespiratory dyskinesia : a case diagnosed by spirography and fibroscopy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Induction of Entityrapid mood cycling during EntityL - dopa treatment in a bipolar patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Drug induced Entitypolymyositis secondary to Entityleuprolide acetate ( Lupron ) therapy for prostate carcinoma. |
| 0.9999 | Adverse-Effect | Drug induced Entitypolymyositis secondary to leuprolide acetate ( EntityLupron ) therapy for prostate carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylaxis to intravenous Entitycyclosporine and tolerance to oral cyclosporine : case report and review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute renal failure in a patient treated by continuous Entitypovidone - iodine mediastinal irrigation. |
| 0.9999 | Adverse-Effect | EntityAcute renal failure in a patient treated by continuous povidone - Entityiodine mediastinal irrigation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the first case of Entitydisseminated salmonellosis in a patient treated with Entitytemozolomide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | New onset of EntityCrohn's disease during treatment of active ankylosing spondylitis with Entityetanercept . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Topical Entitybrimonidine may be associated with Entitycentral nervous system depression in infants. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPseudomembranous colitis readily occurs in at least certain population groups receiving Entitytrimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | EntityPseudomembranous colitis readily occurs in at least certain population groups receiving trimethoprim - Entitysulfamethoxazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We believe that the Entityacute renal failure in our patient was associated with Entityanastrozole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Myoclonus was induced and enhanced by EntityL - dopa , developing into Entitygeneralized seizures . |
| 1.0000 | Adverse-Effect | EntityMyoclonus was induced and enhanced by EntityL - dopa , developing into generalized seizures. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Intravenous administration of levodopa ameliorated a refractory Entityakathisia case induced by Entityinterferon - alpha . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCutaneous seeding after ultrasound - guided percutaneous Entityethanol injection for treatment of hepatocellular carcinoma. |
| Adverse-Effect | EntityCutaneous seeding after ultrasound - guided percutaneous Entityethanol injection for treatment of hepatocellular carcinoma. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient presented with Entitydilated cardiomyopathy after many years of overusing an Entityadrenaline inhaler. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Are nasal decongestants safer than rhinitis? A case of Entityoxymetazoline - induced Entitysyncope . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Sixteen of 33 patients developed significant hyponatremia and Entityhypoosmolality during oral treatment with Entitylorcainide . |
| 1.0000 | Adverse-Effect | Sixteen of 33 patients developed significant Entityhyponatremia and hypoosmolality during oral treatment with Entitylorcainide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Serious Entityphenytoin Entityhypersensitivity reactions may appear as dermatologic, lymphoid, or hepatic syndromes. |
| 0.9999 | Adverse-Effect | Serious Entityphenytoin hypersensitivity reactions may appear as Entitydermatologic, lymphoid, or hepatic syndromes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGemcitabine should be added to the list of drugs known to cause Entityradiation recall . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Symptomatic hypocalcaemia and Entityrenal impairment associated with Entitybisphosphonate treatment in patients with multiple myeloma. |
| 0.9999 | Adverse-Effect | EntitySymptomatic hypocalcaemia and renal impairment associated with Entitybisphosphonate treatment in patients with multiple myeloma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In one case, Entitydisulfiram was the only potential Entityteratogen exposed to the fetus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Conventional and diffusion - weighted MRI findings of Entitymethotrexate related Entitysub - acute neurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHOD : We describe three case - reports concerning Entityhaematological adverse effects of Entityquetiapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Oral intake and Entityacarbose were withheld and the Entityileus spontaneously resolved after 2 days. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityKaposi's sarcoma in a patient treated with Entityimatinib mesylate for chronic myeloid leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Entity2 - CdA induces Entitylymphocytopenia , which may explain the improvement in this patient's psoriasis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Development of Entitytics in a thirteen - year - old male following Entityatomoxetine use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGynecomastia in epileptics treated with Entityphenobarbital , phenytoin and fluoresone : two case reports. |
| 1.0000 | Adverse-Effect | EntityGynecomastia in epileptics treated with phenobarbital, Entityphenytoin and fluoresone : two case reports. |
| 1.0000 | Adverse-Effect | EntityGynecomastia in epileptics treated with phenobarbital, phenytoin and Entityfluoresone : two case reports. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The two middle aged women presented with Entityrespiratory symptoms after prolonged treatment with Entitynitrofurantoin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Visual system side effects caused by Entityparasympathetic dysfunction after Entitybotulinum toxin type B injections. |
| 0.9988 | Adverse-Effect | EntityVisual system side effects caused by parasympathetic dysfunction after Entitybotulinum toxin type B injections. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeutropenic colitis during standard dose combination chemotherapy with Entitynedaplatin and irinotecan for testicular cancer. |
| 1.0000 | Adverse-Effect | EntityNeutropenic colitis during standard dose combination chemotherapy with nedaplatin and Entityirinotecan for testicular cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pharmacokinetic determinants of Entity6 - mercaptopurine Entitymyelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This supports the well - reported potential of Entitybleomycin to trigger Entityacral vascular toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We discuss a variety of bronchopulmonary complications of EntityIBD and their association with Entitysulfasalazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate - induced Entitypapular eruption following treatment of psoriasis has not been previously reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute erythroid leukemia after Entitycyclophosphamide therapy for multiple myeloma : report of two cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityibuprofen - induced Entitymeningitis in an otherwise healthy individual. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityFatal digoxin poisoning Entitydigoxin poisoning : an unsuccessful resuscitation with use of digoxin - immune Fab. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : EntityHeadaches have been reported as a potential side effect of Entitycapecitabine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTransient cardiac arrhythmias related to Entitylopinavir / ritonavir in two patients with HIV infection. |
| 0.9999 | Adverse-Effect | EntityTransient cardiac arrhythmias related to lopinavir / Entityritonavir in two patients with HIV infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityChlorambucil - induced Entitychromosome damage to human lymphocytes is dose - dependent and cumulative. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A complex pattern of melanonychia and Entityonycholysis after treatment with Entitypemetrexed for lung cancer. |
| 1.0000 | Adverse-Effect | A complex pattern of Entitymelanonychia and onycholysis after treatment with Entitypemetrexed for lung cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNiflumic acid - induced Entityskeletal fluorosis : iatrogenic disease or therapeutic perspective for osteoporosis? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Bone marrow aplasia and Entitysevere skin rash after a single low dose of Entitymethotrexate . |
| 0.9999 | Adverse-Effect | EntityBone marrow aplasia and severe skin rash after a single low dose of Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityDelayed pseudocyst of the pancreas can be a complication of intramuscular EntityL - asparaginase . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | EntityDrug rash with eosinophilia and systemic symptoms after Entitychlorambucil treatment in chronic lymphocytic leukaemia. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient was initially treated with hydration and Entityfurosemide but developed Entitycongestive heart failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There are now reports of Entityliver failure following treatment of childhood cancers with EntityAMD . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Calcification and Entityossification of the spinal arachnoid after intrathecal administration of EntityDepo - Medrol . |
| 0.9998 | Adverse-Effect | EntityCalcification and ossification of the spinal arachnoid after intrathecal administration of EntityDepo - Medrol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The association of central diabetes insipidus ( EntityCDI ) with Entitylithium use is rare. |
| 0.9999 | Adverse-Effect | The association of Entitycentral diabetes insipidus ( CDI ) with Entitylithium use is rare. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProcainamide - induced Entityincessant supraventricular tachycardia in the Wolff - Parkinson - White syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityUpper tract urothelial malignancy after Entitycyclophosphamide therapy : a case report and literature review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitysevere visual loss following a single dose of Entityvincristine is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Graves'hyperthyroidism following Entitytransient thyrotoxicosis during Entityinterferon therapy for chronic hepatitis type C. |
| 0.9999 | Adverse-Effect | EntityGraves'hyperthyroidism following transient thyrotoxicosis during Entityinterferon therapy for chronic hepatitis type C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | After 5 weeks of therapy, she stopped taking Entitypantoprazole due to Entitygeneral malaise . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute severe intoxication with Entitycarbamazepine is associated with Entityseizures , coma and respiratory depression. |
| 1.0000 | Adverse-Effect | Acute severe intoxication with Entitycarbamazepine is associated with seizures, coma and Entityrespiratory depression . |
| 0.9999 | Adverse-Effect | Acute severe intoxication with Entitycarbamazepine is associated with seizures, Entitycoma and respiratory depression. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a probable case of Entitytransient global amnesia caused by Entitypropafenone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This clinical course suggests that the Entitysensorimotor polyneuropathy may have been caused by Entity5 - ASA . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Vanishing bile duct and EntityStevens - Johnson syndrome associated with Entityciprofloxacin treated with tacrolimus. |
| 0.9999 | Adverse-Effect | EntityVanishing bile duct and Stevens - Johnson syndrome associated with Entityciprofloxacin treated with tacrolimus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityParadoxical precipitation of tonic seizures by Entitylorazepam in a child with atypical absence seizures. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCaptopril - induced Entitypulmonary infiltrates with eosinophilia in an infant with congenital heart disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reduction of Entitymethylprednisolone dosage rather than insulin therapy resulted in better control of Entityglycemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of chronic use of EntityHCQ associated with Entitytorsade de pointes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatolithiasis ( intrahepatic stone ) during Entityoctreotide therapy for acromegaly : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityglaucoma induced by Entitydoxetaxel therapy for metastatic breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLithium therapy was discontinued because of poor compliance to the medication and intolerable Entitypolyuria . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Horner's syndrome and Entitydemyelinating peripheral neuropathy caused by high - dose Entitycytosine arabinoside . |
| 0.9997 | Adverse-Effect | EntityHorner's syndrome and demyelinating peripheral neuropathy caused by high - dose Entitycytosine arabinoside . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLeiomyosarcoma in urinary bladder after Entitycyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors caution that treatment with Entityalprazolam may be complicated by the induction of Entitymania . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | To treat hepatitis B, Entityinterferon alpha was administered until the proximal Entitymuscle weakness developed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAggressive endometrial carcinoma in a breast cancer patient treated with Entitytamoxifen with normal transvaginal ultrasonography. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two children with rheumatic fever developed Entityanicteric hepatitis while on high - dose Entityaspirin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMyoclonus associated with continuous Entitydobutamine infusion in a patient with end - stage renal disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Induction of Entitysystemic lupus erythematosus by Entityinterferon - gamma in a patient with rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the case of Entityacute hepatitis induced by Entitygliclazide , a second generation sulfonylurea. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcyclovir produces Entityneurologic symptoms that resemble extension of viral infection into the central nervous system. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report the occurrence of Entityanaphylactoid reactions to intraperitoneal Entitycisplatin in 3 patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of polymyositis with Entitydilated cardiomyopathy associated with Entityinterferon alpha treatment for hepatitis B. |
| 0.9996 | Adverse-Effect | A case of Entitypolymyositis with dilated cardiomyopathy associated with Entityinterferon alpha treatment for hepatitis B. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Focal glomerulonephritis and Entityinterstitial nephritis in Entitymethicillin - treated, heroin - related infective endocarditis. |
| 0.9999 | Adverse-Effect | EntityFocal glomerulonephritis and interstitial nephritis in Entitymethicillin - treated, heroin - related infective endocarditis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two women who developed EntityHUS after EntityMMC therapy and presented massive pulmonary bleeding. |
| 0.9999 | Adverse-Effect | We describe two women who developed HUS after EntityMMC therapy and presented Entitymassive pulmonary bleeding . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Basilar invagination and Entitymid - line skeletal abnormalities due to in utero exposure to Entityphenytoin . |
| 1.0000 | Adverse-Effect | EntityBasilar invagination and mid - line skeletal abnormalities due to in utero exposure to Entityphenytoin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : There is very little published information regarding Entityofloxacin - induced Entitytoxic epidermal necrolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | While undergoing treatment with Entityalbendazole , he developed Entityworsening diarrhea with abdominal pain and fever. |
| 1.0000 | Adverse-Effect | While undergoing treatment with Entityalbendazole , he developed worsening diarrhea with Entityabdominal pain and fever. |
| 0.9999 | Adverse-Effect | While undergoing treatment with Entityalbendazole , he developed worsening diarrhea with abdominal pain and Entityfever . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report of Entitypulmonary hypertension in an adult patient during Entitylithium therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCystoid macular edema in a low - risk patient after switching from Entitylatanoprost to bimatoprost. |
| 0.9999 | Adverse-Effect | EntityCystoid macular edema in a low - risk patient after switching from latanoprost to Entitybimatoprost . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient's Entityarthritis flared after the second infusion of Entityinfliximab , which was discontinued. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Therefore, parenteral Entityamiodarone was implicated as the cause of Entityacute hepatitis in this patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The other patient developed Entitytransient intraoperative hypertension immediately after inadvertent submucosal injection of concentrated Entityepinephrine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySustained ventricular tachycardia in a Entitythalidomide - treated patient with primary plasma - cell leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVogt - Koyanagi - Harada disease occurring during Entityinterferon alpha therapy for chronic hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Following discontinuation of Entityclozapine , she was rechallenged and again was observed to have Entityseizures . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Discontinuation of simvastatin and Entitycyclosporine resulted in resolution of Entityrhabdomyolysis and normalization of renal function. |
| 1.0000 | Adverse-Effect | Discontinuation of Entitysimvastatin and cyclosporine resulted in resolution of Entityrhabdomyolysis and normalization of renal function. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClozapine is speculated to cause Entityrhabdomyolysis in patients with defective calcium - activated K + channels. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRecurrent palmar - plantar erythrodysaesthesia following high - dose Entitycytarabine treatment for acute lymphoblastic leukemia. |
| Adverse-Effect | Recurrent Entitypalmar - plantar erythrodysaesthesia following high - dose Entitycytarabine treatment for acute lymphoblastic leukemia. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal tubular acidosis secondary to EntityFK506 in living donor liver transplantation : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 58 - year - old man with rheumatoid arthritis developed Entitylichen planus during treatment with Entitygold . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present an AIDS patient with severe and prolonged Entitylactic acidosis on Entitystavudine and lamivudine. |
| 0.9999 | Adverse-Effect | We present an AIDS patient with severe and prolonged Entitylactic acidosis on stavudine and Entitylamivudine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDiphenylhydantoin apparently adversely affected both the clinical and biochemical parameters of the Entityacute intermittent porphyria . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients who were receiving EntityTolazoline by infusion developed Entityduodenal ulceration and subsequent intestinal perforation. |
| 0.9999 | Adverse-Effect | Two patients who were receiving EntityTolazoline by infusion developed duodenal ulceration and subsequent Entityintestinal perforation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here, we report a case of EntityRFP - induced Entityhypothyroidism without underlying thyroid disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGeneralized maculopapular and papular purpuric eruptions are perhaps the most common Entitythionamide - induced reactions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case illustrates the potential Entitydecoupling of PSA response from disease status in Entityflutamide withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIntracranial haemorrhage from a meningioma in a patient receiving Entityaspirin prophylaxis : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is likely that EntityRA contributed to the Entitydeterioration in renal function in these patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 21 - year - old female patient with Entitydapsone Entityhypersensitivity syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNitrofurantoin - induced Entitylung disease : two cases demonstrating resolution of apparently irreversible CT abnormalities. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere hemolytic uremic syndrome in an advanced ovarian cancer patient treated with Entitycarboplatin and gemcitabine. |
| 1.0000 | Adverse-Effect | EntitySevere hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and Entitygemcitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Polyarthritis, hepatitis and Entityanti - native DNA antibodies after treatment with Entityethambutol and rifampicin. |
| 1.0000 | Adverse-Effect | Polyarthritis, Entityhepatitis and anti - native DNA antibodies after treatment with Entityethambutol and rifampicin. |
| 1.0000 | Adverse-Effect | EntityPolyarthritis , hepatitis and anti - native DNA antibodies after treatment with Entityethambutol and rifampicin. |
| 0.9999 | Adverse-Effect | Polyarthritis, Entityhepatitis and anti - native DNA antibodies after treatment with ethambutol and Entityrifampicin . |
| 0.9999 | Adverse-Effect | Polyarthritis, hepatitis and Entityanti - native DNA antibodies after treatment with ethambutol and Entityrifampicin . |
| 0.9999 | Adverse-Effect | EntityPolyarthritis , hepatitis and anti - native DNA antibodies after treatment with ethambutol and Entityrifampicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There was a clear relationship between restarting the EntityAccutane and recurrence of the Entitytransient myopia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this is the first Entitygranulomatous reaction described after Entitycalcium hydroxylapatite injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Myelodysplasia terminating in Entityacute myeloid leukemia in a hairy cell leukemia patient treated with Entity2 - deoxycoformycin . |
| 0.9999 | Adverse-Effect | EntityMyelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with Entity2 - deoxycoformycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | EntityProconvulsive tendency of imipenem / Entitycilastatin is one of its well - known side effects. | |
| Adverse-Effect | EntityProconvulsive tendency of Entityimipenem / cilastatin is one of its well - known side effects. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thoracoscopic biopsy to confirm metastasis revealed instead Entityfibrotic lesions apparently attributable to Entitybleomycin or cyclophosphamide. |
| 1.0000 | Adverse-Effect | Thoracoscopic biopsy to confirm metastasis revealed instead Entityfibrotic lesions apparently attributable to bleomycin or Entitycyclophosphamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFlecainide - associated Entitypneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome. |
| 0.9998 | Adverse-Effect | EntityFlecainide - associated pneumonitis with Entityacute respiratory failure in a patient with the LEOPARD syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report a case of Entitycontact dermatitis due to Entitysodium bisulfite in Tathion eye drops. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeutrophilic eccrine hidradenitis mimicking cutaneous vasculitis in a lupus patient : a complication of Entitycyclophosphamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityEpsilon - aminocaproic acid and Entityrenal complications : case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The use of Entitybeclomethasone diproprionate inhaler complicated by the development of an Entityeosinophilic pneumonia reaction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDe novo absence status of late onset following withdrawal of Entitylorazepam : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two elderly women suffered an Entityacute deterioration of renal function after treatment with Entitycefoxitin sodium . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case study : a modified topical treatment regimen for sodium Entitywarfarin - induced Entitynecrotizing fasciitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityThyroid dysfunction has been reported in patients with malignant disease treated with Entityrecombinant alpha interferon . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : EntityAccutane a Entityteratogenic prescription drug licensed to treat severe, recalcitrant nodular acne. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The use of Entitycyclosporin has been associated with the development of Entitycholelithiasis in transplant recipients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : These cases suggest that Entitymoxifloxacin may interfere with the healing of Entitycorneal ulcers . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The literature on Entitythiabendazole - induced Entitycholestasis and its association with sicca complex is reviewed. |
| 0.9999 | Adverse-Effect | The literature on Entitythiabendazole - induced cholestasis and its association with Entitysicca complex is reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Patients with vitamin B12 deficiency are exceedingly sensitive to Entityneurologic deterioration following Entitynitrous oxide anesthesia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinicians should include Entityphenolphthalein in their list of possible causes of drug - induced EntityTEN . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityStatin - associated Entitymyasthenia gravis : report of 4 cases and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Fever, pulmonary infiltrates, and Entitypleural effusion following Entityacyclovir therapy for herpes zoster ophthalmicus. |
| 0.9999 | Adverse-Effect | EntityFever , pulmonary infiltrates, and pleural effusion following Entityacyclovir therapy for herpes zoster ophthalmicus. |
| 0.9999 | Adverse-Effect | Fever, Entitypulmonary infiltrates , and pleural effusion following Entityacyclovir therapy for herpes zoster ophthalmicus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, other factors or drugs ( e. g. Entitycresol ) are thought to induce EntityMH . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two cases of Entityneutropenia following Entitycaptopril use in cardiac patients with trisomy 21. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Life - threatening Entityalterations in heart rate after the use of Entityadenosine in atrial flutter. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityliver damage following treatment with EntityDanazol for fibrocystic breast disease is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Alopecia, nausea, and Entityvomiting were attributed to the Entitycyclophosphamide component of the therapy. |
| 1.0000 | Adverse-Effect | Alopecia, Entitynausea , and vomiting were attributed to the Entitycyclophosphamide component of the therapy. |
| 1.0000 | Adverse-Effect | EntityAlopecia , nausea, and vomiting were attributed to the Entitycyclophosphamide component of the therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In one case, the readministration of Entityriluzole was followed by the relapse of Entityhepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySubfulminant hepatitis B after Entityinfliximab in Crohn's disease : need for HBV - screening? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySystemic capillary leak syndrome after Entitygranulocyte colony - stimulating factor ( G - CSF ). |
| 0.9992 | Adverse-Effect | EntitySystemic capillary leak syndrome after granulocyte colony - stimulating factor ( EntityG - CSF ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Markedly Entityincreased pigmementation of skin immediately overlying veins used for multiple Entity5 - fluorouracil infusions was noted. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere hyperkalemia as a complication of Entitytimolol , a topically applied beta - adrenergic antagonist. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the second report of Entitylactic acidosis in a patient on Entitystavudine and lamivudine. |
| 1.0000 | Adverse-Effect | This is the second report of Entitylactic acidosis in a patient on stavudine and Entitylamivudine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Drug - induced Entityeosinophilia is a non - dose - dependent side effect of Entityclozapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A review of the literature showed no previous description of this pattern in Entitybenzodiazepine Entitycoma . |
| 0.9993 | Adverse-Effect | A review of the literature showed no previous description of this pattern in Entitybenzodiazepine Entitybenzodiazepine coma . |
| 0.9159 | Adverse-Effect | A review of the literature showed no previous description of this pattern in Entitybenzodiazepine coma Entitycoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of intrathecal Entitymethotrexate Entityneurotoxicity manifesting as left arm weakness and aphasia. |
| 0.9998 | Adverse-Effect | We report a case of intrathecal Entitymethotrexate neurotoxicity manifesting as left arm weakness and Entityaphasia . |
| 0.9997 | Adverse-Effect | We report a case of intrathecal Entitymethotrexate neurotoxicity manifesting as Entityleft arm weakness and aphasia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prior neurologic illness and the syndrome of irreversible Entitylithium - effectuated Entityneurotoxicity ( SILENT ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Herein we report four patients who underwent liver transplantation and developed Entityneutropenia while receiving EntityMMF . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Multiple myeloma complicated by Entitycongestive heart failure following first administration of Entityrecombinant alpha - interferon . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus, Entitytacrolimus - induced EntityHUS is a rare cause of ARF in nephrotic syndrome. |
| 0.9999 | Adverse-Effect | Thus, Entitytacrolimus - induced HUS is a rare cause of EntityARF in nephrotic syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | According to the Naranjo probability scale, the Entitypapular eruption was probably caused by Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCerebral demyelinating disease developed in a patient during adjuvant therapy with Entitylevamisole for malignant melanoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, re - initiation of Entitysunitinib treatment was followed by Entitybilateral breast enlargement again. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients developed Entitydiabetic coma when taking a combination of a Entitythiazide diuretic and propranolol. |
| 1.0000 | Adverse-Effect | Two patients developed Entitydiabetic coma when taking a combination of a thiazide diuretic and Entitypropranolol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Surprisingly, we found that three patients appeared to develop Entitytardive OGC while taking Entityclozapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | So far, few cases of Entitypulmonary side effects caused by Entityticlopidine have been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : The present findings suggest that Entityfluvoxamine can cause Entityincreased libido in some patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal hypophosphatemia in this patient was caused by the erroneous intake of 1 g Entitydoxycycline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal pulmonary fibrosis induced by Entitypaclitaxel : a case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAdrenal suppression in a fetus due to administration of Entitymethylprednisolone has hitherto been rarely published. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Cis - retinoic acid ( EntityRA ) may further increase the risk of developing EntityBMTN . |
| 0.9999 | Adverse-Effect | EntityCis - retinoic acid ( RA ) may further increase the risk of developing EntityBMTN . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe 3 cases of Entitydiphenhydramine - induced Entitycardiac toxicity that were responsive to bicarbonate. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropoxyphene - induced Entitywide QRS complex dysrhythmia responsive to sodium bicarbonate - - a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPleuropulmonary fibrosis after long - term treatment with the dopamine agonist Entitypergolide for Parkinson Disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute onset of Entitynephrotic syndrome during Entityinterferon - alpha retreatment for chronic active hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySweet's syndrome associated with Entitysargramostim ( granulocyte - macrophage colony stimulating factor ) treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of Entitydoxycycline - induced Entityhypoglycemia in a young nondiabetic man. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Under the suspicion of Entityamiodarone - induced Entityacute pancreatitis , amiodarone was substituted by propafenone. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A diagnosis of Entityinfliximab - induced Entitylupus was made and the drug treatment was withdrawn. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Aggressive management of Entitydoxorubicin - induced Entitycardiomyopathy associated with'low'doses of doxorubicin. |
| 0.9945 | Adverse-Effect | Aggressive management of doxorubicin - induced Entitycardiomyopathy associated with'low'doses of Entitydoxorubicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypertension develops in most patients after transplantation when immunosuppression is based on Entitycyclosporine and prednisone. |
| 1.0000 | Adverse-Effect | EntityHypertension develops in most patients after transplantation when immunosuppression is based on cyclosporine and Entityprednisone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, each infant demonstrated Entityhemodynamic decompensation shortly after Entityverapamil administration and required cardiopulmonary resuscitation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityaseptic pleuropericarditis in a patient with chronic plaque psoriasis under Entitymethotrexate therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a Entitybullous lichenoid eruption due to the intake of Entitycaptopril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Therapy with EntityIFN - beta has rarely been associated with the development of Entityautoimmune disorders . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The side effects of EntityMMF , such as Entitybone marrow toxicity , have been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypoglycemia induced by long - acting Entitysomatostatin analogues in a patient with nonfunctional neuroendocrine tumor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : Symptomatic Entityvisual field constriction thought to be associated with Entityvigabatrin has been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An 11 - day - old infant became lethargic and Entityapneic after a single drop of Entitybrimonidine . |
| 1.0000 | Adverse-Effect | An 11 - day - old infant became Entitylethargic and apneic after a single drop of Entitybrimonidine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Ballistic movements due to Entityischemic infarcts after intravenous Entityheroin overdose : report of two cases. |
| 0.9999 | Adverse-Effect | EntityBallistic movements due to ischemic infarcts after intravenous Entityheroin overdose : report of two cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although myelosuppression is mild, immunosuppression and Entitysuperinfection are potential hazards of treatment with EntityDCF . |
| 0.9999 | Adverse-Effect | Although myelosuppression is mild, Entityimmunosuppression and superinfection are potential hazards of treatment with EntityDCF . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this recurrence of Entityamiodarone Entitypulmonary toxicity has not been reported previously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : EntitySquamous metaplasia in these cases appears to be a consequence of Entityprogestin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient in whom Entitynoncardiogenic pulmonary edema developed during intrabiliary infusion of Entitymonooctanoin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Occurrence of withdrawal Entitydyskinesia indicates that the neuroleptic effects of Entityamoxapine may be clinically significant. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityPulmonary fibrosis is a severe complication associated with Entitybis - chloronitrosourea ( BCNU ) therapy. |
| 0.9997 | Adverse-Effect | EntityPulmonary fibrosis is a severe complication associated with bis - chloronitrosourea ( EntityBCNU ) therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinicians should be aware of the possibility that Entityvinorelbine may cause EntitySIADH and possibly hypokalemia. |
| 1.0000 | Adverse-Effect | Clinicians should be aware of the possibility that Entityvinorelbine may cause SIADH and possibly Entityhypokalemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Early recognition of Entityrenal toxicity of high - dose Entitymethotrexate therapy : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReactivation of cytomegalovirus probably followed the treatment of Wegener's granulomatosis with corticosteroids and Entityazathioprine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInfections are a major adverse effect during the treatment with Entityanti - TNF - alpha . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entity15 - kg weight gain developed in a patient during the third week of Entityibuprofen therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nephrogenic diabetes insipidus ( EntityNDI ) is a well - documented complication of Entitylithium use. |
| 1.0000 | Adverse-Effect | EntityNephrogenic diabetes insipidus ( NDI ) is a well - documented complication of Entitylithium use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Introduction of Entityetanercept was also clinically effective but followed by development of Entitysevere heart failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Nineteen cases of unusual enhanced Entityvincristine Entityneurotoxicity related to itraconazole have been reported in children. |
| 0.9999 | Adverse-Effect | Nineteen cases of unusual enhanced vincristine Entityneurotoxicity related to Entityitraconazole have been reported in children. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropranolol : an unrecognized cause of Entitycentral nervous system dysfunction in patients undergoing cardiopulmonary bypass. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere acidosis in patients taking Entitymetformin - - rapid reversal and survival despite high APACHE score. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a child with fatal Entityvalproate - related Entityhepatotoxic effects despite this supplementation. |
| Adverse-Effect | We report on a child with Entityfatal Entityvalproate - related hepatotoxic effects despite this supplementation. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypogammaglobulinemia associated with Entitygold therapy : evidence for a partial maturation blockade of B cells. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Erythromycin is a macrolide antibiotic that may increase the risk of Entitylovastatin - induced Entityrhabdomyolysis . |
| 0.9997 | Adverse-Effect | EntityErythromycin is a macrolide antibiotic that may increase the risk of lovastatin - induced Entityrhabdomyolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The mechanism of Entityanaphylactoid reaction to Entityzomepirac in this case, therefore, remains unclear. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, the occurrence and management of Entityakathisia induced by Entityfluvoxamine have not been described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Upon discontinuation of EntityMTX , her Entityascites resolved, and her arthritis became more active. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary fibrosis is a complication of Entitypaclitaxel therapy that may occur despite treatments with corticosteroids. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Onset of male Entitygynaecomastia in a patient treated with Entitysunitinib for metastatic renal cell carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethemoglobinemia after axillary block with Entitybupivacaine and additional injection of lidocaine in the operative field. |
| 0.9999 | Adverse-Effect | EntityMethemoglobinemia after axillary block with bupivacaine and additional injection of Entitylidocaine in the operative field. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute dystonia with Entitythalamic and brainstem lesions after initial Entitypenicillamine treatment in Wilson's disease. |
| 0.9999 | Adverse-Effect | EntityAcute dystonia with thalamic and brainstem lesions after initial Entitypenicillamine treatment in Wilson's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In two patients Entityclozapine was reinstated after risperidone was discontinued ; Entityserum triglyceride levels increased . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNifedipine may induce, or aggravate, pre - existing, Entitygastro - oesophageal reflux . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A major limitation in the use of Entityamphotericin B is its potential to cause Entitynephrotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After receiving 3 doses of ifosfamide / Entitymesna , she was found to be Entityunresponsive . |
| 1.0000 | Adverse-Effect | After receiving 3 doses of Entityifosfamide / mesna, she was found to be Entityunresponsive . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRhabdomyolysis caused by tocolysis with oral Entityritodrine hydrochloride in a pregnant patient with myotonic dystrophy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of EntitySIADH associated with Entitydesipramine treatment in an elderly depressed woman is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We assume that EntityrIFN - gamma induced the de novo development of EntitySLE in our patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypernatraemia induced by Entitysodium polystyrene sulphonate ( Kayexalate ) in two extremely low birth weight newborns. |
| 0.9997 | Adverse-Effect | EntityHypernatraemia induced by sodium polystyrene sulphonate ( EntityKayexalate ) in two extremely low birth weight newborns. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRifampicin - induced Entityadrenal insufficiency in the acquired immunodeficiency syndrome : difficulties in diagnosis and treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRituximab - CHOP induced Entityinterstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Early - onset Entityacute transverse myelitis following Entityhepatitis B vaccination and respiratory infection : case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case is presented which illustrates a probably Entityfatal interaction between Entityminoxidil and a coagulation disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient developed transient, Entityacute myopia while on Entityisotretinoin ( Accutane ) therapy for acne. |
| 0.9999 | Adverse-Effect | A patient developed transient, Entityacute myopia while on isotretinoin ( EntityAccutane ) therapy for acne. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient that received Entitymethadone for cancer - associated pain developed Entitymyoclonus as a side effect. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Recovery of the Entitytubular dysfunction took 15 days following cessation of the offending drug, EntityAmikacin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal toxicities have been reported in less than one percent of the patients receiving Entityciprofloxacin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Myoglobinuria and Entityacute renal failure were observed in two patients with Entityvasopressin - treated gastrointestinal hemorrhage. |
| 0.9999 | Adverse-Effect | EntityMyoglobinuria and acute renal failure were observed in two patients with Entityvasopressin - treated gastrointestinal hemorrhage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityValproic acid induced Entitycoma is presented in an adult patient without a history of metabolic disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two patients with Entityinfectious mononucleosis - like syndrome induced by Entitysalazosulfapyridine ( SASP ). |
| 0.9999 | Adverse-Effect | We report two patients with Entityinfectious mononucleosis - like syndrome induced by salazosulfapyridine ( EntitySASP ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | over the past 3 years there have been several reports of Entityuveitis associated with Entityrifabutin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPosterior leukoencephalopathy following Entitycisplatin , bleomycin and vinblastine therapy for germ cell tumor of the ovary. |
| 0.9999 | Adverse-Effect | EntityPosterior leukoencephalopathy following cisplatin, Entitybleomycin and vinblastine therapy for germ cell tumor of the ovary. |
| 0.9998 | Adverse-Effect | EntityPosterior leukoencephalopathy following cisplatin, bleomycin and Entityvinblastine therapy for germ cell tumor of the ovary. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityColonic mucosal necrosis following administration of Entitycalcium polystryrene sulfonate ( Kalimate ) in a uremic patient. |
| 0.9999 | Adverse-Effect | EntityColonic mucosal necrosis following administration of calcium polystryrene sulfonate ( EntityKalimate ) in a uremic patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients are described in whom subtle Entitycognitive impairments are associated with therapeutic doses of Entityamoxapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus, Entitytardive seizures in our cases are thought to be related to Entitypiperacillin and cefotiam. |
| 0.9999 | Adverse-Effect | Thus, Entitytardive seizures in our cases are thought to be related to piperacillin and Entitycefotiam . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySecondary leukemia in a child with neuroblastoma while on oral Entityetoposide : what is the cause? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The incidence of Entityangioedema secondary to Entitylosartan , an angiotensin II receptor antagonist, is unknown. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case report of a patient with probable cisplatin and Entitybleomycin - induced EntityTMA is presented. |
| 0.9998 | Adverse-Effect | A case report of a patient with probable Entitycisplatin and bleomycin - induced EntityTMA is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntitySkin necrosis secondary to Entitylow - molecular weight heparin in a patient with antiphospholipid antibody syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These case reports provide evidence that Entity5 - aminosalicylic acid may induce Entityacute pancreatitis after long term treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The fifth patient exhibited paraesthesia and Entityagitation caused by Entityolanzapine that was misdiagnosed as psychotic agitation. |
| 0.9999 | Adverse-Effect | The fifth patient exhibited Entityparaesthesia and agitation caused by Entityolanzapine that was misdiagnosed as psychotic agitation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere respiratory syncytial virus pulmonary infection in a patient treated with Entityfludarabine for chronic lymphocytic leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report here a case of cardiovascular and Entityneurological depression induced by Entityoxymetalzoline in a toddler. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Dihydropyrimidine dehydrogenase deficiency : a pharmacogenetic defect causing Entitysevere adverse reactions to Entity5 - fluorouracil - based chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThrombotic stroke associated with the use of Entityporcine factor VIII in a patient with acquired haemophilia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe four patients who had Entityseizures while receiving Entityofloxacin ; no other causes were evident. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two adults who received gabapentin ( EntityGBP ) and subsequently developed Entitybehavioural side effects . |
| 0.9999 | Adverse-Effect | We report two adults who received Entitygabapentin ( GBP ) and subsequently developed Entitybehavioural side effects . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When tuberculosis patients on Entityisoniazid eat certain varieties of fish they may develop a Entityhistamine reaction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityexfoliative dermatitis clearly linked to intravenous and intraperitoneal administration of Entitytobramycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Within 24 hours of fluid restriction and cessation of Entitydesmopressin , her symptoms and Entityhyponatremia resolved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hepatitis with bridging fibrosis and Entityreversible hepatic insufficiency in a woman with rheumatoid arthritis taking Entitymethotrexate . |
| 1.0000 | Adverse-Effect | EntityHepatitis with bridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking Entitymethotrexate . |
| 1.0000 | Adverse-Effect | Hepatitis with Entitybridging fibrosis and reversible hepatic insufficiency in a woman with rheumatoid arthritis taking Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 64 - year - old man with schizophrenia developed Entitymyoclonic jerks when given higher doses of Entityquetiapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute renal failure is a rare complication following the administration of intravenous Entityimmunoglobulin ( IVIG ). |
| 1.0000 | Adverse-Effect | Acute Entityrenal failure is a rare complication following the administration of intravenous Entityimmunoglobulin ( IVIG ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is concluded that simultaneous administration of ciprofloxacin and tazobactam / Entitypiperacillin may cause marked Entitythrombocytosis . |
| 0.9999 | Adverse-Effect | It is concluded that simultaneous administration of ciprofloxacin and Entitytazobactam / piperacillin may cause marked Entitythrombocytosis . |
| 0.9999 | Adverse-Effect | It is concluded that simultaneous administration of Entityciprofloxacin and tazobactam / piperacillin may cause marked Entitythrombocytosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The present report describes the first case of Entityacute pancreatitis associated with Entitydanazol treatment of endometriosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Emergence of EntityPhiladelphia positive chronic myeloid leukaemia during treatment with Entityhydroxyurea for Philadelphia negative essential thrombocythaemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient experienced muscle twitches, tremulousness, and Entityanxiety on day 17 of Entityfoscarnet therapy. |
| 1.0000 | Adverse-Effect | The patient experienced muscle twitches, Entitytremulousness , and anxiety on day 17 of Entityfoscarnet therapy. |
| 0.9999 | Adverse-Effect | The patient experienced Entitymuscle twitches , tremulousness, and anxiety on day 17 of Entityfoscarnet therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityScrotal ulceration induced by Entityall - trans retinoic acid in a patient with acute promyelocytic leukemia. |
| Adverse-Effect | EntityScrotal ulceration induced by all - trans Entityretinoic acid in a patient with acute promyelocytic leukemia. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Acute Entityesmolol Entityesmolol toxicity may be self - limiting because of its extremely short half - life. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a surprising case of a woman schizophrenic patient treated with Entityclozapine suffering from EntityEPS . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first description, to our knowledge, of Entityductopenia apparently caused by Entityclindamycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this case is the first published report of Entitylevofloxacin - induced EntityTEN . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCutaneous sarcoidosis during Entityinterferon alfa and ribavirin treatment of hepatitis C virus infection : two cases. |
| 0.9997 | Adverse-Effect | EntityCutaneous sarcoidosis during interferon alfa and Entityribavirin treatment of hepatitis C virus infection : two cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLichen planus induced by Entityhepatitis B vaccination : a new case and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityContact dermatitis due to Entitybudesonide : report of five cases and review of the Japanese literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Potential mechanisms involved in the occurrence of Entityischemic colitis in patients receiving Entitytegaserod are also discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In four patients, Entityspasm occurred spontaneous and in one patient after 0. 05 mg of Entityergonovine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There is a dose - effect relationship between Entitydoxorubicin and the incidence of Entitysymptomatic cardiac failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A rechallenge, performed in both patients, confirmed the diagnosis of Entitymesalamine - induced Entitypancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : The findings in these two patients suggest that Entitycolchicine may Entitydelay corneal wound healing . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 69 - year - old man developed Entitypure red cell aplasia after taking Entityfenoprofen for ten months. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | New onset of CD may be considered as an Entityimmune - mediated injury induced by Entityetanercept . |
| 0.9999 | Adverse-Effect | New onset of EntityCD may be considered as an immune - mediated injury induced by Entityetanercept . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three patients with no history of asthma or allergy developed Entitybronchospasm while taking Entitypropranolol for hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | OBJECTIVE : To report a case of EntityCarbamazepine toxicity following the administration of EntityOxybutynin and Dantrolene. |
| 0.9995 | Adverse-Effect | OBJECTIVE : To report a case of EntityCarbamazepine EntityCarbamazepine toxicity following the administration of Oxybutynin and Dantrolene. |
| 0.9984 | Adverse-Effect | OBJECTIVE : To report a case of EntityCarbamazepine toxicity following the administration of Oxybutynin and EntityDantrolene . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The delayed Entityencephalopathy developed 9 and 22 months respectively after the first dose of intrathecal Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9977 | Adverse-Effect | Hepatotoxicity associated with choline magnesium trisalicylate : case report and review of Entitysalicylate - induced Entityhepatotoxicity . |
| Adverse-Effect | EntityHepatotoxicity associated with Entitycholine magnesium trisalicylate : case report and review of salicylate - induced hepatotoxicity. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySulfasalazine has been associated with Entitybronchopulmonary complications of inflammatory bowel disease ( IBD ) in adults. |
| 1.0000 | Adverse-Effect | EntitySulfasalazine has been associated with bronchopulmonary complications of inflammatory bowel disease ( EntityIBD ) in adults. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityZoledronic acid - induced Entitysevere hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInfliximab therapy may cause a Entitylupus - like syndrome that is reversible upon discontinuing this agent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : This case shows that switching to Entityzidovudine potentially can lead to a Entityhyperlactatemia relapse . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 15 - year follow - up of Entityphenytoin - induced Entityunilateral gingival hyperplasia : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This finding suggests that Entityfluvoxamine can precipitate EntitySchneiderian first - rank symptoms in some susceptible patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The hearing impairment and Entitytinnitus were gradually reduced after EntityPTU withdrawal and corticosteroid and azathioprine treatment. |
| 0.9989 | Adverse-Effect | The Entityhearing impairment and tinnitus were gradually reduced after EntityPTU withdrawal and corticosteroid and azathioprine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The changes were progressive regardless of discontinuation of Entitycyclophosphamide and led to Entitysevere restrictive ventilatory defect . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere hyperkalemia occurred in a patient with radiation pneumonitis and glaucoma shortly after beginning Entityprednisone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGlomerulonephritis in Entityprocainamide induced lupus erythematosus : report of a case and review of the literature. |
| 1.0000 | Adverse-Effect | Glomerulonephritis in Entityprocainamide induced Entitylupus erythematosus : report of a case and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9983 | Adverse-Effect | Atrial fibrillation was induced by diltiazem in two patients and Entityverapamil induced Entitysyncope in one patient. |
| 0.9932 | Adverse-Effect | EntityAtrial fibrillation was induced by Entitydiltiazem in two patients and verapamil induced syncope in one patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To present a single case of Entityzuclopenthixol - induced Entitypriapism and a literature review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityallopurinol Entityhypersensitivity , possibly the first in a black African, is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prolonged used of Entityhydroxyurea in patients with ET may lead to therapy - associated Entityacute leukemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySulfasalazine - induced Entityhypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein - Barr virus. |
| 1.0000 | Adverse-Effect | EntitySulfasalazine - induced hypersensitivity syndrome and Entityhemophagocytic syndrome associated with reactivation of Epstein - Barr virus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In one child, a second course of Entitycarbamazepine resulted in a return of the Entitydystonia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Two patients with ocular inflammation of unknown origin developed Entitysevere chorioretinitis after EntityIVTA injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Flumazenil reversal of Entitybenzodiazepine - induced Entitysedation for a patient with severe pre - ECT anxiety. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These multiple overlapping factors probably lead to Entityrhabdomyolysis in a minority of patients receiving Entityvasopressin infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Six patients with rheumatoid arthritis developed a syndrome resembling Entitylupus erythematosus while being treated with Entitypenicillamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute neutrophilic dermatosis induced by Entityall - trans - retinoic acid treatment for acute promyelocytic leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A second episode of Entityjaundice followed the intravaginal administration of a mixture of Entityfurazolidone and nifuroxime. |
| 1.0000 | Adverse-Effect | A second episode of Entityjaundice followed the intravaginal administration of a mixture of furazolidone and Entitynifuroxime . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In addition, the Entitytachycardia persisted and was repeatedly spontaneously reinitiated for prolonged periods after Entityprocainamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Within 6 months of Entitypranlukast withdrawal, Entityanemia resolved and urinary sediment and renal function normalized. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Successful treatment of hyperthyroidism with amiodarone in a patient with Entitypropylthiouracil - induced Entityacute hepatic failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An objective causality assessment suggests that the EntityJHR in our patient was probably related to Entitypenicillin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute pancreatitis in a child with idiopathic ulcerative colitis on long - term Entity5 - aminosalicylic acid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Systemic disease, most commonly renal dysfunction, preceded all 30 reported cases of Entityacyclovir Entityneurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two cases of Entitypolymorphic ventricular tachycardia induced by the administration of Entityverapamil against paroxysmal supraventricular tachycardia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first case of Entityhydroxyurea - induced Entityacute interstitial pneumonitis reported in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitysub - conjunctival haematoma in a patient receiving Entitywarfarin can pose a significant management challenge. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGemcitabine therapy has been associated with Entityradiation recall reactions when used in the treatment of carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySkin necrosis is a rare complication of subcutaneous Entityheparin therapy that usually occurs at injection sites. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It may cause a severe adverse drug reaction with multiorgan involvement known as Entitydapsone Entityhypersensitivity syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReversible sclerotic changes of lumbar spine and femur due to long - term oral Entityisotretinoin therapy. |
| Adverse-Effect | Reversible Entitysclerotic changes of lumbar spine and femur due to long - term oral Entityisotretinoin therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We explored Entityophthalmic and neurologic findings in two children who have been exposed prenatally to EntityVGB . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The possible role of Entityinterferon beta in the pathogenesis of Entitysarcoidosis in this patient is discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We observed transient Entitypanhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with Entityprednisolone and cyclophosphamide. |
| 0.9999 | Adverse-Effect | We observed transient Entitypanhypogammaglobulinaemia in a patient with neuropsychiatric SLE after treatment with prednisolone and Entitycyclophosphamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMassive prolapse of the urethral mucosa following periurethral injection of Entitycalcium hydroxylapatite for stress urinary incontinence. |
| 1.0000 | Adverse-Effect | Massive prolapse of the Entityurethral mucosa following periurethral injection of Entitycalcium hydroxylapatite for stress urinary incontinence. |
| Adverse-Effect | Massive Entityprolapse of the urethral mucosa following periurethral injection of Entitycalcium hydroxylapatite for stress urinary incontinence. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the second report of acute lung injury and Entitydiffuse alveolar damage caused by Entitymefloquine . |
| 0.9999 | Adverse-Effect | This is the second report of Entityacute lung injury and diffuse alveolar damage caused by Entitymefloquine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySudden death in an infant from methemoglobinemia after administration of " Entitysweet spirits of nitre ". |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with rheumatoid arthritis developed an Entityacute intrahepatic cholestasis after 100 mg of Entitysodium aurothiomalate . |
| Adverse-Effect | A patient with rheumatoid arthritis developed an acute Entityintrahepatic cholestasis after 100 mg of Entitysodium aurothiomalate . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute myopathy with selective Entitydegeneration of myosin filaments following status asthmaticus treated with Entitymethylprednisolone and vecuronium. |
| 1.0000 | Adverse-Effect | Acute myopathy with selective Entitydegeneration of myosin filaments following status asthmaticus treated with methylprednisolone and Entityvecuronium . |
| 0.9999 | Adverse-Effect | EntityAcute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with Entitymethylprednisolone and vecuronium. |
| 0.9998 | Adverse-Effect | EntityAcute myopathy with selective degeneration of myosin filaments following status asthmaticus treated with methylprednisolone and Entityvecuronium . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We discuss the association between Entitycarbamazepine and Entityhyponatremia and the causes of hyponatremia after cardiopulmonary bypass. |
| 0.9998 | Adverse-Effect | We discuss the association between Entitycarbamazepine and hyponatremia and the causes of Entityhyponatremia after cardiopulmonary bypass. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitybarbiturate - induced Entitysubmassive hepatic necrosis is presented and the literature is reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entityreversible toxic liver damage was observed in a non - alcoholic woman treated with Entitydisulfiram . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHaemolytic - uraemic syndrome complicating long - term Entitymitomycin C and 5 - fluorouracil therapy for gastric carcinoma. |
| 0.9999 | Adverse-Effect | EntityHaemolytic - uraemic syndrome complicating long - term mitomycin C and Entity5 - fluorouracil therapy for gastric carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityZidovudine use in pregnancy : a report on 104 cases and the occurrence of Entitybirth defects . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCoagulopathy associated with the use of Entitycephalosporin or moxalactam antibiotics in acute and chronic renal failure. |
| 1.0000 | Adverse-Effect | EntityCoagulopathy associated with the use of cephalosporin or Entitymoxalactam antibiotics in acute and chronic renal failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pulmonary hemorrhage as a clinical manifestation of Entityhemolytic - uremic syndrome associated with Entitymitomycin C therapy. |
| 0.9989 | Adverse-Effect | EntityPulmonary hemorrhage as a clinical manifestation of hemolytic - uremic syndrome associated with Entitymitomycin C therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySyringotropic hypersensitivity reaction associated with Entityinfliximab and leflunomide combination therapy in a child with psoriatic arthritis. |
| 0.9999 | Adverse-Effect | EntitySyringotropic hypersensitivity reaction associated with infliximab and Entityleflunomide combination therapy in a child with psoriatic arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report of a Entitycatatonic syndrome occurring in a patient receiving Entitydisulfiram treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DLST is a good diagnostic tool for EntityAZA Entityallergy , especially for severe drug allergy cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitytimolol - associated Entityheart failure in a 73 - year old white man is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a renal transplant recipient maintained on cyclosporine and Entityprednisone developing EntityNocardia Asteroides brain abscess . |
| 0.9999 | Adverse-Effect | We describe a renal transplant recipient maintained on Entitycyclosporine and prednisone developing EntityNocardia Asteroides brain abscess . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Visceral leishmaniasis and Entitymacrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with Entityadalimumab . |
| 1.0000 | Adverse-Effect | EntityVisceral leishmaniasis and macrophagic activation syndrome in a patient with rheumatoid arthritis under treatment with Entityadalimumab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Cholesterol crystal embolization - associated Entityrenal failure after therapy with recombinant Entitytissue - type plasminogen activator . |
| 0.9969 | Adverse-Effect | EntityCholesterol crystal embolization - associated renal failure after therapy with recombinant Entitytissue - type plasminogen activator . |
| 1.0000 | Adverse-Effect | Cholesterol crystal embolization - associated Entityrenal failure after therapy with Entityrecombinant tissue - type plasminogen activator . |
| 0.9992 | Adverse-Effect | EntityCholesterol crystal embolization - associated renal failure after therapy with Entityrecombinant tissue - type plasminogen activator . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHeparin - induced Entitythrombocytopenia complicated with massive thrombosis of the inferior vena cava after filter placement. |
| 0.9998 | Adverse-Effect | EntityHeparin - induced thrombocytopenia complicated with Entitymassive thrombosis of the inferior vena cava after filter placement. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Cholelithiasis and Entitythrombosis of the central retinal vein in a renal transplant recipient treated with Entitycyclosporin . |
| 1.0000 | Adverse-Effect | EntityCholelithiasis and thrombosis of the central retinal vein in a renal transplant recipient treated with Entitycyclosporin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Young children undergoing Entitycisplatin chemotherapy are known to be at risk for Entityprogressive sensorineural hearing loss . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prolongation of the QT interval and Entityventricular tachyarrhymias have been described in patients on Entityamiodarone therapy. |
| 0.9999 | Adverse-Effect | EntityProlongation of the QT interval and ventricular tachyarrhymias have been described in patients on Entityamiodarone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDiarrhea - associated over - anticoagulation in a patient taking Entitywarfarin : therapeutic role of cholestyramine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient whose case is reviewed had Entitymigraine headaches and received Entitymethysergide maleate for 13 years. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityAcute severe hepatitis though rare is occasionally observed with EGFR inhibitors Entitygefitinib or erlotinib. |
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityAcute severe hepatitis though rare is occasionally observed with EGFR inhibitors gefitinib or Entityerlotinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hypoxia is a predisposing factor for Entitypremature ductal closure and often occurs after maternal Entityindomethacin therapy. |
| 1.0000 | Adverse-Effect | EntityHypoxia is a predisposing factor for premature ductal closure and often occurs after maternal Entityindomethacin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Patients should be informed about the risk of Entityosteonecrosis when taking Entitydexamethasone as an antiemetic drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Rapid onset of Entityquetiapine - induced Entitydiabetic ketoacidosis in an elderly patient : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | On the other hand, Entityaspirin may have promoted the Entityenlargement of spontaneous hemorrhage from meningioma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal failure after high - dose Entitymethotrexate in a child homozygous for MTHFR C677 T polymorphism. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal interstitial pneumonitis associated with Entitydocetaxel administration in a patient with hormone - refractory prostate cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In vitro Entityinhibition of hematopoiesis in a patient with systemic sclerosis treated with EntityD - penicillamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe adenovirus pneumonia ( EntityAVP ) following Entityinfliximab infusion for the treatment of Crohn's disease. |
| 1.0000 | Adverse-Effect | EntitySevere adenovirus pneumonia ( AVP ) following Entityinfliximab infusion for the treatment of Crohn's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCapecitabine was discontinued and the Entityallergic reactions resolved after the woman took diphenhydramine for 1 week. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a unique case of EntityGTBM in a patient with myeloma following treatment with EntityMelphalan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Based on our findings, it is thus concluded that Entitycisplatin may cause EntityC. difficile colitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Administration of excessive Entityinsulin induced Entityhypoglycemia within 4 to 8 hours, followed by rebound hyperglycemia. |
| 0.9996 | Adverse-Effect | Administration of excessive Entityinsulin induced hypoglycemia within 4 to 8 hours, followed by Entityrebound hyperglycemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityfluoxetine induced Entityseizures , in a person with Down syndrome, is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary edema occurred 24 hours after intravenous Entityritodrine therapy and 10 hours after subcutaneous terbutaline therapy. |
| 0.9995 | Adverse-Effect | EntityPulmonary edema occurred 24 hours after intravenous ritodrine therapy and 10 hours after subcutaneous Entityterbutaline therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After treatment with a beta - sympathomimetic drug ( EntityPartusisten ) one fetus developed Entitysupraventricular tachycardia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityChlorambucil Entitycentral nervous toxicity : a significant side effect of chlorambucil therapy in childhood nephrotic syndrome. |
| 1.0000 | Adverse-Effect | Chlorambucil Entitycentral nervous toxicity : a significant side effect of Entitychlorambucil therapy in childhood nephrotic syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitypulmonary toxicity of Entitygold salts is an uncommon cause of life - threatening respiratory failure. |
| 0.9999 | Adverse-Effect | The pulmonary toxicity of Entitygold salts is an uncommon cause of life - threatening Entityrespiratory failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Antacid and Entitysucralfate - induced Entityhypophosphatemic osteomalacia : a case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Following are two clinical case reports demonstrating profound Entitycerebral edema associated with implantation of EntityGliadel wafers. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere visual loss after a single dose of Entityvincristine in a patient with spinal cord astrocytoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus any case of Entitysevere neutropenia occurring in a patient receiving Entityolanzapine is alarming to clinicians. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The 9 other reported cases of EntityD - penicillamine induced Entityrapidly progressive glomerulonephritis have been reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPigmentary disorders are recognized adverse effects of the semi - synthetic tetracycline derivative antibiotic, Entityminocycline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHerpes simplex esophagitis in a renal transplant patient treated with Entitycyclosporine A : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with idiopathic RLS who developed Entityaugmentation after 8 months of Entitylevodopa treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients with osteomyelitis who developed Entityreversible cholestatic jaundice during treatment with Entityoxacillin derivatives are described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Only one report links Entityphenylpropanolamine consumption to an Entityintracerebral hemorrhage in a patient with an AVM. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOlanzapine - induced Entityhyperglycaemic coma and neuroleptic malignant syndrome : case report and review of literature. |
| 0.9999 | Adverse-Effect | EntityOlanzapine - induced hyperglycaemic coma and Entityneuroleptic malignant syndrome : case report and review of literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In all cases, Entityseizures were controlled by withdrawal of Entityphenytoin and reduction of drug levels. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A young patient experienced marked Entitysinus tachycardia while smoking marijuana and receiving therapeutic doses of Entitynortriptyline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A severe form of Entityexophthalmos resulting from Entitylithium therapy has not been described in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Bulbar and Entitypseudobulbar palsy complicating therapy with high - dose Entitycytosine arabinoside in children with leukemia. |
| 0.9998 | Adverse-Effect | EntityBulbar and pseudobulbar palsy complicating therapy with high - dose Entitycytosine arabinoside in children with leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The cause of his bleeding was a Entitysevere thrombocytopoaenia , induced by chronic ingestion of Entityquinine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityL - asparaginase - induced Entityposterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. |
| Adverse-Effect | EntityL - asparaginase - induced Entityposterior reversible encephalopathy syndrome during acute lymphoblastic leukemia treatment in children. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nevertheless, the Entitycoagulopathy seemed to be most closely associated with the administration of the Entitycephalosporin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Favorable outcome of de novo Entityhepatitis B infection after liver transplantation with Entitylamivudine and adefovir therapy. |
| 1.0000 | Adverse-Effect | Favorable outcome of de novo Entityhepatitis B infection after liver transplantation with lamivudine and Entityadefovir therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThrombocytosis induced by Entityenoxaparin has been reported as a rare adverse effect of this medication in adults. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report of Entitynon - convulsive status epilepticus provoked by Entitytiagabine in adolescent patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityL - asparaginase - induced Entitypancreatitis has been reported during or closely following administration of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The majority of Entityradiation recall reactions attributed to Entitygemcitabine are reported to affect internal tissue or organs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMinimal change disease in a patient receiving EntityIFN - alpha therapy for chronic hepatitis C virus infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClozapine - induced Entityeosinophilia and switch to quetiapine in a patient with chronic schizophrenia with suicidal tendencies. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In association with this tocolysis, Entityurinary calculus of Entitymagnesium ammonium phosphate occurred at 34 weeks gestation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Cessation of EntityD - Pen and the start of corticosteroid therapy were followed by recovery from Entitybicytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a 37 - year - old female who complained of moderate Entityhair loss during Entityparoxetine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These novel findings may offer specific therapeutic targets in the treatment of EntityBCNU - associated Entitypulmonary fibrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An insulin - dependent diabetic patient with nephropathy developed Entitysevere acidosis after treatment with Entityacetazolamide for glaucoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Interstitial lung disease ( EntityILD ) related to therapy with the drug Entitygefitinib has been well reported. |
| 1.0000 | Adverse-Effect | EntityInterstitial lung disease ( ILD ) related to therapy with the drug Entitygefitinib has been well reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : This study confirmed that in most patients EntityMTX - induced Entityliver cirrhosis is not aggressive. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Since Entitytamoxifen therapy can induce Entityendometrial disorders , surveillance schemes of women taking tamoxifen have been recommended. |
| 1.0000 | Adverse-Effect | Since tamoxifen therapy can induce Entityendometrial disorders , surveillance schemes of women taking Entitytamoxifen have been recommended. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intravenous cytarabine and Entitymethotrexate appear to act synergistically to enhance the potential for Entitycentral nervous system toxicity . |
| 0.9999 | Adverse-Effect | Intravenous Entitycytarabine and methotrexate appear to act synergistically to enhance the potential for Entitycentral nervous system toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The fundus picture shown in these cases may be typical of EntityASPPC after EntityIVTA injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityLTG overdose may result in a severe but reversible Entityencephalopathy , a previously undescribed phenomenon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Several such EntityHBV reactivations were reported after combined Entityrituximab and multiagent chemotherapy for B - cell lymphomas. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute renal insufficiency is known to occur in patients who are taking Entityciprofloxacin , particularly the elderly. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Soon after its introduction in 1952, Entitychlorpromazine was noted to induce Entitysymptoms resembling Parkinson's disease . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A young woman with epilepsy had Entitytonic - clonic seizures during antineoplastic therapy with Entityadriamycin and cisplatin. |
| 1.0000 | Adverse-Effect | A young woman with epilepsy had Entitytonic - clonic seizures during antineoplastic therapy with adriamycin and Entitycisplatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe six patients who developed Entitytardive dyskinesia after treatment with Entitysulpiride for depression or gastrointestinal symptoms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two heroin addicts, aged 34 and 19 years, developed Entityballistic movements after intravenous Entityheroin overdose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGeneralised pustular psoriasis induced by Entitycyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityClozapine - induced Entitytardive dyskinesia in schizophrenic patients taking clozapine as a first - line antipsychotic drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Interstitial pneumonitis and Entityalveolar hemorrhage complicating use of Entityrituximab : case report and review of the literature. |
| 1.0000 | Adverse-Effect | EntityInterstitial pneumonitis and alveolar hemorrhage complicating use of Entityrituximab : case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Use of the Naranjo probability scale determined the association between Entitycephalosporin use and Entityleukopenia to be probable. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityAmantadine can cause Entityreversible corneal edema but can irreversibly reduce the density of endothelial cells. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Failure of plasmapheresis, corticosteroids and thionamides to ameliorate a case of protracted Entityamiodarone - induced Entitythyroiditis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An asymptomatic HIV - infected woman experienced right - sided Entityrenal colicky pain during treatment with Entityindinavir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The temporal relationship suggests that the Entityspinal cord infarction may be related to the use of Entityzolmitriptan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | To date, there have been few reports of Entityvisual disturbances associated with EntityBTX - B use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two cases of Entityacute pancreatitis that occurred after long term Entitymesalamine therapy for ulcerative colitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Despite administration of phenytoin and lorazepam, the Entityseizures persisted and occurred only during Entityamphotercin B administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In both patients the Entityrippling phenomena worsened with Entitypyridostigmine treatment but markedly improved after immunosuppression with azathioprine. |
| 0.9999 | Adverse-Effect | In both patients the Entityrippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with Entityazathioprine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | Acute Entityhyperphosphatemia caused by Entitysodium phosphate enema in a patient with liver dysfunction and chronic renal failure. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A new case of EntityCreutzfeldt - Jakob disease associated with Entityhuman growth hormone therapy in New Zealand. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Naranjo probability scale suggests a highly probable relationship between EntityAIN and Entitypantoprazole therapy in this patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Inadvertent subsequent rechallenge with Entityceliprolol led to recurrence of the Entitypneumonitis , 10 weeks after drug readministration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report of acute kidney injury due to Entityzonisamide - induced EntityDRESS / DIHS. |
| 1.0000 | Adverse-Effect | This is the first report of Entityacute kidney injury due to Entityzonisamide - induced DRESS / DIHS. |
| 0.9999 | Adverse-Effect | This is the first report of acute kidney injury due to Entityzonisamide - induced DRESS / EntityDIHS . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life - threatening Entityvincristine Entityneurotoxicity . |
| Adverse-Effect | Early recognition of hereditary motor and sensory neuropathy type 1 can avoid Entitylife - threatening vincristine neurotoxicity Entityvincristine neurotoxicity. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is tempting to speculate that Entityinterferon alpha may be involved in the pathogenesis of Entitylichen nitidus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These data indicated that Entityinfliximab possibly triggered Entityproduction of granulocyte and neutrophil autoantibodies with resultant autoimmune agranulocytosis. |
| 1.0000 | Adverse-Effect | These data indicated that Entityinfliximab possibly triggered production of granulocyte and neutrophil autoantibodies with resultant Entityautoimmune agranulocytosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinicians should be aware of Entityfasting hypoglycemia as an unusual but potentially serious complication of Entitydisopyramide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIFNalpha - induced recurrence of EntityGraves'disease ten years after thyroidectomy in chronic viral hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Following 7 days of Entitytigecycline she developed Entitysevere abdominal pain and elevated pancreatic enzymes suggesting acute pancreatitis. |
| 0.9999 | Adverse-Effect | Following 7 days of Entitytigecycline she developed severe abdominal pain and Entityelevated pancreatic enzymes suggesting acute pancreatitis. |
| 0.9999 | Adverse-Effect | Following 7 days of Entitytigecycline she developed severe abdominal pain and elevated pancreatic enzymes suggesting Entityacute pancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Since its FDA approval in 2002, there are no known citations of Entityezetimibe - induced Entitypancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of life - threatening Entityhyponatremia associated with Entitysibutramine use in an obese woman. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 14 - year - old girl with newly diagnosed SLE developed a Entitypruritic bullous eruption while on Entityprednisone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : EntityTamoxifen may cause Entitymalignant transformation of endometriosis through atypical endometriosis even in the postmenopausal state. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Administration of Entitypyridoxine to an infant after a long period of convulsions was followed by Entityacute hypotonia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case report of fatal Entitydapsone - induced Entityagranulocytosis in an Indian mid - borderline leprosy patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9910 | Adverse-Effect | Warfarin - induced skin necrosis and Entityheparin - induced Entitythrombocytopenia following mitral valve replacement for marantic endocarditis. |
| 0.9653 | Adverse-Effect | EntityWarfarin - induced Entityskin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for marantic endocarditis. |
| 0.9996 | Adverse-Effect | Warfarin - induced skin necrosis and heparin - induced Entitythrombocytopenia following Entitymitral valve replacement for marantic endocarditis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinicians should be vigilant when monitoring for Entitycardiotoxicity in patients receiving Entitypentamidine throughout the duration of therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a depressive patient who developed mild parkinsonian signs and Entitycamptocormia after the introduction of Entityolanzapine . |
| 0.9999 | Adverse-Effect | We present a depressive patient who developed Entitymild parkinsonian signs and camptocormia after the introduction of Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Despite the underlying hepatitis C, this case represents Entityrenal abnormalities consistent with EntityIFNalpha therapy for CML. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The ocular motor disturbances are probably an expression of regional Entity5 - FU Entityneurotoxicity primarily affecting the brain stem. |
| 1.0000 | Adverse-Effect | The Entityocular motor disturbances are probably an expression of regional Entity5 - FU neurotoxicity primarily affecting the brain stem. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : EntityQuetiapine was associated with Entityleucopenia in two patients and clinically apparent agranulocytosis in one patient. |
| 0.9996 | Adverse-Effect | RESULTS : EntityQuetiapine was associated with leucopenia in two patients and clinically apparent Entityagranulocytosis in one patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In a 61 - year - old man receiving chronic low - dosage Entityamiodarone an Entityinterstitial pneumopathy was observed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCerebrovascular complications of EntityL - asparaginase therapy in children with leukemia : aphasia and other neuropsychological deficits. |
| 1.0000 | Adverse-Effect | Cerebrovascular complications of EntityL - asparaginase therapy in children with leukemia : Entityaphasia and other neuropsychological deficits. |
| 0.9993 | Adverse-Effect | Cerebrovascular complications of EntityL - asparaginase therapy in children with leukemia : aphasia and other Entityneuropsychological deficits . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitymetoclopramide - induced Entityoculogyric crisis in a 16 - year - old girl with cystic fibrosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of severe aplastic anemia ( EntityAA ) that was probably induced by Entitylenalidomide . |
| 1.0000 | Adverse-Effect | We describe a case of Entitysevere aplastic anemia ( AA ) that was probably induced by Entitylenalidomide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case report : Entitydapsone Entityhypersensitivity syndrome associated with treatment of the bite of a brown recluse spider. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Experience with five patients in whom Entityimpaired renal function developed early during Entityamphotericin B therapy is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : We report a patient who had an Entityanaphylactic reaction during the intravenous infusion of Entitycyclosporine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : There may be an association between Entityraloxifene and the development of Entitymalignant mixed mesodermal tumor . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : To describe the occurrence of Entityocular hypertension in four patients following injection of Entityranibizumab intravitreally. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVancomycin is the most frequently implicated drug, but other agents have been reported to cause EntityLABD . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two of our patients developed EntityTD after 23 months and 34 months of Entityziprasidone monotherapy, respectively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | While both amiodarone and Entitydigoxin can cause permanent Entityvisual changes , the ocular effects are often reversible. |
| 0.9999 | Adverse-Effect | While both amiodarone and Entitydigoxin can cause permanent visual changes, the Entityocular effects are often reversible. |
| 0.9998 | Adverse-Effect | While both Entityamiodarone and digoxin can cause permanent visual changes, the Entityocular effects are often reversible. |
| 0.9998 | Adverse-Effect | While both Entityamiodarone and digoxin can cause permanent Entityvisual changes , the ocular effects are often reversible. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entityfatal massive pulmonary embolus developed in a patient treated with Entitystreptokinase for acute deep vein thrombosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | L - Carnitine supplementation has been recommended to prevent the Entityfatal hepatotoxic effects associated with Entityvalproic acid . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Biopsy - proven Entityacute interstitial nephritis associated with the tyrosine kinase inhibitor Entitysunitinib : a class effect? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four patients receiving high - dose Entitytamoxifen for greater than 1 year have demonstrated similar Entityretinal changes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After five and six weeks of continuous oral administration of Entitymethylprednisolone , the boys developed Entitysteroid diabetes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Multiple complications of Entitypropylthiouracil treatment : Entitygranulocytopenia , eosinophilia, skin reaction and hepatitis with lymphocyte sensitization. |
| 1.0000 | Adverse-Effect | Multiple complications of Entitypropylthiouracil treatment : granulocytopenia, eosinophilia, skin reaction and Entityhepatitis with lymphocyte sensitization. |
| 0.9999 | Adverse-Effect | Multiple complications of Entitypropylthiouracil treatment : granulocytopenia, Entityeosinophilia , skin reaction and hepatitis with lymphocyte sensitization. |
| 0.9999 | Adverse-Effect | Multiple complications of Entitypropylthiouracil treatment : granulocytopenia, eosinophilia, skin reaction and hepatitis with Entitylymphocyte sensitization . |
| 0.9999 | Adverse-Effect | Multiple complications of Entitypropylthiouracil treatment : granulocytopenia, eosinophilia, Entityskin reaction and hepatitis with lymphocyte sensitization. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Myoclonus and Entityseizures in a patient with parkinsonism : induction by Entitylevodopa and its confirmation on SEPs. |
| 0.9999 | Adverse-Effect | EntityMyoclonus and seizures in a patient with parkinsonism : induction by Entitylevodopa and its confirmation on SEPs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient of organic bipolar affective disorder who developed Entityhiccups with the atypical antipsychotic Entityaripiprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Based on the history and clinical features, a diagnosis of Entityinsulin - induced Entitylipohypertrophy was made. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a neonate with a seizure disorder who acutely developed Entitypupillary mydriasis secondary to Entitylidocaine overdose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There are, however, case studies describing patients experiencing recurrences of Entitytics following treatment with Entityatomoxetine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9976 | Adverse-Effect | We report the use of pamidronate for acute, severe hypercalcemia secondary to iatrogenic Entityvitamin D Entityvitamin D poisoning . |
| 0.9744 | Adverse-Effect | We report the use of pamidronate for acute, Entitysevere hypercalcemia secondary to iatrogenic Entityvitamin D poisoning. |
| 0.9994 | Adverse-Effect | We report the use of Entitypamidronate for acute, Entitysevere hypercalcemia secondary to iatrogenic vitamin D poisoning. |
| 0.6577 | Adverse-Effect | We report the use of Entitypamidronate for acute, severe hypercalcemia secondary to iatrogenic Entityvitamin D poisoning . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entityphoto - onycholysis in a patient treated with Entitydoxycycline for acne vulgaris. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We herein report this rare case of acute onset of Entitynephrotic syndrome during Entityinterferon - alpha retreatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The occurrence of severe EntityAIHA in CLL patients treated with Entityfludarabine has been reported by several authors. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present the first case of a patient with Entitypriapism after oral intake of the phenothiazine Entityprothipendylhydrochloride . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of Entityamodiaquine and artesunate. |
| 1.0000 | Adverse-Effect | EntityAcute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and Entityartesunate . |
| Adverse-Effect | Acute Entityasymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of Entityamodiaquine and artesunate. | |
| Adverse-Effect | Acute Entityasymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and Entityartesunate . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case highlights the possible development of Entityacute coronary syndrome as a side effect of EntityCapecitabine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAvascular necrosis of the femoral head in patients with prostate cancer treated with Entitycyproterone acetate and radiotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTorsemide appears to also be a part of a long list of agents that can cause Entitypancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute renal failure most likely was secondary to the nephrotoxic effect of Entitycaptopril on chronically hypoperfused kidneys. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient was given Entitymethimazole instead of propylthiouracil but, 10 weeks later, Entityagranulocytosis again occurred. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The present case is the first report of Entityhypercalcemia induced by Entityvitamin D3 ointment and thiazide simultaneously. |
| 0.9998 | Adverse-Effect | The present case is the first report of Entityhypercalcemia induced by vitamin D3 ointment and Entitythiazide simultaneously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of Entityclozapine - induced Entityseizures in a patient with treatment - resistant schizophrenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPleuropulmonary changes during treatment of Parkinson's disease with a long - acting ergot derivative, Entitycabergoline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | However, because Entitydiphenhydramine also exhibits type IA sodium channel blockade, Entitycardiac toxicity is also possible. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | While 40 mg / day of Entityprednisolone improved hepatic dysfunction dramatically, her Entitydiabetic milieu deteriorated seriously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two cases of Entityhypothyroidism in patients with chronic hepatitis C treated with Entityrecombinant alpha interferon are reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report EntityAZA - induced Entitydrug eruption that developed in two cases of systemic scleroderma with polymyositis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The condition should be suspected in patients who develop unexplained abdominal pain or Entitycollapse following Entityvasopressin treatment. |
| 1.0000 | Adverse-Effect | The condition should be suspected in patients who develop unexplained Entityabdominal pain or collapse following Entityvasopressin treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reversal of Entitygold - induced Entityneutropenia with granulocyte colony - stimulating factor ( G - CSF ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPsychosis in a 12 - year - old HIV - positive girl with an increased serum concentration of Entityefavirenz . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 35 - year - old man with seropositive rheumatoid arthritis developed selective EntityIgA deficiency during treatment with Entityfenclofenac . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of recurrent Entitytorsades de pointes following treatment with pentavalent antimonial drugs and Entityamiodarone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | SUBSEQUENT COURSE : The Entitynephrosis resolved almost completely once the Entityinterferon was stopped and after immunosuppressive treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAsthenozoospermia : possible association with long - term exposure to an anti - epileptic drug of Entitycarbamazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : We studied a case of Entityvortex keratopathy that was associated with the use of Entityatovaquone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report 2 cases of nonconvulsive status epilepticus ( EntityNCSE ) following infusion of Entityifosfamide . |
| 1.0000 | Adverse-Effect | OBJECTIVE : To report 2 cases of Entitynonconvulsive status epilepticus ( NCSE ) following infusion of Entityifosfamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The cause is presumed to be secondary to hypercoagulability due to Entityasparaginase - induced Entityantithrombin III deficiency . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe the development of Entityvalproate - related Entityreproductive endocrine disorders in women with epilepsy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians treating patients with Entitymethotrexate for juvenile rheumatoid arthritis must be aware of this Entityextraarticular side effect . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Slow acetylator genotypes as a possible risk factor for Entityinfectious mononucleosis - like syndrome induced by Entitysalazosulfapyridine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case, to our knowledge, of Entityrituximab - related Entityautoimmune hemolytic anemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A depressed woman with no history of bipolar illness developed a Entitymanic episode during treatment with Entityfluoxetine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | With Entityitraconazole , Entityhepatotoxic reactions have only very rarely been reported, and histologic data are lacking. |
| 1.0000 | Adverse-Effect | With Entityitraconazole , Entityhepatotoxic reactions have only very rarely been reported, and histologic data are lacking. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The other woman had rheumatoid arthritis and developed Entityacute tubular necrosis after treatment with Entitygentamicin and cefoxitin. |
| 0.9999 | Adverse-Effect | The other woman had rheumatoid arthritis and developed Entityacute tubular necrosis after treatment with gentamicin and Entitycefoxitin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of possible Entityfoscarnet - induced Entitysevere hypomagnesemia and other electrolyte disorders. |
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of possible Entityfoscarnet - induced severe hypomagnesemia and other Entityelectrolyte disorders . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CONCLUSION : EntityLipoid pneumonia as a result of Entitymineral oil aspiration still occurs in the pediatric population. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySecretory endometrial adenocarcinoma in a patient on Entitytamoxifen for breast cancer : a report of a case. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : Five cases of Entitycontact dermatitis due to Entitybudesonide , a nonhalogenated steroid, are described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe 2 children with cerebral palsy who suffered significant Entitymorbidity immediately after treatment with Entityhyperbaric oxygen . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Cyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate Entitysimvastatin - induced Entityrhabdomyolysis . |
| 0.9990 | Adverse-Effect | EntityCyclosporine is a potent inhibitor of simvastatin metabolism, and may therefore facilitate simvastatin - induced Entityrhabdomyolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, no prior cases of Entitypenicillamine - induced EntityTTP in RA have been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two patients with acne vulgaris with a fourth type of Entityminocycline - induced Entitycutaneous pigmentation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTumor lysis syndrome after transcatheter arterial infusion of Entitycisplatin and embolization therapy for liver metastases of melanoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere cardiomyopathy following treatment with the tumour necrosis factor - alpha inhibitor Entityadalimumab for Crohn's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Detection of antineutrophil cytoplasmic antibody in a patient with EntityL - tryptophan induced Entityeosinophilia - myalgia syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with seropositive rheumatoid arthritis developed Entityascites while taking weekly doses of Entitymethotrexate ( MTX ). |
| 1.0000 | Adverse-Effect | A patient with seropositive rheumatoid arthritis developed Entityascites while taking weekly doses of methotrexate ( EntityMTX ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe 3 elderly patients with moderate to severe Entityataxia that occurred while they were taking Entitypropafenone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityAluminum intoxication, along with other factors, was considered to be the cause of EntityTC development. |
| 0.9998 | Adverse-Effect | EntityAluminum EntityAluminum intoxication , along with other factors, was considered to be the cause of TC development. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTransient central diabetes insipidus in the setting of underlying chronic nephrogenic diabetes insipidus associated with Entitylithium use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProlongation of the QT interval observed in a Japanese patient with vivax malaria following treatment with Entityhalofantrine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first histopathologically documented case of Entityoral mucosa pigmentation after OLP treatment with topical Entitytacrolimus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After cessation of Entityamantadine , the Entityedema resolved, and the endothelial cell densities were < or = 600 / mm. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A possible mechanism for Entityfocal neurological deficit in brain - damaged patients on Entityphenytoin therapy is discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute generalized exanthematous pustulosis caused by Entitymorphine , confirmed by positive patch test and lymphocyte transformation test. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a patient developing Entityfulminant liver failure while being treated with Entityclarithromycin for pneumonia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient suffered Entitycoronary artery vasospasm , attributed to the use of topical 1 : 1000 Entityepinephrine during surgery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcetazolamide may have accelerated the development of Entityosteomalacia by several mechanisms, including increased renal calcium excretion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The incidence of 5 - fluorouracil ( Entity5 - FU ) - related Entitycardiotoxicity seems to be dosage and schedule dependent. |
| 0.9998 | Adverse-Effect | The incidence of Entity5 - fluorouracil ( 5 - FU ) - related Entitycardiotoxicity seems to be dosage and schedule dependent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A case of Entityacute respiratory failure due to diaphragmatic weakness following Entityadalimumab therapy for psoriasis is described. |
| 1.0000 | Adverse-Effect | A case of acute respiratory failure due to Entitydiaphragmatic weakness following Entityadalimumab therapy for psoriasis is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIndinavir - associated Entitynephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient. |
| 0.9995 | Adverse-Effect | EntityIndinavir - associated nephrolithiasis and chronic Entityinterstitial nephritis were the only possible causes identified in this patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Diagnosis of Entityhypothyroidism during treatment can be difficult because of the common side effects of Entityalpha interferon . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entitycutaneous and hematologic toxicity in a patient treated with EntityIL - 2 . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Improved awareness of and further investigation into the Entityneurotoxic effects of Entityofloxacin may enhance its safe use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Several possible explanations of the mechanism of Entityrenal failure associated with the use of Entitydextran - 40 are discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We postulate that the bolus of Entitysulprostone resulted in possible Entitycoronary spasm that resulted in cardiac arrest. |
| 0.9999 | Adverse-Effect | We postulate that the bolus of Entitysulprostone resulted in possible coronary spasm that resulted in Entitycardiac arrest . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Neurophysiological mechanisms which aid in elucidating the role of Entitydisulfiram in the etiology of Entitycatatonia are discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There is documentation of Entityocular toxicity with Entityethambutol when administered at dosages generally pronounced as being safe. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hydrocortisone may decrease the incidence of mortality associated with Entitycardiac arrhythmias in children receiving Entityamphotericin B overdoses. |
| 0.9995 | Adverse-Effect | Hydrocortisone may decrease the incidence of Entitymortality associated with cardiac arrhythmias in children receiving Entityamphotericin B overdoses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There are no previous reports in the literature about the emergence of EntityCML during treatment with Entityhydroxyurea . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An infertile patient with amenorrhea - galactorrhea syndrome Entitylost vision during a pregnancy occurring after EntityBromocryptine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Herein, we present a patient with severe and prolonged Entityhypoglycemia after long - acting Entityoctreotide treatment. |
| Adverse-Effect | Herein, we present a patient with severe and Entityprolonged hypoglycemia after long - acting Entityoctreotide treatment. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of Entitypneumonitis following local administration of Entitymethotrexate for nonsurgical termination of an ectopic pregnancy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProgressive hypoxemia mandated endotracheal intubation 1 week after Entityrituximab administration and led to death 4 weeks after admission. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityHUS has been reported after several anticancer chemotherapies and most often after Entitymitomycin C - based chemotherapy regimens. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Evidence of neurological improvement and rehabilitation potential after Entitysevere myelopathy due to intrathecal injection of Entitydoxorubicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hyperkalaemia with Entityrenal tubular dysfunction by Entitysulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. |
| 0.9992 | Adverse-Effect | EntityHyperkalaemia with renal tubular dysfunction by Entitysulfamethoxazole - trimethoprim for Pneumocystis carinii pneumonia in patients with lymphoid malignancy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : EntityAtovaquone should be added to the list of agents causing Entityvortex keratopathy involving the corneal epithelium. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPosterior reversible encephalopathy syndrome associated with Entitymethotrexate neurotoxicity : conventional magnetic resonance and diffusion - weighted imaging findings. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 23 - year - old woman with systemic lupus erythematosus had a Entitysevere hypersensitivity reaction to the drug Entityibuprofen . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of EntityGraves'hyperthyroidism induced by long - term Entityinterferon ( IFN ) therapy. |
| 0.9999 | Adverse-Effect | We report a case of EntityGraves'hyperthyroidism induced by long - term interferon ( EntityIFN ) therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of Entityulcerative proctitis after Entityibuprofen treatment in a girl with juvenile systemic lupus erythematosus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These cases indicate that Entitysulpiride can cause Entitytardive dyskinesia and that this drug should be administered with caution. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPremature closure of the ductus arteriosus : variable response among monozygotic twins after in utero exposure to Entityindomethacin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When Entityvague symptoms develop during Entitydesmopressin therapy, hyponatremia must be considered as part of the differential diagnosis. |
| 1.0000 | Adverse-Effect | When vague symptoms develop during Entitydesmopressin therapy, Entityhyponatremia must be considered as part of the differential diagnosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 78 - year - old man with a transvenous cardioverter defibrillator system developed frequent Entityshocks during oral Entityprocainamide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Transient left homonymous hemianopsia and Entityencephalopathy following treatment of testicular carcinoma with Entitycisplatinum , vinblastine, and bleomycin. |
| 1.0000 | Adverse-Effect | EntityTransient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with Entitycisplatinum , vinblastine, and bleomycin. |
| 0.9999 | Adverse-Effect | Transient left homonymous hemianopsia and Entityencephalopathy following treatment of testicular carcinoma with cisplatinum, Entityvinblastine , and bleomycin. |
| 0.9999 | Adverse-Effect | Transient left homonymous hemianopsia and Entityencephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and Entitybleomycin . |
| 0.9999 | Adverse-Effect | EntityTransient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, Entityvinblastine , and bleomycin. |
| 0.9999 | Adverse-Effect | EntityTransient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and Entitybleomycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPirmenol hydrochloride - induced EntityQT prolongation and T wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation. |
| 0.9992 | Adverse-Effect | EntityPirmenol hydrochloride - induced QT prolongation and EntityT wave inversion on electrocardiogram during treatment for symptomatic atrial fibrillation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reported are three children who developed Entityprogressive paraparesis after intrathecal Entitymethotrexate administration followed by complete or partial recovery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Dexamethasone treatment of Entityamiodarone - induced Entitythyrotoxicosis ( AIT ) with or without persistent administration of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Gallstones and Entitybile sludge are common side effects of Entityoctreotide therapy but rarely become symptomatic or require treatment. |
| 1.0000 | Adverse-Effect | EntityGallstones and bile sludge are common side effects of Entityoctreotide therapy but rarely become symptomatic or require treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityIsoniazid inhibits the conversion of tryptophan to niacin and may induce Entitypellagra , particularly in poorly nourished patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : A review of the cases of EntitySS with implication of Entitymirtazapine as the cause was performed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Both 6 - MP and EntityAZA are widely used and are known to cause Entityhepatotoxicity in a proportion of patients. |
| 0.9999 | Adverse-Effect | Both Entity6 - MP and AZA are widely used and are known to cause Entityhepatotoxicity in a proportion of patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of radiotherapy - enhanced Entityaminoglutethimide Entityskin toxicity in a patient with metastatic breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is increasingly recognized that dose adjustment of oral Entityvalacyclovir in renal failure is necessary to avoid Entityneurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Long - term follow - up after Entityneoplastic seeding complicating percutaneous Entityethanol injection for treatment of hepatocellular carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Administration of lamotrigine, especially in combination with Entityvalproic acid , may lead to the development of EntityTEN . |
| 0.9999 | Adverse-Effect | Administration of Entitylamotrigine , especially in combination with valproic acid, may lead to the development of EntityTEN . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We believe that this is the first report of Entitysecretory carcinoma of the endometrium associated with Entitytamoxifen use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, four cases of Entityinterstitial pneumonitis associated with Entityfludarabine have been reported in medical literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two cases of widespread Entitycutaneous vasculitis are described in association with Entitydiltiazem , a recently introduced calcium antagonist. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this is the first reported case of Entitybromide intoxication due to Entitypyridostigmine bromide administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVerapamil is widely used for the termination of paroxysmal supraventricular tachycardia ( PSVT ) with little Entityproarrhythmic effect . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, the amount of Entityprednisone required to maintain normotension resulted in EntityCushingoid features and has been discontinued. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is a case of Entitypseudoephedrine - induced Entityintracerebral hemorrhage in a patient with an underlying vascular malformation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNitrofurantoin - induced Entitypulmonary toxicity during pregnancy : a report of a case and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Knowledge regarding potential adverse effects of EntityCAP is paramount and dose modification is indicated with development of Entityneurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A 75 - year - old man developed Entitybilateral lower leg edema 6 months after switching from troglitazone to Entitypioglitazone . |
| 1.0000 | Adverse-Effect | A 75 - year - old man developed Entitybilateral lower leg edema 6 months after switching from Entitytroglitazone to pioglitazone. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with an allergy to a macrolide antibiotic was given Entitytacrolimus and developed a Entitysudden cutaneous reaction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, there are few reports in the literature of Entityampicillin as a cause of Entityacute interstitial nephritis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pulmonary eosinophilia or granulomas, classically seen in previously reported cases of Entitymethotrexate Entitypneumonitis , were not observed. |
| 1.0000 | Adverse-Effect | Pulmonary eosinophilia or Entitygranulomas , classically seen in previously reported cases of Entitymethotrexate pneumonitis, were not observed. |
| 0.9998 | Adverse-Effect | EntityPulmonary eosinophilia or granulomas, classically seen in previously reported cases of Entitymethotrexate pneumonitis, were not observed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute myelogenous leukemia in patients receiving Entitychlorambucil as long - term adjuvant chemotherapy for stage II breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHepatoxicity is a rare complication of EntitySRL therapy and may be connected with some diagnostic and / or therapeutic problems. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Replacing Entityvalproate with lamotrigine resulted in a Entitydecrease in serum testosterone concentrations in all 3 women. |
| Adverse-Effect | RESULTS : Replacing Entityvalproate with lamotrigine resulted in a decrease in Entityserum testosterone concentrations in all 3 women. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Tacrolimus ( EntityFK506 ), an immunosuppressant, has been associated with Entitymutism in adults after liver transplant. |
| 1.0000 | Adverse-Effect | EntityTacrolimus ( FK506 ), an immunosuppressant, has been associated with Entitymutism in adults after liver transplant. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Both the longitudinal melanonychia and the Entitymultiple skin cancers first appeared after approximately 6 months of Entityhydroxyurea treatment. |
| 1.0000 | Adverse-Effect | Both the Entitylongitudinal melanonychia and the multiple skin cancers first appeared after approximately 6 months of Entityhydroxyurea treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The NZ Pharmacovigilance Centre has received 7 additional reports of Entitysevere infections in patients with RA taking Entityleflunomide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityINH , which is a leading cause of Entitydrug eruptions in the above group of drugs was withdrawn. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two cases of cerebrospinal fluid eosinophilia ( EntityCSFE ) secondary to the intraventricular administration of Entityvancomycin . |
| 1.0000 | Adverse-Effect | We report two cases of Entitycerebrospinal fluid eosinophilia ( CSFE ) secondary to the intraventricular administration of Entityvancomycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : The Naranjo probability scale indicated a probable relationship between Entitysertraline treatment and the onset of Entityrhabdomyolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : We have introduced a case of Entityanaphylaxis by Entitycalcitonin that suggest an IgE mediated hypersensitivity reaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | No explanation for this delay was found, other than the possibility that Entitymagnesium sulfate treatment Entityimpeded lactogenesis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here we report Entityramipril - induced Entitycutaneous vasculitis in a patient who required steroid therapy to control it. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHydroxyurea associated with concomitant occurrence of Entitydiffuse longitudinal melanonychia and multiple squamous cell carcinomas in an elderly subject. |
| 1.0000 | Adverse-Effect | EntityHydroxyurea associated with concomitant occurrence of diffuse longitudinal melanonychia and Entitymultiple squamous cell carcinomas in an elderly subject. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case suggests the importance of careful observation for Entityextramedullary relapse in patients who are treated with EntityATRA . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | With the increasing use of EntityCyclosporine A in transplant patients, the incidence of Entityherpes esophagitis may increase. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIsotretinoin , a drug used for the treatment of acne, has been shown to have Entityteratogenic effects . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityazathioprine dose was low ( 1 mg / kg ) and Entitypancytopenia occurred after 56 days therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 3 patients with Entitysevere hepatocellular damage due to EntityCPA therapy, 2 with fatal fulminant hepatitis. |
| 0.9994 | Adverse-Effect | We report 3 patients with severe hepatocellular damage due to EntityCPA therapy, 2 with Entityfatal fulminant hepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case study describes an atypical case of refractory, Entitysodium warfarin - induced Entitynecrotizing fasciitis and myonecrosis. |
| 0.9995 | Adverse-Effect | This case study describes an atypical case of refractory, Entitysodium warfarin - induced necrotizing fasciitis and Entitymyonecrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 77 - year - old man developed Entityankle, hand, and facial swelling 2 weeks after starting Entityrosiglitazone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It has been reported that Entityfluoroquinolone antimicrobials prolong the corrected QT interval but rarely cause Entitytorsade de pointes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Beneficial effect of low - dose mianserin on Entityfluvoxamine - induced Entityakathisia in an obsessive - compulsive patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLinezolid - associated Entityacute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome. |
| 0.9999 | Adverse-Effect | EntityLinezolid - associated acute interstitial nephritis and Entitydrug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome. |
| 0.9999 | Adverse-Effect | EntityLinezolid - associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms ( EntityDRESS ) syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Immunosuppression elicited by the extensive administration of Entityprednisolone was suspected for the initiation of the generalized Entitymite infestation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : EntityAphthous stomatitis , a common mucocutaneous disorder, is a well accepted complication of Entitysirolimus therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report two cases of acute dystonic reactions ( EntityADRs ) as a side effect of Entitylamivudine . |
| 1.0000 | Adverse-Effect | The authors report two cases of Entityacute dystonic reactions ( ADRs ) as a side effect of Entitylamivudine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 52 - year - old woman developed symmetric sensorimotor polyneuropathy and Entitycerebellar syndrome after 24 months of Entityamiodarone treatment. |
| 0.9999 | Adverse-Effect | A 52 - year - old woman developed Entitysymmetric sensorimotor polyneuropathy and cerebellar syndrome after 24 months of Entityamiodarone treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is hoped that this case report creates awareness that Entityofloxacin - induced Entitytoxic epidermal necrolysis is possible. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A second possibility is an interaction between clarithromycin and Entityisradipine , potentially Entityincreasing the hepatic toxicity of isradipine. |
| 0.9999 | Adverse-Effect | A second possibility is an interaction between clarithromycin and isradipine, potentially Entityincreasing the hepatic toxicity of Entityisradipine . |
| 0.9994 | Adverse-Effect | A second possibility is an interaction between Entityclarithromycin and isradipine, potentially Entityincreasing the hepatic toxicity of isradipine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | These cases highlight the occurrence of Entitylivedo reticularis as an uncommon side - effect of Entityinterferon alpha treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Significant Entityweight loss is a potential adverse event in patients with rheumatoid arthritis treated with Entityleflunomide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityacne fulminans occurring during treatment with Entity13 - cis - retinoic acid for cystic acne. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Fever and Entitymaculopapular rashes appeared at 10 days after Entityphenytoin initiation, and then the drug was discontinued. |
| 0.9999 | Adverse-Effect | EntityFever and maculopapular rashes appeared at 10 days after Entityphenytoin initiation, and then the drug was discontinued. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case and other published evidence should alert physicians to the possibility of fatal Entityerlotinib - induced EntityILD . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityototoxicity of Entityquinine can accurately be studied with ultrahigh frequency audiometry ( up to 20 kHz ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One case of Entitypriapism occurred during Entityheparin therapy for a previous surgical operation to the knee is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This prompted us to suspect that EntityddI might be responsible for Entityfulminant hepatitis in all three AIDS patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDrug eruption caused by Entityazathioprine : value of using the drug - induced lymphocytes stimulation test for diagnosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reye syndrome ( EntityRS ) is believed to occur infrequently among children receiving long - term Entityaspirin therapy. |
| 1.0000 | Adverse-Effect | EntityReye syndrome ( RS ) is believed to occur infrequently among children receiving long - term Entityaspirin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A retrospective study was conducted of 40 Entityloperamide Entityloperamide poisoning cases recorded at the Centre National d'Informations Toxicologiques Veterinaires. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case of a bipolar patient who developed thyrotoxicosis with Entitysevere exophthalmos while on Entitylithium therapy is described. |
| 0.9999 | Adverse-Effect | The case of a bipolar patient who developed Entitythyrotoxicosis with severe exophthalmos while on Entitylithium therapy is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reports of Entitycolonic perforation as a result of the administration of Entitycalcium polystyrene sulfonate and sorbitol are rare. |
| 0.9998 | Adverse-Effect | Reports of Entitycolonic perforation as a result of the administration of calcium polystyrene sulfonate and Entitysorbitol are rare. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : EntityOvarian cancer arising from an endometriotic cyst in a postmenopausal woman under Entitytamoxifen therapy is rare. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Administration of steroid and decreasing the dose of EntityPTU produced a good clinical response and the EntityANCA disappeared. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prior reports have emphasized the Entitytubular and interstitial lesions associated with intermittent or discontinuous Entityrifampin therapy for tuberculosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a Entityscleroderma - like reaction induced by long - term administration of EntityUFT . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityFludarabine induced Entitylung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine. |
| Adverse-Effect | Fludarabine induced lung toxicity must be considered in all patients who develop unexplained Entitylung disease while receiving Entityfludarabine . | |
| Adverse-Effect | EntityFludarabine induced lung toxicity must be considered in all patients who develop unexplained Entitylung disease while receiving fludarabine. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Phenylpropanolamine ( EntityPPA ) recently has been publicly implicated as a cause of Entitystroke and other neurologic events. |
| 1.0000 | Adverse-Effect | Phenylpropanolamine ( EntityPPA ) recently has been publicly implicated as a cause of stroke and other Entityneurologic events . |
| 1.0000 | Adverse-Effect | EntityPhenylpropanolamine ( PPA ) recently has been publicly implicated as a cause of Entitystroke and other neurologic events. |
| 1.0000 | Adverse-Effect | EntityPhenylpropanolamine ( PPA ) recently has been publicly implicated as a cause of stroke and other Entityneurologic events . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first case, to our knowledge, of onset of prolonged Entityinfliximab - induced Entitylupus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRitonavir should be added to the list of drugs that can induce Entityadverse cutaneous reactions in HIV patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | High - dose Entitymethylprednisolone in a pregnant woman with Crohn's disease and Entityadrenal suppression in her newborn. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 55 - year - old woman developed symptoms suggestive of Entityhepatitis 12 weeks after first receiving Entitymethyldopa for hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Successful recovery from Entityinterstitial pneumonitis , induced by Entitybicalutamide and leuprorelin acetate given as treatment for prostate cancer. |
| 0.9996 | Adverse-Effect | Successful recovery from Entityinterstitial pneumonitis , induced by bicalutamide and Entityleuprorelin acetate given as treatment for prostate cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After the patient discontinued Entityrifampicin , the Entityskin lesions cleared completely within 5 weeks without any systemic medication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMannitol - induced EntityARF responds promptly to hemodialysis with rapid resolution of anuria and recovery of renal failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In a patient with severe renovascular hypertension, Entitynonoliguric acute renal failure developed after she received Entitycaptopril treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entitycutaneous leucocytoclastic vasculitis in which Entityamphotericin B might presumably be the aetiological factor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report of an adverse effect of Entityfetal renal circulation by maternal ingestion of Entitynimesulide . |
| Adverse-Effect | This is the first report of an Entityadverse effect of fetal renal circulation by maternal ingestion of Entitynimesulide . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a patient who developed Entityhypersensitivity pneumonitis during treatment with the beta - blocker, Entityceliprolol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He developed recurrent skin rash, fever, hypereosinophilia, and Entityacute renal failure after rechallenge with Entitychlorambucil . |
| 1.0000 | Adverse-Effect | He developed recurrent skin rash, fever, Entityhypereosinophilia , and acute renal failure after rechallenge with Entitychlorambucil . |
| 1.0000 | Adverse-Effect | He developed recurrent skin rash, Entityfever , hypereosinophilia, and acute renal failure after rechallenge with Entitychlorambucil . |
| 0.9999 | Adverse-Effect | He developed recurrent Entityskin rash , fever, hypereosinophilia, and acute renal failure after rechallenge with Entitychlorambucil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a male patient with advanced AIDS who developed Entityhypercalcemia 2 weeks after institution of EntityrhGH therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A rare case of advanced ovarian carcinoma who developed Entitydifficulty walking 25 days after treatment with weekly Entitypaclitaxel . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two cases that developed acute myeloid leukaemia ( EntityAML ) during Entitytamoxifen therapy for breast cancer. |
| 1.0000 | Adverse-Effect | We report two cases that developed Entityacute myeloid leukaemia ( AML ) during Entitytamoxifen therapy for breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report three cases of Entitysevere hypocalcaemia associated with i. v. Entitybisphosphonate treatment in patients with multiple myeloma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The authors report two cases of Entitydelayed elimination of Entitymethotrexate in patients receiving ciprofloxacin, with severe toxicity. |
| 0.9943 | Adverse-Effect | The authors report two cases of Entitydelayed elimination of methotrexate in patients receiving Entityciprofloxacin , with severe toxicity. |
| 0.9983 | Adverse-Effect | The authors report two cases of delayed elimination of methotrexate in patients receiving Entityciprofloxacin , with Entitysevere toxicity . |
| 0.9534 | Adverse-Effect | The authors report two cases of delayed elimination of Entitymethotrexate in patients receiving ciprofloxacin, with Entitysevere toxicity . |
| Adverse-Effect | The authors report two cases of delayed elimination of methotrexate in patients receiving Entityciprofloxacin , with severe Entitytoxicity . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Administration of Entityamantadine was associated with Entitypsychotic decompensations in two schizophrenic patients being maintained on concomitant neuroleptic medication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients are described who developed Entitysensory neuropathy after the ingestion of 30. 6 and 114 g Entitymetronidazole respectively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal ventricular fibrillation after treatment with Entitydigoxin in a 27 - year - old man with mitral leaflet prolapse syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of interstitial pulmonary disease that occurred together with Entitylymphocytic colitis during treatment with Entityticlopidine . |
| 0.9999 | Adverse-Effect | We report a case of Entityinterstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with Entityticlopidine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | These Entityskin lesions may be induced or worsened during antiviral therapy with Entityinterferon - alpha ( IFN ). |
| 0.9996 | Adverse-Effect | These Entityskin lesions may be induced or worsened during antiviral therapy with interferon - alpha ( EntityIFN ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9993 | Adverse-Effect | After treatment with Entitycimetidine , there was a rapid deterioration with Entitydecreased oxygen saturation and arterial PO2 values. |
| 1.0000 | Adverse-Effect | After treatment with Entitycimetidine , there was a rapid Entitydeterioration with decreased oxygen saturation and arterial PO2 values. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFlecainide overdose can rapidly result in profound Entitycardiovascular collapse , and is associated with a relatively high mortality. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The three reported cases demonstrate that Entitytroglitazone is an idiosyncratic hepatotoxin that can lead to Entityirreversible liver injury . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : The aim of this paper is to describe a case of Entityincreased libido during Entityfluvoxamine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The development of erythroid leukemia plus Entitycarcinoma in these two men suggests mutagenic change secondary to Entitycyclophosphamide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute renal failure with Entitysevere tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with Entityenalapril . |
| 1.0000 | Adverse-Effect | EntityAcute renal failure with severe tubulointerstitial changes in a patient with minimal change nephrotic syndrome treated with Entityenalapril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : To our knowledge this is the first reported case of Entitytuberculous uveitis following treatment with Entityetanercept . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityL - asparaginase - induced Entitypancreatitis is an uncommon but potential lethal complication of the treatment of leukemia. |
| 0.9970 | Adverse-Effect | EntityL - asparaginase - induced pancreatitis is an uncommon but potential Entitylethal complication of the treatment of leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The cases of two asthmatic patients who became Entityhypokalemic after inhalation of normal doses of Entityalbuterol are presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | How low can you go? Use of very low dosage of Entitygold in patients with Entitymucocutaneous reactions . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRhabdomyolysis associated with Entityclozapine treatment in a patient with decreased calcium - dependent potassium permeability of cell membranes. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9938 | Adverse-Effect | EntityPosterior reversible encephalopathy syndrome ( PRES ) induced by Entitycyclosporine use in a patient with collapsing focal glomeruloesclerosis. |
| Adverse-Effect | Posterior reversible encephalopathy syndrome ( EntityPRES ) induced by Entitycyclosporine use in a patient with collapsing focal glomeruloesclerosis. | |
| Adverse-Effect | EntityPosterior reversible encephalopathy syndrome ( EntityPRES ) induced by cyclosporine use in a patient with collapsing focal glomeruloesclerosis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The association of Entityvenlafaxine treatment with Entityischaemic events could be explained by its unique pharmacological and haemodynamic properties. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of a Entitydiffuse papular eruption following treatment of psoriasis with Entitymethotrexate injections. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Attenuation of Entityasparaginase - induced Entityhyperglycemia after substitution of the Erwinia carotovora for the Escherichia coli enzyme preparation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Posthypoglycemic hyperglycemia ( Entityrebound hyperglycemia ) after overdosing of Entityinsulin was diagnosed in 6 cats with diabetes mellitus. |
| 0.9999 | Adverse-Effect | EntityPosthypoglycemic hyperglycemia ( rebound hyperglycemia ) after overdosing of Entityinsulin was diagnosed in 6 cats with diabetes mellitus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityclozapine - induced Entitytonic - clonic seizures managed with valproate : implications for clinical care. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes a case of Entityneuroleptic malignant syndrome due to Entityrisperidone in a child with Joubert syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | It has been suggested that EntityPPE caused by Entitycytarabine does not recur with subsequent cytarabine re - challenge. |
| 0.9602 | Adverse-Effect | It has been suggested that EntityPPE caused by cytarabine does not recur with subsequent Entitycytarabine re - challenge. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Treatment of Entityamiodarone - induced Entitythyrotoxicosis ( AIT ) with thionamide, lithium or radioactive iodine is ineffective. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 68 - year - old female patient with advanced ovarian carcinoma Entitycollapsed whilst receiving a Entitycarboplatin and cyclophosphamide infusion. |
| 1.0000 | Adverse-Effect | A 68 - year - old female patient with advanced ovarian carcinoma Entitycollapsed whilst receiving a carboplatin and Entitycyclophosphamide infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityImidazoline EntityImidazoline intoxication due to overdose or accidental ingestion but also after normal therapeutic usage is frequent in children. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The occurrence of EntityBMTN in two children treated with EntityRA in our unit is unlikely to be coincidental. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Multiple pulmonary nodules : an unusual presentation of Entityfludarabine Entitypulmonary toxicity : case report and review of literature. |
| 0.9997 | Adverse-Effect | EntityMultiple pulmonary nodules : an unusual presentation of Entityfludarabine pulmonary toxicity : case report and review of literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityExtrapyramidal symptoms are well - documented complications of therapy with Entityhaloperidol , even when small doses are used. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case report : Entitylife - threatening hypoglycaemia associated with Entitysulfadoxine - pyrimethamine , a commonly used antimalarial drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBenzocaine , an ester - type local anesthetic, was believed responsible for apparent Entitymethemoglobinemia in a cat. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of EntityNEH masquerading as cutaneous vasculitis in a woman receiving Entitycyclophosphamide for lupus nephritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two cases of tenofovir ( EntityTDF ) - associated Entitynephrotoxicity in perinatally HIV - infected adolescents. |
| 0.9997 | Adverse-Effect | We report two cases of Entitytenofovir ( TDF ) - associated Entitynephrotoxicity in perinatally HIV - infected adolescents. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate may rarely provoke Entityserositis , even with low doses and after just a few weeks of therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In addition, Entityethambutol rarely causes Entityvisual loss during the early period or when given at lower doses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCushing's syndrome persisted more than 6 months while EntityTCA concentrations remained detectable for at least 80 days. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients with bipolar affective disorder and a history of bronchospastic phenomena experienced Entitytremor during Entitylithium carbonate therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Both patients experienced a previously unreported side effect - - Entityfalling backward - - associated with Entitybupropion use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVision declined after treatment with Entitymethylprednisolone , after which fundus examination became consistent with progressive outer retinal necrosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with chronic myelomonocytic leukemia developed drug - induced Entitypulmonary toxicity after using low dose oral Entityetoposide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians should be aware of the possible association between the use of Entityalteplase and the development of Entitysubfascial hemorrhage . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient, while on intravenous Entityritodrine therapy for preterm labor, experienced an episode of Entityacute chest pain . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Fever, lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and Entitydermatitis : a severe adverse reaction to Entityminocycline . |
| 1.0000 | Adverse-Effect | Fever, lymphadenopathy, eosinophilia, lymphocytosis, Entityhepatitis , and dermatitis : a severe adverse reaction to Entityminocycline . |
| 1.0000 | Adverse-Effect | Fever, lymphadenopathy, eosinophilia, Entitylymphocytosis , hepatitis, and dermatitis : a severe adverse reaction to Entityminocycline . |
| 0.9999 | Adverse-Effect | Fever, lymphadenopathy, Entityeosinophilia , lymphocytosis, hepatitis, and dermatitis : a severe adverse reaction to Entityminocycline . |
| 0.9999 | Adverse-Effect | EntityFever , lymphadenopathy, eosinophilia, lymphocytosis, hepatitis, and dermatitis : a severe adverse reaction to Entityminocycline . |
| 0.9999 | Adverse-Effect | Fever, Entitylymphadenopathy , eosinophilia, lymphocytosis, hepatitis, and dermatitis : a severe adverse reaction to Entityminocycline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of EntityErythema Multiforme Bullosum in patient of lepromatous leprosy with pulmonary tuberculosis due to EntityRifampicin is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityColchicine - induced Entitymyopathy should be excluded in patients with FMF who present with generalized muscle weakness. |
| 0.9941 | Adverse-Effect | CONCLUSIONS : EntityColchicine - induced myopathy should be excluded in patients with FMF who present with Entitygeneralized muscle weakness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Because of a Entityhypersensitivity reaction , initial therapy with Entitypenicillin G and gentamicin was stopped and substituted with cefazolin. |
| 0.9998 | Adverse-Effect | Because of a Entityhypersensitivity reaction , initial therapy with penicillin G and Entitygentamicin was stopped and substituted with cefazolin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors describe a case of Entityneuroleptic malignant syndrome that occurred in a patient on Entityamitriptyline and lithium carbonate. |
| 0.9996 | Adverse-Effect | The authors describe a case of Entityneuroleptic malignant syndrome that occurred in a patient on amitriptyline and Entitylithium carbonate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Typically, drug - induced Entityneutropenia occurs in a patient receiving a semisynthetic Entitypenicillin for two weeks or more. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethimazole - induced Entityaplastic anemia in third exposure : successful treatment with recombinant human granulocyte colony - stimulating factor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The newborn manifested a four day course of Entitylethargy with unexplained high Entitylithium levels in the adult toxic range. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We experienced 2 cases of Entitymequitazine - induced Entityphotosensitivity reaction in patients who took mequitazine for their dermatologic problems. |
| 1.0000 | Adverse-Effect | We experienced 2 cases of mequitazine - induced Entityphotosensitivity reaction in patients who took Entitymequitazine for their dermatologic problems. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Fixed drug Entityeruption is associated with many drugs but this is the first such report with Entityomeprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFSGS induced by EntityAdriamycin ( Pharmacia & Upjohn, Columbus, OH ) has been observed experimentally in rats. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPulmonary leukostasis secondary to Entityall - trans retinoic acid in the treatment of acute promyelocytic leukemia in first relapse. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An objective causality assessment by use of the Naranjo probability scale revealed that EntityNCSE due to Entityifosfamide was probable. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with acute esophageal variceal bleeding developed Entityfatal rhabdomyolysis during treatment with a continuous intravenous infusion of Entityvasopressin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Electrocardiographic findings and laboratory data indicated a diagnosis of Entityacute myocardial infarction due to the EntityL - thyroxine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Establishment of diuresis with fluids and IV administration of calcium may provide successful treatment of Entitymagnesium Entitymagnesium toxicosis in horses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient who presented with Entitybloody diarrhoea after 15 mg Entitymeloxicam daily for 10 days for osteoarthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four cases of Entityoesophageal damage associated with ingestion of the urinary anti - spasmodic agent Entityemepronium bromide are described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityheatstroke is reported in a 32 - year - old man diagnosed with schizophrenia and on Entityclozapine monotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Due to discomfort, diplopia and lagophthalmos, the Entityhaematoma necessitated suspension of Entitywarfarin therapy and a surgical evacuation. |
| 0.9999 | Adverse-Effect | Due to discomfort, diplopia and Entitylagophthalmos , the haematoma necessitated suspension of Entitywarfarin therapy and a surgical evacuation. |
| 0.9999 | Adverse-Effect | Due to discomfort, Entitydiplopia and lagophthalmos, the haematoma necessitated suspension of Entitywarfarin therapy and a surgical evacuation. |
| 0.9999 | Adverse-Effect | Due to Entitydiscomfort , diplopia and lagophthalmos, the haematoma necessitated suspension of Entitywarfarin therapy and a surgical evacuation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9988 | Adverse-Effect | Atypical ventricular tachycardia ( Entitytorsade de pointes ) induced by Entityamiodarone : arrhythmia previously induced by quinidine and disopyramide. |
| 0.9972 | Adverse-Effect | Atypical ventricular tachycardia ( torsade de pointes ) induced by amiodarone : Entityarrhythmia previously induced by Entityquinidine and disopyramide. |
| 0.9657 | Adverse-Effect | EntityAtypical ventricular tachycardia ( torsade de pointes ) induced by Entityamiodarone : arrhythmia previously induced by quinidine and disopyramide. |
| 0.7344 | Adverse-Effect | Atypical ventricular tachycardia ( torsade de pointes ) induced by amiodarone : Entityarrhythmia previously induced by quinidine and Entitydisopyramide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a case of Entitysertraline - induced Entityrhabdomyolysis in an elderly patient with dementia and comorbidities. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing Entitytryptophan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of a patient in a Entitypromethazine - induced Entitycoma responding to treatment with flumazenil. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityMineral oil , a hydrocarbon, may not elicit a normal protective cough reflex and may Entityimpair mucociliary transport . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 3 children with epilepsy who developed Entityfacial motor tics after initiation of EntityCBZ for complex partial seizures. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 43 - year - old white man developed a shallow Entityerosion of a psoriatic plaque after chronic administration of Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One case of Entitytacrolimus - induced Entityhepatic VOD developing after lung transplantation ( LT ) has been recently reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | While the mechanism of Entitydextran - associated Entityrenal failure remains unsolved, plasma exchange seems to be effective therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Myoclonus and Entityseizures disappeared after discontinuation of EntityL - dopa and the introduction of valproate sodium ( VPA ). |
| 0.9999 | Adverse-Effect | EntityMyoclonus and seizures disappeared after discontinuation of EntityL - dopa and the introduction of valproate sodium ( VPA ). |
| 0.9999 | Adverse-Effect | Myoclonus and Entityseizures disappeared after discontinuation of L - dopa and the introduction of Entityvalproate sodium ( VPA ). |
| 0.9999 | Adverse-Effect | Myoclonus and Entityseizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( EntityVPA ). |
| 0.9995 | Adverse-Effect | EntityMyoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of valproate sodium ( EntityVPA ). |
| 0.9995 | Adverse-Effect | EntityMyoclonus and seizures disappeared after discontinuation of L - dopa and the introduction of Entityvalproate sodium ( VPA ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE DESCRIPTION : A 59 - year - old man with known neurocysticercosis developed a Entitylarge cerebral infarction during Entitypraziquantel therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Atypical endometriosis may act as a precancerous lesion in the process of Entitytamoxifen - induced Entitymalignant transformation of endometriosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Mechanisms and triggering factors of Entityhypoglycaemia induced by Entitymefloquine and some other anti - malarial quinine analogues are discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | a 67 - year - old man with bipolar disorder developed a EntityCreutzfeldt - Jakob like syndrome during Entitylithium carbonate treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTiagabine overdose causes an unusual array of Entityneurological symptoms , many similar to reported adverse effects during therapeutic use. |
| Adverse-Effect | EntityTiagabine overdose causes an Entityunusual array of neurological symptoms , many similar to reported adverse effects during therapeutic use. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Increased lash length, thickness, and Entitypigmentation are well - documented side effects of Entityprostaglandin analog glaucoma drops. |
| 1.0000 | Adverse-Effect | EntityIncreased lash length , thickness, and pigmentation are well - documented side effects of Entityprostaglandin analog glaucoma drops. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We have reported six cases of Entitymetoclopramide - induced Entityparkinsonism seen in consultation over a two - year period. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHOD : We describe two patients who presented with Entitydiabetic ketoacidosis after treatment with Entityquetiapine and risperidone, respectively. |
| 1.0000 | Adverse-Effect | METHOD : We describe two patients who presented with Entitydiabetic ketoacidosis after treatment with quetiapine and Entityrisperidone , respectively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two cases of PSVT that changed to Entitynon - sustained polymorphic ventricular tachycardia after administration of Entityverapamil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Gastric tumor, endometrial carcinoma and Entitycervical adenocarcinoma in situ were detected after treatment with Entitytamoxifen for breast cancer. |
| 1.0000 | Adverse-Effect | EntityGastric tumor , endometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with Entitytamoxifen for breast cancer. |
| 1.0000 | Adverse-Effect | Gastric tumor, Entityendometrial carcinoma and cervical adenocarcinoma in situ were detected after treatment with Entitytamoxifen for breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Intravenous sodium bicarbonate appears to be indicated prophylactically in combating the associated Entitymetabolic acidosis due to absorbed Entityformic acid . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a detailed case of Entityfulminant hepatitis induced by Entitynevirapine ( Viramune ) and treated by liver transplantation. |
| 0.9999 | Adverse-Effect | We describe a detailed case of Entityfulminant hepatitis induced by nevirapine ( EntityViramune ) and treated by liver transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterferon - alpha - induced Entityhyperthyroidism : a three - stage evolution from silent thyroiditis towards Graves'disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A diagnosis of masked Entitytheophylline Entitytheophylline poisoning should be considered in similar situations involving a rapid decrease of insulin requirements. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, our report is one of the first on shock and Entityangio - oedema from Entityirbesartan . |
| 0.9999 | Adverse-Effect | To our knowledge, our report is one of the first on Entityshock and angio - oedema from Entityirbesartan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report a case of Balint syndrome with irreversible Entityposterior leukoencephalopathy on MRI following intrathecal Entitymethotrexate and cytarabine. |
| 1.0000 | Adverse-Effect | The authors report a case of EntityBalint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal Entitymethotrexate and cytarabine. |
| 0.9999 | Adverse-Effect | The authors report a case of Balint syndrome with irreversible Entityposterior leukoencephalopathy on MRI following intrathecal methotrexate and Entitycytarabine . |
| 0.9999 | Adverse-Effect | The authors report a case of EntityBalint syndrome with irreversible posterior leukoencephalopathy on MRI following intrathecal methotrexate and Entitycytarabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Aseptic meningitis, hemolytic anemia, hepatitis, and Entityorthostatic hypotension in a patient treated with Entitytrimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | Aseptic meningitis, hemolytic anemia, hepatitis, and Entityorthostatic hypotension in a patient treated with trimethoprim - Entitysulfamethoxazole . |
| 0.9999 | Adverse-Effect | Aseptic meningitis, hemolytic anemia, Entityhepatitis , and orthostatic hypotension in a patient treated with Entitytrimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | Aseptic meningitis, Entityhemolytic anemia , hepatitis, and orthostatic hypotension in a patient treated with Entitytrimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | EntityAseptic meningitis , hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with Entitytrimethoprim - sulfamethoxazole. |
| 0.9998 | Adverse-Effect | Aseptic meningitis, hemolytic anemia, Entityhepatitis , and orthostatic hypotension in a patient treated with trimethoprim - Entitysulfamethoxazole . |
| 0.9998 | Adverse-Effect | Aseptic meningitis, Entityhemolytic anemia , hepatitis, and orthostatic hypotension in a patient treated with trimethoprim - Entitysulfamethoxazole . |
| 0.9998 | Adverse-Effect | EntityAseptic meningitis , hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim - Entitysulfamethoxazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed Entitypancreatitis caused by Entitymeglumine antimoniate . |
| 0.9995 | Adverse-Effect | Successful treatment of visceral leishmaniasis with allopurinol plus Entityketoconazole in an infant who developed Entitypancreatitis caused by meglumine antimoniate. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CONCLUSIONS : The administration of Entityprostaglandin E1 to neonates can cause Entitygastric - outlet obstruction due to antral hyperplasia. |
| 0.9991 | Adverse-Effect | CONCLUSIONS : The administration of Entityprostaglandin E1 to neonates can cause gastric - outlet obstruction due to Entityantral hyperplasia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of Entityrhabdomyolysis related to the administration of Entityclarithromycin without concurrent use of other medications. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe 2 cases of EntitySJS related to Entitynevirapine use and review the literature on this newly recognized association. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Used injudiciously, Entitynaloxone can lead to Entitywithdrawal syndrome , return of severe pain, and other adverse effects. |
| 0.9999 | Adverse-Effect | Used injudiciously, Entitynaloxone can lead to withdrawal syndrome, return of Entitysevere pain , and other adverse effects. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case concerns the Entitysudden death of a 29 - year - old male during Entityclozapine therapy started 2 weeks before. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prior neurologic illness or CNS insult of any kind is known to increase the vulnerability to Entityneurotoxicity of Entitylithium . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The objective of this report is to describe a case of fixed drug Entityeruption that occurred during Entityomeprazole treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIatrogenic Cushing syndrome after epidural Entitytriamcinolone injections in an HIV type 1 - infected patient receiving therapy with ritonavir - lopinavir. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The clinical symptoms of Entitygastric mucosa foveolar hyperplasia due to long - term EntityPGE1 therapy simulate hypertrophic pyloric stenosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Occasionally, despite good therapeutic response, Entityclozapine must be stopped due to dangerous side effects such as Entityagranulocytosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Findings on discontinuation and rechallenge supported the assumption that the Entityhair loss was a side effect of the Entityparoxetine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPsoriasis triggered by toll - like receptor 7 agonist Entityimiquimod in the presence of dermal plasmacytoid dendritic cell precursors. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIatrogenic hypercalcemia due to Entityvitamin D3 ointment ( 1, 24 ( OH ) 2D3 ) combined with thiazide diuretics in a case of psoriasis. |
| 0.9996 | Adverse-Effect | EntityIatrogenic hypercalcemia due to vitamin D3 ointment ( Entity1, 24 ( OH ) 2D3 ) combined with thiazide diuretics in a case of psoriasis. |
| 0.9994 | Adverse-Effect | EntityIatrogenic hypercalcemia due to vitamin D3 ointment ( 1, 24 ( OH ) 2D3 ) combined with Entitythiazide diuretics in a case of psoriasis. |
| Adverse-Effect | Iatrogenic Entityhypercalcemia due to vitamin D3 ointment ( 1, 24 ( OH ) 2D3 ) combined with Entitythiazide diuretics in a case of psoriasis. | |
| Adverse-Effect | Iatrogenic Entityhypercalcemia due to vitamin D3 ointment ( Entity1, 24 ( OH ) 2D3 ) combined with thiazide diuretics in a case of psoriasis. | |
| Adverse-Effect | Iatrogenic Entityhypercalcemia due to Entityvitamin D3 ointment ( 1, 24 ( OH ) 2D3 ) combined with thiazide diuretics in a case of psoriasis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with ulcerative colitis developed skin pigmentation and Entitydiffuse pulmonary shadowing without respiratory symptomatology, while taking Entitysulfasalazine . |
| 0.9999 | Adverse-Effect | A patient with ulcerative colitis developed Entityskin pigmentation and diffuse pulmonary shadowing without respiratory symptomatology, while taking Entitysulfasalazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this case, EntityCIPS was considered to be probably associated with Entitycyclosporine according to the Naranjo probability scale. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This treatment has the potential to cause severe vision loss as a result of intractable Entitycorticosteroid - induced Entityglaucoma . |
| 0.9999 | Adverse-Effect | This treatment has the potential to cause Entitysevere vision loss as a result of intractable Entitycorticosteroid - induced glaucoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | EntityLithium neurotoxicity should be considered in EntityCreutzfeldt - Jakob disease differential diagnosis, serial electroencephalograms being the most valuable. |
| 1.0000 | Adverse-Effect | EntityLithium Entityneurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis, serial electroencephalograms being the most valuable. |
| Adverse-Effect | EntityLithium EntityLithium neurotoxicity should be considered in Creutzfeldt - Jakob disease differential diagnosis, serial electroencephalograms being the most valuable. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitypenile fibrosis after intracavernous self - injection of a combination of Entityphentolamine and papaverine. |
| 1.0000 | Adverse-Effect | We report a case of Entitypenile fibrosis after intracavernous self - injection of a combination of phentolamine and Entitypapaverine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of a 54 - year - old Turkish woman who presented with Entityceftriaxone - induced EntityFDE . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report such a series of patients who had Entitytransient asymptomatic bradycardia after being treated with continuous infusion Entity5 - FU . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Relief by naloxone of Entitymorphine - induced Entityspasm of the sphincter of Oddi in a post - cholecystectomy patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9993 | Adverse-Effect | The present report suggests that clarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in Entitycarbamazepine Entitycarbamazepine toxicity . |
| 0.9985 | Adverse-Effect | The present report suggests that clarithromycin coadministration induces increased plasma Entitycarbamazepine concentrations, which may result in Entitycarbamazepine toxicity . |
| 0.9926 | Adverse-Effect | The present report suggests that Entityclarithromycin coadministration induces increased plasma carbamazepine concentrations, which may result in Entitycarbamazepine toxicity . |
| Adverse-Effect | The present report suggests that clarithromycin coadministration induces Entityincreased plasma carbamazepine Entitycarbamazepine concentrations, which may result in carbamazepine toxicity. | |
| Adverse-Effect | The present report suggests that Entityclarithromycin coadministration induces Entityincreased plasma carbamazepine concentrations, which may result in carbamazepine toxicity. | |
| Adverse-Effect | The present report suggests that clarithromycin coadministration induces Entityincreased plasma carbamazepine concentrations, which may result in Entitycarbamazepine toxicity. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityphenobarbital Entityexacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. |
| 0.9999 | Adverse-Effect | A case of Entityphenobarbital Entityphenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intracranial hemorrhage and Entityfocal seizures secondary to use of EntityL - asparaginase during induction therapy of acute lymphocytic leukemia. |
| 0.9997 | Adverse-Effect | EntityIntracranial hemorrhage and focal seizures secondary to use of EntityL - asparaginase during induction therapy of acute lymphocytic leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of prolonged Entitysuxamethonium Entityapnoea successfully terminated by the infusion of a commercial preparation of serumcholinesterase is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After the Entitychlorambucil was discontinued, the wbc count began to slowly rise and the patient developed clinical EntityAML . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe 2 patients with prior amputation who experienced phantom limb pain ( EntityPLP ) after receiving Entitypaclitaxel therapy. |
| 1.0000 | Adverse-Effect | We describe 2 patients with prior amputation who experienced Entityphantom limb pain ( PLP ) after receiving Entitypaclitaxel therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Localized panniculitis and subsequent Entitylipoatrophy with subcutaneous Entityglatiramer acetate ( Copaxone ) injection for the treatment of multiple sclerosis. |
| 0.9999 | Adverse-Effect | Localized panniculitis and subsequent Entitylipoatrophy with subcutaneous glatiramer acetate ( EntityCopaxone ) injection for the treatment of multiple sclerosis. |
| 0.9997 | Adverse-Effect | EntityLocalized panniculitis and subsequent lipoatrophy with subcutaneous Entityglatiramer acetate ( Copaxone ) injection for the treatment of multiple sclerosis. |
| 0.9992 | Adverse-Effect | EntityLocalized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate ( EntityCopaxone ) injection for the treatment of multiple sclerosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The aim of our paper was to describe Entityhepatotoxicity of Entitysirolimus ( SRL ) in a kidney graft recipient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of drug - induced Entitypemphigus caused by an angiotensin - converting enzyme inhibitor, Entitycaptopril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9993 | Adverse-Effect | OBJECTIVE : To report Entityteicoplanin - related Entityneutropenia that developed after an episode of neutropenia induced by vancomycin therapy. |
| 0.9988 | Adverse-Effect | OBJECTIVE : To report teicoplanin - related neutropenia that developed after an episode of Entityneutropenia induced by Entityvancomycin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients with HLH developed Entityetoposide - related Entitysecondary acute myeloid leukemia ( sAML ) following therapy for HLH. |
| 0.9999 | Adverse-Effect | Two patients with HLH developed Entityetoposide - related secondary acute myeloid leukemia ( EntitysAML ) following therapy for HLH. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The first patient is undergoing hemodialysis and, though responding to Entitysunitinib , is having significant Entityfatigue and hypertension. |
| 1.0000 | Adverse-Effect | The first patient is undergoing hemodialysis and, though responding to Entitysunitinib , is having significant fatigue and Entityhypertension . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This communication describes a patient who developed EntitySchneiderian first - rank symptoms in the course of treatment with Entityfluvoxamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | Initiation of Entityposaconazole led to clinical improvement until the patient's demise from bacteremic vancomycin - resistant Entityenterococcal peritonitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRed blood cell anemia in a patient with pemphigus vulgaris induced by the use of Entitymycophenolate mofetil and prednisone. |
| 0.9998 | Adverse-Effect | EntityRed blood cell anemia in a patient with pemphigus vulgaris induced by the use of mycophenolate mofetil and Entityprednisone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After 3 - to 13 - month period of therapy without Entityindapamide , glucose levels of all patients decreased and Entitydiabetes disappeared. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entitysevere apnea in an infant exposed to Entitylamotrigine through breast - feeding. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | According to the Naranjo adverse drug reaction probability scale, Entitytigecycline was the probable cause of her Entityacute pancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The time course of events suggested that Entityamphotericin B was the cause of the Entityseizures in this AIDS patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case history and toxicological findings of an infant Entityfatality involving Entitypseudoephedrine , brompheniramine, and dextromethorphan are presented. |
| 1.0000 | Adverse-Effect | The case history and toxicological findings of an infant Entityfatality involving pseudoephedrine, Entitybrompheniramine , and dextromethorphan are presented. |
| 1.0000 | Adverse-Effect | The case history and toxicological findings of an infant Entityfatality involving pseudoephedrine, brompheniramine, and Entitydextromethorphan are presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This regimen could prove useful for other patients who develop Entityhypersensitivity reactions to Entitycarboplatin and allow therapy to continue. |
| 1.0000 | Adverse-Effect | This regimen could prove useful for other patients who develop Entityhypersensitivity reactions to Entitycarboplatin and allow therapy to continue. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The most common side effects associated with Entityamifostine are Entitynausea , vomiting, hypotension, hypocalcemia and allergic reactions. |
| 1.0000 | Adverse-Effect | The most common side effects associated with Entityamifostine are nausea, Entityvomiting , hypotension, hypocalcemia and allergic reactions. |
| 1.0000 | Adverse-Effect | The most common side effects associated with Entityamifostine are nausea, vomiting, Entityhypotension , hypocalcemia and allergic reactions. |
| 0.9999 | Adverse-Effect | The most common side effects associated with Entityamifostine are nausea, vomiting, hypotension, Entityhypocalcemia and allergic reactions. |
| 0.9999 | Adverse-Effect | The most common side effects associated with Entityamifostine are nausea, vomiting, hypotension, hypocalcemia and Entityallergic reactions . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 51 - year old physically fit woman experienced angio - oedema and Entityhypotensive shock after Entityirbesartan ingestion requiring noradrenaline infusion. |
| 0.9997 | Adverse-Effect | A 51 - year old physically fit woman experienced Entityangio - oedema and hypotensive shock after Entityirbesartan ingestion requiring noradrenaline infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case supports the assessment that MH and diabetes are associated diseases and that Entitycresol could possibly trigger EntityMH . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the third report of reversible Entityhepatic decompensation associated with prolonged EntityMTX therapy in patients with rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient is described who developed a poorly differentiated Entitysarcoma after Entitycyclophosphamide was used to treat his rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Both colchicine and Entitystatin therapy may be associated with Entitymyopathy , which usually occurs after several months of therapy. |
| 1.0000 | Adverse-Effect | Both Entitycolchicine and statin therapy may be associated with Entitymyopathy , which usually occurs after several months of therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two patients with anhedonic ejaculation ( Entityejaculation without orgasm ) associated with initiation of treatment with Entitydesipramine . |
| 1.0000 | Adverse-Effect | We report two patients with Entityanhedonic ejaculation ( ejaculation without orgasm ) associated with initiation of treatment with Entitydesipramine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Including our own patient, a total of 26 cases of Entitygemcitabine - associated EntityHUS were identified. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a 5 - year - old girl showed recovery of Entityvincristine induced Entitycranial polyneuropathy with pyridoxine and pyridostigmine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She was placed on adjuvant Adriamycin ( Entitydoxorubicin ) chemotherapy, but 6 months later Entitydied of Adriamycin toxicity. |
| 0.9998 | Adverse-Effect | She was placed on adjuvant EntityAdriamycin ( doxorubicin ) chemotherapy, but 6 months later Entitydied of Adriamycin toxicity. |
| 0.9993 | Adverse-Effect | She was placed on adjuvant Adriamycin ( doxorubicin ) chemotherapy, but 6 months later died of EntityAdriamycin EntityAdriamycin toxicity . |
| 0.9989 | Adverse-Effect | She was placed on adjuvant Adriamycin ( Entitydoxorubicin ) chemotherapy, but 6 months later died of EntityAdriamycin toxicity . |
| 0.9962 | Adverse-Effect | She was placed on adjuvant Adriamycin ( doxorubicin ) chemotherapy, but 6 months later Entitydied of EntityAdriamycin toxicity. |
| 0.9942 | Adverse-Effect | She was placed on adjuvant EntityAdriamycin ( doxorubicin ) chemotherapy, but 6 months later died of EntityAdriamycin toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Quinine and its isomer Entityquinidine are well - known causes of Entityiatrogenic hypoglycaemia , due to excessive insulin secretion. |
| 0.9997 | Adverse-Effect | EntityQuinine and its isomer quinidine are well - known causes of Entityiatrogenic hypoglycaemia , due to excessive insulin secretion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, he developed acute renal failure, hyperkalemia, and Entityhyperuricemia 30 d after receiving the Entitysorafenib treatment. |
| 0.9999 | Adverse-Effect | However, he developed acute renal failure, Entityhyperkalemia , and hyperuricemia 30 d after receiving the Entitysorafenib treatment. |
| 0.9999 | Adverse-Effect | However, he developed Entityacute renal failure , hyperkalemia, and hyperuricemia 30 d after receiving the Entitysorafenib treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : A woman receiving Entityenoxaparin every 12 hours developed signs and symptoms of Entityhepatotoxicity after the second dose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She had been on EntityCopaxone 20 mg / day treatment for 2 years when she first exhibited Entitygastrointestinal symptoms . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, dermatologists should be cautious about a Entityphotosensitivity reaction induced by Entitymequitazine or other phenothiazine - derivative drugs. |
| 1.0000 | Adverse-Effect | However, dermatologists should be cautious about a Entityphotosensitivity reaction induced by Entitymequitazine or other phenothiazine - derivative drugs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To date, this is the first reported case of what appears to be isolated Entitythrombocytopenia associated with Entitylansoprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes the first case of Entityinsulin - induced Entitycardiac failure in a patient without underlying heart disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Patients receiving Entityneutral protamine Hagedorn ( NPH ) insulin are at increased risk for the development of Entityprotamine hypersensitivity . |
| 1.0000 | Adverse-Effect | Patients receiving neutral Entityprotamine Hagedorn ( NPH ) insulin are at increased risk for the development of Entityprotamine hypersensitivity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRadiation recall from Entitygemcitabine is rare, but can potentially arise in any site that has been previously irradiated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNeutropenia is an infrequent complication following administration of the angiotensin - converting enzyme ( ACE ) inhibitor, Entitycaptopril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Cholestatic liver disease with ductopenia ( Entityvanishing bile duct syndrome ) after administration of Entityclindamycin and trimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | EntityCholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of Entityclindamycin and trimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | Cholestatic liver disease with Entityductopenia ( vanishing bile duct syndrome ) after administration of Entityclindamycin and trimethoprim - sulfamethoxazole. |
| 0.9998 | Adverse-Effect | Cholestatic liver disease with ductopenia ( Entityvanishing bile duct syndrome ) after administration of clindamycin and Entitytrimethoprim - sulfamethoxazole . |
| 0.9992 | Adverse-Effect | EntityCholestatic liver disease with ductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and Entitytrimethoprim - sulfamethoxazole . |
| 0.9990 | Adverse-Effect | Cholestatic liver disease with Entityductopenia ( vanishing bile duct syndrome ) after administration of clindamycin and Entitytrimethoprim - sulfamethoxazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians should keep in mind that taxanes such as Entitypaclitaxel have the potential to cause Entitypneumonitis and lung fibrosis. |
| 0.9999 | Adverse-Effect | Physicians should keep in mind that taxanes such as Entitypaclitaxel have the potential to cause pneumonitis and Entitylung fibrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hypersensitivity to Entityaspirin can be manifested as acute asthma, Entityurticaria and / or angioedema, or a systemic anaphylactoid reaction. |
| 0.9999 | Adverse-Effect | Hypersensitivity to Entityaspirin can be manifested as acute asthma, urticaria and / or Entityangioedema , or a systemic anaphylactoid reaction. |
| 0.9999 | Adverse-Effect | Hypersensitivity to Entityaspirin can be manifested as acute asthma, urticaria and / or angioedema, or a Entitysystemic anaphylactoid reaction . |
| 1.0000 | Adverse-Effect | Hypersensitivity to Entityaspirin can be manifested as Entityacute asthma , urticaria and / or angioedema, or a systemic anaphylactoid reaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intravitreal Entitytriamcinolone may have had an influence on the Entityexacerbation of retinochoroiditis in the posterior pole of the patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 30 - year - old pharmacist suffered from Entityacute allergic contact dermatitis due to Entity4 - chloro - 7 - nitrobenzofurazan ( NBD - Cl ). |
| 0.9996 | Adverse-Effect | A 30 - year - old pharmacist suffered from Entityacute allergic contact dermatitis due to 4 - chloro - 7 - nitrobenzofurazan ( EntityNBD - Cl ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPneumonitis is emerging as one of the most unpredictable and potentially serious, adverse effects of treatment with EntityMTX . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The female patient received Entityclozapine in a daily dose of 400 mg, which induced Entityagranulocytosis after 2 months. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She continued to receive regular Entityinsulin 4 times per day over the following 3 years with only occasional Entityhives . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPropoxyphene - induced Entitywide complex dysrhythmia responsive to sodium bicarbonate therapy has not been previously reported in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProgressive anemia following combination therapy with Entityinterferon - alpha and interleukin - 2 in a patient with metastatic renal cell carcinoma. |
| 0.9991 | Adverse-Effect | EntityProgressive anemia following combination therapy with interferon - alpha and Entityinterleukin - 2 in a patient with metastatic renal cell carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVisual changes secondary to initiation of Entityamiodarone : a case report and review involving ocular management in cardiac polypharmacy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9990 | Adverse-Effect | Metabolic balance studies and rechallenge with Entityhydrochlorothiazide were undertaken to investigate the mechanism of the thiazide - induced Entityhyponatremia . |
| 1.0000 | Adverse-Effect | Metabolic balance studies and rechallenge with hydrochlorothiazide were undertaken to investigate the mechanism of the Entitythiazide - induced Entityhyponatremia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9962 | Adverse-Effect | Goiter and hypothyroidism during re - treatment with amiodarone in a patient who previously experienced Entityamiodarone - induced Entitythyrotoxicosis . |
| 0.9934 | Adverse-Effect | Goiter and Entityhypothyroidism during re - treatment with Entityamiodarone in a patient who previously experienced amiodarone - induced thyrotoxicosis. |
| 0.9165 | Adverse-Effect | EntityGoiter and hypothyroidism during re - treatment with Entityamiodarone in a patient who previously experienced amiodarone - induced thyrotoxicosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of Entitytroglitazone without significant Entityhepatotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our case is the second one in which Entityhemorrhage from a meningioma may have been induced by Entityaspirin prophylaxis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report one case of Entityincomplete posterior hyaloid detachment ( PHD ) following intravitreal Entitypegaptanib to treat DME. |
| 1.0000 | Adverse-Effect | The authors report one case of incomplete posterior hyaloid detachment ( EntityPHD ) following intravitreal Entitypegaptanib to treat DME. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityL - DOPA - induced excessive Entitydaytime sleepiness in PD : a placebo - controlled case with MSLT assessment. |
| 1.0000 | Adverse-Effect | EntityL - DOPA - induced Entityexcessive daytime sleepiness in PD : a placebo - controlled case with MSLT assessment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nine azotemic patients who developed a Entitycoagulopathy associated with the use of either Entitycephalosporin or moxalactam antibiotics are reported. |
| 1.0000 | Adverse-Effect | Nine azotemic patients who developed a Entitycoagulopathy associated with the use of either cephalosporin or Entitymoxalactam antibiotics are reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | Two patients treated with Entityalprazolam had histories suggestive of a bipolar disorder and developed lithium - responsive Entitymanic episodes . |
| 1.0000 | Adverse-Effect | Two patients treated with alprazolam had histories suggestive of a bipolar disorder and developed Entitylithium - responsive Entitymanic episodes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with generalized MG was effectively managed with EntityMM but developed EntityCNS lymphoma after 3 years of treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | High - dose intravenous Entitymannitol infusion in various clinical settings may result in Entityacute renal failure ( ARF ). |
| 1.0000 | Adverse-Effect | High - dose intravenous Entitymannitol infusion in various clinical settings may result in acute renal failure ( EntityARF ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This progressed to Entitytracheal compression with stridor after he had taken some Entityaspirin for relief of the neck pain. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : There was a temporal relationship between the onset of Entitynonconvulsive status epilepticus and initiation of Entityifosfamide infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware that EntityCrohn's disease is a potential novel adverse drug effect of EntityCopaxone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 45 - year - old psoriasis patient who developed Entityeruptive mollusca contagiosa during an antipsoriatic treatment with Entityefalizumab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of EntitySweet's syndrome in association with Entitysargramostim treatment following chemotherapy for acute myelogenous leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityScleroderma - like reaction induced by Entityuracil - tegafur ( UFT ), a second - generation anticancer agent. |
| 0.9997 | Adverse-Effect | EntityScleroderma - like reaction induced by uracil - tegafur ( EntityUFT ), a second - generation anticancer agent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : We report a case of Entitycutaneous KS lesions in a patient affected by CML treated with Entityimatinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of a 53 - year - old man who developed Entityacute pneumonitis after Entitybleomycin and moderate oxygen administration is presented. |
| 0.9997 | Adverse-Effect | A case of a 53 - year - old man who developed Entityacute pneumonitis after bleomycin and moderate Entityoxygen administration is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Caution is, therefore, needed to prevent undesired accumulation of EntityTCA that may lead to protracted EntityCushing's syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In a postoperative patient with pre - existent myasthenia gravis, oral Entityverapamil caused a marked Entityexacerbation in myasthenic weakness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The concomitant use, however, of colchicine and Entitystatin has been associated with the rapid onset of Entitymuscle weakness . |
| 0.9998 | Adverse-Effect | The concomitant use, however, of Entitycolchicine and statin has been associated with the rapid onset of Entitymuscle weakness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 64 - year - old man presented with Entityproteinuria during postoperative Entityinterferon ( IFN ) - beta therapy against malignant melanoma. |
| 0.9999 | Adverse-Effect | A 64 - year - old man presented with Entityproteinuria during postoperative interferon ( EntityIFN ) - beta therapy against malignant melanoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Recognition of a potential drug - induced EntityFanconi syndrome is important when managing pediatric oncology patients previously treated with Entityifosfamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We experienced a case of chronic renal failure in a patient suffering from acute hemorrhagic gastritis associated with EntityAZ EntityAZ intoxication . |
| 0.9985 | Adverse-Effect | We experienced a case of chronic renal failure in a patient suffering from Entityacute hemorrhagic gastritis associated with EntityAZ intoxication. |
| 0.9991 | Adverse-Effect | We experienced a case of chronic Entityrenal failure in a patient suffering from acute hemorrhagic gastritis associated with EntityAZ intoxication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient's other comorbidities and medications have not been suggested as possible interactions with Entitysertraline that can cause Entityrhabdomyolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To the best of the authors'knowledge, this is the first reported case of EntityPropecia - associated Entitycataract . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Our patient developed Crohn's disease while on EntityCopaxone treatment as a consequence of Entitylong - term immunosuppression . |
| Adverse-Effect | RESULTS : Our patient developed EntityCrohn's disease while on EntityCopaxone treatment as a consequence of long - term immunosuppression. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this report, we describe a fatal Entitygemcitabine - induced Entitypulmonary toxicity in a patient with gallbladder metastatic adenocarcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We suggest that Entitymeloxicam might have Entityintestinal toxic effects when taken in high doses, because of reduced COX - 2 selectivity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A chronic reaction associated with long - term treatment with Entitynitrofurantoin has also been reported and causes irreversible Entitypulmonary fibrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient developed Entitysevere hyponatremia with serum Na + of 108 mEq / L when Entityhydrochlorothiazide was given to control hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a 43 - year - old man who developed signs and symptoms of Entitybilateral optic neuropathy during treatment with Entityethambutol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitynoncardiogenic pulmonary edema developed after therapeutic trial of EntityEO as sclerosing agent for esophageal varix. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : A patient with CHF and ESRD developed Entitymyoclonic muscle spasms after receiving Entitydobutamine by continuous i. v. infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of an 11 - year - old boy who experienced an Entityanaphylactic reaction after administration of Entitybacitracin ointment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These two cases highlight the importance of considering lopinavir / Entityritonavir induced Entityarrhythmias when dealing with HIV - positive individuals. |
| 0.9999 | Adverse-Effect | These two cases highlight the importance of considering Entitylopinavir / ritonavir induced Entityarrhythmias when dealing with HIV - positive individuals. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | On the other hand, EntityMTX - induced Entitypneumonitis seems to be very rare in psoriatic arthritis ( PsA ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9931 | Adverse-Effect | Patients treated with captopril who develop " atypical cholangitis " should be suspected of having Entitycaptopril - associated Entityliver damage . |
| 0.9883 | Adverse-Effect | Patients treated with Entitycaptopril who develop " Entityatypical cholangitis " should be suspected of having captopril - associated liver damage. |
| 0.9736 | Adverse-Effect | Patients treated with Entitycaptopril who develop " Entityatypical cholangitis " should be suspected of having captopril - associated liver damage. |
| 0.9736 | Adverse-Effect | Patients treated with Entitycaptopril who develop " Entityatypical cholangitis " should be suspected of having captopril - associated liver damage. |
| 0.9735 | Adverse-Effect | Patients treated with Entitycaptopril who develop " Entityatypical cholangitis " should be suspected of having captopril - associated liver damage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He developed fever, nausea, diarrhea, and Entitymalaise and stopped taking on the third day after commencing EntityPentasa . |
| 1.0000 | Adverse-Effect | He developed fever, nausea, Entitydiarrhea , and malaise and stopped taking on the third day after commencing EntityPentasa . |
| 1.0000 | Adverse-Effect | He developed fever, Entitynausea , diarrhea, and malaise and stopped taking on the third day after commencing EntityPentasa . |
| 1.0000 | Adverse-Effect | He developed Entityfever , nausea, diarrhea, and malaise and stopped taking on the third day after commencing EntityPentasa . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors'results suggest that EntityL - dopa may cause Entitydaytime somnolence in some patients with Parkinson's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The aim of this study was to describe the occurrence of Entityacute coronary syndromes in 3 cases of Entityrituximab infusions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Despite a very low complication rate, several Entitysevere arterial thrombotic events have been reported following Entitythrombin injection of pseudoaneurysms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the first patient, two episodes of Entityventricular tachycardia requiring cardioversion occurred in close temporal sequence with administering Entitybretylium . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of multiple episodes of Entityseizure activity in an AIDS patent following Entityamphotericin B infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A drug addict with staphylococcal endocarditis treated with Entitymethicillin , who developed Entitymassive proteinuria and acute nephritic syndrome is described. |
| 1.0000 | Adverse-Effect | A drug addict with staphylococcal endocarditis treated with Entitymethicillin , who developed massive proteinuria and Entityacute nephritic syndrome is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Prolonged exposure to Entityitraconazole , administered either continuously or intermittently, may precipitate Entitysevere and irreversible hepatotoxic events . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient's defects may be due to Entitymethimazole Entityteratogenicity or could represent a previously undescribed syndrome affecting ectodermal structures. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGestational diabetes was no less severe ( degree of hyperglycaemia, need for insulin therapy ) when associated with Entitynorethisterone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityUveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of Entityrifabutin , clarithromycin and ethambutol. |
| 1.0000 | Adverse-Effect | EntityUveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin, Entityclarithromycin and ethambutol. |
| 1.0000 | Adverse-Effect | EntityUveitis during treatment of disseminated Mycobacterium avium - intracellulare complex infection with the combination of rifabutin, clarithromycin and Entityethambutol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Following several of these courses of therapy, Entityrespiratory distress occurred 9 to 12 days after the Entitychlorambucil was given. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three cases of Entityacute renal toxicity in patients receiving long - term therapy with Entitymitomycin C and 5 - fluorouracil are reported. |
| 0.9999 | Adverse-Effect | Three cases of Entityacute renal toxicity in patients receiving long - term therapy with mitomycin C and Entity5 - fluorouracil are reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRamipril - induced Entitycutaneous vasculitis is particularly rare and our case was atypical because the patient had tolerated lisinopril before. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a young adolescent with Entitybenign intracranial hypertension which we attribute to the use of Entityminocycline for acne. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An adolescent male developed acute pancreatitis and Entitypseudocyst of the pancreas 16 weeks after cessation of intramuscular EntityL - asparaginase . |
| 0.9994 | Adverse-Effect | An adolescent male developed Entityacute pancreatitis and pseudocyst of the pancreas 16 weeks after cessation of intramuscular EntityL - asparaginase . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four cases of Entityfat embolism are described in infants receiving prolonged intravenous infusion of fat ( EntityIntralipid 20 % ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | According to the Naranjo probability scale, the relationship of Entitygemcitabine treatment with Entitycutaneous eruption in our patient is possible. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A boy with chronic neutropenia and recurrent inflammatory skin lesions developed Entitymultiple erythematous nodules following administration of EntityG - CSF . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Despite the known Entitypulmonary side effects of Entitynitrofurantoin , there is no report of this toxicity occurring in pregnant patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Evidence is shown in this report that Entityadenosine was associated with dangerous worsening of Entityarrhythmia in patients with atrial flutter. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A third patient experienced Entitydisabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving Entitypaclitaxel . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report a case of urinary incontinence ( EntityUI ) that occurred in a woman after administration of Entityvenlafaxine . |
| 1.0000 | Adverse-Effect | The authors report a case of Entityurinary incontinence ( UI ) that occurred in a woman after administration of Entityvenlafaxine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four days after intravenous EntityZoledronic acid , the patient presented to emergency room with complaints of Entitycarpopedal spasm and bronchospasm. |
| 0.9995 | Adverse-Effect | Four days after intravenous EntityZoledronic acid , the patient presented to emergency room with complaints of carpopedal spasm and Entitybronchospasm . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four patients who manifested symptoms of the antiepileptic drug ( AED ) Entityhypersensitivity syndrome during therapy with Entitycarbamazepine are reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A review of the literature revealed two other cases of Entityhepatic angiosarcoma in patients after long - term Entitycyclophosphamide treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityneurotoxicity seen with EntityHDARAC is dose - related and has occurred in up to 60 percent of treated patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIntra - neural ceroid - like pigment following the treatment of lepromatous leprosy with Entityclofazimine ( B663 ; Lamprene ). |
| 0.9999 | Adverse-Effect | EntityIntra - neural ceroid - like pigment following the treatment of lepromatous leprosy with clofazimine ( B663 ; EntityLamprene ). |
| 0.9999 | Adverse-Effect | EntityIntra - neural ceroid - like pigment following the treatment of lepromatous leprosy with clofazimine ( EntityB663 ; Lamprene ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report on the histopathological findings of thyroid tissue from a patient with Entityamiodarone - induced Entityhypothyroidism . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Herein, we describe 2 patients who developed unusual EntityCD8 + cutaneous lymphoproliferative disorders after treatment with Entityefalizumab and infliximab. |
| 0.9999 | Adverse-Effect | Herein, we describe 2 patients who developed unusual EntityCD8 + cutaneous lymphoproliferative disorders after treatment with efalizumab and Entityinfliximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After excluding other causes of long QT syndrome, the EntityHCQ was suspected as the cause of her Entityventricular tachycardia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We conclude that neurosurgeons and neurologists should be aware of calcium antagonist - - related Entityileus in patients treated with Entitynimodipine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNMS is a drug - related response to various medications, such as EntityHaloperidol , which the patient was receiving. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The noted Entityincrease in the theophylline level after Entityzafirlukast administration is in contrast to the original reports by the manufacturer. |
| 0.9998 | Adverse-Effect | The noted Entityincrease in the theophylline level Entitytheophylline level after zafirlukast administration is in contrast to the original reports by the manufacturer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this is the first case of Entityivermectin - induced Entitysevere liver disease published in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | EntityPalpable purpuric skin lesions on the anterior surface of both legs appeared on the 55th day of Entityamphotericin B treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three years later, treatment with Entityampicillin caused another episode of Entitycholestatic hepatitis with cholestasis and duct paucity on rebiopsy. |
| 1.0000 | Adverse-Effect | Three years later, treatment with Entityampicillin caused another episode of cholestatic hepatitis with Entitycholestasis and duct paucity on rebiopsy. |
| 0.9999 | Adverse-Effect | Three years later, treatment with Entityampicillin caused another episode of cholestatic hepatitis with cholestasis and Entityduct paucity on rebiopsy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9988 | Adverse-Effect | Teicoplanin - induced agranulocytosis that followed Entityvancomycin - induced Entityagranulocytosis suggests a possible cross - reactivity between the 2 drugs. |
| 0.9897 | Adverse-Effect | EntityTeicoplanin - induced Entityagranulocytosis that followed vancomycin - induced agranulocytosis suggests a possible cross - reactivity between the 2 drugs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This unusual pattern of low - grade endometrial carcinoma adds to the spectrum of Entityuterine neoplasia associated with Entitytamoxifen therapy. |
| 0.9999 | Adverse-Effect | This unusual pattern of Entitylow - grade endometrial carcinoma adds to the spectrum of uterine neoplasia associated with Entitytamoxifen therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is a case report of subtle, mild Entityhypothermia in a 54 - year old female patient receiving Entityrisperidone for schizophrenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Infliximab and its serious adverse effects are discussed, and other cases of Entityosteomyelitis with Entityinfliximab use are also reviewed. |
| 0.9943 | Adverse-Effect | EntityInfliximab and its serious adverse effects are discussed, and other cases of Entityosteomyelitis with infliximab use are also reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is a unique autopsy case of Entityhepatocellular carcinoma closely related to Entitydiethylstilbestrol ( DES ) therapy for prostatic cancer. |
| 0.9999 | Adverse-Effect | This is a unique autopsy case of Entityhepatocellular carcinoma closely related to diethylstilbestrol ( EntityDES ) therapy for prostatic cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVigabatrin - induced Entityvisual field defects are at present the most important safety issue in the use of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a child with metastatic osteosarcoma, who experienced an Entityanaphylactic / anaphylactoid reaction to Entitymethotrexate . |
| 1.0000 | Adverse-Effect | We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic Entity/ anaphylactoid reaction to Entitymethotrexate . |
| 1.0000 | Adverse-Effect | We report the case of a child with metastatic osteosarcoma, who experienced an anaphylactic / Entityanaphylactoid reaction to Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9928 | Adverse-Effect | Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included Entitycisplatinum Entitynephrotoxicity and adriamycin cardiotoxicity. |
| 0.9832 | Adverse-Effect | Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included Entitycisplatinum Entitycisplatinum nephrotoxicity and adriamycin cardiotoxicity. |
| Adverse-Effect | Complications of chemotherapy for a synovial sarcoma in an eight - year old boy included cisplatinum nephrotoxicity and Entityadriamycin Entitycardiotoxicity . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RTA is one type of Entitynephrotoxicity induced by EntityFK506 , and it is reversible in mild cases when appropriately treated. |
| 0.9999 | Adverse-Effect | EntityRTA is one type of nephrotoxicity induced by EntityFK506 , and it is reversible in mild cases when appropriately treated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three male patients aged 78 - 83 years are presented, in whom Entitysevere hepatotoxic reactions emerged after EntityCPA administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients with Entityextrapyramidal side effects after the use of Entityfluphenazine decanoate were evaluated by means of IBZM - SPECT. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of Entitycolchicine - induced Entitymyopathy . |
| 1.0000 | Adverse-Effect | Muscle biopsy revealed variation in muscle fiber size and few Entityvacuolated fibers which were features of Entitycolchicine - induced myopathy. |
| 0.9998 | Adverse-Effect | Muscle biopsy revealed Entityvariation in muscle fiber size and few vacuolated fibers which were features of Entitycolchicine - induced myopathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Allergic side effects of AZA are rare, and reported Entityallergic skin eruptions from EntityAZA are very limited in Japan. |
| 0.9999 | Adverse-Effect | Allergic side effects of EntityAZA are rare, and reported Entityallergic skin eruptions from AZA are very limited in Japan. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Adverse effects of Entityamiodarone including Entitypulmonary toxicity , hepatotoxicity, aggravation of arrhythmia, and thyroid diseases are well understood. |
| 0.9999 | Adverse-Effect | Adverse effects of Entityamiodarone including pulmonary toxicity, hepatotoxicity, Entityaggravation of arrhythmia , and thyroid diseases are well understood. |
| 0.9999 | Adverse-Effect | Adverse effects of Entityamiodarone including pulmonary toxicity, hepatotoxicity, aggravation of arrhythmia, and Entitythyroid diseases are well understood. |
| 0.9998 | Adverse-Effect | Adverse effects of Entityamiodarone including pulmonary toxicity, Entityhepatotoxicity , aggravation of arrhythmia, and thyroid diseases are well understood. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient presented with fulminant microangiopathic hemolytic anemia and Entitythrombocytopenia within 48 hr of initiating therapy with Entitytrimethoprim - sulfamethoxazole. |
| 1.0000 | Adverse-Effect | The patient presented with fulminant microangiopathic hemolytic anemia and Entitythrombocytopenia within 48 hr of initiating therapy with trimethoprim - Entitysulfamethoxazole . |
| 0.9999 | Adverse-Effect | The patient presented with Entityfulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with Entitytrimethoprim - sulfamethoxazole. |
| 0.9997 | Adverse-Effect | The patient presented with Entityfulminant microangiopathic hemolytic anemia and thrombocytopenia within 48 hr of initiating therapy with trimethoprim - Entitysulfamethoxazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : For all patients with Entityvancomycin - induced Entityneutropenia , possible cross - reactivity of teicoplanin should be monitored. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | Reinstitution of penicillamine treatment caused a recurrence thus proving a causal relationship between Entitypenicillamine and the described Entitynail - changes . |
| 0.9937 | Adverse-Effect | Reinstitution of Entitypenicillamine treatment caused a recurrence thus proving a causal relationship between penicillamine and the described Entitynail - changes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To investigate the mechanisms involved in Entityhypersensitivity reactions to Entitycyclosporine and determine the feasibility of future cyclosporine use. |
| 0.9990 | Adverse-Effect | OBJECTIVE : To investigate the mechanisms involved in Entityhypersensitivity reactions to cyclosporine and determine the feasibility of future Entitycyclosporine use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitytuberculosis in a patient on EntityEfalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. |
| 1.0000 | Adverse-Effect | A case of Entitytuberculosis in a patient on Efalizumab and EntityEtanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Development of Entitynephrotic syndrome in a patient with acute myeloblastic leukemia after treatment with Entitymacrophage - colony - stimulating factor . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Typical symptoms of active EntityCD occurred 11, 12, and 26 months after start of Entityetanercept therapy, respectively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The dermatology literature heretofore has not noted that Entityanemia is a side effect of patients taking EntityMMF to treat pemphigus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a girl with the Rett syndrome who had Entityacute encephalopathy probably induced by Entitycalcium hopantenate ( HOPA ). |
| 0.9996 | Adverse-Effect | We report a girl with the Rett syndrome who had Entityacute encephalopathy probably induced by calcium hopantenate ( EntityHOPA ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Increased awareness is needed on the possible occurrence of EntityLPD resembling gastric cancer in rheumatoid arthritis patients treated with EntityMTX . |
| 1.0000 | Adverse-Effect | Increased awareness is needed on the possible occurrence of LPD resembling Entitygastric cancer in rheumatoid arthritis patients treated with EntityMTX . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityOptic neuropathy developed in a patient with rheumatoid arthritis who had been receiving EntityD - penicillamine for about 1 year. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Surgeons and physicians should therefore be aware of the potential for EntityRTA to occur with EntityFK506 after any organ transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 4 patients who developed symptoms of Entitymyasthenia gravis within 2 weeks of starting treatment with a Entitystatin drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She was treated with EntityPancrease MT 16 , but had consistent Entityvomiting 1 to 2 hours after administration of enzymes. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report here a rare case of Entityritodrine - hydrochloride - induced Entityrhabdomyolysis in a pregnant patient with myotonic dystrophy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our literature review revealed an additional six cases of onset of Entityinflammatory arthritis in MS patients receiving EntityIFN - beta . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityImatinib mesylate - related Entityfatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | PURPOSE : To describe Entitybilateral optic neuritis that occurred as an adverse effect of recombinant and natural Entityinterferon alpha administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our findings reveal that even in patients without a history of seizures, Entitypregabalin can cause a Entitycortical negative myoclonus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Disseminated intravascular coagulation associated with acute hemoglobinemia or Entityhemoglobinuria following EntityRh ( 0 ) ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura. |
| 0.9993 | Adverse-Effect | Disseminated intravascular coagulation associated with Entityacute hemoglobinemia or hemoglobinuria following EntityRh ( 0 ) ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura. |
| 0.9993 | Adverse-Effect | EntityDisseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following EntityRh ( 0 ) ( D ) immune globulin intravenous administration for immune thrombocytopenic purpura. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pneumocystis pneumonia should be considered in asthmatic patients taking Entitymethotrexate who present with Entityfever , pulmonary infiltrates, and hypoxia. |
| 1.0000 | Adverse-Effect | EntityPneumocystis pneumonia should be considered in asthmatic patients taking Entitymethotrexate who present with fever, pulmonary infiltrates, and hypoxia. |
| 1.0000 | Adverse-Effect | Pneumocystis pneumonia should be considered in asthmatic patients taking Entitymethotrexate who present with fever, pulmonary infiltrates, and Entityhypoxia . |
| 0.9999 | Adverse-Effect | Pneumocystis pneumonia should be considered in asthmatic patients taking Entitymethotrexate who present with fever, Entitypulmonary infiltrates , and hypoxia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9950 | Adverse-Effect | EntityADH hypersecretion in relation to plasma osmolality was reversed by Entitymizoribin withdrawal, suggesting that bredinin might adversely induce SIADH. |
| 0.9997 | Adverse-Effect | ADH hypersecretion in relation to Entityplasma osmolality was reversed by Entitymizoribin withdrawal, suggesting that bredinin might adversely induce SIADH. |
| 0.8839 | Adverse-Effect | ADH hypersecretion in relation to plasma osmolality was reversed by Entitymizoribin withdrawal, suggesting that bredinin might adversely induce EntitySIADH . |
| Adverse-Effect | ADH hypersecretion in relation to plasma osmolality was reversed by mizoribin withdrawal, suggesting that Entitybredinin might adversely induce EntitySIADH . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The known side effects of Entitysibutramine , ie, Entityhypertension and tachycardia, depend on its adrenergic and serotoninergic effects. |
| 0.9998 | Adverse-Effect | The known side effects of Entitysibutramine , ie, hypertension and Entitytachycardia , depend on its adrenergic and serotoninergic effects. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | During the anti - tuberculous therapy, Entityvisual loss can be related to Entityethambutol toxicity or the tuberculosis infection itself. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Late development of Entitydiabetes mellitus after Entityinterferon - alfa and ribavirin therapy for chronic hepatitis C : a case report. |
| 0.9995 | Adverse-Effect | Late development of Entitydiabetes mellitus after interferon - alfa and Entityribavirin therapy for chronic hepatitis C : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVES : To describe clinical and pathologic findings in patients noted to develop Entitylower gastrointestinal symptoms when exposed to Entityrofecoxib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The probability of developing Entityacute leukemia in this study was not significantly correlated to the total cumulative dosage of EntityTreosulfan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Carboplatin Entityhypersensitivity induced by low - dose Entitypaclitaxel / carboplatin in multiple platinum - treated patients with recurrent ovarian cancer. |
| 1.0000 | Adverse-Effect | EntityCarboplatin Entityhypersensitivity induced by low - dose paclitaxel / carboplatin in multiple platinum - treated patients with recurrent ovarian cancer. |
| 0.9995 | Adverse-Effect | Carboplatin Entityhypersensitivity induced by low - dose paclitaxel / Entitycarboplatin in multiple platinum - treated patients with recurrent ovarian cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Elderly patients for whom Entitynitrate has been prescribed should be warned of the occurrence of Entityhypotension , leading to unconsciousness. |
| 0.9999 | Adverse-Effect | Elderly patients for whom Entitynitrate has been prescribed should be warned of the occurrence of hypotension, leading to Entityunconsciousness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityQuetiapine and Entityobsessive - compulsive symptoms ( OCS ) : case report and review of atypical antipsychotic - induced OCS. |
| 0.9999 | Adverse-Effect | EntityQuetiapine and obsessive - compulsive symptoms ( EntityOCS ) : case report and review of atypical antipsychotic - induced OCS. |
| 0.9958 | Adverse-Effect | EntityQuetiapine and obsessive - compulsive symptoms ( OCS ) : case report and review of atypical antipsychotic - induced EntityOCS . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Unintended exposure to Entityacyclovir early in pregnancy, which is not uncommon, may cause Entityexcessive maternal and physician anxiety . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After the second Entityinfliximab infusion, he was found to have a Entitysevere transient neutropenia ( 0. 5 x 10 ( 9 ) / L ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | INTERPRETATION : When high doses of Entityfluticasone propionate are used, Entitygrowth may be retarded and adrenal suppression may occur. |
| 0.9996 | Adverse-Effect | INTERPRETATION : When high doses of Entityfluticasone propionate are used, growth may be retarded and Entityadrenal suppression may occur. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | OBJECTIVE : To report the first five cases of Entityamphotericin B overdose with secondary Entitycardiac complications in a pediatric population. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Because Entitypsoralens sensitize skin to ultraviolet A light, Entityphototoxic reactions are the most frequent adverse effect of this treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A unique case of a transient, nonpigmenting Entityfixed drug eruption caused by the radiopaque contrast medium Entityiothalamate is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityhalothane induced Entityhepatitis is reported in a middle aged woman who underwent gastric surgery for morbid obesity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | With the first Entitycyclosporine dose, the patient complained of Entityleg pain that was most severe during the cyclosporine infusion. |
| 0.9999 | Adverse-Effect | With the first cyclosporine dose, the patient complained of Entityleg pain that was most severe during the Entitycyclosporine infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityColonic necrosis is known as a rare complication following the administration of EntityKayexalate ( sodium polystryrene sulfonate ) in sorbitol. |
| 0.9997 | Adverse-Effect | EntityColonic necrosis is known as a rare complication following the administration of Kayexalate ( Entitysodium polystryrene sulfonate ) in sorbitol. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is suggested therefore that Entitymethotrexate be added to the list of agents capable of inducing Entitydiffuse interstitial pulmonary fibrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The renal insufficiency of three patients and the timing of the Entityseizures implicate accumulation of Entityofloxacin as a contributing factor. |
| 0.9994 | Adverse-Effect | The Entityrenal insufficiency of three patients and the timing of the seizures implicate accumulation of Entityofloxacin as a contributing factor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although an association between exposure to Entitybleomycin and the development of Entityscleroderma has been suspected, few cases are reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The cause of death was determined to be Entityacute intoxication by Entityolanzapine , and the manner of death was accidental. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We recommended periodic examination of the serum proteins in patients receiving Entitydiphenylhydantoin in order to detect development of Entitymonoclonal gammopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute non - lymphocytic leukemia in patients with ovarian carcinoma following long - term treatment with EntityTreosulfan ( = dihydroxybusulfan ). |
| 1.0000 | Adverse-Effect | EntityAcute non - lymphocytic leukemia in patients with ovarian carcinoma following long - term treatment with Treosulfan ( = Entitydihydroxybusulfan ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In our patient, EntityDIAN possibly was related to Entitycefuroxime , but the patient did not experience associated allergic symptoms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASES : Two postmenopausal women treated with Entitytamoxifen and progestational agents for breast carcinoma developed Entityuterine enlargement and intermittent spotting. |
| 1.0000 | Adverse-Effect | CASES : Two postmenopausal women treated with Entitytamoxifen and progestational agents for breast carcinoma developed uterine enlargement and Entityintermittent spotting . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | As far as we know, this is the first case report of acute hemorrhagic gastritis associated with EntityAZ EntityAZ intoxication . |
| 0.9995 | Adverse-Effect | As far as we know, this is the first case report of Entityacute hemorrhagic gastritis associated with EntityAZ intoxication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRitonavir acted as a CYP3A4 inhibitor, Entitydiminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity. |
| 1.0000 | Adverse-Effect | EntityRitonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an Entityincrease in serum levels and clinical toxicity. |
| 0.9999 | Adverse-Effect | EntityRitonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and Entityclinical toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | Diagnosis of Entitysclerosing glomerulonephritis occurred in this patient during Entityanastrozole use, suggesting a newly defined side effect of anastrozole. |
| 0.9647 | Adverse-Effect | Diagnosis of Entitysclerosing glomerulonephritis occurred in this patient during anastrozole use, suggesting a newly defined side effect of Entityanastrozole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient who developed Entityspontaneous splenic infarction after the use of Entitysumatriptan for the treatment of migraine headache. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A potential role for renal and hepatic impairment in the observed protracted course of Entityamiodarone - induced Entitythyrotoxicosis is suggested. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of marked Entityelevation of serum creatine kinase ( CK ) associated with Entityolanzapine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 21 - year - old patient developed Entityrhabdomyolysis during his nineteenth week of treatment with Entityclozapine for drug - resistant schizophrenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of acute renal failure with Entityhyperkalemia associated with the recently marketed direct renin inhibitor Entityaliskiren . |
| 0.9999 | Adverse-Effect | We report the first case of Entityacute renal failure with hyperkalemia associated with the recently marketed direct renin inhibitor Entityaliskiren . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9988 | Adverse-Effect | A case is reported of Entitytheophylline Entitytheophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of viloxazine. |
| 0.9616 | Adverse-Effect | A case is reported of Entitytheophylline intoxication due to a dramatic decrease in theophylline clearance following concomitant administration of Entityviloxazine . |
| 0.4835 | Adverse-Effect | A case is reported of Entitytheophylline intoxication due to a dramatic decrease in Entitytheophylline clearance following concomitant administration of viloxazine. |
| Adverse-Effect | A case is reported of theophylline intoxication due to a dramatic Entitydecrease in theophylline clearance following concomitant administration of Entityviloxazine . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Postoperative Entityhypocalcemic tetany caused by Entityfleet phospho - soda preparation in a patient taking alendronate sodium : report of a case. |
| 0.9988 | Adverse-Effect | Postoperative Entityhypocalcemic tetany caused by fleet phospho - soda preparation in a patient taking Entityalendronate sodium : report of a case. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9987 | Adverse-Effect | The patient expired after seven cycles of treatment had been completed because of Entitypulmonary fibrosis and the drug toxicity of Entitybleomycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus, we confirm that desensitization may be a safe procedure in patients with cancer who experience Entitymethotrexate - induced Entityanaphylaxis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 10 - year - old girl with Lennox - Gastaut syndrome who received intravenous Entitylorazepam for atypical absence status Entityseizures is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The induction of Entityhypoglycaemia with EntityPAS in this patient suggests a potential role for PAS in the treatment of diabetes mellitus. |
| 0.9885 | Adverse-Effect | The induction of Entityhypoglycaemia with PAS in this patient suggests a potential role for EntityPAS in the treatment of diabetes mellitus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In two patients, Entityapomorphine remained effective in the morning, but increased the intensity of the Entitydyskinesias in the afternoon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The visual loss in this patient seems to result from Entityphenol Entityneurotoxicity rather than mechanical compression of the intraorbital optic nerve. |
| 0.9999 | Adverse-Effect | The Entityvisual loss in this patient seems to result from Entityphenol neurotoxicity rather than mechanical compression of the intraorbital optic nerve. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here we describe another case of EntityVOD occurring after LT, but in which the causative role was played by Entityazathioprine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report the safe use of fluorouracil in a patient with breast cancer who had Entityallergic reactions to Entitycapecitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : The patient required insulin desensitization for severe urticaria, angioedema, and occasional Entitywheezing resulting from her Entityinsulin dose. |
| 1.0000 | Adverse-Effect | METHODS : The patient required Entityinsulin desensitization for Entitysevere urticaria , angioedema, and occasional wheezing resulting from her insulin dose. |
| 0.9999 | Adverse-Effect | METHODS : The patient required Entityinsulin desensitization for severe urticaria, Entityangioedema , and occasional wheezing resulting from her insulin dose. |
| 0.9999 | Adverse-Effect | METHODS : The patient required Entityinsulin desensitization for severe urticaria, angioedema, and occasional Entitywheezing resulting from her insulin dose. |
| 0.9999 | Adverse-Effect | METHODS : The patient required insulin desensitization for severe urticaria, Entityangioedema , and occasional wheezing resulting from her Entityinsulin dose. |
| 0.9999 | Adverse-Effect | METHODS : The patient required insulin desensitization for Entitysevere urticaria , angioedema, and occasional wheezing resulting from her Entityinsulin dose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Arrhythmias and Entitycardiac arrest have been reported during Entityamphotericin B administration but no effective technique has been described to prevent them. |
| 0.9998 | Adverse-Effect | EntityArrhythmias and cardiac arrest have been reported during Entityamphotericin B administration but no effective technique has been described to prevent them. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the first case of de novo Entityasthma following treatment with the angiotensin converting enzyme ( ACE ) inhibitor Entitycaptopril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two new cases of Entitysarcoidosis in two patients with hepatitis C virus infection treated with Entityinterferon alfa and ribavirin. |
| 0.9999 | Adverse-Effect | We report two new cases of Entitysarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and Entityribavirin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : Methotrexate ( EntityMTX ) may induce Entityliver damage , which in some psoriatics will lead to fibrosis or cirrhosis. |
| 0.9999 | Adverse-Effect | BACKGROUND : EntityMethotrexate ( MTX ) may induce Entityliver damage , which in some psoriatics will lead to fibrosis or cirrhosis. |
| 0.9999 | Adverse-Effect | BACKGROUND : Methotrexate ( EntityMTX ) may induce liver damage, which in some psoriatics will lead to Entityfibrosis or cirrhosis. |
| 0.9999 | Adverse-Effect | BACKGROUND : Methotrexate ( EntityMTX ) may induce liver damage, which in some psoriatics will lead to fibrosis or Entitycirrhosis . |
| 0.9998 | Adverse-Effect | BACKGROUND : EntityMethotrexate ( MTX ) may induce liver damage, which in some psoriatics will lead to fibrosis or Entitycirrhosis . |
| 0.9997 | Adverse-Effect | BACKGROUND : EntityMethotrexate ( MTX ) may induce liver damage, which in some psoriatics will lead to Entityfibrosis or cirrhosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Inhaled Entitytobramycin solution - associated Entityrecurrent eosinophilia and severe persistent bronchospasm in a patient with cystic fibrosis : a case report. |
| 0.9999 | Adverse-Effect | Inhaled Entitytobramycin solution - associated recurrent eosinophilia and Entitysevere persistent bronchospasm in a patient with cystic fibrosis : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Within 3 weeks of beginning continuous daily isoniazid and Entityrifampin therapy for pulmonary tuberculosis, a patient developed Entityacute renal failure . |
| 0.9999 | Adverse-Effect | Within 3 weeks of beginning continuous daily Entityisoniazid and rifampin therapy for pulmonary tuberculosis, a patient developed Entityacute renal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Patient B developed Entityperioral and upper extremity paresthesias during the fourth cycle of EntityCAP alone ( 2500 mg / m2 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Moreover, these findings suggest that the incidence of EntityBOOP following Entityrituximab therapy may be higher than has been previously appreciated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | This compound, used by adults in the child's home, had caused accidental Entitytheophylline Entitytheophylline poisoning , mimicking diabetic ketoacidosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Up to four percent of patients treated with Entityimatinib may develop Entityhepatotoxicity , which usually resolves with discontinuation of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityL - Thyroxine - induced Entityleukopenia in a patient with Hashimoto's disease : involvement of suppressor - cytotoxic T cells. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate - induced Entityleukoencephalopathy is treatable with high - dose folinic acid : a case report and analysis of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityhyperpigmentation due to Entitybleomycin treatment in a patient with acquired immune deficiency syndrome ( AIDS ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although Entityfluoxetine - induced Entityheadache occurred in one patient, the other five reported no side effects at the doses used. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRifampin can be associated with severe adverse effects such as Entityhepatitis , acute renal failure, hemolytic anemia, and thrombocytopenia. |
| 1.0000 | Adverse-Effect | EntityRifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, Entityhemolytic anemia , and thrombocytopenia. |
| 1.0000 | Adverse-Effect | EntityRifampin can be associated with severe adverse effects such as hepatitis, Entityacute renal failure , hemolytic anemia, and thrombocytopenia. |
| 1.0000 | Adverse-Effect | EntityRifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and Entitythrombocytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To date, eight cases of TEN and one of EntitySJS related to Entitylamotrigine administration have been reported in the literature. |
| 1.0000 | Adverse-Effect | To date, eight cases of EntityTEN and one of SJS related to Entitylamotrigine administration have been reported in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : Patients with Entity5 - FU - induced Entityectropion experience tender, red, scaled lids, making contact lens wear difficult. |
| 0.9999 | Adverse-Effect | DISCUSSION : Patients with Entity5 - FU - induced ectropion experience Entitytender, red, scaled lids , making contact lens wear difficult. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present the case of a 5 - year - old girl who developed Entitybilateral vocal cord paralysis following preoperative peritonsillar Entitybupivacaine infiltration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It remains to be seen whether the Entityhepatotoxicity associated with Entitytroglitazone is a drug - class effect or specific to troglitazone. |
| 0.9966 | Adverse-Effect | It remains to be seen whether the Entityhepatotoxicity associated with troglitazone is a drug - class effect or specific to Entitytroglitazone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere hepatotoxicity from Entityphenobarbital occurred in an infant boy who had a complicated illness with chronic bilateral subdural hematomas and sepsis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To the best of our knowledge, this is the first case of Entitylithium - associated EntityCDI and NDI presenting concurrently. |
| 1.0000 | Adverse-Effect | To the best of our knowledge, this is the first case of Entitylithium - associated CDI and EntityNDI presenting concurrently. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report the finding of Entitysquamous metaplasia within endometrial glands occurring as a result of Entityprogestin therapy of hyperplasia. |
| Adverse-Effect | OBJECTIVE : To report the finding of Entitysquamous metaplasia within endometrial glands occurring as a result of Entityprogestin therapy of hyperplasia. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It was concluded that potassium loss occurred by a non - renal ( intestinal ) route in Entityphosphate - induced Entityhypokalemia . |
| 0.9999 | Adverse-Effect | It was concluded that Entitypotassium loss occurred by a non - renal ( intestinal ) route in Entityphosphate - induced hypokalemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Significant ocular complications such as an Entityirreversible decrease of visual acuity may develop in patients treated with Entitypegylated interferon . |
| 0.9996 | Adverse-Effect | CONCLUSION : Significant Entityocular complications such as an irreversible decrease of visual acuity may develop in patients treated with Entitypegylated interferon . |
| 1.0000 | Adverse-Effect | CONCLUSION : Significant ocular complications such as an irreversible Entitydecrease of visual acuity may develop in patients treated with Entitypegylated interferon . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CD4 T - lymphocyte depletion, myelosuppression, and subsequent Entitysevere infections are the major side effects of Entityfludarabine phosphate therapy. |
| 0.9998 | Adverse-Effect | EntityCD4 T - lymphocyte depletion , myelosuppression, and subsequent severe infections are the major side effects of Entityfludarabine phosphate therapy. |
| 0.9996 | Adverse-Effect | CD4 T - lymphocyte depletion, Entitymyelosuppression , and subsequent severe infections are the major side effects of Entityfludarabine phosphate therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : Repeated blood samples were drawn in a patient with severe Entityacyclovir overdose who developed Entitycoma and nonoliguric renal failure. |
| 1.0000 | Adverse-Effect | METHODS : Repeated blood samples were drawn in a patient with severe Entityacyclovir overdose who developed coma and Entitynonoliguric renal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : This is, to our knowledge, the first report of Entitysevere myelopathy following accidental intrathecal administration of Entitydoxorubicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a man, treated with Entitymesalazine for Crohn's disease who developed drug - induced Entitypericarditis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors presented a case of Entitypulmonary hypertension during Entitylithium therapy, while she has been on lithium for 6 years. |
| 0.9992 | Adverse-Effect | The authors presented a case of Entitypulmonary hypertension during lithium therapy, while she has been on Entitylithium for 6 years. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Following the institution of intravenous therapy with Entityacyclovir , the patient developed Entityfever , hemoptysis, and a pleural friction rub. |
| 1.0000 | Adverse-Effect | Following the institution of intravenous therapy with Entityacyclovir , the patient developed fever, Entityhemoptysis , and a pleural friction rub. |
| 0.9999 | Adverse-Effect | Following the institution of intravenous therapy with Entityacyclovir , the patient developed fever, hemoptysis, and a Entitypleural friction rub . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 3 cases of children with acute lymphoblastic leukemia who developed seizures and Entityaltered sensorium after EntityL - asparaginase therapy. |
| 0.9997 | Adverse-Effect | We report 3 cases of children with acute lymphoblastic leukemia who developed Entityseizures and altered sensorium after EntityL - asparaginase therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : There are only a few confirmed cases of Entitygemcitabine - associated EntityHUS despite the widespread use of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report a case of Entityacute generalized exanthematous pustulosis ( AGEP ) induced by Entitysalazosulfapyridine in a patient with ulcerative colitis. |
| 1.0000 | Adverse-Effect | We report a case of acute generalized exanthematous pustulosis ( EntityAGEP ) induced by Entitysalazosulfapyridine in a patient with ulcerative colitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We presented a patient with status asthmaticus treated with a combination of theophylline and Entityprednisone who developed a Entityperforated gastric ulcer . |
| 1.0000 | Adverse-Effect | We presented a patient with status asthmaticus treated with a combination of Entitytheophylline and prednisone who developed a Entityperforated gastric ulcer . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient described feeling cold with worsening headache and Entitychills approximately one hour after infusion of the first dose of Entitypenicillin . |
| 1.0000 | Adverse-Effect | The patient described feeling cold with Entityworsening headache and chills approximately one hour after infusion of the first dose of Entitypenicillin . |
| 0.9999 | Adverse-Effect | The patient described Entityfeeling cold with worsening headache and chills approximately one hour after infusion of the first dose of Entitypenicillin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The capacity of Entityzuclopenthixol to induce Entitypriapism is thought to be due to its antagonist activity on alpha - adrenergic receptors. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After discontinuing Entitycaptopril and starting systemic steroids, her symptomatology rapidly improved, and her Entityeosinophilia and radiographic abnormalities both resolved. |
| 0.9999 | Adverse-Effect | After discontinuing Entitycaptopril and starting systemic steroids, her symptomatology rapidly improved, and her eosinophilia and Entityradiographic abnormalities both resolved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 13 year - old male who developed life - threatening Entityanaphylaxis early in the course of EntityIncrelex therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To report patients who presented to the oculoplastics department for repair of Entitycicatrical entropion after topical use of Entitydipivefrin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | CONCLUSION : Long - term treatment with Entityrifabutin may have a reversible and previously undescribed Entityside - effect on retinal function . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : EntityClozapine causes few Entityextrapyramidal symptoms and is recommended as a treatment drug for severe tardive dyskinesia ( TD ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 27 - year - old Indian woman who developed maculopapular rash and Entityangioedema secondary to Entitycarbamazepine administration. |
| 1.0000 | Adverse-Effect | We report the case of a 27 - year - old Indian woman who developed Entitymaculopapular rash and angioedema secondary to Entitycarbamazepine administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The present study describes a patient who had Entityunusual weight fluctuation under corticosteroid and psychotropic treatment such as Entitymianserin and aripiprazole. |
| 1.0000 | Adverse-Effect | The present study describes a patient who had Entityunusual weight fluctuation under corticosteroid and psychotropic treatment such as mianserin and Entityaripiprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient who developed Entityheparin associated Entitythrombocytopenia during continuous arteriovenous haemofiltration and discuss its implications and alternative anticoagulant treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case of an adult who developed both hepatic dysfunction and an Entityimpaired macrophage migration after exposure to Entitycimetidine is discussed. |
| 1.0000 | Adverse-Effect | The case of an adult who developed both Entityhepatic dysfunction and an impaired macrophage migration after exposure to Entitycimetidine is discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityIbuprofen rarely causes lower Entitygastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus. |
| 1.0000 | Adverse-Effect | EntityIbuprofen rarely causes Entitylower gastrointestinal adverse reactions but has been implicated in systemic and local side effects in patients with lupus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Presently, treatment of acute Entityibuprofen Entityibuprofen intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The international literature regarding Entityopportunistic infections after immunosuppressive therapy with Entityalemtuzumab with particular attention on fungal infections has also been reviewed. |
| 1.0000 | Adverse-Effect | The international literature regarding opportunistic infections after immunosuppressive therapy with Entityalemtuzumab with particular attention on Entityfungal infections has also been reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Investigation confirmed the diagnosis of rhabdomyolysis, and discontinuation of Entitycolchicine resulted in resolution of clinical and biochemical features of Entityrhabdomylysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a 15 - year - old female patient diagnosed with Entityacute lymphoblastic leukemia presenting with status epilepticus after receiving intrathecal Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The mechanism by which Entitysunitinib induces Entitygynaecomastia is thought to be associated with an unknown direct action on breast hormonal receptors. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the following case report, a patient developed acute interstitial nephritis with renal failure and Entityexfoliative dermatitis following Entityampicillin therapy. |
| 0.9999 | Adverse-Effect | In the following case report, a patient developed acute interstitial nephritis with Entityrenal failure and exfoliative dermatitis following Entityampicillin therapy. |
| 0.9999 | Adverse-Effect | In the following case report, a patient developed Entityacute interstitial nephritis with renal failure and exfoliative dermatitis following Entityampicillin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two dark - skinned patients who developed Entityhyperpigmented skin and tongue lesions during combination therapy with EntityIFN and ribavirin. |
| 1.0000 | Adverse-Effect | We describe two dark - skinned patients who developed hyperpigmented skin and Entitytongue lesions during combination therapy with EntityIFN and ribavirin. |
| 0.9999 | Adverse-Effect | We describe two dark - skinned patients who developed Entityhyperpigmented skin and tongue lesions during combination therapy with IFN and Entityribavirin . |
| 0.9999 | Adverse-Effect | We describe two dark - skinned patients who developed hyperpigmented skin and Entitytongue lesions during combination therapy with IFN and Entityribavirin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entitycolchicine - induced Entitymyopathy in a teenager with familial Mediterranean fever ( FMF ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitybasilar invagination which is thought to have arisen from the patient's intrauterine exposure to Entityphenytoin is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterferon - alpha - induced Entityfocal segmental glomerulosclerosis in chronic myelogenous leukemia : a case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe Entityrupture of a cerebral arterial aneurysm in a 32 year old hypertensive woman following the introduction of Entitynifedipine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Presentation of three palliative care patients who were given Entityketamine as an analgesic and subsequently developed significant and debilitating Entityurological symptoms . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with the Wolff - Parkinson - White syndrome presented with Entityincessant orthodromic atrioventricular tachycardia following initiation of Entityprocainamide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of linear immunoglobulin ( Ig ) A bullous dermatosis ( EntityLABD ) induced by Entitygemcitabine . |
| 0.9999 | Adverse-Effect | OBJECTIVE : To report a case of Entitylinear immunoglobulin ( Ig ) A bullous dermatosis ( LABD ) induced by Entitygemcitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Naranjo probability scale indicated a probable relationship between Entityapnea and exposure to Entitylamotrigine through breast - feeding in this infant. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In patients with Entitymethotrexate - induced Entityanaphylaxis , discontinuation of treatment may increase the risk of death due to cancer progression. |
| 0.9993 | Adverse-Effect | In patients with Entitymethotrexate - induced anaphylaxis, discontinuation of treatment may increase the risk of Entitydeath due to cancer progression. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | On the fifth day of tocolysis with magnesium sulfate, nifedipine, terbutaline and Entitybetamethasone , Entityedema developed in both labia. |
| 0.9999 | Adverse-Effect | On the fifth day of tocolysis with magnesium sulfate, nifedipine, Entityterbutaline and betamethasone, Entityedema developed in both labia. |
| 0.9999 | Adverse-Effect | On the fifth day of tocolysis with magnesium sulfate, Entitynifedipine , terbutaline and betamethasone, Entityedema developed in both labia. |
| 0.9998 | Adverse-Effect | On the fifth day of tocolysis with Entitymagnesium sulfate , nifedipine, terbutaline and betamethasone, Entityedema developed in both labia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityseizure associated with EntityL - asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 28 year old white schizophrenic male has been under Entityrisperidone monotherapy for about one year when he developed Entitydyskinetic movements . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | The second patient, who developed cholestasis after receiving Entitytrimethoprim - sulfamethoxazole , had marked Entityduct paucity in the liver biopsy. | |
| Adverse-Effect | The second patient, who developed Entitycholestasis after receiving Entitytrimethoprim - sulfamethoxazole , had marked duct paucity in the liver biopsy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTiclopidine - induced Entityaplastic anemia : two new case reports, review, and meta - analysis of 55 additional cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFulminant hepatic failure developed in a 24 - year - old black woman who had been treated with Entitypropylthiouracil and propranolol for hyperthyroidism. |
| 0.9999 | Adverse-Effect | EntityFulminant hepatic failure developed in a 24 - year - old black woman who had been treated with propylthiouracil and Entitypropranolol for hyperthyroidism. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Children receiving Entityzonisamide should be monitored for Entityoligohidrosis and the development of neurological symptoms associated with an elevation of body temperature. |
| 0.9999 | Adverse-Effect | Children receiving Entityzonisamide should be monitored for oligohidrosis and the development of Entityneurological symptoms associated with an elevation of body temperature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 72 - year - old woman with a history of thyrotoxicosis presented with sore throat and Entityfever two weeks after starting Entitycarbimazole . |
| 1.0000 | Adverse-Effect | A 72 - year - old woman with a history of thyrotoxicosis presented with Entitysore throat and fever two weeks after starting Entitycarbimazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Soon after introduction of Entityinsulin therapy, she developed Entitysevere anasarca , including marked peripheral oedema, ascites and pleural effusion. |
| 1.0000 | Adverse-Effect | Soon after introduction of Entityinsulin therapy, she developed severe anasarca, including marked Entityperipheral oedema , ascites and pleural effusion. |
| 0.9999 | Adverse-Effect | Soon after introduction of Entityinsulin therapy, she developed severe anasarca, including marked peripheral oedema, Entityascites and pleural effusion. |
| 0.9999 | Adverse-Effect | Soon after introduction of Entityinsulin therapy, she developed severe anasarca, including marked peripheral oedema, ascites and Entitypleural effusion . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNiacin causes a Entityreversible toxic cystoid maculopathy that occurs in approximately 0. 67 % of patients taking high doses of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After the addition of Entitycitalopram , a Entitydesmethylclomipramine plasma level increase and an 8 - hydroacy - desmethylclomipramine plasma level decrease were observed. |
| 0.9998 | Adverse-Effect | After the addition of Entitycitalopram , a desmethylclomipramine plasma level increase and an Entity8 - hydroacy - desmethylclomipramine plasma level decrease were observed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | An 8 - year - old child with familial Mediterranean fever exhibited signs of Entitycolchicine Entitycolchicine intoxication while receiving prophylactic doses of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients treated with 5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of Entity5 - FU Entityneurotoxicity . |
| 1.0000 | Adverse-Effect | Two patients treated with 5 - fluorouracil ( Entity5 - FU ) for disseminated adenocarcinoma of the colon developed Entitycerebellar dysfunction typical of 5 - FU neurotoxicity. |
| 0.9999 | Adverse-Effect | Two patients treated with Entity5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed Entitycerebellar dysfunction typical of 5 - FU neurotoxicity. |
| 0.9993 | Adverse-Effect | Two patients treated with 5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed Entitycerebellar dysfunction typical of Entity5 - FU neurotoxicity. |
| 0.9990 | Adverse-Effect | Two patients treated with Entity5 - fluorouracil ( 5 - FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5 - FU Entityneurotoxicity . |
| 0.9989 | Adverse-Effect | Two patients treated with 5 - fluorouracil ( Entity5 - FU ) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5 - FU Entityneurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the first documented case of Entityazathioprine - induced severe Entitymyelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease. |
| 1.0000 | Adverse-Effect | We describe the first documented case of Entityazathioprine - induced Entitysevere myelosuppression due to thiopurine methyltransferase deficiency in autoimmune liver disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We recommend that clinicians monitor patients for signs and symptoms of pancreatitis, including Entityabdominal pain , during treatment with Entitytigecycline . |
| 1.0000 | Adverse-Effect | We recommend that clinicians monitor patients for signs and symptoms of Entitypancreatitis , including abdominal pain, during treatment with Entitytigecycline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBortezomib - induced Entityparalytic ileus is a potential gastrointestinal side effect of this first - in - class anticancer proteasome inhibitor. |
| 0.9998 | Adverse-Effect | EntityBortezomib - induced paralytic ileus is a potential Entitygastrointestinal side effect of this first - in - class anticancer proteasome inhibitor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The male patient was treated with 225 - mg / day Entityclozapine and the time to the diagnosis of Entityagranulocytosis was 6 weeks. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | BACKGROUND : How to best treat psychotic patients who have had past Entityclozapine - induced agranulocytosis or Entitygranulocytopenia remains a problem. |
| 1.0000 | Adverse-Effect | BACKGROUND : How to best treat psychotic patients who have had past Entityclozapine - induced Entityagranulocytosis or granulocytopenia remains a problem. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We have cared for three children in whom four episodes of dystonia proceeding to Entityopisthotonus occurred in association with Entitycarbamazepine use. |
| 0.9999 | Adverse-Effect | We have cared for three children in whom four episodes of Entitydystonia proceeding to opisthotonus occurred in association with Entitycarbamazepine use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Ten hours after the second Entitymethotrexate injection, the patient experienced a Entitydiffuse pruritic papular eruption located mainly on the limbs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCryptococcus neoformans fatal sepsis in a chronic lymphocytic leukemia patient treated with Entityalemtuzumab : case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The pathogenesis of Entitymethotrexate - induced Entitypapular eruption in collagen vascular diseases may suggest cutaneous small - vessel vasculitis. |
| 0.9947 | Adverse-Effect | CONCLUSIONS : The pathogenesis of Entitymethotrexate - induced papular eruption in collagen vascular diseases may suggest Entitycutaneous small - vessel vasculitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | The patient developed Entityoccipital infarcts and was found to have extremely elevated levels of EntityPPA in his blood and dialysis fluid. | |
| Adverse-Effect | The patient developed occipital infarcts and was found to have Entityextremely elevated levels of PPA EntityPPA in his blood and dialysis fluid. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two cases of childhood - onset schizophrenia associated with Entityclozapine - induced Entityakathisia responsive to beta - blocker treatment are described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPolymyositis is a rare complication of Entityinterferon alpha treatment as a result of immune - modulating role of the drug itself. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | On the next day, after a total dose of only 600 mg of Entitydanazol , Entitygingival bleeding and purpura occurred. |
| 1.0000 | Adverse-Effect | On the next day, after a total dose of only 600 mg of Entitydanazol , gingival bleeding and Entitypurpura occurred. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two patients with Entityaspergillus arthritis of the knee joint following Entityfludarabine - based non - myeloablative stem cell transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Concurrent acute megaloblastic anaemia and Entitypneumonitis : a severe side - effect of low - dose Entitymethotrexate therapy during rheumatoid arthritis. |
| 0.9999 | Adverse-Effect | Concurrent Entityacute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose Entitymethotrexate therapy during rheumatoid arthritis. |
| Adverse-Effect | EntityConcurrent acute megaloblastic anaemia and pneumonitis : a severe side - effect of low - dose Entitymethotrexate therapy during rheumatoid arthritis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present findings from three patients who experienced a Entitypsoriasiform eruption apparently due to the antiepileptic agents Entitysodium valproate and carbamazepine. |
| 0.9999 | Adverse-Effect | We present findings from three patients who experienced a Entitypsoriasiform eruption apparently due to the antiepileptic agents sodium valproate and Entitycarbamazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of a 21 - year - old woman who had developed mild Entityhepatotoxicity while receiving Entitycholine magnesium trisalicylate therapy is described. |
| 1.0000 | Adverse-Effect | A case of a 21 - year - old woman who had developed Entitymild hepatotoxicity while receiving Entitycholine magnesium trisalicylate therapy is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : EntityTopiramate - induced Entityangle - closure glaucoma ( TiACG ) is believed to be related to its sulfonamide moiety. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : We report this case of the concomitant appearance of multiple skin cancers and Entitynail changes associated with Entityhydroxyurea use. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : We report this case of the concomitant appearance of Entitymultiple skin cancers and nail changes associated with Entityhydroxyurea use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report on two patients with Entitycorneal ulcers refractory to conventional treatment while the patients were undergoing oral Entitycolchicine therapy. |
| 1.0000 | Adverse-Effect | The authors report on two patients with Entitycorneal ulcers refractory to conventional treatment while the patients were undergoing oral Entitycolchicine therapy. |
| 1.0000 | Adverse-Effect | The authors report on two patients with Entitycorneal ulcers refractory to conventional treatment while the patients were undergoing oral Entitycolchicine therapy. |
| 1.0000 | Adverse-Effect | The authors report on two patients with Entitycorneal ulcers refractory to conventional treatment while the patients were undergoing oral Entitycolchicine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entityfatal hyperkalemia owing to Entitysuccinylcholine administration in a patient with mucositis secondary to chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 52 - year - old Black woman on Entityphenytoin therapy for post - traumatic epilepsy developed Entitytransient hemiparesis contralateral to the injury. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The pharmacology and toxicology of Entitychloral hydrate are discussed with particular reference to the Entitycardiac arrhythmias that are seen with overdosage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this is the first case of Entitygriseofulvin - exacerbated Entitylupus in which nephrotic syndrome has been observed. |
| 0.9999 | Adverse-Effect | To our knowledge, this is the first case of Entitygriseofulvin - exacerbated lupus in which Entitynephrotic syndrome has been observed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report in detail an unusual adverse reaction to Entityinfliximab therapy, a drug - induced Entitylupus - like clinical syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When the disease recurred conventional Entityamphotericin B was used again, but had to be stopped because of Entitysevere side effects . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report a case of acute Entityhyperphosphatemia secondary to rectal administration of Entitysodium phosphate and sodium biphosphate ( Fleet enema ). |
| 0.9988 | Adverse-Effect | We report a case of acute Entityhyperphosphatemia secondary to rectal administration of sodium phosphate and Entitysodium biphosphate ( Fleet enema ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A case of Entityphenytoin - induced Entityhepatitis with mononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed. |
| 0.9097 | Adverse-Effect | A case of Entityphenytoin - induced hepatitis with Entitymononucleosis is reported, and syndromes associated with phenytoin hypersensitivity reactions are discussed. |
| 0.9871 | Adverse-Effect | A case of phenytoin - induced hepatitis with mononucleosis is reported, and syndromes associated with Entityphenytoin Entityphenytoin hypersensitivity reactions are discussed. |
| Adverse-Effect | A case of phenytoin - induced hepatitis with mononucleosis is reported, and syndromes associated with Entityphenytoin Entityhypersensitivity reactions are discussed. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityClarithromycin may be a cause of Entityfulminant liver failure either alone or by inhibiting the metabolism of other drugs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient who developed EntityNEH on three separate occasions provoked by two different chemotherapeutic agents - - Entitycytarabine and mitoxantrone. |
| 1.0000 | Adverse-Effect | We describe a patient who developed EntityNEH on three separate occasions provoked by two different chemotherapeutic agents - - cytarabine and Entitymitoxantrone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVES : A delayed Entitystroke - like leukoencephalopathy has been observed in patients receiving Entitymethotrexate ( MTX ) for childhood leukemia. |
| 0.9999 | Adverse-Effect | OBJECTIVES : A delayed Entitystroke - like leukoencephalopathy has been observed in patients receiving methotrexate ( EntityMTX ) for childhood leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityacute subdural haematoma originating spontaneously from an angiomatous meningioma in a patient receiving prophylactic Entityaspirin therapy is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a 41 yr old leprosy patient treated for 10 yrs with Entityclofazimine who underwent laparotomy for severe Entityabdominal pain . |
| 1.0000 | Adverse-Effect | We describe a 41 yr old leprosy patient treated for 10 yrs with Entityclofazimine who underwent Entitylaparotomy for severe abdominal pain. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBrugada type electrocardiographic changes induced by concomitant use of Entitylithium and propafenone in patient with Wolff - Parkinson - White syndrome. |
| 1.0000 | Adverse-Effect | EntityBrugada type electrocardiographic changes induced by concomitant use of lithium and Entitypropafenone in patient with Wolff - Parkinson - White syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We evaluated a patient who developed a Entitypsychotic disorder after 4 months of Entityisoniazid prophylaxis for a positive tuberculosis tine test. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, these cases are the first published reports of Entitylovastatin - induced Entityrhabdomyolysis associated with azithromycin and clarithromycin. |
| 1.0000 | Adverse-Effect | To our knowledge, these cases are the first published reports of lovastatin - induced Entityrhabdomyolysis associated with Entityazithromycin and clarithromycin. |
| 0.9998 | Adverse-Effect | To our knowledge, these cases are the first published reports of lovastatin - induced Entityrhabdomyolysis associated with azithromycin and Entityclarithromycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 60 year - old woman with chronic renal failure developed Entityacute proximal muscle weakness after receiving a regular dosage of Entitycolchicine . |
| Adverse-Effect | A 60 year - old woman with chronic renal failure developed acute Entityproximal muscle weakness after receiving a regular dosage of Entitycolchicine . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a fatal case of Entitytoxic epidermal necrolysis in a man who was treated with oral Entityofloxacin for epididymitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with Entityvincristine sulfate , prednisone, and asparaginase. |
| 0.9998 | Adverse-Effect | EntityDural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, Entityprednisone , and asparaginase. |
| 0.9997 | Adverse-Effect | EntityDural sinus thrombosis developed in two children with acute lymphoblastic leukemia during induction treatment with vincristine sulfate, prednisone, and Entityasparaginase . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present the first case ( to our knowledge ) of a potentially serious Entitydrug - drug interaction between Entityzafirlukast and theophylline. |
| 1.0000 | Adverse-Effect | We present the first case ( to our knowledge ) of a potentially serious Entitydrug - drug interaction between zafirlukast and Entitytheophylline . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityfetal valproate syndrome Entityvalproate syndrome ( FVS ) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay. |
| 1.0000 | Adverse-Effect | The fetal Entityvalproate syndrome ( EntityFVS ) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay. |
| 0.9999 | Adverse-Effect | The fetal Entityvalproate syndrome ( FVS ) is characterized by Entitydistinctive facial appearance , major and minor malformations, and developmental delay. |
| 0.9999 | Adverse-Effect | The fetal Entityvalproate syndrome ( FVS ) is characterized by distinctive facial appearance, Entitymajor and minor malformations , and developmental delay. |
| 0.9999 | Adverse-Effect | The fetal Entityvalproate syndrome ( FVS ) is characterized by distinctive facial appearance, major and minor malformations, and Entitydevelopmental delay . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This patient rapidly progressed from mild neurotoxicity to Entityfatal encephalopathy after one dose of intrathecal Entitymethotrexate during his third cycle of chemotherapy. |
| 0.9999 | Adverse-Effect | This patient rapidly progressed from Entitymild neurotoxicity to fatal encephalopathy after one dose of intrathecal Entitymethotrexate during his third cycle of chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She died within six weeks of developing congestive heart failure coupled with liver failure due to Entityhaemosiderosis despite regular use of Entitydesferrioxamine . |
| 0.9999 | Adverse-Effect | She died within six weeks of developing Entitycongestive heart failure coupled with liver failure due to haemosiderosis despite regular use of Entitydesferrioxamine . |
| 0.9999 | Adverse-Effect | She died within six weeks of developing congestive heart failure coupled with Entityliver failure due to haemosiderosis despite regular use of Entitydesferrioxamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A second patient with a similar glucose tolerance test result showed Entitypostprandial hyperglycemia when treated similarly with Entitybetamethasone valerate cream 0. 1 %. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the clinical and liver biopsy morphologic features for 4 patients with Entityminocycline - induced Entityautoimmune hepatitis ( group 1 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Without other causes for the hyponatremia, she was diagnosed with the Entitysyndrome of inappropriate antidiuretic hormone , presumably caused by Entitydesmopressin . |
| 0.9999 | Adverse-Effect | Without other causes for the Entityhyponatremia , she was diagnosed with the syndrome of inappropriate antidiuretic hormone, presumably caused by Entitydesmopressin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In contrast to chronic or subacute thyroiditis, EntityGraves'disease rarely complicates EntityIFN - alpha therapy for chronic viral C hepatitis. |
| 0.9999 | Adverse-Effect | In contrast to chronic or Entitysubacute thyroiditis , Graves'disease rarely complicates EntityIFN - alpha therapy for chronic viral C hepatitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a female acromegalic patient in whom multiple Entityhepatic adenomas appeared soon after Entitydanazol treatment for uterine fibromatosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | CONCLUSIONS : We have seen an increased incidence of acute EntityINH Entityneurotoxicity because of the resurgence of TB in New York City. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityParalytic ileus in patients undergoing Entitybortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established. |
| 0.9743 | Adverse-Effect | EntityParalytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to Entitybortezomib administration has not been established. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | STUDY DESIGN : Case report of a 31 - year - old woman who presented with Entitytoxic myelopathy due to intrathecal administration of Entitydoxorubicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityColchicine - induced Entityrhabdomyolysis is a rare complication, and the postulated mechanisms and risk factors for this severe complication are discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTelescoped digits of the hands and feet developed in a 69 - year - old male with severe chronic tophaceous gout during Entityallopurinol treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | Although other nitrites induce Entitymethemoglobinemia , exposure to Entitymethyl nitrite during phenylpropanolamine production appears to be a new cause of occupational methemoglobinemia. |
| 0.9994 | Adverse-Effect | Although other nitrites induce methemoglobinemia, exposure to Entitymethyl nitrite during phenylpropanolamine production appears to be a new cause of occupational Entitymethemoglobinemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | FINDINGS : Six children with growth retardation noted after treatment with high - dose Entityfluticasone propionate were found to have Entityadrenal suppression . |
| 0.9999 | Adverse-Effect | FINDINGS : Six children with Entitygrowth retardation noted after treatment with high - dose Entityfluticasone propionate were found to have adrenal suppression. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus, the possible in vivo effects of insulin on adipocytes were clearly observed in this case of Entityinsulin - induced Entitylipohypertrophy . |
| 0.9947 | Adverse-Effect | Thus, the possible in vivo effects of Entityinsulin on adipocytes were clearly observed in this case of insulin - induced Entitylipohypertrophy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNaproxen is a commonly used nonsteroidal anti - inflammatory drug ( NSAID ) whose side effects include Entitytinnitus and transient hearing loss. |
| 1.0000 | Adverse-Effect | EntityNaproxen is a commonly used nonsteroidal anti - inflammatory drug ( NSAID ) whose side effects include tinnitus and Entitytransient hearing loss . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We reviewed the records of 3 patients with lymphoproliferative disorders who experienced Entityacute coronary syndromes associated with their initial infusion of Entityrituximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient, a 28 - year - old man suffering from panic disorder, developed several Entityfirst - rank symptoms during Entityfluvoxamine administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although this EntityG - CSF - driven Entityleucocytosis was alarming it did not appear to have adversely affected the patient's prognosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We also describe a new, noninvasive method to assess Entitymagnesium - induced Entityneuromuscular block when curariform muscle relaxant was given simultaneously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute non - lymphocytic leukemia occurred in eight women following long - term treatment with EntityTreosulfan ( = dihydroxybusulfan ) for ovarian carcinoma. |
| 1.0000 | Adverse-Effect | EntityAcute non - lymphocytic leukemia occurred in eight women following long - term treatment with Treosulfan ( = Entitydihydroxybusulfan ) for ovarian carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We concluded that the colonic ulcer and the Entitysigmoidovesical fistula had been caused by the administration of Entitycalcium polystyrene sulfonate and sorbitol. |
| 0.9998 | Adverse-Effect | We concluded that the colonic ulcer and the Entitysigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and Entitysorbitol . |
| 0.9995 | Adverse-Effect | We concluded that the Entitycolonic ulcer and the sigmoidovesical fistula had been caused by the administration of Entitycalcium polystyrene sulfonate and sorbitol. |
| 0.9993 | Adverse-Effect | We concluded that the Entitycolonic ulcer and the sigmoidovesical fistula had been caused by the administration of calcium polystyrene sulfonate and Entitysorbitol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | This case suggests that Entityacyclovir when given intravenously in doses of 10 mg / kg may result in Entityincreased serum lithium concentrations. | |
| Adverse-Effect | This case suggests that acyclovir when given intravenously in doses of 10 mg / kg may result in Entityincreased serum lithium Entitylithium concentrations. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute delirium resulting from Entitylevofloxacin therapy is an exceedingly rare complication that has been thought to occur more commonly in elderly patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Sixteen hours after the first administration of IFN, EntityIFN was suspended by the symptoms of Entitycongestive heart failure ( CHF ). |
| 0.9998 | Adverse-Effect | Sixteen hours after the first administration of IFN, EntityIFN was suspended by the symptoms of congestive heart failure ( EntityCHF ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case of a 4 - year - old girl with Entityvalproate - induced Entitystupor and electroencephalographic pattern of increased fast activity is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of biopsy proven Entitymyositis whose symptoms began within 10 days of receiving Entityleuprolide acetate therapy for prostate cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOsteonecrosis is a serious side effect of antiemetic treatment with Entitydexamethasone and this serious complication should be incorporated in the current guidelines. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case report : lack of control of diabetes and Entityweight gain in a patient on initiation and rechallenge of therapy with Entityolanzapine . |
| 1.0000 | Adverse-Effect | Case report : lack of control of Entitydiabetes and weight gain in a patient on initiation and rechallenge of therapy with Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She developed a generalized rash and itching, sore throat, and Entitydizziness approximately 4 hours after the first dose of Entitycapecitabine . |
| 1.0000 | Adverse-Effect | She developed a generalized rash and itching, Entitysore throat , and dizziness approximately 4 hours after the first dose of Entitycapecitabine . |
| 1.0000 | Adverse-Effect | She developed a Entitygeneralized rash and itching, sore throat, and dizziness approximately 4 hours after the first dose of Entitycapecitabine . |
| 1.0000 | Adverse-Effect | She developed a generalized rash and Entityitching , sore throat, and dizziness approximately 4 hours after the first dose of Entitycapecitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We described the occurrence of EntityL - dopa - induced Entitymyoclonus and seizures in a case of parkinsonism with its SEPs findings. |
| 0.9998 | Adverse-Effect | We described the occurrence of EntityL - dopa - induced myoclonus and Entityseizures in a case of parkinsonism with its SEPs findings. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient developed Entityrestless legs symptoms paralleling the course of Entityinterferon - alpha ( IFN alpha ) therapy for chronic hepatitis C. |
| 0.9997 | Adverse-Effect | A patient developed Entityrestless legs symptoms paralleling the course of interferon - alpha ( EntityIFN alpha ) therapy for chronic hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the other patient, a 78 - year - old woman, EntityNeisseria mucosa knee arthritis occurred after a single Entitysodium hyaluronate injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prominent eye movements during NREM sleep and EntityREM sleep behavior disorder associated with Entityfluoxetine treatment of depression and obsessive - compulsive disorder. |
| 1.0000 | Adverse-Effect | EntityProminent eye movements during NREM sleep and REM sleep behavior disorder associated with Entityfluoxetine treatment of depression and obsessive - compulsive disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In patients with chronic heart failure, Entityspironolactone added to conventional treatment may lead to serious and, occasionally, Entityfatal hyperkalaemia . |
| Adverse-Effect | In patients with chronic heart failure, Entityspironolactone added to conventional treatment may lead to Entityserious and, occasionally, fatal hyperkalaemia . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityvitiligo that occurred during the second month of Entityinterferon alpha 2a therapy for chronic active hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Second, we report a case of Entityneutropenia , which proved to be fatal in a schizophrenia patient receiving Entityolanzapine and thiazide. |
| 0.9999 | Adverse-Effect | Second, we report a case of Entityneutropenia , which proved to be fatal in a schizophrenia patient receiving olanzapine and Entitythiazide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The results of the ultrasound examination combined with clinical anamnesis allowed diagnosis of Entitygastric mucosa foveolar hyperplasia due to prolonged EntityPGE1 therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The potential role of Entitypropranolol in inducing Entitycentral nervous system disturbances is emphasized, and the literature on the subject is reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Therefore, we concluded that this patient's Entitypulmonary disease was caused by Entitycalcium stearate , an additive for an antihistaminic drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DATA SYNTHESIS : A 49 - year - old man developed symptoms of Entitysevere psychosis concomitant with Entityciprofloxacin ( 250 mg bid ) treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a patient with human immunodeficiency virus infection under treatment with Entityfoscarnet for CMV retinitis who complained of Entitythirst and polyuria. |
| 1.0000 | Adverse-Effect | We present a patient with human immunodeficiency virus infection under treatment with Entityfoscarnet for CMV retinitis who complained of thirst and Entitypolyuria . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a fatal case of Entityacute interstitial pneumonitis in a patient treated with Entitycarmustine ( BCNU ) for a brain tumor. |
| 1.0000 | Adverse-Effect | We report a fatal case of Entityacute interstitial pneumonitis in a patient treated with carmustine ( EntityBCNU ) for a brain tumor. |
| 0.9999 | Adverse-Effect | We report a Entityfatal case of acute interstitial pneumonitis in a patient treated with Entitycarmustine ( BCNU ) for a brain tumor. |
| 0.9997 | Adverse-Effect | We report a Entityfatal case of acute interstitial pneumonitis in a patient treated with carmustine ( EntityBCNU ) for a brain tumor. |
| Adverse-Effect | We report a Entityfatal case of acute interstitial pneumonitis in a patient treated with carmustine ( EntityBCNU ) for a brain tumor. | |
| Adverse-Effect | We report a Entityfatal case of acute interstitial pneumonitis in a patient treated with Entitycarmustine ( BCNU ) for a brain tumor. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 10 - year - old white girl with bilateral optic glioma developed a Entityhypersensitivity reaction to Entitycarboplatin after nine courses. |
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 10 - year - old white girl with bilateral optic glioma developed a Entityhypersensitivity reaction to Entitycarboplatin after nine courses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a young healthy woman who presented an early Entityoveranticoagulation when receiving Entityacenocoumarol for a first thromboembolic episode. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Beginning ductopenia was present in two, suggesting that Entityitraconazole might be responsible for the occurrence of prolonged drug - induced Entitycholangiopathy . |
| 1.0000 | Adverse-Effect | Beginning Entityductopenia was present in two, suggesting that Entityitraconazole might be responsible for the occurrence of prolonged drug - induced cholangiopathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Early - onset Entitypentamidine - associated Entitysecond - degree heart block and sinus bradycardia : case report and review of the literature. |
| 1.0000 | Adverse-Effect | Early - onset Entitypentamidine - associated second - degree heart block and Entitysinus bradycardia : case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : We believe this to be the first reported case of EntityrhGH - induced Entityhypercalcemia in an HIV - infected patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We reported a case of Entitydisulfiram - induced Entityhepatitis with unique clinical features and compared our case with others in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of severe Entityhypotension associated with intravenous Entityvalproate used to treat status epilepticus in an 11 - year - old girl. |
| 1.0000 | Adverse-Effect | We report a case of Entitysevere hypotension associated with intravenous Entityvalproate used to treat status epilepticus in an 11 - year - old girl. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | AIM : To report three cases of extensive Entityskin necrosis in cirrhotic patients treated with the vasoconstrictor agent Entityterlipressin ( Glypressin ). |
| 0.9999 | Adverse-Effect | AIM : To report three cases of extensive Entityskin necrosis in cirrhotic patients treated with the vasoconstrictor agent terlipressin ( EntityGlypressin ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The occurrence of neuromuscular blockade and the resulting Entitypotentiation of muscle relaxants during Entitymagnesium sulfate ( MgSO4 ) administration is well known. |
| 0.9999 | Adverse-Effect | The occurrence of neuromuscular blockade and the resulting Entitypotentiation of muscle relaxants during magnesium sulfate ( EntityMgSO4 ) administration is well known. |
| 0.9997 | Adverse-Effect | The occurrence of Entityneuromuscular blockade and the resulting potentiation of muscle relaxants during Entitymagnesium sulfate ( MgSO4 ) administration is well known. |
| 0.9994 | Adverse-Effect | The occurrence of Entityneuromuscular blockade and the resulting potentiation of muscle relaxants during magnesium sulfate ( EntityMgSO4 ) administration is well known. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thirty patients with Entityhepatic reactions to Entitycyclofenil , a non - steroidal drug with a stimulating effect on ovulation, are reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | His symptoms of brain stem compression were alleviated and the role of Entityphenytoin in the production of his Entitycraniocervical abnormality is discussed. |
| 0.9999 | Adverse-Effect | His symptoms of Entitybrain stem compression were alleviated and the role of Entityphenytoin in the production of his craniocervical abnormality is discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The second had acute cystitis and was treated by sulphonamide and the third developed Entitymyopia coincident with Entitymetronidazole treatment for trichomonas vaginalis. |
| 0.9999 | Adverse-Effect | The second had acute cystitis and was treated by Entitysulphonamide and the third developed Entitymyopia coincident with metronidazole treatment for trichomonas vaginalis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The renal biopsy showed Entityfocal segmental glomerulosclerosis , which has only been previously reported in two cases of CML treated with EntityIFNalpha . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The most commonly recognized toxic effect of Entityethambutol is Entityoptic neuropathy , which generally is considered uncommon and reversible in medical literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Based on the clinical status of the patient, it was suspected that several conditions contributed to the Entityabnormal hypersensitivity to Entitywarfarin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case is presented in which a 68 - year - old man became Entitydelirious after being withdrawn from a low dosage of Entityalprazolam . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, Entityadenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause Entityacceleration of the ventricular rate during atrial fibrillation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nonspecific but Entitysignificant abnormalities have been described in the infants of women treated with Entitydisulfiram in the first trimester of their pregnancies. |
| 1.0000 | Adverse-Effect | Nonspecific but significant Entityabnormalities have been described in the infants of women treated with Entitydisulfiram in the first trimester of their pregnancies. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityToxicity , pharmacokinetics, and in vitro hemodialysis clearance of Entityifosfamide and metabolites in an anephric pediatric patient with Wilms'tumor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case resembles two previously reported cases of Entityoptic neuropathy which occurred in patients with Wilson's disease who were receiving Entitypenicillamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the present paper, we discuss the first Japanese vivax malaria patient whose EntityQT interval was prolonged after treatment with Entityhalofantrine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Anaphylactoid shock, disseminated intravascular coagulation, and Entityanuric renal failure requiring dialysis occurred in a patient receiving Entityzomepirac sodium for toothache. |
| 0.9998 | Adverse-Effect | EntityAnaphylactoid shock , disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving Entityzomepirac sodium for toothache. |
| 0.9996 | Adverse-Effect | Anaphylactoid shock, Entitydisseminated intravascular coagulation , and anuric renal failure requiring dialysis occurred in a patient receiving Entityzomepirac sodium for toothache. |
| Adverse-Effect | EntityAnaphylactoid shock , disseminated intravascular coagulation, and anuric renal failure requiring dialysis occurred in a patient receiving Entityzomepirac sodium for toothache. | |
| Adverse-Effect | Anaphylactoid shock, Entitydisseminated intravascular coagulation , and anuric renal failure requiring dialysis occurred in a patient receiving Entityzomepirac sodium for toothache. | |
| Adverse-Effect | Anaphylactoid shock, disseminated intravascular coagulation, and Entityanuric renal failure requiring dialysis occurred in a patient receiving Entityzomepirac sodium for toothache. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | High - resolution computed tomography scan findings were consistent with ILD, which was sufficient to diagnose as Entityerlotinib - induced EntityILD . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She had been taking Entitynabumetone for 6 months, but had discontinued the agent 2 weeks before admission due to progressive Entityedema . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | The reversal of heparin by Entityprotamine may cause Entitysevere hemodynamic deterioration , characterized by systemic hypotension, pulmonary hypertension, and bronchoconstriction. | |
| Adverse-Effect | The reversal of heparin by Entityprotamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, pulmonary hypertension, and Entitybronchoconstriction . | |
| Adverse-Effect | The reversal of heparin by Entityprotamine may cause severe hemodynamic deterioration, characterized by systemic hypotension, Entitypulmonary hypertension , and bronchoconstriction. | |
| Adverse-Effect | The reversal of heparin by Entityprotamine may cause severe hemodynamic deterioration, characterized by Entitysystemic hypotension , pulmonary hypertension, and bronchoconstriction. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To report a case of angiographically documented Entitycystoid macula edema occurring after switching a pseudophakic patient from Entitylatanoprost to bimatoprost. |
| 0.9999 | Adverse-Effect | PURPOSE : To report a case of angiographically documented Entitycystoid macula edema occurring after switching a pseudophakic patient from latanoprost to Entitybimatoprost . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitynodules regressed after withdrawal of Entitymethotrexate therapy in one patient and were arrested with the addition of hydroxychloroquine in the other. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware of the possible association of Entitythrombocytopenia with Entitylansoprazole and discontinue the drug if thrombocytopenia becomes apparent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, these cases represent the first reports of EntityTDF - associated Entityirreversible renal failure and rickets in pediatric patients. |
| 0.9999 | Adverse-Effect | To our knowledge, these cases represent the first reports of EntityTDF - associated irreversible renal failure and Entityrickets in pediatric patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCyclosporin side effects included Entityhirsutism , hypertension, increased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| 1.0000 | Adverse-Effect | EntityCyclosporin side effects included hirsutism, Entityhypertension , increased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| 0.9999 | Adverse-Effect | EntityCyclosporin side effects included hirsutism, hypertension, increased blood levels of urea and creatinine, and Entityabnormalities in liver function tests . |
| 0.9999 | Adverse-Effect | EntityCyclosporin side effects included hirsutism, hypertension, Entityincreased blood levels of urea and creatinine , and abnormalities in liver function tests. |
| 0.9999 | Adverse-Effect | EntityCyclosporin side effects included hirsutism, hypertension, Entityincreased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| 0.9999 | Adverse-Effect | EntityCyclosporin side effects included hirsutism, hypertension, Entityincreased blood levels of urea and creatinine, and abnormalities in liver function tests. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Atrioventricular block complicating Entityamiodarone - induced Entityhypothyroidism in a patient with pre - excitation and rate - dependent bilateral bundle branch block. |
| 1.0000 | Adverse-Effect | EntityAtrioventricular block complicating Entityamiodarone - induced hypothyroidism in a patient with pre - excitation and rate - dependent bilateral bundle branch block. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Behavioral side effects associated with Entityclonazepam may include Entityagitation , aggression, hyperactivity, irritability, property destruction, and temper tantrums. |
| 1.0000 | Adverse-Effect | Behavioral side effects associated with Entityclonazepam may include agitation, Entityaggression , hyperactivity, irritability, property destruction, and temper tantrums. |
| 1.0000 | Adverse-Effect | Behavioral side effects associated with Entityclonazepam may include agitation, aggression, Entityhyperactivity , irritability, property destruction, and temper tantrums. |
| 1.0000 | Adverse-Effect | Behavioral side effects associated with Entityclonazepam may include agitation, aggression, hyperactivity, Entityirritability , property destruction, and temper tantrums. |
| 0.9999 | Adverse-Effect | Behavioral side effects associated with Entityclonazepam may include agitation, aggression, hyperactivity, irritability, property destruction, and Entitytemper tantrums . |
| 0.9999 | Adverse-Effect | Behavioral side effects associated with Entityclonazepam may include agitation, aggression, hyperactivity, irritability, Entityproperty destruction , and temper tantrums. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To determine the frequency of Entityweight loss in patients treated with Entityleflunomide for rheumatoid arthritis at an arthritis referral center. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9994 | Adverse-Effect | A well - recognized complication of Entityethambutol use is Entityoptic neuropathy , but the potential ocular toxicity of isoniazid is often overlooked. |
| 0.9899 | Adverse-Effect | A well - recognized complication of ethambutol use is optic neuropathy, but the potential Entityocular toxicity of Entityisoniazid is often overlooked. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The increasing prevalence of Type 2 diabetes and its treatment with Entitymetformin might result in more cases of Entitylactic acidosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Treatment of APL in pregnancy is controversial as the use of EntityATRA has been questioned due to the Entityteratogenic effect of retinoids. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : One case of recurrent primary peritoneal carcinoma previously treated with a Entitycarboplatin - based regimen, developed a Entityplatinum hypersensitivity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Controversy concerning the nephrotoxicity of lithium is discussed, and recommendations for the evaluation of Entityrenal failure during Entitylithium therapy are provided. |
| 0.9997 | Adverse-Effect | Controversy concerning the Entitynephrotoxicity of Entitylithium is discussed, and recommendations for the evaluation of renal failure during lithium therapy are provided. |
| 0.6897 | Adverse-Effect | Controversy concerning the nephrotoxicity of Entitylithium is discussed, and recommendations for the evaluation of Entityrenal failure during lithium therapy are provided. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To describe Entitybilateral corneal endothelial dysfunction in a patient with Parkinson disease who was treated with long - term Entityamantadine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate - induced Entitypneumonitis in patients with rheumatoid arthritis and psoriatic arthritis : report of five cases and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Type I second - degree AV block ( Mobitz type I, EntityWenckebach AV block ) during Entityritodrine therapy for preterm labor. |
| 1.0000 | Adverse-Effect | Type I second - degree AV block ( EntityMobitz type I , Wenckebach AV block ) during Entityritodrine therapy for preterm labor. |
| 0.9999 | Adverse-Effect | EntityType I second - degree AV block ( Mobitz type I, Wenckebach AV block ) during Entityritodrine therapy for preterm labor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present the case of a 58 - year - old woman who ingested more than 35 g of Entitycaffeine in a Entitysuicide attempt . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInsulin - dependent diabetes mellitus developed in a young woman 8 weeks after the initiation of Entitydanazol for treatment of pelvic endometriosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A patient with coccidioidal meningitis was treated with intrathecally administered Entityamphotericin B , and an Entityacute toxic delirium with EEG abnormalities developed. |
| 0.9992 | Adverse-Effect | A patient with coccidioidal meningitis was treated with intrathecally administered Entityamphotericin B , and an acute toxic delirium with EntityEEG abnormalities developed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 46 - yr - old woman with ovarian carcinoma who developed Entityporphyria cutanea tarda while undergoing treatment with Entitycisplatin and cyclophosphamide. |
| 1.0000 | Adverse-Effect | We report a 46 - yr - old woman with ovarian carcinoma who developed Entityporphyria cutanea tarda while undergoing treatment with cisplatin and Entitycyclophosphamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Based on these findings, the patient was diagnosed with Entitydiabetes insipidus secondary to Entitylithium therapy and was treated successfully with amiloride. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus, the patient's clinical course and workup strongly support a diagnosis of Entitylenalidomide - induced Entityhypersensitivity pneumonitis - like syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe EntityC. difficile colitis occurred in 2 patients ( 6. 1 % ) after receiving Entitycisplatin - based combination chemotherapy for ovarian malignancies. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians should be aware of the potential for developing a Entitygemcitabine - induced Entityradiation recall reaction resulting in hemodynamically significant pericardial effusion. |
| 0.9998 | Adverse-Effect | Physicians should be aware of the potential for developing a Entitygemcitabine - induced radiation recall reaction resulting in hemodynamically significant Entitypericardial effusion . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A cause - effect relationship to capecitabine was suggested due to resolution of Entityheadache with Entitycapecitabine withdrawal and reappearance with capecitabine rechallenge. |
| 0.9998 | Adverse-Effect | A cause - effect relationship to Entitycapecitabine was suggested due to resolution of Entityheadache with capecitabine withdrawal and reappearance with capecitabine rechallenge. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report highlights a case of drug - induced Entitydysphagia in a patient receiving Entityhaloperidol for obsessive nocturnal thoughts and auditory disturbances. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Does the use of Entityinsulin in a patient with liver dysfunction increase water retention in the body, i. e. cause insulin Entityoedema ? |
| 0.9950 | Adverse-Effect | Does the use of Entityinsulin in a patient with liver dysfunction increase water retention in the body, i. e. cause Entityinsulin oedema ? |
| 0.5166 | Adverse-Effect | Does the use of insulin in a patient with liver dysfunction increase water retention in the body, i. e. cause Entityinsulin oedema Entityoedema ? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This article describes the case of a 25 - year - old man found Entitydead at home who had been prescribed Entityolanzapine for schizophrenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is very likely that the Entitydexamethasone used in the antiemetic drug regimen contributed to the development of Entityosteonecrosis in these patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAngioedema , a rare side effect of Entitycarbamazepine , involves vascular leakage in dermis and subcutis mediated by immunoglobulin E and / or bradykinins. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Like other atypical neuroleptics Entityolanzapine is considered to show a reduced prevalence of Entityextrapyramidal side effects when compared to classical neuroleptic drugs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The favourable outcome in these two patients contrasts with the Entityfatal outcome of the two other reported cases of Entitynitrofurantoin induced BOOP. |
| 1.0000 | Adverse-Effect | The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of Entitynitrofurantoin induced EntityBOOP . |
| Adverse-Effect | The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of Entitynitrofurantoin Entitynitrofurantoin induced BOOP . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : A clinical diagnosis of Entityfixed drug eruption owing to use of the PDE5 inhibitor Entitytadalafil ( Cialis ) was made. |
| 1.0000 | Adverse-Effect | RESULTS : A clinical diagnosis of Entityfixed drug eruption owing to use of the PDE5 inhibitor tadalafil ( EntityCialis ) was made. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Protease inhibitors ( ritonavir and Entitysaquinavir ) were added to the treatment and the patient developed Entityprogressive ataxia related to carbamazepine toxicity. |
| 0.9999 | Adverse-Effect | Protease inhibitors ( Entityritonavir and saquinavir ) were added to the treatment and the patient developed Entityprogressive ataxia related to carbamazepine toxicity. |
| 0.9999 | Adverse-Effect | Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to Entitycarbamazepine Entitycarbamazepine toxicity . |
| 0.9987 | Adverse-Effect | Protease inhibitors ( ritonavir and Entitysaquinavir ) were added to the treatment and the patient developed progressive ataxia related to Entitycarbamazepine toxicity . |
| 0.9984 | Adverse-Effect | Protease inhibitors ( ritonavir and saquinavir ) were added to the treatment and the patient developed Entityprogressive ataxia related to Entitycarbamazepine toxicity. |
| 0.9965 | Adverse-Effect | Protease inhibitors ( Entityritonavir and saquinavir ) were added to the treatment and the patient developed progressive ataxia related to Entitycarbamazepine toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 56 - year - old male parkinsonian patient developed a unique Entitybehavioral change following the oral administration of Entitycinepazide , a cerebral vasodilator. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOvarian endometrioid adenocarcinoma arising from an endometriotic cyst in a postmenopausal woman under Entitytamoxifen therapy for breast cancer : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first case of EntityTMP - SMX - induced Entityhypersensitivity syndrome associated with the reactivation of a latent viral infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of 48 - year - old woman with seizure disorder on divalproex sodium ( EntityDepakote ) who presented with Entitydyspnea . |
| 0.9999 | Adverse-Effect | We report a case of 48 - year - old woman with seizure disorder on Entitydivalproex sodium ( Depakote ) who presented with Entitydyspnea . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Skin rash began after 2 weeks of treatment, and signs of Entityhepatocellular failure developed 3 weeks after Entityphenobarbital had been started. |
| 0.9995 | Adverse-Effect | EntitySkin rash began after 2 weeks of treatment, and signs of hepatocellular failure developed 3 weeks after Entityphenobarbital had been started. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | OBJECTIVE : To report a case of Entitysevere chloroquine toxicity Entitychloroquine toxicity in the presence of high - grade chloroquine - resistant Plasmodium vivax. |
| 0.9993 | Adverse-Effect | OBJECTIVE : To report a case of severe Entitychloroquine Entitychloroquine toxicity in the presence of high - grade chloroquine - resistant Plasmodium vivax. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Ethambutol, and to a lesser extent Entityisoniazid , are both implicated in the Entitydevelopment of visually related side effects . |
| 1.0000 | Adverse-Effect | RESULTS : EntityEthambutol , and to a lesser extent isoniazid, are both implicated in the Entitydevelopment of visually related side effects . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our objective is to present a retrospective analysis of the DWI findings in four patients who suffered Entitysubacute neurotoxicity after intrathecal EntityMTX . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Rituximab - based therapy for Entitygemcitabine - induced Entityhemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma : a case report. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient receiving chronic Entitylithium therapy who presented with a transient EntityCDI occurring in the setting of underlying chronic NDI. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Syndrome of inappropriate secretion of ADH ( EntitySIADH ) following Entitycisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion. |
| 0.9998 | Adverse-Effect | EntitySyndrome of inappropriate secretion of ADH ( SIADH ) following Entitycisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this paper, we report a patient with primary anti - phospholipid syndrome treated by Entitycorticosteroid , who developed Entitydisseminated nocardiosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A wide variety of Entityadverse central nervous system effects have been reported in association with Entitypropafenone ; dizziness is the most common. |
| 1.0000 | Adverse-Effect | A wide variety of adverse central nervous system effects have been reported in association with Entitypropafenone ; Entitydizziness is the most common. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the EntityHUS associated with EntityMMC therapy. |
| 0.9999 | Adverse-Effect | Pulmonary hemorrhage is an uncommon feature in the EntityHUS , and seems to appear especially in the HUS associated with EntityMMC therapy. |
| 0.9999 | Adverse-Effect | EntityPulmonary hemorrhage is an uncommon feature in the HUS, and seems to appear especially in the HUS associated with EntityMMC therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Center for Disease Control has received numerous reports of an Entityeosinophilia - myalgia syndrome related to products containing EntityL - tryptophan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityfatal pulmonary toxicity in a patient with advanced non - small cell lung cancer who received Entityerlotinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 76 - year - old man who developed an Entityacute blistering eruption following high - dose Entitypenicillin treatment for pneumococcal septicaemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The spectrum of Entityrenal lesions occurring during antituberculous therapy, particularly in association with Entityrifampin , may be wider than previously suspected. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Complications associated with Entityprimary and secondary perforation of the bladder following immediate instillations of Entityepirubicin after transurethral resection of superficial urothelial tumours. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Entity2 - Chloro - deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to Entitynon - Hodgkin's lymphoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 42 year old man, treated for testicular carcinoma with combination chemotherapy that included Entitybleomycin , developed life threatening Entityinterstitial pneumonitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Severe histological Entityosteomalacia developed in a woman with Crohn's disease 2 years after ileal resection and the start of Entitycholestyramine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of Entityherpes esophagitis in a renal transplant patient treated with EntityCyclosporine A while on chronic steroid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case is reported of a 40 year old woman treated with intraventricular EntityIL - 2 for leptomeningeal disease who developed progressive Entitycognitive dysfunction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although the essential cause of EntityPV is unclear, its onset has occasionally been associated with drug therapy, in particular Entitypenicillamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case history of a 15 - year - old boy who developed incapacitating Entitytardive dyskinesia that resolved during treatment with Entitydeanol is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These cases suggest the possibility that, in some patients, leukopenia or Entityagranulocytosis during Entityolanzapine treatment might be dose - related. |
| 0.9999 | Adverse-Effect | These cases suggest the possibility that, in some patients, Entityleukopenia or agranulocytosis during Entityolanzapine treatment might be dose - related. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterferon - induced Entitypsychosis as a " psychiatric contraindication " to hepatitis C treatment : a review and case - based discussion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The use of fluorouracil treatment with careful monitoring can be considered in a patient with mild Entityallergic reactions to Entitycapecitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | In patients with a known access to INH, Entityseizures should be considered to be caused by EntityINH toxicity unless proved otherwise. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | During the first treatment, dysarthria and Entityataxia were seen after completion of the patient's eighth and final dose of EntityHDARAC . |
| 1.0000 | Adverse-Effect | During the first treatment, Entitydysarthria and ataxia were seen after completion of the patient's eighth and final dose of EntityHDARAC . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe onset of syndrome of inappropriate antidiuretic hormone ( EntitySIADH ) associated with Entityvinorelbine therapy for advanced breast cancer. |
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe onset of Entitysyndrome of inappropriate antidiuretic hormone ( SIADH ) associated with Entityvinorelbine therapy for advanced breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pancreatitis has been associated with the tetracycline class of antibiotics and concerns about Entitytigecycline - induced Entityacute pancreatitis have recently been raised. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Only one case of Entitysevere symptomatic hepatitis occurring after pulse therapy with Entityitraconazole for onychomycosis and requiring transplantation has been reported previously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of rapidly occurring Entityhyperglycemia that occurred in a geriatric patient 3 days after treatment with Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | While on a maximal dose of Entityphenylephrine she developed prominent Entitypositive U waves , which disappeared with the cessation of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is suggested that the fatal stroke may have resulted from Entityarterial spasm caused by Entityergotamine overdosage and possibly complicated by thrombosis. |
| 0.9999 | Adverse-Effect | It is suggested that the Entityfatal stroke may have resulted from arterial spasm caused by Entityergotamine overdosage and possibly complicated by thrombosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Electro - oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with Entityvigabatrin - attributed Entityvisual field constriction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Recombinant VIIa concentrate in the management of bleeding following Entityprothrombin complex concentrate - related Entitymyocardial infarction in patients with haemophilia and inhibitors. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityfatal fulminant hepatitis caused by the use of Entitydisulfiram in a man with previously normal hepatocellular function. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a 73 - year - old woman who developed serious systemic vasculitis with associated Entitythrombocytopenia in the course of treatment with Entitycladribine . |
| 0.9997 | Adverse-Effect | We describe a 73 - year - old woman who developed serious Entitysystemic vasculitis with associated thrombocytopenia in the course of treatment with Entitycladribine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A combination of behavioural and cognitive adverse effects is illustrated in this case report of a recurrent Entitytriazolam - induced Entityeating disorder . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Extra caution should be taken in using Entityoctreotide or its long - acting analog in patients otherwise predisposed to Entityintrahepatic bile stasis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 3 cases of HIV - 1 infected patients who experienced symptomatic Entityangiolipomas shortly after starting antiretroviral therapy including the protease inhibitor Entityindinavir . |
| 1.0000 | Adverse-Effect | We report 3 cases of HIV - 1 infected patients who experienced Entitysymptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor Entityindinavir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this case Entitysenna was likely the cause of a Entitysubacute cholestatic hepatitis exemplifying again the potential role of herbal related liver injury. |
| 0.9998 | Adverse-Effect | In this case Entitysenna was likely the cause of a subacute cholestatic hepatitis exemplifying again the potential role of herbal related Entityliver injury . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Chronic myelogenous leukemia ( CML ), hepatitis C, and interferon alpha ( EntityIFNalpha ) have all been associated with Entityrenal dysfunction . |
| 0.9998 | Adverse-Effect | Chronic myelogenous leukemia ( CML ), hepatitis C, and Entityinterferon alpha ( IFNalpha ) have all been associated with Entityrenal dysfunction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors conclude that among patients taking high doses of oral Entityniacin only those who experience Entityvisual symptoms need to be ophthalmologically evaluated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 37 - year - old woman with relapsing invasive vertebral aspergillosis received intravenous EntityVRC and developed Entityangio - oedema 10 days after starting therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case demonstrates the association of selective EntityIgA deficiency with remission in rheumatoid arthritis induced by Entityfenclofenac as well as aurothiomalate and sulphasalazine. |
| 0.9997 | Adverse-Effect | This case demonstrates the association of selective EntityIgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as aurothiomalate and Entitysulphasalazine . |
| 0.9997 | Adverse-Effect | This case demonstrates the association of selective EntityIgA deficiency with remission in rheumatoid arthritis induced by fenclofenac as well as Entityaurothiomalate and sulphasalazine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : A 55 - year - old woman became Entitystuporous after overdose with Entitylamotrigine ( LTG ) and valproic acid ( VPA ) tablets. |
| 1.0000 | Adverse-Effect | METHODS : A 55 - year - old woman became Entitystuporous after overdose with lamotrigine ( EntityLTG ) and valproic acid ( VPA ) tablets. |
| 1.0000 | Adverse-Effect | METHODS : A 55 - year - old woman became Entitystuporous after overdose with lamotrigine ( LTG ) and valproic acid ( EntityVPA ) tablets. |
| 0.9999 | Adverse-Effect | METHODS : A 55 - year - old woman became Entitystuporous after overdose with lamotrigine ( LTG ) and Entityvalproic acid ( VPA ) tablets. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She received an accidental 450 - mg bolus injection of Entitymorphine intrathecally and developed Entityhypertension , status epilepticus, intracerebral hemorrhage, and respiratory failure. |
| 1.0000 | Adverse-Effect | She received an accidental 450 - mg bolus injection of Entitymorphine intrathecally and developed hypertension, status epilepticus, Entityintracerebral hemorrhage , and respiratory failure. |
| 1.0000 | Adverse-Effect | She received an accidental 450 - mg bolus injection of Entitymorphine intrathecally and developed hypertension, status epilepticus, intracerebral hemorrhage, and Entityrespiratory failure . |
| 0.9999 | Adverse-Effect | She received an accidental 450 - mg bolus injection of Entitymorphine intrathecally and developed hypertension, Entitystatus epilepticus , intracerebral hemorrhage, and respiratory failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 49 - year - old man with Crohn's disease treated with prednisone and mesalamine ( Entity5 - ASA ) developed Entityworsening respiratory distress and fever. |
| 1.0000 | Adverse-Effect | A 49 - year - old man with Crohn's disease treated with prednisone and Entitymesalamine ( 5 - ASA ) developed Entityworsening respiratory distress and fever. |
| 1.0000 | Adverse-Effect | A 49 - year - old man with Crohn's disease treated with Entityprednisone and mesalamine ( 5 - ASA ) developed Entityworsening respiratory distress and fever. |
| 0.9999 | Adverse-Effect | A 49 - year - old man with Crohn's disease treated with prednisone and Entitymesalamine ( 5 - ASA ) developed worsening respiratory distress and Entityfever . |
| 0.9999 | Adverse-Effect | A 49 - year - old man with Crohn's disease treated with Entityprednisone and mesalamine ( 5 - ASA ) developed worsening respiratory distress and Entityfever . |
| 0.9999 | Adverse-Effect | A 49 - year - old man with Crohn's disease treated with prednisone and mesalamine ( Entity5 - ASA ) developed worsening respiratory distress and Entityfever . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Massive pulmonary embolism due to late - onset Entityheparin - induced Entitythrombocytopenia following coronary artery bypass graft surgery : successful treatment with lepirudin. |
| 0.9994 | Adverse-Effect | EntityMassive pulmonary embolism due to late - onset Entityheparin - induced thrombocytopenia following coronary artery bypass graft surgery : successful treatment with lepirudin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethemoglobinemia is another common finding among patients receiving Entitydapsone therapy, but rarely does it result in prominent symptoms other than transient pallor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians using this " new " drug must be aware of the potential danger of Entitysulfonamide - induced Entityinjury to the urinary tract . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9885 | Adverse-Effect | Since the Entitybronchospasm was relieved with discontinuation of Entitypropranolol and supportive bronchodilator therapy, the bronchospasm was believed to be caused by propranolol. |
| 0.9694 | Adverse-Effect | Since the bronchospasm was relieved with discontinuation of propranolol and supportive bronchodilator therapy, the Entitybronchospasm was believed to be caused by Entitypropranolol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Destructive Entitythyrotoxicosis appeared 4 - 6 months after starting EntityIFN - alpha , followed by Graves'hyperthyroidism within 8 to 11 months. |
| 0.9985 | Adverse-Effect | Destructive thyrotoxicosis appeared 4 - 6 months after starting EntityIFN - alpha , followed by EntityGraves'hyperthyroidism within 8 to 11 months. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Sagittal sinus thrombosis associated with Entitytransient free protein S deficiency after EntityL - asparaginase treatment : case report and review of the literature. |
| 0.9993 | Adverse-Effect | EntitySagittal sinus thrombosis associated with transient free protein S deficiency after EntityL - asparaginase treatment : case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityReversible leukopenia was documented in an 81 - year - old woman treated with adjunctive Entityibopamine 100 mg t. i. d. for chronic congestive heart failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The possibility of severe rhabdomyolysis should be considered in a patient with Entitywater intoxication due to massive ingestion of Entitycaffeine - containing beverages. |
| 0.9999 | Adverse-Effect | The possibility of severe Entityrhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of Entitycaffeine - containing beverages. |
| 0.9999 | Adverse-Effect | The possibility of Entitysevere rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of Entitycaffeine - containing beverages. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The second patient developed both autoimmune thyroid disease and a Entityrefractory pre - patellar bursitis after 50 months of EntityIFN - beta therapy. |
| 0.9996 | Adverse-Effect | The second patient developed both Entityautoimmune thyroid disease and a refractory pre - patellar bursitis after 50 months of EntityIFN - beta therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityAmiodarone hydrochloride , a new antiarrhythmic agent, has been associated with Entitypulmonary toxicity characterized by cough, dyspnea and diffuse pulmonary infiltrates. |
| 0.9998 | Adverse-Effect | EntityAmiodarone hydrochloride , a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by Entitycough , dyspnea and diffuse pulmonary infiltrates. |
| 0.9998 | Adverse-Effect | EntityAmiodarone hydrochloride , a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, Entitydyspnea and diffuse pulmonary infiltrates. |
| 0.9997 | Adverse-Effect | EntityAmiodarone hydrochloride , a new antiarrhythmic agent, has been associated with pulmonary toxicity characterized by cough, dyspnea and Entitydiffuse pulmonary infiltrates . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9918 | Adverse-Effect | The biochemistry of paracetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the Entityhepatotoxic effects of Entityparacetamol is remarked upon. |
| 0.9896 | Adverse-Effect | The biochemistry of Entityparacetamol Entityhepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon. |
| 0.9701 | Adverse-Effect | The biochemistry of Entityparacetamol Entityparacetamol hepatotoxicity is outlined and the increased susceptibility of alcoholic patients to the hepatotoxic effects of paracetamol is remarked upon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the development of Entitysquamous - cell carcinoma within a basal - cell epithelioma that was treated with intralesional injections of Entity5 - FU . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient presented with a Entitypainful , oedematous, cyanosed hand having injected a solution of Entitydiamorphine and methylphenidate into his radial artery. |
| 0.9999 | Adverse-Effect | A patient presented with a Entitypainful , oedematous, cyanosed hand having injected a solution of diamorphine and Entitymethylphenidate into his radial artery. |
| Adverse-Effect | A patient presented with a Entitypainful, oedematous, cyanosed hand having injected a solution of Entitydiamorphine and methylphenidate into his radial artery. | |
| Adverse-Effect | A patient presented with a Entitypainful, oedematous, cyanosed hand having injected a solution of diamorphine and Entitymethylphenidate into his radial artery. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on three patients who developed Entityacute liver damage during therapy with Entityitraconazole , and in whom liver biopsy specimens were obtained. |
| Adverse-Effect | We report on three patients who developed acute Entityliver damage during therapy with Entityitraconazole , and in whom liver biopsy specimens were obtained. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thiopurine methyltransferase deficiency occurs at a frequency of one in 300 and is associated with profound Entitymyelosuppression after a short course of Entityazathioprine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | AIM : To report a patient with diabetic rubeosis who suffered from acute retinal ischemic change and Entitystroke after intravitreal injection of Entitybevacizumab . |
| 1.0000 | Adverse-Effect | AIM : To report a patient with diabetic rubeosis who suffered from Entityacute retinal ischemic change and stroke after intravitreal injection of Entitybevacizumab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is a case report of possible association of Entitymethylphenidate and Entityenuresis in an 11 - year - old boy with attention deficit hyperactivity disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Methylene blue in the treatment and prevention of Entityifosfamide - induced Entityencephalopathy : report of 12 cases and a review of the literature. |
| Adverse-Effect | Methylene blue in the treatment and prevention of Entityifosfamide Entityifosfamide - induced encephalopathy : report of 12 cases and a review of the literature. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNCSE , an epileptic disorder in which typical convulsive activity is absent, has previously been reported in only 4 patients receiving Entityifosfamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first case of EntityHBV reactivation occurring during the year following Entityrituximab monotherapy in the absence of any other immunosuppressive factor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of Entitysubcutaneous metastasis along the needle track after percutaneous Entityethanol injection ( PEI ) for treatment of hepatocellular carcinoma. |
| 1.0000 | Adverse-Effect | We describe a case of Entitysubcutaneous metastasis along the needle track after percutaneous Entityethanol injection ( PEI ) for treatment of hepatocellular carcinoma. |
| 0.9999 | Adverse-Effect | We describe a case of Entitysubcutaneous metastasis along the needle track after percutaneous ethanol injection ( EntityPEI ) for treatment of hepatocellular carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes an unexpected drug - induced Entityhepatitis in a previously healthy young woman exposed to 2 doses of Entityamodiaquine and artesunate. |
| 1.0000 | Adverse-Effect | This report describes an unexpected drug - induced Entityhepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and Entityartesunate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTumor - volume increase at beginning of primary treatment with topical Entityinterferon alpha 2 - beta in a case of conjunctiva - cornea intraepithelial neoplasia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | This entity is probably related to a combination of high doses of corticosteroids, Entityvecuronium administration and metabolic abnormalities associated with Entityrespiratory failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient who, after receiving his first dose of Entitypregabalin to relieve neuropathic pain, presented with a Entitynegative myoclonus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient who had a Entitysystemic allergic contact dermatitis to Entity8 - MOP develop during her second course of PUVA treatment for psoriasis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In two of these cases Entityakathisia resolved after withdrawal of Entityolanzapine and substitution by a classical or an atypical neuroleptic agent, respectively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although the Entitymovement disorder could not with certainty be attributed to Entitytrazodone alone, the drug at least acted as an eliciting agent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : EntityCentral nervous system ( CNS ) toxicity has been described with Entityifosfamide , with most cases reported in the pediatric population. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Albeit rare among Western patients, such Entitylithium - associated Entitythyroid dysfunctions appeared to be more likely to occur in Hong Kong Chinese. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFever caused by the use of Entityfurosemide was proved ; the fever resolved after discontinuation of this medication and recurred after its reintroduction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a 10 - year - old boy with ulcerative colitis who developed Entityacute pancreatitis while on long - term treatment with Entity5 - aminosalicylic acid . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | This case represents the third example of Entityerythroid aplasia associated with an anti - inflammatory agent and the first instance due to Entityfenoprofen . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After approximately two weeks of Entitysertraline treatment he noted an Entityintense itching sensation in his scalp after eating a piece of chocolate cake. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEosinophilia has been encountered from 0. 2 to 61. 7 % in Entityclozapine - treated patients, mostly with a transient course and spontaneous remission. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute intravascular hemolysis developed when a diabetic patient, previously treated with Entityglyburide , was started on another oral sulfonylurea drug, chlorpropamide. |
| 0.9998 | Adverse-Effect | EntityAcute intravascular hemolysis developed when a diabetic patient, previously treated with glyburide, was started on another oral sulfonylurea drug, Entitychlorpropamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus, clinical recognition of Entitysleep disordered breathing should be taken into account when rheumatoid arthritis patients are to be treated with Entityinfliximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with disseminated herpes zoster developed a syndrome of inappropriate antidiuretic hormone and profound Entityhyponatremia secondary to the administration of Entityadenine arabinoside . |
| 0.9995 | Adverse-Effect | A patient with disseminated herpes zoster developed a Entitysyndrome of inappropriate antidiuretic hormone and profound hyponatremia secondary to the administration of Entityadenine arabinoside . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : We report a case of Entityacute severe hepatitis resulting from Entityerlotinib monotherapy in a patient with locally advanced pancreatic cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Described here are 2 patients who developed Entitythrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug Entitygemcitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of Entitychlorambucil - induced EntityDRESS syndrome in a 70 - year - old man recently diagnosed with chronic lymphocytic leukaemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this report, we describe a patient receiving Entitylenalidomide in whom Entitydyspnea , fever, hypoxia, and diffuse pulmonary infiltrates developed. |
| 1.0000 | Adverse-Effect | In this report, we describe a patient receiving Entitylenalidomide in whom dyspnea, fever, Entityhypoxia , and diffuse pulmonary infiltrates developed. |
| 1.0000 | Adverse-Effect | In this report, we describe a patient receiving Entitylenalidomide in whom dyspnea, Entityfever , hypoxia, and diffuse pulmonary infiltrates developed. |
| 0.9999 | Adverse-Effect | In this report, we describe a patient receiving Entitylenalidomide in whom dyspnea, fever, hypoxia, and Entitydiffuse pulmonary infiltrates developed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Based on the Naranjo probability scale, Entityserotonin syndrome was a probable adverse reaction associated with co - administration of Entitycitalopram and fentanyl. |
| 1.0000 | Adverse-Effect | Based on the Naranjo probability scale, Entityserotonin syndrome was a probable adverse reaction associated with co - administration of citalopram and Entityfentanyl . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHOD : The authors followed a patient with chronic HCV who received interferon and Entityribavirin and who developed Entityhallucinations ultimately requiring psychiatric hospitalization. |
| 1.0000 | Adverse-Effect | METHOD : The authors followed a patient with chronic HCV who received Entityinterferon and ribavirin and who developed Entityhallucinations ultimately requiring psychiatric hospitalization. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case 2 : A 43 - year - old male alcoholic remained completely abstinent with Entitycyanamide treatment for 5 years and complained of Entitygeneral fatigue . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A healthy, 30 - year - old man, exposed to Entitysulindac on two separate occasions, had an incapacitating Entityisolated idential sensory neuropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | According to the Naranjo et al. adverse - reaction probability scale, Entityenoxaparin was the probable cause of Entityhepatotoxicity in this patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Clinicians treating elderly patients with Entityolanzapine should be aware of the potential for rapidly developing Entityhyperglycemia and monitor such patients accordingly. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with extranodal non - Hodgkin lymphoma who developed Entitysystemic candidiasis after treatment with a Entitycyclophosphamide - based chemotherapy regimen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Mitomycin C ( EntityMMC ) is an alkylating agent that has been recently associated with the Entityhemolytic - uremic syndrome ( HUS ). |
| 0.9999 | Adverse-Effect | Mitomycin C ( EntityMMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( EntityHUS ). |
| 0.9998 | Adverse-Effect | EntityMitomycin C ( MMC ) is an alkylating agent that has been recently associated with the Entityhemolytic - uremic syndrome ( HUS ). |
| 0.9997 | Adverse-Effect | EntityMitomycin C ( MMC ) is an alkylating agent that has been recently associated with the hemolytic - uremic syndrome ( EntityHUS ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : EntityOlanzapine , like other atypical antipsychotic drugs, may cause Entitymuscle injury with concomitant elevations of serum CK of muscle origin. |
| Adverse-Effect | DISCUSSION : EntityOlanzapine , like other atypical antipsychotic drugs, may cause Entitymuscle injury with concomitant elevations of serum CK of muscle origin. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : Two children with attention deficit disorder treated with Entitymethylphenidate as a simple drug developed Entityfixed drug eruption of the scrotum . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Jet - injection devices might constitute a helpful method to treat those patients affected by severe Entityhuman insulin - induced Entitylipoatrophy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAkathisia is a relatively rare side effect with the newer atypical antipsychotic agents, particularly Entityclozapine , and is easily misdiagnosed in children. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS / RESULTS : This paper presents a new case of Entityrifabutin Entityuveitis and a review of the various published reports to date. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Effect of beta - blockade on symptomatic Entitydexamethasone - induced Entityhypertrophic obstructive cardiomyopathy in premature infants : three case reports and literature review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVES : To describe the presentation and treatment of acute isoniazid ( EntityINH ) Entityneurotoxicity appearing at an inner - city municipal hospital. |
| 0.9996 | Adverse-Effect | OBJECTIVES : To describe the presentation and treatment of acute Entityisoniazid ( INH ) Entityneurotoxicity appearing at an inner - city municipal hospital. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An 11 - year - old boy developed a Entitysevere enteropathy 2 years after initiation of Entityclofazimine treatment for graft - versus - host disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Because the Entitycerebellar toxicity may be worsened by continuation of therapy after initial onset of symptoms, prompt termination of EntityHDARAC is recommended. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this is the first case of spontaneous remission of EntityMTX - associated Entitygastric LPD after discontinuation of MTX therapy. |
| 0.9999 | Adverse-Effect | To our knowledge, this is the first case of spontaneous remission of MTX - associated Entitygastric LPD after discontinuation of EntityMTX therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Under certain circumstances topical Entitybrimonidine can cause Entityparadoxical raised IOP necessitating vigilance in follow - up of patients on topical brimonidine. |
| 1.0000 | Adverse-Effect | CONCLUSION : Under certain circumstances topical Entitybrimonidine can cause Entityparadoxical raised IOP necessitating vigilance in follow - up of patients on topical brimonidine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitypropranolol overdose complicated by Entityesophageal spasm preventing extrication of an orogastric lavage tube and relieved by intravenous glucagon is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present the first case of ovarian endometrioid carcinoma and Entityendometriosis in a postmenopausal patient who was treated with Entitytamoxifen for breast cancer. |
| 0.9999 | Adverse-Effect | We present the first case of Entityovarian endometrioid carcinoma and endometriosis in a postmenopausal patient who was treated with Entitytamoxifen for breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinicians should be cognizant of this possibility and consider a diagnosis of HDAs in patients with ongoing Entitythrombosis who are receiving Entityheparin therapy. |
| 1.0000 | Adverse-Effect | Clinicians should be cognizant of this possibility and consider a diagnosis of EntityHDAs in patients with ongoing thrombosis who are receiving Entityheparin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Second cancers including various types of Entityhematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or Entityinterferon alfa . |
| 0.9999 | Adverse-Effect | EntitySecond cancers including various types of hematological malignancy have been reported in patients with hairy cell leukemia treated with chemotherapy or Entityinterferon alfa . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityabnormal rhythm disappeared with the withdrawal of Entitypropranolol and when the drug was restarted a 2 / 1 S - A block was seen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In both cases, high fever, skin rash, liver dysfunction and Entityatypical lymphocytosis developed 3 weeks after initiating treatment with EntitySASP . |
| 1.0000 | Adverse-Effect | In both cases, Entityhigh fever , skin rash, liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with EntitySASP . |
| 0.9999 | Adverse-Effect | In both cases, high fever, skin rash, Entityliver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with EntitySASP . |
| 0.9999 | Adverse-Effect | In both cases, high fever, Entityskin rash , liver dysfunction and atypical lymphocytosis developed 3 weeks after initiating treatment with EntitySASP . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the specifics of 12 cases of Entitysevere hypertension after the intraoperative use of topical Entityphenylephrine , submucosal epinephrine, or both. |
| 1.0000 | Adverse-Effect | We report the specifics of 12 cases of Entitysevere hypertension after the intraoperative use of topical phenylephrine, submucosal Entityepinephrine , or both. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Three patients who developed symptoms of inflammatory bowel disease ( EntityIBD ) during Entityrofecoxib exposure are described along with pathology findings. |
| 1.0000 | Adverse-Effect | RESULTS : Three patients who developed symptoms of Entityinflammatory bowel disease ( IBD ) during Entityrofecoxib exposure are described along with pathology findings. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of secondary Entityglaucoma caused by epithelial downgrowth in which filtration surgery was performed with adjunctive use of subconjunctival Entity5 - fluorouracil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report an allogeneic bone marrow transplant recipient who developed EntityCMV infection refractory to sequential therapy with Entityganciclovir , foscarnet, and cidofovir. |
| 1.0000 | Adverse-Effect | We report an allogeneic bone marrow transplant recipient who developed EntityCMV infection refractory to sequential therapy with ganciclovir, Entityfoscarnet , and cidofovir. |
| 1.0000 | Adverse-Effect | We report an allogeneic bone marrow transplant recipient who developed EntityCMV infection refractory to sequential therapy with ganciclovir, foscarnet, and Entitycidofovir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPtosis occurring 24 h after Entitychloroquine therapy, with full recovery 48 h after cessation of chloroquine, has not been described previously. |
| 0.9997 | Adverse-Effect | EntityPtosis occurring 24 h after chloroquine therapy, with full recovery 48 h after cessation of Entitychloroquine , has not been described previously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Dyspnea, hypoxemia, and Entitypleuritic chest pain occurred within 24 hours of Entityrituximab administration, and there was no other apparent explanation. |
| 1.0000 | Adverse-Effect | Dyspnea, Entityhypoxemia , and pleuritic chest pain occurred within 24 hours of Entityrituximab administration, and there was no other apparent explanation. |
| 1.0000 | Adverse-Effect | EntityDyspnea , hypoxemia, and pleuritic chest pain occurred within 24 hours of Entityrituximab administration, and there was no other apparent explanation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Emphasis is given to the differentiation of Entitydiphenylhydantoin induced Entitygingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9992 | Adverse-Effect | Most cases of Entitypancreatitis associated with EntityL - asparaginase toxicity are self - limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation. |
| 0.9938 | Adverse-Effect | Most cases of pancreatitis associated with EntityL - asparaginase EntityL - asparaginase toxicity are self - limiting and respond favorably to nasogastric decompression and intravenous hyperalimentation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of significant over - anticoagulation temporally associated with a bout of protracted Entitydiarrhea in a patient on Entitywarfarin therapy. |
| 0.9998 | Adverse-Effect | We present a case of significant Entityover - anticoagulation temporally associated with a bout of protracted diarrhea in a patient on Entitywarfarin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Regardless of a negative history of asthma, therefore, life - threatening Entitybronchospasm must be considered a possible complication of Entitypropranolol therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After three weeks of Entitycarbamazepine therapy, the patient arrived at the emergency department ( ED ) with Entitysevere agitation and aggressive behavior. |
| 1.0000 | Adverse-Effect | After three weeks of Entitycarbamazepine therapy, the patient arrived at the emergency department ( ED ) with severe agitation and Entityaggressive behavior . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of Entityintoxication of a 41 - year - old female patient suffering from major depression with Entitymirtazapine complicated by severe hypothermia. |
| 0.9912 | Adverse-Effect | We report the case of intoxication of a 41 - year - old female patient suffering from major depression with Entitymirtazapine complicated by Entitysevere hypothermia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 57 - year - old woman developed Entitypulmonary sarcoidosis during therapy with Entityinterferon beta for advanced renal cell carcinoma metastatic to mediastinal lymph nodes. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In addition to the recognized arrhythmic complications, the authors emphasize myocardial necrosis as a possible further manifestation of Entityamsacrine - related Entitycardiotoxicity . |
| 0.9989 | Adverse-Effect | In addition to the recognized arrhythmic complications, the authors emphasize Entitymyocardial necrosis as a possible further manifestation of Entityamsacrine - related cardiotoxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This article presents a case of an Entityatypical localized cutaneous eruption with an unusual course and protracted resolution time associated with Entitysorafenib therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Infant twins sustained Entitysevere circumoral and pharyngeal burns from a concentrated solution of Entitybenzalkonium ( Zephiran ) chloride prescribed for treatment of candidiasis. |
| 0.9999 | Adverse-Effect | Infant twins sustained Entitysevere circumoral and pharyngeal burns from a concentrated solution of benzalkonium ( EntityZephiran ) chloride prescribed for treatment of candidiasis. |
| Adverse-Effect | Infant twins sustained severe Entitycircumoral and pharyngeal burns from a concentrated solution of Entitybenzalkonium ( Zephiran ) chloride prescribed for treatment of candidiasis. | |
| Adverse-Effect | Infant twins sustained severe Entitycircumoral and pharyngeal burns from a concentrated solution of benzalkonium ( EntityZephiran ) chloride prescribed for treatment of candidiasis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEpstein - Barr virus - associated lymphoproliferative disorder in a patient with rheumatoid arthritis on Entitymethotrexate and rofecoxib : idiosyncratic reaction or pharmacogenetics? |
| 0.9999 | Adverse-Effect | EntityEpstein - Barr virus - associated lymphoproliferative disorder in a patient with rheumatoid arthritis on methotrexate and Entityrofecoxib : idiosyncratic reaction or pharmacogenetics? |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityNorethisterone in these 69 pregnancies accounted for 33. 3 % ( 5 of 15 ) cases of Entityclitoral hypertrophy diagnosed in 100, 756 consecutive births. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityocular toxicity of EntityDCF , previously described as conjunctivitis, appears to be a keratitis of moderate severity which requires further study. |
| 0.9997 | Adverse-Effect | The ocular toxicity of EntityDCF , previously described as Entityconjunctivitis , appears to be a keratitis of moderate severity which requires further study. |
| 0.9994 | Adverse-Effect | The ocular toxicity of EntityDCF , previously described as conjunctivitis, appears to be a Entitykeratitis of moderate severity which requires further study. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a rare case of recurrent ( stuttering ) Entitypriapism in a patient with protein C deficiency while maintained on EntityWarfarin therapy. |
| 1.0000 | Adverse-Effect | We report a rare case of recurrent ( Entitystuttering ) priapism in a patient with protein C deficiency while maintained on EntityWarfarin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | We report a case of severe Entityrespiratory failure due to Entitygold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation. |
| 0.9998 | Adverse-Effect | We report a case of Entitysevere respiratory failure due to Entitygold salt toxicity in a patient suffering from rheumatoid arthritis requiring mechanical ventilation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He was diagnosed with possible Entityserotonin syndrome ; his symptoms resolved after Entityclomipramine was stopped but before clozapine was restarted eight days later. |
| 0.9994 | Adverse-Effect | He was diagnosed with possible Entityserotonin syndrome ; his symptoms resolved after clomipramine was stopped but before Entityclozapine was restarted eight days later. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Since amiodarone was first marketed in 1992 in Japan, the incidence of Entityamiodarone - induced Entitythyrotoxicosis ( AIT ) has been increasing. |
| 0.9984 | Adverse-Effect | Since amiodarone was first marketed in 1992 in Japan, the incidence of Entityamiodarone - induced thyrotoxicosis ( EntityAIT ) has been increasing. |
| 0.9920 | Adverse-Effect | Since Entityamiodarone was first marketed in 1992 in Japan, the incidence of amiodarone - induced Entitythyrotoxicosis ( AIT ) has been increasing. |
| 0.9871 | Adverse-Effect | Since Entityamiodarone was first marketed in 1992 in Japan, the incidence of amiodarone - induced thyrotoxicosis ( EntityAIT ) has been increasing. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient suffering from a rare enzyme deficiency developed a Entitymalignant neuroleptic syndrome after having been treated with one single dose of Entityhaloperidol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One of the subjects who was using extemporaneous topical Entityminoxidil had Entityhypertension and arteriosclerotic disease and the other died of a myocardial infarction. |
| 0.9999 | Adverse-Effect | One of the subjects who was using extemporaneous topical Entityminoxidil had hypertension and Entityarteriosclerotic disease and the other died of a myocardial infarction. |
| 0.9997 | Adverse-Effect | One of the subjects who was using extemporaneous topical Entityminoxidil had hypertension and arteriosclerotic disease and the other died of a Entitymyocardial infarction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAutoimmune thyroid disease is a common side - effect of Entityinterferon - alpha ( IFN - alpha ) treatment of viral hepatitis C. |
| 0.9996 | Adverse-Effect | EntityAutoimmune thyroid disease is a common side - effect of interferon - alpha ( EntityIFN - alpha ) treatment of viral hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A noninvasive method in the differential diagnosis of vecuronium - induced and Entitymagnesium - induced Entityprotracted neuromuscular block in a severely preeclamptic patient. |
| 0.9993 | Adverse-Effect | A noninvasive method in the differential diagnosis of Entityvecuronium - induced and magnesium - induced Entityprotracted neuromuscular block in a severely preeclamptic patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient received only the ophthalmic Entitysulfonamide , and it was used for one day, but he developed EntityStevens - Johnson syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This review presents the first case series of DIC associated with acute hemoglobinemia or Entityhemoglobinuria following Entityanti - D IGIV administration for ITP. |
| 0.9997 | Adverse-Effect | This review presents the first case series of EntityDIC associated with acute hemoglobinemia or hemoglobinuria following Entityanti - D IGIV administration for ITP. |
| 0.9991 | Adverse-Effect | This review presents the first case series of DIC associated with Entityacute hemoglobinemia or hemoglobinuria following Entityanti - D IGIV administration for ITP. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Patient A reported right leg weakness ( Entityfoot drop ) during week 4 of EntityCAP - XRT ( 1600 mg / m2 ). |
| 0.9998 | Adverse-Effect | Patient A reported Entityright leg weakness ( foot drop ) during week 4 of EntityCAP - XRT ( 1600 mg / m2 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two case reports of Entitybilateral granulomatous anterior uveitis are described in patients with open angle glaucoma treated with Entitymetripranolol 0. 6 % eye drops. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 58 - year - old white woman developed Entityfulminant liver failure while being treated with the macrolide antibiotic Entityclarithromycin for pneumonia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethamphetamine ' s extensive physiologic effects, inconsistent street purity, and multiple routes of administration offer many possibilities for Entityinjury to the cornea . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | TREATMENT / OUTCOME : Standard anti - tuberculosis therapy was administered but was complicated by interaction with Entitycyclosporine and drug - induced Entitycholestasis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We suggest that objective evaluation of retinal function with electrophysiological methods should be performed in patients with Entityvisual disturbance during treatment with Entityrifabutin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After reviewing the literature we suggest the EntityCPM was a complication of Entitylithium toxicity which affected the lateral geniculate nucleus which produced blindness. |
| 0.9998 | Adverse-Effect | After reviewing the literature we suggest the CPM was a complication of Entitylithium toxicity which affected the lateral geniculate nucleus which produced Entityblindness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after Entitydestruction of CD20 positive cells by Entityrituximab . |
| 0.9999 | Adverse-Effect | The pathophysiological mechanisms remain unknown, although the drug could act through Entitymassive cytokines liberation after destruction of CD20 positive cells by Entityrituximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a patient with Entityciprofloxacin - induced EntitySJS and acute onset of VBDS, and reviewed the related literature. |
| 0.9997 | Adverse-Effect | We report a case of a patient with Entityciprofloxacin - induced SJS and acute onset of EntityVBDS , and reviewed the related literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : EntityZidovudine is well a known cause of Entityanaemia and thus should be used with caution in the initiation of antiretroviral therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMotor fluctuations appear after 2 - 3 years of Entitylevodopa treatment, and affect at least 50 % of patients after five years. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The second patient experienced Entitymild nitritoid symptoms following several EntityGSTM injections prior experiencing a cerebrovascular accident within several hours of her next injection. |
| 1.0000 | Adverse-Effect | The second patient experienced mild nitritoid symptoms following several EntityGSTM injections prior experiencing a Entitycerebrovascular accident within several hours of her next injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We describe a case of Entityfibrosing alveolitis , diagnosed by lung biopsy, in a patient receiving Entityamiodarone which responded to corticosteroid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One type of SMON is associated with Entityacrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of Entityclioquinol . |
| 1.0000 | Adverse-Effect | One type of EntitySMON is associated with acrodermatitis enteropathica which has a very high frequency of occurrence in association with administration of Entityclioquinol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Intrahepatic cholestasis and Entitycutaneous bullae associated with Entityglibenclamide therapy are described in a 61 - year - old diabetic patient who presented wit hypoglycaemic coma. |
| 0.9999 | Adverse-Effect | EntityIntrahepatic cholestasis and cutaneous bullae associated with Entityglibenclamide therapy are described in a 61 - year - old diabetic patient who presented wit hypoglycaemic coma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entitysevere unilateral posterior scleritis associated with Entityzoledronic acid administration that was recognized and treated in a timely manner. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Both had impaired lung function and Entityabnormal computed tomographic scans , and their condition improved when Entitynitrofurantoin was withdrawn and corticosteroid treatment commenced. |
| 1.0000 | Adverse-Effect | Both had Entityimpaired lung function and abnormal computed tomographic scans, and their condition improved when Entitynitrofurantoin was withdrawn and corticosteroid treatment commenced. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first biopsy confirmed occurrence of Entityacute interstitial nephritis in a patient receiving treatment with EntitySunitinib for metastatic renal cell cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMeperidine - associated Entitycentral nervous system ( CNS ) excitatory toxicities are believed to be caused by accumulation of the active metabolite normeperidine. |
| 0.9965 | Adverse-Effect | EntityMeperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by Entityaccumulation of the active metabolite normeperidine . |
| 0.9983 | Adverse-Effect | EntityMeperidine - associated central nervous system ( CNS ) excitatory toxicities are believed to be caused by Entityaccumulation of the active metabolite normeperidine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | EntityAmiodarone is well recognized as an anti - arrhythmic drug containing a high dose of iodine with considerable potential to cause Entitythyroid dysfunction . |
| 1.0000 | Adverse-Effect | Amiodarone is well recognized as an anti - arrhythmic drug containing a high dose of Entityiodine with considerable potential to cause Entitythyroid dysfunction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case report of the Entityhypersensitivity syndrome occurring in a patient being treated with Entitydapsone for a brown recluse spider bite is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of Entitysulfasalazine - induced Entitylupus syndrome . |
| 0.9954 | Adverse-Effect | Physicians who use Entitysulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced Entitylupus syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this article, we describe a Japanese patient with Entitysevere interstitial pneumonia probably caused by Entitysorafenib treatment for metastatic renal cell carcinoma. |
| 1.0000 | Adverse-Effect | In this article, we describe a Japanese patient with severe Entityinterstitial pneumonia probably caused by Entitysorafenib treatment for metastatic renal cell carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent Entitysevere neurotoxicity of polychemotherapy by avoiding Entityvincristine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She was diagnosed with Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD ) due to Entityimmunodeficiency caused by EntityMTX administration. |
| 0.9971 | Adverse-Effect | She was diagnosed with Epstein - Barr virus - associated polymorphic lymphoproliferative disorder ( EntityLPD ) due to immunodeficiency caused by EntityMTX administration. |
| 0.9949 | Adverse-Effect | She was diagnosed with EntityEpstein - Barr virus - associated polymorphic lymphoproliferative disorder ( LPD ) due to immunodeficiency caused by EntityMTX administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present three cases from the Provincial Toxicology Center of British Columbia, Canada in which Entitysuicidal overdose deaths were associated with Entityquetiapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although Entitytaxol has shown significant activity in advanced ovarian cancer, Entityperipheral neuropathy is likely to become the major dose - limiting toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It was concluded that ANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with EntityPTU appeared to induce EntityANCA . |
| 0.9997 | Adverse-Effect | It was concluded that EntityANCA is closely related to the pathogenesis of crescentic glomerulonephritis and that treatment with EntityPTU appeared to induce ANCA. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | We recommend the cautious use of Entityketorolac in patients with underlying illnesses where NSAID - induced Entityototoxicity could result in adverse otologic consequences. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAnaphylaxis to Entitycisplatin is an infrequent life - threatening complication which may occur even in patients who have received prior treatment with cisplatin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of significant Entityelevation of serum transaminases in a patient treated with Entity6 - TG for a flare of Crohn's disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Similar to previous findings of drug - induced vortex keratopathy, Entityatovaquone Entityvortex keratopathy is presumably caused by its lipophilic properties. |
| 0.9973 | Adverse-Effect | RESULTS : Similar to previous findings of drug - induced Entityvortex keratopathy , Entityatovaquone vortex keratopathy is presumably caused by its lipophilic properties. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Although a definite association has not been proven, clinicians should be aware of the possibility of Entityagranulocytosis while using Entityquetiapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 54 - year - old man developed EntityTEN 4 weeks after beginning Entitylamotrigine for complex partial seizures related to a glioblastoma multiforme brain tumor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We have safely used recombinant factor VIIa to treat bleeding in the immediate and long - term period following EntityPCC - related EntityMI . |
| 0.9977 | Adverse-Effect | We have safely used Entityrecombinant factor VIIa to treat bleeding in the immediate and long - term period following PCC - related EntityMI . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient with inoperable pancreatic cancer who developed gastrointestinal bleeding secondary to Entityradiation - recall related to Entitygemcitabine and review literature. |
| 0.9999 | Adverse-Effect | We report a patient with inoperable pancreatic cancer who developed Entitygastrointestinal bleeding secondary to radiation - recall related to Entitygemcitabine and review literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | METHODS : EntityGrowth retardation was observed in six severely asthmatic children after introduction of high - dose Entityfluticasone propionate treatment ( dry powder ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 40 - year - old woman who developed fulminant hepatic failure and Entityaplastic anaemia following a course of oral Entityflucloxacillin . |
| 1.0000 | Adverse-Effect | We report the case of a 40 - year - old woman who developed Entityfulminant hepatic failure and aplastic anaemia following a course of oral Entityflucloxacillin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The hospital course of the acute renal failure is presented with a review of the literature on cases of Entityacute renal failure after EntityIVIG . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Use of the Naranjo probability scale indicated a highly probable relationship between the observed Entitycardiac toxicity and Entityamphotericin B deoxycholate therapy in this patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9985 | Adverse-Effect | We describe 2 patients with cutaneous lupus erythematosus who developed severe Entitydapsone Entitydapsone reaction after low dose therapy, with a fatal outcome in one. |
| 0.9977 | Adverse-Effect | We describe 2 patients with cutaneous lupus erythematosus who developed severe Entitydapsone reaction after low dose therapy, with a Entityfatal outcome in one. |
| 0.9994 | Adverse-Effect | We describe 2 patients with cutaneous lupus erythematosus who developed severe Entitydapsone reaction after low dose therapy, with a Entityfatal outcome in one. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Because of its structural similarity to the other vinca alkaloids, Entityvinorelbine is believed to be responsible for EntitySIADH in our patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityInterferon - based treatments have the potential to decrease the burden of disease, but are complicated by side effects, including Entityneuropsychiatric symptoms . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySevere osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of Entityphenytoin , phenobarbital, and acetazolamide. |
| 1.0000 | Adverse-Effect | EntitySevere osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin, Entityphenobarbital , and acetazolamide. |
| 1.0000 | Adverse-Effect | EntitySevere osteomalacia was present in two epileptic patients who were under long - term treatment with congeners of phenytoin, phenobarbital, and Entityacetazolamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Acute myeloid leukemia and Entitylung cancer occurring in a chronic lymphocytic leukemia patient treated with Entityfludarabine and autologous peripheral blood stem - cell transplantation. |
| 1.0000 | Adverse-Effect | EntityAcute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with Entityfludarabine and autologous peripheral blood stem - cell transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving Entityadalimumab who developed Entityfever , pancytopenia, splenomegaly, and extreme hyperferritinemia. |
| 1.0000 | Adverse-Effect | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving Entityadalimumab who developed fever, Entitypancytopenia , splenomegaly, and extreme hyperferritinemia. |
| 1.0000 | Adverse-Effect | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving Entityadalimumab who developed fever, pancytopenia, Entitysplenomegaly , and extreme hyperferritinemia. |
| 0.9999 | Adverse-Effect | OBJECTIVE : 1 ) To describe a patient with rheumatoid arthritis receiving Entityadalimumab who developed fever, pancytopenia, splenomegaly, and Entityextreme hyperferritinemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The hyperpigmentation was diffuse scattered, flagellate like and linear streaking which was thought to be mainly related to the Entityskin toxicity of Entitybleomycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | OBJECTIVE : This case report outlines a significant type of morbidity due to continued use of Entitygabapentin during an episode of Entityacute renal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The findings were judged to be consistent with Entitysoft - tissue injury associated with intravenous administration of Entityphenytoin , also termed purple glove syndrome. |
| 0.9999 | Adverse-Effect | The findings were judged to be consistent with soft - tissue injury associated with intravenous administration of Entityphenytoin , also termed Entitypurple glove syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Several case reports of Entityaplastic anemia with use of Entityacetazolamide , and two cases with use of methazolamide, have appeared in the literature. |
| 0.9995 | Adverse-Effect | Several case reports of Entityaplastic anemia with use of acetazolamide, and two cases with use of Entitymethazolamide , have appeared in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 2 - year - old mentally retarded boy with frontal lobe epilepsy presented with an episode that resembled Entityheat stroke during the administration of Entityzonisamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFracture of the femoral neck occurred in one patient during EntityPSL therapy, although the relationship between the fracture and PSL therapy was uncertain. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Despite a postulated dopaminergic mechanism, there seems to have been only one previous report of Entityamantadine ' s Entityprecipitating psychosis in a schizophrenic patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 78 - year - old man who had Entityacute unilateral total visual loss after retrogasserian Entityphenol injection for the treatment of trigeminal neuralgia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In addition to its known effect on gallbladder stasis, Entityoctreotide Entityalters bile acid composition and may thus hasten intrahepatic sludge and stone formation. |
| 1.0000 | Adverse-Effect | In addition to its known effect on Entitygallbladder stasis , Entityoctreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation. |
| 0.9999 | Adverse-Effect | In addition to its known effect on gallbladder stasis, Entityoctreotide alters bile acid composition and may thus Entityhasten intrahepatic sludge and stone formation. |
| 0.9996 | Adverse-Effect | In addition to its known effect on gallbladder stasis, Entityoctreotide alters bile acid composition and may thus hasten intrahepatic sludge and Entitystone formation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this is the first case reported in the English literature of a Entitygeneralized exanthem due to subcutaneous injection of Entityenoxaparin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In keeping with findings in the literature, the Entityaortic wall in this case was damaged by secondary changes following irradiation and EntityBleomycin treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a patient with Entityincreased cerebral cortical excitability following intoxication with Entityflupirtine , a centrally acting analgesic and antispastic drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 10 - year - old asthmatic boy began to suffer from urticarial rash and Entitymoderately severe bronchospasm after 8 weeks'treatment with Entitydisodium cromoglycate . |
| 0.9998 | Adverse-Effect | A 10 - year - old asthmatic boy began to suffer from Entityurticarial rash and moderately severe bronchospasm after 8 weeks'treatment with Entitydisodium cromoglycate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of long lasting Entityrespiratory depression after intravenous administration of Entitymorphine to a 7 year old girl with haemolytic uraemic syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We believe that these skin eruptions belong to a spectrum of Entityneutrophilic dermatoses that can be induced or aggravated by EntityG - CSF therapy. |
| 0.9990 | Adverse-Effect | We believe that these Entityskin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by EntityG - CSF therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the clinical course of 2 patients with Crohn's disease ( CD ) in whom Entitylymphoma was diagnosed after treatment with Entityinfliximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Ovarian endometrioid carcinoma and Entityendometriosis developing in a postmenopausal breast cancer patient during Entitytamoxifen therapy : a case report and review of the literature. |
| 0.9999 | Adverse-Effect | EntityOvarian endometrioid carcinoma and endometriosis developing in a postmenopausal breast cancer patient during Entitytamoxifen therapy : a case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9938 | Adverse-Effect | We report here two cases of Entitydyserythropoietic anaemia associated with long - term Entitylinezolid use that share striking similarities to chloramphenicol - associated myelotoxicity. |
| 0.9922 | Adverse-Effect | We report here two cases of dyserythropoietic anaemia associated with long - term linezolid use that share striking similarities to Entitychloramphenicol - associated Entitymyelotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | With the negative viral serologies, the clinical picture was most consistent with an infectious Entitymononucleosis - like syndrome produced by the Entityminocycline ingestion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The association between Entityheparin and Entitypriapism is often recognized ; abnormal platelet aggregation could play a role in the pathogenesis of this side effect. |
| 0.9999 | Adverse-Effect | The association between Entityheparin and priapism is often recognized ; Entityabnormal platelet aggregation could play a role in the pathogenesis of this side effect. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a premenopausal woman who, while having Entitytamoxifen due to a diagnosis of in situ ductal carcinoma, developed Entityendometriosis requiring surgery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case describes Entityfulminant hepatic failure in a patient taking Entitydisulfiram with no previous liver disease and report of being compliant with alcohol abstinence. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Ophthalmologists should be aware of the Entityocular side effects of EntityIFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and thrombocytopenia. |
| 1.0000 | Adverse-Effect | Ophthalmologists should be aware of the ocular side effects of EntityIFN therapy and carefully monitor patients for the possible occurrence of Entityhypoalbuminemia and thrombocytopenia. |
| 0.9997 | Adverse-Effect | Ophthalmologists should be aware of the ocular side effects of EntityIFN therapy and carefully monitor patients for the possible occurrence of hypoalbuminemia and Entitythrombocytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors describe Entitypericardial hemorrhage , which is related to the use of low - dose Entityacetylsalicylic acid in a patient with essential thrombocythemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case of a 29 - year - old man suffering from falciparum malaria disease who got a Entityreversible hearing loss from Entityquinine therapy is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of Entityinterstitial hypoxaemiant pneumonitis probably related to Entityflecainide in a patient with the LEOPARD syndrome, a rare congenital disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, the syndrome of fever, pulmonary infiltrates, and Entitypleural effusion following use of Entityacyclovir has not been previously reported. |
| 1.0000 | Adverse-Effect | To our knowledge, the syndrome of Entityfever , pulmonary infiltrates, and pleural effusion following use of Entityacyclovir has not been previously reported. |
| 1.0000 | Adverse-Effect | To our knowledge, the syndrome of fever, Entitypulmonary infiltrates , and pleural effusion following use of Entityacyclovir has not been previously reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report two patients who developed intense Entitylivedo reticularis clearly related to the administration of Entityinterferon alpha 2b as an adjuvant therapy for melanoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This profile should trigger a " red flag " as to the possibility of Entityphenobarbital Entitybehavioral side effects or exacerbation of preexisting maladaptive behaviors. |
| 0.9998 | Adverse-Effect | This profile should trigger a " red flag " as to the possibility of Entityphenobarbital behavioral side effects or Entityexacerbation of preexisting maladaptive behaviors . |
| 0.9999 | Adverse-Effect | This profile should trigger a " red flag " as to the possibility of Entityphenobarbital Entityphenobarbital behavioral side effects or exacerbation of preexisting maladaptive behaviors. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 70 - year - old man was admitted to our hospital because of Entitydyspnea after taking an antihistaminic agent ( Entityhomochlorcyclizine hydrochloride ) for itching. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Marked QT prolongation and torsades de pointes secondary to Entityacute ischemia in an elderly man taking Entitydofetilide for atrial fibrillation : a cautionary tale. |
| 1.0000 | Adverse-Effect | Marked QT prolongation and Entitytorsades de pointes secondary to acute ischemia in an elderly man taking Entitydofetilide for atrial fibrillation : a cautionary tale. |
| 0.9999 | Adverse-Effect | EntityMarked QT prolongation and torsades de pointes secondary to acute ischemia in an elderly man taking Entitydofetilide for atrial fibrillation : a cautionary tale. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case is described of Entitysevere splenic hemorrhage and rupture which developed 3 h after completion of EntitytPA infusion for suspected acute myocardial infarction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors present a case report of a granulomatous reaction leading to Entityurethral prolapse , 3 months after the transurethral injection of Entitycalcium hydroxylapatite . |
| 0.9998 | Adverse-Effect | The authors present a case report of a Entitygranulomatous reaction leading to urethral prolapse, 3 months after the transurethral injection of Entitycalcium hydroxylapatite . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After only the third dose of Entitypentamidine , it was noted that the patient's Entityheart rate had decreased to 48 beats / minute. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, prolongation of 5 - FU half - life and an Entityincrease in INR have been reported with the concurrent use of Entity5 - FU and warfarin. |
| 1.0000 | Adverse-Effect | However, prolongation of 5 - FU half - life and an Entityincrease in INR have been reported with the concurrent use of 5 - FU and Entitywarfarin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The association with prolonged unopposed estrogen - like stimulation with Entitytamoxifen as a possible factor in the development of Entityovarian endometrioid carcinoma is discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a patient with asymptomatic bronchial asthma and hypertension who developed an Entityacute asthma attack after receiving sustained - release Entityverapamil . |
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a patient with asymptomatic bronchial asthma and hypertension who developed an Entityacute asthma attack after receiving sustained - release Entityverapamil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 53 - year - old - man who developed rippling muscle disease ( EntityRMD ) 2 months after starting Entitysimvastatin therapy for hypercholesterolemia. |
| 1.0000 | Adverse-Effect | We report a 53 - year - old - man who developed Entityrippling muscle disease ( RMD ) 2 months after starting Entitysimvastatin therapy for hypercholesterolemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case report describes a 38 - year - old male in whom EntitySIADH was strongly suspected secondary to EntityTegretol therapy to control a seizure disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : The aim of this study was to report on the possible development of Entitycorneal endothelial deposits resulting from the use of Entityrifabutin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : In an institutional practice setting, two women, aged 25 and 45, developed Entityacute myopia after starting Entitytopiramate for epilepsy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our case points to the need for increased awareness by the general pediatricians of the Entitypotential hazards of Entitymineral oil use for chronic constipation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although lung specimens were lacking from these three patients, it is suggested that the Entitypulmonary toxicity of EntityCCNU may be dose - related. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBaclofen Entitywithdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged fever in the intensive care unit. |
| 1.0000 | Adverse-Effect | Baclofen Entitywithdrawal syndrome resulting from underdosing of oral Entitybaclofen should be considered as a potential source of prolonged fever in the intensive care unit. |
| 0.9999 | Adverse-Effect | Baclofen withdrawal syndrome resulting from underdosing of oral Entitybaclofen should be considered as a potential source of prolonged Entityfever in the intensive care unit. |
| 0.9990 | Adverse-Effect | EntityBaclofen withdrawal syndrome resulting from underdosing of oral baclofen should be considered as a potential source of prolonged Entityfever in the intensive care unit. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9758 | Adverse-Effect | PURPOSE : We evaluated the in vitro hemodialysis ratio and subsequent Entitytoxicity and pharmacokinetics of Entityifosfamide in an anephric patient with Wilms'tumor. |
| Adverse-Effect | PURPOSE : We evaluated the in vitro hemodialysis ratio and subsequent Entitytoxicity and pharmacokinetics of Entityifosfamide in an anephric patient with Wilms'tumor. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Five of 70 patients who had begun Entityleflunomide therapy had significant Entityweight loss that could not be linked to other identifiable etiologies. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Eleven days after initiation of therapy with Entityamiodarone , the patient experienced Entitysyncope and was noted to have recurrent episodes of polymorphous ventricular tachycardia. |
| 0.9998 | Adverse-Effect | Eleven days after initiation of therapy with Entityamiodarone , the patient experienced syncope and was noted to have recurrent episodes of Entitypolymorphous ventricular tachycardia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe loss of vision after removal of Entitycataract caused by intravitreal Entitytriamcinolone in combination with photodynamic therapy for exudative age - related macular degeneration. |
| 1.0000 | Adverse-Effect | EntitySevere loss of vision after removal of cataract caused by intravitreal Entitytriamcinolone in combination with photodynamic therapy for exudative age - related macular degeneration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : The risk / benefit ratio of Entitywarfarin therapy changes in the over 75s, when Entityhaemorrhagic side - effects become more common. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case report of a patient who developed a Entityprolonged QT while being treated with oral Entitymethadone for a chronic pain syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : EntityMethotrexate - induced Entitypapular eruption is rarely reported shortly after beginning methotrexate therapy in patients with acute exacerbation of collagen vascular diseases. |
| 0.9990 | Adverse-Effect | DISCUSSION : Methotrexate - induced Entitypapular eruption is rarely reported shortly after beginning Entitymethotrexate therapy in patients with acute exacerbation of collagen vascular diseases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : Both cases presented here describe Entitycorneal ulcers that persisted and showed signs of worsening during weeks of frequent topical dosing with Entitymoxifloxacin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entityhemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with Entityoxaliplatin , 5 - fluorouracil and leucovorin. |
| 1.0000 | Adverse-Effect | We present a case of Entityhemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, Entity5 - fluorouracil and leucovorin. |
| 1.0000 | Adverse-Effect | We present a case of Entityhemolytic - uremic syndrome that developed during the 4th cycle of combination chemotherapy with oxaliplatin, 5 - fluorouracil and Entityleucovorin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors think that although Entitylamivudine is widely used and well tolerated, it can cause EntityADRs , which are reversible after drug withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case of a patient with infectious mononucleosis treated with Entitycephalexin who later showed a Entityrash is presented and the previous literature is reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Twenty - four hours after the administration of Entitygemcitabine , a Entitysymmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 4 patients, 2 on methylphenidate and 2 on Entitydextroamphetamine who presented with Entityacral cyanosis , livedo reticularis, or Raynaud phenomenon. |
| 0.9999 | Adverse-Effect | We report 4 patients, 2 on methylphenidate and 2 on Entitydextroamphetamine who presented with acral cyanosis, livedo reticularis, or EntityRaynaud phenomenon . |
| 0.9999 | Adverse-Effect | We report 4 patients, 2 on methylphenidate and 2 on Entitydextroamphetamine who presented with acral cyanosis, Entitylivedo reticularis , or Raynaud phenomenon. |
| 0.9998 | Adverse-Effect | We report 4 patients, 2 on Entitymethylphenidate and 2 on dextroamphetamine who presented with Entityacral cyanosis , livedo reticularis, or Raynaud phenomenon. |
| 0.9998 | Adverse-Effect | We report 4 patients, 2 on Entitymethylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, livedo reticularis, or EntityRaynaud phenomenon . |
| 0.9997 | Adverse-Effect | We report 4 patients, 2 on Entitymethylphenidate and 2 on dextroamphetamine who presented with acral cyanosis, Entitylivedo reticularis , or Raynaud phenomenon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | From these data, acute generalized dystonia with Entitybrainstem and thalamic lesions may occur in WD patients after an initial Entityd - penicillamine therapy. |
| 0.9995 | Adverse-Effect | From these data, Entityacute generalized dystonia with brainstem and thalamic lesions may occur in WD patients after an initial Entityd - penicillamine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case report of a patient with typhoid fever who experienced a Entityhypersensitivity reaction subsequent to the infusion of Entitychloramphenicol sodium succinate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A patient who had been treated with large doses of Entitythyroid hormone for several years developed features of secondary Entityhypothyroidism after thyroid hormone withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySeizures occurred in two patients with probable Alzheimer's disease who were receiving long - term treatment with Entitymetrifonate , an irreversible acetylcholinesterase inhibitor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | RESULTS : A previously healthy 42 - year - old woman presented with Entityacute - onset delirium with psychotic features as a consequence of Entitylevofloxacin therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The Entityexacerbation of psoriasis was accompanied by a massive induction of lesional type I interferon activity, detected by MxA expression after Entityimiquimod therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although adverse effects are usually mild, the author reports here a case of leucocytopenia and Entitythrombocytopenia with Entityquetiapine treatment that required its discontinuation. |
| 0.9999 | Adverse-Effect | Although adverse effects are usually mild, the author reports here a case of Entityleucocytopenia and thrombocytopenia with Entityquetiapine treatment that required its discontinuation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | EntityMethanol toxicity can cause Entitysevere central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies. |
| 0.9992 | Adverse-Effect | EntityMethanol toxicity can cause severe central nervous system insult in which a characteristic pattern of Entitybilateral putaminal injury is noted on brain imaging studies. |
| Adverse-Effect | EntityMethanol EntityMethanol toxicity can cause severe central nervous system insult in which a characteristic pattern of bilateral putaminal injury is noted on brain imaging studies. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a 14 - year - old boy with severe haemophilia A who developed a Entityportal vein thrombosis during continuous infusion of EntityF VIII . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The 3 cases presented here illustrate the development of Entityreproductive endocrine disorders after the initiation of Entityvalproate therapy in women with epilepsy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitysevere AVP three weeks following the administration of Entityinfliximab for the treatment of Crohn's disease ( CD ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : During and after EntityIFN therapy, OCT is a useful examination technique for revealing Entitymacular edema in patients who have decreased vision. |
| 0.9998 | Adverse-Effect | CONCLUSION : During and after EntityIFN therapy, OCT is a useful examination technique for revealing macular edema in patients who have Entitydecreased vision . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9988 | Adverse-Effect | The increasing prevalence of methamphetamine abuse and the severity of the associated ulcers should alert ophthalmologists to the problem of Entitymethamphetamine - related Entitykeratitis . |
| 0.9978 | Adverse-Effect | The increasing prevalence of Entitymethamphetamine abuse and the severity of the associated Entityulcers should alert ophthalmologists to the problem of methamphetamine - related keratitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with Entitycabergoline , developed progressive Entitypleuropulmonary abnormalities during the latter therapy. |
| 0.9998 | Adverse-Effect | A patient with Parkinson's disease, initially treated with Entitybromocriptine and subsequently with cabergoline, developed progressive Entitypleuropulmonary abnormalities during the latter therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is believed that this is the first reported case of reversible Entityazathioprine - induced Entitycholestasis associated with histological evidence of bile duct injury. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The pathogenic mechanisms involved in the development of Entityadriamycin Entitycardiomyopathy are reviewed, and the possible synergistic effect of other antitumor antibiotics is discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One should therefore be aware of possible Entityextrapyramidal side effects with Entityolanzapine that are reduced compared to classical neuroleptic drugs but not completely eliminated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Development of Entitysarcoidosis during Entityinterferon alpha 2b and ribavirin combination therapy for chronic hepatitis C - - a case report and review of the literature. |
| 0.9999 | Adverse-Effect | Development of Entitysarcoidosis during interferon alpha 2b and Entityribavirin combination therapy for chronic hepatitis C - - a case report and review of the literature. |
| 1.0000 | Adverse-Effect | Development of Entitysarcoidosis during Entityinterferon alpha 2b and ribavirin combination therapy for chronic hepatitis C - - a case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Exacerbation of Entityanthracycline - induced Entityearly chronic cardiomyopathy with ATRA : role of B - type natriuretic peptide as an indicator of cardiac dysfunction. |
| 0.9863 | Adverse-Effect | Exacerbation of Entityanthracycline - induced early chronic cardiomyopathy with ATRA : role of B - type natriuretic peptide as an indicator of Entitycardiac dysfunction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : A male and a female patient with spasticity treated with intrathecal Entitybaclofen were recognized to have Entitysexual dysfunction side effects from treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The diagnosis of Entityhypothermia was delayed until it was apparent for several days but resolved with the discontinuation of Entityrisperidone and continuation of clozapine. |
| 0.9999 | Adverse-Effect | The diagnosis of Entityhypothermia was delayed until it was apparent for several days but resolved with the discontinuation of risperidone and continuation of Entityclozapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Other potential causes of Entityrenal failure were not present in our patient and his renal function gradually recovered with the cessation of Entitysuramin treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this paper we report a case of Entitynimodipine overdosage resulting in Entityprolonged hypotension and hypoxemia, which was successfully treated with calcium gluconate. |
| 0.9999 | Adverse-Effect | In this paper we report a case of Entitynimodipine overdosage resulting in prolonged hypotension and Entityhypoxemia , which was successfully treated with calcium gluconate. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The first case concerns a 70 - year - old man who developed severe Entityaplastic anemia 7 weeks after treatment with 500 mg of Entityticlopidine daily. |
| 1.0000 | Adverse-Effect | The first case concerns a 70 - year - old man who developed Entitysevere aplastic anemia 7 weeks after treatment with 500 mg of Entityticlopidine daily. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thus, an immunological mechanism might be involved in the mechanism of Entitypirmenol - induced EntityQT prolongation and T wave inversion on the electrocardiogram. |
| 0.9999 | Adverse-Effect | Thus, an immunological mechanism might be involved in the mechanism of Entitypirmenol - induced QT prolongation and EntityT wave inversion on the electrocardiogram. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : EntityColchicine , the most important drug in treatment of FMF, can cause Entitymyopathy in patients with impaired renal and hepatic function. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | After other potential causes of liver toxicity were excluded, EntityTMP - SMX was determined to be the cause of his Entityacute liver toxicity . |
| 0.9996 | Adverse-Effect | After other potential causes of Entityliver toxicity were excluded, EntityTMP - SMX was determined to be the cause of his acute liver toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The autopsy findings and a detailed medical history supported the conclusion that Entityclozapine - induced Entityhypersensitivity myocarditis was the most likely cause of death. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, tacrolimus, and Entityinterferon - alpha can induce a condition resembling EntityRPLS . |
| 0.9999 | Adverse-Effect | Moreover, treatment with immunosuppressive drugs such as cyclosporine, Entitycisplatin , tacrolimus, and interferon - alpha can induce a condition resembling EntityRPLS . |
| 0.9998 | Adverse-Effect | Moreover, treatment with immunosuppressive drugs such as cyclosporine, cisplatin, Entitytacrolimus , and interferon - alpha can induce a condition resembling EntityRPLS . |
| 0.9998 | Adverse-Effect | Moreover, treatment with immunosuppressive drugs such as Entitycyclosporine , cisplatin, tacrolimus, and interferon - alpha can induce a condition resembling EntityRPLS . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We have recently encountered a patient with acquired haemophilia who developed a Entitythrombotic left middle cerebral artery distribution stroke while being treated with EntitypFVIII . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | We believe this is the first report of myocardial infarction due to Entitycoronary spasm , demonstrated by angiography associated with EntityL - thyroxine therapy. |
| 0.9982 | Adverse-Effect | We believe this is the first report of Entitymyocardial infarction due to coronary spasm, demonstrated by angiography associated with EntityL - thyroxine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present the case of an adult Crohn's disease patient with a parvovirus B19 infection and Entityleukopenia during long - term EntityAZA therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityThalidomide Entityneuropathy is often associated with proximal weakness and may progress even after discontinuation of treatment, in the phenomenon of'coasting '. |
| 0.9997 | Adverse-Effect | EntityThalidomide neuropathy is often associated with Entityproximal weakness and may progress even after discontinuation of treatment, in the phenomenon of'coasting '. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The possibility of Entityphenytoin Entityhypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy. |
| 0.9997 | Adverse-Effect | The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving Entityphenytoin have unusual symptoms, particularly Entityfever , rash, and lymphadenopathy. |
| 0.9997 | Adverse-Effect | The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving Entityphenytoin have unusual symptoms, particularly fever, Entityrash , and lymphadenopathy. |
| 0.9996 | Adverse-Effect | The possibility of phenytoin Entityhypersensitivity reactions should be considered when patients receiving Entityphenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy. |
| 0.9990 | Adverse-Effect | The possibility of phenytoin hypersensitivity reactions should be considered when patients receiving Entityphenytoin have unusual symptoms, particularly fever, rash, and Entitylymphadenopathy . |
| 0.9973 | Adverse-Effect | The possibility of Entityphenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, Entityrash , and lymphadenopathy. |
| 0.9960 | Adverse-Effect | The possibility of Entityphenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly Entityfever , rash, and lymphadenopathy. |
| 0.9947 | Adverse-Effect | The possibility of Entityphenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and Entitylymphadenopathy . |
| 0.9994 | Adverse-Effect | The possibility of Entityphenytoin Entityphenytoin hypersensitivity reactions should be considered when patients receiving phenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy. |
| 0.9962 | Adverse-Effect | The possibility of Entityphenytoin hypersensitivity reactions should be considered when patients receiving Entityphenytoin have unusual symptoms, particularly fever, rash, and lymphadenopathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She was administered Entitymetoclopramide because of nausea and, within 2 hours, developed Entityagitation , dysarthria, diaphoresis, and a movement disorder. |
| 1.0000 | Adverse-Effect | She was administered Entitymetoclopramide because of nausea and, within 2 hours, developed agitation, Entitydysarthria , diaphoresis, and a movement disorder. |
| 1.0000 | Adverse-Effect | She was administered Entitymetoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, Entitydiaphoresis , and a movement disorder. |
| 0.9999 | Adverse-Effect | She was administered Entitymetoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a Entitymovement disorder . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four Chinese female patients who suffered from manic - depressive disorder and underlying autoimmune thyroiditis developed transient episodes of Entitythyrotoxicosis during maintenance Entitylithium therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient described in this paper was a 78 - year - old diabetic man who developed Entityoral lesions of PV following institution of Entityglibenclamide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report on the possible development of Entityserotonin syndrome in a patient receiving Entityclomipramine after clozapine was withdrawn from the treatment regimen. |
| 0.9996 | Adverse-Effect | OBJECTIVE : To report on the possible development of Entityserotonin syndrome in a patient receiving clomipramine after Entityclozapine was withdrawn from the treatment regimen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two patients with rheumatoid factor - positive, polyarticular - onset juvenile rheumatoid arthritis in whom Entityaccelerated nodulosis developed during Entitymethotrexate therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Development of an Entityextensive skin rash following a single dose of EntityMTX may be an early warning sign for life - threatening bone marrow aplasia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, follow - up revealed that Entitygestational diabetes when associated with Entitynorethisterone had a lesser risk of emerging diabetes mellitus and impaired glucose tolerance. |
| 1.0000 | Adverse-Effect | However, follow - up revealed that gestational diabetes when associated with Entitynorethisterone had a lesser risk of emerging Entitydiabetes mellitus and impaired glucose tolerance. |
| 1.0000 | Adverse-Effect | However, follow - up revealed that gestational diabetes when associated with Entitynorethisterone had a lesser risk of emerging diabetes mellitus and Entityimpaired glucose tolerance . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | After administration of Oxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of EntityCarbamazepine EntityCarbamazepine intoxication . |
| 0.9967 | Adverse-Effect | After administration of Oxybutynin concomitantly with an increase in the dose of EntityDantrolene , she presented the clinical symptoms and laboratory finding of EntityCarbamazepine intoxication . |
| 0.9928 | Adverse-Effect | After administration of EntityOxybutynin concomitantly with an increase in the dose of Dantrolene, she presented the clinical symptoms and laboratory finding of EntityCarbamazepine intoxication . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report a case of Entitycodeine Entitycodeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 5 cases of Entityacute reversible renal failure coinciding with the onset of treatment with Entitycaptopril in patients with severe drug - resistant hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We present a Entityfatal case of subacute Entitymethanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression. |
| 0.9999 | Adverse-Effect | We present a fatal case of subacute Entitymethanol toxicity with associated Entitydiffuse brain involvement , including bilateral putaminal necrosis and cerebral edema with ventricular compression. |
| 0.9997 | Adverse-Effect | We present a fatal case of subacute Entitymethanol toxicity with associated diffuse brain involvement, including Entitybilateral putaminal necrosis and cerebral edema with ventricular compression. |
| 0.9997 | Adverse-Effect | We present a fatal case of subacute Entitymethanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with Entityventricular compression . |
| 0.9995 | Adverse-Effect | We present a fatal case of subacute Entitymethanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and Entitycerebral edema with ventricular compression. |
| Adverse-Effect | We present a fatal case of subacute Entitymethanol Entitymethanol toxicity with associated diffuse brain involvement, including bilateral putaminal necrosis and cerebral edema with ventricular compression. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Abrupt, accidental withdrawal of Entitytrihexyphenidyl triggered severe exacerbation of the Entitycranial dystonia associated with inspiratory stridor and acute respiratory difficulties, prompting emergency admission. |
| 1.0000 | Adverse-Effect | Abrupt, accidental withdrawal of Entitytrihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with Entityinspiratory stridor and acute respiratory difficulties, prompting emergency admission. |
| 0.9999 | Adverse-Effect | Abrupt, accidental withdrawal of Entitytrihexyphenidyl triggered severe exacerbation of the cranial dystonia associated with inspiratory stridor and Entityacute respiratory difficulties , prompting emergency admission. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Such a case induced by Entityhypothyroidism complicating long - term therapy with Entityamiodarone in a 45 year old woman with pre - excitation is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After having received Entitygemcitabine on day 1 of the second course, the patient developed Entitydry cough , subfebrile temperatures and dyspnea within 48 h. |
| 1.0000 | Adverse-Effect | After having received Entitygemcitabine on day 1 of the second course, the patient developed dry cough, Entitysubfebrile temperatures and dyspnea within 48 h. |
| 1.0000 | Adverse-Effect | After having received Entitygemcitabine on day 1 of the second course, the patient developed dry cough, subfebrile temperatures and Entitydyspnea within 48 h. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, headache, and Entityseizure after receiving Entitycyclosporine . |
| 1.0000 | Adverse-Effect | We report a case of a young woman with SLE and thrombocytopenia, who developed severe perspiration, Entityheadache , and seizure after receiving Entitycyclosporine . |
| 1.0000 | Adverse-Effect | We report a case of a young woman with SLE and thrombocytopenia, who developed Entitysevere perspiration , headache, and seizure after receiving Entitycyclosporine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The more common grade 3 or 4 adverse effects of Entitysunitinib include Entityhypertension , fatigue, hand - foot syndrome, elevated lipase and lymphopenia. |
| 1.0000 | Adverse-Effect | The more common grade 3 or 4 adverse effects of Entitysunitinib include hypertension, Entityfatigue , hand - foot syndrome, elevated lipase and lymphopenia. |
| 1.0000 | Adverse-Effect | The more common grade 3 or 4 adverse effects of Entitysunitinib include hypertension, fatigue, hand - foot syndrome, elevated lipase and Entitylymphopenia . |
| 0.9999 | Adverse-Effect | The more common grade 3 or 4 adverse effects of Entitysunitinib include hypertension, fatigue, Entityhand - foot syndrome , elevated lipase and lymphopenia. |
| 0.9999 | Adverse-Effect | The more common grade 3 or 4 adverse effects of Entitysunitinib include hypertension, fatigue, hand - foot syndrome, Entityelevated lipase and lymphopenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four patients in whom Entitypulmonary oedema developed during tocolysis with Entityhexoprenaline are described and the aetiological factors and pathogenesis of this potentially lethal complication discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of a diabetic patient taking glyburide who was prescribed Entityciprofloxacin and developed Entityprolonged hypoglycemia , which persisted for over 24 hours. |
| 0.9995 | Adverse-Effect | We present a case of a diabetic patient taking Entityglyburide who was prescribed ciprofloxacin and developed Entityprolonged hypoglycemia , which persisted for over 24 hours. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityZiprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing Entityextrapyramidal symptoms , including tardive dyskinesia ( TD ). |
| 1.0000 | Adverse-Effect | EntityZiprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia ( EntityTD ). |
| 1.0000 | Adverse-Effect | EntityZiprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including Entitytardive dyskinesia ( TD ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Drug - induced Entityhepatitis in an acromegalic patient during combined treatment with Entitypegvisomant and octreotide long - acting repeatable attributed to the use of pegvisomant. |
| 0.9998 | Adverse-Effect | Drug - induced Entityhepatitis in an acromegalic patient during combined treatment with pegvisomant and Entityoctreotide long - acting repeatable attributed to the use of pegvisomant. |
| 0.9997 | Adverse-Effect | Drug - induced Entityhepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long - acting repeatable attributed to the use of Entitypegvisomant . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | MATERIALS AND METHODS : We present two cases of significant morbidity related to Entityprimary and secondary perforation of the bladder following two instillations of Entityepirubicin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our patient developed both nephrogenic diabetes insipidus and Entityrenal tubular acidosis with a temporal pattern that demonstrated a link between Entityfoscarnet therapy and these abnormalities. |
| 0.9999 | Adverse-Effect | Our patient developed both Entitynephrogenic diabetes insipidus and renal tubular acidosis with a temporal pattern that demonstrated a link between Entityfoscarnet therapy and these abnormalities. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There have been numerous case reports of Entityhyperglycemia with Entityolanzapine in the literature, but none reported hyperglycemia within days of initiation of the medication. |
| 0.9970 | Adverse-Effect | There have been numerous case reports of hyperglycemia with Entityolanzapine in the literature, but none reported Entityhyperglycemia within days of initiation of the medication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, drug - induced Entityfever has not been reported with the use of Entitydiltiazem hydrochloride , a commonly prescribed calcium channel blocker. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | We present the case of a postictal patient with lethargy, Entityhyperammonemia , otherwise normal liver function tests, and a therapeutic Entityvalproic acid level. |
| 0.9995 | Adverse-Effect | We present the case of a postictal patient with Entitylethargy , hyperammonemia, otherwise normal liver function tests, and a therapeutic Entityvalproic acid level. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In two patients with mycosis fungoides, a Entitysquamous cell carcinoma developed during therapy with Entitypsoralens plus long - wave ultraviolet radiation ( PUVA ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySunburn may sometimes be a major injury in Entitypsoralen users because high doses or inappropriate use of the drug may render the skin extremely sensitive. |
| 1.0000 | Adverse-Effect | Sunburn may sometimes be a major injury in Entitypsoralen users because high doses or inappropriate use of the drug may render the Entityskin extremely sensitive . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A 35 - year - old nephrotic man developed Entityacute renal failure with serum creatinine to 1543 micromol / l after a month of therapy with Entityenalapril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 33 - year - old man with a history of recreational Entitybenztropine abuse presented to the emergency department with Entityconfusion , abdominal pain, and distention. |
| 1.0000 | Adverse-Effect | A 33 - year - old man with a history of recreational Entitybenztropine abuse presented to the emergency department with confusion, Entityabdominal pain , and distention. |
| 1.0000 | Adverse-Effect | A 33 - year - old man with a history of recreational Entitybenztropine abuse presented to the emergency department with confusion, abdominal pain, and Entitydistention . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a fatal case of toxic epidermal necrolysis ( EntityTEN ) resulting from a high dose of Entitycytosine arabinoside ( ARA - C ). |
| 0.9998 | Adverse-Effect | We report a fatal case of toxic epidermal necrolysis ( EntityTEN ) resulting from a high dose of cytosine arabinoside ( EntityARA - C ). |
| 0.9997 | Adverse-Effect | We report a fatal case of Entitytoxic epidermal necrolysis ( TEN ) resulting from a high dose of Entitycytosine arabinoside ( ARA - C ). |
| 0.9987 | Adverse-Effect | We report a fatal case of Entitytoxic epidermal necrolysis ( TEN ) resulting from a high dose of cytosine arabinoside ( EntityARA - C ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a third case of a 6 - week - old infant with Escherichia coli sepsis who received Entityampicillin and other antibiotics and subsequently developed EntityTEN . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 58 - year old patient is reported who developed an Entityischaemic cerebrovascular accident 22 hours after successful thrombolysis with Entitystreptokinase for life - threatening pulmonary emboli. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It should be recognized that Entityibuprofen may be associated with Entitysalt and water retention in the same fashion as previously described with phenylbutazone and indomethacin. |
| 1.0000 | Adverse-Effect | It should be recognized that ibuprofen may be associated with Entitysalt and water retention in the same fashion as previously described with Entityphenylbutazone and indomethacin. |
| 0.9998 | Adverse-Effect | It should be recognized that ibuprofen may be associated with Entitysalt and water retention in the same fashion as previously described with phenylbutazone and Entityindomethacin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, we describe the first reported case of isolated paresthesia and Entityperipheral neuropathy , without systemic involvement, secondary to Entitysulindac administration. |
| 0.9999 | Adverse-Effect | To our knowledge, we describe the first reported case of Entityisolated paresthesia and peripheral neuropathy, without systemic involvement, secondary to Entitysulindac administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetoclopramide - induced Entityparkinsonism is not rare, and appropriate dose reduction in patients with renal failure will help reduce the incidence of this morbidity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : EntityPhenolphthalein is the active ingredient in several over - the - counter laxative preparations and has only rarely been reported to cause EntityTEN . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Charcoal haemoperfusion and cysteamine therapy led to the rapid removal of the Entityparacetamol from the body and consequently prevented the development of Entitysevere hepatic necrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on three patients with acute schizophrenia, who developed Entitysevere akathisia during treatment with Entityolanzapine ( 20 - 25 mg / d ). |
| 1.0000 | Adverse-Effect | We report on three patients with acute schizophrenia, who developed severe Entityakathisia during treatment with Entityolanzapine ( 20 - 25 mg / d ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMultiple syncopal episodes started to occur during Entitythalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of sustained ventricular tachycardia. |
| 0.9996 | Adverse-Effect | Multiple syncopal episodes started to occur during Entitythalidomide treatment, and a Holter electrocardiogram showed multiple abnormalities, with an episode of Entitysustained ventricular tachycardia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He had an immediate Entityhypersensitivity reaction during the initiation of the EntityMTX infusion with diffuse urticaria, facial swelling, cough, and chest tightness. |
| 1.0000 | Adverse-Effect | He had an immediate hypersensitivity reaction during the initiation of the EntityMTX infusion with Entitydiffuse urticaria , facial swelling, cough, and chest tightness. |
| 0.9999 | Adverse-Effect | He had an immediate hypersensitivity reaction during the initiation of the EntityMTX infusion with diffuse urticaria, facial swelling, Entitycough , and chest tightness. |
| 0.9999 | Adverse-Effect | He had an immediate hypersensitivity reaction during the initiation of the EntityMTX infusion with diffuse urticaria, Entityfacial swelling , cough, and chest tightness. |
| 0.9996 | Adverse-Effect | He had an immediate hypersensitivity reaction during the initiation of the EntityMTX infusion with diffuse urticaria, facial swelling, cough, and Entitychest tightness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report presents a case of Entitycolon perforation which occurred 4 months after treatment with intraperitoneal Entitychromic phosphate for stage IB ovarian papillary serous cystadenocarcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We suggest that Entityitraconazole should be added to the list of drugs that may be responsible for a drug - induced Entityvanishing bile duct syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | AIM : Report of a case of a woman patient who developed Entityceliac disease after Entitypegylated interferon alpha - 2a and ribavirin use for chronic hepatitis C. |
| 0.9999 | Adverse-Effect | AIM : Report of a case of a woman patient who developed Entityceliac disease after pegylated interferon alpha - 2a and Entityribavirin use for chronic hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These findings suggest that Entitybicytopenia in this patient was caused by EntityD - Pen and may be due to different sensitivities in the hematopoietic lineage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We describe a case of needle - track Entitycutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous Entityethanol injection ( PEI ). |
| 1.0000 | Adverse-Effect | We describe a case of needle - track Entitycutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous Entityethanol injection ( PEI ). |
| 0.9999 | Adverse-Effect | We describe a case of needle - track Entitycutaneous seeding of hepatocellular carcinoma ( HCC ) after sonographically guided percutaneous ethanol injection ( EntityPEI ). |
| 0.9983 | Adverse-Effect | We describe a case of needle - track Entitycutaneous seeding of hepatocellular carcinoma ( EntityHCC ) after sonographically guided percutaneous ethanol injection ( PEI ). |
| 0.6993 | Adverse-Effect | We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( EntityHCC ) after sonographically guided percutaneous Entityethanol injection ( PEI ). |
| 0.5987 | Adverse-Effect | We describe a case of needle - track cutaneous seeding of hepatocellular carcinoma ( EntityHCC ) after sonographically guided percutaneous Entityethanol injection ( PEI ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This article reports the occurrence of Entityrifampin - associated Entitythrombocytopenia in an indigent patient after a four - month lapse in therapy for pulmonary tuberculosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | Recent studies have shown that under experimental conditions Entityferrous sulfate may Entityreduce the gastrointestinal absorption of orally administered levothyroxine sodium in patients with primary hypothyroidism. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We postulate that cyclosporin, possibly together with Entityganciclovir , can produce Entitytransient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients. |
| 0.9999 | Adverse-Effect | We postulate that Entitycyclosporin , possibly together with ganciclovir, can produce Entitytransient brain stem or neuromuscular dysfunction with eye movement abnormality in occasional patients. |
| 0.9999 | Adverse-Effect | We postulate that cyclosporin, possibly together with Entityganciclovir , can produce transient brain stem or neuromuscular dysfunction with Entityeye movement abnormality in occasional patients. |
| 0.9997 | Adverse-Effect | We postulate that Entitycyclosporin , possibly together with ganciclovir, can produce transient brain stem or neuromuscular dysfunction with Entityeye movement abnormality in occasional patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We believe that this is the first description of Entityacute hepatitis caused by an idiosyncratic adverse reaction to Entitygliclazide or to one of its metabolites. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The second is a 29 - year - old man with CD in whom Entitynodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with Entityinfliximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Five personal observations of an Entityacute amnestic episode in younger individuals after intake of Entityclioquinol are described together with three observations from the medical literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this case, Entityinterferon alpha induced Entitypolymyositis and cardiomyopathy is diagnosed in a 33 - yr - old male patient with history of chronic hepatitis B. |
| 0.9994 | Adverse-Effect | In this case, Entityinterferon alpha induced polymyositis and Entitycardiomyopathy is diagnosed in a 33 - yr - old male patient with history of chronic hepatitis B. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case 3 : A 29 - year - old female alcoholic complained of general fatigue and a slight Entityfever after 1. 5 years of abstinence with Entitycyanamide treatment. |
| 0.9999 | Adverse-Effect | Case 3 : A 29 - year - old female alcoholic complained of Entitygeneral fatigue and a slight fever after 1. 5 years of abstinence with Entitycyanamide treatment. |
| Adverse-Effect | Case 3 : A 29 - year - old female alcoholic complained of general Entityfatigue and a slight fever after 1. 5 years of abstinence with Entitycyanamide treatment. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A twelve year - old - girl with idiopathic partial epilepsy with secondary generalization, developed Entityacute psychosis 10 days after the administration of Entitylevetiracetam . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In addition to disease refractoriness, rare instances of disease progression from chronic phase to Entityblast crisis during Entityimatinib therapy have recently been anecdotally reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors suggest that in patients with Entitycorneal ulcers refractory to conventional treatment who are receiving Entitycolchicine , cessation of colchicine therapy should be considered. |
| 0.9994 | Adverse-Effect | The authors suggest that in patients with Entitycorneal ulcers refractory to conventional treatment who are receiving colchicine, cessation of Entitycolchicine therapy should be considered. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a case of Entitycefazolin - induced Entityleukopenia in a critically ill patient who developed this adverse reaction upon rechallenge with cefoxitin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of infection with EntityMycobacterium abscessus in a 67 - year - old woman receiving Entityinfliximab as a component of her therapy for RA. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | This case study is the second report of Entitylocalized purpura after prolonged Entitylamotrigine treatment suggesting this may be an atypical lamotrigine - induced drug reaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming Entitysepsis associated with Entitymetamizole use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although a few case reports link Entitymetronidazole with the development of Entitypseudomembranous colitis , albendazole has not been associated with the development of this condition. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Three cases of Entitypseudocyst of the pancreas in two women and one man have previously been reported with the use of intravenous EntityL - asparaginase . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityoligohidrosis caused by Entityzonisamide was reversible in that the patient regained the ability to sweat within 2 weeks of the cessation of drug administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Massive EntityCBZ OD may produce a Entityreversible encephalopathy that includes cortical hyperexcitability, a profound burst - suppression EEG pattern, and cranial nerve areflexia. |
| 0.9999 | Adverse-Effect | Massive EntityCBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a Entityprofound burst - suppression EEG pattern , and cranial nerve areflexia. |
| 0.9998 | Adverse-Effect | Massive EntityCBZ OD may produce a reversible encephalopathy that includes Entitycortical hyperexcitability , a profound burst - suppression EEG pattern, and cranial nerve areflexia. |
| 0.9998 | Adverse-Effect | Massive EntityCBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst - suppression EEG pattern, and Entitycranial nerve areflexia . |
| 0.9996 | Adverse-Effect | Massive EntityCBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst - suppression EEG pattern, and cranial Entitynerve areflexia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProgressive interstitial fibrosis with roentgenographic honeycombing developed in the case of a psoriatic patient who had been on a regimen of Entitymethotrexate for 18 years. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case 4 : A 61 - year - old male alcoholic who remained completely abstinent while taking Entitycyanamide for 3 years showed slight Entityelevation of serum transaminases . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A retrospective review of TTP patients with Entityquinine - associated Entitythrombotic microangiopathy ( TMA ) for whom ADAMTS13 was measured before plasma exchange was performed. |
| 0.9991 | Adverse-Effect | A retrospective review of TTP patients with Entityquinine - associated thrombotic microangiopathy ( EntityTMA ) for whom ADAMTS13 was measured before plasma exchange was performed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited drug - seeking behavior or Entityanticholinergic symptoms with the use of Entitydiphenhydramine . |
| 1.0000 | Adverse-Effect | We describe children and adolescents with chronic hematologic and oncologic diseases who exhibited Entitydrug - seeking behavior or anticholinergic symptoms with the use of Entitydiphenhydramine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three patients are reported without a history of angina pectoris who had clinical and electrocardiographic evidence of Entitymyocardial ischemia during and immediately after EntityBCNU infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | No cases of renal acidosis, and only one case of Entitynephrogenic diabetes insipidus , has been previously reported as a complication of Entityfoscarnet treatment. |
| 0.9999 | Adverse-Effect | No cases of Entityrenal acidosis , and only one case of nephrogenic diabetes insipidus, has been previously reported as a complication of Entityfoscarnet treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for Entitylithium - induced Entitypolyuria and nephrogenic diabetes insipidus. |
| 0.9989 | Adverse-Effect | Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for Entitylithium - induced polyuria and Entitynephrogenic diabetes insipidus . |
| 0.9490 | Adverse-Effect | Clinicians have been aware of Entitylithium toxicity for many years and traditionally have administered thiazide diuretics for lithium - induced Entitypolyuria and nephrogenic diabetes insipidus. |
| 0.9259 | Adverse-Effect | Clinicians have been aware of Entitylithium toxicity for many years and traditionally have administered thiazide diuretics for lithium - induced polyuria and Entitynephrogenic diabetes insipidus . |
| 0.9978 | Adverse-Effect | Clinicians have been aware of lithium toxicity for many years and traditionally have administered Entitythiazide diuretics for lithium - induced Entitypolyuria and nephrogenic diabetes insipidus. |
| 0.9909 | Adverse-Effect | Clinicians have been aware of lithium toxicity for many years and traditionally have administered Entitythiazide diuretics for lithium - induced polyuria and Entitynephrogenic diabetes insipidus . |
| Adverse-Effect | Clinicians have been aware of Entitylithium Entitylithium toxicity for many years and traditionally have administered thiazide diuretics for lithium - induced polyuria and nephrogenic diabetes insipidus. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Thrombotic thrombocytopenic purpura ( EntityTTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1 / 2 months of treatment with Entitypenicillamine . |
| 0.9999 | Adverse-Effect | EntityThrombotic thrombocytopenic purpura ( TTP ) developed in a patient with seropositive rheumatoid arthritis ( RA ) after 2 1 / 2 months of treatment with Entitypenicillamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These evolutional changes in both proteinuria and glomerular histology suggest a close linkage between the EntityM - CSF treatment and Entitymacrophage - related glomerular injury . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A previous review described data on 15 patients who experienced acute hemoglobinemia or Entityhemoglobinuria following Entityanti - D IGIV administration for ITP or secondary thrombocytopenia. |
| 0.9992 | Adverse-Effect | A previous review described data on 15 patients who experienced Entityacute hemoglobinemia or hemoglobinuria following Entityanti - D IGIV administration for ITP or secondary thrombocytopenia. |
| 1.0000 | Adverse-Effect | A previous review described data on 15 patients who experienced acute hemoglobinemia or Entityhemoglobinuria following Entityanti - D IGIV administration for ITP or secondary thrombocytopenia. |
| 0.9992 | Adverse-Effect | A previous review described data on 15 patients who experienced Entityacute hemoglobinemia or hemoglobinuria following Entityanti - D IGIV administration for ITP or secondary thrombocytopenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is an image and brief case report of a 13 - year - old boy who presented with Entitysevere rash and systemic symptoms after starting Entityoxcarbazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors describe a case of Entityoral - facial dyskinesia that occurred after discontinuation of Entityamoxapine , and antidepressant which may also have neuroleptic effects. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | After Entitygastric - outlet obstruction was recognized in several infants who received Entityprostaglandin E1 , we studied the association between the drug and this complication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGynecomastia developed in two epileptic patients some months after the addition of oral Entityfluoresone 750 mg daily to the phenobarbital and phenytoin already being administered. |
| 0.9999 | Adverse-Effect | EntityGynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the Entityphenobarbital and phenytoin already being administered. |
| 0.9999 | Adverse-Effect | EntityGynecomastia developed in two epileptic patients some months after the addition of oral fluoresone 750 mg daily to the phenobarbital and Entityphenytoin already being administered. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case admitted with a first - detected, Entitysymptomatic paroxysmal atrial fibrillation in a healthy patient after self - medication with Entityvardenafil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : We present a case of a patient with CML who developed EntityKS 12 months after starting treatment with Entityimatinib 400 mg / d. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The probable Entityproarrhythmic action of Entityamiodarone , although rare, is reviewed along with a discussion of the novel use of intravenous magnesium sulfate therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report three cases of EntityIFN beta induced Entityhepatitis in MS and discuss the pathology findings and possible mechanisms of drug - induced liver injury. |
| 0.9964 | Adverse-Effect | We report three cases of EntityIFN beta induced hepatitis in MS and discuss the pathology findings and possible mechanisms of drug - induced Entityliver injury . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We conclude that low - dose EntityHU therapy in patients with thalassemia intermedia may Entityincrease total Hb levels sufficiently to eliminate the need for transfusions. |
| 1.0000 | Adverse-Effect | We conclude that low - dose EntityHU therapy in patients with thalassemia intermedia may Entityincrease total Hb levels sufficiently to eliminate the need for transfusions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case report describes the development of asymptomatic visual field defects ( EntityVFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive Entitytiagabine treatment. |
| 0.9999 | Adverse-Effect | This case report describes the development of asymptomatic Entityvisual field defects ( VFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive Entitytiagabine treatment. |
| 1.0000 | Adverse-Effect | This case report describes the development of Entityasymptomatic visual field defects ( VFDs ) in a psychiatric patient with bipolar disorder receiving adjunctive Entitytiagabine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAmiodarone was the third drug to induce EntityAVT in this patient ; she received 200 mg / day six days per week for six months. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three days after receiving intravitreal injection of Entitybevacizumab ( 1. 25 mg in 0. 1 ml ), he developed Entityacute vision loss and change of consciousness. |
| 1.0000 | Adverse-Effect | Three days after receiving intravitreal injection of Entitybevacizumab ( 1. 25 mg in 0. 1 ml ), he developed acute vision loss and Entitychange of consciousness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two of these patients, who also received the anti - emetic Entityprochlorperazine , Entitylost consciousness for 48 - 72 h and then fully recovered. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CONCLUSIONS : This is the second case report that describes Entitygemcitabine - induced Entityradiation recall in rectus abdominus muscles after gemcitabine - based radiation therapy. |
| 0.9557 | Adverse-Effect | CONCLUSIONS : This is the second case report that describes gemcitabine - induced Entityradiation recall in rectus abdominus muscles after Entitygemcitabine - based radiation therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The 5 patients had severe renovascular disease which might thus represent a significant risk factor in the development of Entitycaptopril - induced Entityacute renal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although Entityvasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of Entitycladribine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Treatment of ELP in children is generally supportive, with the symptoms and Entityroentgenographic abnormalities resolving within months after stopping the use of Entitymineral oil . |
| 0.9998 | Adverse-Effect | Treatment of EntityELP in children is generally supportive, with the symptoms and roentgenographic abnormalities resolving within months after stopping the use of Entitymineral oil . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | This case illustrates that the Entityhemophagocytic syndrome associated with reactivation of EBV can occur as part of drug hypersensitivity reactions in RA patients taking Entitysulfasalazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient was an 80 - year - old woman who was admitted for EntityStaphylococcus aureus knee arthritis after several intraarticular injections of Entitysodium hyaluronate and corticosteroids. |
| 1.0000 | Adverse-Effect | One patient was an 80 - year - old woman who was admitted for EntityStaphylococcus aureus knee arthritis after several intraarticular injections of sodium hyaluronate and Entitycorticosteroids . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The incidence of oral - Entityverapamil - induced Entityhypotension in the presence of concomitant beta - adrenergic blockade by the oral route is quite rare. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Painful Entityneutrophilic skin lesions were observed in two children receiving Entitygranulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia. |
| 0.9994 | Adverse-Effect | Painful Entityneutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( EntityG - CSF ) for treatment of idiopathic neutropenia. |
| 1.0000 | Adverse-Effect | EntityPainful neutrophilic skin lesions were observed in two children receiving Entitygranulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia. |
| 0.9998 | Adverse-Effect | EntityPainful neutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( EntityG - CSF ) for treatment of idiopathic neutropenia. |
| Adverse-Effect | EntityPainful neutrophilic skin lesions were observed in two children receiving Entitygranulocyte colony - stimulating factor ( G - CSF ) for treatment of idiopathic neutropenia. | |
| Adverse-Effect | EntityPainful neutrophilic skin lesions were observed in two children receiving granulocyte colony - stimulating factor ( EntityG - CSF ) for treatment of idiopathic neutropenia. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case had radiation fibrosis, so we suggest that radiation fibrosis may be another contributor of the occurrence of EntityILD in patients taking Entityerlotinib . |
| 0.9998 | Adverse-Effect | This case had radiation fibrosis, so we suggest that Entityradiation fibrosis may be another contributor of the occurrence of ILD in patients taking Entityerlotinib . |
| 0.9989 | Adverse-Effect | This case had Entityradiation fibrosis , so we suggest that radiation fibrosis may be another contributor of the occurrence of ILD in patients taking Entityerlotinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic Entitycibenzoline Entitycibenzoline intoxication . |
| 0.9998 | Adverse-Effect | We cared for a patient with progressive renal impairment who presented with Entityblurred vision , QRS broadening and cardiac failure due to chronic Entitycibenzoline intoxication. |
| 0.9997 | Adverse-Effect | We cared for a patient with progressive renal impairment who presented with blurred vision, EntityQRS broadening and cardiac failure due to chronic Entitycibenzoline intoxication. |
| 0.9993 | Adverse-Effect | We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and Entitycardiac failure due to chronic Entitycibenzoline intoxication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Seizures and Entityextrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with Entityinterferon beta - 1a and clomipramine. |
| 0.9998 | Adverse-Effect | Seizures and Entityextrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta - 1a and Entityclomipramine . |
| 0.9997 | Adverse-Effect | EntitySeizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with Entityinterferon beta - 1a and clomipramine. |
| 0.9996 | Adverse-Effect | EntitySeizures and extrapyramidal symptoms in a patient with Tourette's syndrome, Asperger's syndrome, and multiple sclerosis treated with interferon beta - 1a and Entityclomipramine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : EntityColchicine has a known adverse effect on Entitywound healing through its inhibitory effect on tubulin - dependent cell functions and through collagenase activation. |
| Adverse-Effect | BACKGROUND : EntityColchicine has a known Entityadverse effect on wound healing through its inhibitory effect on tubulin - dependent cell functions and through collagenase activation. | |
| Adverse-Effect | BACKGROUND : EntityColchicine has a known adverse effect on wound healing through its inhibitory effect on tubulin - dependent cell functions and through Entitycollagenase activation . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Thrombolytic therapy with tissue plasminogen activator ( EntitytPA ) for acute myocardial infarction may result in major bleeding complications such as Entitygastrointestinal or intracranial bleeding . |
| 0.9998 | Adverse-Effect | Thrombolytic therapy with Entitytissue plasminogen activator ( tPA ) for acute myocardial infarction may result in major bleeding complications such as Entitygastrointestinal or intracranial bleeding . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the development of Entitycutaneous scleroderma in 3 patients coincident with the use of Entitybleomycin in low cumulative doses of less than 100 U. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Drug - induced Entitypsychosis resulted from the administration of Entityquinacrine hydrochloride at a dosage of 100 mg twice daily for the treatment of discoid lupus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9987 | Adverse-Effect | The interval between initiating treatment with Entityinterferon alfa and onset of Entityanterior ischemic optic neuropathy was similar to that of interferon - associated vascular retinopathy. |
| 0.9952 | Adverse-Effect | The interval between initiating treatment with interferon alfa and onset of anterior ischemic optic neuropathy was similar to that of Entityinterferon - associated Entityvascular retinopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of AILD in an 80 - year - old male who presented with a generalized pruritic maculopapular eruption and Entityfever following Entitydoxycycline administration. |
| 1.0000 | Adverse-Effect | We report a case of EntityAILD in an 80 - year - old male who presented with a generalized pruritic maculopapular eruption and fever following Entitydoxycycline administration. |
| 1.0000 | Adverse-Effect | We report a case of AILD in an 80 - year - old male who presented with a Entitygeneralized pruritic maculopapular eruption and fever following Entitydoxycycline administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Post marketing studies of Interferon - beta ( EntityIFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of Entityhepatotoxicity . |
| 0.9993 | Adverse-Effect | Post marketing studies of EntityInterferon - beta ( IFN beta ) therapy in multiple sclerosis ( MS ) have demonstrated surprisingly high rates of Entityhepatotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypersensitivity to Entitycarboplatin has been reported in up to 44 % of patients receiving this antineoplastic agent, usually occurring after several courses of treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | During her third cycle, she again received Entitycisplatin Entity100 mg / m2 over 30 minutes and developed palmar pruritus, urticaria, and edema. |
| 0.9999 | Adverse-Effect | During her third cycle, she again received Entitycisplatin 100 mg / m2 over 30 minutes and developed Entitypalmar pruritus , urticaria, and edema. |
| 0.9999 | Adverse-Effect | During her third cycle, she again received Entitycisplatin 100 mg / m2 over 30 minutes and developed palmar pruritus, Entityurticaria , and edema. |
| 0.9999 | Adverse-Effect | During her third cycle, she again received Entitycisplatin 100 mg / m2 over 30 minutes and developed palmar pruritus, urticaria, and Entityedema . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report a further case of Entitymethimazole - associated Entityliver damage and present a brief review of eleven previous cases found in the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of fulminant Entityneuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six - hourly intravenous Entitymetoclopramide . |
| 1.0000 | Adverse-Effect | We report a case of Entityfulminant neuroleptic malignant syndrome in a man aged 70 developing within 12 hours of starting six - hourly intravenous Entitymetoclopramide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We describe 3 AS patients treated with Entityetanercept for active AS who developed new onset of EntityCD while AS related symptoms responded well to etanercept. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | After a two - month interruption of interferon administration, natural Entityinterferon alpha was given but followed by another episode of the same Entityneurological manifestations . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with androgen - independent prostate cancer in whom EntityPSA continued to decrease for a period of 15 months after Entityflutamide withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | 46 - year - old woman developed painful ulcers over her lower abdomen in the form of Entityreticulate erythema after injecting Entityinterferon beta - 1b subcutaneously for multiple sclerosis. |
| 0.9997 | Adverse-Effect | 46 - year - old woman developed Entitypainful ulcers over her lower abdomen in the form of reticulate erythema after injecting Entityinterferon beta - 1b subcutaneously for multiple sclerosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of EntitySJS in a 14 - year - old male with nephrotic syndrome, who was treated with oral Entityprednisolone for 6 weeks. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Data have been published regarding the possibility that Entitytamoxifen may be responsible for the subsequent development of Entitycarcinoma of the corpus uteri in these patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 56 - year - old Caucasian man who received concomitant chemotherapy and radiation for head and neck cancer developed Entityfever concurrent with the administration of Entityamifostine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCalcipotriol ( Daivonex R ; Leo Pharmaceuticals, Zurich, Switzerland ) may cause Entityirritation of the skin , whereas allergic reactions are less common. |
| 1.0000 | Adverse-Effect | EntityCalcipotriol ( Daivonex R ; Leo Pharmaceuticals, Zurich, Switzerland ) may cause irritation of the skin, whereas Entityallergic reactions are less common. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CONCLUSION : Patients with Entityinsulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant Entityprotamine allergy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | OBJECTIVE : To report a case of Entitytoxin - positive Clostridium difficile - induced colitis ( CDIC ) after use of Entityclindamycin phosphate vaginal cream. |
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of toxin - positive Clostridium difficile - induced colitis ( EntityCDIC ) after use of Entityclindamycin phosphate vaginal cream. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | Pathogenesis of methotrexate - induced papular eruption in psoriasis may involve immune mechanisms other than those of Entitymethotrexate - induced Entitycutaneous vasculitis in collagen vascular disease. |
| 0.9996 | Adverse-Effect | Pathogenesis of Entitymethotrexate - induced Entitypapular eruption in psoriasis may involve immune mechanisms other than those of methotrexate - induced cutaneous vasculitis in collagen vascular disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two of the five patients who worsened motorically also developed Entityencephalopathy during Entityrisperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment. |
| 0.9998 | Adverse-Effect | Two of the five patients who Entityworsened motorically also developed encephalopathy during Entityrisperidone treatment ; the encephalopathy resolved when the patients were switched to clozapine treatment. |
| 0.9999 | Adverse-Effect | Two of the five patients who worsened motorically also developed encephalopathy during risperidone treatment ; the Entityencephalopathy resolved when the patients were switched to Entityclozapine treatment. |
| 0.9890 | Adverse-Effect | Two of the five patients who worsened motorically also developed encephalopathy during Entityrisperidone treatment ; the Entityencephalopathy resolved when the patients were switched to clozapine treatment. |
| 0.9818 | Adverse-Effect | Two of the five patients who Entityworsened motorically also developed encephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to Entityclozapine treatment. |
| 0.9608 | Adverse-Effect | Two of the five patients who worsened motorically also developed Entityencephalopathy during risperidone treatment ; the encephalopathy resolved when the patients were switched to Entityclozapine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAcute ocular ischemic change may be associated with intravitreal injection of Entitybevacizumab in patients with vascular compromised diabetic retinopathy and / or underlying stenosis of the carotid artery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | She was receiving phenytoin sodium 300 mg / day ; Entitycarbamazepine 200 mg four times daily had been discontinued four days before admission because of Entityleukopenia . |
| 0.9992 | Adverse-Effect | She was receiving Entityphenytoin sodium 300 mg / day ; carbamazepine 200 mg four times daily had been discontinued four days before admission because of Entityleukopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | His Entityimpaired memory was found to be due to the Entityatenolol he was on and he made a complete recovery on withdrawing the beta - blocker. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe two cases of Entityrhabdomyolysis in patients taking Entitylovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and azithromycin. |
| 0.9999 | Adverse-Effect | OBJECTIVE : To describe two cases of Entityrhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics Entityclarithromycin and azithromycin. |
| 0.9998 | Adverse-Effect | OBJECTIVE : To describe two cases of Entityrhabdomyolysis in patients taking lovastatin that were precipitated by the use of the newer macrolide antibiotics clarithromycin and Entityazithromycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This experience supports the hypothesis that heparin can be readministered early to patients with Entityheparin - associated Entitythrombocytopenia and thrombosis, provided antiplatelet therapy is given. |
| 0.9994 | Adverse-Effect | This experience supports the hypothesis that heparin can be readministered early to patients with Entityheparin - associated thrombocytopenia and Entitythrombosis , provided antiplatelet therapy is given. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The frequency and relationship of Entitygranulocytopenia caused by sustained - release Entityprocainamide in patients with tachyarrhythmias are briefly discussed, and prior reported cases are reviewed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this is the first report of significant Entityhypotension associated with intravenous Entityvalproate in the treatment of status epilepticus in the pediatric population. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with rheumatoid arthritis treated with Entitygold salts, who developed Entitybilateral interstitial pulmonary abnormalities and showed a dramatic response on corticosteroid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this case, discontinuing Entitypiroxicam , a nonsteroidal anti - inflammatory drug, and starting a palliative treatment plan helped resolve a patient's Entityulcers . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We observed Entityventricular fibrillation in 2 patients who presented to the emergency department with pre - excited atrial fibrillation and were given 12 mg of Entityadenosine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | On the 3rd day, an inferior vena cava ( IVC ) filter was placed with a Entityheparin flush, after which massive EntityIVC thrombosis developed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An 8 - year - old girl, who had been vaccinated with EntityBCG without subsequent regional reactions, developed Entityosteomyelitis in the left calcaneus 7 months later. |
| 1.0000 | Adverse-Effect | An 8 - year - old girl, who had been vaccinated with EntityBCG without subsequent regional reactions, developed Entityosteomyelitis in the left calcaneus 7 months later. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In a female with acute lymphoblastic leukemia, inadvertent Entitydoxorubicin administration intrathecally caused severe, life - threatening, Entityacute encephalopathy with high - pressure hydrocephalus. |
| 0.9999 | Adverse-Effect | In a female with acute lymphoblastic leukemia, inadvertent Entitydoxorubicin administration intrathecally caused severe, life - threatening, acute encephalopathy with Entityhigh - pressure hydrocephalus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In conclusion, this case strongly suggests that Entitygliclazide can induce Entityacute icteric liver necro - inflammation which may be misdiagnosed clinically as acute viral hepatitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of reversible DKA and new - onset EntityDM that developed in a demented patient who was treated with Entityquetiapine for 14 days. |
| 1.0000 | Adverse-Effect | We report a case of reversible EntityDKA and new - onset DM that developed in a demented patient who was treated with Entityquetiapine for 14 days. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Mean time between initiation of Entitygemcitabine therapy and onset of EntityHUS was 7. 4 + / - 3. 5 months, or 21. 9 + / - 10. 9 doses of gemcitabine. |
| 1.0000 | Adverse-Effect | Mean time between initiation of gemcitabine therapy and onset of EntityHUS was 7. 4 + / - 3. 5 months, or 21. 9 + / - 10. 9 doses of Entitygemcitabine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Sodium phenylbutyrate was added to treatment with EntityHU in two patients, but failed to produce an increase in total Hb despite Entityincreasing Hb F levels. |
| 0.9994 | Adverse-Effect | EntitySodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite Entityincreasing Hb F levels. |
| 1.0000 | Adverse-Effect | Sodium phenylbutyrate was added to treatment with EntityHU in two patients, but failed to produce an Entityincrease in total Hb despite increasing Hb F levels. |
| 0.9998 | Adverse-Effect | EntitySodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an Entityincrease in total Hb despite increasing Hb F levels. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | INTERVENTIONS AND RESULTS : EntityCardiac complications were observed in five pediatric patients who received between 4. 6 and 40. 8 mg / kg / d of Entityamphotericin B . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the case of a nonatopic 17 - year - old girl with bronchial asthma and aspirin intolerance who developed a dramatic Entityanaphylactic reaction to oral Entityprednisone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with Entityheparin - induced Entitythrombocytopenia , especially in children. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal failure is a rare complication associated with the use of Entityrifampicin for the treatment of tuberculosis, usually occurring well into the course of therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Of the four patients who responded to EntityHU with an Entityincrease in total Hb , all reported symptomatic improvement and three have not required further transfusions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although moderate myelosuppression is not uncommonly seen in patients treated with Entitylenalidomide , Entityaplastic anemia has not previously been reported to be associated with this agent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The disease - modifying drugs he was taking, cyclosporin and Entitymethotrexate , were stopped, and the Entitylymphoma resolved spontaneously without the use of chemotherapy. |
| 0.9999 | Adverse-Effect | The disease - modifying drugs he was taking, Entitycyclosporin and methotrexate, were stopped, and the Entitylymphoma resolved spontaneously without the use of chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The results clearly demonstrate that EntityCPH82 was associated with suppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical Entityhypercortisolism . |
| Adverse-Effect | The results clearly demonstrate that EntityCPH82 was associated with Entitysuppression of the endogeneous production of ACTH and cortisol with a concomitant paradoxical picture of clinical hypercortisolism. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, peripheral neuropathy and Entitybone marrow depression led to Entitylinezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients. |
| 0.9999 | Adverse-Effect | However, Entityperipheral neuropathy and bone marrow depression led to Entitylinezolid withdrawal in seven patients, and neuropathy may not be fully reversible in all patients. |
| 0.9999 | Adverse-Effect | However, peripheral neuropathy and bone marrow depression led to Entitylinezolid withdrawal in seven patients, and Entityneuropathy may not be fully reversible in all patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDocetaxel induced EntityMeibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entitystroke after EntityPPA ingestion that occurred 4 months after the recall in an 8 - year - old boy on chronic peritoneal dialysis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors describe a case of combined lithium and Entityhaloperidol toxicity characterized by Entityhyperpyrexia , severe rigidity, mutism, and development of irreversible tardive dyskinesia. |
| 0.9999 | Adverse-Effect | The authors describe a case of combined lithium and Entityhaloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of Entityirreversible tardive dyskinesia . |
| 0.9999 | Adverse-Effect | The authors describe a case of combined lithium and Entityhaloperidol toxicity characterized by hyperpyrexia, severe rigidity, Entitymutism , and development of irreversible tardive dyskinesia. |
| 0.9998 | Adverse-Effect | The authors describe a case of combined lithium and Entityhaloperidol toxicity characterized by hyperpyrexia, Entitysevere rigidity , mutism, and development of irreversible tardive dyskinesia. |
| 0.9998 | Adverse-Effect | The authors describe a case of combined Entitylithium and haloperidol toxicity characterized by Entityhyperpyrexia , severe rigidity, mutism, and development of irreversible tardive dyskinesia. |
| 0.9997 | Adverse-Effect | The authors describe a case of combined Entitylithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, mutism, and development of Entityirreversible tardive dyskinesia . |
| 0.9996 | Adverse-Effect | The authors describe a case of combined Entitylithium and haloperidol toxicity characterized by hyperpyrexia, severe rigidity, Entitymutism , and development of irreversible tardive dyskinesia. |
| 0.9993 | Adverse-Effect | The authors describe a case of combined Entitylithium and haloperidol toxicity characterized by hyperpyrexia, Entitysevere rigidity , mutism, and development of irreversible tardive dyskinesia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a child with yolk sac tumor who developed Entitylocalized pigmentation after the first course of chemotherapy regimen that included Entitycisplatin , etoposide and bleomycin. |
| 1.0000 | Adverse-Effect | We report a child with yolk sac tumor who developed Entitylocalized pigmentation after the first course of chemotherapy regimen that included cisplatin, Entityetoposide and bleomycin. |
| 1.0000 | Adverse-Effect | We report a child with yolk sac tumor who developed Entitylocalized pigmentation after the first course of chemotherapy regimen that included cisplatin, etoposide and Entitybleomycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The site of thrombosis and the chronological relationship with the IIR implicates a Entityhypersensitivity to Entityinfliximab in the causation of the venous thrombosis in this case. |
| 0.9998 | Adverse-Effect | The site of thrombosis and the chronological relationship with the EntityIIR implicates a hypersensitivity to Entityinfliximab in the causation of the venous thrombosis in this case. |
| 0.9997 | Adverse-Effect | The site of thrombosis and the chronological relationship with the IIR implicates a hypersensitivity to Entityinfliximab in the causation of the Entityvenous thrombosis in this case. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The authors describe three families in whom the occurrence of EntityFVS in all the siblings strongly suggests hereditary susceptibility to Entityvalproic acid - induced adverse outcome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 60 - year - old woman who developed erythema and Entityerosions in the axilla and groin while on EntityPLD for breast cancer. |
| 1.0000 | Adverse-Effect | We report the case of a 60 - year - old woman who developed Entityerythema and erosions in the axilla and groin while on EntityPLD for breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 73 - year - old woman presented with fever and Entitycough 2 weeks after completing the third cycle of Entityfludarabine for chronic lymphocytic leukemia ( CLL ). |
| 1.0000 | Adverse-Effect | A 73 - year - old woman presented with Entityfever and cough 2 weeks after completing the third cycle of Entityfludarabine for chronic lymphocytic leukemia ( CLL ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We observed 3 diabetic patients with intolerable dizziness followed by nausea and Entityvomiting immediately after an initial administration of the alpha - glucosidase inhibitor, Entityvoglibose . |
| 1.0000 | Adverse-Effect | We observed 3 diabetic patients with intolerable dizziness followed by Entitynausea and vomiting immediately after an initial administration of the alpha - glucosidase inhibitor, Entityvoglibose . |
| 1.0000 | Adverse-Effect | We observed 3 diabetic patients with Entityintolerable dizziness followed by nausea and vomiting immediately after an initial administration of the alpha - glucosidase inhibitor, Entityvoglibose . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Despite minimal short - term side effects and apparent efficacy, chronic treatment of MG with EntityMM may be associated with increased risk of Entitylymphoproliferative disorders . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 62 - year - old Indian with diabetic nephropathy controlled with Entitymetformin , developed Entitymiliary tuberculosis for which he was treated with rifampicin, isoniazid and ethambutol. |
| 1.0000 | Adverse-Effect | A 62 - year - old Indian with diabetic nephropathy controlled with metformin, developed Entitymiliary tuberculosis for which he was treated with Entityrifampicin , isoniazid and ethambutol. |
| 0.9999 | Adverse-Effect | A 62 - year - old Indian with diabetic nephropathy controlled with metformin, developed Entitymiliary tuberculosis for which he was treated with rifampicin, Entityisoniazid and ethambutol. |
| 0.9999 | Adverse-Effect | A 62 - year - old Indian with diabetic nephropathy controlled with metformin, developed Entitymiliary tuberculosis for which he was treated with rifampicin, isoniazid and Entityethambutol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entityethylenediamine - induced Entitydelayed hypersensitivity reaction in a 46 - year - old woman who received parenteral aminophylline for an acute asthma exacerbation. |
| 1.0000 | Adverse-Effect | We present a case of ethylenediamine - induced Entitydelayed hypersensitivity reaction in a 46 - year - old woman who received parenteral Entityaminophylline for an acute asthma exacerbation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy developed an abnormal posture of extreme forward flexion, called Entitycamptocormia , during Entityvalproate monotherapy. |
| 0.9999 | Adverse-Effect | A mentally retarded 23 - year - old woman with myoclonic astatic epilepsy developed an Entityabnormal posture of extreme forward flexion , called camptocormia, during Entityvalproate monotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To the best of our knowledge, Entitycorneoscleral melting in the first postoperative week after a single intraoperative application of Entitymitomycin C has not been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To describe spectral - domain optical coherence tomography ( SD - OCT ) and adaptive optics ( AO ) imaging in Entityhydroxychloroquine Entityretinal toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient who received Entityclindamycin had liver biopsy findings of Entitymarked cholestasis , portal inflammation, bile duct injury and bile duct paucity ( ductopenia ). |
| 0.9999 | Adverse-Effect | One patient who received Entityclindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and bile duct paucity ( Entityductopenia ). |
| 0.9999 | Adverse-Effect | One patient who received Entityclindamycin had liver biopsy findings of marked cholestasis, portal inflammation, Entitybile duct injury and bile duct paucity ( ductopenia ). |
| 0.9999 | Adverse-Effect | One patient who received Entityclindamycin had liver biopsy findings of marked cholestasis, Entityportal inflammation , bile duct injury and bile duct paucity ( ductopenia ). |
| 0.9999 | Adverse-Effect | One patient who received Entityclindamycin had liver biopsy findings of marked cholestasis, portal inflammation, bile duct injury and Entitybile duct paucity ( ductopenia ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case in which Entitydipyridamole induced Entityhigh - grade atrioventricular ( AV ) block that responded promptly to intravenous aminophylline but not to atropine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of acute generalized exanthematous pustulosis ( EntityAGEP ) in a 50 - year - old woman that was attributed to the ingestion of Entitynimesulide . |
| 1.0000 | Adverse-Effect | We report a case of Entityacute generalized exanthematous pustulosis ( AGEP ) in a 50 - year - old woman that was attributed to the ingestion of Entitynimesulide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A girl with cystic fibrosis and cyclic neutropenia developed an Entityerythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with EntityG - CSF . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Life - threatening Entityanaphylactoid reaction to Entityamifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis : a case report with literature review. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To the best of our knowledge only two previous cases of EntityAML have been linked to treatment of HCL with purine analogs, both with Entity2 - chlorodeoxyadenosine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of Entitytamoxifen associated with Entityendometrial carcinoma and endometriosis. |
| 0.9992 | Adverse-Effect | The possible effects of tamoxifen upon the uterus are discussed in this article, in view of reports of Entitytamoxifen associated with endometrial carcinoma and Entityendometriosis . |
| 0.9938 | Adverse-Effect | The possible effects of Entitytamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with Entityendometrial carcinoma and endometriosis. |
| 0.9914 | Adverse-Effect | The possible effects of Entitytamoxifen upon the uterus are discussed in this article, in view of reports of tamoxifen associated with endometrial carcinoma and Entityendometriosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is suggested that the patient had Entitysulfasalazine - induced Entitylupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms. |
| 0.9999 | Adverse-Effect | It is suggested that the patient had Entitysulfasalazine - induced lupus, which manifested with Entityserositis and pulmonary parenchymal involvement in the absence of joint symptoms. |
| 0.9999 | Adverse-Effect | It is suggested that the patient had Entitysulfasalazine - induced lupus, which manifested with serositis and Entitypulmonary parenchymal involvement in the absence of joint symptoms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report a case of a patient who received Entityalteplase for acute myocardial infarction and developed spontaneous Entitysubfascial hematoma without any evidence of direct trauma. |
| 1.0000 | Adverse-Effect | The authors report a case of a patient who received Entityalteplase for acute myocardial infarction and developed Entityspontaneous subfascial hematoma without any evidence of direct trauma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report five cases of restless legs syndrome ( RLS ) and periodic limb movements during sleep ( EntityPLMS ) that were probably associated with Entityolanzapine . |
| 1.0000 | Adverse-Effect | We report five cases of Entityrestless legs syndrome ( RLS ) and periodic limb movements during sleep ( PLMS ) that were probably associated with Entityolanzapine . |
| 1.0000 | Adverse-Effect | We report five cases of restless legs syndrome ( RLS ) and Entityperiodic limb movements during sleep ( PLMS ) that were probably associated with Entityolanzapine . |
| 1.0000 | Adverse-Effect | We report five cases of restless legs syndrome ( EntityRLS ) and periodic limb movements during sleep ( PLMS ) that were probably associated with Entityolanzapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The successful development and implementation of this protocol will have impact on patients who have Entityanaphylactic reactions to EntityMTX but require this medication for specific diseases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Rapid identification of Entityspeech loss linked to EntityFK506 may be important because reduction or cessation of the drug may be associated with reverse of speech loss. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOcular hypertension occurred 1 month after the second Entityranibizumab injection in patients 1 and 3, and 1 month after the first ranibizumab in patient 2. |
| 0.9919 | Adverse-Effect | EntityOcular hypertension occurred 1 month after the second ranibizumab injection in patients 1 and 3, and 1 month after the first Entityranibizumab in patient 2. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBSERVATIONS : We observed Entityaggravation and spreading of a psoriatic plaque when treated topically with the toll - like receptor ( TLR ) 7 agonist Entityimiquimod . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 59 - year - old woman with myasthenia gravis who received a large dose of Entitypyridostigmine bromide developed Entitypostoperative psychosis and was diagnosed as having bromide intoxication. |
| 0.9980 | Adverse-Effect | A 59 - year - old woman with myasthenia gravis who received a large dose of Entitypyridostigmine bromide developed postoperative psychosis and was diagnosed as having Entitybromide intoxication . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : EntityHydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with Entitymucocutaneous adverse events and nail hyperpigmentation. |
| 0.9999 | Adverse-Effect | BACKGROUND : EntityHydroxyurea is a cytostatic agent used to treat myeloproliferative disorders and long - term treatment is associated with mucocutaneous adverse events and Entitynail hyperpigmentation . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Due to the increasing use of EntityTMP - SMX in children, clinicians should be aware of this potentially life - threatening, Entityimmunemediated hypersensitivity reaction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitygeneralized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing Entitybromocil , diuron and aminotriazole. |
| 0.9998 | Adverse-Effect | We report a case of Entitygeneralized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, diuron and Entityaminotriazole . |
| 0.9998 | Adverse-Effect | We report a case of Entitygeneralized cutaneous sclerosis associated with muscle and oesophageal involvement in a patient exposed to herbicides containing bromocil, Entitydiuron and aminotriazole. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These findings suggest that the Entitycorneal and retinal changes are the result of a toxic effect of Entitytamoxifen when used in the doses and duration described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a premature infant who developed Entityseizures associated with intraventricular administration of Entitynafcillin and discuss the need for electroencephalographic monitoring of patients receiving intraventricular antibiotics. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the successful treatment of Entityheparin - induced Entitythrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2 - year - old child with Danaparoid ( orgaran ). |
| 0.9999 | Adverse-Effect | We report the successful treatment of Entityheparin - induced thrombocytopenia and subsequent Entityhemorrhagic complications postoperatively in a 2 - year - old child with Danaparoid ( orgaran ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This patient, who had a history of osteoarthritis, had severe Entityhepatitis 5 weeks after being started on Entitydiclofenac for increasing pain in the joints. |
| 1.0000 | Adverse-Effect | This patient, who had a history of osteoarthritis, had Entitysevere hepatitis 5 weeks after being started on Entitydiclofenac for increasing pain in the joints. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : The main adverse effects of Entityleflunomide consist of Entitydiarrhea , nausea, liver enzyme elevation, hypertension, alopecia, and allergic skin reactions. |
| 1.0000 | Adverse-Effect | DISCUSSION : The main adverse effects of Entityleflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, Entityalopecia , and allergic skin reactions. |
| 1.0000 | Adverse-Effect | DISCUSSION : The main adverse effects of Entityleflunomide consist of diarrhea, Entitynausea , liver enzyme elevation, hypertension, alopecia, and allergic skin reactions. |
| 1.0000 | Adverse-Effect | DISCUSSION : The main adverse effects of Entityleflunomide consist of diarrhea, nausea, liver enzyme elevation, Entityhypertension , alopecia, and allergic skin reactions. |
| 1.0000 | Adverse-Effect | DISCUSSION : The main adverse effects of Entityleflunomide consist of diarrhea, nausea, liver enzyme elevation, hypertension, alopecia, and Entityallergic skin reactions . |
| 1.0000 | Adverse-Effect | DISCUSSION : The main adverse effects of Entityleflunomide consist of diarrhea, nausea, Entityliver enzyme elevation , hypertension, alopecia, and allergic skin reactions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case supports the view that in Entitygold - induced Entitypneumonitis a prolonged treatment with corticosteroids may be necessary, as lung function continued to improve. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : A patient who developed dramatic, permanent Entityvision loss after a 9 - month course of treatment with Entityethambutol and isoniazid for pulmonary tuberculosis is presented. |
| 1.0000 | Adverse-Effect | METHODS : A patient who developed dramatic, permanent Entityvision loss after a 9 - month course of treatment with ethambutol and Entityisoniazid for pulmonary tuberculosis is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The occurrence of symptoms that could be ascribed to an Entityacute coronary syndrome should always be taken seriously during the first Entityrituximab infusion and investigated aggressively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There have been many reports of probable Entitylithium - induced Entityorganic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range. |
| 0.9991 | Adverse-Effect | There have been many reports of probable lithium - induced Entityorganic brain syndromes occurring when serum Entitylithium levels are within or close to the therapeutic range. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case demonstrates that Entityhypersensitivity reaction to Entitypranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered. |
| 0.9999 | Adverse-Effect | The case demonstrates that hypersensitivity reaction to Entitypranlukast and resultant EntityATIN is possible, and that periodic urine testing in patients receiving pranlukast should be considered. |
| 0.9980 | Adverse-Effect | The case demonstrates that hypersensitivity reaction to pranlukast and resultant EntityATIN is possible, and that periodic urine testing in patients receiving Entitypranlukast should be considered. |
| 0.9825 | Adverse-Effect | The case demonstrates that Entityhypersensitivity reaction to pranlukast and resultant ATIN is possible, and that periodic urine testing in patients receiving Entitypranlukast should be considered. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After 1 week of Entitynefazodone therapy the patient experienced Entityheadache , confusion, and " gray areas " in her vision, without abnormal ophthalmologic findings. |
| 1.0000 | Adverse-Effect | After 1 week of Entitynefazodone therapy the patient experienced headache, Entityconfusion , and " gray areas " in her vision, without abnormal ophthalmologic findings. |
| 0.9999 | Adverse-Effect | After 1 week of Entitynefazodone therapy the patient experienced headache, confusion, and " Entitygray areas " in her vision, without abnormal ophthalmologic findings. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The diagnosis was supported by the temporal course of Entityrenal deterioration during exposure to Entitycefuroxime and improvement on its discontinuation ; the pattern repeated with rechallenge. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although interferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of Entitysarcoidosis associated with Entityinterferon alpha therapy have been reported. |
| 0.9507 | Adverse-Effect | Although Entityinterferon gamma has been implicated in the pathogenesis of sarcoidosis, only a few cases of Entitysarcoidosis associated with interferon alpha therapy have been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Anti - tuberculous drugs had been stopped on the 2nd day of therapy due to development of Entityoptic neuritis secondary to Entityethambutol administration at another hospital. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case is presented of a patient who experienced Entitybenzodiazepine withdrawal symptoms on discontinuation of Entitynefazodone , an antidepressant that inhibits the cytochrome P450 3A4 isoenzyme. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We reported 3 patients who developed acute generalized dystonia and Entityakinetic rigid syndrome following an initial therapy with Entityd - penicillamine 125 - 500 mg daily. |
| 0.9996 | Adverse-Effect | We reported 3 patients who developed Entityacute generalized dystonia and akinetic rigid syndrome following an initial therapy with Entityd - penicillamine 125 - 500 mg daily. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case presentation is of a patient who had the clinical appearance of epiglottitis, but actually had an Entityoro - pharyngeal dystonic reaction to Entityprochlorperazine . |
| 1.0000 | Adverse-Effect | This case presentation is of a patient who had the clinical appearance of Entityepiglottitis , but actually had an oro - pharyngeal dystonic reaction to Entityprochlorperazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Therapy with EntityIFN - alpha may be associated with a number of Entityneuropsychiatric symptoms , such as Parkinsonism, akathisia, seizure, and depressive disorders. |
| 0.9997 | Adverse-Effect | Therapy with EntityIFN - alpha may be associated with a number of neuropsychiatric symptoms, such as EntityParkinsonism , akathisia, seizure, and depressive disorders. |
| 0.9997 | Adverse-Effect | Therapy with EntityIFN - alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, seizure, and Entitydepressive disorders . |
| 0.9997 | Adverse-Effect | Therapy with EntityIFN - alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, Entityakathisia , seizure, and depressive disorders. |
| 0.9997 | Adverse-Effect | Therapy with EntityIFN - alpha may be associated with a number of neuropsychiatric symptoms, such as Parkinsonism, akathisia, Entityseizure , and depressive disorders. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9982 | Adverse-Effect | CONCLUSIONS : Low dosages of Entityquinacrine used for malaria prophylaxis can be associated with a delayed, Entitysevere maculopathy indistinguishable from chloroquine maculopathy in certain patients. |
| 0.9964 | Adverse-Effect | CONCLUSIONS : Low dosages of Entityquinacrine used for malaria prophylaxis can be associated with a delayed, severe Entitymaculopathy indistinguishable from chloroquine maculopathy in certain patients. |
| Adverse-Effect | CONCLUSIONS : Low dosages of quinacrine used for malaria prophylaxis can be associated with a delayed, severe maculopathy indistinguishable from Entitychloroquine Entitymaculopathy in certain patients. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, a recent post - marketing survey in Japan revealed that Entityinterstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with Entitysorafenib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three patients received respectively 190 mg, 175 mg, and 196 mg of Entitymethotrexate and developed Entitybilateral pulmonary infiltrates without evidence of peripheral blood eosinophilia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An infant who developed Entitypancreatitis during Entitymeglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported. |
| 0.9998 | Adverse-Effect | An infant who developed Entitypancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and Entityketoconazole is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Normalization of generalized retinal function and progression of maculopathy after cessation of therapy in a case of severe Entityhydroxychloroquine Entityretinopathy with 19 years follow - up. |
| 1.0000 | Adverse-Effect | Normalization of generalized retinal function and Entityprogression of maculopathy after cessation of therapy in a case of severe Entityhydroxychloroquine retinopathy with 19 years follow - up. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, as illustrated by these and other cases reported to date, the onset of Entitytroglitazone - induced Entityliver injury is insidious and temporally variable. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 55 - year - old woman presented an episode of acute urticaria and Entitylabial angioedema 60 minutes after ingesting 500 mg of Entitycloxacillin for a skin abscess. |
| 0.9999 | Adverse-Effect | A 55 - year - old woman presented an episode of Entityacute urticaria and labial angioedema 60 minutes after ingesting 500 mg of Entitycloxacillin for a skin abscess. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These features have not previously been reported as side effects of glibenclamide therapy, but Entityintrahepatic cholestasis may occur with Entitychlorpropamide , a similar sulphonylurea agent. |
| 0.9997 | Adverse-Effect | These features have not previously been reported as side effects of Entityglibenclamide therapy, but Entityintrahepatic cholestasis may occur with chlorpropamide, a similar sulphonylurea agent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The relation between tacrolimus treatment and staining was suggested by the appearance of Entitypigmentation during topical Entitytacrolimus treatment and its clinical disappearance when treatment was stopped. |
| 0.9994 | Adverse-Effect | The relation between Entitytacrolimus treatment and staining was suggested by the appearance of Entitypigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityhypercalcemia responded to discontinuation of EntityrhGH and a single dose of intravenous pamidronate disodium and has not recurred in 8 months of follow - up. |
| 0.9998 | Adverse-Effect | The Entityhypercalcemia responded to discontinuation of rhGH and a single dose of intravenous Entitypamidronate disodium and has not recurred in 8 months of follow - up. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We document the abrupt development of an extensive Entitychoroidal detachment after initiation of Entitydorzolamide therapy in a surgically untreated eye with primary open - angle glaucoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with the antiphospholipid syndrome who had Entityskin necrosis develop from Entitylow - molecular weight heparin therapy at sites distant from injection sites. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Since this amount of FAB was insufficient to bind all DGTX present in the serum, Entitycardiac DGTX toxicity EntityDGTX toxicity ( total AV - block ) persisted. |
| 0.9990 | Adverse-Effect | Since this amount of FAB was insufficient to bind all DGTX present in the serum, cardiac EntityDGTX toxicity ( Entitytotal AV - block ) persisted. |
| 0.9990 | Adverse-Effect | Since this amount of FAB was insufficient to bind Entityall DGTX present in the serum, Entitycardiac DGTX toxicity ( total AV - block ) persisted. |
| 0.9983 | Adverse-Effect | Since this amount of FAB was insufficient to bind Entityall DGTX present in the serum, cardiac DGTX toxicity ( Entitytotal AV - block ) persisted. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | We report four patients, three of whom first developed Entitypsoriasis and one who had an aggravation of the condition during treatment with Entityinterferon - alpha . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three months following splenectomy, Entitymultiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the EntityCHOP regimen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The possible development of a drug - induced vasculitis or Entitylupus - like syndrome should be added to the list of rare toxic effects of Entityvancomycin . |
| 0.9999 | Adverse-Effect | The possible development of a drug - induced Entityvasculitis or lupus - like syndrome should be added to the list of rare toxic effects of Entityvancomycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : In these 3 cases, the unique positive ocular finding was Entitycorneal endothelial deposits , which may be related to the use of Entityrifabutin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityExacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics Entityactinomycin - D ( NSC - 3053 ) and mithramycin ( NSC - 24559 ). |
| 0.9999 | Adverse-Effect | EntityExacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin - D ( NSC - 3053 ) and Entitymithramycin ( NSC - 24559 ). |
| 0.9999 | Adverse-Effect | EntityExacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin - D ( EntityNSC - 3053 ) and mithramycin ( NSC - 24559 ). |
| 0.9999 | Adverse-Effect | EntityExacerbations of the heart failure were temporally related to the administration of the antitumor antibiotics actinomycin - D ( NSC - 3053 ) and mithramycin ( EntityNSC - 24559 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A female patient with HER2 positive, metastatic breast cancer presented with pulmonary infiltrates, and a Entityplural effusion dyspnoea after several months of Entitytrastuzumab treatment. |
| 0.9999 | Adverse-Effect | A female patient with HER2 positive, metastatic breast cancer presented with Entitypulmonary infiltrates , and a plural effusion dyspnoea after several months of Entitytrastuzumab treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMorphine , an opium alkaloid, frequently causes side effects such as Entityhyperhidrosis and facial flushing, but serious cutaneous adverse drug reactions are seldom observed. |
| 0.9999 | Adverse-Effect | EntityMorphine , an opium alkaloid, frequently causes side effects such as hyperhidrosis and Entityfacial flushing , but serious cutaneous adverse drug reactions are seldom observed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | CONCLUSIONS : EntitySpontaneous hemothorax is a rare phenomenon in conjunction with EntityLMWH but should be considered in cases of acute respiratory distress following commencement of LMWH. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : Spontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of Entityacute respiratory distress following commencement of EntityLMWH . |
| 0.9985 | Adverse-Effect | CONCLUSIONS : Spontaneous hemothorax is a rare phenomenon in conjunction with EntityLMWH but should be considered in cases of Entityacute respiratory distress following commencement of LMWH. |
| 0.9964 | Adverse-Effect | CONCLUSIONS : EntitySpontaneous hemothorax is a rare phenomenon in conjunction with LMWH but should be considered in cases of acute respiratory distress following commencement of EntityLMWH . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient suffering from Entityheparin - associated Entitythrombocytopenia ( HAT ), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described. |
| 1.0000 | Adverse-Effect | A patient suffering from heparin - associated thrombocytopenia ( HAT ), recurrent arteriothromboses, and Entityacute renal failure after treatment with standard Entityheparin is described. |
| 0.9999 | Adverse-Effect | A patient suffering from heparin - associated thrombocytopenia ( HAT ), Entityrecurrent arteriothromboses , and acute renal failure after treatment with standard Entityheparin is described. |
| 0.9999 | Adverse-Effect | A patient suffering from Entityheparin - associated thrombocytopenia ( HAT ), Entityrecurrent arteriothromboses , and acute renal failure after treatment with standard heparin is described. |
| 0.9999 | Adverse-Effect | A patient suffering from Entityheparin - associated thrombocytopenia ( EntityHAT ), recurrent arteriothromboses, and acute renal failure after treatment with standard heparin is described. |
| 0.9999 | Adverse-Effect | A patient suffering from heparin - associated thrombocytopenia ( EntityHAT ), recurrent arteriothromboses, and acute renal failure after treatment with standard Entityheparin is described. |
| 0.9999 | Adverse-Effect | A patient suffering from Entityheparin - associated thrombocytopenia ( HAT ), recurrent arteriothromboses, and Entityacute renal failure after treatment with standard heparin is described. |
| 0.9998 | Adverse-Effect | A patient suffering from heparin - associated Entitythrombocytopenia ( HAT ), recurrent arteriothromboses, and acute renal failure after treatment with standard Entityheparin is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | AIMS : To present a case of Entitypiloerection after replacing Entityfluvoxamine maleate with milnacipran hydrochloride, and to analyse this effect based on receptor occupancy theory. |
| 0.9998 | Adverse-Effect | AIMS : To present a case of Entitypiloerection after replacing fluvoxamine maleate with Entitymilnacipran hydrochloride , and to analyse this effect based on receptor occupancy theory. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | PURPOSE : To determine the cause of Entityspontaneous choroidal hemorrhage in a 67 - year - old man after a myocardial infarction and administration of Entitytissue plasminogen activator . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In one instance a systemic hypoglycemic reaction resulting in head trauma and Entityconfusion ended in an emegency hospital admission following the substitution of Entityacetohexamide for acetazolamide. |
| 0.9999 | Adverse-Effect | In one instance a Entitysystemic hypoglycemic reaction resulting in head trauma and confusion ended in an emegency hospital admission following the substitution of Entityacetohexamide for acetazolamide. |
| 0.9999 | Adverse-Effect | In one instance a systemic hypoglycemic reaction resulting in Entityhead trauma and confusion ended in an emegency hospital admission following the substitution of Entityacetohexamide for acetazolamide. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityItraconazole - induced Entityliver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : EntityItraconazole - induced liver injury presents with a Entitycholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : EntityItraconazole - induced liver injury presents with a cholestatic pattern of injury with Entitydamage to the interlobular bile ducts , possibly leading to ductopenia. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : EntityItraconazole - induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to Entityductopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report four cases of encephalopathy coincident with elevated aluminum levels as well as one patient who developed Entityseizures while receiving continuous bladder irrigations with Entityalum . |
| 0.9990 | Adverse-Effect | We report four cases of Entityencephalopathy coincident with elevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with Entityalum . |
| 0.9990 | Adverse-Effect | We report four cases of encephalopathy coincident with Entityelevated aluminum levels as well as one patient who developed seizures while receiving continuous bladder irrigations with Entityalum . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and Entitythiazide , respectively, resulting in Entityhypercalciuria and hypercalcemia. |
| 0.9999 | Adverse-Effect | We experienced a male patient with psoriasis and hypertension whose conditions were treated with Entitytacalcitol ointment and thiazide, respectively, resulting in Entityhypercalciuria and hypercalcemia. |
| 0.9998 | Adverse-Effect | We experienced a male patient with psoriasis and hypertension whose conditions were treated with Entitytacalcitol ointment and thiazide, respectively, resulting in hypercalciuria and Entityhypercalcemia . |
| 0.9992 | Adverse-Effect | We experienced a male patient with psoriasis and hypertension whose conditions were treated with tacalcitol ointment and Entitythiazide , respectively, resulting in hypercalciuria and Entityhypercalcemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent Entitychanges in serotonergic or noradrenergic neurotransmission caused by EntityIFN - alpha . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | As Entitylinezolid has been shown to have Entityhematologic side effects , blood count monitoring is recommended in patients receiving this drug for long - term therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients with extrinsic asthma and coexistent insulin - dependent diabetes mellitus sustained an Entityanaphylactoid reaction after the intravenous administration of 50 % solution of Entitydextrose . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient is described who developed a rapid onset of Entitypulmonary fibrosis following treatment with a new non - steroidal anti - inflammatory drug, Entitynabumetone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although its side effects are few, Entitytamoxifen increases the incidence of Entityproliferative lesions of the endometrium , which theoretically should be preventable with progestational agents. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In four patients, thrombosis occurred 2 - 45 days after severe hepatic veno - occlusive disease ( EntityHVOD ) secondary to intensive chemotherapy containing Entitybusulfan . |
| 1.0000 | Adverse-Effect | In four patients, Entitythrombosis occurred 2 - 45 days after severe hepatic veno - occlusive disease ( HVOD ) secondary to intensive chemotherapy containing Entitybusulfan . |
| 1.0000 | Adverse-Effect | In four patients, thrombosis occurred 2 - 45 days after severe Entityhepatic veno - occlusive disease ( HVOD ) secondary to intensive chemotherapy containing Entitybusulfan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | CONCLUSIONS : Although Entitybudesonide may be beneficial because of its anti - inflammatory effects, clinicians should be alert to its potential for causing Entitycontact dermatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient was found to have Entityno motile sperm with a normal sperm count, while taking a dose of 400 mg / day of Entitycarbamazepine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing Entitybusulfan and to be associated with HVOD. |
| 0.9999 | Adverse-Effect | PVT during chemotherapy in children is a rare event and appears to be closely related to intensive chemotherapy containing Entitybusulfan and to be associated with EntityHVOD . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The development of cutaneous ecchymosis associated with a Entitysudden fall in hemoglobin after the administration of Entityalteplase should strongly suggest the possibility of diffuse subfascial hematoma. |
| 0.9998 | Adverse-Effect | The development of Entitycutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of Entityalteplase should strongly suggest the possibility of diffuse subfascial hematoma. |
| 0.9998 | Adverse-Effect | The development of cutaneous ecchymosis associated with a sudden fall in hemoglobin after the administration of Entityalteplase should strongly suggest the possibility of Entitydiffuse subfascial hematoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : A 52 - year - old woman with Parkinson disease who had taken Entityamantadine for 6 years had Entitybilateral corneal edema for 2 months at baseline. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A few recent individual case reports have suggested that a Entitymyasthenic syndrome may be associated with Entitystatin treatment, but this association is not well described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityamiodarone - induced Entitythyrotoxicosis of protracted duration, unresponsive to conventional thionamide therapy, with therapy limited by severe adverse drug reactions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We hypothesize that decreased renal elimination of EntityMTX induced by the COX - 2 inhibitor resulted in enhanced Entityhematopoietic toxicity and immunosuppression causing the EBV - associated lymphoproliferative disease. |
| 0.9992 | Adverse-Effect | We hypothesize that decreased renal elimination of EntityMTX induced by the COX - 2 inhibitor resulted in enhanced hematopoietic toxicity and Entityimmunosuppression causing the EBV - associated lymphoproliferative disease. |
| 0.9992 | Adverse-Effect | We hypothesize that decreased renal elimination of EntityMTX induced by the COX - 2 inhibitor resulted in enhanced hematopoietic toxicity and immunosuppression causing the EntityEBV - associated lymphoproliferative disease . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMTX - induced Entityhepatic injury and liver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. |
| 0.9999 | Adverse-Effect | EntityMTX - induced hepatic injury and Entityliver enzyme elevations have been demonstrated after treatment of leukemia, gestational disease and during treatment of psoriasis and rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We herein described an additional patient with BCR - ABL ( ela2 ) positive acute lymphoblastic leukemia who developed Entitytumor lysis syndrome after 10 - day treatment with Entityimatinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and Entitycalcitriol resulting in two admissions to the hospital for Entitymilk - alkali syndrome . |
| 0.9997 | Adverse-Effect | This article presents a patient with hypoparathyroidism who was treated with Entitycalcium carbonate and calcitriol resulting in two admissions to the hospital for Entitymilk - alkali syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Management of hypophosphatemia induced by high - flux hemodiafiltration for the treatment of Entityvancomycin Entityvancomycin toxicity : intravenous phosphorus therapy versus use of a phosphorus - enriched dialysate. |
| 0.9989 | Adverse-Effect | Management of Entityhypophosphatemia induced by high - flux hemodiafiltration for the treatment of Entityvancomycin toxicity : intravenous phosphorus therapy versus use of a phosphorus - enriched dialysate. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although this combination agent has been associated with a hypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of EntityTMP - SMX - induced Entityhepatotoxicity are rare. |
| 0.9674 | Adverse-Effect | Although this combination agent has been associated with a hypersensitivity syndrome involving Entitycutaneous skin eruptions , pediatric cases of EntityTMP - SMX - induced hepatotoxicity are rare. |
| 0.9475 | Adverse-Effect | Although this combination agent has been associated with a Entityhypersensitivity syndrome involving cutaneous skin eruptions, pediatric cases of EntityTMP - SMX - induced hepatotoxicity are rare. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The addition of intrathecal Entitymethotrexate to treatment protocols has increased survival rates in children with acute lymphoblastic leukemia but is also associated with varying degrees of Entityneurotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A teenage girl with crescentic glomerulonephritis had Entityantineutrophil cytoplasmic antibody ( ANCA ) detected after she had received Entitypropylthiouracil ( PTU ) for hyperthyroidism without cutaneous vasculitis. |
| 1.0000 | Adverse-Effect | A teenage girl with crescentic glomerulonephritis had Entityantineutrophil cytoplasmic antibody ( ANCA ) detected after she had received propylthiouracil ( EntityPTU ) for hyperthyroidism without cutaneous vasculitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for Entityintracranial bleeding while receiving Entityaspirin and clopidogrel. |
| 1.0000 | Adverse-Effect | A 64 year old woman with previous history of coronary stenting five days before was admitted in our institution for Entityintracranial bleeding while receiving aspirin and Entityclopidogrel . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9985 | Adverse-Effect | OBJECTIVE : To study therapy with indapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of Entitydiabetes induced by Entityindapamide . |
| 0.6736 | Adverse-Effect | OBJECTIVE : To study therapy with Entityindapamide impairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of Entitydiabetes induced by indapamide. |
| 0.9466 | Adverse-Effect | OBJECTIVE : To study therapy with indapamide impairing Entitycarbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of Entitydiabetes induced by indapamide. |
| Adverse-Effect | OBJECTIVE : To study therapy with Entityindapamide Entityimpairing carbohydrate metabolism in essential hypertension patients and achieve earlier prevention, diagnoses and treatment of diabetes induced by indapamide. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | Coadministration of antidepressant agents such as nefazodone, or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to Entityinterfere with tacrolimus metabolism Entitytacrolimus metabolism. |
| 0.9984 | Adverse-Effect | Coadministration of antidepressant agents such as Entitynefazodone , or any other drug that inhibits the CYP3A4 isoenzyme subfamily, should be anticipated to Entityinterfere with tacrolimus metabolism . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and Entityhyperandrogenism seem to be common among women treated with Entitysodium valproate for epilepsy. |
| 0.9998 | Adverse-Effect | BACKGROUND : Reproductive endocrine disorders characterized by Entitymenstrual disorders , polycystic ovaries, and hyperandrogenism seem to be common among women treated with Entitysodium valproate for epilepsy. |
| 0.9998 | Adverse-Effect | BACKGROUND : Reproductive endocrine disorders characterized by menstrual disorders, Entitypolycystic ovaries , and hyperandrogenism seem to be common among women treated with Entitysodium valproate for epilepsy. |
| 0.9998 | Adverse-Effect | BACKGROUND : EntityReproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with Entitysodium valproate for epilepsy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 52 - year - old, white female developed low - grade fever, cough, and Entitydyspnea after 8 weeks treatment with Entitysodium aurothiomalate for rheumatoid arthritis. |
| 0.9998 | Adverse-Effect | A 52 - year - old, white female developed low - grade fever, Entitycough , and dyspnea after 8 weeks treatment with Entitysodium aurothiomalate for rheumatoid arthritis. |
| 0.9998 | Adverse-Effect | A 52 - year - old, white female developed Entitylow - grade fever , cough, and dyspnea after 8 weeks treatment with Entitysodium aurothiomalate for rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a 60 - year - old woman affected by squamous lung carcinoma, who developed Entityparoxysmal supraventricular tachycardia during Entitycisplatin and etoposide combination chemotherapy. |
| 0.9999 | Adverse-Effect | We report a case of a 60 - year - old woman affected by squamous lung carcinoma, who developed Entityparoxysmal supraventricular tachycardia during cisplatin and Entityetoposide combination chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient experienced hallucinations, agitation, vomiting, tachycardia and Entityseizures after ingestion of 1050 ( 48 mg / kg ) of extended - release Entitybupropion . |
| 1.0000 | Adverse-Effect | The patient experienced hallucinations, agitation, vomiting, Entitytachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release Entitybupropion . |
| 1.0000 | Adverse-Effect | The patient experienced Entityhallucinations , agitation, vomiting, tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release Entitybupropion . |
| 1.0000 | Adverse-Effect | The patient experienced hallucinations, agitation, Entityvomiting , tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release Entitybupropion . |
| 1.0000 | Adverse-Effect | The patient experienced hallucinations, Entityagitation , vomiting, tachycardia and seizures after ingestion of 1050 ( 48 mg / kg ) of extended - release Entitybupropion . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors describe Entityvalproate - induced Entityhyperammonemia and mental status changes in an 88 - year - old man, the first known reported case in an elderly patient. |
| 0.9998 | Adverse-Effect | The authors describe Entityvalproate - induced hyperammonemia and Entitymental status changes in an 88 - year - old man, the first known reported case in an elderly patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : No published clinical studies in patients receiving Entityclindamycin vaginal cream for bacterial vaginosis have documented C. difficile toxin in stool samples of patients with Entitydiarrhea . |
| 1.0000 | Adverse-Effect | DISCUSSION : No published clinical studies in patients receiving Entityclindamycin vaginal cream for bacterial vaginosis have documented EntityC. difficile toxin in stool samples of patients with diarrhea. |
| Adverse-Effect | DISCUSSION : No published clinical studies in patients receiving Entityclindamycin vaginal cream for bacterial vaginosis have documented EntityC. difficile toxin in stool samples of patients with diarrhea. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When Entitythrombosis develops during Entityheparin treatment, it is important to suspect HITTs and to assay for the associated antibodies, regardless of the actual platelet count. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with Wegener's granulomatosis rapidly developed a Entitycircumferential subglottic stenosis while on a Entitycyclophosphamide regimen that had caused resolution of systemic symptoms and pulmonary infiltrates. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In each of the three reported patients, alteration of eyelid appearance with Entitydeepening of the lid sulcus was evident as the result of topical Entitybimatoprost therapy. |
| 1.0000 | Adverse-Effect | In each of the three reported patients, Entityalteration of eyelid appearance with deepening of the lid sulcus was evident as the result of topical Entitybimatoprost therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To evaluate the efficacy of the administration of insulin by a jet - injector device in stopping and reversing severe Entityhuman insulin - induced Entitylipoatrophy . |
| 0.9979 | Adverse-Effect | OBJECTIVE : To evaluate the efficacy of the administration of Entityinsulin by a jet - injector device in stopping and reversing severe human insulin - induced Entitylipoatrophy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors intend to carry out a case - control study on patients treated with Entitytamoxifen for breast carcinoma to reveal the possible presence of Entityendometrial carcinoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Therefore, clinicians should pay close attention to possible onset of EntityRD in patients with multiple risk factors for TD, even when EntitySDA therapy is used. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Children with acute lymphoblastic leukemia ( ALL ), treated with EntityL - asparaginase are at risk for Entitycerebral thrombosis or hemorrhage because of coagulation protein deficiencies. |
| 0.9998 | Adverse-Effect | Children with acute lymphoblastic leukemia ( ALL ), treated with EntityL - asparaginase are at risk for cerebral thrombosis or Entityhemorrhage because of coagulation protein deficiencies. |
| 0.9994 | Adverse-Effect | Children with acute lymphoblastic leukemia ( ALL ), treated with EntityL - asparaginase are at risk for cerebral thrombosis or hemorrhage because of Entitycoagulation protein deficiencies . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a patient with chronic lymphocytic leukemia ( CLL ) who developed fatal intravascular autoimmune hemolytic anemia ( EntityAIHA ) after Entityfludarabine treatment. |
| 1.0000 | Adverse-Effect | We report the case of a patient with chronic lymphocytic leukemia ( CLL ) who developed Entityfatal intravascular autoimmune hemolytic anemia ( AIHA ) after Entityfludarabine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two ELBW infants affected by hyperkalaemia, treated with EntityKayexalate , who developed serious Entityhypernatraemia , that has never been reported before in preterm infants. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : To the best of our knowledge, this is the first time Entitycolchicine Entitycolchicine intoxication in this age group has been described in the English literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Initial treatment with Entityheparin was substituted with thrombolysis, which resulted in clinical improvement and dissolution of right heart thrombus but was followed by Entityfatal intracerebral haemorrhage . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nine Entitydelirious patients suffering from Entitylithium intoxication were examined with the Mini - Mental State Exam ( MMS ) to describe the clinical course of the disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with Methotrexate ( EntityMTX ) and Entitymalignant lymphoma developing. |
| 0.9999 | Adverse-Effect | Recently, some studies have also reported association between patients with juvenile rheumatoid arthritis ( JRA ) treated with EntityMethotrexate ( MTX ) and Entitymalignant lymphoma developing. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | EntityRifampin ( RFP ) increases hepatic microsomal enzyme activity, and there are case reports of RFP - induced Entityhypothyroidism , all associated with Hashimoto's thyroiditis. |
| 0.9996 | Adverse-Effect | Rifampin ( EntityRFP ) increases hepatic microsomal enzyme activity, and there are case reports of RFP - induced Entityhypothyroidism , all associated with Hashimoto's thyroiditis. |
| 0.9995 | Adverse-Effect | EntityRifampin ( RFP ) increases hepatic microsomal enzyme activity, and there are case reports of RFP - induced hypothyroidism, all associated with EntityHashimoto's thyroiditis . |
| 0.9994 | Adverse-Effect | Rifampin ( EntityRFP ) increases hepatic microsomal enzyme activity, and there are case reports of RFP - induced hypothyroidism, all associated with EntityHashimoto's thyroiditis . |
| 1.0000 | Adverse-Effect | Rifampin ( RFP ) increases hepatic microsomal enzyme activity, and there are case reports of EntityRFP - induced Entityhypothyroidism , all associated with Hashimoto's thyroiditis. |
| 0.9993 | Adverse-Effect | Rifampin ( RFP ) increases hepatic microsomal enzyme activity, and there are case reports of EntityRFP - induced hypothyroidism, all associated with EntityHashimoto's thyroiditis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report the late development of Entityimmune - mediated diabetes mellitus after completion of Entityalfa - interferon therapy for hepatitis C in an Asian patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors describe a woman with chronic schizophrenia who experienced delirium, grand mal seizure, and Entityphotosensitivity after the addition of Entitypropranolol to her neuroleptic regimen. |
| 1.0000 | Adverse-Effect | The authors describe a woman with chronic schizophrenia who experienced Entitydelirium , grand mal seizure, and photosensitivity after the addition of Entitypropranolol to her neuroleptic regimen. |
| 0.9999 | Adverse-Effect | The authors describe a woman with chronic schizophrenia who experienced delirium, Entitygrand mal seizure , and photosensitivity after the addition of Entitypropranolol to her neuroleptic regimen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Seven patients with hematologic malignancies who were treated with Entitymiconazole for either suspected or proven fungal infections developed eight episodes of major adverse Entitycardiorespiratory and anaphylactic reactions . |
| 1.0000 | Adverse-Effect | Seven patients with hematologic malignancies who were treated with Entitymiconazole for either suspected or proven fungal infections developed eight episodes of major Entityadverse cardiorespiratory and anaphylactic reactions . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | k bipolar manic - depressive patient, developed while on Entitylithium prophylaxis, Entityakathisia at therapeutic serum lithium levels and subsequently bucco - linguo - masticatory dyskinesia. |
| 0.9985 | Adverse-Effect | k bipolar manic - depressive patient, developed while on Entitylithium prophylaxis, akathisia at therapeutic serum lithium levels and subsequently Entitybucco - linguo - masticatory dyskinesia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hydroxyurea ( HU ) and Entitysodium phenylbutyrate ( SPB ) have been shown to Entityincrease fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia. |
| 0.9999 | Adverse-Effect | EntityHydroxyurea ( HU ) and sodium phenylbutyrate ( SPB ) have been shown to Entityincrease fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia. |
| 0.9999 | Adverse-Effect | Hydroxyurea ( EntityHU ) and sodium phenylbutyrate ( SPB ) have been shown to Entityincrease fetal hemoglobin ( Hb F ) levels in patients with thalassemia intermedia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The second was an 82 - year - old man receiving Entityticlopidine for 2 years when, during a febrile episode, he was found Entityneutropenic with marrow aplasia. |
| 0.9999 | Adverse-Effect | The second was an 82 - year - old man receiving Entityticlopidine for 2 years when, during a febrile episode, he was found neutropenic with Entitymarrow aplasia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 73 - year - old woman with non - Hodgkin's lymphoma had two episodes of severe, bilateral, Entitysensori - neural hearing loss after Entityvincristine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal radiation myelopathy after high - dose Entitybusulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma : a review of the literature and implications for practice. |
| 1.0000 | Adverse-Effect | EntityFatal radiation myelopathy after high - dose busulfan and Entitymelphalan chemotherapy and radiotherapy for Ewing's sarcoma : a review of the literature and implications for practice. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 57 - year - old man developed chronic, Entitywatery diarrhea four weeks after Helicobacter pylori eradication therapy including Entitylansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. |
| 0.9997 | Adverse-Effect | A 57 - year - old man developed chronic, Entitywatery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by Entitylansoprazole monotherapy for gastroesophageal reflux disease. |
| Adverse-Effect | A 57 - year - old man developed Entitychronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including Entitylansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease. | |
| Adverse-Effect | A 57 - year - old man developed Entitychronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by Entitylansoprazole monotherapy for gastroesophageal reflux disease. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : EntityCyanamide , an aversive agent widely used in Japan, is known to induce various degrees of Entityhepatic lesion with ground - glass inclusion bodies . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : To assess the nature, incidence, and risk factors of Entityretinopathy associated with Entitypegylated interferon and ribavirin combination therapy in chronic hepatitis C patients. |
| 0.9997 | Adverse-Effect | BACKGROUND : To assess the nature, incidence, and risk factors of Entityretinopathy associated with pegylated interferon and Entityribavirin combination therapy in chronic hepatitis C patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These cases were chosen for study because they were all Entitydeaths as a result of suicidal ingestion of drugs in which Entityquetiapine was considered a significant factor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Exposure of the fetus to Entityindomethacin by administration of the drug to the mother may cause many side effects, including Entitypremature closure of the ductus arteriosus . |
| 1.0000 | Adverse-Effect | EntityExposure of the fetus to Entityindomethacin by administration of the drug to the mother may cause many side effects, including premature closure of the ductus arteriosus. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of Entityelevated serum triglyceride levels in Entityclozapine - treated patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitytoxic hepatitis caused by combination therapy with Entitymethotrexate and etretinate in the treatment of severe psoriasis is presented in a 47 - year - old woman. |
| 1.0000 | Adverse-Effect | A case of Entitytoxic hepatitis caused by combination therapy with methotrexate and Entityetretinate in the treatment of severe psoriasis is presented in a 47 - year - old woman. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of Entityrespiratory failure occurring in a woman at 16 weeks'gestation who was being treated with Entitynitrofurantoin for a urinary tract infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTiclopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with Entitysevere bone marrow suppression , typically aplastic anemia. |
| 1.0000 | Adverse-Effect | EntityTiclopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease and is rarely associated with severe bone marrow suppression, typically Entityaplastic anemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pellagra should be suspected whenever tuberculous patients under treatment with Entityisoniazid develop Entitymental, neurological or gastrointestinal symptoms , even in the absence of typical pellagra dermatitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Treatment with Entityinfliximab is known to produce an Entityincrease of autoantibodies ( antinuclear antibodies, anti - double - stranded DNA ), but not clinical disease. |
| 1.0000 | Adverse-Effect | Treatment with Entityinfliximab is known to produce an increase of autoantibodies ( Entityantinuclear antibodies , anti - double - stranded DNA ), but not clinical disease. |
| 1.0000 | Adverse-Effect | Treatment with Entityinfliximab is known to produce an increase of autoantibodies ( antinuclear antibodies, Entityanti - double - stranded DNA ), but not clinical disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 21 - year - old man with Tourette's syndrome, pedophilia, Asperger's syndrome, and multiple sclerosis experienced Entityseizures after receiving therapy with Entityinterferon beta - 1a . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of a 58 - year - old female patient with Graves'disease who developed EntityAA in the third exposure to Entitymethimazole ( MMI ). |
| 1.0000 | Adverse-Effect | We present a case of a 58 - year - old female patient with Graves'disease who developed EntityAA in the third exposure to methimazole ( EntityMMI ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityHypersensitivity to Entitycarboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving carboplatin therapy. |
| 0.9997 | Adverse-Effect | Hypersensitivity to Entitycarboplatin is a rare but real complication of therapy and should be considered in patients presenting with Entityhyperacute changes on ECG whilst receiving carboplatin therapy. |
| 1.0000 | Adverse-Effect | Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with Entityhyperacute changes on ECG whilst receiving Entitycarboplatin therapy. |
| 0.9999 | Adverse-Effect | Hypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute Entitychanges on ECG whilst receiving Entitycarboplatin therapy. |
| 0.9987 | Adverse-Effect | Hypersensitivity to Entitycarboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute Entitychanges on ECG whilst receiving carboplatin therapy. |
| 0.9577 | Adverse-Effect | EntityHypersensitivity to carboplatin is a rare but real complication of therapy and should be considered in patients presenting with hyperacute changes on ECG whilst receiving Entitycarboplatin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityARA - C is frequently associated with Entitydermatologic toxicity , but this is only the second case of toxic epidermal necrolysis described in connection with this drug. |
| 0.9985 | Adverse-Effect | EntityARA - C is frequently associated with dermatologic toxicity, but this is only the second case of Entitytoxic epidermal necrolysis described in connection with this drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After 5 days of treatment with EntityIL - 2 , the patient developed a Entityhemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia. |
| 0.9997 | Adverse-Effect | After 5 days of treatment with EntityIL - 2 , the patient developed a hemorrhagic lesion that progressed to Entitytoxic epidermal necrolysis , as well as grade 4 pancytopenia. |
| 0.9995 | Adverse-Effect | After 5 days of treatment with EntityIL - 2 , the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 Entitypancytopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | IV Entitypropranolol was used as the initial treatment for his hyperadrenergic state, resulting in a Entitydecrease in heart rate but a paroxsymal increase in blood pressure. |
| 1.0000 | Adverse-Effect | IV Entitypropranolol was used as the initial treatment for his hyperadrenergic state, resulting in a decrease in heart rate but a Entityparoxsymal increase in blood pressure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The currently available clinical and neuropharmacologic data suggest that Entitycarbamazepine may be an antagonist of dopamine and that this property is responsible for the production of Entitydystonia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | All developed Entitymucocutaneous side effects within 20 weeks of beginning i m Entitygold therapy, at a time when RA had improved markedly compared to pretreatment status. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present three patients with paradoxical Entityseizures ; their serum Entityphenytoin levels were 43. 5 mcg / mL, 46. 5 mcg / mL and 38. 3 mcg / mL. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of Entityclofazimine , showed Entitydiscoloration of nail plate , subungual hyperkeratosis and onycholysis. |
| 1.0000 | Adverse-Effect | Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of Entityclofazimine , showed discoloration of nail plate, Entitysubungual hyperkeratosis and onycholysis. |
| 0.9999 | Adverse-Effect | Two cases of lepromatous leprosy with erythema nodosum leprosum who were on high doses of Entityclofazimine , showed discoloration of nail plate, subungual hyperkeratosis and Entityonycholysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Patients receiving intravitreal injections of Entitybevacizumab should be evaluated for potential systemic risk factors such as Entitycarotid insufficiency , coagulopathy and poorly controlled diabetes mellitus. |
| 1.0000 | Adverse-Effect | CONCLUSIONS : Patients receiving intravitreal injections of Entitybevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, Entitycoagulopathy and poorly controlled diabetes mellitus. |
| 1.0000 | Adverse-Effect | CONCLUSIONS : Patients receiving intravitreal injections of Entitybevacizumab should be evaluated for potential systemic risk factors such as carotid insufficiency, coagulopathy and Entitypoorly controlled diabetes mellitus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 53 - year - old man developed Entitylower leg edema 4 weeks after Entityrosiglitazone was increased from 4 mg once / day to 4 mg twice / day. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 68 - year - old woman developed a dry, Entityirritating cough within one month of starting Entityquinapril therapy for the treatment of essential hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of Entityfluoxetine - induced Entityakathisia were identical, although somewhat milder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Shortly after chemotherapy and an injection of Entitypegfilgrastim , the patient developed poorly defined, Entityrapidly progressive erythema , edema, and pain in his right forearm. |
| 1.0000 | Adverse-Effect | Shortly after chemotherapy and an injection of Entitypegfilgrastim , the patient developed poorly defined, rapidly progressive erythema, edema, and Entitypain in his right forearm . |
| 1.0000 | Adverse-Effect | Shortly after chemotherapy and an injection of Entitypegfilgrastim , the patient developed poorly defined, rapidly progressive erythema, Entityedema , and pain in his right forearm. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : The results suggest that olanzapine may be useful in treating patients with Entityclozapine - induced Entitygranulocytopenia without the risk of recurrence of hematologic side effects. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : EntityGemcitabine - induced Entityrecall pneumonitis is a rarely reported phenomenon and should be taken into account even after extended time interval to the previous radiotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In one patient, treatment with EntityDCA was associated with a Entitydecrease in blood lactate levels from 11. 2 mM before treatment to 0. 8 mM 16 h later. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMitomycin - C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of Entityhemolytic uremic syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPancreatitis has been noted to be a complication in 2 - 16 % of patients undergoing treatment with EntityL - asparaginase for a variety of pediatric neoplasms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : EntityBrimonidine was observed to cause EntityIOP elevation , confirmed on rechallenge, scoring 8 ( strong probability ) on an adverse drug reaction probability score. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of EntityPRES in a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) with complete recovery after withdrawal of Entitycyclosporine ( CSA ). |
| 1.0000 | Adverse-Effect | We describe a case of EntityPRES in a patient with collapsing focal glomeruloesclerosis ( collapsing FGS ) with complete recovery after withdrawal of cyclosporine ( EntityCSA ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three of 50 patients treated with Entityisotretinoin ( 1 mg / kg / day ) for cystic acne complained of Entitypoor night vision and / or excessive glare sensitivity. |
| 1.0000 | Adverse-Effect | Three of 50 patients treated with Entityisotretinoin ( 1 mg / kg / day ) for cystic acne complained of poor night vision and / or Entityexcessive glare sensitivity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : A six - year - old boy with transfusion - dependent beta - thalassaemia developed a Entityunilateral hearing loss shortly after commencing Entitydesferrioxamine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE : A Entitymalignant mixed mesodermal tumor was diagnosed in a 64 - year - old woman with a bicornuate uterus while she was taking Entityraloxifene for osteoporosis prevention. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two cases that illustrate the use of Entitylithium in the treatment of veterans with PTSD who complained of serious problems with Entityirritability or angry outbursts. |
| 0.9999 | Adverse-Effect | We describe two cases that illustrate the use of Entitylithium in the treatment of veterans with PTSD who complained of serious problems with irritability or Entityangry outbursts . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityDiazepam use by pregnant women can be associated with a later presentation of Entitywithdrawal symptoms in the neonate than that induced by the use of other drugs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | She had just finished a 3 - week course of intravenous Entitytobramycin for bronchiectasis and had an elevated serum tobramycin trough level 1 week before the onset of Entitytetany . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first fatal case of Entitytype I anaphylaxis resulting from Entityprotamine . |
| 0.9982 | Adverse-Effect | Although adverse reactions to Entityprotamine are reported infrequently and are usually mild, we recently observed the first Entityfatal case of type I anaphylaxis resulting from protamine. |
| 0.9951 | Adverse-Effect | Although adverse reactions to Entityprotamine are reported infrequently and are usually mild, we recently observed the first fatal case of Entitytype I anaphylaxis resulting from protamine. |
| 0.9924 | Adverse-Effect | Although adverse reactions to protamine are reported infrequently and are usually mild, we recently observed the first Entityfatal case of type I anaphylaxis resulting from Entityprotamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The treatment for acidosis and hyperkalaemia should be started as soon as EntityRTA is diagnosed, and the dosage of EntityFK506 should also be reduced if possible. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityLithium is known to cause Entityacute renal failure and tubulo - interstitial disease, but the recently described association with proteinuria or nephrotic syndrome is little recognized. |
| 0.9999 | Adverse-Effect | EntityLithium is known to cause acute renal failure and Entitytubulo - interstitial disease , but the recently described association with proteinuria or nephrotic syndrome is little recognized. |
| 0.9999 | Adverse-Effect | EntityLithium is known to cause acute renal failure and tubulo - interstitial disease, but the recently described association with proteinuria or Entitynephrotic syndrome is little recognized. |
| 0.9999 | Adverse-Effect | EntityLithium is known to cause acute renal failure and tubulo - interstitial disease, but the recently described association with Entityproteinuria or nephrotic syndrome is little recognized. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Awareness of this route of intoxication might be important in patients in whom neurologic or Entitypsychiatric symptoms develop while large amounts of Entitylidocaine cream are being used. |
| 1.0000 | Adverse-Effect | Awareness of this route of intoxication might be important in patients in whom Entityneurologic or psychiatric symptoms develop while large amounts of Entitylidocaine cream are being used. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 4 - year - old girl who presented with acute bilateral blindness, a focal seizure and Entityhypertension 10 days after commencing Entityoxybutynin to treat enuresis. |
| 1.0000 | Adverse-Effect | We report a 4 - year - old girl who presented with Entityacute bilateral blindness , a focal seizure and hypertension 10 days after commencing Entityoxybutynin to treat enuresis. |
| 0.9999 | Adverse-Effect | We report a 4 - year - old girl who presented with acute bilateral blindness, a Entityfocal seizure and hypertension 10 days after commencing Entityoxybutynin to treat enuresis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The purpose of this study was to examine the incidence and cause of EntityClostridium difficile colitis occurring after Entitycisplatin - based combination chemotherapy in ovarian cancer patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAgranulocytosis is a rare adverse effect associated with prolonged Entityvancomycin therapy, and is potentially serious, especially in end stage renal disease ( ESRD ) patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two days after administration of EntityKalimate enema, he had Entityprofuse hematochezia , and a sigmoidoscopy showed diffuse colonic mucosal necrosis in the rectum and sigmoid colon. |
| 0.9997 | Adverse-Effect | Two days after administration of EntityKalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed Entitydiffuse colonic mucosal necrosis in the rectum and sigmoid colon. |
| Adverse-Effect | Two days after administration of EntityKalimate enema, he had profuse hematochezia, and a sigmoidoscopy showed diffuse Entitycolonic mucosal necrosis in the rectum and sigmoid colon. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : A 34 - year - old man acquired visual field defects and Entitysevere vision loss in both eyes after intravitreal injection of Entitytriamcinolone for diabetic macular edema. |
| 1.0000 | Adverse-Effect | RESULTS : A 34 - year - old man acquired Entityvisual field defects and severe vision loss in both eyes after intravitreal injection of Entitytriamcinolone for diabetic macular edema. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : A case is presented of a 45 - year - old woman on prolonged Entitygemcitabine treatment for ovarian cancer who developed EntityHUS and recovered after drug discontinuation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | The failure of therapy with disopyramide and mexiletine to reproduce this observation suggests either a previously unreported Entityelectrophysiologic effect of, or idiosyncratic response to, Entityprocainamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In 2 of the 3 cases the patients were also taking Entitylithium carbonate and beta - blockers, both of which could have contributed to the Entityincontinence . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two cases are reported of patients who developed a Entityhematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with Entityetoglucid , doxorubicin, and mitomycin C. |
| 0.9999 | Adverse-Effect | Two cases are reported of patients who developed a Entityhematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, Entitydoxorubicin , and mitomycin C. |
| 0.9998 | Adverse-Effect | Two cases are reported of patients who developed a Entityhematologic malignancy several years after intravesical chemotherapy of superficial bladder cancer with etoglucid, doxorubicin, and Entitymitomycin C . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although differential diagnostic alternatives can be considered in all described cases it is very likely that Entityvincristine does cause Entitysevere visual loss in a small number of patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of neuroleptic malignant syndrome ( EntityNMS ) associated with Entityfluphenazine in a schizophrenic patient and review the literature related to this condition. |
| 0.9999 | Adverse-Effect | OBJECTIVE : To report a case of Entityneuroleptic malignant syndrome ( NMS ) associated with Entityfluphenazine in a schizophrenic patient and review the literature related to this condition. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This latest ( third ) report suggests that the safety profile should be reexamined and at least raises the question of potential Entityrenal toxicity of Entityinterferons in MS. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After a second dose of Entitymetoclopramide , these symptoms recurred and were associated with Entityconfusion , agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension. |
| 1.0000 | Adverse-Effect | After a second dose of Entitymetoclopramide , these symptoms recurred and were associated with confusion, Entityagitation , fever, diaphoresis, tachypnea, tachycardia, and hypertension. |
| 1.0000 | Adverse-Effect | After a second dose of Entitymetoclopramide , these symptoms recurred and were associated with confusion, agitation, fever, Entitydiaphoresis , tachypnea, tachycardia, and hypertension. |
| 1.0000 | Adverse-Effect | After a second dose of Entitymetoclopramide , these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, Entitytachypnea , tachycardia, and hypertension. |
| 1.0000 | Adverse-Effect | After a second dose of Entitymetoclopramide , these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, Entitytachycardia , and hypertension. |
| 1.0000 | Adverse-Effect | After a second dose of Entitymetoclopramide , these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and Entityhypertension . |
| 1.0000 | Adverse-Effect | After a second dose of Entitymetoclopramide , these symptoms recurred and were associated with confusion, agitation, Entityfever , diaphoresis, tachypnea, tachycardia, and hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Sulindac ( EntityClinoril ), a nonsteroidal anti - inflammatory agent, has few reported Entityneurologic toxic effects , all of which have been associated with systemic disease. |
| 0.9999 | Adverse-Effect | EntitySulindac ( Clinoril ), a nonsteroidal anti - inflammatory agent, has few reported Entityneurologic toxic effects , all of which have been associated with systemic disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 59 - year - old patient with chronic myeloid leukemia, who developed Entitysevere interstitial lung fibrosis after short term and sequential treatment with Entitymelphalan and busulfan. |
| 1.0000 | Adverse-Effect | We report a 59 - year - old patient with chronic myeloid leukemia, who developed Entitysevere interstitial lung fibrosis after short term and sequential treatment with melphalan and Entitybusulfan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An association of granulocytopenia, eosinophilia, skin reaction and Entityhepatitis during Entitypropylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 1.0000 | Adverse-Effect | An association of granulocytopenia, eosinophilia, skin reaction and Entityhepatitis during propylthiouracil ( EntityPTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9999 | Adverse-Effect | An association of granulocytopenia, Entityeosinophilia , skin reaction and hepatitis during Entitypropylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9999 | Adverse-Effect | An association of Entitygranulocytopenia , eosinophilia, skin reaction and hepatitis during Entitypropylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9999 | Adverse-Effect | An association of granulocytopenia, eosinophilia, Entityskin reaction and hepatitis during Entitypropylthiouracil ( PTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9998 | Adverse-Effect | An association of granulocytopenia, Entityeosinophilia , skin reaction and hepatitis during propylthiouracil ( EntityPTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9998 | Adverse-Effect | An association of Entitygranulocytopenia , eosinophilia, skin reaction and hepatitis during propylthiouracil ( EntityPTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| 0.9997 | Adverse-Effect | An association of granulocytopenia, eosinophilia, Entityskin reaction and hepatitis during propylthiouracil ( EntityPTU ) therapy for thyrotoxicosis in a 47 year old black female is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report five cases of Entitytremor related to Entityitraconazole therapy, which occurred within 1 - 12 months of initiating treatment and resolved gradually following itraconazole withdrawal. |
| 0.9966 | Adverse-Effect | The authors report five cases of Entitytremor related to itraconazole therapy, which occurred within 1 - 12 months of initiating treatment and resolved gradually following Entityitraconazole withdrawal. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this case, unlike those previously reported, Entityhyponatremia recurred 5 months after switching from Entitycitalopram to mirtazapine, which is believed to be a safe antidepressant. |
| 1.0000 | Adverse-Effect | In this case, unlike those previously reported, Entityhyponatremia recurred 5 months after switching from citalopram to Entitymirtazapine , which is believed to be a safe antidepressant. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityTorsades de Pointes induced by a combination of Entitygarenoxacin and disopyramide and other cytochrome P450, family 3, subfamily A polypeptide - 4 - influencing drugs during hypokalemia due to licorice. |
| 1.0000 | Adverse-Effect | EntityTorsades de Pointes induced by a combination of garenoxacin and Entitydisopyramide and other cytochrome P450, family 3, subfamily A polypeptide - 4 - influencing drugs during hypokalemia due to licorice. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When the data of the 57 patients are evaluated, a reversible direct Entitycytotoxic effect of Entityticlopidine on the pluripotent / bipotent hematopoietic progenitor stem cell is proposed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of ( sub ) fulminant hepatitis and Entitycirrhosis related to Entitybenzarone . |
| 0.9977 | Adverse-Effect | Our cases constitute the most severe cases of Entitybenzarone Entityhepatotoxicity reported so far, and comprise the first cases of ( sub ) fulminant hepatitis and cirrhosis related to benzarone. |
| Adverse-Effect | Our cases constitute the most severe cases of benzarone hepatotoxicity reported so far, and comprise the first cases of Entity( sub ) fulminant hepatitis and cirrhosis related to Entitybenzarone . | |
| Adverse-Effect | Our cases constitute the most severe cases of Entitybenzarone hepatotoxicity reported so far, and comprise the first cases of Entity( sub ) fulminant hepatitis and cirrhosis related to benzarone. | |
| Adverse-Effect | Our cases constitute the most severe cases of Entitybenzarone hepatotoxicity reported so far, and comprise the first cases of ( sub ) fulminant hepatitis and Entitycirrhosis related to benzarone. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case 2 demonstrated after 40 months on Entitychlorambucil the presence of a Entitybalanced translocation , t ( 1 ; 5 ) ( p36 ; q31 ) in 90 % of the cells. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityFDE from Entitycephalosporins has been rarely reported, and to the best of our knowledge there is no published report of ceftriaxone - induced FDE in the literature. |
| Adverse-Effect | FDE from cephalosporins has been rarely reported, and to the best of our knowledge there is no published report of Entityceftriaxone - induced EntityFDE in the literature. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : We report the case of a 58 year old patient who, after 2 days of treatment with roxithromycin and Entitybetamethasone , manifested Entityacute pancreatitis . |
| 0.9999 | Adverse-Effect | CASE REPORT : We report the case of a 58 year old patient who, after 2 days of treatment with Entityroxithromycin and betamethasone, manifested Entityacute pancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient had a lower average heart rate and two patients had Entitylower average mean blood pressure values during Entitypropranolol treatment, none of which was clinically significant. |
| 0.9999 | Adverse-Effect | One patient had a Entitylower average heart rate and two patients had lower average mean blood pressure values during Entitypropranolol treatment, none of which was clinically significant. |
| 1.0000 | Adverse-Effect | One patient had a lower average heart rate and two patients had Entitylower average mean blood pressure values during Entitypropranolol treatment, none of which was clinically significant. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | These cases and a review of the literature suggested that Entityhepatotoxicity , though rare, should be added to the list of adverse reactions to EntityD - penicillamine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a patient with multiple myeloma who developed Entityacute life - threatening water intoxication following treatment with oral Entityindomethacin and low dose intravenous cyclophosphamide. |
| 1.0000 | Adverse-Effect | We report the case of a patient with multiple myeloma who developed acute life - threatening Entitywater intoxication following treatment with oral Entityindomethacin and low dose intravenous cyclophosphamide. |
| 0.9999 | Adverse-Effect | We report the case of a patient with multiple myeloma who developed Entityacute life - threatening water intoxication following treatment with oral indomethacin and low dose intravenous Entitycyclophosphamide . |
| 0.9998 | Adverse-Effect | We report the case of a patient with multiple myeloma who developed acute life - threatening Entitywater intoxication following treatment with oral indomethacin and low dose intravenous Entitycyclophosphamide . |
| Adverse-Effect | We report the case of a patient with multiple myeloma who developed acute Entitylife - threatening water intoxication following treatment with oral Entityindomethacin and low dose intravenous cyclophosphamide. | |
| Adverse-Effect | We report the case of a patient with multiple myeloma who developed acute Entitylife - threatening water intoxication following treatment with oral indomethacin and low dose intravenous Entitycyclophosphamide . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report the occurrence of renal failure due to Entitycholesterol crystal embolization following thrombolytic therapy with intravenous Entityrecombinant tissue - type plasminogen activator ( t - PA ). |
| 0.9996 | Adverse-Effect | We report the occurrence of renal failure due to Entitycholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( Entityt - PA ). |
| 0.9996 | Adverse-Effect | We report the occurrence of Entityrenal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous Entityrecombinant tissue - type plasminogen activator ( t - PA ). |
| 0.9994 | Adverse-Effect | We report the occurrence of Entityrenal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant tissue - type plasminogen activator ( Entityt - PA ). |
| 0.9997 | Adverse-Effect | We report the occurrence of renal failure due to Entitycholesterol crystal embolization following thrombolytic therapy with intravenous recombinant Entitytissue - type plasminogen activator ( t - PA ). |
| 0.9993 | Adverse-Effect | We report the occurrence of Entityrenal failure due to cholesterol crystal embolization following thrombolytic therapy with intravenous recombinant Entitytissue - type plasminogen activator ( t - PA ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : The occurrence of Entitymyoclonus associated with continuous i. v. infusion of Entitydobutamine in a patient with end - stage renal disease ( ESRD ) is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | I saw two patients with kala - azar resistant to sodium stibogluconate who developed Entitycardiac arrest after Entityamphotericin infusion ( in spite of tolerating a test dose ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, in order to avoid Entityneuropathic side effects , patients under Entitythalidomide therapy should be monitored every 6 months with nerve conduction studies while taking the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitytoxicity and plasma concentrations of Entityifosfamide , chloroacetaldehyde, and 4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of ifosfamide. |
| 0.9998 | Adverse-Effect | The Entitytoxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and 4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of Entityifosfamide . |
| 0.9998 | Adverse-Effect | The Entitytoxicity and plasma concentrations of ifosfamide, Entitychloroacetaldehyde , and 4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of ifosfamide. |
| 0.9998 | Adverse-Effect | The Entitytoxicity and plasma concentrations of ifosfamide, chloroacetaldehyde, and Entity4 - hydroxyifosfamide were then determined over 24 h after a single 1. 6 g / m2 dose of ifosfamide. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A brief review of reported cases of Entitychloramphenicol Entityhypersensitivity in the English - language literature, as well as possible alternative explanations in this case, are provided. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In this paper, we report a case of 3 years - old boy who developed Entityacute onset tetraparesia following a viral respiratory infecction and Entityhepatitis B vaccination . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient who developed EntityHUS after treatment with Entitymitomycin C ( total dose 144 mg / m2 ) due to a carcinoma of the ascending colon. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | However, as the use of Entityhepatitis B vaccination is growing, adverse side effects, including Entitymental nerve neuropathy , should be observed with an increased frequency. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a relatively healthy, 9 - year - old boy who developed a CA - MRSA skin and Entitysoft tissue infection and was treated with EntityTMP - SMX . |
| 0.9993 | Adverse-Effect | We describe a relatively healthy, 9 - year - old boy who developed a EntityCA - MRSA skin and soft tissue infection and was treated with EntityTMP - SMX . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The mild immunosuppression that occurs with Entitymethotrexate therapy probably places patients with rheumatoid arthritis at added risk of developing Entitylymphoproliferative diseases , but coincidence can not be excluded. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | These are the first reported patients to show mfERG abnormalities that correspond to Entitybitemporal visual field defects and add to the growing evidence that Entityethambutol damages the retina. |
| 0.9998 | Adverse-Effect | These are the first reported patients to show EntitymfERG abnormalities that correspond to bitemporal visual field defects and add to the growing evidence that Entityethambutol damages the retina. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMusculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms'tumors with Entityifosfamide , a derivative of cyclophosphamide. |
| 0.9997 | Adverse-Effect | EntityMusculoskeletal complaints were the presenting symptoms in four of 44 children ( 9 % ) treated for relapsed Wilms'tumors with ifosfamide, a derivative of Entitycyclophosphamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9991 | Adverse-Effect | This case suggests that EntityBH - AC , a derivative of cytosine arabinoside ( 1 - beta - D - arabinofuranosylcytosine ) could be a cause of reversible Entityencephalopathy syndrome . |
| 1.0000 | Adverse-Effect | This case suggests that BH - AC, a derivative of cytosine arabinoside ( Entity1 - beta - D - arabinofuranosylcytosine ) could be a cause of reversible Entityencephalopathy syndrome . |
| 0.9996 | Adverse-Effect | This case suggests that BH - AC, a derivative of Entitycytosine arabinoside ( 1 - beta - D - arabinofuranosylcytosine ) could be a cause of reversible Entityencephalopathy syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although the data indicate an immune - complex cause for Entitygold - salt Entitynephropathy , the incident antigen ( or antigens ) and mechanism of action remain unidentified. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 40 - year - old man with a long standing history of rheumatoid arthritis was treated with EntityMTX over a 6 month period and developed an Entityoverwhelming hepatic necrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a 64 - year - old man with secondary Entityadrenocortical insufficiency who has been on a chronic transdermal Entityfentanyl treatment because of sciatic pain syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We now report the first known cancer patient who developed Entitylife - threatening complications after treatment with topical Entity5 - FU and was shown subsequently to have profound DPD deficiency. |
| 0.9999 | Adverse-Effect | We now report the first known cancer patient who developed life - threatening complications after treatment with topical Entity5 - FU and was shown subsequently to have profound EntityDPD deficiency . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 62 - year - old Caucasian man with atrial fibrillation who was taking Entitywarfarin reported an episode of Entityhematochezia ; his international normalized ratio ( INR ) was 1. 74. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 9 - year - old boy developed Entityacute renal failure following intravenous Entityacyclovir ( 30 mg / kg per day ) administered for 6 days to treat herpetic encephalitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with acute leukemia who developed Horner's syndrome and a severe demyelinating peripheral neuropathy leading to Entitydeath after receiving high - dose Entitycytosine arabinoside . |
| 0.9998 | Adverse-Effect | We describe a patient with acute leukemia who developed Horner's syndrome and a Entitysevere demyelinating peripheral neuropathy leading to death after receiving high - dose Entitycytosine arabinoside . |
| 0.9997 | Adverse-Effect | We describe a patient with acute leukemia who developed EntityHorner's syndrome and a severe demyelinating peripheral neuropathy leading to death after receiving high - dose Entitycytosine arabinoside . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a 23 - year - old man who developed a Entityvancomycin - induced Entityanaphylactic reaction in the treatment of methicillin - resistant Staphylococcus aureus infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We observed 2 cases of Entityhepatotoxicity after a high - dose Entitymethylprednisolone treatment of a demyelinating disease and evaluated the potential relationship in the light of available evidence. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMasculinization of a female fetus occurred in 5 of 39 ( 12. 8 % ) exposed to Entitynorethisterone ; all were cases of clitoral hypertrophy not requiring surgical treatment. |
| 0.9999 | Adverse-Effect | Masculinization of a female fetus occurred in 5 of 39 ( 12. 8 % ) exposed to Entitynorethisterone ; all were cases of Entityclitoral hypertrophy not requiring surgical treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Observations in our patient suggest that the Entityleukoencephalopathy that developed in previously reported patients who received Entity5 - fluorouracil and levamisole may have been caused at least partly by levamisole. |
| 0.9996 | Adverse-Effect | Observations in our patient suggest that the Entityleukoencephalopathy that developed in previously reported patients who received 5 - fluorouracil and Entitylevamisole may have been caused at least partly by levamisole. |
| 0.9992 | Adverse-Effect | Observations in our patient suggest that the Entityleukoencephalopathy that developed in previously reported patients who received 5 - fluorouracil and levamisole may have been caused at least partly by Entitylevamisole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : In some abstainers who take Entitycyanamide for several years, thin Entityseptum - like liver fibrosis progresses along with the emergence of ground - glass hepatocytes. |
| 0.9999 | Adverse-Effect | CONCLUSION : In some abstainers who take Entitycyanamide for several years, thin septum - like liver fibrosis progresses along with the emergence of Entityground - glass hepatocytes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityArgatroban is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant renal impairment, but conversely has prolonged effects in Entityhepatic failure . |
| 0.9999 | Adverse-Effect | EntityArgatroban is hepatically cleared and may be the preferred direct thrombin inhibitor in the presence of significant Entityrenal impairment , but conversely has prolonged effects in hepatic failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In patients with cirrhosis, the metabolism of Entitymeperidine is decreased, leading to Entityaccumulation of the parent drug and possible CNS depressive effects similar to hepatic encephalopathy. |
| 0.9997 | Adverse-Effect | In patients with cirrhosis, the metabolism of Entitymeperidine is decreased, leading to accumulation of the parent drug and possible EntityCNS depressive effects similar to hepatic encephalopathy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityhepatolithiasis ( intrahepatic stone ) complicated by gram - negative sepsis in a 37 year old male with acromegaly being treated with Entityoctreotide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entityrash seen in this patient, who was treated with Entitycephalexin , may be similar to the rash seen with ampicillin treatment of patients with infectious mononucleosis. |
| 0.9789 | Adverse-Effect | The rash seen in this patient, who was treated with Entitycephalexin , may be similar to the Entityrash seen with ampicillin treatment of patients with infectious mononucleosis. |
| Adverse-Effect | The rash seen in this patient, who was treated with cephalexin, may be similar to the Entityrash seen with Entityampicillin treatment of patients with infectious mononucleosis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on three observations of parkinsonian patients with Entitylevo - dopa - induced Entitydiphasic dyskinesias , who received subcutaneous apomorphine to reduce the duration of abnormal movements. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe two cases of Entitysulfadiazine - induced Entitycrystalluria and renal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis. |
| 1.0000 | Adverse-Effect | We describe two cases of Entitysulfadiazine - induced crystalluria and Entityrenal failure in patients with acquired immunodeficiency syndrome, review the pertinent literature, and discuss the pathogenesis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and Entitycalcitriol are Entitysecondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind. |
| 0.9998 | Adverse-Effect | Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and Entitycalcitriol are secondary hyperparathyroidism and vitamin D intoxication, Entitypotassium loss also should be kept in mind. |
| 0.9996 | Adverse-Effect | Although major hazards of treatment of hypophosphatemic osteomalacia with phosphate and Entitycalcitriol are secondary hyperparathyroidism and Entityvitamin D intoxication , potassium loss also should be kept in mind. |
| 0.9994 | Adverse-Effect | Although major hazards of treatment of hypophosphatemic osteomalacia with Entityphosphate and calcitriol are secondary hyperparathyroidism and vitamin D intoxication, Entitypotassium loss also should be kept in mind. |
| 0.9993 | Adverse-Effect | Although major hazards of treatment of hypophosphatemic osteomalacia with Entityphosphate and calcitriol are Entitysecondary hyperparathyroidism and vitamin D intoxication, potassium loss also should be kept in mind. |
| 0.9979 | Adverse-Effect | Although major hazards of treatment of hypophosphatemic osteomalacia with Entityphosphate and calcitriol are secondary hyperparathyroidism and Entityvitamin D intoxication , potassium loss also should be kept in mind. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After 39 hours on Entityargatroban , the infusion was stopped when minor Entitybleeding was observed with a concurrent activated partial thromboplastin time ( aPTT ) of 100 seconds. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report rules out other causes of Entitytoxic epidermal necrolysis and implicates Entityofloxacin in what appears to be an atypical presentation of drug - induced toxic epidermal necrolysis. |
| 0.9998 | Adverse-Effect | This report rules out other causes of toxic epidermal necrolysis and implicates Entityofloxacin in what appears to be an atypical presentation of drug - induced Entitytoxic epidermal necrolysis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntitySensorineural hearing loss due to Entityquinine therapy for malaria has frequently been mentioned in the literature but has not been a subject of research during the last decades. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 31 - year - old female developed multiple episodes of Entitygrand mal seizures after combination chemotherapy with Entitycisplatin , vinblastine and bleomycin for germ cell ovarian cancer stage Ic. |
| 1.0000 | Adverse-Effect | A 31 - year - old female developed multiple episodes of Entitygrand mal seizures after combination chemotherapy with cisplatin, Entityvinblastine and bleomycin for germ cell ovarian cancer stage Ic. |
| 1.0000 | Adverse-Effect | A 31 - year - old female developed multiple episodes of Entitygrand mal seizures after combination chemotherapy with cisplatin, vinblastine and Entitybleomycin for germ cell ovarian cancer stage Ic. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 12 year old patient with atrial flutter is presented, in whom intravenous Entityadenosine was followed by Entityacceleration of the heart rate to a potentially dangerous arrhythmia. |
| 0.9999 | Adverse-Effect | A 12 year old patient with atrial flutter is presented, in whom intravenous Entityadenosine was followed by acceleration of the heart rate to a potentially dangerous Entityarrhythmia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case in which Entityhemorrhage occurred in an asymptomatic falx meningioma known beforehand, after the internal use of low - dose Entityaspirin for 16 months. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityhypoglycaemia after Entitymefloquine therapy ( 1, 500 mg over two days ) for severe gastrointestinal cryptosporidiasis in a cachectic AIDS patient with protracted diarrhoea. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes a case of paradoxical, intravenous Entityvalproic acid - induced Entityseizure exacerbation in a child with juvenile absence epilepsy, documented by video - electroencephalography. |
| 0.9966 | Adverse-Effect | This report describes a case of Entityparadoxical , intravenous valproic acid - induced Entityseizure exacerbation in a child with juvenile absence epilepsy, documented by video - electroencephalography. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | That review suggested that patients receiving Entityanti - D IGIV be monitored for those and other potential complications of Entityhemoglobinemia , particularly disseminated intravascular coagulation ( DIC ). |
| 0.9998 | Adverse-Effect | That review suggested that patients receiving Entityanti - D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly disseminated intravascular coagulation ( EntityDIC ). |
| 0.9995 | Adverse-Effect | That review suggested that patients receiving Entityanti - D IGIV be monitored for those and other potential complications of hemoglobinemia, particularly Entitydisseminated intravascular coagulation ( DIC ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Mequitazine seemed to play a part similar to chlorpromazine, and absence of Entitymequitazine - induced Entityphotosensitivity may be due to a relatively low dosage of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors suggest that Entityrisperidone may Entityincrease affect in patients with schizophrenia and that some patients, especially those with anxiety, may have difficulty managing the increase. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The risk of new - onset Entitydiabetic ketoacidosis in patients with diabetic risk factors who are taking Entityperospirone hydrochloride or other atypical antipsychotics should be kept in mind. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Among the many presentations of Entityifosfamide Entityneurotoxicity , clinicians should consider NCSE as a possible explanation for changes in consciousness in a patient receiving this agent. |
| 0.9831 | Adverse-Effect | CONCLUSIONS : Among the many presentations of Entityifosfamide neurotoxicity, clinicians should consider EntityNCSE as a possible explanation for changes in consciousness in a patient receiving this agent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case showed sequential manifestation from transient thyrotoxicosis to the appearance of TSH - receptor autoantibodies, and then the occurrence of EntityGraves'hyperthyroidism during EntityIFN therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A transient tonic pupillary response, denervation supersensitivity, and Entityabnormal visual - evoked potentials in Entityquinine toxicity, to our knowledge, have not been previously reported. |
| 0.9998 | Adverse-Effect | A Entitytransient tonic pupillary response , denervation supersensitivity, and abnormal visual - evoked potentials in Entityquinine toxicity, to our knowledge, have not been previously reported. |
| 0.9998 | Adverse-Effect | A transient tonic pupillary response, Entitydenervation supersensitivity , and abnormal visual - evoked potentials in Entityquinine toxicity, to our knowledge, have not been previously reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | An encephalopathy and Entitycardiomyopathy developed in a seventeen - year - old girl with chemotherapy - induced renal failure while receiving an intravesical Entityaluminum infusion for hemorrhagic cystitis. |
| 0.9998 | Adverse-Effect | An Entityencephalopathy and cardiomyopathy developed in a seventeen - year - old girl with chemotherapy - induced renal failure while receiving an intravesical Entityaluminum infusion for hemorrhagic cystitis. |
| 1.0000 | Adverse-Effect | An encephalopathy and cardiomyopathy developed in a seventeen - year - old girl with chemotherapy - induced Entityrenal failure while receiving an intravesical Entityaluminum infusion for hemorrhagic cystitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9991 | Adverse-Effect | Pancreatitis is a very rare adverse effect associated with the use of amiodarone, and only four cases of Entityamiodarone - induced Entitypancreatitis have been reported in literature. |
| 0.9967 | Adverse-Effect | EntityPancreatitis is a very rare adverse effect associated with the use of Entityamiodarone , and only four cases of amiodarone - induced pancreatitis have been reported in literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONTEXT : Previous investigators have reported Entitydiscrepancies between hematologic, marrow morphologic, and cytogenetic responses to Entityimatinib mesylate among patients with chronic myeloid leukemia ( CML ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : The administration of Entitytissue plasminogen activator was responsible for the large extent of Entityhemorrhage and should be considered in the differential diagnosis of hemorrhagic choroidal detachment. |
| 0.9993 | Adverse-Effect | CONCLUSION : The administration of Entitytissue plasminogen activator was responsible for the large extent of hemorrhage and should be considered in the differential diagnosis of Entityhemorrhagic choroidal detachment . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To describe Entitytransient structured visual hallucinations in a patient with vascular age - related macular degeneration ( AMD ), following an intravitreal EntityAvastin - injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAtaxia caused by Entitypropafenone has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with Entityolanzapine and lithium. |
| 1.0000 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, Entityleukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with Entityolanzapine and lithium. |
| 0.9999 | Adverse-Effect | A 16 - year - old boy developed Entityfever , generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with Entityolanzapine and lithium. |
| 0.9999 | Adverse-Effect | A 16 - year - old boy developed fever, Entitygeneralized rigidity , leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with Entityolanzapine and lithium. |
| 0.9999 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Entitylithium . |
| 0.9998 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, Entityleukocytosis , and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Entitylithium . |
| 0.9998 | Adverse-Effect | A 16 - year - old boy developed Entityfever , generalized rigidity, leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Entitylithium . |
| 0.9998 | Adverse-Effect | A 16 - year - old boy developed fever, Entitygeneralized rigidity , leukocytosis, and increased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Entitylithium . |
| 1.0000 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with Entityolanzapine and lithium. |
| 1.0000 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with Entityolanzapine and lithium. |
| 1.0000 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with Entityolanzapine and lithium. |
| 1.0000 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with Entityolanzapine and lithium. |
| 1.0000 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Entitylithium . |
| 0.9999 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Entitylithium . |
| 0.9999 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Entitylithium . |
| 0.9998 | Adverse-Effect | A 16 - year - old boy developed fever, generalized rigidity, leukocytosis, and Entityincreased serum transaminase and creatine kinase levels while receiving treatment with olanzapine and Entitylithium . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed Entitydilated pupils in neonates treated with Entitylidocaine . |
| 0.9993 | Adverse-Effect | We suggest adding this side effect to the list of untoward effects of Entitylidocaine and to the differential diagnosis of fixed Entitydilated pupils in neonates treated with lidocaine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We conclude that Entitymyocardial infarction may develop in patients treated with high - dose Entityglucocorticoids for Graves'ophthalmopathy, and increased blood pressure may herald this complication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After intravitreal injection of Entitytriamcinolone acetonide , Entitycataract may rapidly develop in eyes that have been intensively treated, topically and systemically, by corticosteroids for several years. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The current study investigated the visual fields and visual electrophysiology of eight patients with known Entityvigabatrin - attributed Entityvisual field loss , three of whom were reported previously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityQuinapril is an angiotensin - converting enzyme inhibitor ( ACE - inhibitor ) and overdose can lead to Entityprolonged hypotension and, less frequently, transient renal impairment. |
| 1.0000 | Adverse-Effect | EntityQuinapril is an angiotensin - converting enzyme inhibitor ( ACE - inhibitor ) and overdose can lead to prolonged hypotension and, less frequently, Entitytransient renal impairment . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 60 - year - old woman with diabetes mellitus ( type 2 ) developed an Entityacute icteric hepatitis - like illness 6 weeks after the initiation of Entitygliclazide therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 58 - yr - old male patient with essential thrombocythaemia ( ET ) developed chronic myeloid leukaemia ( EntityCML ) after continuous uneventful treatment with Entityhydroxyurea for 18 yr. |
| 1.0000 | Adverse-Effect | A 58 - yr - old male patient with essential thrombocythaemia ( ET ) developed Entitychronic myeloid leukaemia ( CML ) after continuous uneventful treatment with Entityhydroxyurea for 18 yr. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | The purpose of this report is to document a new case of in utero EntityCP exposure with Entitymultiple congenital anomalies and to establish an apparent CP embryopathy phenotype. | |
| Adverse-Effect | The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent EntityCP Entityembryopathy phenotype. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entitycalcineurin - induced Entitypain syndrome ( CIPS ) in a child undergoing his second hematopoietic stem cell transplant ( HSCT ). |
| 0.9999 | Adverse-Effect | OBJECTIVE : To report a case of Entitycalcineurin - induced pain syndrome ( EntityCIPS ) in a child undergoing his second hematopoietic stem cell transplant ( HSCT ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever, skin eruptions, leukocytopenia, and Entitythrombocytopenia , 3 weeks after treatment with Entitysulfasalazine . |
| 1.0000 | Adverse-Effect | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever, skin eruptions, Entityleukocytopenia , and thrombocytopenia, 3 weeks after treatment with Entitysulfasalazine . |
| 1.0000 | Adverse-Effect | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed Entityfever , skin eruptions, leukocytopenia, and thrombocytopenia, 3 weeks after treatment with Entitysulfasalazine . |
| 0.9999 | Adverse-Effect | A 58 - year - old woman with rheumatoid arthritis ( RA ) developed fever, Entityskin eruptions , leukocytopenia, and thrombocytopenia, 3 weeks after treatment with Entitysulfasalazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In deciding if tamoxifen therapy is warranted, all potentially life - threatening adverse events associated with Entitytamoxifen should be considered, including Entityendometrial adenocarcinoma or uterine sarcoma. |
| 0.9995 | Adverse-Effect | In deciding if Entitytamoxifen therapy is warranted, all potentially life - threatening adverse events associated with tamoxifen should be considered, including Entityendometrial adenocarcinoma or uterine sarcoma. |
| 0.9995 | Adverse-Effect | In deciding if tamoxifen therapy is warranted, all potentially life - threatening adverse events associated with Entitytamoxifen should be considered, including endometrial adenocarcinoma or Entityuterine sarcoma . |
| 0.9986 | Adverse-Effect | In deciding if Entitytamoxifen therapy is warranted, all potentially life - threatening adverse events associated with tamoxifen should be considered, including endometrial adenocarcinoma or Entityuterine sarcoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although various manifestations of Entitypentamidine - induced Entitycardiotoxicity have been reported, to our knowledge, second - degree heart block associated with this agent has not been described. |
| 0.9973 | Adverse-Effect | Although various manifestations of Entitypentamidine - induced cardiotoxicity have been reported, to our knowledge, Entitysecond - degree heart block associated with this agent has not been described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | We report the syndrome of inappropriate Entityantidiuresis as a much earlier side - effect of Entitycarbamazepine administration in a 29 - year Nigerian female patient with generalized tonic - elonic seizures. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Amphotericin B ( EntityAmB ) is effective, but its use is limited by toxicity : Entityrenal impairment , anaemia, fever, malaise, and hypokalaemia are common. |
| 1.0000 | Adverse-Effect | Amphotericin B ( EntityAmB ) is effective, but its use is limited by toxicity : renal impairment, Entityanaemia , fever, malaise, and hypokalaemia are common. |
| 1.0000 | Adverse-Effect | Amphotericin B ( EntityAmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, fever, Entitymalaise , and hypokalaemia are common. |
| 0.9999 | Adverse-Effect | Amphotericin B ( EntityAmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, fever, malaise, and Entityhypokalaemia are common. |
| 0.9999 | Adverse-Effect | Amphotericin B ( EntityAmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, Entityfever , malaise, and hypokalaemia are common. |
| 0.9998 | Adverse-Effect | EntityAmphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, Entityanaemia , fever, malaise, and hypokalaemia are common. |
| 0.9998 | Adverse-Effect | EntityAmphotericin B ( AmB ) is effective, but its use is limited by toxicity : Entityrenal impairment , anaemia, fever, malaise, and hypokalaemia are common. |
| 0.9998 | Adverse-Effect | EntityAmphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, fever, Entitymalaise , and hypokalaemia are common. |
| 0.9998 | Adverse-Effect | EntityAmphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, fever, malaise, and Entityhypokalaemia are common. |
| 0.9997 | Adverse-Effect | EntityAmphotericin B ( AmB ) is effective, but its use is limited by toxicity : renal impairment, anaemia, Entityfever , malaise, and hypokalaemia are common. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | This case suggests that sarcoidosis and Entitypravastatin , two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical Entitymyotonia in humans. |
| 0.9999 | Adverse-Effect | This case suggests that sarcoidosis and Entitypravastatin , two entities not frequently associated with Entitymyotonia , may interact in a synergistic manner to produce severe clinical myotonia in humans. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | We present two cases of Entityanaphylaxis under anaesthesia where return of spontaneous circulation was refractory to epinephrine, but occurred following the administration of the alpha - agonist Entitymetaraminol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present the cases of two female patients diagnosed with relapsing - remitting multiple sclerosis ( RRMS ) who developed Entityinflammatory musculoskeletal manifestations , following EntityIFN - beta therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBSERVATIONS : A 48 - year - old woman presented with Entitydisfiguring facial edema 10 weeks after she began antiviral therapy with Entitypeginterferon alfa - 2a and ribavirin for chronic hepatitis C infection. |
| 0.9999 | Adverse-Effect | OBSERVATIONS : A 48 - year - old woman presented with Entitydisfiguring facial edema 10 weeks after she began antiviral therapy with peginterferon alfa - 2a and Entityribavirin for chronic hepatitis C infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityAkathisia appeared to be a common side effect of Entityfluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol, dose reduction, or both. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection, on Entityimatinib treatment, presenting with Entityherpetic rash and acute liver failure. |
| 1.0000 | Adverse-Effect | We report a 45 - year - old Chinese man with CML and chronic hepatitis B virus infection, on Entityimatinib treatment, presenting with herpetic rash and Entityacute liver failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal agranulocytosis in an Indian male receiving 100 mg of Entitydapsone daily, hospitalized for mid - borderline leprosy in type I reaction with triple nerve paralysis is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We believe that mucositis was a contributing factor to this case of Entityfatal hyperkalemia after administration of Entitysuccinylcholine , with a mechanism similar to that reported with thermal injury. |
| 0.9998 | Adverse-Effect | We believe that Entitymucositis was a contributing factor to this case of fatal hyperkalemia after administration of Entitysuccinylcholine , with a mechanism similar to that reported with thermal injury. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In eight patients, a mean Entitydecrease in serum Na + of 8. 25 + / - 3. 2 mEq / L was observed after a single 200 mg intravenous dose of Entitylorcainide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9993 | Adverse-Effect | Since early symptoms of the toxic effects of Entitytheophylline can mimic Entitypeptic ulcer disease , cimetidine might be prescribed for the gastrointestinal symptoms with subsequent worsening of theophylline poisoning. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9988 | Adverse-Effect | Clinicians should be aware of the signs and symptoms of Entityneurotoxicity during treatment, as well as predisposing factors that put patients receiving Entitymethotrexate at risk for neurotoxic effects. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case describes a 52 - year - old white woman who developed a Entityspontaneous nasal septal perforation after given the antiangiogenic drug, Entitybevacizumab , for metastatic ovarian cancer treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is the first report of a Entityfluoxetine - related Entitydeath in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCutaneous necrosis as a result of Entityinterferon alfa is an infrequent complication with unknown pathogenesis, in which a cutaneous local immune - mediated inflammatory process might be involved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | There have been more than 20 observations of the appearance or aggravation of this Entitygranulomatosis with Entityinterferon alfa and more recently with the combination of interferon alfa plus ribavirin. |
| 0.9997 | Adverse-Effect | There have been more than 20 observations of the appearance or aggravation of this Entitygranulomatosis with interferon alfa and more recently with the combination of interferon alfa plus Entityribavirin . |
| 0.9995 | Adverse-Effect | There have been more than 20 observations of the appearance or aggravation of this Entitygranulomatosis with interferon alfa and more recently with the combination of Entityinterferon alfa plus ribavirin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | We describe a patient with Wilson's disease who presented with neurologic disease, was treated with EntityD - penicillamine , and suffered sudden Entityneurologic deterioration coincident with therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to hypoxia and thus was more susceptible to Entityductal closure in response to Entityindomethacin exposure. |
| 0.9999 | Adverse-Effect | This selective closure of the ductus arteriosus suggests that the affected twin was predisposed to Entityhypoxia and thus was more susceptible to ductal closure in response to Entityindomethacin exposure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This Entityeruption emerged after 1 month of therapy with Entitysalsalate , persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication. |
| 0.9995 | Adverse-Effect | This Entityeruption emerged after 1 month of therapy with salsalate, persisted for as long as Entitysalsalate was administered, and cleared within 3 weeks of discontinuing the medication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitycough following the administration of Entityquinapril , with complete resolution after changing to the alternative ACE inhibitor fosinopril in a patient with essential hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Recent reports have shown that Decadron ( dexamethasone ; Merck Sharp & Dohme, West Point, Pa ) has a significant antiemetic effect on Entitycisplatin - induced Entityvomiting . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and Entitysevere hypersensitivity reactions to Entitycarboplatin . |
| 0.9996 | Adverse-Effect | Prick tests and intradermal tests with a series of dilutions of carboplatin and Entitycisplatin were performed on three patients who had exhibited medium and Entitysevere hypersensitivity reactions to carboplatin. |
| 0.9978 | Adverse-Effect | Prick tests and intradermal tests with a series of dilutions of Entitycarboplatin and cisplatin were performed on three patients who had exhibited medium and Entitysevere hypersensitivity reactions to carboplatin. |
| Adverse-Effect | Prick tests and intradermal tests with a series of dilutions of carboplatin and cisplatin were performed on three patients who had exhibited medium and Entitysevere hypersensitivity reactions to Entitycarboplatin . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We believe that this represents an unusual case of moderate - dose EntityMTX - induced Entityneurotoxicity in a patient with gastric cancer, which has not previously been reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and vincristine and Entityactinomycin D in case 2, were given before the Entityhepatotoxicity developed. |
| 0.9994 | Adverse-Effect | The chemotherapeutics, including vincristine, actinomycin D, and epirubicin in case 1 and Entityvincristine and actinomycin D in case 2, were given before the Entityhepatotoxicity developed. |
| 0.9990 | Adverse-Effect | The chemotherapeutics, including Entityvincristine , actinomycin D, and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the Entityhepatotoxicity developed. |
| 0.9990 | Adverse-Effect | The chemotherapeutics, including vincristine, actinomycin D, and Entityepirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the Entityhepatotoxicity developed. |
| 0.9984 | Adverse-Effect | The chemotherapeutics, including vincristine, Entityactinomycin D , and epirubicin in case 1 and vincristine and actinomycin D in case 2, were given before the Entityhepatotoxicity developed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a patient with renal artery stenosis who had only 1 kidney and in whom acute renal impairment developed with Entitytransient anuria after the administration of Entitycaptopril . |
| 0.9999 | Adverse-Effect | We report on a patient with renal artery stenosis who had only 1 kidney and in whom Entityacute renal impairment developed with transient anuria after the administration of Entitycaptopril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Sweet's syndrome is an Entityacute febrile neutrophilic dermatosis that is a known complication of the administration of Entityfilgrastim , a drug that causes increased neutrophil proliferation and differentiation. |
| 1.0000 | Adverse-Effect | EntitySweet's syndrome is an acute febrile neutrophilic dermatosis that is a known complication of the administration of Entityfilgrastim , a drug that causes increased neutrophil proliferation and differentiation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMetformin - associated Entitylactic acidosis ( MALA ) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure. |
| 0.9966 | Adverse-Effect | Metformin - associated Entitylactic acidosis ( MALA ) is a serious metabolic complication that occurs because of Entitymetformin accumulation in patients who become dehydrated or developed acute renal failure. |
| 0.9989 | Adverse-Effect | Metformin - associated lactic acidosis ( EntityMALA ) is a serious metabolic complication that occurs because of Entitymetformin accumulation in patients who become dehydrated or developed acute renal failure. |
| 0.9987 | Adverse-Effect | EntityMetformin - associated lactic acidosis ( EntityMALA ) is a serious metabolic complication that occurs because of metformin accumulation in patients who become dehydrated or developed acute renal failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, a new episode of Entityneutropenia , with a WBC count of 2. 8 x 10 ( 3 ) / mm3 and ANC of 0. 448 x 10 ( 3 ) / mm3, occurred 11 days after Entityteicoplanin initiation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitysevere anemia , which responded well to steroid therapy, in a patient receiving EntityIL - 2 plus IFN - alpha for metastatic renal cell carcinoma. |
| 0.9998 | Adverse-Effect | We report a case of Entitysevere anemia , which responded well to steroid therapy, in a patient receiving IL - 2 plus EntityIFN - alpha for metastatic renal cell carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After extensive neurological'work up ', we realized that the Entityanisocoria was related to the transdermal Entityscopolamine patch that we had prescribed for weaning off the opioid. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient in whom the anti - depressant trazodone hydrochloride ( EntityMolipaxin , Roussel ), a serotonin antagonist, provoked Entitygeneralized pustular psoriasis ( GPP ). |
| 0.9999 | Adverse-Effect | We report a patient in whom the anti - depressant trazodone hydrochloride ( EntityMolipaxin , Roussel ), a serotonin antagonist, provoked generalized pustular psoriasis ( EntityGPP ). |
| 0.9998 | Adverse-Effect | We report a patient in whom the anti - depressant Entitytrazodone hydrochloride ( Molipaxin, Roussel ), a serotonin antagonist, provoked Entitygeneralized pustular psoriasis ( GPP ). |
| 0.9995 | Adverse-Effect | We report a patient in whom the anti - depressant Entitytrazodone hydrochloride ( Molipaxin, Roussel ), a serotonin antagonist, provoked generalized pustular psoriasis ( EntityGPP ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In addition, there is a report on Entityprolonged ECT seizure related to Entityciprofloxacin , which has an epileptogenic property with a similar action to beta - lactam antibiotics. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here, we present a case of Entitysirolimus - associated Entityinterstitial pneumonitis in a cardiac transplant recipient that resolved completely with withdrawal of the drug and treatment with corticosteroids. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In rare cases mitomycin C ( EntityMMC ) may induce cancer - associated Entityhemolytic uremic syndrome , which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| 0.9998 | Adverse-Effect | In rare cases mitomycin C ( EntityMMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by Entityhemolytic anemia , thrombocytopenia and progressive renal failure. |
| 0.9997 | Adverse-Effect | In rare cases Entitymitomycin C ( MMC ) may induce cancer - associated Entityhemolytic uremic syndrome , which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| 0.9997 | Adverse-Effect | In rare cases mitomycin C ( EntityMMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, Entitythrombocytopenia and progressive renal failure. |
| 0.9995 | Adverse-Effect | In rare cases Entitymitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by Entityhemolytic anemia , thrombocytopenia and progressive renal failure. |
| 0.9995 | Adverse-Effect | In rare cases mitomycin C ( EntityMMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and Entityprogressive renal failure . |
| 0.9993 | Adverse-Effect | In rare cases Entitymitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, Entitythrombocytopenia and progressive renal failure. |
| 0.9988 | Adverse-Effect | In rare cases Entitymitomycin C ( MMC ) may induce cancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and Entityprogressive renal failure . |
| 0.9995 | Adverse-Effect | In rare cases mitomycin C ( MMC ) may induce Entitycancer - associated Entityhemolytic uremic syndrome , which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| 0.9895 | Adverse-Effect | In rare cases mitomycin C ( EntityMMC ) may induce Entitycancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| 0.9796 | Adverse-Effect | In rare cases mitomycin C ( MMC ) may induce Entitycancer - associated hemolytic uremic syndrome, which is characterized by Entityhemolytic anemia , thrombocytopenia and progressive renal failure. |
| 0.9714 | Adverse-Effect | In rare cases mitomycin C ( MMC ) may induce Entitycancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, Entitythrombocytopenia and progressive renal failure. |
| 0.9475 | Adverse-Effect | In rare cases mitomycin C ( MMC ) may induce Entitycancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and Entityprogressive renal failure . |
| 0.5681 | Adverse-Effect | In rare cases Entitymitomycin C ( MMC ) may induce Entitycancer - associated hemolytic uremic syndrome, which is characterized by hemolytic anemia, thrombocytopenia and progressive renal failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityBisphosphonate - related Entityosteonecrosis of the jaw ( BRONJ ) is reported in up to 18. 6 % of patients treated with intravenous bisphosphonates and can result in significant morbidity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Hypersensitivity reaction should be considered in patients who develop recurrent eosinophilia and Entitydeterioration of pulmonary function following the use of Entitytobramycin by inhalation or by intravenous administration. |
| 1.0000 | Adverse-Effect | CONCLUSION : Hypersensitivity reaction should be considered in patients who develop Entityrecurrent eosinophilia and deterioration of pulmonary function following the use of Entitytobramycin by inhalation or by intravenous administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Finally, Entityreserpine Entityreserpine toxicity , in particular central nervous system ( CNS ) disturbances, was reported more frequently in patients also receiving barbiturates, suggesting additive CNS effects. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : At our institution, no children appeared with acute EntityINH Entityneurotoxicity in the period 1985 through 1990, whereas seven patients were treated from 1991 through 1993. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An 83 - year - old man receiving glipizide 10 mg bid developed Entitysymptomatic hypoglycemia within three days of adding Entitytrimethoprim / sulfamethoxazole ( TMP / SMX ) to his regimen. |
| 1.0000 | Adverse-Effect | An 83 - year - old man receiving Entityglipizide 10 mg bid developed Entitysymptomatic hypoglycemia within three days of adding trimethoprim / sulfamethoxazole ( TMP / SMX ) to his regimen. |
| 0.9999 | Adverse-Effect | An 83 - year - old man receiving glipizide 10 mg bid developed Entitysymptomatic hypoglycemia within three days of adding trimethoprim / Entitysulfamethoxazole ( TMP / SMX ) to his regimen. |
| 0.9999 | Adverse-Effect | An 83 - year - old man receiving glipizide 10 mg bid developed Entitysymptomatic hypoglycemia within three days of adding trimethoprim / sulfamethoxazole ( EntityTMP / SMX ) to his regimen. |
| 0.9999 | Adverse-Effect | An 83 - year - old man receiving glipizide 10 mg bid developed Entitysymptomatic hypoglycemia within three days of adding trimethoprim / sulfamethoxazole ( TMP / EntitySMX ) to his regimen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors present a case of Entityt - AML that developed in a child with metastatic neuroblastoma 18 months after he received oral Entityetoposide , given for palliation purpose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the case of a 50 - year - old woman with advanced non - small cell lung cancer who developed Entitystatus epilepticus shortly after receiving Entitycisplatin and gemcitabine chemotherapy. |
| 0.9999 | Adverse-Effect | We describe the case of a 50 - year - old woman with advanced non - small cell lung cancer who developed Entitystatus epilepticus shortly after receiving cisplatin and Entitygemcitabine chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a rare case of Entitycolonic mucosal necrosis following EntityKalimate ( calcium polystryrene sulfonate ), an analogue of Kayexalate without sorbitol in a 34 - yr - old man. |
| 0.9992 | Adverse-Effect | We report a rare case of Entitycolonic mucosal necrosis following Kalimate ( Entitycalcium polystryrene sulfonate ), an analogue of Kayexalate without sorbitol in a 34 - yr - old man. |
| 0.9985 | Adverse-Effect | We report a rare case of Entitycolonic mucosal necrosis following Kalimate ( calcium polystryrene sulfonate ), an analogue of EntityKayexalate without sorbitol in a 34 - yr - old man. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The most likely cause of Entityliver failure in this patient was, therefore, Entityclarithromycin , which undergoes hepatic metabolism and has been reported to cause fulminant hepatic failure. |
| 0.9999 | Adverse-Effect | The most likely cause of liver failure in this patient was, therefore, Entityclarithromycin , which undergoes hepatic metabolism and has been reported to cause Entityfulminant hepatic failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The development of an IgG lambda - type monoclonal gammopathy and subsequent Entitymultiple myeloma in an epilepsy patient on Entitydiphenylhydantoin ( DILANTIN ) therapy for 20 years is reported. |
| 1.0000 | Adverse-Effect | The development of an EntityIgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on Entitydiphenylhydantoin ( DILANTIN ) therapy for 20 years is reported. |
| 1.0000 | Adverse-Effect | The development of an IgG lambda - type monoclonal gammopathy and subsequent Entitymultiple myeloma in an epilepsy patient on diphenylhydantoin ( EntityDILANTIN ) therapy for 20 years is reported. |
| 0.9999 | Adverse-Effect | The development of an EntityIgG lambda - type monoclonal gammopathy and subsequent multiple myeloma in an epilepsy patient on diphenylhydantoin ( EntityDILANTIN ) therapy for 20 years is reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In all three cases, autopsy revealed gross and microscopic features indistinguishable from those seen in the Hamman - Rich syndrome, and Entitymethotrexate Entityhepatotoxicity was present in one. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 44 - year - old woman with t - MDS ( Entityrefractory anemia with excess blasts ) following treatment of recurrent anaplastic astrocytoma with Entitytemozolomide ( TMZ ). |
| 1.0000 | Adverse-Effect | We report a 44 - year - old woman with t - MDS ( Entityrefractory anemia with excess blasts ) following treatment of recurrent anaplastic astrocytoma with temozolomide ( EntityTMZ ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE : To report a case of severe Entitycorticosteroid - induced Entityglaucoma after intravitreal injection of triamcinolone acetate in a 34 - year - old man without a history of glaucoma. |
| 0.9997 | Adverse-Effect | PURPOSE : To report a case of severe corticosteroid - induced Entityglaucoma after intravitreal injection of Entitytriamcinolone acetate in a 34 - year - old man without a history of glaucoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present two children with acute lymphocytic leukemia who developed Entityleukoencephalopathy following administration of a combination of intravenous Entityara = C and methotrexate during the consolidation phase of chemotherapy. |
| 0.9999 | Adverse-Effect | We present two children with acute lymphocytic leukemia who developed Entityleukoencephalopathy following administration of a combination of intravenous ara = C and Entitymethotrexate during the consolidation phase of chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | On the second day of hospitalization, it was noted that the patient's dyspnea and Entitysinus bradycardia could be related to a recent increase in his Entitytimolol dosage. |
| 0.9999 | Adverse-Effect | On the second day of hospitalization, it was noted that the patient's Entitydyspnea and sinus bradycardia could be related to a recent increase in his Entitytimolol dosage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinicians should be aware that an erythematous and Entityexfoliative rash may be induced by Entitytemozolomide , and be familiar with the pharmacologic and supportive measures necessary for its treatment. |
| 0.9998 | Adverse-Effect | Clinicians should be aware that an Entityerythematous and exfoliative rash may be induced by Entitytemozolomide , and be familiar with the pharmacologic and supportive measures necessary for its treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians should be aware of the potential for the development of EntityRS among children who are receiving long - term Entityaspirin therapy for the treatment of systemic inflammatory illnesses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A review of the literature found 11 children and 2 adults in whom intranasal Entitydesmopressin was associated with Entityhyponatremia , all of whom experienced seizures or altered mental status. |
| 0.9999 | Adverse-Effect | A review of the literature found 11 children and 2 adults in whom intranasal Entitydesmopressin was associated with hyponatremia, all of whom experienced Entityseizures or altered mental status. |
| 0.9999 | Adverse-Effect | A review of the literature found 11 children and 2 adults in whom intranasal Entitydesmopressin was associated with hyponatremia, all of whom experienced seizures or Entityaltered mental status . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a case of severe Entityskin necrosis resulting from peripheral intravenous administration of low - dose Entityvasopressin in a patient with catecholamine - resistant septic shock. |
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a case of Entitysevere skin necrosis resulting from peripheral intravenous administration of low - dose Entityvasopressin in a patient with catecholamine - resistant septic shock. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Clinicians who manage cachectic patients, particularly those with protracted diarrhoea and / or receiving anti - malarial drugs including Entitymefloquine , should be aware of the risk of Entitysevere hypoglycaemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 25 - year - old postpartum white woman developed multiple watery stools and Entityabdominal cramping on day 6 of therapy with Entityclindamycin vaginal cream for bacterial vaginosis. |
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 25 - year - old postpartum white woman developed Entitymultiple watery stools and abdominal cramping on day 6 of therapy with Entityclindamycin vaginal cream for bacterial vaginosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware of this adverse reaction when facing similar complex Entityneurologic symptoms in patients who are receiving the antibiotic treatment described here, especially Entityvancomycin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a Entitypulmonary adverse reaction , a feature never previously associated with Entityoxaliplatinum and 5 - fluorouracil regimens. |
| 0.9999 | Adverse-Effect | It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a Entitypulmonary adverse reaction , a feature never previously associated with oxaliplatinum and Entity5 - fluorouracil regimens. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | For patients who suffer from osteogenic sarcoma and have Entityanaphylactic reactions to EntityMTX , this desensitization protocol will allow these patients to continue with needed therapeutic or palliative chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Here we present the case of a Entitygeneralized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with Entityinterferon alpha and ribavirin. |
| 0.9999 | Adverse-Effect | Here we present the case of a Entitygeneralized lichen nitidus with involvement of the palms in a patient with hepatitis C after systemic treatment with interferon alpha and Entityribavirin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | First, a review of the literature produced 41 anecdotic cases of neutropenia or Entityagranulocytosis during treatment with Entityolanzapine ( Zyprexa ) reported in a total of 24 publications. |
| 1.0000 | Adverse-Effect | First, a review of the literature produced 41 anecdotic cases of neutropenia or Entityagranulocytosis during treatment with olanzapine ( EntityZyprexa ) reported in a total of 24 publications. |
| 0.9999 | Adverse-Effect | First, a review of the literature produced 41 anecdotic cases of Entityneutropenia or agranulocytosis during treatment with Entityolanzapine ( Zyprexa ) reported in a total of 24 publications. |
| 0.9998 | Adverse-Effect | First, a review of the literature produced 41 anecdotic cases of Entityneutropenia or agranulocytosis during treatment with olanzapine ( EntityZyprexa ) reported in a total of 24 publications. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCisplatin - induced Entitysyndrome of inappropriate antidiuretic hormone ( SIADH ) in a patient with neuroendocrine tumor of the cervix : a case report and review of the literature. |
| 0.9999 | Adverse-Effect | EntityCisplatin - induced syndrome of inappropriate antidiuretic hormone ( EntitySIADH ) in a patient with neuroendocrine tumor of the cervix : a case report and review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 21 - year - old woman suffering from bipolar affective disorder developed systemic lupus erythematosus ( EntitySLE ) with characteristic laboratory findings, 18 months after starting Entitycarbamazepine maintenance treatment. |
| 1.0000 | Adverse-Effect | A 21 - year - old woman suffering from bipolar affective disorder developed Entitysystemic lupus erythematosus ( SLE ) with characteristic laboratory findings, 18 months after starting Entitycarbamazepine maintenance treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : To our knowledge, this is the first case report illustrating Entityneuralgic amyotrophy triggered by exposure to the antibiotics Entityvancomycin , tobramycin, and piperacillin / tazobactam. |
| 1.0000 | Adverse-Effect | DISCUSSION : To our knowledge, this is the first case report illustrating Entityneuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, Entitytobramycin , and piperacillin / tazobactam. |
| 1.0000 | Adverse-Effect | DISCUSSION : To our knowledge, this is the first case report illustrating Entityneuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and piperacillin / Entitytazobactam . |
| 0.9999 | Adverse-Effect | DISCUSSION : To our knowledge, this is the first case report illustrating Entityneuralgic amyotrophy triggered by exposure to the antibiotics vancomycin, tobramycin, and Entitypiperacillin / tazobactam. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : We hereby report a case of radiation recall dermatitis and Entitymyositis occurring on Entitygemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer. |
| 0.9999 | Adverse-Effect | CASE REPORT : We hereby report a case of Entityradiation recall dermatitis and myositis occurring on Entitygemcitabine monotherapy, five months after completing chemoradiation for locally advanced pancreatic cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Caution in longterm usage and early recognition of Entitypentazocine Entitypentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug - induced fibrous myopathy and localized neuropathy. |
| 0.9986 | Adverse-Effect | Caution in longterm usage and early recognition of Entitypentazocine toxicity as a Entityneuromuscular complication are important in order to prevent irreversible drug - induced fibrous myopathy and localized neuropathy. |
| 0.9964 | Adverse-Effect | Caution in longterm usage and early recognition of Entitypentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug - induced Entityfibrous myopathy and localized neuropathy. |
| 0.9960 | Adverse-Effect | Caution in longterm usage and early recognition of Entitypentazocine toxicity as a neuromuscular complication are important in order to prevent irreversible drug - induced fibrous myopathy and localized Entityneuropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 40 - year - old man with advanced HIV infection and Mycobacterium avium complex infection experienced Entityrapid cognitive decline after commencement of Entityethambutol , and symptoms fully resolved with cessation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He was started on Entitydigoxin , 0. 25 mg daily, because of echocardiographically demonstrated Entityleft ventricular dilatation and functional impairment ; he died of ventricular fibrillation 15 days later. |
| 0.9999 | Adverse-Effect | He was started on Entitydigoxin , 0. 25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and functional impairment ; he died of Entityventricular fibrillation 15 days later. |
| 0.9998 | Adverse-Effect | He was started on Entitydigoxin , 0. 25 mg daily, because of echocardiographically demonstrated left ventricular dilatation and Entityfunctional impairment ; he died of ventricular fibrillation 15 days later. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of EntityMMC - related Entityhemolytic uremic syndrome , and discuss the etiologic parameters, clinical aspects, prognosis and treatment modalities of this severe syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An obese patient, not diabetic, treated with Entitymetformin for some weeks, was referred to us with Entitysevere inferior digestive hemorrhage , diagnosed with Meckel's diverticulum. |
| 0.9999 | Adverse-Effect | An obese patient, not diabetic, treated with Entitymetformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with EntityMeckel's diverticulum . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed Entitygeneralized erythema with high fever 3 weeks after taking Entitysulfamethoxazole / trimethoprim. |
| 0.9999 | Adverse-Effect | A 61 - year - old man with early diffuse cutaneous scleroderma with myositis and progressive interstitial pneumonia developed Entitygeneralized erythema with high fever 3 weeks after taking sulfamethoxazole / Entitytrimethoprim . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient had recurrence of urticaria and Entityangioedema a year and a half later, at which point the EntityNPH was stopped and she was desensitized to regular insulin. |
| 0.9999 | Adverse-Effect | The patient had recurrence of urticaria and Entityangioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular Entityinsulin . |
| 0.9998 | Adverse-Effect | The patient had recurrence of Entityurticaria and angioedema a year and a half later, at which point the EntityNPH was stopped and she was desensitized to regular insulin. |
| 0.9998 | Adverse-Effect | The patient had recurrence of Entityurticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular Entityinsulin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient was positive for antibody against complexes of heparin and platelet factor 4, and was diagnosed as Entityheparin - induced Entitythrombocytopenia with thrombosis syndrome ( HITTS ). |
| 0.9997 | Adverse-Effect | The patient was positive for antibody against complexes of heparin and platelet factor 4, and was diagnosed as Entityheparin - induced thrombocytopenia with Entitythrombosis syndrome ( HITTS ). |
| 0.9987 | Adverse-Effect | The patient was positive for antibody against complexes of Entityheparin and platelet factor 4, and was diagnosed as heparin - induced Entitythrombocytopenia with thrombosis syndrome ( HITTS ). |
| 0.9979 | Adverse-Effect | The patient was positive for antibody against complexes of Entityheparin and platelet factor 4, and was diagnosed as heparin - induced thrombocytopenia with Entitythrombosis syndrome ( HITTS ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 73 year - old patient with Wolff - Parkinson - White syndrome and paroxysmic supraventricular tachycardia developed an Entityacute reversible encephalopathy within 15 days of initiation of Entityflecainide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To the best of our knowledge, this is the first reported patient with Entitycaptopril - induced Entitypemphigus in whom no new lesions developed after subsequent treatment with enalapril. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although Entitypraziquantel administration may have been effective in killing the parasite in both patients, we are concerned about the production of marked Entityinflammation as a result of treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report the occurrence of Entityanterior ischemic optic neuropathy as a complication of treatment with Entityinterferon alfa and to consider the possible underlying mechanisms for this association. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The authors describe a patient with hemiparesis who developed the syndrome of irreversible Entitylithium - effectuated Entityneurotoxicity ( SILENT ) while being treated with lithium for a manic episode. |
| 0.9917 | Adverse-Effect | The authors describe a patient with hemiparesis who developed the syndrome of irreversible lithium - effectuated Entityneurotoxicity ( SILENT ) while being treated with Entitylithium for a manic episode. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of unintentional overdose of oral Entitypilocarpine tablets that resulted in Entitybradycardia , mild hypotension, and muscarinic symptoms in a patient with Sjogren's syndrome. |
| 1.0000 | Adverse-Effect | We report a case of unintentional overdose of oral Entitypilocarpine tablets that resulted in bradycardia, Entitymild hypotension , and muscarinic symptoms in a patient with Sjogren's syndrome. |
| 1.0000 | Adverse-Effect | We report a case of unintentional overdose of oral Entitypilocarpine tablets that resulted in bradycardia, mild hypotension, and Entitymuscarinic symptoms in a patient with Sjogren's syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGold - salt therapy may result in Entitydamage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an autoimmune membranous nephropathy. |
| 0.9978 | Adverse-Effect | EntityGold - salt therapy may result in damage to proximal tubules that leak renal tubular antigens, which in turn complex with autoantibody and produce an Entityautoimmune membranous nephropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the present paper, we describe two patients with active UC who developed a Entitysevere systemic CMV infection during a treatment with an oral microemulsion form of Entitycyclosporine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe Entitylithium Entityneurotoxicity . |
| 0.9989 | Adverse-Effect | When the acute manic state is characterized by marked Entitypsychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe Entitylithium neurotoxicity. |
| 0.9987 | Adverse-Effect | When the acute manic state is characterized by marked psychotic symptoms and Entityintense anxiety , it may be associated with increased vulnerability to the development of severe Entitylithium neurotoxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a patient with an embryonal teratocarcinoma of the testicle who had the syndrome of Entityinappropriate secretion of antidiuretic hormone after receiving a high dose of Entityvinblastine . |
| 1.0000 | Adverse-Effect | We report on a patient with an embryonal teratocarcinoma of the testicle who had the Entitysyndrome of inappropriate secretion of antidiuretic hormone after receiving a high dose of Entityvinblastine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although a lot of Entityamiodarone - induced Entitytorsades de pointe have been published, a review of all these cases and the underlying risk - factors has never been made. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Type II Entityheparin - induced Entitythrombocytopenia ( HIT ) is an immunological disorder characterized by antibodies to heparin - platelet factor 4 complexes and a high risk of thrombotic complications. |
| 0.9991 | Adverse-Effect | Type II Entityheparin - induced thrombocytopenia ( EntityHIT ) is an immunological disorder characterized by antibodies to heparin - platelet factor 4 complexes and a high risk of thrombotic complications. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of Entitydihydrotachysterol by rifampicin, could have led to Entityincreased calcium - release into the circulation. |
| 1.0000 | Adverse-Effect | Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by Entityrifampicin , could have led to Entityincreased calcium - release into the circulation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although useful in the management of chronic alcoholism, Entitydisulfiram is being increasingly associated with a wide spectrum of side effects and untoward medical sequelae, which now include Entitycatatonia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient was enrolled in a weight - loss clinic, and his diabetes medications were adjusted. Subsequently, Entityolanzapine was discontinued because of Entityweight gain and uncontrolled diabetes. |
| 1.0000 | Adverse-Effect | The patient was enrolled in a weight - loss clinic, and his diabetes medications were adjusted. Subsequently, Entityolanzapine was discontinued because of weight gain and Entityuncontrolled diabetes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | I report a 35 - year - old woman with occult coronary artery disease who experienced Entitycardiac arrest within minutes after receiving a first - time dose of subcutaneous Entitysumatriptan for migraine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Despite a hematologic response in all 3 patients, none of them achieved cytogenetic remission, and all progressed to Entityblast crisis at 7 to 10 months of Entityimatinib therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Because Entitysumatriptan can cause Entitycoronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of sumatriptan. |
| 0.9968 | Adverse-Effect | Because sumatriptan can cause Entitycoronary artery vasospasm , patients with significant risk factors for coronary artery disease should be carefully evaluated for cardiovascular disease prior to the use of Entitysumatriptan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a Entityseizure during consolidation treatment with EntityL - asparaginase . |
| 0.9995 | Adverse-Effect | We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated Entitytransient ischemic attacks followed by a seizure during consolidation treatment with EntityL - asparaginase . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityProliferation of abnormal bone marrow histiocytes , an undesired effect of Entitygranulocyte macrophage - colony - stimulating factor therapy in a patient with Hurler's syndrome undergoing bone marrow transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The diagnosis was based on the rapid onset of Entityrenal failure , presence of eosinophilia, skin rash, and characteristic renal biopsy finding, following the administration of Entityampicillin . |
| 1.0000 | Adverse-Effect | The diagnosis was based on the rapid onset of renal failure, presence of eosinophilia, Entityskin rash , and characteristic renal biopsy finding, following the administration of Entityampicillin . |
| 1.0000 | Adverse-Effect | The diagnosis was based on the rapid onset of renal failure, presence of Entityeosinophilia , skin rash, and characteristic renal biopsy finding, following the administration of Entityampicillin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Monitoring of liver function tests should be mandatory in patients receiving high doses of Entitycyproterone acetate ; the drug should be withdrawn immediately if Entityabnormal liver function tests are found. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The first patient developed a Entitymonoarthritis 2 weeks after initiation of EntityIFN - beta , which persisted during the 14 months of therapy and resolved with discontinuation of the medication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityNaproxen , the most common offender, has been associated with a dimorphic clinical pattern : a PCT - like presentation and one simulating Entityerythropoietic protoporphyria in the pediatric population. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Parenteral pyridoxine, the specific antidote for EntityINH - induced Entityrefractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB. |
| 0.9997 | Adverse-Effect | Parenteral Entitypyridoxine , the specific antidote for INH - induced Entityrefractory seizures , should be readily available in every emergency department in the areas similarly experiencing increasing trends of TB. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Alternating sinus rhythm and Entityintermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman, under treatment for angina with 80 mg Entitypropranolol daily. |
| 1.0000 | Adverse-Effect | EntityAlternating sinus rhythm and intermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman, under treatment for angina with 80 mg Entitypropranolol daily. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the development of Entityischemic colitis in a woman who was treated with Entitytegaserod and review the relationship among ischemic colitis, tegaserod use, and irritable bowel syndrome. |
| 1.0000 | Adverse-Effect | We describe the development of ischemic colitis in a woman who was treated with Entitytegaserod and review the relationship among Entityischemic colitis , tegaserod use, and irritable bowel syndrome. |
| 0.9999 | Adverse-Effect | We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, Entitytegaserod use, and Entityirritable bowel syndrome . |
| 0.9992 | Adverse-Effect | We describe the development of ischemic colitis in a woman who was treated with tegaserod and review the relationship among Entityischemic colitis , Entitytegaserod use, and irritable bowel syndrome. |
| 0.9991 | Adverse-Effect | We describe the development of Entityischemic colitis in a woman who was treated with tegaserod and review the relationship among ischemic colitis, Entitytegaserod use, and irritable bowel syndrome. |
| 0.9987 | Adverse-Effect | We describe the development of ischemic colitis in a woman who was treated with Entitytegaserod and review the relationship among ischemic colitis, tegaserod use, and Entityirritable bowel syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 7 - year - old girl developed diabetes mellitus and Entityexocrine pancreatic insufficiency after 3. 5 years of almost continuous treatment with Entityazathioprine and / or prednisone for idiopathic auto - immune haemolytic anaemia. |
| 1.0000 | Adverse-Effect | A 7 - year - old girl developed Entitydiabetes mellitus and exocrine pancreatic insufficiency after 3. 5 years of almost continuous treatment with Entityazathioprine and / or prednisone for idiopathic auto - immune haemolytic anaemia. |
| 1.0000 | Adverse-Effect | A 7 - year - old girl developed diabetes mellitus and Entityexocrine pancreatic insufficiency after 3. 5 years of almost continuous treatment with azathioprine and / or Entityprednisone for idiopathic auto - immune haemolytic anaemia. |
| 0.9999 | Adverse-Effect | A 7 - year - old girl developed Entitydiabetes mellitus and exocrine pancreatic insufficiency after 3. 5 years of almost continuous treatment with azathioprine and / or Entityprednisone for idiopathic auto - immune haemolytic anaemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Flare of Kaposi's sarcoma ( EntityKS ) is well described in immunosuppressed patients treated with corticosteroids and Entityrituximab , but has not yet been reported during treatment with imatinib. |
| 1.0000 | Adverse-Effect | Flare of EntityKaposi's sarcoma ( KS ) is well described in immunosuppressed patients treated with corticosteroids and Entityrituximab , but has not yet been reported during treatment with imatinib. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | The uncomplicated long - term use of adequately - dosed EntityAZA and stable non - toxic metabolite levels could not acknowledge TPMT deficiency as a primary cause of the Entityleukopenia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Theoretical basal ganglia toxicologic mechanisms of Entitymethanol Entitymethanol poisoning are reviewed, and the role of brain imaging studies will regard to diagnosis, prognosis and impact on management is discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of biopsy - proven Entityacute tubulointerstitial nephritis associated with a second course of Entityflurbiprofen , a nonsteroidal anti - inflammatory drug of the propionic acid class. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a Entitysyringotropic hypersensitivity reaction after 9 months of therapy with Entityinfliximab and leflunomide is described. |
| 1.0000 | Adverse-Effect | A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a Entitysyringotropic hypersensitivity reaction after 9 months of therapy with infliximab and Entityleflunomide is described. |
| 1.0000 | Adverse-Effect | A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a Entitysyringotropic hypersensitivity reaction after 9 months of therapy with Entityinfliximab and leflunomide is described. |
| 0.9999 | Adverse-Effect | A 17 - year - old boy with refractory psoriatic arthritis and alpha - 1 antitrypsin deficiency who developed a Entitysyringotropic hypersensitivity reaction after 9 months of therapy with infliximab and Entityleflunomide is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Dipyrone, also known as Entitymetamizole , is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with Entityagranulocytosis . |
| 0.9999 | Adverse-Effect | EntityDipyrone , also known as metamizole, is an analgesic and antipyretic drug that was banned by the United States Food and Drug Administration because of its association with Entityagranulocytosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This is, to the best of our knowledge, the first report of a case in which Entityagranulocytosis followed treatment with both Entitypropylthiouracil and methimazole in the same patient. |
| 1.0000 | Adverse-Effect | This is, to the best of our knowledge, the first report of a case in which Entityagranulocytosis followed treatment with both propylthiouracil and Entitymethimazole in the same patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although they had only a few nodules at diagnosis, the Entitynodules increased in number and size 3 to 4 months after the start of Entitymethotrexate therapy in both patients. |
| 0.9997 | Adverse-Effect | Although they had only a few Entitynodules at diagnosis, the nodules increased in number and size 3 to 4 months after the start of Entitymethotrexate therapy in both patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE : We present an 11 - year old male with Budd - Chiari syndrome who experienced profound Entityworsening of chronic aphthous ulcers after immunosuppressive therapy was changed from Entitytacrolimus to sirolimus. |
| 1.0000 | Adverse-Effect | CASE : We present an 11 - year old male with Budd - Chiari syndrome who experienced profound Entityworsening of chronic aphthous ulcers after immunosuppressive therapy was changed from tacrolimus to Entitysirolimus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Though hypotension, dry mouth, and constipation are well - documented possible adverse effects, the possibility of Entityclonidine - induced Entitybradycardia is less well recognized and is rare. |
| 0.9998 | Adverse-Effect | Though hypotension, dry mouth, and Entityconstipation are well - documented possible adverse effects, the possibility of Entityclonidine - induced bradycardia is less well recognized and is rare. |
| 0.9992 | Adverse-Effect | Though Entityhypotension , dry mouth, and constipation are well - documented possible adverse effects, the possibility of Entityclonidine - induced bradycardia is less well recognized and is rare. |
| 0.9992 | Adverse-Effect | Though hypotension, Entitydry mouth , and constipation are well - documented possible adverse effects, the possibility of Entityclonidine - induced bradycardia is less well recognized and is rare. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASES : " A " was an 8 - year - old boy with attention deficit and chronic tic disorder who developed Entityobsessive - compulsive symptoms within 2 weeks of starting Entityrisperidone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 71 - year male with castration - resistant metastatic prostate cancer who was treated with weekly Entitydocetaxel for 12 weeks and developed significant Entityeye irritation and dryness during treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : All doctors need to be aware of the need to review the indications for Entitygabapentin use during periods of acute illness, especially with regard to Entityrenal impairment . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the presented case Entityfluvoxamine - induced Entityakathisia in an OCD patient was partially resistant to the anticholinergic agent biperiden, and was successfully treated with the 5 - HT2A / 5 - HT2C antagonist mianserin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9975 | Adverse-Effect | The wide use of phenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to Entityphenytoin Entityphenytoin toxicity . |
| 0.9891 | Adverse-Effect | The wide use of Entityphenytoin during the recent tuberculosis epidemic makes it imperative to suspect this drug interaction in patients exhibiting clinical features that might be related to Entityphenytoin toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Review of the literature relating to Entitymethicillin - induced Entitynephropathy suggests a hypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis. |
| 0.9794 | Adverse-Effect | Review of the literature relating to Entitymethicillin - induced nephropathy suggests a Entityhypersensitivity origin for this disorder, but immunologic and ultrastructural investigation to date has failed to elucidate pathogenesis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We hypothesize that Entitycaffeine Entitycaffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis. |
| 0.9992 | Adverse-Effect | We hypothesize that Entitycaffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe Entityrhabdomyolysis . |
| 0.9991 | Adverse-Effect | We hypothesize that Entitycaffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the Entitycoexisting hyponatremia , to result in unusually severe rhabdomyolysis. |
| 0.9990 | Adverse-Effect | We hypothesize that Entitycaffeine toxicity injured the muscle cells, which were fragile due to the Entitypotassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis. |
| Adverse-Effect | We hypothesize that Entitycaffeine toxicity Entityinjured the muscle cells , which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In conclusion, EntityRSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( EntityCyA or tacrolimus ), even under monotherapy or with a low steroid dose. |
| 1.0000 | Adverse-Effect | In conclusion, EntityRSDS is a relevant osteoarticular complication in patients receiving either anticalcineurinic drug ( CyA or Entitytacrolimus ), even under monotherapy or with a low steroid dose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityinterstitial pneumonitis induced by Entitybicalutamide and / or leuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment. |
| 0.9993 | Adverse-Effect | We report a case of Entityinterstitial pneumonitis induced by bicalutamide and / or Entityleuprorelin acetate given as therapy for prostate cancer, in which the pneumonitis was successfully managed by steroid treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative hypophosphatemia and Entityhypocalcemic tetany after bowel preparation with EntityFleet Phospho - Soda . |
| 1.0000 | Adverse-Effect | This case report describes a patient who was previously prescribed alendronate ( EntityFosamax ) and presented with postoperative Entityhypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9999 | Adverse-Effect | This case report describes a patient who was previously prescribed alendronate ( EntityFosamax ) and presented with postoperative hypophosphatemia and Entityhypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9999 | Adverse-Effect | This case report describes a patient who was previously prescribed Entityalendronate ( Fosamax ) and presented with postoperative Entityhypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9998 | Adverse-Effect | This case report describes a patient who was previously prescribed Entityalendronate ( Fosamax ) and presented with postoperative hypophosphatemia and Entityhypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9995 | Adverse-Effect | This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with postoperative Entityhypophosphatemia and hypocalcemic tetany after bowel preparation with EntityFleet Phospho - Soda . |
| 1.0000 | Adverse-Effect | This case report describes a patient who was previously prescribed alendronate ( EntityFosamax ) and presented with Entitypostoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9999 | Adverse-Effect | This case report describes a patient who was previously prescribed Entityalendronate ( Fosamax ) and presented with Entitypostoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho - Soda. |
| 0.9997 | Adverse-Effect | This case report describes a patient who was previously prescribed alendronate ( Fosamax ) and presented with Entitypostoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with EntityFleet Phospho - Soda . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Patients from endemic areas referred to transplant centers may be at high risk for Entitydisseminated histoplasmosis when treated with long - term Entityprednisone for graft - versus - host disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The third patient had been suffering from serious Entityakathisia while on Entityrisperidone , and was cured after switching to olanzapine, but thereafter the patient suffered from RLS at nighttime. |
| 1.0000 | Adverse-Effect | The third patient had been suffering from serious akathisia while on risperidone, and was cured after switching to Entityolanzapine , but thereafter the patient suffered from EntityRLS at nighttime. |
| 0.9999 | Adverse-Effect | The third patient had been suffering from serious akathisia while on Entityrisperidone , and was cured after switching to olanzapine, but thereafter the patient suffered from EntityRLS at nighttime. |
| 0.9995 | Adverse-Effect | The third patient had been suffering from serious Entityakathisia while on risperidone, and was cured after switching to Entityolanzapine , but thereafter the patient suffered from RLS at nighttime. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : We recently experienced a case of fatal Entityerlotinib - induced EntityILD , diagnosed based on clinical and radiologic findings, which occurred in a patient with radiation fibrosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the second case, five cardiac arrests due to ventricular tachycardia and Entityfibrillation occurred during several hours after beginning a trial of Entitybretylium maintenance therapy for complex ventricular ectopy. |
| 0.9999 | Adverse-Effect | In the second case, five cardiac arrests due to Entityventricular tachycardia and fibrillation occurred during several hours after beginning a trial of Entitybretylium maintenance therapy for complex ventricular ectopy. |
| 0.9999 | Adverse-Effect | In the second case, five Entitycardiac arrests due to ventricular tachycardia and fibrillation occurred during several hours after beginning a trial of Entitybretylium maintenance therapy for complex ventricular ectopy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and Entitytachycardia soon after administration of EntityCBDCA . |
| 1.0000 | Adverse-Effect | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, Entityhypotension , and tachycardia soon after administration of EntityCBDCA . |
| 1.0000 | Adverse-Effect | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed Entityeruptions , hypotension, and tachycardia soon after administration of EntityCBDCA . |
| 0.9999 | Adverse-Effect | However, one patient exhibited severe hypersensitivity reactions including Entitycardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of EntityCBDCA . |
| 0.9999 | Adverse-Effect | However, one patient exhibited severe hypersensitivity reactions including cardiac arrest and Entityapnea , and another four patients developed eruptions, hypotension, and tachycardia soon after administration of EntityCBDCA . |
| 0.9999 | Adverse-Effect | However, one patient exhibited Entitysevere hypersensitivity reactions including cardiac arrest and apnea, and another four patients developed eruptions, hypotension, and tachycardia soon after administration of EntityCBDCA . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9883 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with Entitybusulphan for 4 - 5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and Entityjaundice . |
| 0.9865 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with Entitybusulphan for 4 - 5 years, developed signs of busulphan toxicity and portal hypertension with ascites, Entityoesophageal varices and jaundice. |
| 0.9864 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with Entitybusulphan for 4 - 5 years, developed signs of busulphan toxicity and portal hypertension with Entityascites , oesophageal varices and jaundice. |
| 0.9737 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with Entitybusulphan for 4 - 5 years, developed signs of busulphan toxicity and Entityportal hypertension with ascites, oesophageal varices and jaundice. |
| 0.9988 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with Entitybusulphan for 4 - 5 years, developed signs of Entitybusulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice. |
| 0.9874 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of Entitybusulphan Entitybusulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice. |
| 0.8683 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of Entitybusulphan toxicity and portal hypertension with Entityascites , oesophageal varices and jaundice. |
| 0.8632 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of Entitybusulphan toxicity and portal hypertension with ascites, Entityoesophageal varices and jaundice. |
| 0.8610 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of Entitybusulphan toxicity and portal hypertension with ascites, oesophageal varices and Entityjaundice . |
| 0.7955 | Adverse-Effect | A patient with chronic myeloid leukaemia treated with busulphan for 4 - 5 years, developed signs of Entitybusulphan toxicity and Entityportal hypertension with ascites, oesophageal varices and jaundice. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 65 - year - old woman, in the intensive care unit because of septic shock and acute renal failure, had a Entitysmall - bowel obstruction due to EntityAmphojel concretions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To our knowledge, this is the first case report that demonstrates the occurrence of Entityfever with low - dose Entityamifostine therapy without the manifestation of accompanying rash or hypotension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 17 - year - old boy with acute lymphoblastic leukemia developed Entityacute renal failure within 48 h of an intravenous high - dose Entitymethotrexate ( 5 g / m2 ) infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 17 - year - old male who developed chest pain, elevated cardiac biomarkers, and Entityacute left ventricular dysfunction following a single dose of Entitymethylphenidate . |
| 1.0000 | Adverse-Effect | We report the case of a 17 - year - old male who developed chest pain, Entityelevated cardiac biomarkers , and acute left ventricular dysfunction following a single dose of Entitymethylphenidate . |
| 0.9999 | Adverse-Effect | We report the case of a 17 - year - old male who developed Entitychest pain , elevated cardiac biomarkers, and acute left ventricular dysfunction following a single dose of Entitymethylphenidate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entityfatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with Entitylevomepromazine , diazepam and lithium carbonate. |
| 0.9998 | Adverse-Effect | A Entityfatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, Entitydiazepam and lithium carbonate. |
| 0.9995 | Adverse-Effect | A Entityfatal pancytopenia occurred in a patient with an history of depression with hypomanic rebounds, admitted for a manic episode and treated with levomepromazine, diazepam and Entitylithium carbonate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although Entitytardive dyskinesia is a known adverse reaction of sustained treatment with traditional neuroleptic agents, it was only rarely reported in association with Entitysulpiride , a selective D2 - receptor antagonist. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 58 - year - old woman developed Entityunilateral acute angle - closure glaucoma four days after the application of a patch of transdermal Entityscopolamine delivery system ( TRANSDERM - V ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | At the end of his fifth cycle of Entitysunitinib therapy, the patient complained of the Entitydevelopment of abnormally large mammary glands associated with pain and peri - areolar erythema. |
| 1.0000 | Adverse-Effect | At the end of his fifth cycle of Entitysunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with Entitypain and peri - areolar erythema. |
| 0.9999 | Adverse-Effect | At the end of his fifth cycle of Entitysunitinib therapy, the patient complained of the development of abnormally large mammary glands associated with pain and Entityperi - areolar erythema . |
| 1.0000 | Adverse-Effect | At the end of his fifth cycle of Entitysunitinib therapy, the patient complained of the development of Entityabnormally large mammary glands associated with pain and peri - areolar erythema. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CONCLUSIONS : This observation of " on - off " risperidone treatment suggests that Entityrisperidone may have worsened both Entitypsychiatric and physical manifestations of the mitochondrial disorder in this adolescent. |
| 0.9993 | Adverse-Effect | CONCLUSIONS : This observation of " on - off " Entityrisperidone treatment suggests that risperidone may have worsened both Entitypsychiatric and physical manifestations of the mitochondrial disorder in this adolescent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 50 - year - old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a Entityspinal cord lesion following the use of Entityzolmitriptan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : Healthcare professionals should be aware of the possible development of Entityserotonin syndrome as a complication of initiation of Entityfentanyl and other phenylpiperidine opioids in patients treated with SSRIs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes a case of acute compromise of renal function associated with Entityhypotension in a 7 - year - old boy treated with the ACE inhibitor Entitylisinopril and the ARB losartan. |
| 1.0000 | Adverse-Effect | This report describes a case of acute compromise of renal function associated with Entityhypotension in a 7 - year - old boy treated with the ACE inhibitor lisinopril and the ARB Entitylosartan . |
| 0.9998 | Adverse-Effect | This report describes a case of Entityacute compromise of renal function associated with hypotension in a 7 - year - old boy treated with the ACE inhibitor Entitylisinopril and the ARB losartan. |
| 0.9994 | Adverse-Effect | This report describes a case of Entityacute compromise of renal function associated with hypotension in a 7 - year - old boy treated with the ACE inhibitor lisinopril and the ARB Entitylosartan . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The first patient developed mild nitritoid symptoms and pain in a band - like distribution, corresponding to EntityT10 - T12 dermatomes , shortly after Entitygold sodium thiomalate ( GSTM ) injection. |
| 0.9998 | Adverse-Effect | The first patient developed mild nitritoid symptoms and pain in a band - like distribution, corresponding to EntityT10 - T12 dermatomes , shortly after gold sodium thiomalate ( EntityGSTM ) injection. |
| 0.9998 | Adverse-Effect | The first patient developed mild nitritoid symptoms and Entitypain in a band - like distribution, corresponding to T10 - T12 dermatomes, shortly after Entitygold sodium thiomalate ( GSTM ) injection. |
| 0.9997 | Adverse-Effect | The first patient developed Entitymild nitritoid symptoms and pain in a band - like distribution, corresponding to T10 - T12 dermatomes, shortly after Entitygold sodium thiomalate ( GSTM ) injection. |
| 0.9993 | Adverse-Effect | The first patient developed mild nitritoid symptoms and Entitypain in a band - like distribution, corresponding to T10 - T12 dermatomes, shortly after gold sodium thiomalate ( EntityGSTM ) injection. |
| 0.9993 | Adverse-Effect | The first patient developed Entitymild nitritoid symptoms and pain in a band - like distribution, corresponding to T10 - T12 dermatomes, shortly after gold sodium thiomalate ( EntityGSTM ) injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of an 11 - month - old female infant with a Entitydepressed level of consciousness after ingestion of Entityibuprofen whose mental status markedly improved with administration of naloxone. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9969 | Adverse-Effect | Acute EntityINH Entityneurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute INH neurotoxicity was made. |
| 0.9950 | Adverse-Effect | Acute INH neurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute EntityINH Entityneurotoxicity was made. |
| 0.9828 | Adverse-Effect | Acute INH neurotoxicity was not suspected on the first admission ; however, when readmitted 4 weeks later with another seizure, the diagnosis of acute EntityINH EntityINH neurotoxicity was made. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 58 - year - old man with advanced renal cell carcinoma developed grade 3 Entityproteinuria ( 8. 5 g / 24 h ) without microscopic hematuria or renal insufficiency five days after Entitytemsirolimus infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients treated for chronic myeloid leukemia with high doses of EntityCCNU ( 1100 mg / m2 and 1240 mg / m2, respectively ) developed a Entityfatal pulmonary fibrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the cases of two patients who developed Entityacute hepatitis after taking Entityriluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks, respectively. |
| Adverse-Effect | We report the cases of two patients who developed acute Entityhepatitis after taking Entityriluzole at the recommended dose ( 100 mg daily ) for 7 and 4 weeks, respectively. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and Entityaseptic meningitis simultaneously after using Entitytrimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, hepatitis, orthostatic hypotension, and Entityaseptic meningitis simultaneously after using trimethoprim - Entitysulfamethoxazole . |
| 0.9999 | Adverse-Effect | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, hepatitis, Entityorthostatic hypotension , and aseptic meningitis simultaneously after using Entitytrimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed Entityhemolytic anemia , hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using Entitytrimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, Entityhepatitis , orthostatic hypotension, and aseptic meningitis simultaneously after using Entitytrimethoprim - sulfamethoxazole. |
| 0.9999 | Adverse-Effect | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed Entityhemolytic anemia , hepatitis, orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim - Entitysulfamethoxazole . |
| 0.9998 | Adverse-Effect | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, hepatitis, Entityorthostatic hypotension , and aseptic meningitis simultaneously after using trimethoprim - Entitysulfamethoxazole . |
| 0.9998 | Adverse-Effect | CONCLUSION : A 37 - year - old African - American man with G6PD deficiency developed hemolytic anemia, Entityhepatitis , orthostatic hypotension, and aseptic meningitis simultaneously after using trimethoprim - Entitysulfamethoxazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHashimoto's disease during Entityinterferon - alpha therapy in a patient with pre - treatment negative anti - thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It should be emphasized that the recurrence of Entitynephrotic syndrome was observed after the following chemotherapy, including EntityM - CSF , whereas the bone marrow still remained completely remitted. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of Entityceftriaxone with Entityelevated hepato - biliary enzymes and transient biliary stasis. |
| 0.9991 | Adverse-Effect | Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of Entityceftriaxone with elevated hepato - biliary enzymes and Entitytransient biliary stasis . |
| 0.9969 | Adverse-Effect | EntityCeftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with Entityelevated hepato - biliary enzymes and transient biliary stasis. |
| 0.9953 | Adverse-Effect | EntityCeftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato - biliary enzymes and Entitytransient biliary stasis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a women in whom a Entitymalignant mixed mesodermal tumor was diagnosed while she was taking Entityraloxifene , which is also a selective estrogen receptor modulator. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The risk of drug - induced Entityrhabdomyolysis due to the potential interaction between Entitylovastatin and azithromycin or clarithromycin should be considered before the concomitant use of these agents. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : The risk of drug - induced Entityrhabdomyolysis due to the potential interaction between lovastatin and Entityazithromycin or clarithromycin should be considered before the concomitant use of these agents. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : The risk of drug - induced Entityrhabdomyolysis due to the potential interaction between lovastatin and azithromycin or Entityclarithromycin should be considered before the concomitant use of these agents. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four days after the initial injection of 3. 6 mg of Entitygoserelin acetate , Entitysevere dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare - up. |
| 0.9994 | Adverse-Effect | Four days after the initial injection of 3. 6 mg of Entitygoserelin acetate , severe dyspnea developed due to Entityworsening pleuritis carcinomatosa , which was considered as a flare - up. |
| 0.9991 | Adverse-Effect | Four days after the initial injection of 3. 6 mg of Entitygoserelin acetate , severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a Entityflare - up . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 43 - year - old woman with multiple sclerosis ( MS ) had Entitynephrotic syndrome 21 months after starting treatment with Entityinterferon ( IFN ) - beta - 1b ( subcutaneous administration ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : Interferon ( EntityIFN ) - associated Entityretinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9998 | Adverse-Effect | BACKGROUND : Interferon ( EntityIFN ) - associated retinopathy is typically characterized by Entityretinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9998 | Adverse-Effect | BACKGROUND : Interferon ( EntityIFN ) - associated retinopathy is typically characterized by retinal hemorrhages and Entitycotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9997 | Adverse-Effect | BACKGROUND : EntityInterferon ( IFN ) - associated Entityretinopathy is typically characterized by retinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9992 | Adverse-Effect | BACKGROUND : EntityInterferon ( IFN ) - associated retinopathy is typically characterized by Entityretinal hemorrhages and cotton wool spots at the posterior fundus, but visual function is usually maintained. |
| 0.9992 | Adverse-Effect | BACKGROUND : EntityInterferon ( IFN ) - associated retinopathy is typically characterized by retinal hemorrhages and Entitycotton wool spots at the posterior fundus, but visual function is usually maintained. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four months after receiving an orthotopic liver transplant, a 51 - year - old man was admitted for progressive liver failure and Entitysevere hepatocellular necrosis thought to be due to Entitytacrolimus . |
| 0.9999 | Adverse-Effect | Four months after receiving an orthotopic liver transplant, a 51 - year - old man was admitted for Entityprogressive liver failure and severe hepatocellular necrosis thought to be due to Entitytacrolimus . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We present a case of a 20 - year - old woman who ingested 900 mg of Entityglyburide causing refractory Entityhypoglycemia resistant to treatment with intravenous dextrose, glucagon, and diazoxide. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 25 - year - old man with a history of mid - borderline ( BB ) Hansen's disease developing a Entityreversal reaction after starting Entitydapsone and rifampin therapy is presented. |
| 1.0000 | Adverse-Effect | A 25 - year - old man with a history of mid - borderline ( BB ) Hansen's disease developing a Entityreversal reaction after starting dapsone and Entityrifampin therapy is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One of these was Entityclofazimine , an aniline aposafranine derivative known to produce a Entityceroid - like pigment in the tissues of patients treated with this drug or lepromatous leprosy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It was restarted 6 weeks later, and 10 weeks after that, the patient presented with Entityfulminant hepatic failure , which resolved rapidly after cessation of Entitynicotinic acid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report a case of an infant with complex congenital heart disease who was placed on Entitycaptopril for afterload reduction following cardiac surgery and subsequently developed Entitypulmonary infiltrates with eosinophilia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic Entitymineral oil ingestion presenting as asymptomatic Entityexogenous lipoid pneumonia ( ELP ). |
| 0.9999 | Adverse-Effect | We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic Entitymineral oil ingestion presenting as asymptomatic exogenous lipoid pneumonia ( EntityELP ). |
| 1.0000 | Adverse-Effect | We report a case of a child with neurodevelopmental delay with chronic constipation and a history of chronic Entitymineral oil ingestion presenting as Entityasymptomatic exogenous lipoid pneumonia ( ELP ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a previously healthy, postmenopausal woman who developed Entityanticonvulsant hypersensitivity syndrome while taking EntityBellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes. |
| 0.9999 | Adverse-Effect | We report a case of a previously healthy, postmenopausal woman who developed Entityanticonvulsant hypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; ergotamine ; Entityphenobarbital ) for hot flashes. |
| 0.9999 | Adverse-Effect | We report a case of a previously healthy, postmenopausal woman who developed Entityanticonvulsant hypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; Entityergotamine ; phenobarbital ) for hot flashes. |
| 0.9999 | Adverse-Effect | We report a case of a previously healthy, postmenopausal woman who developed Entityanticonvulsant hypersensitivity syndrome while taking Bellamine S ( Entitybelladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes. |
| 1.0000 | Adverse-Effect | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant Entityhypersensitivity syndrome while taking EntityBellamine S ( belladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes. |
| 0.9998 | Adverse-Effect | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant Entityhypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; ergotamine ; Entityphenobarbital ) for hot flashes. |
| 0.9998 | Adverse-Effect | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant Entityhypersensitivity syndrome while taking Bellamine S ( belladonna alkaloids ; Entityergotamine ; phenobarbital ) for hot flashes. |
| 0.9998 | Adverse-Effect | We report a case of a previously healthy, postmenopausal woman who developed anticonvulsant Entityhypersensitivity syndrome while taking Bellamine S ( Entitybelladonna alkaloids ; ergotamine ; phenobarbital ) for hot flashes. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | EntityPortal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of EntityF VIII after intramural jejunal bleeding - - successful thrombolysis under heparin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Oncologists supervising future clinical trials for lung cancer should be alert to the fact that Entitysorafenib can potentially induce serious Entityinterstitial lung disease , although this might depend on racial differences. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate tachycardia in the control state but Entitytachycardia was always reinitiated by an identical escape sequence after Entityprocainamide . |
| 0.9921 | Adverse-Effect | Escape atrial complexes, which occurred following junctional premature complexes, failed to initiate Entitytachycardia in the control state but tachycardia was always reinitiated by an identical escape sequence after Entityprocainamide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for Entityerlotinib Entitypulmonary toxicity . |
| 0.9997 | Adverse-Effect | Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known Entitypulmonary fibrosis may be at particular risk for Entityerlotinib pulmonary toxicity. |
| 0.9958 | Adverse-Effect | Similar to reports in patients receiving Entitygefitinib , those with pathologic findings of UIP on resected lung specimens or known Entitypulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity. |
| 0.9744 | Adverse-Effect | Similar to reports in patients receiving Entitygefitinib , those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib Entitypulmonary toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient who experienced chronic nausea and an episode of Entityconfusion while treated with a small, stable dose of oral Entitymorphine in the setting of mild renal insufficiency. |
| 1.0000 | Adverse-Effect | We describe a patient who experienced Entitychronic nausea and an episode of confusion while treated with a small, stable dose of oral Entitymorphine in the setting of mild renal insufficiency. |
| 1.0000 | Adverse-Effect | We describe a patient who experienced chronic Entitynausea and an episode of confusion while treated with a small, stable dose of oral Entitymorphine in the setting of mild renal insufficiency. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 22 - year - old drug - abuser injected Entityflunitrazepam tablets dissolved in tap water into her left femoral artery and presented with clinical signs of Entityacute ischaemia of the left leg . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report four cases of hemodynamically significant Entitypericardial effusion in patients with refractory lymphoma who were receiving Entitygemcitabine , all of whom had a history of mediastinal radiation without subcarinal blocking. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHyperammonemia has been described as a complication of Entityvalproic acid therapy but may often be overlooked as a cause of lethargy in the postictal patient who presents to the emergency department. |
| 0.9996 | Adverse-Effect | Hyperammonemia has been described as a complication of Entityvalproic acid therapy but may often be overlooked as a cause of Entitylethargy in the postictal patient who presents to the emergency department. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 66 - year - old mand suffering from severe coronary heart disease took Entitydigoxin with suicidal intent an was treated for the ensuing Entitycomplete atrioventricular block with digoxin - specific antibody fragments. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We described a very atypical case of a high stage, high grade Entityendometrial cancer associated with Entitytamoxifen in a 64 - year - old woman with a past history of breast cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of an acute flare of Entityeosinophilic cystitis in a 51 - year - old woman after bladder instillation with Entitydimethyl sulfoxide ( DMSO ) for presumed interstitial cystitis. |
| 0.9999 | Adverse-Effect | We report the first case of an acute flare of Entityeosinophilic cystitis in a 51 - year - old woman after bladder instillation with dimethyl sulfoxide ( EntityDMSO ) for presumed interstitial cystitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We conclude that vincristine and Entityactinomycin D were the cause of this rare from of Entityhepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery. |
| 0.9998 | Adverse-Effect | We conclude that Entityvincristine and actinomycin D were the cause of this rare from of Entityhepatotoxicity and that chemotherapy for the underlying malignant disease could be given safely after clinical recovery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityTransient anuria following administration of angiotensin I - converting enzyme inhibitor ( EntitySQ 14225 ) in a patient with renal artery stenosis of the solitary kidney successfully treated with renal autotransplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Flutamide withdrawal syndrome is characterized by a Entitydecrease in prostate - specific antigen ( PSA ) after Entityflutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. |
| 0.9995 | Adverse-Effect | EntityFlutamide withdrawal syndrome is characterized by a Entitydecrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. |
| 1.0000 | Adverse-Effect | EntityFlutamide Entitywithdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. |
| 0.9999 | Adverse-Effect | Flutamide Entitywithdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after Entityflutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. |
| Adverse-Effect | EntityFlutamide withdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after Entityflutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. | |
| Adverse-Effect | EntityFlutamide EntityFlutamide withdrawal syndrome is characterized by a decrease in prostate - specific antigen ( PSA ) after flutamide withdrawal in a subset of patients with progressing metastatic carcinoma of the prostate. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | All patients had taken Entityphenytoin for variable time periods ( range 16 - 80 days ; mean : 40 ) and were on the medication when the Entityskin lesions first appeared. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | On day 7 of Entitylinezolid treatment, the patient developed Entitysevere pruritus , macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis. |
| 1.0000 | Adverse-Effect | On day 7 of Entitylinezolid treatment, the patient developed severe pruritus, Entitymacular rash , facial edema, eosinophilia, marked increase in serum creatinine level, and mild hepatitis. |
| 1.0000 | Adverse-Effect | On day 7 of Entitylinezolid treatment, the patient developed severe pruritus, macular rash, Entityfacial edema , eosinophilia, marked increase in serum creatinine level, and mild hepatitis. |
| 1.0000 | Adverse-Effect | On day 7 of Entitylinezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, Entitymarked increase in serum creatinine level , and mild hepatitis. |
| 1.0000 | Adverse-Effect | On day 7 of Entitylinezolid treatment, the patient developed severe pruritus, macular rash, facial edema, Entityeosinophilia , marked increase in serum creatinine level, and mild hepatitis. |
| 0.9999 | Adverse-Effect | On day 7 of Entitylinezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked increase in serum creatinine level, and Entitymild hepatitis . |
| 0.9999 | Adverse-Effect | On day 7 of Entitylinezolid treatment, the patient developed severe pruritus, macular rash, facial edema, eosinophilia, marked Entityincrease in serum creatinine level , and mild hepatitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityGemcitabine is a known risk factor for Entityhemolytic uremic syndrome ( HUS ), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis. |
| 1.0000 | Adverse-Effect | EntityGemcitabine is a known risk factor for hemolytic uremic syndrome ( EntityHUS ), which can often have a rapidly fatal clinical course despite intervention with steroids, plasmapheresis and hemodialysis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE : We report a case of a woman with severe Entityhuman insulin - induced Entitylipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of IDDM. |
| 0.9999 | Adverse-Effect | CASE : We report a case of a woman with severe human insulin - induced Entitylipoatrophy who has been treated exclusively with Entityrecombinant DNA human insulin since the onset of IDDM. |
| 0.9999 | Adverse-Effect | CASE : We report a case of a woman with severe human insulin - induced lipoatrophy who has been treated exclusively with Entityrecombinant DNA human insulin since the onset of EntityIDDM . |
| 0.9971 | Adverse-Effect | CASE : We report a case of a woman with severe Entityhuman insulin - induced lipoatrophy who has been treated exclusively with recombinant DNA human insulin since the onset of EntityIDDM . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of Entitypolymorphic ventricular tachycardia with normal QT interval associated with the oral use of Entitylevofloxacin in the absence of other etiologies known to cause these arrhythmias. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low - dose Entitymethotrexate therapy might have promoted the development of Entitylung cancer . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Based on our experience and on previously published data, serum ammonia levels appear to be indicated in all ED patients on Entityvalproic acid therapy who present with Entityaltered mental status . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9992 | Adverse-Effect | CONCLUSIONS : Optic neuritis in combination with other Entityneurological signs , simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural Entityinterferon alpha administration. |
| 0.9988 | Adverse-Effect | CONCLUSIONS : EntityOptic neuritis in combination with other neurological signs, simulating multiple sclerosis, should be included in the list of adverse effects of recombinant and natural Entityinterferon alpha administration. |
| 0.9996 | Adverse-Effect | CONCLUSIONS : Optic neuritis in combination with other neurological signs, simulating Entitymultiple sclerosis , should be included in the list of adverse effects of recombinant and natural Entityinterferon alpha administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low - dose Entitymethotrexate : an Entityacute megaloblastic anaemia and a pneumonitis. |
| 0.9999 | Adverse-Effect | In a patient suffering from rheumatoid arthritis, we report the first simultaneous occurrence of two side effects of low - dose Entitymethotrexate : an acute megaloblastic anaemia and a Entitypneumonitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, synovitis, and Entitypossible vasculitis , after receiving Entityall - trans retinoic acid therapy. |
| 0.9998 | Adverse-Effect | Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed acute focal myositis, Entitysynovitis , and possible vasculitis, after receiving Entityall - trans retinoic acid therapy. |
| 0.9996 | Adverse-Effect | Here we report a patient with newly diagnosed acute promyelocytic leukemia who developed Entityacute focal myositis , synovitis, and possible vasculitis, after receiving Entityall - trans retinoic acid therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : We report a case of Entityintracerebral hemorrhage occurring in a middle - aged man who suffered from chronic sinusitis and had been ingesting Entitypseudoephedrine daily for one year. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In addition, an immediate Entityerythematous macule was observed on the photopatch test site of Entitymequitazine directly after UV exposure which was similar to the immediate erythema noted in chlorpromazine photoallergy. |
| 0.9962 | Adverse-Effect | In addition, an immediate erythematous macule was observed on the photopatch test site of Entitymequitazine directly after UV exposure which was similar to the immediate Entityerythema noted in chlorpromazine photoallergy. |
| Adverse-Effect | In addition, an immediate erythematous macule was observed on the photopatch test site of Entitymequitazine directly after UV exposure which was similar to the Entityimmediate erythema noted in chlorpromazine photoallergy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present here a female patient who developed Entityacute bilateral parotitis within minutes of i. v. Entityenalaprilat injection and recovered within 24 hours of stopping the drug and with symptomatic treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed fatal cerebral edema and Entitybrainstem herniation after she received a single dose of intravenous Entitymethotrexate . |
| 1.0000 | Adverse-Effect | A patient with intracranial osteosarcoma that arose 16 years after radiation therapy for hereditary retinoblastoma developed Entityfatal cerebral edema and brainstem herniation after she received a single dose of intravenous Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 20 - year - old female with polyarteritis nodosa ( PAN ) who developed Entitybilateral sensorineural hearing loss 25 minutes after receiving 30 mg of intravenous Entityketoralac . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with Entityincreased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 Entitylevothyroxine product to another. |
| 1.0000 | Adverse-Effect | CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of hypothyroidism with increased serum thyroid - stimulating hormone ( EntityTSH ) concentrations after switching from 1 Entitylevothyroxine product to another. |
| 1.0000 | Adverse-Effect | CASE SUMMARIES : Two patients with stable hypothyroidism experienced symptoms of Entityhypothyroidism with increased serum thyroid - stimulating hormone ( TSH ) concentrations after switching from 1 Entitylevothyroxine product to another. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A search of the United States Food and Drug Administration's Adverse Event Reporting System identified nine cases of Entityoxcarbazepine - associated Entityangioedema in pediatric patients aged 16 years and younger. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This fourth type of cutaneous Entityminocycline Entityhyperpigmentation may be a variant of Type I, but based on clinical, pathological and microanalytical differences, appears to be a new entity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report presents a case of Entityacute lung injury developing within hours after administration of Entitymefloquine for a low - level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with Entityvalproate for epilepsy, especially if they develop Entitymenstrual cycle disturbances during treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We speculate that platelet activation induced by EntitypFVIII may have contributed to Entitythrombosis and suggest that pFVIII be used with caution in elderly patients with pre - existing cardiovascular risk factors. |
| 0.9999 | Adverse-Effect | We speculate that Entityplatelet activation induced by EntitypFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre - existing cardiovascular risk factors. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We strongly suspect that this Entitylethal anuria was mainly due to Entityifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension. |
| 0.9995 | Adverse-Effect | We strongly suspect that this Entitylethal anuria was mainly due to ifosfamide, occurring in a patient having received previous Entitycisplatin chemotherapy and with poor kidney perfusion due to transient hypotension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A study following large patient groups on theophylline and a combination of Entitytheophylline and steroids might clarify the risk of Entityulcer formation in patients being treated with these medications for asthma. |
| 1.0000 | Adverse-Effect | A study following large patient groups on Entitytheophylline and a combination of theophylline and steroids might clarify the risk of Entityulcer formation in patients being treated with these medications for asthma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CONCLUSION : The chronic use of EntityHCQ for rheumatic diseases, or as an anti - malarial drug, should be balanced against the risk of developing potentially lethal Entitycardiac arrhythmias . |
| 1.0000 | Adverse-Effect | CONCLUSION : The chronic use of EntityHCQ for rheumatic diseases, or as an anti - malarial drug, should be balanced against the risk of developing potentially Entitylethal cardiac arrhythmias . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When the patient was treated again with Entityfludarabine nine months later, the EntityDAT became positive with anti - IgG and anti - C3d antiglobulins after the second course of treatment. |
| Adverse-Effect | When the patient was treated again with Entityfludarabine nine months later, the EntityDAT became positive with anti - IgG and anti - C3d antiglobulins after the second course of treatment. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CASE SUMMARIES : While conducting a protocol evaluating the efficacy of intraperitoneal Entitycisplatin and hyperthermia in the treatment of recurrent ovarian cancer, 3 patients were noted to exhibit Entityanaphylactoid reactions . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityRecombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset . |
| 0.9999 | Adverse-Effect | EntityRecombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | Recombinant human Entityinterferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | Recombinant Entityhuman interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | EntityRecombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | EntityRecombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | EntityRecombinant human interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | Recombinant human Entityinterferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset . |
| 0.9999 | Adverse-Effect | Recombinant human Entityinterferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | Recombinant human Entityinterferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | Recombinant Entityhuman interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset . |
| 0.9999 | Adverse-Effect | Recombinant human Entityinterferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | Recombinant Entityhuman interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | Recombinant Entityhuman interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| 0.9999 | Adverse-Effect | Recombinant Entityhuman interferon - alpha has been used in the treatment of several cancers, but there have been several reports that it may Entityexacerbate psoriasis or trigger off its onset. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to Entitytamoxifen may not reduce of developing Entityendometrial lesions , including carcinoma. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : The value of multihormonal therapy in breast carcinoma is not established, and the addition of progestogens to Entitytamoxifen may not reduce of developing endometrial lesions, including Entitycarcinoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : This case describes the clinically significant Entityincrease of INR in an elderly patient after adding a chemotherapy regimen of Entitylevamisole and 5 - FU to a previous regimen of warfarin alone. |
| 1.0000 | Adverse-Effect | CONCLUSIONS : This case describes the clinically significant Entityincrease of INR in an elderly patient after adding a chemotherapy regimen of levamisole and Entity5 - FU to a previous regimen of warfarin alone. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : This case describes the clinically significant Entityincrease of INR in an elderly patient after adding a chemotherapy regimen of levamisole and 5 - FU to a previous regimen of Entitywarfarin alone. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In addition, a 31 - year - old man with obsessive - compulsive disorder developed EntityRBD soon after starting Entityfluoxetine therapy, which persisted at PSG study 19 months after fluoxetine discontinuation. |
| 0.9997 | Adverse-Effect | In addition, a 31 - year - old man with obsessive - compulsive disorder developed EntityRBD soon after starting fluoxetine therapy, which persisted at PSG study 19 months after Entityfluoxetine discontinuation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing Entityheparin - induced Entitythrombocytopenia ( HIT ) postoperatively. |
| 0.9991 | Adverse-Effect | Most cardiac surgical patients have had previous exposure to heparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing Entityheparin - induced thrombocytopenia ( EntityHIT ) postoperatively. |
| 0.9907 | Adverse-Effect | Most cardiac surgical patients have had previous exposure to Entityheparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin - induced Entitythrombocytopenia ( HIT ) postoperatively. |
| 0.9860 | Adverse-Effect | Most cardiac surgical patients have had previous exposure to Entityheparin for diagnostic or therapeutic interventions and hence have an increased susceptibility to developing heparin - induced thrombocytopenia ( EntityHIT ) postoperatively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of cimetidine in Entitytolazoline induced Entityupper gastrointestinal hemorrhage should deserve more attention. |
| 0.9971 | Adverse-Effect | However, given the clinically significant result to the interaction between tolazoline and cimetidine we report, the use of Entitycimetidine in tolazoline induced Entityupper gastrointestinal hemorrhage should deserve more attention. |
| 0.9963 | Adverse-Effect | However, given the clinically significant result to the interaction between tolazoline and Entitycimetidine we report, the use of cimetidine in tolazoline induced Entityupper gastrointestinal hemorrhage should deserve more attention. |
| 0.9957 | Adverse-Effect | However, given the clinically significant result to the interaction between Entitytolazoline and cimetidine we report, the use of cimetidine in tolazoline induced Entityupper gastrointestinal hemorrhage should deserve more attention. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this case report, we present clinical and laboratory findings of a case with chronic hepatitis B that developed Entityacute dystonia soon after the first dose of Entitypegylated interferon alpha . |
| 0.9999 | Adverse-Effect | In this case report, we present clinical and laboratory findings of a case with chronic Entityhepatitis B that developed Entityacute dystonia soon after the first dose of pegylated interferon alpha. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of Entityinsulin ( > 110 units / day ), suggesting the existence of Entityinsulin insensitivity and hyperinsulinaemia. |
| 0.9997 | Adverse-Effect | The induced hyperglycaemia could not be controlled sufficiently, despite a high dose of Entityinsulin ( > 110 units / day ), suggesting the existence of insulin insensitivity and Entityhyperinsulinaemia . |
| 1.0000 | Adverse-Effect | The induced Entityhyperglycaemia could not be controlled sufficiently, despite a high dose of Entityinsulin ( > 110 units / day ), suggesting the existence of insulin insensitivity and hyperinsulinaemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Continuous EEG monitoring is helpful in managing Entityseizures that occur as a complication of EntityCBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( EntityCHB ) following administration of Entitydisopyramide phosphate ( Norpace ). |
| 0.9999 | Adverse-Effect | A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed complete heart block ( EntityCHB ) following administration of disopyramide phosphate ( EntityNorpace ). |
| 0.9999 | Adverse-Effect | A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed Entitycomplete heart block ( CHB ) following administration of Entitydisopyramide phosphate ( Norpace ). |
| 0.9997 | Adverse-Effect | A 57 - year - old woman with right bundle branch block + LPH and ventricular premature contractions developed Entitycomplete heart block ( CHB ) following administration of disopyramide phosphate ( EntityNorpace ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Use of the Naranjo adverse drug reaction probability scale indicated a probable relationship ( score of 5 ) between the patient's development of Entityhepatotoxicity and the EntityTMP - SMX therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 40 - year - old man with relapsing - remitting multiple sclerosis ( MS ) developed primary central nervous system lymphoma ( EntityPCNSL ) after having received 21 doses of Entitynatalizumab monotherapy. |
| 1.0000 | Adverse-Effect | A 40 - year - old man with relapsing - remitting multiple sclerosis ( MS ) developed Entityprimary central nervous system lymphoma ( PCNSL ) after having received 21 doses of Entitynatalizumab monotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityWarfarin - associated Entitybleeding generally is considered deleterious ; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life. |
| 0.9995 | Adverse-Effect | EntityWarfarin - associated bleeding generally is considered Entitydeleterious ; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 44 - year - old woman is described in whom amiodarone, disopyramide, and Entityquinidine , administered alone separately, induced Entityatypical ventricular tachycardia ( AVT, torsade de pointes ). |
| 0.9999 | Adverse-Effect | A 44 - year - old woman is described in whom amiodarone, Entitydisopyramide , and quinidine, administered alone separately, induced Entityatypical ventricular tachycardia ( AVT, torsade de pointes ). |
| 0.9999 | Adverse-Effect | A 44 - year - old woman is described in whom Entityamiodarone , disopyramide, and quinidine, administered alone separately, induced Entityatypical ventricular tachycardia ( AVT, torsade de pointes ). |
| 0.9999 | Adverse-Effect | A 44 - year - old woman is described in whom amiodarone, disopyramide, and Entityquinidine , administered alone separately, induced atypical ventricular tachycardia ( AVT, Entitytorsade de pointes ). |
| 0.9997 | Adverse-Effect | A 44 - year - old woman is described in whom amiodarone, disopyramide, and Entityquinidine , administered alone separately, induced atypical ventricular tachycardia ( EntityAVT , torsade de pointes ). |
| 0.9997 | Adverse-Effect | A 44 - year - old woman is described in whom amiodarone, Entitydisopyramide , and quinidine, administered alone separately, induced atypical ventricular tachycardia ( AVT, Entitytorsade de pointes ). |
| 0.9997 | Adverse-Effect | A 44 - year - old woman is described in whom Entityamiodarone , disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia ( AVT, Entitytorsade de pointes ). |
| 0.9993 | Adverse-Effect | A 44 - year - old woman is described in whom amiodarone, Entitydisopyramide , and quinidine, administered alone separately, induced atypical ventricular tachycardia ( EntityAVT , torsade de pointes ). |
| 0.9993 | Adverse-Effect | A 44 - year - old woman is described in whom Entityamiodarone , disopyramide, and quinidine, administered alone separately, induced atypical ventricular tachycardia ( EntityAVT , torsade de pointes ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report four cases of Entitysensorimotor axonal neuropathy in children aged 10 - 15 years, treated with Entitythalidomide for myxopapillary ependymoma, Crohn's disease and recurrent giant aphthous ulceration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entityserotonin syndrome associated with interaction between Entityfentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. |
| 0.9998 | Adverse-Effect | OBJECTIVE : To report a case of Entityserotonin syndrome associated with interaction between fentanyl and Entitycitalopram , as evidenced by medication history, clinical features and reversal following discontinuation of fentanyl. |
| 0.9993 | Adverse-Effect | OBJECTIVE : To report a case of Entityserotonin syndrome associated with interaction between fentanyl and citalopram, as evidenced by medication history, clinical features and reversal following discontinuation of Entityfentanyl . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We review the literature on previously reported cases of Entitycutaneous necrosis after injection of standard Entityinterferon alfa or pegylated interferon alfa - 2b and discuss the different pathophysiologic mechanisms that might be involved. |
| 0.9997 | Adverse-Effect | We review the literature on previously reported cases of Entitycutaneous necrosis after injection of standard interferon alfa or Entitypegylated interferon alfa - 2b and discuss the different pathophysiologic mechanisms that might be involved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a pediatric patient with leukemia and a severe, EntityL - asparaginase - induced Entitynecrotizing pancreatitis , treated successfully with percutaneous drainage used to flush the infected necrotic parts. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9994 | Adverse-Effect | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a Entitylithium Entitylithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. |
| 0.9991 | Adverse-Effect | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a Entityneuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily Entitythioridazine . |
| 0.9952 | Adverse-Effect | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a Entitylithium toxicity that occurs in combination with phenothiazines, primarily Entitythioridazine . |
| 0.9940 | Adverse-Effect | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a Entityneuroleptic malignant extrapyramidal syndrome and a Entitylithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. |
| 0.9997 | Adverse-Effect | The authors postulate that two types of combined Entitylithium - neuroleptic toxicity occur : a Entityneuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. |
| 0.9991 | Adverse-Effect | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a Entityneuroleptic malignant extrapyramidal syndrome and a lithium toxicity that occurs in combination with Entityphenothiazines , primarily thioridazine. |
| 0.9984 | Adverse-Effect | The authors postulate that two types of combined lithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a Entitylithium toxicity that occurs in combination with Entityphenothiazines , primarily thioridazine. |
| 0.9882 | Adverse-Effect | The authors postulate that two types of combined Entitylithium - neuroleptic toxicity occur : a neuroleptic malignant extrapyramidal syndrome and a Entitylithium toxicity that occurs in combination with phenothiazines, primarily thioridazine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The possibility can be raised that EntityM - CSF accelerated the underlying Entityrenal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of nephrotic syndrome. |
| 0.9989 | Adverse-Effect | The possibility can be raised that EntityM - CSF accelerated the underlying renal disease in this case through enhancing macrophage accumulation into the glomerulus, leading to the development of Entitynephrotic syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report here on a heretofore undescribed Entityrespiratory syncytial virus ( RSV ) infection in a patient with a long - standing history of refractory CLL that was treated with Entityfludarabine phosphate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of hyponatremia associated with a Entitygrand mal seizure in a 28 month - old child after intra - nasal Entitydesmopressin administration for high fluid intake with nocturnal enuresis. |
| 1.0000 | Adverse-Effect | We report a case of Entityhyponatremia associated with a grand mal seizure in a 28 month - old child after intra - nasal Entitydesmopressin administration for high fluid intake with nocturnal enuresis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report an additional case of Entityisotretinoin Entityteratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts. |
| 0.9999 | Adverse-Effect | We report an additional case of Entityisotretinoin teratogenicity in which the patient had Entityagenesis of the cerebellar vermis , multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and abnormalities of the corticospinal tracts. |
| 0.9999 | Adverse-Effect | We report an additional case of Entityisotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, hydrocephalus, and Entityabnormalities of the corticospinal tracts . |
| 0.9998 | Adverse-Effect | We report an additional case of Entityisotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, Entitymultiple leptomeningeal neuroglial heterotopias , hydrocephalus, and abnormalities of the corticospinal tracts. |
| 0.9998 | Adverse-Effect | We report an additional case of Entityisotretinoin teratogenicity in which the patient had agenesis of the cerebellar vermis, multiple leptomeningeal neuroglial heterotopias, Entityhydrocephalus , and abnormalities of the corticospinal tracts. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, continued low - dose EntityMTX led, in spite of normal liver tests, 8 years after the last biopsy to Entityliver failure and death in 1 of our patients. |
| 0.9999 | Adverse-Effect | However, continued low - dose EntityMTX led, in spite of normal liver tests, 8 years after the last biopsy to liver failure and Entitydeath in 1 of our patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 56 - year - old woman with scleroderma developed rapidly progressive glomerulonephritis with epithelial crescents associated with Entityhemoptysis after 27 months of EntityD - penicillamine therapy and a cumulative dose of 1, 200 g. |
| 0.9996 | Adverse-Effect | A 56 - year - old woman with scleroderma developed rapidly progressive glomerulonephritis with Entityepithelial crescents associated with hemoptysis after 27 months of EntityD - penicillamine therapy and a cumulative dose of 1, 200 g. |
| 0.9995 | Adverse-Effect | A 56 - year - old woman with scleroderma developed Entityrapidly progressive glomerulonephritis with epithelial crescents associated with hemoptysis after 27 months of EntityD - penicillamine therapy and a cumulative dose of 1, 200 g. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In a phase II study of Entityhycanthone in patients with breast cancer we have recently observed Entitysevere hepatotoxicity , even at lower doses, which resulted in two drug - related deaths. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The development of systemic lupus erythematosus ( EntitySLE ) after 38 months of therapy with Entityrecombinant human interferon gamma ( rIFN - gamma ) was observed in a patient with rheumatoid arthritis. |
| 0.9998 | Adverse-Effect | The development of systemic lupus erythematosus ( EntitySLE ) after 38 months of therapy with recombinant human interferon gamma ( EntityrIFN - gamma ) was observed in a patient with rheumatoid arthritis. |
| 0.9997 | Adverse-Effect | The development of Entitysystemic lupus erythematosus ( SLE ) after 38 months of therapy with Entityrecombinant human interferon gamma ( rIFN - gamma ) was observed in a patient with rheumatoid arthritis. |
| 0.9985 | Adverse-Effect | The development of Entitysystemic lupus erythematosus ( SLE ) after 38 months of therapy with recombinant human interferon gamma ( EntityrIFN - gamma ) was observed in a patient with rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report 2 cases of maculopapular eruption and Entityfever in patients infected with human immunodeficiency virus ( HIV ) on the 2nd day of first administration of Entityritonavir , a protease inhibitor. |
| 1.0000 | Adverse-Effect | We report 2 cases of Entitymaculopapular eruption and fever in patients infected with human immunodeficiency virus ( HIV ) on the 2nd day of first administration of Entityritonavir , a protease inhibitor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of Entityquinine - induced Entitythrombocytopenia . |
| 0.9762 | Adverse-Effect | Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe Entitythrombocytopenia , and confirmed the etiology of Entityquinine - induced thrombocytopenia. |
| 0.9844 | Adverse-Effect | Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of Entitysevere thrombocytopenia , and confirmed the etiology of Entityquinine - induced thrombocytopenia. |
| Adverse-Effect | Even after a strict warning, he took another Entityquinine tablet that evening, which triggered his fifth episode of severe Entitythrombocytopenia , and confirmed the etiology of quinine - induced thrombocytopenia. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Six patients developed Entityperipheral neuropathy and five patients bone marrow depression, blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of Entitylinezolid . |
| 0.9999 | Adverse-Effect | Six patients developed peripheral neuropathy and five patients Entitybone marrow depression , blood transfusions were given to three patients and in all five patients bone marrow function normalized after cessation of Entitylinezolid . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9962 | Adverse-Effect | Herein is reported an unusual case of coexistent warfarin - induced skin necrosis and Entityheparin - induced Entitythrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma. |
| 0.9957 | Adverse-Effect | Herein is reported an unusual case of coexistent Entitywarfarin - induced Entityskin necrosis and heparin - induced thrombocytopenia following mitral valve replacement for thromboembolic phenomena associated with marantic endocarditis and bronchial adenocarcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( EntityASPPC ) that developed after intravitreal Entitytriamcinolone acetonide ( IVTA ) injection. |
| 0.9999 | Adverse-Effect | BACKGROUND : We describe the ophthalmic features and clinical course of two cases of acute syphilitic posterior placoid chorioretinitis ( EntityASPPC ) that developed after intravitreal triamcinolone acetonide ( EntityIVTA ) injection. |
| 0.9999 | Adverse-Effect | BACKGROUND : We describe the ophthalmic features and clinical course of two cases of Entityacute syphilitic posterior placoid chorioretinitis ( ASPPC ) that developed after intravitreal Entitytriamcinolone acetonide ( IVTA ) injection. |
| 0.9996 | Adverse-Effect | BACKGROUND : We describe the ophthalmic features and clinical course of two cases of Entityacute syphilitic posterior placoid chorioretinitis ( ASPPC ) that developed after intravitreal triamcinolone acetonide ( EntityIVTA ) injection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of intraoperative Entitygelatine - induced Entityanaphylaxis whose diagnosis was delayed as the use of gelatine during surgical procedures was omitted for two times in patient's medical records. |
| 0.9999 | Adverse-Effect | We describe a case of intraoperative gelatine - induced Entityanaphylaxis whose diagnosis was delayed as the use of Entitygelatine during surgical procedures was omitted for two times in patient's medical records. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here, we describe a case of EntityVogt - Koyanagi - Harada disease occurring 4 months after the start of Entityinterferon alpha treatment, probably induced by the immunomodulatory effects of interferon. |
| 0.9960 | Adverse-Effect | Here, we describe a case of EntityVogt - Koyanagi - Harada disease occurring 4 months after the start of interferon alpha treatment, probably induced by the immunomodulatory effects of Entityinterferon . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityPheripheral edema was observed in five female patients after taking proton pump inhibitors Entityomeprazole , lansoprazole, or pantoprazole for 7 - 15 days for peptic acid diseases in recommended standard doses. |
| 0.9999 | Adverse-Effect | EntityPheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, Entitylansoprazole , or pantoprazole for 7 - 15 days for peptic acid diseases in recommended standard doses. |
| 0.9999 | Adverse-Effect | EntityPheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or Entitypantoprazole for 7 - 15 days for peptic acid diseases in recommended standard doses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We describe two patients in whom painful erosions of their psoriasis developed as the presenting sign of Entitymethotrexate Entitymethotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation. |
| 0.9995 | Adverse-Effect | We describe two patients in whom Entitypainful erosions of their psoriasis developed as the presenting sign of Entitymethotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation. |
| 0.9991 | Adverse-Effect | We describe two patients in whom painful Entityerosions of their psoriasis developed as the presenting sign of Entitymethotrexate toxicity and review the literature, emphasizing the risk factors associated with this manifestation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We recommend that a TMA in association with quinine be consistently referred to as Entityquinine - associated Entitythrombotic microangiopathy ( quinine - TMA ) to better distinguish this entity from idiopathic TTP. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 77 - year - old woman with no history of epilepsy presented a probable Entitynonconvulsive status epilepticus while receiving continuous intravenous Entitymorphine for back pain relating to vertebral metastasis of a malignant lymphoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of the syndrome of inappropriate antidiuretic hormone ( EntitySIADH ) secondary to Entitycisplatin therapy in a patient with advanced - stage large cell neuroendocrine carcinoma of the cervix. |
| 0.9999 | Adverse-Effect | We present a case of the Entitysyndrome of inappropriate antidiuretic hormone ( SIADH ) secondary to Entitycisplatin therapy in a patient with advanced - stage large cell neuroendocrine carcinoma of the cervix. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prenatal cytomegalovirus ( CMV ) infection associated with severe Entitybrain damage was detected in an infant whose mother had been treated with Entityprednisolone and azathioprine for systemic lupus erythematosus ( SLE ). |
| 1.0000 | Adverse-Effect | Prenatal cytomegalovirus ( CMV ) infection associated with severe Entitybrain damage was detected in an infant whose mother had been treated with prednisolone and Entityazathioprine for systemic lupus erythematosus ( SLE ). |
| 1.0000 | Adverse-Effect | EntityPrenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with Entityprednisolone and azathioprine for systemic lupus erythematosus ( SLE ). |
| 0.9999 | Adverse-Effect | EntityPrenatal cytomegalovirus ( CMV ) infection associated with severe brain damage was detected in an infant whose mother had been treated with prednisolone and Entityazathioprine for systemic lupus erythematosus ( SLE ). |
| 1.0000 | Adverse-Effect | Prenatal cytomegalovirus ( CMV ) infection associated with Entitysevere brain damage was detected in an infant whose mother had been treated with Entityprednisolone and azathioprine for systemic lupus erythematosus ( SLE ). |
| 1.0000 | Adverse-Effect | Prenatal cytomegalovirus ( CMV ) infection associated with Entitysevere brain damage was detected in an infant whose mother had been treated with prednisolone and Entityazathioprine for systemic lupus erythematosus ( SLE ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant Entitymethemoglobinemia after an axillary block with Entitybupivacaine and additional injection of lidocaine in the operative field. |
| 0.9999 | Adverse-Effect | We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant Entitymethemoglobinemia after an axillary block with bupivacaine and additional injection of Entitylidocaine in the operative field. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Review of this and previously reported cases indicates the need for early diagnosis of Entityamiodarone Entitypneumonitis , immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two years later, 24 hours following an increase in the dose of Entitydisopyramide from 300 to 600 mg / day, EntityAVT with syncope occurred ; isoproterenol abolished the arrhythmia instantly. |
| 0.9999 | Adverse-Effect | Two years later, 24 hours following an increase in the dose of Entitydisopyramide from 300 to 600 mg / day, AVT with Entitysyncope occurred ; isoproterenol abolished the arrhythmia instantly. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 74 - year - old patient with idiopathic Parkinson's disease was evaluated for Entityunintended sleep episodes that occurred after long - term treatment with 400 mg / day of EntityL - dopa . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Prior to surgery, Entitylevodopa induced Entitydyskinesia had improved ( < or = 50 % ) under treatment with amantadine ( 400 mg / day, po ) in all three patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a patient with acromegaly who developed severe drug - induced Entityhepatitis during combined treatment with the long - acting somatostatin - analog Entityoctreotide and the GH receptor antagonist pegvisomant. |
| 0.9999 | Adverse-Effect | We report on a patient with acromegaly who developed severe drug - induced Entityhepatitis during combined treatment with the long - acting somatostatin - analog octreotide and the GH receptor antagonist Entitypegvisomant . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityTopiramate may be associated with Entityciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle - closure glaucoma. |
| 1.0000 | Adverse-Effect | CONCLUSIONS : EntityTopiramate may be associated with ciliochoroidal effusion with forward Entitydisplacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in acute myopia and angle - closure glaucoma. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : EntityTopiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in acute myopia and Entityangle - closure glaucoma . |
| 0.9999 | Adverse-Effect | CONCLUSIONS : EntityTopiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and anterior chamber shallowing, resulting in Entityacute myopia and angle - closure glaucoma. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : EntityTopiramate may be associated with ciliochoroidal effusion with forward displacement of the lens - iris diaphragm and Entityanterior chamber shallowing , resulting in acute myopia and angle - closure glaucoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of high - grade endometrial stromal sarcoma, confined into an Entityintrauterine polypoid growth , in a woman with a history of breast cancer who was treated with adjuvant Entitytamoxifen . |
| 1.0000 | Adverse-Effect | A case of Entityhigh - grade endometrial stromal sarcoma , confined into an intrauterine polypoid growth, in a woman with a history of breast cancer who was treated with adjuvant Entitytamoxifen . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Because of serious side effects of an increase in the QT interval causing Entitytorsades de pointes , Entitydofetilide must be initiated with close monitoring of the QT interval in an inpatient setting. |
| 0.9999 | Adverse-Effect | Because of serious side effects of an Entityincrease in the QT interval causing torsades de pointes, Entitydofetilide must be initiated with close monitoring of the QT interval in an inpatient setting. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The typical Entityfluoxetine - induced symptoms of Entityrestlessness , constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.9999 | Adverse-Effect | The typical Entityfluoxetine - induced symptoms of restlessness, constant pacing, Entitypurposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.9999 | Adverse-Effect | The typical Entityfluoxetine - induced symptoms of restlessness, Entityconstant pacing , purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.9997 | Adverse-Effect | The typical Entityfluoxetine - induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and Entitymarked anxiety were indistinguishable from those of neuroleptic - induced akathisia. |
| 0.8799 | Adverse-Effect | The typical Entityfluoxetine - induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic - induced Entityakathisia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entityphenolphthalein - induced Entitytoxic epidermal necrolysis ( TEN ) in a patient maintained on several other medications more commonly known to be associated with TEN. |
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of Entityphenolphthalein - induced toxic epidermal necrolysis ( EntityTEN ) in a patient maintained on several other medications more commonly known to be associated with TEN. |
| 0.9998 | Adverse-Effect | OBJECTIVE : To report a case of Entityphenolphthalein - induced toxic epidermal necrolysis ( TEN ) in a patient maintained on several other medications more commonly known to be associated with EntityTEN . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After Entityinfliximab treatment, additional sleep studies revealed an Entityincrease in the number of apneic events and SaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea. |
| 0.9999 | Adverse-Effect | After Entityinfliximab treatment, additional sleep studies revealed an increase in the number of apneic events and EntitySaO2 dips suggesting that TNFalpha plays an important role in the pathophysiology of sleep apnea. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : We report a patient who developed neutropenia on Entityclozapine , but behind the cell count decrease showed to be a Entitydiurnal variation of the white blood cells ( WBC ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | An infant girl with choanal atresia, Entityathelia , minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with Entitymethimazole and propranolol. |
| 0.9999 | Adverse-Effect | An infant girl with Entitychoanal atresia , athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with Entitymethimazole and propranolol. |
| 0.9998 | Adverse-Effect | An infant girl with choanal atresia, Entityathelia , minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and Entitypropranolol . |
| 0.9997 | Adverse-Effect | An infant girl with Entitychoanal atresia , athelia, minor anomalies, and mild to moderate mental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and Entitypropranolol . |
| Adverse-Effect | An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate Entitymental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with Entitymethimazole and propranolol. | |
| Adverse-Effect | An infant girl with choanal atresia, athelia, minor anomalies, and mild to moderate Entitymental retardation was born to a woman treated for hyperthyroidism throughout pregnancy with methimazole and Entitypropranolol . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | Acute Entitynitrite Entitynitrite toxicity results from industrial exposure, accidental ingestion ( e. g., abuse of organic nitrites as an aphrodisiac, especially in the male homosexual population ), and suicidal ingestion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Severe rash, including the Stevens - Johnson syndrome ( EntitySJS ), is the major toxicity of Entitynevirapine and is described in the package labeling with a prominent, boxed warning. |
| 0.9999 | Adverse-Effect | EntitySevere rash , including the Stevens - Johnson syndrome ( SJS ), is the major toxicity of Entitynevirapine and is described in the package labeling with a prominent, boxed warning. |
| 0.9999 | Adverse-Effect | Severe rash, including the EntityStevens - Johnson syndrome ( SJS ), is the major toxicity of Entitynevirapine and is described in the package labeling with a prominent, boxed warning. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of sulphasalazine ( EntitySASP ) therapy developed a severe and lasting Entitypsoriasis - like skin reaction . |
| 0.9999 | Adverse-Effect | Presented is a case story of a woman with classical rheumatoid arthritis, who during introduction of Entitysulphasalazine ( SASP ) therapy developed a severe and lasting Entitypsoriasis - like skin reaction . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case is reported in which severe hypocalcemia, with a low plasma parathyroid hormone ( EntityPTH ) concentration, resulted from the therapeutic use of Entitymagnesium sulfate for toxemia of pregnancy. |
| 0.9999 | Adverse-Effect | A case is reported in which severe hypocalcemia, with a Entitylow plasma parathyroid hormone ( PTH ) concentration, resulted from the therapeutic use of Entitymagnesium sulfate for toxemia of pregnancy. |
| 0.9998 | Adverse-Effect | A case is reported in which Entitysevere hypocalcemia , with a low plasma parathyroid hormone ( PTH ) concentration, resulted from the therapeutic use of Entitymagnesium sulfate for toxemia of pregnancy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | The electrocardiogram ( ECG ), which was read as normal prior to ritodrine infusion, demonstrated a Entitytype I second - degree AV block which disappeared upon discontinuation of Entityritodrine therapy. |
| 0.9997 | Adverse-Effect | The electrocardiogram ( ECG ), which was read as normal prior to Entityritodrine infusion, demonstrated a Entitytype I second - degree AV block which disappeared upon discontinuation of ritodrine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case is reported of an elderly woman who developed Entityfebrile agranulocytosis several weeks after commencing Entityticlopidine but who had a favorable outcome after cessation of that drug and treatment with filgastrim. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | METHODS : Two patients with exudative age - related macular degeneration were treated sequentially with an intravitreal injection of Entitybevacizumab and developed signs of severe but Entitypainless infectious endophthalmitis 2 days later. |
| 1.0000 | Adverse-Effect | METHODS : Two patients with exudative age - related Entitymacular degeneration were treated sequentially with an intravitreal injection of Entitybevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later. |
| Adverse-Effect | METHODS : Two patients with exudative Entityage - related macular degeneration were treated sequentially with an intravitreal injection of Entitybevacizumab and developed signs of severe but painless infectious endophthalmitis 2 days later. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | 3. Thus, the Entitydecreased plasma cortisol level during Entityalprazolam treatment of panic disorder was suggested to be caused not by symptom alleviation due to alprazolam but by alprazolam administration itself. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although the Entityt - AML developed following oral Entityetoposide therapy, the child had previously received high - dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 66 - year - old Japanese woman with severe scleroderma developed anemia and Entitythrombocytopenia due to EntityD - penicillamine ( D - Pen ) treatment, although the leukopenia was not markedly severe. |
| 0.9996 | Adverse-Effect | A 66 - year - old Japanese woman with severe scleroderma developed Entityanemia and thrombocytopenia due to EntityD - penicillamine ( D - Pen ) treatment, although the leukopenia was not markedly severe. |
| 0.9994 | Adverse-Effect | A 66 - year - old Japanese woman with severe scleroderma developed anemia and Entitythrombocytopenia due to D - penicillamine ( EntityD - Pen ) treatment, although the leukopenia was not markedly severe. |
| 0.9988 | Adverse-Effect | A 66 - year - old Japanese woman with severe scleroderma developed Entityanemia and thrombocytopenia due to D - penicillamine ( EntityD - Pen ) treatment, although the leukopenia was not markedly severe. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | While Entitydoxorubicin was administered, the patient presented Entitythoracic pain and breathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum. |
| 0.9999 | Adverse-Effect | While Entitydoxorubicin was administered, the patient presented thoracic pain and Entitybreathing distress due to superior vena cava perforation by the central catheter and subsequent extravasation of the drug into the mediastinum. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 67 - year - old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of Entitysevere cholestasis 3 months after initiation of Entityazathioprine therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a life threatening side effect of acute Entityepoprostenol infusion ( Entitypulmonary edema ) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia / Entityinfarction shortly after Entitycis - diamine - dichloroplatinum II ( cisplatin ) - based chemotherapy. |
| 0.9998 | Adverse-Effect | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia / Entityinfarction shortly after cis - diamine - dichloroplatinum II ( Entitycisplatin ) - based chemotherapy. |
| 0.9997 | Adverse-Effect | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed Entityacute coronary ischemia / infarction shortly after Entitycis - diamine - dichloroplatinum II ( cisplatin ) - based chemotherapy. |
| 0.9990 | Adverse-Effect | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed Entityacute coronary ischemia / infarction shortly after cis - diamine - dichloroplatinum II ( Entitycisplatin ) - based chemotherapy. |
| 1.0000 | Adverse-Effect | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed acute coronary ischemia / Entityinfarction shortly after Entitycis - diamine - dichloroplatinum II ( cisplatin ) - based chemotherapy. |
| 0.9997 | Adverse-Effect | Six patients with no previous signs or symptoms suggestive of coronary artery disease developed Entityacute coronary ischemia / infarction shortly after Entitycis - diamine - dichloroplatinum II ( cisplatin ) - based chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In three of these patients the infection was clinically unsuspected ; in the fourth, Entitycutaneous herpes zoster developed after administration of 300 mg of Entitycytarabine daily for the preceding five days. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | INTRODUCTION - The aim of this case report is to present a 15 - year follow - up of a patient with phenytoin ( EntityPHT ) intoxication with Entityunilateral gingival hyperplasia ( GH ). |
| 0.9993 | Adverse-Effect | INTRODUCTION - The aim of this case report is to present a 15 - year follow - up of a patient with Entityphenytoin ( PHT ) intoxication with Entityunilateral gingival hyperplasia ( GH ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of Entitynevirapine - associated EntitySJS has been documented in the dermatology literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityGrade 3 hepatotoxicity ( AST and ALT > 5 to 20 upper limit normal ) or higher has been observed in as many as 1. 4 % of MS patients on EntityIFN beta . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVES : To describe the clinicopathologic features of 3 patients with CML who rapidly progressed from chronic phase to Entityblast crisis while taking Entityimatinib and to perform a review of the literature. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The purpose of this review is to increase awareness among physicians and other health care professionals that EntityDIC may be a rare but potentially severe complication of Entityanti - D IGIV treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our patient was a 72 - year - old man with advanced Parkinson's disease ( PD ) who received Entitylevodopa and anti - cholinergic drugs and whose head had become almost Entitycompletely bald . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : These results suggest that Entityclozapine may cause EntityTD ; however, the prevalence is low and the severity is relatively mild, with no or mild self - reported discomfort. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : These results suggest that Entityclozapine may cause TD ; however, the prevalence is low and the severity is relatively mild, with no or mild self - reported Entitydiscomfort . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The observation that Entityneurotoxicity developed with a delay of 24 to 48 hours after Entityacyclovir peak serum concentrations could explain the wide range of acyclovir levels reported in similar cases. |
| 0.9998 | Adverse-Effect | CONCLUSIONS : The observation that Entityneurotoxicity developed with a delay of 24 to 48 hours after acyclovir peak serum concentrations could explain the wide range of Entityacyclovir levels reported in similar cases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We highlight two instances of Entitysystemic allergic reaction , and discuss the potential side effects of local Entityaprotinin injections in the orthopaedic setting as well as the evidence base for its use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Diarrhoea, T - CD4 + lymphopenia and Entitybilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with Entityoxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma. |
| 1.0000 | Adverse-Effect | EntityDiarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with Entityoxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma. |
| 0.9999 | Adverse-Effect | Diarrhoea, EntityT - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with Entityoxaliplatinum and 5 - fluorouracil for unresectable rectum carcinoma. |
| 0.9999 | Adverse-Effect | Diarrhoea, T - CD4 + lymphopenia and Entitybilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and Entity5 - fluorouracil for unresectable rectum carcinoma. |
| 0.9999 | Adverse-Effect | EntityDiarrhoea , T - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and Entity5 - fluorouracil for unresectable rectum carcinoma. |
| 0.9998 | Adverse-Effect | Diarrhoea, EntityT - CD4 + lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and Entity5 - fluorouracil for unresectable rectum carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Several cases of Entitylithium - induced EntityCreutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " lithium serum levels. |
| 0.9999 | Adverse-Effect | Several cases of lithium - induced EntityCreutzfeldt - Jakob syndrome have been reported to date ; all of them were elderly patients and a half had " therapeutic " Entitylithium serum levels. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entityfulminant hepatic failure associated with Entitydidanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin who developed acute respiratory distress syndrome ( EntityARDS ) after a single infusion of Entityrituximab . |
| 1.0000 | Adverse-Effect | We report the case of a 43 - year - old man with ITP refractory to steroids and intravenous immunoglobulin who developed Entityacute respiratory distress syndrome ( ARDS ) after a single infusion of Entityrituximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report an unusual case of simultaneous transitional cell carcinoma of the renal pelvis and Entitydistal ureter without transitional cell carcinoma of the bladder occurring after chronic Entitycyclophosphamide therapy for nonHodgkin's lymphoma. |
| 1.0000 | Adverse-Effect | We report an unusual case of simultaneous Entitytransitional cell carcinoma of the renal pelvis and distal ureter without transitional cell carcinoma of the bladder occurring after chronic Entitycyclophosphamide therapy for nonHodgkin's lymphoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One week after the initial - dose of Entityadalimumab ( 160 mg ), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a Entityfulminant cardiomyopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Because there were no other obvious causes of renal failure in either patient, we propose that Entityskeletal muscle ischemia developed during Entityvasopressin infusion, followed by release of myoglobin and renal damage. |
| 0.9975 | Adverse-Effect | Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during Entityvasopressin infusion, followed by release of myoglobin and Entityrenal damage . |
| 0.9995 | Adverse-Effect | Because there were no other obvious causes of Entityrenal failure in either patient, we propose that skeletal muscle ischemia developed during Entityvasopressin infusion, followed by release of myoglobin and renal damage. |
| 0.9804 | Adverse-Effect | Because there were no other obvious causes of renal failure in either patient, we propose that Entityskeletal muscle ischemia developed during vasopressin infusion, followed by release of Entitymyoglobin and renal damage. |
| 0.9510 | Adverse-Effect | Because there were no other obvious causes of Entityrenal failure in either patient, we propose that skeletal muscle ischemia developed during vasopressin infusion, followed by release of Entitymyoglobin and renal damage. |
| 0.6259 | Adverse-Effect | Because there were no other obvious causes of renal failure in either patient, we propose that skeletal muscle ischemia developed during vasopressin infusion, followed by release of Entitymyoglobin and Entityrenal damage . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors describe a case of Entityvalvular heart disease in a 48 - year - old woman receiving Entitybenfluorex ( 150 mg t. i. d. for 8 years ) and leading to surgical mitral valve replacement. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCD20 - negative T - cell - rich B - cell lymphoma as a progression of a nodular lymphocyte - predominant Hodgkin's lymphoma treated with Entityrituximab : a molecular analysis using laser capture microdissection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 65 - year - old man on Entitywarfarin therapy with a sudden spontaneous onset of Entitysub - conjunctival haematoma associated with bloody tears was assessed in the clinic following a referral from an optometrist. |
| 0.9999 | Adverse-Effect | A 65 - year - old man on Entitywarfarin therapy with a sudden spontaneous onset of sub - conjunctival haematoma associated with Entitybloody tears was assessed in the clinic following a referral from an optometrist. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the clinical response, as determined by Entityincreases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with EntityHU alone or in combination with SPB. |
| 0.9999 | Adverse-Effect | We describe the clinical response, as determined by Entityincreases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with EntitySPB . |
| 1.0000 | Adverse-Effect | We describe the clinical response, as determined by increases in total Hb and Entitydecreased transfusion needs , in five patients with thalassemia intermedia treated with EntityHU alone or in combination with SPB. |
| 0.9998 | Adverse-Effect | We describe the clinical response, as determined by increases in total Hb and Entitydecreased transfusion needs , in five patients with thalassemia intermedia treated with HU alone or in combination with EntitySPB . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 31 - year - old women with recurrent Hodgkin's lymphoma and unrecognized HMSN - 1 who developed Entitysevere motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of Entityvincristine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This paper reports an autopsy case of a 78 - year - old male with Entitymultiple nodules in the liver developed after long - termed administration of Entityphosphate diethylstilbestrol ( PDES ) for prostatic cancer. |
| 0.9999 | Adverse-Effect | This paper reports an autopsy case of a 78 - year - old male with Entitymultiple nodules in the liver developed after long - termed administration of phosphate diethylstilbestrol ( EntityPDES ) for prostatic cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true thymic hyperplasia ), mediastinal lymphadenopathy and Entitypleurisy associated with systemic symptoms under EntityEtanercept treatment. |
| 0.9999 | Adverse-Effect | In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true thymic hyperplasia ), Entitymediastinal lymphadenopathy and pleurisy associated with systemic symptoms under EntityEtanercept treatment. |
| 0.9999 | Adverse-Effect | In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement ( true Entitythymic hyperplasia ), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under EntityEtanercept treatment. |
| 0.9999 | Adverse-Effect | In this report we described a case of juvenile idiopathic arthritis patient who developed Entitythymic enlargement ( true thymic hyperplasia ), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under EntityEtanercept treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, the use of Entitylithium should be avoided with any patient who is purging, since it may exacerbate the Entityloss of intracellular potassium , thereby increasing the risk of cardiac toxicity. |
| 0.9999 | Adverse-Effect | However, the use of Entitylithium should be avoided with any patient who is purging, since it may exacerbate the loss of intracellular potassium, thereby increasing the risk of Entitycardiac toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between propafenone and Entitycitalopram , which caused propafenone adverse effects ( eg, Entitydizziness , falls ) and mimicked coronary artery disease. |
| 0.9994 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between Entitypropafenone and citalopram, which caused propafenone adverse effects ( eg, Entitydizziness , falls ) and mimicked coronary artery disease. |
| 0.9993 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between propafenone and Entitycitalopram , which caused propafenone adverse effects ( eg, dizziness, Entityfalls ) and mimicked coronary artery disease. |
| 0.9990 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between Entitypropafenone and citalopram, which caused propafenone adverse effects ( eg, dizziness, Entityfalls ) and mimicked coronary artery disease. |
| 0.9989 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between propafenone and Entitycitalopram , which caused propafenone adverse effects ( eg, dizziness, falls ) and mimicked Entitycoronary artery disease . |
| 0.9984 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between Entitypropafenone and citalopram, which caused propafenone adverse effects ( eg, dizziness, falls ) and mimicked Entitycoronary artery disease . |
| 0.9998 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused Entitypropafenone adverse effects ( Entityeg , dizziness, falls ) and mimicked coronary artery disease. |
| 0.9997 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between propafenone and Entitycitalopram , which caused propafenone adverse effects ( Entityeg , dizziness, falls ) and mimicked coronary artery disease. |
| 0.9996 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused Entitypropafenone adverse effects ( eg, Entitydizziness , falls ) and mimicked coronary artery disease. |
| 0.9995 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between Entitypropafenone and citalopram, which caused propafenone adverse effects ( Entityeg , dizziness, falls ) and mimicked coronary artery disease. |
| 0.9993 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused Entitypropafenone adverse effects ( eg, dizziness, Entityfalls ) and mimicked coronary artery disease. |
| 0.9991 | Adverse-Effect | CONCLUSIONS : This is the first report of a possible interaction between propafenone and citalopram, which caused Entitypropafenone adverse effects ( eg, dizziness, falls ) and mimicked Entitycoronary artery disease . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus ( LE ) cell preparation, and Entitydiffuse proliferative glomerulonephritis following 26 months of Entityprocainamide therapy. |
| 1.0000 | Adverse-Effect | A 61 - year - old man developed Entityclinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of Entityprocainamide therapy. |
| 1.0000 | Adverse-Effect | A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, Entitypositive lupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of Entityprocainamide therapy. |
| 0.9999 | Adverse-Effect | A 61 - year - old man developed clinical lupus syndrome with Entitypositive antinuclear antibody , positive lupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of Entityprocainamide therapy. |
| 0.9999 | Adverse-Effect | A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, positive lupus erythematosus ( EntityLE ) cell preparation , and diffuse proliferative glomerulonephritis following 26 months of Entityprocainamide therapy. |
| Adverse-Effect | A 61 - year - old man developed clinical lupus syndrome with positive antinuclear antibody, positive Entitylupus erythematosus ( LE ) cell preparation, and diffuse proliferative glomerulonephritis following 26 months of Entityprocainamide therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes a case of Entityflucytosine - associated Entityulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing, ulceration, and marked separation of loops of bowel. |
| 0.9999 | Adverse-Effect | This report describes a case of Entityflucytosine - associated ulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing, Entityulceration , and marked separation of loops of bowel. |
| 0.9999 | Adverse-Effect | This report describes a case of Entityflucytosine - associated ulcerating enteritis in which the small bowel x - ray demonstrated Entitysevere luminal narrowing , ulceration, and marked separation of loops of bowel. |
| 0.9998 | Adverse-Effect | This report describes a case of Entityflucytosine - associated ulcerating enteritis in which the small bowel x - ray demonstrated severe luminal narrowing, ulceration, and Entitymarked separation of loops of bowel . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The Entitypro - arrhythmic effects of Entityprocainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by prolongation of refractoriness in the accessory pathway. |
| 0.9999 | Adverse-Effect | The pro - arrhythmic effects of Entityprocainamide may be explained on the basis of both its vagolytic action on the atrioventricular node as well as by Entityprolongation of refractoriness in the accessory pathway . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | When Entitypilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid Entitylife - threatening arrhythmias due to high plasma concentrations of the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Sodium valproate and Entitycarbamazepine , antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce Entitypsoriasiform eruptions . |
| 0.9997 | Adverse-Effect | EntitySodium valproate and carbamazepine, antiepileptic drugs that are associated with a relatively low rate of adverse cutaneous reactions, should be added to the growing list of drugs that produce Entitypsoriasiform eruptions . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal pulmonary fibrosis associated with EntityBCNU : the relative role of platelet - derived growth factor - B, insulin - like growth factor I, transforming growth factor - beta1 and cyclooxygenase - 2. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the development of Entityscrotal ulcer in a patient with acute promyleocytic leukemia ( APL ) within 10 days of treatment with EntityATRA at a dose of 40 mg orally twice daily. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( EntitySIADH ) following systemic chemotherapy with Entitycisplatin ( CDDP ) and vindesine ( VDS ). |
| 1.0000 | Adverse-Effect | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( EntitySIADH ) following systemic chemotherapy with cisplatin ( EntityCDDP ) and vindesine ( VDS ). |
| 1.0000 | Adverse-Effect | We report a patient with pulmonary adenocarcinoma complicated by the Entitysyndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with Entitycisplatin ( CDDP ) and vindesine ( VDS ). |
| 1.0000 | Adverse-Effect | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( EntitySIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and Entityvindesine ( VDS ). |
| 1.0000 | Adverse-Effect | We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone ( EntitySIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( EntityVDS ). |
| 0.9999 | Adverse-Effect | We report a patient with pulmonary adenocarcinoma complicated by the Entitysyndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( EntityCDDP ) and vindesine ( VDS ). |
| 0.9999 | Adverse-Effect | We report a patient with pulmonary adenocarcinoma complicated by the Entitysyndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and Entityvindesine ( VDS ). |
| 0.9999 | Adverse-Effect | We report a patient with pulmonary adenocarcinoma complicated by the Entitysyndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) following systemic chemotherapy with cisplatin ( CDDP ) and vindesine ( EntityVDS ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 60 - year - old white man with chronic bronchitis was noted to develop acute respiratory failure and Entitymetabolic acidosis four days after being started on Entitymethazolamide ( Neptazane ) for an ophthalmologic problem. |
| 1.0000 | Adverse-Effect | A 60 - year - old white man with chronic bronchitis was noted to develop acute respiratory failure and Entitymetabolic acidosis four days after being started on methazolamide ( EntityNeptazane ) for an ophthalmologic problem. |
| 1.0000 | Adverse-Effect | A 60 - year - old white man with chronic bronchitis was noted to develop Entityacute respiratory failure and metabolic acidosis four days after being started on Entitymethazolamide ( Neptazane ) for an ophthalmologic problem. |
| 0.9999 | Adverse-Effect | A 60 - year - old white man with chronic bronchitis was noted to develop Entityacute respiratory failure and metabolic acidosis four days after being started on methazolamide ( EntityNeptazane ) for an ophthalmologic problem. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : A 76 - year - old woman with primary open - angle glaucoma and no history of ocular surgery developed a Entitychoroidal detachment 12 hours after initiation of therapy with Entitydorzolamide eye drops. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case report describes an adolescent with Entitysevere lupus erythematosus who received Entitycyclophosphamide ( CY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli. |
| 0.9999 | Adverse-Effect | This case report describes an adolescent with Entitysevere lupus erythematosus who received cyclophosphamide ( EntityCY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli. |
| 1.0000 | Adverse-Effect | This case report describes an adolescent with severe Entitylupus erythematosus who received Entitycyclophosphamide ( CY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli. |
| 0.9999 | Adverse-Effect | This case report describes an adolescent with severe Entitylupus erythematosus who received cyclophosphamide ( EntityCY ) paired with taste ( cod liver oil ) and smell ( rose perfume ) as conditioned stimuli. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityARDS has been associated with the administration of other monoclonal antibodies, such as Entityinfliximab , gemtuzumab ozogamicin, and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines. |
| 0.9999 | Adverse-Effect | EntityARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, Entitygemtuzumab ozogamicin , and OKT3 and is believed to be directly mediated by release of proinflammatory cytokines. |
| 0.9999 | Adverse-Effect | EntityARDS has been associated with the administration of other monoclonal antibodies, such as infliximab, gemtuzumab ozogamicin, and EntityOKT3 and is believed to be directly mediated by release of proinflammatory cytokines. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Well - differentiated Entityendometrial adenocarcinoma of the secretory type ( FIGO Grade 1 ) with minimal myometrial invasion occurred in a postmenopausal patient on Entitytamoxifen therapy 5 years after mastectomy for breast carcinoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitysevere acute hepatitis caused by Entitycyproterone acetate in a 71 year old man with prostatic carcinoma is reported with a review of the literature on hepatic reactions to this drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of an 11 - year - old female treated for mediastinal T - cell lymphoma who presented Entityrenal failure following the second cycle of high - dose Entitymethotrexate ( HDMTX ). |
| 1.0000 | Adverse-Effect | We report the case of an 11 - year - old female treated for mediastinal T - cell lymphoma who presented Entityrenal failure following the second cycle of high - dose methotrexate ( EntityHDMTX ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9986 | Adverse-Effect | Since Entityethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of ethambutol sufficient to produce Entityoptic neuropathy . |
| 0.9999 | Adverse-Effect | Since ethambutol is actively excreted via the renal system, compromise of renal function such as due to renal tuberculosis may lead to serum concentration elevations of Entityethambutol sufficient to produce Entityoptic neuropathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Autopsy evidence of Entityherpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of Entitycytarabine ( cytosine arabinoside ; Ara - C ) shortly before their death. |
| 0.9999 | Adverse-Effect | Autopsy evidence of Entityherpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine ( Entitycytosine arabinoside ; Ara - C ) shortly before their death. |
| 0.9999 | Adverse-Effect | Autopsy evidence of Entityherpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine ( cytosine arabinoside ; EntityAra - C ) shortly before their death. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report three patients, all of whom had preexisting diabetic dyslipidemia, who showed a profound Entityreduction in plasma HDL cholesterol and apolipoprotein AI levels soon after the initiation of Entityrosiglitazone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report marked QT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from Entityacute myocardial ischemia in a patient who was being treated with Entitydofetilide for atrial fibrillation. |
| 0.9999 | Adverse-Effect | We report marked QT prolongation and torsades de pointes in a setting of Entityflash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with Entitydofetilide for atrial fibrillation. |
| 0.9999 | Adverse-Effect | We report marked QT prolongation and Entitytorsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with Entitydofetilide for atrial fibrillation. |
| 0.9999 | Adverse-Effect | We report marked EntityQT prolongation and torsades de pointes in a setting of flash pulmonary edema resulting from acute myocardial ischemia in a patient who was being treated with Entitydofetilide for atrial fibrillation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious Entityextrapyramidal reactions in patients receiving Entitysertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious Entityextrapyramidal reactions in patients receiving sertraline or Entityvenlafaxine when metoclopramide is coadministered even in a single, conventional dose. |
| 0.9998 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware of a risk of Entityserotonin syndrome with serious extrapyramidal reactions in patients receiving Entitysertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose. |
| 0.9998 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware of a risk of serotonin syndrome with serious Entityextrapyramidal reactions in patients receiving sertraline or venlafaxine when Entitymetoclopramide is coadministered even in a single, conventional dose. |
| 0.9995 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware of a risk of Entityserotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or Entityvenlafaxine when metoclopramide is coadministered even in a single, conventional dose. |
| 0.9993 | Adverse-Effect | CONCLUSIONS : Clinicians should be aware of a risk of Entityserotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when Entitymetoclopramide is coadministered even in a single, conventional dose. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although both patients recovered from the colitis after the administration of vancomycin, the first case demonstrated a relapse of the Entitycolitis after receiving a subsequent course of the same chemotherapy with Entitycisplatin . |
| 0.9993 | Adverse-Effect | Although both patients recovered from the colitis after the administration of Entityvancomycin , the first case demonstrated a relapse of the Entitycolitis after receiving a subsequent course of the same chemotherapy with cisplatin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of MP developed Entitytransient renal failure following an EntityMP pulse therapy. |
| 0.9999 | Adverse-Effect | Three nephrotic patients who had reduced renal function and active renal disease with progressive deterioration of renal function prior to the use of EntityMP developed Entitytransient renal failure following an MP pulse therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We discuss a patient who developed Entitysevere renal tubular dysfunction secondary to short - term therapy with EntityAmikacin , resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria. |
| 1.0000 | Adverse-Effect | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with EntityAmikacin , resulting in Entityrefractory hypokalemia , hypocalcemia, hypomagnesemia, metabolic alkalosis, and polyuria. |
| 0.9999 | Adverse-Effect | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with EntityAmikacin , resulting in refractory hypokalemia, Entityhypocalcemia , hypomagnesemia, metabolic alkalosis, and polyuria. |
| 0.9999 | Adverse-Effect | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with EntityAmikacin , resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, metabolic alkalosis, and Entitypolyuria . |
| 0.9999 | Adverse-Effect | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with EntityAmikacin , resulting in refractory hypokalemia, hypocalcemia, Entityhypomagnesemia , metabolic alkalosis, and polyuria. |
| 0.9999 | Adverse-Effect | We discuss a patient who developed severe renal tubular dysfunction secondary to short - term therapy with EntityAmikacin , resulting in refractory hypokalemia, hypocalcemia, hypomagnesemia, Entitymetabolic alkalosis , and polyuria. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The most serious dental side effect of Entitybisphosphonate treatment ( particularly when it is administered intravenously ) is, paradoxically, Entityosteonecrosis of the mandible or the maxilla represented by exposed nonhealing bone. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityThrombin is highly effective for stopping intractable arterial hemorrhage during stereotactic brain biopsy ; however, it is a vasospastic agent and may have been responsible for the Entitycerebral infarctions in one patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We suggest that Entitysarcoidosis may develop in chronic hepatitis C patients during Entityinterferon alpha and / or ribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow - ups. |
| 0.9998 | Adverse-Effect | We suggest that Entitysarcoidosis may develop in chronic hepatitis C patients during interferon alpha and / or Entityribavirin treatment, and diagnostic tests for this adverse effect should be performed during the follow - ups. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9985 | Adverse-Effect | We postulate that gastritis caused by dexamethasone, Entitymucositis caused by Entitydoxorubicin , and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event. |
| 0.9816 | Adverse-Effect | We postulate that Entitygastritis caused by Entitydexamethasone , mucositis caused by doxorubicin, and the unique anatomic nature of a Meckel diverticulum may have contributed to this extremely unlikely and previously unreported event. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present two cases of Entitynitrofurantoin - induced Entitypulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis. |
| 0.9998 | Adverse-Effect | We present two cases of Entitynitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated Entitydistortion of the lung parenchyma , thought to represent established fibrosis. |
| 0.9998 | Adverse-Effect | We present two cases of Entitynitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a Entitywidespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis. |
| 0.9997 | Adverse-Effect | We present two cases of Entitynitrofurantoin - induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established Entityfibrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a case of exacerbated Entitymania potentially related to an interaction between Entitylopinavir / ritonavir and valproic acid ( VPA ) and propose a mechanism of action for this interaction. |
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a case of exacerbated Entitymania potentially related to an interaction between lopinavir / Entityritonavir and valproic acid ( VPA ) and propose a mechanism of action for this interaction. |
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe a case of exacerbated Entitymania potentially related to an interaction between lopinavir / ritonavir and valproic acid ( EntityVPA ) and propose a mechanism of action for this interaction. |
| 0.9999 | Adverse-Effect | OBJECTIVE : To describe a case of exacerbated Entitymania potentially related to an interaction between lopinavir / ritonavir and Entityvalproic acid ( VPA ) and propose a mechanism of action for this interaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | EntityTranstubular potassium gradient ( TTKG ) also decreased and an inverse correlation was found between TTKG and doses of Entityphosphate ( r = - 0. 37 ; p < 0. 02 ; N = 38 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The first known report of Entityquetiapine Entityexacerbating OCS in a 43 - year - old man with obsessive - compulsive disorder ( OCD ), trichotillomania, delusional disorder and bipolar II disorder is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : A 79 - year - old woman being treated with Entityimiquimod 5 days per week for a nodular basal cell developed a Entityverrucous plaque over the treatment area after 7 weeks of therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 57 - year - old female with cardiomyopathy and " sulfa " ( trimethoprim / sulfamethoxazole ) allergy documented as pancreatitis presented with symptoms consistent with Entitypancreatitis after use of Entityfurosemide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We thus concluded that an excessive dose of EntityAZ had probably Entitydestroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis. |
| 0.9999 | Adverse-Effect | We thus concluded that an excessive dose of EntityAZ had probably destroyed the gastric mucosal barrier or thrombocytopenia due to bone marrow disorder and thus eventually led to the development of Entityhemorrhagic gastritis . |
| 0.9997 | Adverse-Effect | We thus concluded that an excessive dose of EntityAZ had probably destroyed the gastric mucosal barrier or Entitythrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis. |
| Adverse-Effect | We thus concluded that an excessive dose of EntityAZ had probably destroyed the gastric mucosal barrier or Entitythrombocytopenia due to bone marrow disorder and thus eventually led to the development of hemorrhagic gastritis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this article, we present the case of a vitiligo patient who was admitted to our facility with an Entityintense burn after the topical use of Entity8 - methoxypsoralen solution as a suntanning agent. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 36 - year - old man being treated with cisplatinum, vinblastine, and Entitybleomycin for testicular carcinoma developed a dense Entityleft homonymous hemianopsia , encephalopathy, and a partial nondominant parietal lobe syndrome. |
| 0.9999 | Adverse-Effect | A 36 - year - old man being treated with cisplatinum, vinblastine, and Entitybleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, Entityencephalopathy , and a partial nondominant parietal lobe syndrome. |
| 0.9999 | Adverse-Effect | A 36 - year - old man being treated with cisplatinum, vinblastine, and Entitybleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a Entitypartial nondominant parietal lobe syndrome . |
| 0.9999 | Adverse-Effect | A 36 - year - old man being treated with cisplatinum, Entityvinblastine , and bleomycin for testicular carcinoma developed a dense Entityleft homonymous hemianopsia , encephalopathy, and a partial nondominant parietal lobe syndrome. |
| 0.9998 | Adverse-Effect | A 36 - year - old man being treated with Entitycisplatinum , vinblastine, and bleomycin for testicular carcinoma developed a dense Entityleft homonymous hemianopsia , encephalopathy, and a partial nondominant parietal lobe syndrome. |
| 0.9998 | Adverse-Effect | A 36 - year - old man being treated with cisplatinum, Entityvinblastine , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, Entityencephalopathy , and a partial nondominant parietal lobe syndrome. |
| 0.9997 | Adverse-Effect | A 36 - year - old man being treated with Entitycisplatinum , vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, Entityencephalopathy , and a partial nondominant parietal lobe syndrome. |
| 0.9997 | Adverse-Effect | A 36 - year - old man being treated with cisplatinum, Entityvinblastine , and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a Entitypartial nondominant parietal lobe syndrome . |
| 0.9996 | Adverse-Effect | A 36 - year - old man being treated with Entitycisplatinum , vinblastine, and bleomycin for testicular carcinoma developed a dense left homonymous hemianopsia, encephalopathy, and a Entitypartial nondominant parietal lobe syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARIES : In each case, the patients were treated over 5 years with Entitylovastatin and developed Entityrhabdomyolysis that coincided with the completion of a prescribed regimen of a newer macrolide antibiotic. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Retinal abnormalities, including retinal hemorrhage and Entity" cotton - wool " spots , often occur within the first 8 weeks in the course of Entityinterferon therapy in patients with chronic hepatitis C. |
| 0.9999 | Adverse-Effect | Retinal abnormalities, including Entityretinal hemorrhage and " cotton - wool " spots, often occur within the first 8 weeks in the course of Entityinterferon therapy in patients with chronic hepatitis C. |
| 0.9999 | Adverse-Effect | EntityRetinal abnormalities , including retinal hemorrhage and " cotton - wool " spots, often occur within the first 8 weeks in the course of Entityinterferon therapy in patients with chronic hepatitis C. |
| 1.0000 | Adverse-Effect | Retinal abnormalities, including retinal hemorrhage and " Entitycotton - wool " spots , often occur within the first 8 weeks in the course of Entityinterferon therapy in patients with chronic hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | To date, only three cases of Entityseizures associated with Entityamphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Zolpidem ( EntityAmbien ), a relatively new nonbenzodiazepine sedative - hypnotic, was involved in the Entitydeath of a 39 - year - old obese male who was being treated for depression and insomnia. |
| 1.0000 | Adverse-Effect | EntityZolpidem ( Ambien ), a relatively new nonbenzodiazepine sedative - hypnotic, was involved in the Entitydeath of a 39 - year - old obese male who was being treated for depression and insomnia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 45 - year - old woman with steroid - dependent Crohn's colitis, successfully managed with maintenance infliximab infusions and Entitymethotrexate , developed a Entitylupus - like syndrome eight months after her initial infusion. |
| 0.9996 | Adverse-Effect | A 45 - year - old woman with steroid - dependent Crohn's colitis, successfully managed with maintenance Entityinfliximab infusions and methotrexate, developed a Entitylupus - like syndrome eight months after her initial infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although there have been numerous reports of effusions, none have provided complete pleural fluid analysis ; therefore, we report 2 patients with Entitydasatinib - induced Entitypleural effusion with complete pleural fluid analysis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete Entityright bundle branch block after ingestion of 10 g and 4 g of Entitycarbamazepine respectively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 65 - year - old female patient presented with jaundice followed 2 days later by severe dyspnea and Entitytachypnea which worsened when patient was lying flat, 1 week after the fourth dose of Entityadalimumab . |
| 0.9999 | Adverse-Effect | A 65 - year - old female patient presented with Entityjaundice followed 2 days later by severe dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of Entityadalimumab . |
| 0.9999 | Adverse-Effect | A 65 - year - old female patient presented with jaundice followed 2 days later by Entitysevere dyspnea and tachypnea which worsened when patient was lying flat, 1 week after the fourth dose of Entityadalimumab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE PRESENTATION : We report a patient with CF who developed recurrent eosinophilia and Entitysevere persistent bronchospasm following repeated administration of preservative - free Entitytobramycin by inhalation, beginning at 16 months of age. |
| 1.0000 | Adverse-Effect | CASE PRESENTATION : We report a patient with CF who developed Entityrecurrent eosinophilia and severe persistent bronchospasm following repeated administration of preservative - free Entitytobramycin by inhalation, beginning at 16 months of age. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9989 | Adverse-Effect | Three patients with Entityniacin - induced Entityvisual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. |
| 0.9901 | Adverse-Effect | Three patients with niacin - induced visual symptoms had cystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of Entityvisual symptoms upon discontinuation of Entityniacin . |
| 0.9279 | Adverse-Effect | Three patients with Entityniacin - induced visual symptoms had Entitycystoid maculopathy without leakage on fluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. |
| 0.9295 | Adverse-Effect | Three patients with niacin - induced visual symptoms had Entitycystoid maculopathy without leakage on Entityfluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. |
| 0.6200 | Adverse-Effect | Three patients with niacin - induced Entityvisual symptoms had cystoid maculopathy without leakage on Entityfluorescein angiography, and a fourth patient with no fundus abnormality experienced cessation of visual symptoms upon discontinuation of niacin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After an extensive review of the literature, we believe that this is the first communication of the successful use of amiodarone to control hyperthyroidism in a patient with EntityPTU - induced Entityfulminant hepatitis . |
| 0.9065 | Adverse-Effect | After an extensive review of the literature, we believe that this is the first communication of the successful use of Entityamiodarone to control hyperthyroidism in a patient with PTU - induced Entityfulminant hepatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors present a case study of a mentally healthy man who repeatedly experienced short - lived, Entityobsessional - like suicidal ideas and images after ingestion of the anti - fungal drug Entityketoconazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 50 - year - old diabetic and hypertensive male patient is reported who had Entityticlopidine - induced Entitymarrow aplasia partially responsive to colony - stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this case report, we have described a patient with Crohn's disease who developed Entitysubfulminant hepatitis B after the fourth infusion of Entityinfliximab due to an unrecognized HBs - antigen carrier state. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Although Entityretinoic acid is well tolerated by the majority of patients with this disease, a potentially Entityfatal complication of this kind of treatment has been reported : " the retinoic acid syndrome ". |
| 0.9993 | Adverse-Effect | Although Entityretinoic acid is well tolerated by the majority of patients with this disease, a potentially fatal complication of this kind of treatment has been reported : " the Entityretinoic acid syndrome ". |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Preliminary results suggest that the higher concentrations of Entitydextrose induce Entityincreased histamine release from blood cells, and that this phenomenon is more marked in diabetic, and particularly diabetic - allergic, individuals. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9966 | Adverse-Effect | The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism ( s ) of Entitymannitol Entitynephrotoxicity are discussed. |
| 0.9954 | Adverse-Effect | The literature is also reviewed for EntityARF associated with Entitymannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism ( s ) of mannitol nephrotoxicity are discussed. |
| 0.9860 | Adverse-Effect | The literature is also reviewed for ARF associated with mannitol infusion in patients who received dialysis and those who did not receive dialysis ; and the possible mechanism ( s ) of Entitymannitol Entitymannitol nephrotoxicity are discussed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and Entityraised intracranial pressure ( ICP ) after severe Entitysodium valproic acid ( VPA ) intoxication. |
| 0.9994 | Adverse-Effect | INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with Entitysevere cerebral swelling and raised intracranial pressure ( ICP ) after severe Entitysodium valproic acid ( VPA ) intoxication. |
| 0.9984 | Adverse-Effect | INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with severe cerebral swelling and Entityraised intracranial pressure ( ICP ) after severe sodium valproic acid ( EntityVPA ) intoxication. |
| 0.9980 | Adverse-Effect | INTRODUCTION : We describe the neurointensive care ( NIC ) management of a patient with Entitysevere cerebral swelling and raised intracranial pressure ( ICP ) after severe sodium valproic acid ( EntityVPA ) intoxication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Four years after the beginning of EntityIFN therapy, he acutely developed Entitymoderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units / day of insulin injection was started. |
| 0.9997 | Adverse-Effect | Four years after the beginning of EntityIFN therapy, he acutely developed moderate hyperglycemia and Entitysevere ketonuria with positive islet cell antibody, and then 28 units / day of insulin injection was started. |
| 0.9998 | Adverse-Effect | Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with Entitypositive islet cell antibody , and then 28 units / day of Entityinsulin injection was started. |
| 0.9997 | Adverse-Effect | Four years after the beginning of EntityIFN therapy, he acutely developed moderate hyperglycemia and severe ketonuria with Entitypositive islet cell antibody , and then 28 units / day of insulin injection was started. |
| 0.9990 | Adverse-Effect | Four years after the beginning of IFN therapy, he acutely developed moderate hyperglycemia and Entitysevere ketonuria with positive islet cell antibody, and then 28 units / day of Entityinsulin injection was started. |
| 0.9989 | Adverse-Effect | Four years after the beginning of IFN therapy, he acutely developed Entitymoderate hyperglycemia and severe ketonuria with positive islet cell antibody, and then 28 units / day of Entityinsulin injection was started. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityARDS is rarely associated with Entityrituximab infusion for lympho - proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops severe pulmonary symptoms soon after infusion. |
| 0.9995 | Adverse-Effect | ARDS is rarely associated with rituximab infusion for lympho - proliferative disorders, but it should be considered by those administering Entityrituximab , especially when a patient develops Entitysevere pulmonary symptoms soon after infusion. |
| 0.8815 | Adverse-Effect | EntityARDS is rarely associated with rituximab infusion for lympho - proliferative disorders, but it should be considered by those administering Entityrituximab , especially when a patient develops severe pulmonary symptoms soon after infusion. |
| 0.7604 | Adverse-Effect | ARDS is rarely associated with Entityrituximab infusion for lympho - proliferative disorders, but it should be considered by those administering rituximab, especially when a patient develops Entitysevere pulmonary symptoms soon after infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, a large case - control study included three cases of either Stevens - Johnson syndrome or Entitytoxic epidermal necrolysis associated with Entityofloxacin use, but no details of the cases were given. |
| 0.9999 | Adverse-Effect | However, a large case - control study included three cases of either EntityStevens - Johnson syndrome or toxic epidermal necrolysis associated with Entityofloxacin use, but no details of the cases were given. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The reported case represents an unusual association between medication with the proton pump inhibitor Entitylansoprazole and the development of Entitycollagenous colitis suggesting the importance of evaluation of drug use in patients with microscopic colitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of Entitypulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of Entityetanercept therapy. |
| Adverse-Effect | This report details the pulmonary pathologic findings in four patients with rheumatoid arthritis, who developed new onset of Entitypulmonary signs and symptoms with alveolar infiltrates temporally related to the institution of Entityetanercept therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9951 | Adverse-Effect | The former patient had complained once that his Entityvisual acuity had decreased after the termination of EntityIFN therapy, and the latter patient complained twice during IFN therapy that his visual acuity had decreased. |
| 0.9712 | Adverse-Effect | The former patient had complained once that his visual acuity had decreased after the termination of IFN therapy, and the latter patient complained twice during EntityIFN therapy that his Entityvisual acuity had decreased . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 39 - year - old white Jewish schizophrenic man treated with Entityolanzapine developed an Entityelevated serum CK concentration with a peak concentration of 4000 IU / L ( normal < 230 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We are concerned that the Entitymacular lesion was a retinal toxic effect of Entitygentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug. |
| 1.0000 | Adverse-Effect | We are concerned that the macular lesion was a Entityretinal toxic effect of Entitygentamicin because of the recent description of similar lesions occurring after the inadvertent intraocular injection of massive doses of this drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Seventy - four per cent of patients with epileptogenic disorders seen at the Emergency Unit at Groote Schuur Hospital were on Entityphenytoin and 11. 6 % of these had Entityblood levels in the toxic range . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of Entitypoisoning with Entity3, 4 - methylenedioxymet - amphetamine Ecstasy that presented with all the features suggestive of a fatal outcome, including a creatinine phosphokinase level markedly higher than any previously reported. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Total blindness with a transient tonic pupillary response, denervation supersensitivity, and Entityabnormal visual - evoked potentials developed in a 54 - year - old man after the use of Entityquinine sulfate for leg cramps. |
| 0.9997 | Adverse-Effect | Total blindness with a transient tonic pupillary response, Entitydenervation supersensitivity , and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of Entityquinine sulfate for leg cramps. |
| 0.9997 | Adverse-Effect | Total blindness with a Entitytransient tonic pupillary response , denervation supersensitivity, and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of Entityquinine sulfate for leg cramps. |
| 0.9994 | Adverse-Effect | EntityTotal blindness with a transient tonic pupillary response, denervation supersensitivity, and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of Entityquinine sulfate for leg cramps. |
| Adverse-Effect | EntityTotal blindness with a transient tonic pupillary response , denervation supersensitivity, and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of Entityquinine sulfate for leg cramps. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a patient who developed polyserositis ( pericardial effusion, pleural effusion, and Entitypericarditis ) after being started on Entityclozapine , and whose symptoms remitted upon discontinuation of clozapine. |
| 0.9999 | Adverse-Effect | We report the case of a patient who developed polyserositis ( pericardial effusion, pleural effusion, and Entitypericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of Entityclozapine . |
| 0.9998 | Adverse-Effect | We report the case of a patient who developed Entitypolyserositis ( pericardial effusion, pleural effusion, and pericarditis ) after being started on Entityclozapine , and whose symptoms remitted upon discontinuation of clozapine. |
| 0.9998 | Adverse-Effect | We report the case of a patient who developed polyserositis ( pericardial effusion, Entitypleural effusion , and pericarditis ) after being started on Entityclozapine , and whose symptoms remitted upon discontinuation of clozapine. |
| 0.9998 | Adverse-Effect | We report the case of a patient who developed polyserositis ( Entitypericardial effusion , pleural effusion, and pericarditis ) after being started on Entityclozapine , and whose symptoms remitted upon discontinuation of clozapine. |
| 0.9995 | Adverse-Effect | We report the case of a patient who developed Entitypolyserositis ( pericardial effusion, pleural effusion, and pericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of Entityclozapine . |
| 0.9995 | Adverse-Effect | We report the case of a patient who developed polyserositis ( pericardial effusion, Entitypleural effusion , and pericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of Entityclozapine . |
| 0.9994 | Adverse-Effect | We report the case of a patient who developed polyserositis ( Entitypericardial effusion , pleural effusion, and pericarditis ) after being started on clozapine, and whose symptoms remitted upon discontinuation of Entityclozapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This article reports the case of an otherwise healthy patient who experienced permanent Entitysensorineural hearing loss after a brief course of Entitynaproxen and reviews the literature on NSAID - related permanent sensorineural hearing loss. |
| 0.9962 | Adverse-Effect | This article reports the case of an otherwise healthy patient who experienced permanent sensorineural hearing loss after a brief course of Entitynaproxen and reviews the literature on NSAID - related permanent Entitysensorineural hearing loss . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityHypo - oestrogenic and anabolic / androgenic side - effects of Entitydanazol are well known by the gynaecologist and some of them are present in > 50 % of patients being treated for endometriosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and Entitysulfadiazine for reactivated chorioretinitis developed Entityfever , severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 1.0000 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and Entitysulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, Entityabdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 1.0000 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and Entitysulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, Entityswelling , abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 1.0000 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and Entitysulfadiazine for reactivated chorioretinitis developed fever, Entitysevere cutaneous involvement , swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 1.0000 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took pyrimethamine and Entitysulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and Entitytransaminitis , persisting weeks after withholding medicines. |
| 0.9999 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took Entitypyrimethamine and sulfadiazine for reactivated chorioretinitis developed Entityfever , severe cutaneous involvement, swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9999 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took Entitypyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, Entityabdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9999 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took Entitypyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, Entityswelling , abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9999 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took Entitypyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, Entitysevere cutaneous involvement , swelling, abdominal pain and transaminitis, persisting weeks after withholding medicines. |
| 0.9999 | Adverse-Effect | A 7 - year - old with congenital toxoplasmosis who took Entitypyrimethamine and sulfadiazine for reactivated chorioretinitis developed fever, severe cutaneous involvement, swelling, abdominal pain and Entitytransaminitis , persisting weeks after withholding medicines. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The case reported here is of a child given a large dose of intravenous Entityiron sucrose ( 16 mg / kg ) over 3 hours, who subsequently developed features of Entitysystemic iron toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The first patient was a 61 - year - old man with a 30 - year history of fistulizing CD in whom EntityB - cell non - Hodgkin's lymphoma was diagnosed 9 months after treatment with Entityinfliximab . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report a case of focal myocardial necrosis, presenting clinically as an Entityacute myocardial infarction during the administration of the antineoplastic drug, Entityamsacrine , in a patient without coronary artery disease. |
| 1.0000 | Adverse-Effect | The authors report a case of Entityfocal myocardial necrosis , presenting clinically as an acute myocardial infarction during the administration of the antineoplastic drug, Entityamsacrine , in a patient without coronary artery disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : The authors described a case of Entityinterferon - induced Entitypsychosis as a framework to review the literature and discuss the decision to pursue antiviral treatment in psychiatrically ill patients with hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and Entitystatus epilepticus secondary to Entitygabapentin withdrawal. |
| 0.9995 | Adverse-Effect | Although Entitygabapentin withdrawal has been previously reported and usually consists of Entityanxiety , diaphoresis, and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal. |
| 0.9892 | Adverse-Effect | Although gabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with Entitygeneralized seizures and status epilepticus secondary to Entitygabapentin withdrawal. |
| 0.9793 | Adverse-Effect | Although Entitygabapentin withdrawal has been previously reported and usually consists of anxiety, Entitydiaphoresis , and palpitations, this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal. |
| 0.9128 | Adverse-Effect | Although Entitygabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and Entitypalpitations , this is the first reported patient with generalized seizures and status epilepticus secondary to gabapentin withdrawal. |
| 0.5342 | Adverse-Effect | Although Entitygabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with Entitygeneralized seizures and status epilepticus secondary to gabapentin withdrawal. |
| Adverse-Effect | Although Entitygabapentin withdrawal has been previously reported and usually consists of anxiety, diaphoresis, and palpitations, this is the first reported patient with generalized seizures and Entitystatus epilepticus secondary to gabapentin withdrawal. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The possibility of Entitydeep vein thrombosis caused by the compression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with Entityimatinib . |
| 1.0000 | Adverse-Effect | The possibility of deep vein thrombosis caused by the Entitycompression of the veins by necrotic tumor should be considered in patients with abdominal or pelvic metastases of GIST, including patients treated with Entityimatinib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Though proteinuria and Entitynephrotic syndrome is a rare adverse effect of EntityIFN - beta - 1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings. |
| 0.9998 | Adverse-Effect | Though Entityproteinuria and nephrotic syndrome is a rare adverse effect of EntityIFN - beta - 1b therapy, physicians treating MS patients with this agent should pay careful attention to new clinical symptoms and laboratory findings. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Possible mechanisms by which Entityclonidine decreases spasticity are described, probable mechanisms of induced Entitybradycardia are reviewed, and specific treatment recommendations for the use of clonidine in spinal cord injured patients are presented. |
| 0.9997 | Adverse-Effect | Possible mechanisms by which clonidine decreases spasticity are described, probable mechanisms of induced Entitybradycardia are reviewed, and specific treatment recommendations for the use of Entityclonidine in spinal cord injured patients are presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | None of them had a history of cardiac disease, and with the possible exception of one case of Entitycardiac arrest , where the patient received Entitydoxorubicin , no predisposing factors could be found. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Interestingly, the use of carboplatin ( CBDCA ) and VDS in the subsequent treatment course was well tolerated indicating that the EntitySIADH was most likely to have been induced by administration of EntityCDDP . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A woman 38 - year - old, suffering for about ten years from multiple sclerosis and treated with repeated therapy cycles of intrathecal EntityDepo - Medrol , developed a Entityspastic paraparesis at the lower limbs . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with acute myeloblastic leukemia ( AML ) who developed Entitynephrotic syndrome after receiving several courses of chemotherapy, including Entitymacrophage - colony - stimulating factor ( M - CSF ). |
| 0.9999 | Adverse-Effect | We describe a patient with acute myeloblastic leukemia ( AML ) who developed Entitynephrotic syndrome after receiving several courses of chemotherapy, including macrophage - colony - stimulating factor ( EntityM - CSF ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Only after three subsequent episodes of severe, symptomatic Entitythrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take Entityquinine for night leg cramps. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityCaptopril is an angiotensin - converting enzyme ( ACE ) inhibitor and their Entitycutaneous side - effects are documented, but little has been published concerning the usefulness of patch test when they occur. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Slow acetylators, who comprise roughly 50 % of the South African population, are likely to develop clinical and biochemical features of Entityphenytoin Entityphenytoin toxicity when this drug is given together with antituberculosis therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | During intravenous treatment with Entityterlipressin for recurrent gastrointestinal ( GI ) bleeding, a 50 - year - old male with no history of heart disease developed a newly Entityprolonged QT interval and torsade de pointes. |
| 1.0000 | Adverse-Effect | During intravenous treatment with Entityterlipressin for recurrent gastrointestinal ( GI ) bleeding, a 50 - year - old male with no history of heart disease developed a newly prolonged QT interval and Entitytorsade de pointes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | OBJECTIVE : To describe what is believed, as of November 4, 2003, to be the first case published in the literature of Entityacute interstitial nephritis ( AIN ) due to Entitypantoprazole . |
| 1.0000 | Adverse-Effect | OBJECTIVE : To describe what is believed, as of November 4, 2003, to be the first case published in the literature of acute interstitial nephritis ( EntityAIN ) due to Entitypantoprazole . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 33 - year - old male presented with Entitybrown discolouration of the fingernails following the application of Entity4 % hydroquinone in sorbolene cream and 0. 1 % tretinoin cream to the face intermittently for 9 months. |
| 0.9980 | Adverse-Effect | A 33 - year - old male presented with Entitybrown discolouration of the fingernails following the application of 4 % hydroquinone in sorbolene cream and Entity0. 1 % tretinoin cream to the face intermittently for 9 months. |
| Adverse-Effect | A 33 - year - old male presented with Entitybrown discolouration of the fingernails following the application of 4 % hydroquinone in sorbolene cream and Entity0. 1 % tretinoin cream to the face intermittently for 9 months. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | CONCLUSION : This report describes a case of a probable interaction between topical econazole lotion 1 % and Entityacenocoumarol that resulted in overanticoagulation and a life - threatening Entitylaryngeal hematoma in this elderly patient. |
| 0.9991 | Adverse-Effect | CONCLUSION : This report describes a case of a probable interaction between topical Entityeconazole lotion 1 % and acenocoumarol that resulted in overanticoagulation and a life - threatening Entitylaryngeal hematoma in this elderly patient. |
| 1.0000 | Adverse-Effect | CONCLUSION : This report describes a case of a probable interaction between topical econazole lotion 1 % and Entityacenocoumarol that resulted in Entityoveranticoagulation and a life - threatening laryngeal hematoma in this elderly patient. |
| 0.9995 | Adverse-Effect | CONCLUSION : This report describes a case of a probable interaction between topical Entityeconazole lotion 1 % and acenocoumarol that resulted in Entityoveranticoagulation and a life - threatening laryngeal hematoma in this elderly patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : We report a patient who developed a EntityDAT - positive hemolytic episode after a red cell ( RBC ) transfusion was delivered during the infusion of her 17th cycle of Entityoxaliplatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a patient with the acquired immunodeficiency syndrome treated with Entityrifampicin who had a'normal'screening test for adrenal insufficiency, yet had clinical evidence of Entityadrenal failure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityParaplegia following prophylactic intrathecal Entitycytosine arabinoside ( Ara - C ) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg / m2 / d for 5 consecutive days. |
| 0.9999 | Adverse-Effect | EntityParaplegia following prophylactic intrathecal cytosine arabinoside ( EntityAra - C ) is described in a patient with acute myelogenous leukemia in remission who received doses of 100 mg / m2 / d for 5 consecutive days. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Infants are particularly susceptible to chronic Entitynitrate - induced Entitymethemoglobinemia because of their low stomach acid production, large numbers of nitrite - reducing bacteria, and the relatively easy oxidation of fetal hemoglobin. |
| 0.7845 | Adverse-Effect | Infants are particularly susceptible to chronic nitrate - induced Entitymethemoglobinemia because of their low stomach acid production, large numbers of Entitynitrite - reducing bacteria, and the relatively easy oxidation of fetal hemoglobin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this study, we report on three individual patients who received BTX - B and who subsequently developed Entityparasympathetic dysfunction of the visual system after injections of EntityBTX - B at remote sites. |
| 0.9999 | Adverse-Effect | In this study, we report on three individual patients who received EntityBTX - B and who subsequently developed Entityparasympathetic dysfunction of the visual system after injections of BTX - B at remote sites. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Reversible Entityvalproic acid - induced Entitydementia was documented in a 21 - year - old man with epilepsy who had a 3 - year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a patient with subarachnoid haemorrhage who developed an acute life - threatening pseudo - obstruction of the colon, a variant of Entityadynamic ileus , while being treated with intravenous Entitynimodipine . |
| 0.9999 | Adverse-Effect | We report on a patient with subarachnoid haemorrhage who developed an acute life - threatening Entitypseudo - obstruction of the colon , a variant of adynamic ileus, while being treated with intravenous Entitynimodipine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Although high - dose Entitymethotrexate has been shown to be useful in the treatment of primary osteogenic sarcoma, the tumoricidal effects of therapy appear to have caused a Entityfatal rise in intracranial pressure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Five and one - half years after the diagnosis of myeloma, while in remission on Entitycyclophosphamide therapy, the patient experienced severe Entityabdominal right lower quadrant pain due to a large cecal lymphoma. |
| 0.9998 | Adverse-Effect | Five and one - half years after the diagnosis of myeloma, while in remission on Entitycyclophosphamide therapy, the patient experienced severe abdominal right lower quadrant pain due to a large Entitycecal lymphoma . |
| 1.0000 | Adverse-Effect | Five and one - half years after the diagnosis of myeloma, while in remission on Entitycyclophosphamide therapy, the patient experienced Entitysevere abdominal right lower quadrant pain due to a large cecal lymphoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe the exceptional development of AML and Entitylung cancer in a patient with previously diagnosed CLL in minimal residual disease status after Entityfludarabine treatment followed by autologous peripheral blood stem - cell transplantation. |
| 1.0000 | Adverse-Effect | We describe the exceptional development of EntityAML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after Entityfludarabine treatment followed by autologous peripheral blood stem - cell transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Three of these patients had Entityconvulsions attributed to Entityimipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / cilastatin administrations was followed by a seizure attack. |
| 0.9976 | Adverse-Effect | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / Entitycilastatin administrations was followed by a Entityseizure attack. |
| 0.9782 | Adverse-Effect | Three of these patients had Entityconvulsions attributed to imipenem / Entitycilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / cilastatin administrations was followed by a seizure attack. |
| 0.9579 | Adverse-Effect | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of Entityimipenem / cilastatin administrations was followed by a Entityseizure attack. |
| 0.5234 | Adverse-Effect | Three of these patients had convulsions attributed to imipenem / Entitycilastatin ; 3. 6 % of the patients had Entityseizure , or 2 % of imipenem / cilastatin administrations was followed by a seizure attack. |
| 0.9987 | Adverse-Effect | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of imipenem / Entitycilastatin administrations was followed by a Entityseizure attack . |
| 0.9764 | Adverse-Effect | Three of these patients had convulsions attributed to imipenem / cilastatin ; 3. 6 % of the patients had seizure, or 2 % of Entityimipenem / cilastatin administrations was followed by a Entityseizure attack . |
| Adverse-Effect | Three of these patients had convulsions attributed to Entityimipenem / cilastatin ; 3. 6 % of the patients had Entityseizure , or 2 % of imipenem / cilastatin administrations was followed by a seizure attack. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Since elevated cortisol levels in Cushing's disease poses a threat for pancreatitis, there is a possibility that patients with Cushing's disease might be more prone to Entityacute pancreatitis following Entitypropofol administration. |
| 0.9966 | Adverse-Effect | Since elevated cortisol levels in Cushing's disease poses a threat for Entitypancreatitis , there is a possibility that patients with Cushing's disease might be more prone to acute pancreatitis following Entitypropofol administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitytorsade de pointes following a single oral dose of Entityamiodarone ( 1400 mg or 30 mg kg - 1 ) administered after short intravenous loading for prevention of paroxysmal atrial flutter. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Eighty - two patients with various malignancies who received imipenem / Entitycilastatin 143 times for Entityneutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. |
| 1.0000 | Adverse-Effect | Eighty - two patients with various malignancies who received Entityimipenem / cilastatin 143 times for Entityneutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 36 - y - o patient with schizophrenia, who had consumed gradually increasing quantities of Entityoolong tea that eventually reached 15 L each day, became Entitydelirious and was admitted to a psychiatric hospital. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this report, two cases of ET which evolved into EntityAL without prior exposure to radiation or alkylating agents, and which were treated with long - term Entityhydroxyurea therapy, are described. |
| 1.0000 | Adverse-Effect | In this report, two cases of EntityET which evolved into AL without prior exposure to radiation or alkylating agents, and which were treated with long - term Entityhydroxyurea therapy, are described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Animals treated with EntityHAL showed a highly significant 32 % - 46 Entity% loss of tyrosine hydroxylase ( TH ) immunoreactive neurons in the substantia nigra, and 20 % contraction of the TH stained dendritic arbour. |
| 1.0000 | Adverse-Effect | Animals treated with EntityHAL showed a highly significant 32 % - 46 % Entityloss of tyrosine hydroxylase ( TH ) immunoreactive neurons in the substantia nigra, and 20 % contraction of the TH stained dendritic arbour. |
| Adverse-Effect | Animals treated with EntityHAL showed a highly Entitysignificant 32 % - 46 % loss of tyrosine hydroxylase ( TH ) immunoreactive neurons in the substantia nigra, and 20 % contraction of the TH stained dendritic arbour. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient's clinical presentation, histologic features on liver biopsy and favorable course after stopping the drug suggest that Entitybarbiturates can be added to the list of agents which can cause Entitysubmassive hepatic necrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and Entitypositive autoantibodies developed in a 43 - year - old man, who was receiving long - term Entitysulfasalazine therapy for chronic ulcerative colitis. |
| 1.0000 | Adverse-Effect | Pneumonitis, bilateral pleural effusions, echocardiographic evidence of Entitycardiac tamponade , and positive autoantibodies developed in a 43 - year - old man, who was receiving long - term Entitysulfasalazine therapy for chronic ulcerative colitis. |
| 1.0000 | Adverse-Effect | EntityPneumonitis , bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43 - year - old man, who was receiving long - term Entitysulfasalazine therapy for chronic ulcerative colitis. |
| 1.0000 | Adverse-Effect | Pneumonitis, Entitybilateral pleural effusions , echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43 - year - old man, who was receiving long - term Entitysulfasalazine therapy for chronic ulcerative colitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | The present report illustrates a rare case of refractory Entityakathisia after Entityinterferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon - alpha. |
| 0.9988 | Adverse-Effect | The present report illustrates a rare case of refractory akathisia after interferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the Entityneurotoxicity associated with Entityinterferon - alpha . |
| 0.9999 | Adverse-Effect | The present report illustrates a rare case of Entityrefractory akathisia after Entityinterferon - alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon - alpha. |
| 0.6066 | Adverse-Effect | The present report illustrates a rare case of refractory akathisia after interferon - alpha treatment and also that Entitylevodopa treatment would be theoretically and practically useful in reducing the Entityneurotoxicity associated with interferon - alpha. |
| 0.5589 | Adverse-Effect | The present report illustrates a rare case of Entityrefractory akathisia after interferon - alpha treatment and also that Entitylevodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon - alpha. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report the case of a young woman with Graves'disease in whom ototoxicity developed because of propylthiouracil ( EntityPTU ) - induced Entityantineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis . |
| 1.0000 | Adverse-Effect | OBJECTIVE : To report the case of a young woman with Graves'disease in whom Entityototoxicity developed because of Entitypropylthiouracil ( PTU ) - induced antineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis. |
| 0.9999 | Adverse-Effect | OBJECTIVE : To report the case of a young woman with Graves'disease in whom ototoxicity developed because of Entitypropylthiouracil ( PTU ) - induced Entityantineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis . |
| 0.9990 | Adverse-Effect | OBJECTIVE : To report the case of a young woman with Graves'disease in whom Entityototoxicity developed because of propylthiouracil ( EntityPTU ) - induced antineutrophil cytoplasmic antibody ( ANCA ) - associated vasculitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 20 - year - old woman originally from Cameroon who was infected by the L. loa parasite and developed Entitysevere hepatitis , identified 1 month after a single dose of Entityivermectin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Rapamycin / sirolimus ( SR ), trade named EntityRapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with Entitymyelosuppression , hypertension, hyperlipidemia, and infection. |
| 1.0000 | Adverse-Effect | Rapamycin / sirolimus ( SR ), trade named EntityRapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, Entityhypertension , hyperlipidemia, and infection. |
| 0.9999 | Adverse-Effect | Rapamycin / sirolimus ( SR ), trade named EntityRapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, Entityhyperlipidemia , and infection. |
| 0.9999 | Adverse-Effect | EntityRapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with Entitymyelosuppression , hypertension, hyperlipidemia, and infection. |
| 0.9999 | Adverse-Effect | EntityRapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, Entityhypertension , hyperlipidemia, and infection. |
| 0.9999 | Adverse-Effect | Rapamycin / Entitysirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with Entitymyelosuppression , hypertension, hyperlipidemia, and infection. |
| 0.9999 | Adverse-Effect | EntityRapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, Entityhyperlipidemia , and infection. |
| 0.9999 | Adverse-Effect | Rapamycin / sirolimus ( SR ), trade named EntityRapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and Entityinfection . |
| 0.9999 | Adverse-Effect | Rapamycin / Entitysirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, Entityhypertension , hyperlipidemia, and infection. |
| 0.9999 | Adverse-Effect | Rapamycin / Entitysirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, Entityhyperlipidemia , and infection. |
| 0.9999 | Adverse-Effect | EntityRapamycin / sirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and Entityinfection . |
| 0.9999 | Adverse-Effect | Rapamycin / Entitysirolimus ( SR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and Entityinfection . |
| Adverse-Effect | Rapamycin / sirolimus ( EntitySR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, Entityhyperlipidemia , and infection. | |
| Adverse-Effect | Rapamycin / sirolimus ( EntitySR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, Entityhypertension , hyperlipidemia, and infection. | |
| Adverse-Effect | Rapamycin / sirolimus ( EntitySR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with myelosuppression, hypertension, hyperlipidemia, and Entityinfection . | |
| Adverse-Effect | Rapamycin / sirolimus ( EntitySR ), trade named Rapammune ( Wyeth - Ayerst, Sydney, Australia ), is a potent immunosuppressive drug associated with Entitymyelosuppression , hypertension, hyperlipidemia, and infection. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | The main side - effects of EntityLp - TAE combined with HT were Entitylow - grade fever , localized pain, myelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9997 | Adverse-Effect | The main side - effects of EntityLp - TAE combined with HT were low - grade fever, Entitylocalized pain , myelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9993 | Adverse-Effect | The main side - effects of EntityLp - TAE combined with HT were low - grade fever, localized pain, Entitymyelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9989 | Adverse-Effect | The main side - effects of EntityLp - TAE combined with HT were low - grade fever, localized pain, myelo - suppression and Entityliver dysfunction , but these were transient and eventually disappeared. |
| 1.0000 | Adverse-Effect | The main side - effects of Lp - TAE combined with EntityHT were Entitylow - grade fever , localized pain, myelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9998 | Adverse-Effect | The main side - effects of Lp - TAE combined with EntityHT were low - grade fever, Entitylocalized pain , myelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9994 | Adverse-Effect | The main side - effects of Lp - TAE combined with EntityHT were low - grade fever, localized pain, Entitymyelo - suppression and liver dysfunction, but these were transient and eventually disappeared. |
| 0.9990 | Adverse-Effect | The main side - effects of Lp - TAE combined with EntityHT were low - grade fever, localized pain, myelo - suppression and Entityliver dysfunction , but these were transient and eventually disappeared. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Hyperkalaemia with Entityrenal tubular dysfunction by oral therapy of Entitysulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. |
| 0.9998 | Adverse-Effect | EntityHyperkalaemia with renal tubular dysfunction by oral therapy of Entitysulfamethoxazole - trimethoprim ( co - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. |
| 0.9996 | Adverse-Effect | Hyperkalaemia with Entityrenal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( Entityco - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. |
| 0.9992 | Adverse-Effect | EntityHyperkalaemia with renal tubular dysfunction by oral therapy of sulfamethoxazole - trimethoprim ( Entityco - trimoxazole ) is described in 2 elderly Japanese patients with lymphoid malignancy, who developed Pneumocystis carinii pneumonia and improved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9634 | Adverse-Effect | A young diamond dealer developed visual impairment attributed to Entitybilateral posterior subcapsular cataracts following only four courses of intermittent EntityDecadron used as part of a five - drug antiemetic regimen for cisplatin - associated nausea. |
| 0.7002 | Adverse-Effect | A young diamond dealer developed Entityvisual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent EntityDecadron used as part of a five - drug antiemetic regimen for cisplatin - associated nausea. |
| Adverse-Effect | A young diamond dealer developed visual impairment attributed to bilateral posterior subcapsular cataracts following only four courses of intermittent Decadron used as part of a five - drug antiemetic regimen for Entitycisplatin - associated Entitynausea . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 22 - year - old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a Entitygeneralized, pruritic, macular eruption 3 weeks after starting Entityminocycline therapy for acne. |
| 1.0000 | Adverse-Effect | A 22 - year - old black man developed fever, Entitychills , fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting Entityminocycline therapy for acne. |
| 1.0000 | Adverse-Effect | A 22 - year - old black man developed fever, chills, Entityfatigue , night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting Entityminocycline therapy for acne. |
| 0.9999 | Adverse-Effect | A 22 - year - old black man developed Entityfever , chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting Entityminocycline therapy for acne. |
| 0.9999 | Adverse-Effect | A 22 - year - old black man developed fever, chills, fatigue, Entitynight sweats , tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting Entityminocycline therapy for acne. |
| 0.9999 | Adverse-Effect | A 22 - year - old black man developed fever, chills, fatigue, night sweats, Entitytender lymphadenopathy , and a generalized, pruritic, macular eruption 3 weeks after starting Entityminocycline therapy for acne. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report a case of chronic, nonproductive Entitycough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor Entityquinapril , with complete resolution after switching to another ACE inhibitor, fosinopril. |
| 0.9995 | Adverse-Effect | OBJECTIVE : To report a case of chronic, nonproductive Entitycough secondary to the angiotensin - converting enzyme ( ACE ) inhibitor quinapril, with complete resolution after switching to another ACE inhibitor, Entityfosinopril . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We have described three patients with hepatitis C for whom IFN - alpha and Entityribavirin were prescribed and who developed two successive phases of silent Entitythyroiditis followed by hyperthryroidism relapse due to Graves'disease. |
| 0.9998 | Adverse-Effect | We have described three patients with hepatitis C for whom IFN - alpha and Entityribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by Entityhyperthryroidism relapse due to Graves'disease. |
| 0.9995 | Adverse-Effect | We have described three patients with hepatitis C for whom EntityIFN - alpha and ribavirin were prescribed and who developed two successive phases of silent Entitythyroiditis followed by hyperthryroidism relapse due to Graves'disease. |
| 0.9984 | Adverse-Effect | We have described three patients with hepatitis C for whom EntityIFN - alpha and ribavirin were prescribed and who developed two successive phases of silent thyroiditis followed by Entityhyperthryroidism relapse due to Graves'disease. |
| 1.0000 | Adverse-Effect | We have described three patients with hepatitis C for whom IFN - alpha and Entityribavirin were prescribed and who developed two successive phases of Entitysilent thyroiditis followed by hyperthryroidism relapse due to Graves'disease. |
| 0.9997 | Adverse-Effect | We have described three patients with hepatitis C for whom EntityIFN - alpha and ribavirin were prescribed and who developed two successive phases of Entitysilent thyroiditis followed by hyperthryroidism relapse due to Graves'disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In patients with swallowing dysfunction and pneumonia, a history of Entitymineral oil use should be obtained and a diagnosis of EntityELP should be considered in the differential diagnoses if mineral oil use has occurred. |
| 0.9999 | Adverse-Effect | In patients with swallowing dysfunction and Entitypneumonia , a history of Entitymineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred. |
| 0.9997 | Adverse-Effect | In patients with swallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of EntityELP should be considered in the differential diagnoses if Entitymineral oil use has occurred. |
| 0.9990 | Adverse-Effect | In patients with Entityswallowing dysfunction and pneumonia, a history of Entitymineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if mineral oil use has occurred. |
| 0.9933 | Adverse-Effect | In patients with Entityswallowing dysfunction and pneumonia, a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if Entitymineral oil use has occurred. |
| 0.9933 | Adverse-Effect | In patients with swallowing dysfunction and Entitypneumonia , a history of mineral oil use should be obtained and a diagnosis of ELP should be considered in the differential diagnoses if Entitymineral oil use has occurred. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Life - threatening Entityadrenal suppression , requiring hydrocortisone supplementation and intensive therapy, was observed and successfully treated in a newborn, whose mother had received high - dose Entitymethylprednisolone in late pregnancy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We believe the temporal association of the abnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of Entity6 - TG as a cause of Entityliver enzyme abnormalities . |
| 1.0000 | Adverse-Effect | We believe the temporal association of the Entityabnormal liver enzymes in this patient, in the absence of other offending agents, argues strongly in favor of Entity6 - TG as a cause of liver enzyme abnormalities. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two patients with imminent gangrene of the extremities caused by Entityergot - induced Entityarteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement. |
| 1.0000 | Adverse-Effect | Two patients with imminent Entitygangrene of the extremities caused by Entityergot - induced arteriospasm underwent mechanical dilatation of the arteries when conventional measures such as anticoagulation, vasodilation, and sympathetic blockade produced no improvement. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Patients receiving Entityamifostine who develop only Entityfever should be evaluated for an adverse drug reaction, as well as for sepsis and fevers of neutropenia, and it may be necessary to discontinue the drug. |
| 1.0000 | Adverse-Effect | Patients receiving Entityamifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for Entitysepsis and fevers of neutropenia, and it may be necessary to discontinue the drug. |
| 0.9999 | Adverse-Effect | Patients receiving Entityamifostine who develop only fever should be evaluated for an adverse drug reaction, as well as for sepsis and Entityfevers of neutropenia , and it may be necessary to discontinue the drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9937 | Adverse-Effect | Retrospectively, Entitybucillamine was believed to be the cause of the Entitygiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.9636 | Adverse-Effect | Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to EntityD - penicillamine , which was the subject of an abundance of reports of Entitymammary hyperplasia . |
| 0.9969 | Adverse-Effect | Retrospectively, bucillamine was believed to be the cause of the Entitygiant hypertrophy because of its structural similarity Entityto D - penicillamine , which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.9888 | Adverse-Effect | Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of Entitymammary Entitymammary hyperplasia . |
| 0.9859 | Adverse-Effect | Retrospectively, Entitybucillamine was believed to be the cause of the Entitygiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.9857 | Adverse-Effect | Retrospectively, Entitybucillamine was believed to be the cause of the Entitygiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.9856 | Adverse-Effect | Retrospectively, Entitybucillamine was believed to be the cause of the Entitygiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.9855 | Adverse-Effect | Retrospectively, Entitybucillamine was believed to be the cause of the Entitygiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.9852 | Adverse-Effect | Retrospectively, Entitybucillamine was believed to be the cause of the Entitygiant hypertrophy because of its structural similarity to D - penicillamine, which was the subject of an abundance of reports of mammary hyperplasia. |
| 0.8666 | Adverse-Effect | Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity Entityto D - penicillamine , which was the subject of an abundance of reports of Entitymammary hyperplasia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Both patients were then treated with a carboplatin alternative to Entitycisplatin in the following courses, which resulted in neither a relapse of the Entitycolitis nor a recurrence of the malignancies up to this time. |
| 0.9999 | Adverse-Effect | Both patients were then treated with a carboplatin alternative to Entitycisplatin in the following courses, which resulted in neither a relapse of the colitis nor a recurrence of the Entitymalignancies up to this time. |
| 0.9999 | Adverse-Effect | Both patients were then treated with a Entitycarboplatin alternative to cisplatin in the following courses, which resulted in neither a relapse of the Entitycolitis nor a recurrence of the malignancies up to this time. |
| 0.9996 | Adverse-Effect | Both patients were then treated with a Entitycarboplatin alternative to cisplatin in the following courses, which resulted in neither a relapse of the colitis nor a recurrence of the Entitymalignancies up to this time. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PURPOSE / OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency, which predisposes patients with cancer to potentially Entitylethal adverse reactions following Entity5 - fluorouracil ( 5 - FU ) - based chemotherapy. |
| 0.9999 | Adverse-Effect | PURPOSE / OBJECTIVES : To describe the pharmacogenetic syndrome of dihydropyrimidine dehydrogenase ( DPD ) deficiency, which predisposes patients with cancer to potentially Entitylethal adverse reactions following 5 - fluorouracil ( Entity5 - FU ) - based chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a Entitynonconvulsive generalized status epilepticus following acute withdrawal of Entitylorazepam . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 71 - year - old man with paroxysmal atrial fibrillation who had a previous anterior myocardial infarction exhibited Entitygranulocytopenia 8 days following the administration of oral sustained - release Entityprocainamide ( 750 mg / day ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a continuous ambulatory peritoneal dialysis ( CAPD ) patient that developed Entityvancomycin - induced Entityagranulocytosis during treatment for methicillin - resistant Staphylococcus aureus ( MRSA ) - associated external cuff infection and pneumonia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although Entityisradipine has been associated with Entityhepatocellular injury , there are no reports of fulminant liver failure with this agent, and our patient had been treated for > 2 years without signs of toxicity. |
| 0.9998 | Adverse-Effect | Although Entityisradipine has been associated with hepatocellular injury, there are no reports of Entityfulminant liver failure with this agent, and our patient had been treated for > 2 years without signs of toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with CREST syndrome ( calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia ) who paradoxically experienced Entityworsening of Raynaud's phenomenon when using Entityyohimbine for ED. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A patient is described with the characteristic features of Entityphenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, Entitytibial and facial oedema , pinhead - sized facial pustules and abnormal liver function tests. |
| 0.9999 | Adverse-Effect | A patient is described with the characteristic features of Entityphenytoin hypersensitivity syndrome ( PHS ) including fever, Entityerythroderma , tibial and facial oedema, pinhead - sized facial pustules and abnormal liver function tests. |
| 0.9999 | Adverse-Effect | A patient is described with the characteristic features of Entityphenytoin hypersensitivity syndrome ( PHS ) including Entityfever , erythroderma, tibial and facial oedema, pinhead - sized facial pustules and abnormal liver function tests. |
| 0.9998 | Adverse-Effect | A patient is described with the characteristic features of Entityphenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, tibial and facial oedema, Entitypinhead - sized facial pustules and abnormal liver function tests. |
| 0.9998 | Adverse-Effect | A patient is described with the characteristic features of Entityphenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, tibial and facial oedema, pinhead - sized facial pustules and Entityabnormal liver function tests . |
| Adverse-Effect | A patient is described with the characteristic features of Entityphenytoin Entityphenytoin hypersensitivity syndrome ( PHS ) including fever, erythroderma, tibial and facial oedema, pinhead - sized facial pustules and abnormal liver function tests. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Although transient increases in ectopy after Entitybretylium therapy have been described, presumably due to catecholamine release, the occurrence of life - threatening Entityventricular arrhythmia leading to cardiac arrest has not previously been emphasized. |
| 0.9998 | Adverse-Effect | Although transient increases in ectopy after Entitybretylium therapy have been described, presumably due to catecholamine release, the occurrence of life - threatening ventricular arrhythmia leading to Entitycardiac arrest has not previously been emphasized. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Entitypancytopenia in a 23 - year - old man with Crohn's disease who was treated with Entity5 - aminosalicylic acid ( Pentasa ; Nisshin, Tokyo, Japan ) 3. 0 g / day. |
| 0.9999 | Adverse-Effect | We report a case of Entitypancytopenia in a 23 - year - old man with Crohn's disease who was treated with 5 - aminosalicylic acid ( EntityPentasa ; Nisshin, Tokyo, Japan ) 3. 0 g / day. |
| 0.9998 | Adverse-Effect | We report a case of Entitypancytopenia in a 23 - year - old man with Crohn's disease who was treated with 5 - aminosalicylic acid ( Pentasa ; EntityNisshin , Tokyo, Japan ) 3. 0 g / day. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | EntityExtrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ), i. e. Entityfluoxetine and sertraline, have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ). |
| 0.9997 | Adverse-Effect | EntityExtrapyramidal side effects induced by some selective serotonin reuptake inhibitors ( SSRIs ), i. e. fluoxetine and Entitysertraline , have been previously reported in patients with depression and obsessive - compulsive disorder ( OCD ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Because Entityetoposide - induced Entitypulmonary toxicity is an uncommon but serious adverse event, clinicians must be vigilant about the possibility of it, so that the optimal treatment can start as soon as possible. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Five cases ( four from the literature and one new case ) are presented in which patients unsuspected of having vitamin B12 deficiency developed Entitysubacute combined degeneration of the spinal cord following Entitynitrous oxide anesthesia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of a man treated with an EGFR - inhibitor ( Entityerlotinib ) for a cell lung cancer who developed Entityskin manifestations localized in an uncommon area and with an atypical evolution. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | Physicians should be cognizant of this potential complication in patients receiving Entitythalidomide or thalidomide - like drugs who present with Entityfever and pulmonary infiltrates and fail to improve despite treatment with broad - spectrum antibiotics. |
| 0.9994 | Adverse-Effect | Physicians should be cognizant of this potential complication in patients receiving Entitythalidomide or thalidomide - like drugs who present with fever and Entitypulmonary infiltrates and fail to improve despite treatment with broad - spectrum antibiotics. |
| 0.9999 | Adverse-Effect | Physicians should be cognizant of this potential complication in patients receiving thalidomide or Entitythalidomide - like drugs who present with Entityfever and pulmonary infiltrates and fail to improve despite treatment with broad - spectrum antibiotics. |
| 0.9998 | Adverse-Effect | Physicians should be cognizant of this potential complication in patients receiving thalidomide or Entitythalidomide - like drugs who present with fever and Entitypulmonary infiltrates and fail to improve despite treatment with broad - spectrum antibiotics. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9987 | Adverse-Effect | This article describes two cases of aplastic anemia, at least one of which was almost certainly induced by the use of methazolamide, and one case of Entityagranulocytosis related to the use of Entitymethazolamide . |
| 0.5641 | Adverse-Effect | This article describes two cases of Entityaplastic anemia , at least one of which was almost certainly induced by the use of Entitymethazolamide , and one case of agranulocytosis related to the use of methazolamide. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Common adverse events ( frequency 10 % ) of Entitylacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., Entitydizziness , ataxia, diplopia, and somnolence ). |
| 1.0000 | Adverse-Effect | Common adverse events ( frequency 10 % ) of Entitylacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., dizziness, ataxia, Entitydiplopia , and somnolence ). |
| 1.0000 | Adverse-Effect | Common adverse events ( frequency 10 % ) of Entitylacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., dizziness, Entityataxia , diplopia, and somnolence ). |
| 1.0000 | Adverse-Effect | Common adverse events ( frequency 10 % ) of Entitylacosamide doses up to 600 mg / day include nonspecific central nervous system effects ( e. g., dizziness, ataxia, diplopia, and Entitysomnolence ). |
| 1.0000 | Adverse-Effect | Common adverse events ( frequency 10 % ) of Entitylacosamide doses up to 600 mg / day include Entitynonspecific central nervous system effects ( e. g., dizziness, ataxia, diplopia, and somnolence ). |
| 1.0000 | Adverse-Effect | Common adverse events ( frequency 10 % ) of Entitylacosamide doses up to 600 mg / day include nonspecific Entitycentral nervous system effects ( e. g., dizziness, ataxia, diplopia, and somnolence ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this healthy population, the relative risk of developing Entityendometrial carcinoma in the Entitytamoxifen arm was 2. 54, although when stratified by age, in women over 50, the risk grew to 4. 01. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if Entityweight loss had occurred as an adverse event in patients treated with Entityleflunomide between November 1998 and January 2000. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A sixty - year - old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with Entityanuria , the day after 5 g / m2 bolus Entityifosfamide . |
| 0.9999 | Adverse-Effect | A sixty - year - old woman with advanced breast cancer, previously treated with cisplatin, developed an Entityirreversible lethal renal failure with anuria, the day after 5 g / m2 bolus Entityifosfamide . |
| 1.0000 | Adverse-Effect | A sixty - year - old woman with advanced breast cancer, previously treated with Entitycisplatin , developed an Entityirreversible lethal renal failure with anuria, the day after 5 g / m2 bolus ifosfamide. |
| 0.9998 | Adverse-Effect | A sixty - year - old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible Entitylethal renal failure with anuria, the day after 5 g / m2 bolus Entityifosfamide . |
| 0.9998 | Adverse-Effect | A sixty - year - old woman with advanced breast cancer, previously treated with Entitycisplatin , developed an irreversible Entitylethal renal failure with anuria, the day after 5 g / m2 bolus ifosfamide. |
| 0.9997 | Adverse-Effect | A sixty - year - old woman with advanced breast cancer, previously treated with Entitycisplatin , developed an irreversible lethal renal failure with Entityanuria , the day after 5 g / m2 bolus ifosfamide. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9990 | Adverse-Effect | Until additional data are available, if intravenous acyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of Entitylithium Entitylithium toxicity and measuring serum lithium levels every second or third day. |
| 0.9946 | Adverse-Effect | Until additional data are available, if intravenous Entityacyclovir is administered concurrently with lithium, we recommend closely monitoring patients for signs of Entitylithium toxicity and measuring serum lithium levels every second or third day. |
| 0.9990 | Adverse-Effect | Until additional data are available, if intravenous acyclovir is administered concurrently with Entitylithium , we recommend closely monitoring patients for signs of Entitylithium toxicity and measuring serum lithium levels every second or third day. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although they had complex medical problems, the high serum concentrations of ampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the Entityseizures were related to the Entityampicillin therapy. |
| 0.9993 | Adverse-Effect | Although they had complex medical problems, the high serum concentrations of Entityampicillin at the time of seizures without their recurrence after discontinuing the antibiotic suggest that the Entityseizures were related to the ampicillin therapy. |
| 0.9999 | Adverse-Effect | Although they had complex medical problems, the high serum concentrations of Entityampicillin at the time of Entityseizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the ampicillin therapy. |
| 0.9995 | Adverse-Effect | Although they had complex medical problems, the high serum concentrations of ampicillin at the time of Entityseizures without their recurrence after discontinuing the antibiotic suggest that the seizures were related to the Entityampicillin therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of an elderly woman with a pre - existing history of ischaemic heart disease, who was treated with Entityvenlafaxine , and developed Entityacute myocardial ischaemia within the first week of treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a severe Entitybullous eruption , following successive cycles of high - dose Entitycytarabine for the treatment of acute lymphoblastic leukaemia. |
| 0.9999 | Adverse-Effect | We report a patient with recurrent, increasingly severe episodes of EntityPPE , ultimately complicated by a severe bullous eruption, following successive cycles of high - dose Entitycytarabine for the treatment of acute lymphoblastic leukaemia. |
| 1.0000 | Adverse-Effect | We report a patient with recurrent, increasingly severe episodes of PPE, ultimately complicated by a Entitysevere bullous eruption , following successive cycles of high - dose Entitycytarabine for the treatment of acute lymphoblastic leukaemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The evidence of high plasmatic levels of CBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of EntityCBZ could have represented the precipitating of the episode of Entityacute pancreatitis . |
| 0.9983 | Adverse-Effect | The evidence of high plasmatic levels of EntityCBZ and the absence of other aetiologic factors lead the authors to conclude that the overdose of CBZ could have represented the precipitating of the episode of Entityacute pancreatitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Assessment of cortisol response was by Entityinsulin - induced Entityhypoglycaemia in three cases, by short tetracosactrin test in two, and by low - dose tetracosactrin and 24 - hour urinary cortisol / creatinine ratio in one. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityanaphylactoid reaction due solely to the use of EntityGelofusine in a patient with non - haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : While Entitythrombosis has been reported with EntityGnRH - a therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the massive tumor size. |
| 0.9998 | Adverse-Effect | CONCLUSION : While thrombosis has been reported with EntityGnRH - a therapy in men with prostate cancer, its association with treatment in this benign case may have been a consequence of the Entitymassive tumor size . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9990 | Adverse-Effect | Idiosyncratic factors involving vasopressin receptor affinity and distribution, Entityvasopressin - associated Entityvasodilation in some vascular beds, and the effect of vasopressin on the renin - angiotensin system may further contribute to impaired tissue perfusion. |
| 0.9842 | Adverse-Effect | Idiosyncratic factors involving vasopressin receptor affinity and distribution, vasopressin - associated vasodilation in some vascular beds, and the effect of Entityvasopressin on the renin - angiotensin system may further contribute to Entityimpaired tissue perfusion . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 35 - year - old woman presented with neurotoxicity correlated to an i. v. regimen of Entity5 - fluorouracil as episodes of Entityacute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum. |
| 0.9998 | Adverse-Effect | A 35 - year - old woman presented with Entityneurotoxicity correlated to an i. v. regimen of Entity5 - fluorouracil as episodes of acute confusional state and abnormalities of symmetrically restricted diffusion in the periventricular white matter and corpus callosum. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of Entitycicatricial entropion after at least 2 years of twice - a - day application of Entitydipivefrin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMethotrexate - associated Entitynephropathy is a rare complication in pediatric oncology, and a review of the literature suggests that exposure to nephrotoxic agents may be a significant but perhaps underrecognized risk factor for its development. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this paper, we report a case of Entitysevere hypercalcemia of immobilization in a 40 - year - old hemodialyzed woman treated by Entitycinacalcet HCl for a severe HPTH - II ( PTH > 1, 000 pg / mL ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Although combinations of belladonna, ergotamine, and Entityphenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with Entityanticonvulsant hypersensitivity syndrome . |
| 0.9996 | Adverse-Effect | Although combinations of Entitybelladonna , ergotamine, and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with Entityanticonvulsant hypersensitivity syndrome . |
| 0.9996 | Adverse-Effect | Although combinations of belladonna, Entityergotamine , and phenobarbital have been used for medical treatment of menopausal symptoms since the 1960s, this is the first known case report of its association with Entityanticonvulsant hypersensitivity syndrome . |
| 1.0000 | Adverse-Effect | Although combinations of belladonna, ergotamine, and Entityphenobarbital have been used for medical treatment of Entitymenopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome. |
| 0.9999 | Adverse-Effect | Although combinations of belladonna, Entityergotamine , and phenobarbital have been used for medical treatment of Entitymenopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome. |
| 0.9999 | Adverse-Effect | Although combinations of Entitybelladonna , ergotamine, and phenobarbital have been used for medical treatment of Entitymenopausal symptoms since the 1960s, this is the first known case report of its association with anticonvulsant hypersensitivity syndrome. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9985 | Adverse-Effect | OBJECTIVE : To report the occurrence of acute cytolytic hepatitis in a patient exposed to pulse itraconazole therapy for 24 weeks and provide a concise review of the literature on cases of Entityitraconazole - induced Entityhepatitis . |
| 0.9846 | Adverse-Effect | OBJECTIVE : To report the occurrence of Entityacute cytolytic hepatitis in a patient exposed to pulse Entityitraconazole therapy for 24 weeks and provide a concise review of the literature on cases of itraconazole - induced hepatitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | INTRODUCTION : In resource limited settings patients on antiretroviral treatment who develop Entitystavudine induced Entityhyperlactatemia are often switched to zidovudine on the basis of published studies that demonstrate that this agent can be a safe alternative. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Although Entitymirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing EntitySS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The first reported case, in an adult, of Entitycholestyramine induced Entityhyperchloremic metabolic acidosis is a 70 year old female with a two year history of primary biliary cirrhosis confirmed by histologic and immunologic criteria. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We have successfully overcome Entitysevere neutropenia in an RA patient treated with Entitygold salts, using granulocyte colony - stimulating factor ( G - CSF ), reducing the duration of neutropenia and risk of infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and Entitygemcitabine producing Entitysevere respiratory insufficiency , and simulating a progression of the tumor. |
| 1.0000 | Adverse-Effect | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with EntityBOOP after chemotherapy with Entitydocetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor. |
| 0.9999 | Adverse-Effect | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with EntityBOOP after chemotherapy with docetaxel and Entitygemcitabine producing severe respiratory insufficiency, and simulating a progression of the tumor. |
| 0.9999 | Adverse-Effect | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with Entitydocetaxel and gemcitabine producing Entitysevere respiratory insufficiency , and simulating a progression of the tumor. |
| 0.9999 | Adverse-Effect | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with docetaxel and Entitygemcitabine producing severe respiratory insufficiency, and simulating a Entityprogression of the tumor . |
| 0.9997 | Adverse-Effect | We report the case of a lung cancer patient with bronquiloalveolar carcinoma ( BAC ) presenting with BOOP after chemotherapy with Entitydocetaxel and gemcitabine producing severe respiratory insufficiency, and simulating a Entityprogression of the tumor . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report details a case of Entitybilateral avascular necrosis of the femoral heads in a patient receiving'standard'doses of Entitydexamethasone as part of the antiemetic regimen used in cisplatin - based combination chemotherapy. |
| 0.9989 | Adverse-Effect | This report details a case of Entitybilateral avascular necrosis of the femoral heads in a patient receiving'standard'doses of dexamethasone as part of the antiemetic regimen used in Entitycisplatin - based combination chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In the present paper the authors describe 2 female patients who developed Entityincontinence secondary to the selective serotonin reuptake inhibitors Entityparoxetine and sertraline, as well as a third who developed this side effect on venlafaxine. |
| 0.9999 | Adverse-Effect | In the present paper the authors describe 2 female patients who developed Entityincontinence secondary to the selective serotonin reuptake inhibitors paroxetine and Entitysertraline , as well as a third who developed this side effect on venlafaxine. |
| 0.9967 | Adverse-Effect | In the present paper the authors describe 2 female patients who developed Entityincontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on Entityvenlafaxine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Exacerbation of Entity5 - FU Entitydermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre - existing dermatologic conditions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | In this report, two newborns with congenital heart anomalies demonstrated the Entityharlequin color change , one whose skin findings showed a course related to the dose of systemic Entityprostaglandin E1 , suggesting a possible association. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | One explanation for the noted Entityincrease in the theophylline level Entitytheophylline level is that metabolism occurs mainly by cytochrome P450 ( CYP 1A2 ), an enzyme that is known to be inhibited with high concentrations of zafirlukast. |
| 0.9995 | Adverse-Effect | One explanation for the noted Entityincrease in the theophylline level is that metabolism occurs mainly by cytochrome P450 ( CYP 1A2 ), an enzyme that is known to be inhibited with high concentrations of Entityzafirlukast . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | With the use of optical coherence tomography ( OCT ), two patients with EntityIFN - associated Entityretinopathy who had developed macular edema and reduced visual acuity during the clinical course of IFN therapy were observed. |
| 0.9999 | Adverse-Effect | With the use of optical coherence tomography ( OCT ), two patients with IFN - associated retinopathy who had developed macular edema and Entityreduced visual acuity during the clinical course of EntityIFN therapy were observed. |
| 0.9985 | Adverse-Effect | With the use of optical coherence tomography ( OCT ), two patients with IFN - associated retinopathy who had developed Entitymacular edema and reduced visual acuity during the clinical course of EntityIFN therapy were observed. |
| 0.9980 | Adverse-Effect | With the use of optical coherence tomography ( OCT ), two patients with EntityIFN - associated retinopathy who had developed Entitymacular edema and reduced visual acuity during the clinical course of IFN therapy were observed. |
| 0.9974 | Adverse-Effect | With the use of optical coherence tomography ( OCT ), two patients with EntityIFN - associated retinopathy who had developed macular edema and Entityreduced visual acuity during the clinical course of IFN therapy were observed. |
| 0.9937 | Adverse-Effect | With the use of optical coherence tomography ( OCT ), two patients with IFN - associated Entityretinopathy who had developed macular edema and reduced visual acuity during the clinical course of EntityIFN therapy were observed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entitysideroblastic anemia is presented in a patient with a left ventricular assist device drive - line infection who was receiving Entitylinezolid , an antibiotic used for serious infections with gram - positive organisms. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and Entityperspiration immediately after the administration of salmon Entitycalcitonin with nasal spray or intramuscular administration ( Calsynar ). |
| 1.0000 | Adverse-Effect | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and Entityperspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( EntityCalsynar ). |
| 1.0000 | Adverse-Effect | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, Entityconjunctivitis and perspiration immediately after the administration of salmon Entitycalcitonin with nasal spray or intramuscular administration ( Calsynar ). |
| 0.9999 | Adverse-Effect | We introduce a case of a sixty years old woman with several previous episodes of Entityrhinitis , conjunctivitis and perspiration immediately after the administration of salmon Entitycalcitonin with nasal spray or intramuscular administration ( Calsynar ). |
| 0.9999 | Adverse-Effect | We introduce a case of a sixty years old woman with several previous episodes of Entityrhinitis , conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( EntityCalsynar ). |
| 0.9999 | Adverse-Effect | We introduce a case of a sixty years old woman with several previous episodes of rhinitis, Entityconjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration ( EntityCalsynar ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma Entitylevodopa levels demonstrated Entitymarked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with painful dysesthesia. |
| 1.0000 | Adverse-Effect | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma Entitylevodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and flexor spasms, associated with Entitypainful dysesthesia . |
| 1.0000 | Adverse-Effect | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma Entitylevodopa levels demonstrated marked motor hyperactivity during augmentation, with Entityanarchic discharges of motor unit potentials , tonic grouped discharges and flexor spasms, associated with painful dysesthesia. |
| 0.9999 | Adverse-Effect | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma Entitylevodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, Entitytonic grouped discharges and flexor spasms, associated with painful dysesthesia. |
| 0.9999 | Adverse-Effect | Videopolysomnographic and pharmacokinetic studies with monitoring of plasma Entitylevodopa levels demonstrated marked motor hyperactivity during augmentation, with anarchic discharges of motor unit potentials, tonic grouped discharges and Entityflexor spasms , associated with painful dysesthesia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Currently the use of Entityzidovudine is one of the few specific measures available, and as a potentially Entityteratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage. |
| 0.9999 | Adverse-Effect | Currently the use of Entityzidovudine is one of the few specific measures available, and as a potentially teratogenic and fetotoxic agent, any decision for its use requires evaluation of the potential for Entityfetal damage . |
| 0.9999 | Adverse-Effect | Currently the use of Entityzidovudine is one of the few specific measures available, and as a potentially teratogenic and Entityfetotoxic agent, any decision for its use requires evaluation of the potential for fetal damage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient is presented with typical hyperthyroidism, who developed a severe proximal muscle weakness and a Entityraised creatine phosphokinase after treatment for hyperthyroidism with Entitypropylthiouracil ( 100 mg orally, three times a day ). |
| 1.0000 | Adverse-Effect | A patient is presented with typical hyperthyroidism, who developed a Entitysevere proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with Entitypropylthiouracil ( 100 mg orally, three times a day ). |
| 0.9999 | Adverse-Effect | A patient is presented with typical Entityhyperthyroidism , who developed a severe proximal muscle weakness and a raised creatine phosphokinase after treatment for hyperthyroidism with Entitypropylthiouracil ( 100 mg orally, three times a day ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | After a six - week course of low - dose Entitycyclosporine A , she developed a severe but reversible Entityloss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels. |
| 0.9997 | Adverse-Effect | After a six - week course of low - dose Entitycyclosporine A , she developed a severe but reversible loss of glomerular filtration rate and Entityeffective renal plasma flow despite of low cyclosporine A plasma levels. |
| 0.9998 | Adverse-Effect | After a six - week course of low - dose Entitycyclosporine A , she developed a severe but Entityreversible loss of glomerular filtration rate and effective renal plasma flow despite of low cyclosporine A plasma levels. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We suggest that the previous classification of Entitynitrofurantoin induced Entitylung injury into " acute " and " chronic " injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged. |
| Adverse-Effect | We suggest that the previous classification of Entitynitrofurantoin Entitynitrofurantoin induced lung injury into " acute " and " chronic " injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To report the clinical course of a woman with cryptococcal meningitis and no previous cardiac disease who developed a Entityfatal cardiac arrhythmia after an acute overdose of Entityamphotericin B and to review its toxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of Entityolanzapine to metabolic changes manifested as Entityuncontrolled diabetes mellitus and weight gain. |
| 0.9998 | Adverse-Effect | The following is a case report analysis intended to draw attention to the need for better care coordination by describing the observed relationship of Entityolanzapine to metabolic changes manifested as uncontrolled diabetes mellitus and Entityweight gain . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We consider asterixis to be an easily overlooked sign of Entityneurotoxicity , which may occur even at low or moderate dosage levels, if certain drugs as Entitylithium or clozapine are used in combination with CBZ. |
| 0.9999 | Adverse-Effect | We consider asterixis to be an easily overlooked sign of Entityneurotoxicity , which may occur even at low or moderate dosage levels, if certain drugs as lithium or Entityclozapine are used in combination with CBZ. |
| 0.9999 | Adverse-Effect | We consider asterixis to be an easily overlooked sign of Entityneurotoxicity , which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with EntityCBZ . |
| 0.9998 | Adverse-Effect | We consider Entityasterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as Entitylithium or clozapine are used in combination with CBZ. |
| 0.9995 | Adverse-Effect | We consider Entityasterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or Entityclozapine are used in combination with CBZ. |
| 0.9995 | Adverse-Effect | We consider Entityasterixis to be an easily overlooked sign of neurotoxicity, which may occur even at low or moderate dosage levels, if certain drugs as lithium or clozapine are used in combination with EntityCBZ . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It was hypothesized that valproic acid may interfere with glucuronidation of Entitylamotrigine , leading to Entityincreased serum lamotrigine levels , or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite. |
| 0.9995 | Adverse-Effect | It was hypothesized that Entityvalproic acid may interfere with glucuronidation of lamotrigine, leading to Entityincreased serum lamotrigine levels , or perhaps alter the drug's metabolism, resulting in accumulation of a toxic intermediate metabolite. |
| 0.9995 | Adverse-Effect | It was hypothesized that valproic acid may interfere with glucuronidation of Entitylamotrigine , leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in Entityaccumulation of a toxic intermediate metabolite . |
| 0.9990 | Adverse-Effect | It was hypothesized that Entityvalproic acid may interfere with glucuronidation of lamotrigine, leading to increased serum lamotrigine levels, or perhaps alter the drug's metabolism, resulting in Entityaccumulation of a toxic intermediate metabolite . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : A retrospective report of the first case of Entitygemcitabine - related EntityHUS , in a patient with metastatic pancreatic adenocarcinoma, treated with a variety of standard therapies in addition to rituximab is presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case of EntityHUS in an advanced ovarian cancer patient treated with Entitycarboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow - up. |
| 1.0000 | Adverse-Effect | We present a case of EntityHUS in an advanced ovarian cancer patient treated with carboplatin and Entitygemcitabine , and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow - up. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an Entityabnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with Entitypiritrexim , a methotrexate analog. |
| 0.9999 | Adverse-Effect | We describe a patient with transitional cell carcinoma of the renal pelvis who developed Entityrespiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with Entitypiritrexim , a methotrexate analog. |
| 0.9999 | Adverse-Effect | We describe a patient with transitional cell carcinoma of the renal pelvis who developed respiratory dysfunction and an Entityabnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a Entitymethotrexate analog. |
| 0.9998 | Adverse-Effect | We describe a patient with transitional cell carcinoma of the renal pelvis who developed Entityrespiratory dysfunction and an abnormal chest x - ray with diffuse interstitial opacities while on chemotherapy with piritrexim, a Entitymethotrexate analog. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : The Entitypiloerection observed after the replacement of Entityfluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran. |
| 0.9978 | Adverse-Effect | CONCLUSIONS : The Entitypiloerection observed after the replacement of fluvoxamine with Entitymilnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous norepinephrine induced by milnacipran. |
| 0.9850 | Adverse-Effect | CONCLUSIONS : The Entitypiloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous Entitynorepinephrine induced by milnacipran. |
| 0.9799 | Adverse-Effect | CONCLUSIONS : The Entitypiloerection observed after the replacement of fluvoxamine with milnacipran in this patient appears to have been due to an increase in the alpha ( 1 ) - adrenoceptor occupancy by endogenous norepinephrine induced by Entitymilnacipran . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In summary, we report herein the first case of EntitySIADH believed to be an adverse effect of Entitymizoribin , which may therefore needed to be added to the list of drugs which can induce SIADH. |
| 1.0000 | Adverse-Effect | In summary, we report herein the first case of SIADH believed to be an adverse effect of Entitymizoribin , which may therefore needed to be added to the list of drugs which can induce EntitySIADH . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | During the first days of Entityarsenic trioxide treatment a rapid Entitydecrease in the D - dimers was seen ( normal values reached until day 7 ), together with a slight decrease in peripheral blood leukocytes. |
| 0.9994 | Adverse-Effect | During the first days of Entityarsenic trioxide treatment a rapid decrease in the D - dimers was seen ( normal values reached until day 7 ), together with a Entityslight decrease in peripheral blood leukocytes . |
| 0.9993 | Adverse-Effect | During the first days of Entityarsenic trioxide treatment a rapid decrease in the D - dimers was seen ( normal values reached until day 7 ), together with a slight Entitydecrease in peripheral blood leukocytes . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Therefore, although Entitygarenoxacin reportedly causes fewer adverse reactions for Entitycardiac rhythms than third - generation quinolone antibiotics, one must be cautious of the interference of other drugs during hypokalemia in order to prevent TdP. |
| 0.9993 | Adverse-Effect | Therefore, although Entitygarenoxacin reportedly causes fewer adverse reactions for cardiac rhythms than third - generation quinolone antibiotics, one must be cautious of the interference of other drugs during Entityhypokalemia in order to prevent TdP. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Two children, 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis, presented an episode of seizures and Entitytransient blindness at different times after i. v. pulse Entitymethylprednisolone ( IVPMP ) treatment. |
| 1.0000 | Adverse-Effect | Two children, 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis, presented an episode of Entityseizures and transient blindness at different times after i. v. pulse Entitymethylprednisolone ( IVPMP ) treatment. |
| 1.0000 | Adverse-Effect | Two children, 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis, presented an episode of seizures and Entitytransient blindness at different times after i. v. pulse methylprednisolone ( EntityIVPMP ) treatment. |
| 0.9999 | Adverse-Effect | Two children, 1 with idiopathic nephrotic syndrome and 1 with endo - extracapillary glomerulonephritis, presented an episode of Entityseizures and transient blindness at different times after i. v. pulse methylprednisolone ( EntityIVPMP ) treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A Entitydapsone Entityhypersensitivity syndrome , consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9999 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of fever, headache, nausea, Entityvomiting , lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9999 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of fever, headache, Entitynausea , vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9999 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of fever, Entityheadache , nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9999 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, Entityhepatitis , hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9999 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, Entityhemolysis , leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9999 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, Entityleukopenia , and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9999 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of Entityfever , headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9999 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, Entitylymphadenopathy , hepatitis, hemolysis, leukopenia, and mononucleosis, has been described in patients treated with the drug for leprosy. |
| 0.9998 | Adverse-Effect | A Entitydapsone hypersensitivity syndrome, consisting of fever, headache, nausea, vomiting, lymphadenopathy, hepatitis, hemolysis, leukopenia, and Entitymononucleosis , has been described in patients treated with the drug for leprosy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9992 | Adverse-Effect | Cardiac glycosides are thought to prevent Entitydoxorubicin Entitycardiomyopathy by competitively inhibiting doxorubicin at its receptor sites, but ouabain has a much shorter half life than doxorubicin and its metabolites and so is less effective than digoxin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard Entityinsulin desensitization, could control Entityallergic symptoms in a patient allergic to both NPH and regular insulin. |
| 0.9988 | Adverse-Effect | OBJECTIVE : The purpose of this study was to determine whether desensitization to EntityNPH insulin , as well as standard insulin desensitization, could control Entityallergic symptoms in a patient allergic to both NPH and regular insulin. |
| 1.0000 | Adverse-Effect | OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control Entityallergic symptoms in a patient allergic to both EntityNPH and regular insulin. |
| 0.9998 | Adverse-Effect | OBJECTIVE : The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control Entityallergic symptoms in a patient allergic to both NPH and regular Entityinsulin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including respiratory dyskinesia [ RD ], limb dyskinesia, and Entityorofacial dyskinesia ) following abrupt withdrawal of Entityrisperidone therapy. |
| 1.0000 | Adverse-Effect | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including respiratory dyskinesia [ EntityRD ], limb dyskinesia, and orofacial dyskinesia ) following abrupt withdrawal of Entityrisperidone therapy. |
| 1.0000 | Adverse-Effect | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including respiratory dyskinesia [ RD ], Entitylimb dyskinesia , and orofacial dyskinesia ) following abrupt withdrawal of Entityrisperidone therapy. |
| 1.0000 | Adverse-Effect | The authors present an elderly patient with mixed dementia who developed TD at multiple sites, ( including Entityrespiratory dyskinesia [ RD ], limb dyskinesia, and orofacial dyskinesia ) following abrupt withdrawal of Entityrisperidone therapy. |
| 1.0000 | Adverse-Effect | The authors present an elderly patient with mixed dementia who developed EntityTD at multiple sites, ( including respiratory dyskinesia [ RD ], limb dyskinesia, and orofacial dyskinesia ) following abrupt withdrawal of Entityrisperidone therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We conjectured that the side effects of Entityinsulin , such as Entityanti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia. |
| 0.9993 | Adverse-Effect | We conjectured that the side effects of Entityinsulin , such as anti - natriuresis and Entityincreased vascular permeability , might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and hypoalbuminaemia. |
| 0.9992 | Adverse-Effect | We conjectured that the side effects of Entityinsulin , such as anti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, Entityhyperinsulinaemia and hypoalbuminaemia. |
| 0.9990 | Adverse-Effect | We conjectured that the side effects of Entityinsulin , such as anti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies insulin insensitivity, hyperinsulinaemia and Entityhypoalbuminaemia . |
| 0.9975 | Adverse-Effect | We conjectured that the side effects of Entityinsulin , such as anti - natriuresis and increased vascular permeability, might be pronounced in the presence of the hepatic dysfunction that accompanies Entityinsulin insensitivity , hyperinsulinaemia and hypoalbuminaemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We present two cases in which both patients suffered with EntityCLS , which we believe was caused following administration of Entitygranulocyte colony - stimulating factor , to our knowledge not described in the intensive care patient previously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The principle treatment for DPD - deficient patients with severe acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe Entity5 - FU - induced Entityneurologic symptoms such as encephalopathy and coma. |
| 0.9998 | Adverse-Effect | The principle treatment for DPD - deficient patients with severe acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe Entity5 - FU - induced neurologic symptoms such as Entityencephalopathy and coma. |
| 0.9998 | Adverse-Effect | The principle treatment for DPD - deficient patients with severe acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe Entity5 - FU - induced neurologic symptoms such as encephalopathy and Entitycoma . |
| 0.9996 | Adverse-Effect | The principle treatment for DPD - deficient patients with severe acute Entity5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced Entityneurologic symptoms such as encephalopathy and coma. |
| 0.9995 | Adverse-Effect | The principle treatment for DPD - deficient patients with severe acute Entity5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced neurologic symptoms such as encephalopathy and Entitycoma . |
| 0.9994 | Adverse-Effect | The principle treatment for DPD - deficient patients with severe acute Entity5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced neurologic symptoms such as Entityencephalopathy and coma. |
| Adverse-Effect | The principle treatment for DPD - deficient patients with Entitysevere acute 5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe Entity5 - FU - induced neurologic symptoms such as encephalopathy and coma. | |
| Adverse-Effect | The principle treatment for DPD - deficient patients with Entitysevere acute 5 - FU reactions Entity5 - FU reactions is supportive care ; however, the administration of thymidine potentially may reverse severe 5 - FU - induced neurologic symptoms such as encephalopathy and coma. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A case report is presented concerning the administration of ketanserin in the treatment of pulmonary vasoconstriction and Entityright ventricular failure following the infusion of Entityprotamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. |
| 0.9987 | Adverse-Effect | A case report is presented concerning the administration of ketanserin in the treatment of Entitypulmonary vasoconstriction and right ventricular failure following the infusion of Entityprotamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. |
| 0.9997 | Adverse-Effect | A case report is presented concerning the administration of Entityketanserin in the treatment of Entitypulmonary vasoconstriction and right ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. |
| 0.9974 | Adverse-Effect | A case report is presented concerning the administration of Entityketanserin in the treatment of pulmonary vasoconstriction and Entityright ventricular failure following the infusion of protamine in a patient undergoing coronary artery bypass surgery and mitral valve replacement. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This patient developed sequential symptoms including alternative hemiparesis, dysarthria and Entityaltered consciousness 5 days after the second course of EntityHD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue. |
| 0.9999 | Adverse-Effect | This patient developed sequential symptoms including alternative hemiparesis, Entitydysarthria and altered consciousness 5 days after the second course of EntityHD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue. |
| 0.9998 | Adverse-Effect | This patient developed sequential symptoms including alternative Entityhemiparesis , dysarthria and altered consciousness 5 days after the second course of EntityHD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with leucovorin rescue. |
| 0.9994 | Adverse-Effect | This patient developed sequential symptoms including alternative hemiparesis, dysarthria and Entityaltered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with Entityleucovorin rescue. |
| 0.9989 | Adverse-Effect | This patient developed sequential symptoms including alternative hemiparesis, Entitydysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with Entityleucovorin rescue. |
| 0.9983 | Adverse-Effect | This patient developed sequential symptoms including alternative Entityhemiparesis , dysarthria and altered consciousness 5 days after the second course of HD - MTX ( 8 gm / m2 by 6 h continuous infusion ) with Entityleucovorin rescue. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFK506 , which began to be administered 12 days earlier, rose to a level of 44 ng / mL ( normal range, 10 - 20 ng / mL ) 1 day before Entityneurologic abnormalities began. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.6453 | Adverse-Effect | From 1996 to 2002 several medications were changed due to their adverse effects : Entityindinavir ( renal colic and Entityfever ), nelfinavir ( cutaneous rash ), and efavirenz ( nausea and temporary memory loss ). |
| Adverse-Effect | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), nelfinavir ( cutaneous rash ), and Entityefavirenz ( nausea and Entitytemporary memory loss ). | |
| Adverse-Effect | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), nelfinavir ( cutaneous rash ), and Entityefavirenz ( Entitynausea and temporary memory loss ). | |
| Adverse-Effect | From 1996 to 2002 several medications were changed due to their adverse effects : Entityindinavir ( Entityrenal colic and fever ), nelfinavir ( cutaneous rash ), and efavirenz ( nausea and temporary memory loss ). | |
| Adverse-Effect | From 1996 to 2002 several medications were changed due to their adverse effects : indinavir ( renal colic and fever ), Entitynelfinavir ( Entitycutaneous rash ), and efavirenz ( nausea and temporary memory loss ). | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A 74 - year - old man received oral administration of Entitypilsicainide , a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed Entityloss of consciousness two days later. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Based on the Naranjo algorithm, the adverse reaction observed was probably related to the hydroxyurea treatment ( score = 6 ) ; however, the Entityhydroxyurea chemotherapy could not be discontinued because of the Entitymyeloproliferative disorder . |
| 0.9983 | Adverse-Effect | Based on the Naranjo algorithm, the adverse reaction observed was probably related to the Entityhydroxyurea treatment ( score = 6 ) ; however, the hydroxyurea chemotherapy could not be discontinued because of the Entitymyeloproliferative disorder . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityMinor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving Entityouabain , and none of the 16 who were receiving digoxin. |
| 0.9998 | Adverse-Effect | EntityMinor electrocardiographical changes were noted in five out of six patients who were not receiving a cardiac glycoside and four out of six who were receiving ouabain, and none of the 16 who were receiving Entitydigoxin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Phenytoin was discontinued after admission ; however, Entityphenytoin 1 g i. v. was given for a tonic - clonic seizure two days after admission, after which Entityswelling of the face and legs and pruritus developed. |
| 0.9998 | Adverse-Effect | Phenytoin was discontinued after admission ; however, Entityphenytoin 1 g i. v. was given for a tonic - clonic seizure two days after admission, after which swelling of the face and legs and Entitypruritus developed. |
| 0.9994 | Adverse-Effect | EntityPhenytoin was discontinued after admission ; however, phenytoin 1 g i. v. was given for a tonic - clonic seizure two days after admission, after which Entityswelling of the face and legs and pruritus developed. |
| 0.9992 | Adverse-Effect | EntityPhenytoin was discontinued after admission ; however, phenytoin 1 g i. v. was given for a tonic - clonic seizure two days after admission, after which swelling of the face and legs and Entitypruritus developed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9990 | Adverse-Effect | It is concluded that ' Entitycerebral atrophy ' on CT scans may represent an accumulative effect of EntityACTH and that ACTH should be given with the utmost discretion, and in as low a dose as possible. |
| 0.9266 | Adverse-Effect | It is concluded that ' Entitycerebral atrophy ' on CT scans may represent an accumulative effect of ACTH and that EntityACTH should be given with the utmost discretion, and in as low a dose as possible. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and Entityloss of proprioception 25 days after treatment with weekly Entitytaxol ( 80 mg / m ( 2 ) x3 ). |
| 1.0000 | Adverse-Effect | We describe a case of advanced ovarian carcinoma who developed difficulty walking because of Entitymarked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly Entitytaxol ( 80 mg / m ( 2 ) x3 ). |
| 0.9999 | Adverse-Effect | We describe a case of advanced ovarian carcinoma who developed Entitydifficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly Entitytaxol ( 80 mg / m ( 2 ) x3 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report here a 26 - year - old female with diffuse large B - cell lymphoma who died of Entitysevere pulmonary fibrosis 81 days after the administration of high - dose EntityBCNU ( 600 mg / m2 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Symptoms and signs of Entityaugmentation were related to low plasma Entitylevodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. |
| 0.9985 | Adverse-Effect | Symptoms and signs of Entityaugmentation were related to low plasma levodopa levels, abating 75 minutes after oral Entitylevodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma levodopa concentration. |
| 0.9977 | Adverse-Effect | Symptoms and signs of Entityaugmentation were related to low plasma levodopa levels, abating 75 minutes after oral levodopa administration and reappearing after 3 hours, closely mirroring the rapid rise and fall of plasma Entitylevodopa concentration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : Double - blind, placebo - controlled titrated oral challenges with pancreatic enzymes resulted in definite Entityvomiting within 1 to 1. 5 hours after challenges with EntityViokase and Pancrease MT 16, but not with placebo. |
| 0.9999 | Adverse-Effect | METHODS : Double - blind, placebo - controlled titrated oral challenges with pancreatic enzymes resulted in definite Entityvomiting within 1 to 1. 5 hours after challenges with Viokase and EntityPancrease MT 16 , but not with placebo. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After ruling out a hydrotelluric source of fluorine, the patient's Entityfluorosis was linked to chronic use of Entityniflumic acid , following the publication in 1978 of the 2 previously reported cases affected by this drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | PURPOSE : To investigate the concentration - side effect relationship in a patient with severe Entityacyclovir - induced Entityneurotoxicity and to summarize the information available in the literature about central nervous system side effects due to acyclovir. |
| 0.9967 | Adverse-Effect | PURPOSE : To investigate the concentration - side effect relationship in a patient with severe acyclovir - induced neurotoxicity and to summarize the information available in the literature about Entitycentral nervous system side effects due to Entityacyclovir . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 5 - year - old boy with CF who had a stricture of the hepatic flexure region with associated narrowing due to Entitysubmucosal fibrosis of the transverse colon , secondary to Entityhigh - lipase pancreatin therapy. |
| 0.9996 | Adverse-Effect | We report a 5 - year - old boy with CF who had a stricture Entityof the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to Entityhigh - lipase pancreatin therapy. |
| 0.9996 | Adverse-Effect | We report a 5 - year - old boy with CF who had a stricture of Entitythe hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to Entityhigh - lipase pancreatin therapy. |
| 0.9995 | Adverse-Effect | We report a 5 - year - old boy with CF who had a stricture of the Entityhepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to Entityhigh - lipase pancreatin therapy. |
| Adverse-Effect | We report a 5 - year - old boy with CF who had a Entitystricture of the hepatic flexure region with associated narrowing due to submucosal fibrosis of the transverse colon, secondary to Entityhigh - lipase pancreatin therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The presented patient was treated with 200 mg EntityTCA and developed EntityCushing's syndrome 6 weeks later ( cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms / l ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Such a rapid and relentless progression of Entitymethyldopa - induced Entityliver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit liver function abnormalities early in the course of therapy. |
| 0.9986 | Adverse-Effect | Such a rapid and relentless progression of Entitymethyldopa - induced liver injury is undoubtedly rare, but it may be prevented by careful supervision of patients who exhibit Entityliver function abnormalities early in the course of therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report an HIV - infected woman who developed mild leukopenia as the first sign of a Entitynevirapine - related adverse event, which was followed by Entityskin and hepatic toxicity associated with a more severe leukopenia. |
| 0.9996 | Adverse-Effect | We report an HIV - infected woman who developed mild Entityleukopenia as the first sign of a Entitynevirapine - related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia. |
| 0.9994 | Adverse-Effect | We report an HIV - infected woman who developed mild leukopenia as the first sign of a Entitynevirapine - related adverse event, which was followed by skin and hepatic toxicity associated with a more severe Entityleukopenia . |
| 0.9997 | Adverse-Effect | We report an HIV - infected woman who developed Entitymild leukopenia as the first sign of a Entitynevirapine - related adverse event, which was followed by skin and hepatic toxicity associated with a more severe leukopenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | An 11 - year - old boy who was treated with a relatively high dose of methotrimeprazine meleate ( EntityLevemepromazine ) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from Entityrespiratory distress syndrome . |
| 0.9996 | Adverse-Effect | An 11 - year - old boy who was treated with a relatively high dose of Entitymethotrimeprazine meleate ( Levemepromazine ) a phenothiazine antipsychotic drug, was admitted to the pediatric intensive care unit suffering from Entityrespiratory distress syndrome . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The day after clozapine was stopped, while he was still receiving Entityclomipramine 150 mg / d, he began Entitybehaving oddly , started sweating profusely, shivering, and became tremulous, agitated, and confused. |
| 0.9999 | Adverse-Effect | The day after Entityclozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began Entitybehaving oddly , started sweating profusely, shivering, and became tremulous, agitated, and confused. |
| 0.9999 | Adverse-Effect | The day after clozapine was stopped, while he was still receiving Entityclomipramine 150 mg / d, he began behaving oddly, started Entitysweating profusely , shivering, and became tremulous, agitated, and confused. |
| 0.9999 | Adverse-Effect | The day after clozapine was stopped, while he was still receiving Entityclomipramine 150 mg / d, he began behaving oddly, started sweating profusely, Entityshivering , and became tremulous, agitated, and confused. |
| 0.9999 | Adverse-Effect | The day after clozapine was stopped, while he was still receiving Entityclomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became Entitytremulous , agitated, and confused. |
| 0.9999 | Adverse-Effect | The day after clozapine was stopped, while he was still receiving Entityclomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, Entityagitated , and confused. |
| 0.9998 | Adverse-Effect | The day after clozapine was stopped, while he was still receiving Entityclomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and Entityconfused . |
| 0.9998 | Adverse-Effect | The day after Entityclozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, Entityshivering , and became tremulous, agitated, and confused. |
| 0.9998 | Adverse-Effect | The day after Entityclozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started Entitysweating profusely , shivering, and became tremulous, agitated, and confused. |
| 0.9998 | Adverse-Effect | The day after Entityclozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became Entitytremulous , agitated, and confused. |
| 0.9997 | Adverse-Effect | The day after Entityclozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, Entityagitated , and confused. |
| 0.9997 | Adverse-Effect | The day after Entityclozapine was stopped, while he was still receiving clomipramine 150 mg / d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and Entityconfused . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | PATIENTS : Two patients, ages 40 and 51 years, undergoing treatment with Entityinterferon alfa for malignant neoplasms experienced Entitysudden bilateral, sequential visual loss with disc - related field defects and segmental optic disc edema. |
| 0.9996 | Adverse-Effect | PATIENTS : Two patients, ages 40 and 51 years, undergoing treatment with Entityinterferon alfa for malignant neoplasms experienced sudden bilateral, Entitysequential visual loss with disc - related field defects and segmental optic disc edema. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present the case of a patient who had undergone cholecystectomy previously, but in whom Entitymorphine given in the Emergency Department precipitated Entitypain consistent with biliary colic ; the pain resolved promptly after administration of naloxone. |
| 0.9999 | Adverse-Effect | We present the case of a patient who had undergone cholecystectomy previously, but in whom Entitymorphine given in the Emergency Department precipitated pain consistent with Entitybiliary colic ; the pain resolved promptly after administration of naloxone. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a 74 - year - old man with rheumatoid arthritis ( RA ) who developed syndrome of inappropriate secretion of antidiuretic hormone ( EntitySIADH ) 1. 5 months after commencement of Entitymizoribin prescription when his arthritis was improved. |
| 0.9999 | Adverse-Effect | We describe a 74 - year - old man with rheumatoid arthritis ( RA ) who developed Entitysyndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) 1. 5 months after commencement of Entitymizoribin prescription when his arthritis was improved. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Rapamycin / Entitysirolimus - induced Entitypneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. |
| 0.9996 | Adverse-Effect | EntityRapamycin / sirolimus - induced Entitypneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a pulmonary infiltrate that reversed after ceasing SR therapy. |
| 0.9193 | Adverse-Effect | Rapamycin / Entitysirolimus - induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a Entitypulmonary infiltrate that reversed after ceasing SR therapy. |
| 0.9026 | Adverse-Effect | EntityRapamycin / sirolimus - induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a Entitypulmonary infiltrate that reversed after ceasing SR therapy. |
| Adverse-Effect | Rapamycin / sirolimus - induced pneumonitis has been described previously in renal transplant recipients, and this report describes a stable heart - lung transplant recipient who developed a Entitypulmonary infiltrate that reversed after ceasing EntitySR therapy. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a 14 - year - old female with acute promyelocytic leukemia who developed Entitysymptomatic cardiomyopathy only 4 months into treatment with a combination of Entitydaunomycin and all - trans retinoic acid ( ATRA ). |
| 0.9999 | Adverse-Effect | We report the case of a 14 - year - old female with acute promyelocytic leukemia who developed Entitysymptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and all - trans retinoic acid ( EntityATRA ). |
| 0.9996 | Adverse-Effect | We report the case of a 14 - year - old female with acute promyelocytic leukemia who developed Entitysymptomatic cardiomyopathy only 4 months into treatment with a combination of daunomycin and Entityall - trans retinoic acid ( ATRA ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which EntityL - dopa Entityshortened the manic - depressive cycle length when administered in a double - blind trial. |
| 0.9999 | Adverse-Effect | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which EntityL - dopa Entitydopa shortened the manic - depressive cycle length when administered in a double - blind trial. |
| 0.9997 | Adverse-Effect | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which EntityL - dopa Entity- dopa shortened the manic - depressive cycle length when administered in a double - blind trial. |
| 0.9994 | Adverse-Effect | The authors report a longitudinal case study of a woman with a history of bipolar affective disorder in which EntityL - dopa EntityL - dopa shortened the manic - depressive cycle length when administered in a double - blind trial. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Purple glove syndrome, named for its distinctive purple discoloration and Entityswelling of the hands in the distribution of a glove, is an uncommon complication of intravenous Entityphenytoin administration through small dorsal veins of the hands. |
| 0.9999 | Adverse-Effect | EntityPurple glove syndrome , named for its distinctive purple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous Entityphenytoin administration through small dorsal veins of the hands. |
| 0.9999 | Adverse-Effect | Purple glove syndrome, named for its distinctive Entitypurple discoloration and swelling of the hands in the distribution of a glove, is an uncommon complication of intravenous Entityphenytoin administration through small dorsal veins of the hands. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this report, we present a case of Entityhypoglycaemic coma associated with EntitySP , an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of SP increases. |
| 0.9992 | Adverse-Effect | In this report, we present a case of Entityhypoglycaemic coma associated with SP, an adverse reaction that is likely to be underreported and expected to occur with greater frequency as the use of EntitySP increases. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Administration of intravenous Entitynitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an Entityincrease in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an increase in pulmonary vascular resistance. |
| 1.0000 | Adverse-Effect | Administration of intravenous Entitynitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a Entitydecrease in blood flow that is best explained by an increase in pulmonary vascular resistance. |
| 1.0000 | Adverse-Effect | Administration of intravenous Entitynitroglycerin in a patient with idiopathic pulmonary hypertension resulted in an increase in pulmonary artery pressure associated with a decrease in blood flow that is best explained by an Entityincrease in pulmonary vascular resistance . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It was postulated that the Entityallergic reaction was most likely caused by Entitycapecitabine or the intermediate metabolites based on the immediate reappearance of symptoms from the rechallenge, pharmacokinetic data, and well - tolerance of fluorouracil. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Prolonged responses were achieved with low doses of EntityHU ( 3 - 10 mg / kg / day ) and higher doses were associated with mild reversible hematologic or Entityhepatic toxicity and no further increases in Hb. |
| Adverse-Effect | Prolonged responses were achieved with low doses of EntityHU ( 3 - 10 mg / kg / day ) and higher doses were associated with Entitymild reversible hematologic or hepatic toxicity and no further increases in Hb. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | This Entitypanic anxiety was not relieved by taking etizolam and flunitrazepam again, but subsided rapidly by the re - administration of Entitymianserin 30 mg / day, and because of that the depressive symptom also disappeared. |
| 1.0000 | Adverse-Effect | This Entitypanic anxiety was not relieved by taking Entityetizolam and flunitrazepam again, but subsided rapidly by the re - administration of mianserin 30 mg / day, and because of that the depressive symptom also disappeared. |
| 0.9998 | Adverse-Effect | This Entitypanic anxiety was not relieved by taking etizolam and Entityflunitrazepam again, but subsided rapidly by the re - administration of mianserin 30 mg / day, and because of that the depressive symptom also disappeared. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and Entityaltered mental status after Entityzonisamide treatment was begun or its dosage increased. |
| 0.9998 | Adverse-Effect | Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex Entityvisual hallucinations and altered mental status after Entityzonisamide treatment was begun or its dosage increased. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A child in whom a Entityphenobarbital Entityhypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 1.0000 | Adverse-Effect | A child in whom a Entityphenobarbital hypersensitivity drug reaction developed which consisted of Entityfever , a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9999 | Adverse-Effect | A child in whom a Entityphenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, Entityalopecia , icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9999 | Adverse-Effect | A child in whom a Entityphenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, Entitymyositis , and nephritis, is described. |
| 0.9999 | Adverse-Effect | A child in whom a Entityphenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, Entityicterus , protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9999 | Adverse-Effect | A child in whom a Entityphenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and Entitynephritis , is described. |
| 0.9999 | Adverse-Effect | A child in whom a Entityphenobarbital hypersensitivity drug reaction developed which consisted of fever, Entitya pruritic desquamating erythrodermic rash , alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9999 | Adverse-Effect | A child in whom a Entityphenobarbital hypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, Entityprotein - losing enteropathy , myositis, and nephritis, is described. |
| 1.0000 | Adverse-Effect | A child in whom a Entityphenobarbital Entityhypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 1.0000 | Adverse-Effect | A child in whom a Entityphenobarbital Entityhypersensitivity drug reaction developed which consisted of fever, a pruritic desquamating erythrodermic rash, alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| 0.9999 | Adverse-Effect | A child in whom a Entityphenobarbital hypersensitivity drug reaction developed which consisted of fever, a Entitypruritic desquamating erythrodermic rash , alopecia, icterus, protein - losing enteropathy, myositis, and nephritis, is described. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We observed 5 reactions in 3 patients that appear to be related to a high dose - infusion time ratio, indicating that dose and rate of infusion may be important factors in precipitating Entityanaphylactoid reactions with Entitycisplatin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an Entityirritant type of reaction after treatment with Entitycalcipotriol . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : Rhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with Entityrhabdomyolysis , including Entitylovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor. |
| 0.9998 | Adverse-Effect | DISCUSSION : EntityRhabdomyolysis is a clinical syndrome resulting from the destruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including Entitylovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor. |
| 0.9995 | Adverse-Effect | DISCUSSION : Rhabdomyolysis is a clinical syndrome resulting from the Entitydestruction of skeletal muscle that may progress to renal failure Several drugs have been associated with rhabdomyolysis, including Entitylovastatin , a hydroxymethylglutaryl - coenzyme A reductase inhibitor. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | After initiation of topical vitamin D3 ointment ( 20 micro g / g of Entitytacalcitol ) 10 g / day for the skin lesions, both the Entityserum level of calcium and urinary excretion of calcium increased gradually. |
| 0.9964 | Adverse-Effect | After initiation of topical Entityvitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day for the skin lesions, both the Entityserum level of calcium and urinary excretion of calcium increased gradually. |
| Adverse-Effect | After initiation of topical Entityvitamin D3 ointment ( 20 micro g / g of tacalcitol ) 10 g / day for the skin lesions, both the Entityserum level of calcium and urinary excretion of calcium increased gradually. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which EntityMTX appeared to potentiate opportunistic infections and Entityaccelerate HIV disease . |
| 0.9998 | Adverse-Effect | The use of Entitymethotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and Entityaccelerate HIV disease . |
| 0.9998 | Adverse-Effect | The use of methotrexate ( EntityMTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to potentiate opportunistic infections and Entityaccelerate HIV disease . |
| 1.0000 | Adverse-Effect | The use of methotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which EntityMTX appeared to Entitypotentiate opportunistic infections and accelerate HIV disease. |
| 0.9998 | Adverse-Effect | The use of Entitymethotrexate ( MTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to Entitypotentiate opportunistic infections and accelerate HIV disease. |
| 0.9998 | Adverse-Effect | The use of methotrexate ( EntityMTX ) has been contraindicated for treatment of severe psoriasis in HIV infection on the basis of six previously reported cases in which MTX appeared to Entitypotentiate opportunistic infections and accelerate HIV disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe Entitytoxic symptoms of Entitycarbamazepine , such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 1.0000 | Adverse-Effect | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and Entityataxia , which resolved within 5 days after Entityclarithromycin discontinuation. |
| 1.0000 | Adverse-Effect | During Entityclarithromycin coadministration, four out of the seven patients developed moderate - to - severe Entitytoxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.9999 | Adverse-Effect | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as drowsiness, Entitydizziness , and ataxia, which resolved within 5 days after Entityclarithromycin discontinuation. |
| 0.9999 | Adverse-Effect | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as Entitydrowsiness , dizziness, and ataxia, which resolved within 5 days after Entityclarithromycin discontinuation. |
| 0.9997 | Adverse-Effect | During Entityclarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as Entitydrowsiness , dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.9997 | Adverse-Effect | During Entityclarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as drowsiness, Entitydizziness , and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.9997 | Adverse-Effect | During Entityclarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of carbamazepine, such as drowsiness, dizziness, and Entityataxia , which resolved within 5 days after clarithromycin discontinuation. |
| 0.9997 | Adverse-Effect | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of Entitycarbamazepine , such as Entitydrowsiness , dizziness, and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.9996 | Adverse-Effect | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of Entitycarbamazepine , such as drowsiness, Entitydizziness , and ataxia, which resolved within 5 days after clarithromycin discontinuation. |
| 0.9996 | Adverse-Effect | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe Entitytoxic symptoms of carbamazepine, such as drowsiness, dizziness, and ataxia, which resolved within 5 days after Entityclarithromycin discontinuation. |
| 0.9996 | Adverse-Effect | During clarithromycin coadministration, four out of the seven patients developed moderate - to - severe toxic symptoms of Entitycarbamazepine , such as drowsiness, dizziness, and Entityataxia , which resolved within 5 days after clarithromycin discontinuation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : We report the case of a 31 - year - old patient hospitalized due to behavioral alterations and treated with oral Entityzuclopenthixol , an antipsychotic from the thioxanthene family, who developed an acute, Entitypainful erection . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DIAGNOSIS : Severe Entitytemozolomide - induced Entityimmunosuppression , exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9999 | Adverse-Effect | DIAGNOSIS : Severe Entitytemozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and Entitycutaneous Kaposi's sarcoma . |
| 0.9999 | Adverse-Effect | DIAGNOSIS : Severe Entitytemozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic Entityinfections with Pneumocystis jiroveci pneumonia , brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9998 | Adverse-Effect | DIAGNOSIS : Severe Entitytemozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, Entitybrain abscess with Listeria monocytogenes , and cutaneous Kaposi's sarcoma. |
| 0.9997 | Adverse-Effect | DIAGNOSIS : Severe Entitytemozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound EntityT - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9999 | Adverse-Effect | DIAGNOSIS : Severe Entitytemozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and Entitysimultaneous opportunistic infections with Pneumocystis jiroveci pneumonia , brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9999 | Adverse-Effect | DIAGNOSIS : Severe Entitytemozolomide - induced immunosuppression, exacerbated by corticosteroids, with profound T - cell lymphocytopenia and simultaneous Entityopportunistic infections with Pneumocystis jiroveci pneumonia , brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| 0.9998 | Adverse-Effect | DIAGNOSIS : Severe Entitytemozolomide - induced immunosuppression, Entityexacerbated by corticosteroids , with profound T - cell lymphocytopenia and simultaneous opportunistic infections with Pneumocystis jiroveci pneumonia, brain abscess with Listeria monocytogenes, and cutaneous Kaposi's sarcoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Many clinicians appear to be concerned about the potential Entityhepatotoxicity of the opiate antagonist Entitynaltrexone ( NTX ) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers. |
| 1.0000 | Adverse-Effect | Many clinicians appear to be concerned about the potential Entityhepatotoxicity of the opiate antagonist naltrexone ( EntityNTX ) and this may be one reason why it is not used more widely in treating both heroin and alcohol abusers. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our review of 194 RA patients and 38 PsA patients receiving MTX has identified four RA patients and one PsA patient with EntityMTX - induced Entitypneumonitis , giving a prevalence of 2. 1 % and 0. 03 %, respectively. |
| 0.9759 | Adverse-Effect | Our review of 194 RA patients and 38 PsA patients receiving EntityMTX has identified four RA patients and one PsA patient with MTX - induced Entitypneumonitis , giving a prevalence of 2. 1 % and 0. 03 %, respectively. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 7 - year - old boy developed a Entitysevere unilateral grand mal seizure at the age of 5 years ( Entityphenobarbitone therapy ) ; 1. 5 years later valproate ( 2 - propylpentanoic acid, VPA ) was added to the therapy. |
| 0.9999 | Adverse-Effect | A 7 - year - old boy developed a Entitysevere unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1. 5 years later Entityvalproate ( 2 - propylpentanoic acid, VPA ) was added to the therapy. |
| 0.9998 | Adverse-Effect | A 7 - year - old boy developed a Entitysevere unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1. 5 years later valproate ( 2 - propylpentanoic acid, EntityVPA ) was added to the therapy. |
| 0.9997 | Adverse-Effect | A 7 - year - old boy developed a Entitysevere unilateral grand mal seizure at the age of 5 years ( phenobarbitone therapy ) ; 1. 5 years later valproate ( Entity2 - propylpentanoic acid , VPA ) was added to the therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9989 | Adverse-Effect | The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of Entityfluoxetine - induced Entityakathisia and tricyclic antidepressant - induced " jitteriness " may be identical. |
| 0.9982 | Adverse-Effect | The authors suggest that Entityfluoxetine - induced Entityakathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced " jitteriness " may be identical. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of Entitytoxic liver damage caused by Entitynitrofurantoin . |
| 0.9778 | Adverse-Effect | Given that discontinuation of nitrofurantoin and introduction of Entitymethylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of Entitytoxic liver damage caused by nitrofurantoin. |
| 0.9524 | Adverse-Effect | Given that discontinuation of Entitynitrofurantoin and introduction of methylprednisolon therapy significantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was probably the case of Entitytoxic liver damage caused by nitrofurantoin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this report we present four patients treated with a combination of different psychotropic drugs, in whom Entityasterixis was triggered either by adding Entitycarbamazepine ( CBZ ) to a treatment regimen, or by increasing its dosage. |
| 1.0000 | Adverse-Effect | In this report we present four patients treated with a combination of different psychotropic drugs, in whom Entityasterixis was triggered either by adding carbamazepine ( EntityCBZ ) to a treatment regimen, or by increasing its dosage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Approximately 15 min after the first administration of nebulised Entitymorphine the patient became markedly Entitybradypneic ( respiratory rate : 4 - 5 bpm ), hypotensive ( BP 70 / 40 mmHg ), and responded only partially to command. |
| 0.9999 | Adverse-Effect | Approximately 15 min after the first administration of nebulised Entitymorphine the patient became markedly bradypneic ( respiratory rate : 4 - 5 bpm ), Entityhypotensive ( BP 70 / 40 mmHg ), and responded only partially to command. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Replicate brain magnetic resonance imaging examinations after six weeks and 11 months of Entitypenicillamine therapy documented the development of new Entitybrain lesions during this period, while liver biopsy specimen data disclosed that excellent hepatic decoppering had occurred. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case emphasizes the importance of the evaluation of Entitylithium - associated Entitypolyuria with a direct measurement of plasma vasopressin, interpreted with simultaneous plasma and urine osmolality to secure the correct diagnosis and ensure appropriate therapeutic management. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of Entitycyclosporin A induced a Entitygeneralised pustular exacerbation and a aggravation of the joint condition. |
| 0.9996 | Adverse-Effect | We report a 50 - year - old male patient with a 15 - year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of Entitycyclosporin A induced a generalised pustular exacerbation and a Entityaggravation of the joint condition . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An objective causality assessment indicated a probable relationship between Entityclotting abnormality and Entitywarfarin administration, although the degree of elevation of the INR was unusual in the light of the daily warfarin dose and duration of its exposure. |
| 0.9401 | Adverse-Effect | An objective causality assessment indicated a probable relationship between Entityclotting abnormality and warfarin administration, although the degree of elevation of the INR was unusual in the light of the daily Entitywarfarin dose and duration of its exposure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Even though only a few cases of this adverse event have been reported in the literature, severe Entitydocetaxel - induced Entitypulmonary toxicity needs to be considered in the differential diagnosis when such patients present with respiratory symptoms. |
| 0.9994 | Adverse-Effect | Even though only a few cases of this adverse event have been reported in the literature, severe Entitydocetaxel - induced pulmonary toxicity needs to be considered in the differential diagnosis when such patients present with Entityrespiratory symptoms . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHODS : A 68 - year - old man developed intense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to Entitybimatoprost 9 months after cataract surgery in an eye at low - risk for this Entitycystoid macular edema . |
| 1.0000 | Adverse-Effect | METHODS : A 68 - year - old man developed intense conjunctival hyperemia and Entitycystoid macula edema after switching from Entitylatanoprost to bimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema. |
| 0.9999 | Adverse-Effect | METHODS : A 68 - year - old man developed Entityintense conjunctival hyperemia and cystoid macula edema after switching from Entitylatanoprost to bimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema. |
| 0.9999 | Adverse-Effect | METHODS : A 68 - year - old man developed intense conjunctival hyperemia and cystoid macula edema after switching from Entitylatanoprost to bimatoprost 9 months after cataract surgery in an eye at low - risk for this Entitycystoid macular edema . |
| 0.9999 | Adverse-Effect | METHODS : A 68 - year - old man developed intense conjunctival hyperemia and Entitycystoid macula edema after switching from latanoprost to Entitybimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema. |
| 0.9997 | Adverse-Effect | METHODS : A 68 - year - old man developed Entityintense conjunctival hyperemia and cystoid macula edema after switching from latanoprost to Entitybimatoprost 9 months after cataract surgery in an eye at low - risk for this cystoid macular edema. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : A woman of 80 years, on long - term Entitywarfarin therapy presented with an Entityacute dissecting thoracic aortic aneurysm ; on investigation the only precipitating factor found was an international normalised ratio of 4. 8. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a 57 - year - old man with acral erythrocyanosis progressing to acute digital ischemia and Entitygangrene that developed after combined chemotherapy ( Entitybleomycin and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx. |
| 1.0000 | Adverse-Effect | We describe a 57 - year - old man with acral erythrocyanosis progressing to acute digital ischemia and Entitygangrene that developed after combined chemotherapy ( bleomycin and Entitymethotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx. |
| 1.0000 | Adverse-Effect | We describe a 57 - year - old man with acral erythrocyanosis progressing to Entityacute digital ischemia and gangrene that developed after combined chemotherapy ( Entitybleomycin and methotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx. |
| 0.9999 | Adverse-Effect | We describe a 57 - year - old man with acral erythrocyanosis progressing to Entityacute digital ischemia and gangrene that developed after combined chemotherapy ( bleomycin and Entitymethotrexate ) used to treat a metastatic squamous cell carcinoma of the hypopharynx. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | One patient required nursing home placement and a feeding gastrostomy as a result of the Entityworsening parkinsonism during Entityrisperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine. |
| 0.9993 | Adverse-Effect | One patient required nursing home placement and a Entityfeeding gastrostomy as a result of the worsening parkinsonism during Entityrisperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to clozapine. |
| 0.9990 | Adverse-Effect | One patient required nursing home placement and a feeding gastrostomy as a result of the Entityworsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from Entityrisperidone to clozapine. |
| 0.9961 | Adverse-Effect | One patient required nursing home placement and a Entityfeeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from Entityrisperidone to clozapine. |
| 0.9990 | Adverse-Effect | One patient required nursing home placement and a feeding gastrostomy as a result of the Entityworsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to Entityclozapine . |
| 0.9962 | Adverse-Effect | One patient required nursing home placement and a Entityfeeding gastrostomy as a result of the worsening parkinsonism during risperidone treatment, but was able to return home and have the gastrostomy removed after switching from risperidone to Entityclozapine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and Entityhyperkalemia shortly after completing a course of intravenous Entityimmunoglobulin ( IVIG ). |
| 1.0000 | Adverse-Effect | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, shortness of breath, azotemia, and Entityhyperkalemia shortly after completing a course of intravenous immunoglobulin ( EntityIVIG ). |
| 1.0000 | Adverse-Effect | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, shortness of breath, Entityazotemia , and hyperkalemia shortly after completing a course of intravenous Entityimmunoglobulin ( IVIG ). |
| 1.0000 | Adverse-Effect | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, Entityshortness of breath , azotemia, and hyperkalemia shortly after completing a course of intravenous Entityimmunoglobulin ( IVIG ). |
| 1.0000 | Adverse-Effect | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with Entitynausea , shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous Entityimmunoglobulin ( IVIG ). |
| 0.9999 | Adverse-Effect | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, shortness of breath, Entityazotemia , and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( EntityIVIG ). |
| 0.9999 | Adverse-Effect | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with nausea, Entityshortness of breath , azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( EntityIVIG ). |
| 0.9999 | Adverse-Effect | We report the case of an 87 - year - old white woman with myasthenia gravis who presented with Entitynausea , shortness of breath, azotemia, and hyperkalemia shortly after completing a course of intravenous immunoglobulin ( EntityIVIG ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After therapy for diabetic coma with insulin ( containing the preservative Entitycresol ) and electrolyte solutions was started, the patient complained of Entityincreasing myalgia , developed a high fever and respiratory and metabolic acidosis and lost consciousness. |
| 0.9999 | Adverse-Effect | After therapy for diabetic coma with insulin ( containing the preservative Entitycresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a Entityhigh fever and respiratory and metabolic acidosis and lost consciousness. |
| 0.9999 | Adverse-Effect | After therapy for diabetic coma with insulin ( containing the preservative Entitycresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and Entityrespiratory and metabolic acidosis and lost consciousness. |
| 0.9999 | Adverse-Effect | After therapy for diabetic coma with Entityinsulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of Entityincreasing myalgia , developed a high fever and respiratory and metabolic acidosis and lost consciousness. |
| 0.9999 | Adverse-Effect | After therapy for diabetic coma with insulin ( containing the preservative Entitycresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and Entitylost consciousness . |
| 0.9998 | Adverse-Effect | After therapy for diabetic coma with Entityinsulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and Entityrespiratory and metabolic acidosis and lost consciousness. |
| 0.9998 | Adverse-Effect | After therapy for diabetic coma with Entityinsulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a Entityhigh fever and respiratory and metabolic acidosis and lost consciousness. |
| 0.9998 | Adverse-Effect | After therapy for diabetic coma with Entityinsulin ( containing the preservative cresol ) and electrolyte solutions was started, the patient complained of increasing myalgia, developed a high fever and respiratory and metabolic acidosis and Entitylost consciousness . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A study of in vitro reactivity to L - T4, as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed Entityleukopenia during treatment with EntityL - T4 . |
| 0.9992 | Adverse-Effect | A study of in vitro reactivity to EntityL - T4 , as assessed by peripheral blood lymphocyte transformation, was carried out in a patient with Hashimoto's disease who developed Entityleukopenia during treatment with L - T4. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The clinical course suggests that Entitycaffeine , which is present in oolong tea, was mainly responsible for the Entityrhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| 0.9999 | Adverse-Effect | The clinical course suggests that Entitycaffeine , which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the Entitydelirium , although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| 0.9997 | Adverse-Effect | The clinical course suggests that Entitycaffeine , which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause Entityrhabdomyolysis on rare occasions. |
| 0.9995 | Adverse-Effect | The clinical course suggests that Entitycaffeine , which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe Entityhyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| 0.9997 | Adverse-Effect | The clinical course suggests that Entitycaffeine , which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although Entitysevere hyponatremia has been reported to cause rhabdomyolysis on rare occasions. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and Entityataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of Entitypentobarbital and pyrilamine maleate. |
| 0.9999 | Adverse-Effect | A toxic encephalopathy characterized by Entitydepressed level of consciousness , marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of Entitypentobarbital and pyrilamine maleate. |
| 0.9999 | Adverse-Effect | A Entitytoxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of Entitypentobarbital and pyrilamine maleate. |
| 0.9999 | Adverse-Effect | A toxic encephalopathy characterized by depressed level of consciousness, marked irritability, and Entityataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and Entitypyrilamine maleate . |
| 0.9999 | Adverse-Effect | A toxic encephalopathy characterized by depressed level of consciousness, Entitymarked irritability , and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of Entitypentobarbital and pyrilamine maleate. |
| 0.9994 | Adverse-Effect | A Entitytoxic encephalopathy characterized by depressed level of consciousness, marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and Entitypyrilamine maleate . |
| 0.9994 | Adverse-Effect | A toxic encephalopathy characterized by Entitydepressed level of consciousness , marked irritability, and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and Entitypyrilamine maleate . |
| 0.9993 | Adverse-Effect | A toxic encephalopathy characterized by depressed level of consciousness, Entitymarked irritability , and ataxia developed in seven children, 5 years of age and younger, following administration of an antiemetic combination of pentobarbital and Entitypyrilamine maleate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Careful follow - up of so - called " self - limited " Entityinsulin Entityedema is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure. |
| 0.9995 | Adverse-Effect | Careful follow - up of so - called " self - limited " Entityinsulin Entityinsulin edema is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure. |
| 0.4880 | Adverse-Effect | Careful follow - up of so - called " self - limited " Entityinsulin edema Entityedema is encouraged, and the early institution of diuretic therapy is advocated in elderly patients to prevent the development of overt cardiac failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of Entitymeningitis after using Entitytrimethoprim / sulfamethoxazole ( TMP / SMX ). |
| 1.0000 | Adverse-Effect | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of Entitymeningitis after using trimethoprim / Entitysulfamethoxazole ( TMP / SMX ). |
| 1.0000 | Adverse-Effect | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of Entitymeningitis after using trimethoprim / sulfamethoxazole ( TMP / EntitySMX ). |
| 1.0000 | Adverse-Effect | We present a 46 - year - old African - American man with AIDS who was admitted on two different occasions within three weeks for signs and symptoms of Entitymeningitis after using trimethoprim / sulfamethoxazole ( EntityTMP / SMX ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report ( to our knowledge, for the first time in a child ) the emergence of Entitypsychosis in a 12 - year old white girl with an increased Entityefavirenz concentration and heterozygous gene polymorphism of the CYP2B6 - G516 T. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of a human immunodeficiency virus type 1 ( HIV - 1 ) - infected individual receiving combination antiretroviral therapy, which included ritonavir, who developed EntityCushing syndrome with profound complications after epidural Entitytriamcinolone injections. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with rifampicin and Entityethambutol a nine - year - old boy developed Entitypolyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 1.0000 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with rifampicin and Entityethambutol a nine - year - old boy developed polyarthritis, Entityrash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 1.0000 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with rifampicin and Entityethambutol a nine - year - old boy developed polyarthritis, rash and Entityhepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9999 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with rifampicin and Entityethambutol a nine - year - old boy developed polyarthritis, rash and hepatitis in association with Entityanti - native DNA antibodies and positive antinuclear factor. |
| 1.0000 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with Entityrifampicin and ethambutol a nine - year - old boy developed Entitypolyarthritis , rash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9999 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with rifampicin and Entityethambutol a nine - year - old boy developed polyarthritis, rash and hepatitis in association with anti - native DNA antibodies and Entitypositive antinuclear factor . |
| 0.9999 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with Entityrifampicin and ethambutol a nine - year - old boy developed polyarthritis, Entityrash and hepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9999 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with Entityrifampicin and ethambutol a nine - year - old boy developed polyarthritis, rash and Entityhepatitis in association with anti - native DNA antibodies and positive antinuclear factor. |
| 0.9998 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with Entityrifampicin and ethambutol a nine - year - old boy developed polyarthritis, rash and hepatitis in association with Entityanti - native DNA antibodies and positive antinuclear factor. |
| 0.9998 | Adverse-Effect | After seven months'continuous treatment for suspected tuberculosis with Entityrifampicin and ethambutol a nine - year - old boy developed polyarthritis, rash and hepatitis in association with anti - native DNA antibodies and Entitypositive antinuclear factor . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a 43 - year - old woman who developed sore throat, swelling of the lips and oral cavity and Entitydysphagia , 2 weeks after the use of Entitybudesonide spray ( Budefat ) for treatment of bronchial asthma. |
| 1.0000 | Adverse-Effect | We report a 43 - year - old woman who developed sore throat, swelling of the lips and oral cavity and Entitydysphagia , 2 weeks after the use of budesonide spray ( EntityBudefat ) for treatment of bronchial asthma. |
| 1.0000 | Adverse-Effect | We report a 43 - year - old woman who developed Entitysore throat , swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of Entitybudesonide spray ( Budefat ) for treatment of bronchial asthma. |
| 1.0000 | Adverse-Effect | We report a 43 - year - old woman who developed sore throat, Entityswelling of the lips and oral cavity and dysphagia, 2 weeks after the use of Entitybudesonide spray ( Budefat ) for treatment of bronchial asthma. |
| 0.9999 | Adverse-Effect | We report a 43 - year - old woman who developed Entitysore throat , swelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray ( EntityBudefat ) for treatment of bronchial asthma. |
| 0.9998 | Adverse-Effect | We report a 43 - year - old woman who developed sore throat, Entityswelling of the lips and oral cavity and dysphagia, 2 weeks after the use of budesonide spray ( EntityBudefat ) for treatment of bronchial asthma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, in the mid - to - late 1980s, a series of letters to the editor and case reports announced an association between Entitytamoxifen therapy in women with breast cancer and the development of Entityendometrial carcinoma . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9967 | Adverse-Effect | We report a cae of Entityparanoid psychosis following use of a decongestant containing EntityPPA and summarize the case report literature of psychiatric adverse effects to PPA in which doses were known and stated to be within recommended guidelines. |
| 0.4335 | Adverse-Effect | We report a cae of Entityparanoid psychosis following use of a decongestant containing PPA and summarize the case report literature of psychiatric adverse effects to EntityPPA in which doses were known and stated to be within recommended guidelines. |
| Adverse-Effect | We report a cae of paranoid psychosis following use of a decongestant containing PPA and summarize the case report literature of Entitypsychiatric adverse effects to EntityPPA in which doses were known and stated to be within recommended guidelines. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new - onset psychotic and Entityincreased mood symptoms during treatment with Entityrisperidone . |
| 1.0000 | Adverse-Effect | OBJECTIVE : To our knowledge, this is the first published case report of an adolescent girl with a mitochondrial disorder and depression who displayed both new - onset Entitypsychotic and increased mood symptoms during treatment with Entityrisperidone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Ten days after Entityitraconazole was started, he developed Entityparalytic ileus , neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| 1.0000 | Adverse-Effect | Ten days after Entityitraconazole was started, he developed paralytic ileus, Entityneurogenic bladder , mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| 1.0000 | Adverse-Effect | Ten days after Entityitraconazole was started, he developed paralytic ileus, neurogenic bladder, Entitymild left ptosis , and absence of deep reflexes, with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| 1.0000 | Adverse-Effect | Ten days after Entityitraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and Entityabsence of deep reflexes , with severe paralysis of the lower extremities and mild weakness of the upper extremities. |
| 1.0000 | Adverse-Effect | Ten days after Entityitraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with severe paralysis of the lower extremities and Entitymild weakness of the upper extremities . |
| 1.0000 | Adverse-Effect | Ten days after Entityitraconazole was started, he developed paralytic ileus, neurogenic bladder, mild left ptosis, and absence of deep reflexes, with Entitysevere paralysis of the lower extremities and mild weakness of the upper extremities. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Administration of intrathecal EntityAra - C in the same dose over longer intervals within 3 - 5 days between consecutive doses resulted in mild, transient neurological symptoms ( Entityparesthesias ) in only one of 30 patients so treated. |
| 1.0000 | Adverse-Effect | Administration of intrathecal EntityAra - C in the same dose over longer intervals within 3 - 5 days between consecutive doses resulted in Entitymild, transient neurological symptoms ( paresthesias ) in only one of 30 patients so treated. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | PATIENT AND METHOD : A 34 - year - old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha - 2a and Entityribavirin for 6 months, developed Entityprogressive malaise and anemia 6 months after the end of treatment. |
| 0.9999 | Adverse-Effect | PATIENT AND METHOD : A 34 - year - old woman with chronic hepatitis C, genotype 3, receiving pegylated interferon alpha - 2a and Entityribavirin for 6 months, developed progressive malaise and Entityanemia 6 months after the end of treatment. |
| 0.9992 | Adverse-Effect | PATIENT AND METHOD : A 34 - year - old woman with chronic hepatitis C, genotype 3, receiving Entitypegylated interferon alpha - 2a and ribavirin for 6 months, developed progressive malaise and Entityanemia 6 months after the end of treatment. |
| 0.9992 | Adverse-Effect | PATIENT AND METHOD : A 34 - year - old woman with chronic hepatitis C, genotype 3, receiving Entitypegylated interferon alpha - 2a and ribavirin for 6 months, developed Entityprogressive malaise and anemia 6 months after the end of treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 46 - year - old African - American man experienced recurrent Entitygrand mal seizures during intravenous infusion of Entityamphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. |
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 46 - year - old African - American man experienced Entityrecurrent grand mal seizures during intravenous infusion of Entityamphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. |
| 0.9836 | Adverse-Effect | CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of Entityamphotericin B , then Entitypetit mal seizures as the infusion was stopped and the drug concentrations decreased with time. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case of a young man, affected by rheumatoid arthritis who developed a rapid - onset short - of - breath, hemoptysis, and Entitysevere weakness , about 2 weeks after the administration of Entityleflunomide . |
| 1.0000 | Adverse-Effect | We report the case of a young man, affected by rheumatoid arthritis who developed a rapid - onset short - of - breath, Entityhemoptysis , and severe weakness, about 2 weeks after the administration of Entityleflunomide . |
| 1.0000 | Adverse-Effect | We report the case of a young man, affected by rheumatoid arthritis who developed a rapid - onset Entityshort - of - breath , hemoptysis, and severe weakness, about 2 weeks after the administration of Entityleflunomide . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week sulphasalazine syndrome ", a rare, but often fatal, Entityimmunoallergic reaction to Entitysulphasalazine . |
| 0.9999 | Adverse-Effect | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week sulphasalazine syndrome ", a rare, but often Entityfatal , immunoallergic reaction to Entitysulphasalazine . |
| 0.9972 | Adverse-Effect | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week Entitysulphasalazine Entitysulphasalazine syndrome ", a rare, but often fatal, immunoallergic reaction to sulphasalazine. |
| 0.9959 | Adverse-Effect | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week Entitysulphasalazine syndrome ", a rare, but often Entityfatal , immunoallergic reaction to sulphasalazine. |
| 0.9917 | Adverse-Effect | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week Entitysulphasalazine syndrome ", a rare, but often fatal, Entityimmunoallergic reaction to sulphasalazine. |
| 0.9910 | Adverse-Effect | It is thought that the clinico - pathological features and chronology of this case bore the hallmarks of the so - called " 3 - week Entitysulphasalazine syndrome ", a rare, but often fatal, immunoallergic reaction to Entitysulphasalazine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | After several unrevealing medical work - ups, he was found to have a Entityhigh blood lead level Entitylead level ( 122 microg / dL ) ; he has a history of scraping and sanding lead paint without adequate protective measures. |
| 0.9950 | Adverse-Effect | After several unrevealing medical work - ups, he was found to have a Entityhigh blood lead level ( 122 microg / dL ) ; he has a history of scraping and sanding Entitylead paint without adequate protective measures. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVES : The authors described a case of EntityHashimoto's disease during Entityinterferon - alpha ( IFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease. |
| 0.9997 | Adverse-Effect | OBJECTIVES : The authors described a case of EntityHashimoto's disease during interferon - alpha ( EntityIFN - alpha ) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A high dose of Entitycotrimoxazole induced Entityhyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious. |
| 0.9999 | Adverse-Effect | A high dose of Entitycotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; Entityone patient became unconscious . |
| 0.9999 | Adverse-Effect | A high dose of Entitycotrimoxazole induced hyperkalaemia with the Entityelevation of serum creatinine and blood urea , and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious. |
| 0.9999 | Adverse-Effect | A high dose of Entitycotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and Entityincreased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became unconscious. |
| 0.9999 | Adverse-Effect | A high dose of Entitycotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one Entitypatient became unconscious . |
| 0.9999 | Adverse-Effect | A high dose of Entitycotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient Entitybecame unconscious . |
| 0.9999 | Adverse-Effect | A high dose of Entitycotrimoxazole induced hyperkalaemia with the elevation of serum creatinine and blood urea, and increased urinary N - acetyl glucosaminase after several days of the drug administration in these patients ; one patient became Entityunconscious . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on 7 patients ( 2 women, 5 men ) with chronic renal failure, who developed under a high dosage of the new diuretic Entitymuzolimine ( range 240 to 1440 mg per day ) Entityfatal neuromyeloencephalopathy . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the first case of fulminant adult respiratory distress syndrome ( EntityARDS ) associated with Entitypegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9998 | Adverse-Effect | We report the first case of fulminant Entityadult respiratory distress syndrome ( ARDS ) associated with Entitypegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9997 | Adverse-Effect | We report the first case of fulminant adult respiratory distress syndrome ( EntityARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and Entityribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9995 | Adverse-Effect | We report the first case of fulminant Entityadult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and Entityribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9995 | Adverse-Effect | We report the first case of fulminant adult respiratory distress syndrome ( EntityARDS ) associated with pegylated interferon alpha - 2a ( EntitypegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9990 | Adverse-Effect | We report the first case of fulminant Entityadult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( EntitypegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9998 | Adverse-Effect | We report the first case of Entityfulminant adult respiratory distress syndrome ( ARDS ) associated with Entitypegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9996 | Adverse-Effect | We report the first case of Entityfulminant adult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( pegIFNalpha - 2a ) and Entityribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| 0.9992 | Adverse-Effect | We report the first case of Entityfulminant adult respiratory distress syndrome ( ARDS ) associated with pegylated interferon alpha - 2a ( EntitypegIFNalpha - 2a ) and ribavirin use for hepatitis C, complicated by subsequent and ultimately fatal sepsis and multiorgan failure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction ( IIR ), complicated 1 day later by Entitysevere swelling of the forearm and hand ipsilateral to the site of Entityinfliximab infusion. |
| 0.9997 | Adverse-Effect | Here we describe a patient with Crohn's disease who developed a severe Entityinfliximab infusion reaction ( EntityIIR ), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion. |
| 0.9995 | Adverse-Effect | Here we describe a patient with Crohn's disease who developed a severe Entityinfliximab infusion reaction ( IIR ), complicated 1 day later by Entitysevere swelling of the forearm and hand ipsilateral to the site of infliximab infusion. |
| 0.9995 | Adverse-Effect | Here we describe a patient with Crohn's disease who developed a severe infliximab infusion reaction ( EntityIIR ), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of Entityinfliximab infusion. |
| Adverse-Effect | Here we describe a patient with Crohn's disease who developed a Entitysevere infliximab infusion reaction Entityinfliximab infusion reaction ( IIR ), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of infliximab infusion. | |
| Adverse-Effect | Here we describe a patient with Crohn's disease who developed a Entitysevere infliximab infusion reaction ( IIR ), complicated 1 day later by severe swelling of the forearm and hand ipsilateral to the site of Entityinfliximab infusion. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, there remain questions concerning whether these drugs, especially methimazole ( EntityMMI ), may be associated with Entityaplasia cutis congenita ( ACC ) and how best to avoid impairment of fetal thyroid function during their use. |
| 1.0000 | Adverse-Effect | However, there remain questions concerning whether these drugs, especially Entitymethimazole ( MMI ), may be associated with Entityaplasia cutis congenita ( ACC ) and how best to avoid impairment of fetal thyroid function during their use. |
| 0.9999 | Adverse-Effect | However, there remain questions concerning whether these drugs, especially Entitymethimazole ( MMI ), may be associated with aplasia cutis congenita ( EntityACC ) and how best to avoid impairment of fetal thyroid function during their use. |
| 0.9999 | Adverse-Effect | However, there remain questions concerning whether these drugs, especially methimazole ( EntityMMI ), may be associated with aplasia cutis congenita ( EntityACC ) and how best to avoid impairment of fetal thyroid function during their use. |
| 0.9997 | Adverse-Effect | However, there remain questions concerning whether these drugs, especially Entitymethimazole ( MMI ), may be associated with aplasia cutis congenita ( ACC ) and how best to avoid Entityimpairment of fetal thyroid function during their use. |
| 0.9996 | Adverse-Effect | However, there remain questions concerning whether these drugs, especially methimazole ( EntityMMI ), may be associated with aplasia cutis congenita ( ACC ) and how best to avoid Entityimpairment of fetal thyroid function during their use. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Case 2, a 29 - year - old woman, developed bilateral optic neuritis combined with numbness of the lower extremities as well as Entitybowel and bladder dysfunction after a 22 - month use of Entityrecombinant interferon alpha - 2b for chronic myelogenous leukemia. |
| 0.9998 | Adverse-Effect | Case 2, a 29 - year - old woman, developed bilateral optic neuritis combined with Entitynumbness of the lower extremities as well as bowel and bladder dysfunction after a 22 - month use of Entityrecombinant interferon alpha - 2b for chronic myelogenous leukemia. |
| 0.9997 | Adverse-Effect | Case 2, a 29 - year - old woman, developed Entitybilateral optic neuritis combined with numbness of the lower extremities as well as bowel and bladder dysfunction after a 22 - month use of Entityrecombinant interferon alpha - 2b for chronic myelogenous leukemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9996 | Adverse-Effect | We report a case of a patient with mild chronic renal insufficiency who had been taking simvastatin for over a year and developed Entityacute weakness within 3 weeks after the start of treatment with Entitycolchicine for acute gouty bursitis. |
| 0.9783 | Adverse-Effect | We report a case of a patient with mild chronic renal insufficiency who had been taking Entitysimvastatin for over a year and developed Entityacute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis. |
| Adverse-Effect | We report a case of a patient with Entitymild chronic renal insufficiency who had been taking Entitysimvastatin for over a year and developed acute weakness within 3 weeks after the start of treatment with colchicine for acute gouty bursitis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with Entityepoprostenol , presented with Entityrapidly progressive erythema , scaling, nausea and vomiting, and fever. |
| 1.0000 | Adverse-Effect | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with Entityepoprostenol , presented with rapidly progressive erythema, Entityscaling , nausea and vomiting, and fever. |
| 1.0000 | Adverse-Effect | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with Entityepoprostenol , presented with rapidly progressive erythema, scaling, Entitynausea and vomiting, and fever. |
| 1.0000 | Adverse-Effect | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with Entityepoprostenol , presented with rapidly progressive erythema, scaling, nausea and Entityvomiting , and fever. |
| 1.0000 | Adverse-Effect | We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with Entityepoprostenol , presented with rapidly progressive erythema, scaling, nausea and vomiting, and Entityfever . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : This case report showed that the clinical appearance of EntityHashimoto's disease after EntityIFN - alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition ( DR5 ) for this pathology. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of a patient with rheumatoid arthritis treated with low - dose Entitymethotrexate ( 15 mg / week ) who developed Entityinfection with both M. tuberculosis and M. chelonae after the revision of a prosthetic hip. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case histories are presented of two patients who developed lung disease associated with the use of Entitynitrofurantoin with histological features of Entitybronchiolitis obliterans organising pneumonia ( BOOP ), a rare but recognised form of drug induced injury. |
| 1.0000 | Adverse-Effect | The case histories are presented of two patients who developed Entitylung disease associated with the use of Entitynitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia ( BOOP ), a rare but recognised form of drug induced injury. |
| 1.0000 | Adverse-Effect | The case histories are presented of two patients who developed lung disease associated with the use of Entitynitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia ( EntityBOOP ), a rare but recognised form of drug induced injury. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A selective association between Entityfluoxetine and extensive, prominent Entityeye movements in nonrapid eye movement ( NREM ) sleep was detected, utilizing Fisher's exact one - tailed statistic ( p less than 0. 00001 for each comparison ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our findings suggest that Entityhyperkalemia can develop with the use of low - dose Entityheparin , within seven days of initiating heparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication. |
| 0.9998 | Adverse-Effect | Our findings suggest that Entityhyperkalemia can develop with the use of low - dose heparin, within seven days of initiating Entityheparin therapy, and that patients with diabetes mellitus or chronic renal insufficiency are especially predisposed to this complication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe a case of disseminated muscular cysticercosis followed by myositis ( fever, diffuse myalgia, weakness of the lower limbs, and Entityinflammatory reaction around dying cysticerci ) induced by Entitypraziquantel therapy, an event not described previously. |
| 1.0000 | Adverse-Effect | We describe a case of disseminated muscular cysticercosis followed by Entitymyositis ( fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by Entitypraziquantel therapy, an event not described previously. |
| 1.0000 | Adverse-Effect | We describe a case of disseminated muscular cysticercosis followed by myositis ( fever, diffuse myalgia, Entityweakness of the lower limbs , and inflammatory reaction around dying cysticerci ) induced by Entitypraziquantel therapy, an event not described previously. |
| 0.9999 | Adverse-Effect | We describe a case of disseminated muscular cysticercosis followed by myositis ( Entityfever , diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by Entitypraziquantel therapy, an event not described previously. |
| 0.9999 | Adverse-Effect | We describe a case of disseminated muscular cysticercosis followed by myositis ( fever, Entitydiffuse myalgia , weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by Entitypraziquantel therapy, an event not described previously. |
| 0.9999 | Adverse-Effect | We describe a case of Entitydisseminated muscular cysticercosis followed by myositis ( fever, diffuse myalgia, weakness of the lower limbs, and inflammatory reaction around dying cysticerci ) induced by Entitypraziquantel therapy, an event not described previously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 51 - yr - old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed Entityattacks of asthma when Entitycaptopril was added to the nadolol and dyazide treatment for his high blood pressure. |
| 0.9997 | Adverse-Effect | A 51 - yr - old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed Entityattacks of asthma when captopril was added to the Entitynadolol and dyazide treatment for his high blood pressure. |
| 0.9996 | Adverse-Effect | A 51 - yr - old nonsmoking male patient without any history of previous allergies, asthma, hay fever, or urticaria developed Entityattacks of asthma when captopril was added to the nadolol and Entitydyazide treatment for his high blood pressure. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Despite a response of the meningeal tumor the patient developed in the third week of EntityMTX treatment a Entityprogressive visual loss and loss of consciousness which worsened during subsequent Ara - C treatment and led to death within 3 weeks. |
| 0.9999 | Adverse-Effect | Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and Entityloss of consciousness which worsened during subsequent EntityAra - C treatment and led to death within 3 weeks. |
| 0.9999 | Adverse-Effect | Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent EntityAra - C treatment and led to Entitydeath within 3 weeks. |
| 0.9997 | Adverse-Effect | Despite a response of the meningeal tumor the patient developed in the third week of MTX treatment a Entityprogressive visual loss and loss of consciousness which worsened during subsequent EntityAra - C treatment and led to death within 3 weeks. |
| 0.9995 | Adverse-Effect | Despite a response of the meningeal tumor the patient developed in the third week of EntityMTX treatment a progressive visual loss and Entityloss of consciousness which worsened during subsequent Ara - C treatment and led to death within 3 weeks. |
| 0.9990 | Adverse-Effect | Despite a response of the meningeal tumor the patient developed in the third week of EntityMTX treatment a progressive visual loss and loss of consciousness which worsened during subsequent Ara - C treatment and led to Entitydeath within 3 weeks. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 32 - year - old man with a family history of type 2 diabetes mellitus presented with circulatory collapse and Entitydeep coma after 9 days of treatment with Entityperospirone hydrochloride , a recently developed atypical antipsychotic agent available only in Japan. |
| 0.9999 | Adverse-Effect | A 32 - year - old man with a family history of type 2 diabetes mellitus presented with Entitycirculatory collapse and deep coma after 9 days of treatment with Entityperospirone hydrochloride , a recently developed atypical antipsychotic agent available only in Japan. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A woman with a 20 - year history of acral pustular psoriasis of Hallopeau and recurrent pustular lesions of the forearms and lower legs, developed a EntityB - cell lymphoma of the lip following 4 1 / 2 years of treatment with Entityrazoxane . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityFatal lung fibrosis caused by Entitypaclitaxel toxicity has not been reported In this report, we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer. |
| 0.9995 | Adverse-Effect | EntityFatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62 - year - old woman who received six cycles of Entitypaclitaxel and carboplatin as combination chemotherapy for advanced ovarian cancer. |
| 0.9995 | Adverse-Effect | EntityFatal lung fibrosis caused by paclitaxel toxicity has not been reported In this report, we describe the case of a 62 - year - old woman who received six cycles of paclitaxel and Entitycarboplatin as combination chemotherapy for advanced ovarian cancer. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Since Entityimiquimod induces Entitylarge amounts of type I interferon production from TLR7 - expressing plasmacytoid dendritic cell precursors ( PDCs ), the natural interferon - producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | As this relapse coincided with development of a strong delayed - type Entityhypersensitivity response to Entitytuberculin and improved after treatment with the anti - inflammatory agent oxpentifylline, it was probably caused by restoration of pathogen - specific cellular immunity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In view of our experience in the present case, it should be stressed that close monitoring of coagulation capacity is necessary in critically ill patients in order to avoid Entityfatal haemorrhage after initiating Entitywarfarin therapy regardless of the dosage. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | On day 4, following 3 doses of Entitydalteparin , the patient developed Entityacute respiratory distress attributable to a massive right hemothorax confirmed by computed tomography pulmonary angiography ( CTPA ) and intercostal drainage of 1500 mL of frank blood. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report an 82 - year - old man who developed ventricular tachycardia and Torsades de Pointes ( EntityTdP ) after oral administration of Entitygarenoxacin , a novel quinolone antibiotic agent that differs from the third - generation quinolones, for pneumonia. |
| 1.0000 | Adverse-Effect | We report an 82 - year - old man who developed ventricular tachycardia and EntityTorsades de Pointes ( TdP ) after oral administration of Entitygarenoxacin , a novel quinolone antibiotic agent that differs from the third - generation quinolones, for pneumonia. |
| 0.9999 | Adverse-Effect | We report an 82 - year - old man who developed Entityventricular tachycardia and Torsades de Pointes ( TdP ) after oral administration of Entitygarenoxacin , a novel quinolone antibiotic agent that differs from the third - generation quinolones, for pneumonia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | After the dose of Entitymethylprednisolone was reduced from 40 mg to 20 mg i. v. q6h and shifted to other anti - asthma treatment by procaterol metered dose inhaler via spacer, the Entitypsychotic reaction disappeared a few hours later. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The cases are important in documenting that drug - induced dystonias do occur in patients with dementia, that Entityrisperidone appears to have contributed to Entitydystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification. |
| 0.9965 | Adverse-Effect | The cases are important in documenting that drug - induced Entitydystonias do occur in patients with dementia, that Entityrisperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He was started on oral Entitylansoprazole 60 mg twice daily and, on hospital day 2, his Entityplatelet count decreased to 102 x 10 ( 3 ) / mm ( 3 ) ; on hospital day 3, the platelet count was 36 x 10 ( 3 ) / mm ( 3 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Here we present the case of a woman who received high doses of Entitymethylprednisolone ( 1 g iv daily ) for active Graves'ophthalmopathy, and developed Entitysevere hypertension followed by myocardial infarction on the fifth day of treatment. |
| 0.9999 | Adverse-Effect | Here we present the case of a woman who received high doses of Entitymethylprednisolone ( 1 g iv daily ) for active Graves'ophthalmopathy, and developed severe hypertension followed by Entitymyocardial infarction on the fifth day of treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on three cases wherein treatment of Entitydexmedetomidine - induced Entitybradycardia with i. v. glycopyrrolate ( 5. 0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an exaggerated increase of arterial blood pressure. |
| 0.9997 | Adverse-Effect | We report on three cases wherein treatment of dexmedetomidine - induced bradycardia with i. v. Entityglycopyrrolate ( 5. 0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an Entityexaggerated increase of arterial blood pressure . |
| 0.9837 | Adverse-Effect | We report on three cases wherein treatment of Entitydexmedetomidine - induced bradycardia with i. v. glycopyrrolate ( 5. 0 microg / kg ) not only resulting in resolution of bradycardia but also resulting in an Entityexaggerated increase of arterial blood pressure . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | While the introduction of carmustine wafers ( EntityGliadel wafers ) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant Entitycerebral edema is a potential adverse effect. |
| 0.9996 | Adverse-Effect | While the introduction of Entitycarmustine wafers ( Gliadel wafers ) into the tumor resection cavity has been shown to be a beneficial therapy for malignant glioma, it is recognized that clinically significant Entitycerebral edema is a potential adverse effect. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CASE REPORT : We present a case of a 28 - yr - old male who developed a severe case of Entitynephrotic syndrome while being treated for relapsing / remitting Multiple Sclerosis ( RRMS ) with weekly injections of Entityinterferon beta 1a . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of ST elevation in right precordial leads compatible with Entitytype 1 Brugada syndrome following administration of Entitypropafenone in a patient with Wolff - Parkinson - White syndrome who was receiving lithium at concentrations within therapeutic levels. |
| 0.9996 | Adverse-Effect | We report a case of EntityST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of Entitypropafenone in a patient with Wolff - Parkinson - White syndrome who was receiving lithium at concentrations within therapeutic levels. |
| 0.9979 | Adverse-Effect | We report a case of ST elevation in right precordial leads compatible with Entitytype 1 Brugada syndrome following administration of propafenone in a patient with Wolff - Parkinson - White syndrome who was receiving Entitylithium at concentrations within therapeutic levels. |
| 0.9973 | Adverse-Effect | We report a case of EntityST elevation in right precordial leads compatible with type 1 Brugada syndrome following administration of propafenone in a patient with Wolff - Parkinson - White syndrome who was receiving Entitylithium at concentrations within therapeutic levels. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors report a case of acute pancreatitis ( EntityAP ) occurring in a patient under treatment with Entitycarbamazepine ( CBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. |
| 1.0000 | Adverse-Effect | The authors report a case of Entityacute pancreatitis ( AP ) occurring in a patient under treatment with Entitycarbamazepine ( CBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. |
| 1.0000 | Adverse-Effect | The authors report a case of acute pancreatitis ( EntityAP ) occurring in a patient under treatment with carbamazepine ( EntityCBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. |
| 0.9999 | Adverse-Effect | The authors report a case of Entityacute pancreatitis ( AP ) occurring in a patient under treatment with carbamazepine ( EntityCBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. |
| Adverse-Effect | The authors report a case of acute Entitypancreatitis ( AP ) occurring in a patient under treatment with Entitycarbamazepine ( CBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. | |
| Adverse-Effect | The authors report a case of acute Entitypancreatitis ( AP ) occurring in a patient under treatment with carbamazepine ( EntityCBZ ) for post - traumatic petit mal epilepsy, and review the current literature of drug - induced AP. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course : 3 of these patients Entitydied of PCP occurring during the first month of treatment with Entityprednisone . |
| 1.0000 | Adverse-Effect | These cases were considered unusual in light of the short delay of their onset after initiation of immunosuppressive therapy and their fulminant course : 3 of these patients died of EntityPCP occurring during the first month of treatment with Entityprednisone . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A small initial dose of prazosin ranging from 0. 5 to 1 mg has been recommended to avoid the first - dose phenomenon characterized by a sudden and Entitysevere drop in blood pressure after the administration of the first dose of Entityprazosin . |
| 0.9998 | Adverse-Effect | A small initial dose of Entityprazosin ranging from 0. 5 to 1 mg has been recommended to avoid the first - dose phenomenon characterized by a sudden and Entitysevere drop in blood pressure after the administration of the first dose of prazosin. |
| 1.0000 | Adverse-Effect | A small initial dose of prazosin ranging from 0. 5 to 1 mg has been recommended to avoid the first - dose phenomenon characterized by a sudden and severe Entitydrop in blood pressure after the administration of the first dose of Entityprazosin . |
| 0.9997 | Adverse-Effect | A small initial dose of Entityprazosin ranging from 0. 5 to 1 mg has been recommended to avoid the first - dose phenomenon characterized by a sudden and severe Entitydrop in blood pressure after the administration of the first dose of prazosin. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In a postural challenge test after administration of Entityisosorbide dinitrate ( 5 mg ), Entityblood pressure decreased from 120 / 67 to 65 / 35 mmHg, followed by syncope with a sudden decrease in pulse rate from 85 to 60 beats / min. |
| 0.9997 | Adverse-Effect | In a postural challenge test after administration of Entityisosorbide dinitrate ( 5 mg ), blood pressure decreased from 120 / 67 to 65 / 35 mmHg, followed by Entitysyncope with a sudden decrease in pulse rate from 85 to 60 beats / min. |
| 0.9996 | Adverse-Effect | In a postural challenge test after administration of Entityisosorbide dinitrate ( 5 mg ), blood pressure decreased from 120 / 67 to 65 / 35 mmHg, followed by syncope with a Entitysudden decrease in pulse rate from 85 to 60 beats / min. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of Entitydiarrhea and Entityclindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. |
| 1.0000 | Adverse-Effect | CONCLUSIONS : This report indicates Entityclindamycin phosphate vaginal cream as the most probable cause of EntityCDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and Entityclindamycin administration, lack of concomitant medications, and documentation of EntityC. difficile toxin . |
| 0.9998 | Adverse-Effect | CONCLUSIONS : This report indicates clindamycin phosphate vaginal cream as the most probable cause of EntityCDIC due to the temporal relationship between the occurrence of diarrhea and Entityclindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. |
| 0.9997 | Adverse-Effect | CONCLUSIONS : This report indicates Entityclindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of Entitydiarrhea and clindamycin administration, lack of concomitant medications, and documentation of C. difficile toxin. |
| 0.9990 | Adverse-Effect | CONCLUSIONS : This report indicates Entityclindamycin phosphate vaginal cream as the most probable cause of CDIC due to the temporal relationship between the occurrence of diarrhea and clindamycin administration, lack of concomitant medications, and documentation of EntityC. difficile toxin . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | DISCUSSION : EntityAmphotericin B deoxycholate has been reported to produce significant Entitycardiac toxicity , with ventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates. |
| 0.9997 | Adverse-Effect | DISCUSSION : EntityAmphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with ventricular arrhythmias and Entitybradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates. |
| 0.9997 | Adverse-Effect | DISCUSSION : EntityAmphotericin B deoxycholate has been reported to produce significant cardiac toxicity, with Entityventricular arrhythmias and bradycardia reported in overdoses in children and in adults with preexisting cardiac disease, even when administered in conventional dosages and infusion rates. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report suggests that Entityanemia can occur due to EntityMMF , in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used. |
| 0.9996 | Adverse-Effect | This report suggests that Entityanemia can occur due to MMF, in particular when it is given with Entityprednisone , a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and prednisone is used. |
| 0.9994 | Adverse-Effect | This report suggests that Entityanemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, Entitycyclosporine and prednisone is used. |
| 0.9992 | Adverse-Effect | This report suggests that Entityanemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of EntityMMF , cyclosporine and prednisone is used. |
| 0.9992 | Adverse-Effect | This report suggests that Entityanemia can occur due to MMF, in particular when it is given with prednisone, a side effect well documented in the transplantation literature when the triple combination of MMF, cyclosporine and Entityprednisone is used. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 79 - year - old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, myalgia, and Entityleg weakness , shortly after starting treatment with Entitycolchicine . |
| 1.0000 | Adverse-Effect | A 79 - year - old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of fatigue, Entitymyalgia , and leg weakness, shortly after starting treatment with Entitycolchicine . |
| 1.0000 | Adverse-Effect | A 79 - year - old man with ischemic heart disease, chronic atrial fibrillation, chronic renal failure, hypothyroidism, and gout arthritis was hospitalized because of Entityfatigue , myalgia, and leg weakness, shortly after starting treatment with Entitycolchicine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, hearing impairment in the left ear ( with progression to the right ear ), and Entityvertigo developed after 3 years of therapy with EntityPTU . |
| 1.0000 | Adverse-Effect | RESULTS : In a 22 - year - old Thai woman with Graves'disease, Entitytinnitus , hearing impairment in the left ear ( with progression to the right ear ), and vertigo developed after 3 years of therapy with EntityPTU . |
| 1.0000 | Adverse-Effect | RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, hearing impairment in the left ear ( with Entityprogression to the right ear ), and vertigo developed after 3 years of therapy with EntityPTU . |
| 0.9999 | Adverse-Effect | RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, Entityhearing impairment in the left ear ( with progression to the right ear ), and vertigo developed after 3 years of therapy with EntityPTU . |
| Adverse-Effect | RESULTS : In a 22 - year - old Thai woman with Graves'disease, tinnitus, Entityhearing impairment in the left ear ( with progression to the right ear ) , and vertigo developed after 3 years of therapy with EntityPTU . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case is remarkable since 1 ) ECM developed after subcutaneous and not after intramuscular injection, 2 ) the injection was given by the patient himself, and 3 ) Entityglatiramer acetate can induce Entityskin necrosis as a side effect. |
| 0.9986 | Adverse-Effect | This case is remarkable since 1 ) EntityECM developed after subcutaneous and not after intramuscular injection, 2 ) the injection was given by the patient himself, and 3 ) Entityglatiramer acetate can induce skin necrosis as a side effect. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Subsequent in vivo / vitro studies clearly demonstrated that the Entityneurological effects were due to a synergistic action of Entitydesferrioxamine and prochlorperazine, probably resulting in exceptional fluxes of intra / extra cellular iron / copper disturbing noradrenergic and serotonergic systems. |
| 0.9999 | Adverse-Effect | Subsequent in vivo / vitro studies clearly demonstrated that the Entityneurological effects were due to a synergistic action of desferrioxamine and Entityprochlorperazine , probably resulting in exceptional fluxes of intra / extra cellular iron / copper disturbing noradrenergic and serotonergic systems. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom Entityinfliximab therapy was associated with Entityperipheral neuropathy due to necrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other. |
| 0.9999 | Adverse-Effect | We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom Entityinfliximab therapy was associated with peripheral neuropathy due to Entitynecrotizing vasculitis in one patient and to progression of preexisting mononeuritis multiplex in the other. |
| 0.9999 | Adverse-Effect | We describe 2 patients with severe erosive rheumatoid arthritis and rheumatoid vasculitis, respectively, in whom Entityinfliximab therapy was associated with peripheral neuropathy due to necrotizing vasculitis in one patient and to Entityprogression of preexisting mononeuritis multiplex in the other. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityMI related to the use of activated and non - activated EntityPCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report on a 56 - year - old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked prolongation of the QT interval and EntityT wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral Entitypirmenol therapy. |
| 1.0000 | Adverse-Effect | We report on a 56 - year - old female who exhibited drug refractory paroxysmal atrial fibrillation, in which marked Entityprolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral Entitypirmenol therapy. |
| 0.9999 | Adverse-Effect | We report on a 56 - year - old female who exhibited Entitydrug refractory paroxysmal atrial fibrillation , in which marked prolongation of the QT interval and T wave inversion on electrocardiogram was demonstrated reproducibly shortly after the administration of oral Entitypirmenol therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This case of Entitylinezolid - associated Entityacute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug. |
| 0.9997 | Adverse-Effect | This case of linezolid - associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( EntityDRESS ) syndrome in a patient treated with Entitylinezolid raises concerns about the presumed renal safety of this drug. |
| 0.9989 | Adverse-Effect | This case of linezolid - associated acute interstitial nephritis within the context of a Entitydrug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with Entitylinezolid raises concerns about the presumed renal safety of this drug. |
| 0.9988 | Adverse-Effect | This case of Entitylinezolid - associated acute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( EntityDRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug. |
| 0.9988 | Adverse-Effect | This case of Entitylinezolid - associated acute interstitial nephritis within the context of a Entitydrug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with linezolid raises concerns about the presumed renal safety of this drug. |
| 0.9954 | Adverse-Effect | This case of linezolid - associated Entityacute interstitial nephritis within the context of a drug rash with eosinophilia and systemic symptoms ( DRESS ) syndrome in a patient treated with Entitylinezolid raises concerns about the presumed renal safety of this drug. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9983 | Adverse-Effect | INTRODUCTION : Although Entitygefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of Entityinterstitial lung disease ( ILD ), few case reports on erlotinib - induced ILD have been issued. |
| 0.9949 | Adverse-Effect | INTRODUCTION : Although Entitygefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( EntityILD ), few case reports on erlotinib - induced ILD have been issued. |
| 0.9931 | Adverse-Effect | INTRODUCTION : Although gefitinib used for the treatment of non - small - cell lung cancer is a well - known cause of interstitial lung disease ( ILD ), few case reports on Entityerlotinib - induced EntityILD have been issued. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : A 44 - year - old man taking naproxen for chronic low back pain and a 20 - year - old woman on Entityoxaprozin for rheumatoid arthritis presented with Entitytense bullae and cutaneous fragility on the face and the back of the hands. |
| 0.9999 | Adverse-Effect | RESULTS : A 44 - year - old man taking naproxen for chronic low back pain and a 20 - year - old woman on Entityoxaprozin for rheumatoid arthritis presented with tense bullae and Entitycutaneous fragility on the face and the back of the hands. |
| 0.9994 | Adverse-Effect | RESULTS : A 44 - year - old man taking Entitynaproxen for chronic low back pain and a 20 - year - old woman on oxaprozin for rheumatoid arthritis presented with Entitytense bullae and cutaneous fragility on the face and the back of the hands. |
| 0.9991 | Adverse-Effect | RESULTS : A 44 - year - old man taking Entitynaproxen for chronic low back pain and a 20 - year - old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and Entitycutaneous fragility on the face and the back of the hands. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9979 | Adverse-Effect | The patient's previous rash and the temporal relation of this event and the ingestion of phenolphthalein, as well as the similarity of this case to other reports, point to Entityphenolphthalein as the cause of EntityTEN in this patient. |
| 0.9892 | Adverse-Effect | The patient's previous Entityrash and the temporal relation of this event and the ingestion of Entityphenolphthalein , as well as the similarity of this case to other reports, point to phenolphthalein as the cause of TEN in this patient. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case history confirms that Entitygold treatment, even in the same patient, can give rise to a wide range of Entityskin disturbances , which in many cases do not break out until long after the drug has been withdrawn. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient receiving Entityvancomycin for a serious staphylococcal infection had a Entitylupus - like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. |
| 1.0000 | Adverse-Effect | A patient receiving Entityvancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a Entitymalar rash , pain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. |
| 1.0000 | Adverse-Effect | A patient receiving Entityvancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, pain and Entityerythema of the cartilage of both ears , and tender erythematous and hemorrhagic lesions of the finger tips. |
| 0.9999 | Adverse-Effect | A patient receiving Entityvancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and tender erythematous and Entityhemorrhagic lesions of the finger tips . |
| 0.9999 | Adverse-Effect | A patient receiving Entityvancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, Entitypain and erythema of the cartilage of both ears, and tender erythematous and hemorrhagic lesions of the finger tips. |
| 0.9999 | Adverse-Effect | A patient receiving Entityvancomycin for a serious staphylococcal infection had a lupus - like syndrome characterized by a malar rash, pain and erythema of the cartilage of both ears, and Entitytender erythematous and hemorrhagic lesions of the finger tips. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Because the combination of Entitybleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Kaposi's sarcoma, clinicians should be aware of the risk of provoking acral necrosis in patients who develop EntityRaynaud's phenomenon under chemotherapy. |
| 0.9997 | Adverse-Effect | Because the combination of Entitybleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related Kaposi's sarcoma, clinicians should be aware of the risk of provoking Entityacral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. |
| 0.9999 | Adverse-Effect | Because the combination of Entitybleomycin and vinca alkaloids is commonly used for the treatment of AIDS - related EntityKaposi's sarcoma , clinicians should be aware of the risk of provoking acral necrosis in patients who develop Raynaud's phenomenon under chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | Methotrexate ( MTX ) is a commonly used second line agent for RA, and there have been several recent reports of EntityEpstein - Barr virus ( EBV ) - associated polyclonal B cell lymphoproliferative disorder in EntityMTX - treated RA patients. | |
| Adverse-Effect | Methotrexate ( EntityMTX ) is a commonly used second line agent for RA, and there have been several recent reports of EntityEpstein - Barr virus ( EBV ) - associated polyclonal B cell lymphoproliferative disorder in MTX - treated RA patients. | |
| Adverse-Effect | EntityMethotrexate ( MTX ) is a commonly used second line agent for RA, and there have been several recent reports of EntityEpstein - Barr virus ( EBV ) - associated polyclonal B cell lymphoproliferative disorder in MTX - treated RA patients. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9977 | Adverse-Effect | We present a case of acute Entityepinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed Entitysevere allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. |
| 0.9871 | Adverse-Effect | We present a case of acute epinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed Entitysevere allergic reaction to intravenous immunoglobulin, and was subsequently given Entityepinephrine by mistake intravenously rather than subcutaneously. |
| 0.9862 | Adverse-Effect | We present a case of acute Entityepinephrine toxicity resulting in Entityacute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. |
| 0.9974 | Adverse-Effect | We present a case of acute Entityepinephrine Entityepinephrine toxicity resulting in acute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given epinephrine by mistake intravenously rather than subcutaneously. |
| 0.7901 | Adverse-Effect | We present a case of acute epinephrine toxicity resulting in Entityacute myocardial ischemia in a young boy with combined variable immunodeficiency syndrome who developed severe allergic reaction to intravenous immunoglobulin, and was subsequently given Entityepinephrine by mistake intravenously rather than subcutaneously. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a myeloma patient who developed Entitysevere paralytic ileus during Entitybortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with Entityamiodarone - induced Entitydestructive thyroiditis , as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis. |
| 0.9985 | Adverse-Effect | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with Entityamiodarone - induced destructive thyroiditis, as reported in patients with Entitydestructive thyroiditis , such as subacute and silent thyroiditis. |
| 0.9972 | Adverse-Effect | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with Entityamiodarone - induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent Entitythyroiditis . |
| 0.9981 | Adverse-Effect | These in vitro findings and clinical course suggest that EntityTRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced Entitydestructive thyroiditis , as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis. |
| 0.9976 | Adverse-Effect | These in vitro findings and clinical course suggest that TRAb / TBII without thyroid - stimulating activity may develop in patients with Entityamiodarone - induced destructive thyroiditis, as reported in patients with destructive Entitythyroiditis , such as subacute and silent thyroiditis. |
| 0.9940 | Adverse-Effect | These in vitro findings and clinical course suggest that EntityTRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced destructive thyroiditis, as reported in patients with Entitydestructive thyroiditis , such as subacute and silent thyroiditis. |
| 0.9902 | Adverse-Effect | These in vitro findings and clinical course suggest that EntityTRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced destructive thyroiditis, as reported in patients with destructive Entitythyroiditis , such as subacute and silent thyroiditis. |
| 0.9900 | Adverse-Effect | These in vitro findings and clinical course suggest that EntityTRAb / TBII without thyroid - stimulating activity may develop in patients with amiodarone - induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent Entitythyroiditis . |
| Adverse-Effect | These in vitro findings and clinical course suggest that EntityTRAb / TBII without thyroid - stimulating activity may develop in patients with Entityamiodarone - induced destructive thyroiditis, as reported in patients with destructive thyroiditis, such as subacute and silent thyroiditis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | When SASP was changed to 5 - aminosalicylic acid ( Entity5 - ASA ), his skin eruptions were resolved, however, he developed Entityweakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9998 | Adverse-Effect | When SASP was changed to 5 - aminosalicylic acid ( Entity5 - ASA ), his skin eruptions were resolved, however, he developed weakness and Entityatrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9995 | Adverse-Effect | When SASP was changed to 5 - aminosalicylic acid ( Entity5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive Entityworsening of the dysesthesia in his legs and gait disturbance. |
| 0.9995 | Adverse-Effect | When SASP was changed to 5 - aminosalicylic acid ( Entity5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and Entitygait disturbance . |
| 0.9995 | Adverse-Effect | When SASP was changed to Entity5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed Entityweakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9994 | Adverse-Effect | When SASP was changed to Entity5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and Entityatrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9987 | Adverse-Effect | When SASP was changed to Entity5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive Entityworsening of the dysesthesia in his legs and gait disturbance. |
| 0.9987 | Adverse-Effect | When SASP was changed to Entity5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and Entitygait disturbance . |
| 0.9999 | Adverse-Effect | When SASP was changed to 5 - aminosalicylic acid ( Entity5 - ASA ), his Entityskin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9995 | Adverse-Effect | When EntitySASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed Entityweakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9994 | Adverse-Effect | When EntitySASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his Entityskin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9994 | Adverse-Effect | When EntitySASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and Entityatrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9993 | Adverse-Effect | When SASP was changed to Entity5 - aminosalicylic acid ( 5 - ASA ), his Entityskin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and gait disturbance. |
| 0.9987 | Adverse-Effect | When EntitySASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive Entityworsening of the dysesthesia in his legs and gait disturbance. |
| 0.9987 | Adverse-Effect | When EntitySASP was changed to 5 - aminosalicylic acid ( 5 - ASA ), his skin eruptions were resolved, however, he developed weakness and atrophy in his right arm as well as progressive worsening of the dysesthesia in his legs and Entitygait disturbance . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : Soon after initiation of Entityamiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of Entityvisual " shining , " glare, color vision anomalies, and gradually decreased vision. |
| 0.9998 | Adverse-Effect | CASE REPORT : Soon after initiation of Entityamiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of visual " shining, " Entityglare , color vision anomalies, and gradually decreased vision. |
| 0.9997 | Adverse-Effect | CASE REPORT : Soon after initiation of Entityamiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of visual " shining, " glare, Entitycolor vision anomalies , and gradually decreased vision. |
| 0.9996 | Adverse-Effect | CASE REPORT : Soon after initiation of Entityamiodarone HCl ( 200 mg / day ), a 76 - year - old man came to us with symptoms of visual " shining, " glare, color vision anomalies, and gradually Entitydecreased vision . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The mechanism of the Entitydecrease in plasma potassium induced by Entityphosphate treatment was investigated in a 24 - year - old hypertensive patient with hypophosphatemic osteomalacia, who was the youngest of four patients, belonging to a 23 number kindred of five generations. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 16 - year - old white male with acute biphenotypic leukemia developed evidence of the Entityeosinophilia myalgia syndrome associated with total parenteral nutritional support with solutions containing Entitytryptophan , which were given during his initial induction chemotherapy and also after autologous marrow transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Subsequently, he developed Entityhyperglycemia ( fasting blood glucose 138 mg / dL ) that resolved when Entityolanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with olanzapine 2. 5 mg twice daily. |
| 0.9994 | Adverse-Effect | Subsequently, he developed Entityhyperglycemia ( fasting blood glucose 138 mg / dL ) that resolved when olanzapine was stopped and recurred ( fasting blood glucose 150 mg / dL ) after 2 days of rechallenge with Entityolanzapine 2. 5 mg twice daily. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The potential development of SJS / EntityTEN , a severe life - threatening illness, emphasizes the need for judicious use of EntityTMP - Sx and close monitoring and follow - up for patients who were given TMP - Sx for SSTIs. |
| 0.9999 | Adverse-Effect | The potential development of EntitySJS / TEN, a severe life - threatening illness, emphasizes the need for judicious use of EntityTMP - Sx and close monitoring and follow - up for patients who were given TMP - Sx for SSTIs. |
| 0.9997 | Adverse-Effect | The potential development of SJS / EntityTEN , a severe life - threatening illness, emphasizes the need for judicious use of TMP - Sx and close monitoring and follow - up for patients who were given EntityTMP - Sx for SSTIs. |
| 0.9996 | Adverse-Effect | The potential development of EntitySJS / TEN, a severe life - threatening illness, emphasizes the need for judicious use of TMP - Sx and close monitoring and follow - up for patients who were given EntityTMP - Sx for SSTIs. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor - alpha blocking agent Entityetanercept for severe plaque psoriasis, experienced Entitypersistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Case 1, a 62 - year - old woman, developed bilateral optic neuritis with decreased sensation of vibration and Entityincreased deep tendon reflex in the lower extremities after a seven - month use of Entityrecombinant interferon alpha - 2a for chronic active hepatitis C. |
| 0.9998 | Adverse-Effect | Case 1, a 62 - year - old woman, developed Entitybilateral optic neuritis with decreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven - month use of Entityrecombinant interferon alpha - 2a for chronic active hepatitis C. |
| 0.9997 | Adverse-Effect | Case 1, a 62 - year - old woman, developed bilateral optic neuritis with Entitydecreased sensation of vibration and increased deep tendon reflex in the lower extremities after a seven - month use of Entityrecombinant interferon alpha - 2a for chronic active hepatitis C. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In all cases, drugs in addition to quetiapine were detected, but in cases # 1 and # 2, the cause of Entitydeath was considered to be a Entityquetiapine overdose and the other drugs were not considered to be contributory. |
| 0.9997 | Adverse-Effect | In all cases, drugs in addition to Entityquetiapine were detected, but in cases # 1 and # 2, the cause of Entitydeath was considered to be a quetiapine overdose and the other drugs were not considered to be contributory. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Of particular interest in this patient is the Entityfluctuation of the QT interval at a stable dose of Entitymethadone , suggesting that a single normal electrocardiogram ( ECG ) does not guarantee that the patient is not at risk of ventricular arrhythmias. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityEthambutol is frequently used in the treatment of tuberculosis, and, although Entityoptic neuropathies have been reported with the use of ethambutol, this adverse side effect has been considered to be rare and generally reversible with discontinuation of the medication. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | The authors suggest that in the absence of any proven benefit of itraconazole prophylaxis, and given the interaction of this drug with Entityvincristine leading to severe and even potentially Entityfatal toxicities , the combination use of these drugs should be avoided. |
| 0.9996 | Adverse-Effect | The authors suggest that in the absence of any proven benefit of Entityitraconazole prophylaxis, and given the interaction of this drug with vincristine leading to severe and even potentially Entityfatal toxicities , the combination use of these drugs should be avoided. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Two 65 - year - old white men with coronary heart disease, given Entityniacin therapy for dyslipidemia for 5 months, developed Entityintense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment. |
| 0.9998 | Adverse-Effect | Two 65 - year - old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed Entityintense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of Entityniacin treatment. |
| 0.9997 | Adverse-Effect | Two 65 - year - old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense Entitydental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of Entityniacin treatment. |
| 0.9995 | Adverse-Effect | Two 65 - year - old white men with coronary heart disease, given Entityniacin therapy for dyslipidemia for 5 months, developed intense Entitydental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related Entityhemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of Entitycisplatin , bleomycin, and methotrexate. |
| 1.0000 | Adverse-Effect | A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related Entityhemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, Entitybleomycin , and methotrexate. |
| 0.9999 | Adverse-Effect | A 62 - year - old woman who was being treated for squamous cell carcinoma of the head and neck developed a chemotherapy - related Entityhemolytic - uremic syndrome during the second cycle of neoadjuvant chemotherapy consisting of cisplatin, bleomycin, and Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A case of Entityskeletal fluorosis induced by prolonged treatment with Entityniflumic acid , a fast - acting non - steroid antiinflammatory agent, is reported in a 35 - year - old woman suffering from rheumatoid arthritis and treated, in addition, with corticosteroids. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : growth deficiency, Entitydevelopmental delay , craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 1.0000 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, Entitycraniosynostosis , blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 1.0000 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, Entityflat nasal bridge , abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 1.0000 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, Entityblepharophimosis , flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9999 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including Entityhypoplastic thumbs and oligodactyly. |
| 0.9999 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and Entitydistal limb defects including hypoplastic thumbs and oligodactyly. |
| 0.9999 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and Entityoligodactyly . |
| 1.0000 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : Entitygrowth deficiency , developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly. |
| 1.0000 | Adverse-Effect | The reported cases of in utero exposure to Entitycyclosposphamide shared the following manifestations with our patient : growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, Entityabnormal ears , and distal limb defects including hypoplastic thumbs and oligodactyly. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Seven of the eight cases of Entityacute leukemia occurred in a series of 553 patients treated with EntityTreosulfan for ovarian cancer in the period from 1970 to 1977 and followed closely for a total of 1159 patient - years up to February 1978. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In addition, while cases of loop diuretic - induced Entitypancreatitis , including Entityfurosemide , have been published, the allergic manifestations with both sulfonamide antibiotics and non - antibiotics in our patient suggest possible cross - reactivity between these 2 drug classes. |
| 1.0000 | Adverse-Effect | In addition, while cases of loop diuretic - induced pancreatitis, including furosemide, have been published, the Entityallergic manifestations with both Entitysulfonamide antibiotics and non - antibiotics in our patient suggest possible cross - reactivity between these 2 drug classes. |
| 0.9958 | Adverse-Effect | In addition, while cases of loop diuretic - induced pancreatitis, including Entityfurosemide , have been published, the Entityallergic manifestations with both sulfonamide antibiotics and non - antibiotics in our patient suggest possible cross - reactivity between these 2 drug classes. |
| 0.9643 | Adverse-Effect | In addition, while cases of loop diuretic - induced Entitypancreatitis , including furosemide, have been published, the allergic manifestations with both Entitysulfonamide antibiotics and non - antibiotics in our patient suggest possible cross - reactivity between these 2 drug classes. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The cause of these previously unreported side effects of Entityniacin therapy is uncertain but may be related to Entityprostaglandin - mediated vasodilatation , hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of pain to the teeth. |
| 1.0000 | Adverse-Effect | The cause of these previously unreported side effects of Entityniacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation, hyperalgesia of sensory nerve receptors, and potentiation of inflammation in the gingiva with referral of Entitypain to the teeth . |
| 0.9999 | Adverse-Effect | The cause of these previously unreported side effects of Entityniacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation, Entityhyperalgesia of sensory nerve receptors , and potentiation of inflammation in the gingiva with referral of pain to the teeth. |
| 0.9999 | Adverse-Effect | The cause of these previously unreported side effects of Entityniacin therapy is uncertain but may be related to prostaglandin - mediated vasodilatation, hyperalgesia of sensory nerve receptors, and Entitypotentiation of inflammation in the gingiva with referral of pain to the teeth. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | OBJECTIVE : To document a case of serotonin syndrome ( EntitySS ) associated with Entitymirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction. |
| 1.0000 | Adverse-Effect | OBJECTIVE : To document a case of Entityserotonin syndrome ( SS ) associated with Entitymirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction. |
| 0.9981 | Adverse-Effect | OBJECTIVE : To document a case of serotonin syndrome ( SS ) associated with Entitymirtazapine monotherapy, review the previously reported cases of EntitySS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A variety of Entitymovement disorders are known to occur in association with Entitycarbamazepine ( CBZ ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders. |
| 1.0000 | Adverse-Effect | A variety of movement disorders are known to occur in association with carbamazepine ( EntityCBZ ) therapy in adults and children, but development of Entitytics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders. |
| 0.9999 | Adverse-Effect | A variety of movement disorders are known to occur in association with Entitycarbamazepine ( CBZ ) therapy in adults and children, but development of Entitytics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders. |
| 0.9999 | Adverse-Effect | A variety of Entitymovement disorders are known to occur in association with carbamazepine ( EntityCBZ ) therapy in adults and children, but development of tics has been described infrequently and only in patients with underlying Tourette's syndrome or other movement disorders. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of Entitylidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of Entitymethemoglobinemia . |
| 0.9986 | Adverse-Effect | Although the two local anesthetics usually do not cause Entitymethemoglobinemia , we suspect that the displacement of Entitylidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Herein, we describe a patient with AIDS who presented to medical attention with Entitypancytopenia 48 months postchemotherapy with Entityetoposide , prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 1.0000 | Adverse-Effect | Herein, we describe a patient with AIDS who presented to medical attention with Entitypancytopenia 48 months postchemotherapy with etoposide, Entityprednisone , vincristine, cyclophosphamide, doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 1.0000 | Adverse-Effect | Herein, we describe a patient with AIDS who presented to medical attention with Entitypancytopenia 48 months postchemotherapy with etoposide, prednisone, Entityvincristine , cyclophosphamide, doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 1.0000 | Adverse-Effect | Herein, we describe a patient with AIDS who presented to medical attention with Entitypancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, Entitycyclophosphamide , doxorubicin, and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 1.0000 | Adverse-Effect | Herein, we describe a patient with AIDS who presented to medical attention with Entitypancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, Entitydoxorubicin , and rituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 1.0000 | Adverse-Effect | Herein, we describe a patient with AIDS who presented to medical attention with Entitypancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and Entityrituximab ( R - EPOCH ) for diffuse large B - cell lymphoma. |
| 0.9990 | Adverse-Effect | Herein, we describe a patient with AIDS who presented to medical attention with Entitypancytopenia 48 months postchemotherapy with etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab ( EntityR - EPOCH ) for diffuse large B - cell lymphoma. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report five cases of carboplatin ( CBDCA ) Entityhypersensitivity after weekly low - dose Entitypaclitaxel ( 60 mg / m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy. |
| 1.0000 | Adverse-Effect | We report five cases of carboplatin ( EntityCBDCA ) Entityhypersensitivity after weekly low - dose paclitaxel ( 60 mg / m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy. |
| 0.9984 | Adverse-Effect | We report five cases of Entitycarboplatin ( CBDCA ) Entityhypersensitivity after weekly low - dose paclitaxel ( 60 mg / m2 ) / CBDCA ( area under the concentration curve = 2 ) therapy in patients with recurrent ovarian cancer receiving multiple platinum - based chemotherapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | However, we recently saw two patients with renal tuberculosis treated with Entityethambutol in whom Entityvisual loss from toxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function. |
| 0.9999 | Adverse-Effect | However, we recently saw two patients with renal tuberculosis treated with Entityethambutol in whom visual loss from Entitytoxic optic neuropathies was severe and irreversible despite careful ophthalmological monitoring and prompt discontinuation of the agent at the first sign of impaired visual function. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The aim of this paper is to report the case of Entityrosaceiform eruption induced by Entityerlotinib in an 81 - year - old - man and to discuss the pathogenetic role of Demodex folliculorum mites, found in the present patient, using skin scraping. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Recently, her serum Entitytheophylline Entitytheophylline levels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9996 | Adverse-Effect | Recently, her serum Entitytheophylline levels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of Entityzafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9987 | Adverse-Effect | Recently, her serum Entitytheophylline levels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( EntityAccolate , Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 1.0000 | Adverse-Effect | Recently, her serum Entitytheophylline Entitylevels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 1.0000 | Adverse-Effect | Recently, her serum Entitytheophylline levels Entityhad increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 1.0000 | Adverse-Effect | Recently, her serum theophylline Entitylevels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of Entityzafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 1.0000 | Adverse-Effect | Recently, her serum theophylline levels Entityhad increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of Entityzafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 1.0000 | Adverse-Effect | Recently, her serum theophylline levels had Entityincreased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of Entityzafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9999 | Adverse-Effect | Recently, her serum Entitytheophylline levels had Entityincreased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( Accolate, Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9999 | Adverse-Effect | Recently, her serum theophylline Entitylevels had increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( EntityAccolate , Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9999 | Adverse-Effect | Recently, her serum theophylline levels Entityhad increased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( EntityAccolate , Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| 0.9999 | Adverse-Effect | Recently, her serum theophylline levels had Entityincreased to the toxic range ( 133. 2 micromol / L [ 24 microg / mL ] ) shortly after the addition of zafirlukast ( EntityAccolate , Zeneca Pharmaceuticals, Wilmington, Del ) to her regimen. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The current report describes a man who was prescribed Entityzonisamide for epilepsy and subsequently developed widespread Entityskin rash , acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 1.0000 | Adverse-Effect | The current report describes a man who was prescribed Entityzonisamide for epilepsy and subsequently developed widespread skin rash, Entityacute kidney injury , high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 1.0000 | Adverse-Effect | The current report describes a man who was prescribed Entityzonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, Entityhigh - grade fever , eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 1.0000 | Adverse-Effect | The current report describes a man who was prescribed Entityzonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, Entityeosinophilia , liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 1.0000 | Adverse-Effect | The current report describes a man who was prescribed Entityzonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, Entitylymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 1.0000 | Adverse-Effect | The current report describes a man who was prescribed Entityzonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, Entityliver dysfunction , lymphadenopathy and an increase in antihuman herpesvirus - 6 immunoglobulin G titer. |
| 0.9999 | Adverse-Effect | The current report describes a man who was prescribed Entityzonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and an increase in antihuman herpesvirus - 6 Entityimmunoglobulin G titer . |
| Adverse-Effect | The current report describes a man who was prescribed Entityzonisamide for epilepsy and subsequently developed widespread skin rash, acute kidney injury, high - grade fever, eosinophilia, liver dysfunction, lymphadenopathy and Entityan increase in antihuman herpesvirus - 6 immunoglobulin G titer . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityOxcarbazepine - associated Entityangioedema manifested by swelling of the face, eyes, lips, or tongue or difficulty swallowing or breathing ( or both ) is a rare but potentially life - threatening reaction for which early recognition and management are vital. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of Entitysymptomatic hyperlactatemia after being switched from Entitystavudine to zidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda. |
| 0.9999 | Adverse-Effect | CASE REPORT : We describe here a case of a 60 year old female that experienced a relapse of Entitysymptomatic hyperlactatemia after being switched from stavudine to Entityzidovudine and how the case was managed at the Infectious Diseases Institute, Kampala, Uganda. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | CONCLUSIONS : SD - OCT and AO detected abnormalities that correlate topographically with visual field loss from Entityhydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or Entityobjective visual field loss . |
| 0.9992 | Adverse-Effect | CONCLUSIONS : SD - OCT and AO detected abnormalities that correlate topographically with Entityvisual field loss from Entityhydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss. |
| 0.9987 | Adverse-Effect | CONCLUSIONS : SD - OCT and AO detected Entityabnormalities that correlate topographically with visual field loss from Entityhydroxychloroquine toxicity as demonstrated by HVF 10 - 2 and may be useful in the detection of subclinical abnormalities that precede symptoms or objective visual field loss. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and Entitybone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg / m2 Entitymethotrexate ( MTX ). |
| 1.0000 | Adverse-Effect | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed Entitysevere skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg / m2 Entitymethotrexate ( MTX ). |
| 1.0000 | Adverse-Effect | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed severe skin rash and Entitybone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg / m2 methotrexate ( EntityMTX ). |
| 0.9999 | Adverse-Effect | A 64 year old man with recurrent metastatic squamous cell carcinoma of the head and neck developed Entitysevere skin rash and bone marrow aplasia 4 and 7 days, respectively, following a single dose of 40 mg / m2 methotrexate ( EntityMTX ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The clinical course suggested that recombinant alpha - 2b peginterferon plus Entityribavirin provoked Entitytype 1 diabetes mellitus , therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment. |
| 0.9997 | Adverse-Effect | The clinical course suggested that Entityrecombinant alpha - 2b peginterferon plus ribavirin provoked Entitytype 1 diabetes mellitus , therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment. |
| 0.9997 | Adverse-Effect | The clinical course suggested that recombinant Entityalpha - 2b peginterferon plus ribavirin provoked Entitytype 1 diabetes mellitus , therefore, in patients who are candidates for interferon therapy the presence of pancreatic autoantibodies and the fasting plasma glucose level should be investigated before and during treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | An episode of Entityleukoencephalopathy is reported in a 13 - year - old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 Entitymethotrexate and 12 mg intrathecal methotrexate. |
| 0.9999 | Adverse-Effect | An episode of Entityleukoencephalopathy is reported in a 13 - year - old girl who, after standard radiotherapy for a posterior fossa medulloblastoma, received 8 treatments with a protocol containing a 4 - hour infusion of 500 mg / m2 methotrexate and 12 mg intrathecal Entitymethotrexate . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this report, one patient who developed Entitygangrene after Entitybleomycin and vincristine / vinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. |
| 0.9999 | Adverse-Effect | In this report, one patient who developed Entitygangrene after bleomycin and Entityvincristine / vinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. |
| 0.9999 | Adverse-Effect | In this report, one patient who developed Entitygangrene after bleomycin and vincristine / Entityvinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of severe Raynaud's phenomenon related to the same regimen are presented. |
| 0.9997 | Adverse-Effect | In this report, one patient who developed gangrene after bleomycin and vincristine / Entityvinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of Entitysevere Raynaud's phenomenon related to the same regimen are presented. |
| 0.9994 | Adverse-Effect | In this report, one patient who developed gangrene after bleomycin and Entityvincristine / vinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of Entitysevere Raynaud's phenomenon related to the same regimen are presented. |
| 0.9993 | Adverse-Effect | In this report, one patient who developed gangrene after Entitybleomycin and vincristine / vinblastine chemotherapy for AIDS - related Kaposi's sarcoma and another HIV - infected patient who exhibited symptoms of Entitysevere Raynaud's phenomenon related to the same regimen are presented. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9990 | Adverse-Effect | The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed Entityamenorrhea while being treated with Entityvalproate lost weight and resumed menstruating after the change in medication. |
| 0.9909 | Adverse-Effect | The Entitypolycystic changes disappeared from the ovaries in 2 of the women after Entityvalproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication. |
| Adverse-Effect | The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had Entitygained weight and developed amenorrhea while being treated with Entityvalproate lost weight and resumed menstruating after the change in medication. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of Entityrisperidone had an initial good response to the medication followed by development of Entityintolerable affect , including feelings of agitation and depression and periods of crying and insomnia. |
| 1.0000 | Adverse-Effect | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of Entityrisperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and periods of crying and Entityinsomnia . |
| 1.0000 | Adverse-Effect | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of Entityrisperidone had an initial good response to the medication followed by development of intolerable affect, including Entityfeelings of agitation and depression and periods of crying and insomnia. |
| 1.0000 | Adverse-Effect | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of Entityrisperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and Entitydepression and periods of crying and insomnia. |
| 1.0000 | Adverse-Effect | Six of 13 outpatients with schizophrenia who participated in a ten - week open trial of Entityrisperidone had an initial good response to the medication followed by development of intolerable affect, including feelings of agitation and depression and Entityperiods of crying and insomnia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of drug - induced EntityKaposi's sarcoma ( KS ) on the sole of the right foot in a 71 - year - old man, treated for 6 months with corticosteroid therapy ( Entityprednisolone 25 mg / day ) for pericardial effusion. |
| 1.0000 | Adverse-Effect | We report a case of drug - induced Kaposi's sarcoma ( EntityKS ) on the sole of the right foot in a 71 - year - old man, treated for 6 months with corticosteroid therapy ( Entityprednisolone 25 mg / day ) for pericardial effusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and Entityazathioprine , developed Entitythrombosis of the central retinal vein 5 years following the transplantation. |
| 0.9999 | Adverse-Effect | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, Entityprednisone and azathioprine, developed Entitythrombosis of the central retinal vein 5 years following the transplantation. |
| 0.9999 | Adverse-Effect | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of Entitycyclosporin , prednisone and azathioprine, developed Entitythrombosis of the central retinal vein 5 years following the transplantation. |
| 1.0000 | Adverse-Effect | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, prednisone and Entityazathioprine , developed Entitythrombosis of the central retinal vein 5 years following the transplantation. |
| 0.9999 | Adverse-Effect | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of cyclosporin, Entityprednisone and azathioprine, developed Entitythrombosis of the central retinal vein 5 years following the transplantation. |
| 0.9999 | Adverse-Effect | In this report, a patient who had undergone a renal transplantation as a result of malignant hypertension, and who was on immunosuppressive therapy consisting of Entitycyclosporin , prednisone and azathioprine, developed Entitythrombosis of the central retinal vein 5 years following the transplantation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for Entitycyclosporine A Entitynephrotoxicity . |
| 0.9997 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the Entityincrease in proteinuria , we suggest that in this case the tubules and / or interstitium are the main targets for Entitycyclosporine A nephrotoxicity. |
| 0.9986 | Adverse-Effect | Based upon the observed Entityfall of the filtration fraction , the rise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for Entitycyclosporine A nephrotoxicity. |
| 0.9795 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the Entityrise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for Entitycyclosporine A nephrotoxicity. |
| 1.0000 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the Entityrise in the relative clearance of Entity99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 1.0000 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the Entityrise in the relative clearance of Entity99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 0.9988 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the Entityrise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for Entitycyclosporine A nephrotoxicity. |
| 0.9988 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the Entityrise in the relative clearance of 99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for Entitycyclosporine A nephrotoxicity. |
| 0.9983 | Adverse-Effect | Based upon the observed Entityfall of the filtration fraction , the rise in the relative clearance of Entity99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 0.9975 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the Entityrise in the relative clearance of 99Tc - dimercaptosuccinic acid Entity99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| 0.9952 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the rise in the relative clearance of Entity99Tc - dimercaptosuccinic acid and the increase in proteinuria, we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A Entitynephrotoxicity . |
| 0.9820 | Adverse-Effect | Based upon the observed fall of the filtration fraction, the rise in the relative clearance of Entity99Tc - dimercaptosuccinic acid and the Entityincrease in proteinuria , we suggest that in this case the tubules and / or interstitium are the main targets for cyclosporine A nephrotoxicity. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Although there is one case report of Entitycholesterol crystal embolization following Entityt - PA therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following t - PA therapy. |
| 0.9999 | Adverse-Effect | Although there is one case report of cholesterol crystal embolization following t - PA therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of Entityatheroembolic acute renal failure following Entityt - PA therapy. |
| 0.9878 | Adverse-Effect | Although there is one case report of cholesterol crystal embolization following Entityt - PA therapy with only Entityextrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following t - PA therapy. |
| 0.9964 | Adverse-Effect | Although there is one case report of Entitycholesterol crystal embolization following t Entity- PA therapy with only extrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following t - PA therapy. |
| 0.9882 | Adverse-Effect | Although there is one case report of cholesterol crystal embolization following t Entity- PA therapy with only Entityextrarenal manifestations ( N Engl J Med 321 : 1270, 1989 ), this is the first reported case of atheroembolic acute renal failure following t - PA therapy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Rebound Entityhyperglycemia was observed with both intermediate ( Entityneutral protamine hagedorn ) and long - acting ( protamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. |
| 0.9998 | Adverse-Effect | Rebound Entityhyperglycemia was observed with both intermediate ( neutral Entityprotamine hagedorn ) and long - acting ( protamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. |
| 0.9997 | Adverse-Effect | Rebound Entityhyperglycemia was observed with both intermediate ( neutral protamine hagedorn ) and long - acting ( Entityprotamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. |
| Adverse-Effect | EntityRebound hyperglycemia was observed with both intermediate ( neutral Entityprotamine hagedorn ) and long - acting ( protamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. | |
| Adverse-Effect | EntityRebound hyperglycemia was observed with both intermediate ( neutral protamine hagedorn ) and long - acting ( Entityprotamine zinc iletin ) insulins, and the range of insulin doses at which the disorder developed overlapped previously determined therapeutic doses for these insulins in the cat. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into Entitystatus migrainosus after the introduction of Entityoxcarbazepine ( OXC ), as part of a switch off from carbamazepine ( CBZ ). |
| 1.0000 | Adverse-Effect | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into Entitystatus migrainosus after the introduction of oxcarbazepine ( EntityOXC ), as part of a switch off from carbamazepine ( CBZ ). |
| 0.9999 | Adverse-Effect | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into Entitystatus migrainosus after the introduction of oxcarbazepine ( OXC ), as part of a switch off from carbamazepine ( EntityCBZ ). |
| 0.9999 | Adverse-Effect | The goal of this study is to describe three patients diagnosed with migraine and epilepsy ( both under control ) who evolved into Entitystatus migrainosus after the introduction of oxcarbazepine ( OXC ), as part of a switch off from Entitycarbamazepine ( CBZ ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or Entitypositivation of the DAT during previous Entityfludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment. |
| 0.9999 | Adverse-Effect | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of EntityAIHA or positivation of the DAT during previous Entityfludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment. |
| 0.9999 | Adverse-Effect | Physicians should be aware of the risk of severe EntityAIHA in CLL patients with a history of AIHA or positivation of the DAT during previous Entityfludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during fludarabine treatment. |
| 0.9997 | Adverse-Effect | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of AIHA or Entitypositivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during Entityfludarabine treatment. |
| 0.9996 | Adverse-Effect | Physicians should be aware of the risk of severe AIHA in CLL patients with a history of EntityAIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during Entityfludarabine treatment. |
| 0.9996 | Adverse-Effect | Physicians should be aware of the risk of severe EntityAIHA in CLL patients with a history of AIHA or positivation of the DAT during previous fludarabine administration, or in case of secondary fixation of complement to the red cell membrane occurring during Entityfludarabine treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report a case of Stevens - Johnson syndrome / toxic epidermal necrolysis ( SJS / EntityTEN ) secondary to Entitytrimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9997 | Adverse-Effect | We report a case of Stevens - Johnson syndrome / toxic epidermal necrolysis ( EntitySJS / TEN ) secondary to Entitytrimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9997 | Adverse-Effect | We report a case of Stevens - Johnson syndrome / toxic epidermal necrolysis ( SJS / EntityTEN ) secondary to trimethoprim - sulfamethoxazole ( EntityTMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9996 | Adverse-Effect | We report a case of EntityStevens - Johnson syndrome / toxic epidermal necrolysis ( SJS / TEN ) secondary to Entitytrimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9996 | Adverse-Effect | We report a case of Stevens - Johnson syndrome / Entitytoxic epidermal necrolysis ( SJS / TEN ) secondary to Entitytrimethoprim - sulfamethoxazole ( TMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9991 | Adverse-Effect | We report a case of Stevens - Johnson syndrome / toxic epidermal necrolysis ( EntitySJS / TEN ) secondary to trimethoprim - sulfamethoxazole ( EntityTMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9989 | Adverse-Effect | We report a case of EntityStevens - Johnson syndrome / toxic epidermal necrolysis ( SJS / TEN ) secondary to trimethoprim - sulfamethoxazole ( EntityTMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| 0.9986 | Adverse-Effect | We report a case of Stevens - Johnson syndrome / Entitytoxic epidermal necrolysis ( SJS / TEN ) secondary to trimethoprim - sulfamethoxazole ( EntityTMP - Sx ) therapy for presumed community - associated methicillin - resistant Staphylococcus aureus ( CA - MRSA ) infection. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSIONS : Sustained - release Entityverapamil is thought to be the cause of the Entityasthma attack in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained - release verapamil and were relieved after its discontinuation. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : Sustained - release verapamil is thought to be the cause of the Entityasthma attack in this patient because she was not taking any other preparations ; the symptoms started with the administration of sustained - release Entityverapamil and were relieved after its discontinuation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of Entitythyroid disorders during the EntityIFN - alpha treatment. |
| 0.9980 | Adverse-Effect | Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop Entityautoimmune thyroiditis , in order to make a early diagnosis of thyroid disorders during the EntityIFN - alpha treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed postprandial hyperglycemia and Entityglycosuria during a period of topical administration of a corticosteroid cream, Entityhalcinonide cream 0. 1 %, under occlusion. |
| 1.0000 | Adverse-Effect | A patient with psoriasis is described who had an abnormal response to the glucose tolerance test without other evidence of diabetes and then developed Entitypostprandial hyperglycemia and glycosuria during a period of topical administration of a corticosteroid cream, Entityhalcinonide cream 0. 1 %, under occlusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and Entitypositive anti - nuclear antibody ( ANA ) two weeks after administration of Entitycarbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 1.0000 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, Entityleukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of Entitycarbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 1.0000 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, Entityrash , fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of Entitycarbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 1.0000 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, Entityfever , leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of Entitycarbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, Entityrash , fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( EntityCBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, Entityleukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( EntityCBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, Entityrash , fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; EntityTegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed Entitysystemic lupus erythematosus ( SLE ) - like symptoms , rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of Entitycarbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, Entityleukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; EntityTegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and Entitypositive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( EntityCBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and Entitypositive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; EntityTegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, Entityfever , leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( EntityCBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, Entityfever , leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; EntityTegretol ) used against benign Rolandic epilepsy. |
| 0.9998 | Adverse-Effect | A 14 - year - old female developed Entitysystemic lupus erythematosus ( SLE ) - like symptoms , rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( EntityCBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9998 | Adverse-Effect | A 14 - year - old female developed Entitysystemic lupus erythematosus ( SLE ) - like symptoms , rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; EntityTegretol ) used against benign Rolandic epilepsy. |
| 1.0000 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and positive anti - nuclear antibody ( EntityANA ) two weeks after administration of Entitycarbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 1.0000 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and positive anti - nuclear antibody ( EntityANA ) two weeks after administration of carbamazepine ( EntityCBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 1.0000 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( SLE ) - like symptoms, rash, fever, leukopenia and positive anti - nuclear antibody ( EntityANA ) two weeks after administration of carbamazepine ( CBZ ; EntityTegretol ) used against benign Rolandic epilepsy. |
| 0.9999 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( EntitySLE ) - like symptoms , rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of Entitycarbamazepine ( CBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9998 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( EntitySLE ) - like symptoms , rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( EntityCBZ ; Tegretol ) used against benign Rolandic epilepsy. |
| 0.9998 | Adverse-Effect | A 14 - year - old female developed systemic lupus erythematosus ( EntitySLE ) - like symptoms , rash, fever, leukopenia and positive anti - nuclear antibody ( ANA ) two weeks after administration of carbamazepine ( CBZ ; EntityTegretol ) used against benign Rolandic epilepsy. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Since the Entitythrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of Entityciprofloxacin and tazobactam / piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative. |
| 0.9998 | Adverse-Effect | Since the Entitythrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and tazobactam / Entitypiperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative. |
| 0.9998 | Adverse-Effect | Since the Entitythrombocyte count started to increase immediately after initiation and dropped immediately after discontinuation of ciprofloxacin and Entitytazobactam / piperacillin and all other drugs were discontinued already before or were started after the nadir of the thrombocyte count, these two antibiotics were regarded causative. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Our findings suggest that significant Entityprogression of marrow reticulin fibrosis during Entityimatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, imatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment. |
| 0.4811 | Adverse-Effect | Our findings suggest that significant Entityprogression of marrow reticulin fibrosis during imatinib therapy can be an indicator for a return or progression of CML and, in some patients with CML, Entityimatinib may promote cytogenetic clonal evolution, resulting in a poor response to treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Ciprofloxacin is among the standard treatments for infected ischemic ulcers ; in the rare case of Entityciprofloxacin - induced Entityhemorrhagic vasculitis , it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment. |
| 0.9991 | Adverse-Effect | Ciprofloxacin is among the standard treatments for infected ischemic ulcers ; in the rare case of Entityciprofloxacin - induced hemorrhagic vasculitis, it might be interpreted as Entityprogression of infection , instead of a complication of the treatment, thus leading to faulty diagnosis and treatment. |
| 0.9805 | Adverse-Effect | EntityCiprofloxacin is among the standard treatments for infected ischemic ulcers ; in the rare case of ciprofloxacin - induced Entityhemorrhagic vasculitis , it might be interpreted as progression of infection, instead of a complication of the treatment, thus leading to faulty diagnosis and treatment. |
| 0.9709 | Adverse-Effect | EntityCiprofloxacin is among the standard treatments for infected ischemic ulcers ; in the rare case of ciprofloxacin - induced hemorrhagic vasculitis, it might be interpreted as Entityprogression of infection , instead of a complication of the treatment, thus leading to faulty diagnosis and treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and Entitymoxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including Entityheadache , dizziness and insomnia. |
| 1.0000 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and Entitymoxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, Entitydizziness and insomnia. |
| 1.0000 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and Entitymoxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and Entityinsomnia . |
| 1.0000 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( Entitylevofloxacin , sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including Entityheadache , dizziness and insomnia. |
| 1.0000 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, Entitygatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including Entityheadache , dizziness and insomnia. |
| 1.0000 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, Entitytrovafloxacin , gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including Entityheadache , dizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, Entitysparfloxacin , grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including Entityheadache , dizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( Entitylevofloxacin , sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and Entityinsomnia . |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, Entitytrovafloxacin , gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and Entityinsomnia . |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, Entitygatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and Entityinsomnia . |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( Entitylevofloxacin , sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, Entitydizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, Entitytrovafloxacin , gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, Entitydizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, Entitygatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, Entitydizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, Entitygrepafloxacin , trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including Entityheadache , dizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, Entitysparfloxacin , grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and Entityinsomnia . |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, Entitysparfloxacin , grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, Entitydizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, Entitygrepafloxacin , trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, dizziness and Entityinsomnia . |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, Entitygrepafloxacin , trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause central nervous system - related adverse effects, including headache, Entitydizziness and insomnia. |
| 1.0000 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and Entitymoxifloxacin ), also called gyrase inhibitors, are known for their potential to cause Entitycentral nervous system - related adverse effects , including headache, dizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( Entitylevofloxacin , sparfloxacin, grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause Entitycentral nervous system - related adverse effects , including headache, dizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, Entitygatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause Entitycentral nervous system - related adverse effects , including headache, dizziness and insomnia. |
| 0.9999 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, grepafloxacin, Entitytrovafloxacin , gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause Entitycentral nervous system - related adverse effects , including headache, dizziness and insomnia. |
| 0.9998 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, Entitysparfloxacin , grepafloxacin, trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause Entitycentral nervous system - related adverse effects , including headache, dizziness and insomnia. |
| 0.9998 | Adverse-Effect | CONCLUSION : The new quinolone derivatives ( levofloxacin, sparfloxacin, Entitygrepafloxacin , trovafloxacin, gatifloxacin and moxifloxacin ), also called gyrase inhibitors, are known for their potential to cause Entitycentral nervous system - related adverse effects , including headache, dizziness and insomnia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected Entityinsulin could explain the Entitydedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. |
| 1.0000 | Adverse-Effect | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the Entityreversion that was induced by the local injection of Entitydexamethasone . |
| 0.9999 | Adverse-Effect | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected Entityinsulin could explain the Entitydedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. |
| 0.9999 | Adverse-Effect | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the Entitydedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of Entitydexamethasone . |
| 0.9998 | Adverse-Effect | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected insulin could explain the Entitydedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of Entitydexamethasone . |
| 0.9990 | Adverse-Effect | CONCLUSIONS : In our reported case, a local hyperproduction of TNF - alpha from macrophages that was induced by the injected Entityinsulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the Entityreversion that was induced by the local injection of dexamethasone. |
| Adverse-Effect | CONCLUSIONS : In our reported case, a local Entityhyperproduction of TNF - alpha from macrophages that was induced by the injected Entityinsulin could explain the dedifferentiation of the adipocytes of the subcutaneous tissue and the reversion that was induced by the local injection of dexamethasone. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Factors that suggested an association between the Entitysevere angioedematous reaction and EntityBP topical application include the strong reaction to BP in the patch - test, the temporal relationship, the complete resolution of symptoms after the drug was withdrawn and the absence of other identified explanations. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | To develop information on the relative rarity or frequency of Entityneurologic worsening with the initiation of Entitypenicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine. |
| 0.9872 | Adverse-Effect | To develop information on the Entityrelative rarity or frequency of neurologic worsening with the initiation of Entitypenicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with neurologic disease and having been treated with penicillamine. |
| Adverse-Effect | To develop information on the relative rarity or frequency of neurologic worsening with the initiation of penicillamine therapy, we conducted a retrospective survey of 25 additional patients with Wilson's disease who met the criteria of presenting with Entityneurologic disease and having been treated with Entitypenicillamine . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The risk of developing EntitysAML is estimated to be between 1 % and 5 %, 2 - 20 years after exposure to Entityetoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co - administration of other antineoplastic agents. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The presence of a lymphocyte alveolitis with a predominance of CD4 + T cells in 3 RA patients and CD8 + T cells with a concomitant increase in neutrophils in another case suggests that immunologically mediated reactions may be one damage mechanism in EntityMTX - induced Entitypneumonitis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityRenal failure appeared 8 to 17 days after beginning Entitygentamicin therapy and was characterized by creatinine clearances 4 to 10 ml / min, urine to plasma creatinine ratios less than 20, urinary sodium concentrations 16 to 60 mEq / liter, proteinuria, and cylindruria. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of Entityheadaches , dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9999 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, Entitydifficulty with speech , weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9999 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, Entityweakness , and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9999 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, Entitydizziness , difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9999 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of Entityheadaches , dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9998 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a Entitymaculopapular rash was noted. |
| 0.9997 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, Entitydifficulty with speech , weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9996 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, Entityweakness , and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9996 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, Entitydizziness , difficulty with speech, weakness, and itching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9995 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9995 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and itching on the trunk of his body and legs, where a Entitymaculopapular rash was noted. |
| 0.9985 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9999 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs , where a maculopapular rash was noted. |
| 0.9996 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs , where a maculopapular rash was noted. |
| 0.9996 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9996 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9995 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9995 | Adverse-Effect | He had been taking trimethoprim - Entitysulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9986 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9985 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9985 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| 0.9985 | Adverse-Effect | He had been taking Entitytrimethoprim - sulfamethoxazole for approximately eight days when he revisited his family physician, complaining of headaches, dizziness, difficulty with speech, weakness, and Entityitching on the trunk of his body and legs, where a maculopapular rash was noted. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A clinically atypical, neuropathologically verified case of EntityCreutzfeldt - Jakob disease is described in a 32 - year - old New Zealand woman with idiopathic hypopituitarism who had been treated in late adolescence ( 1970 to 1973 ) with Entityhuman growth hormone processed from pooled cadaveric pituitary glands. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In a series of 104 cases of intentional or inadvertent use of Entityzidovudine at differing gestations in pregnancy, there were eight spontaneous Entityfirst trimester abortions , eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed. |
| 0.9999 | Adverse-Effect | In a series of 104 cases of intentional or inadvertent use of Entityzidovudine at differing gestations in pregnancy, there were eight spontaneous first trimester abortions, eight therapeutic terminations, and eight cases of Entityfetal abnormality occurring among a total of 88 cases where the pregnancy progressed. |
| 1.0000 | Adverse-Effect | In a series of 104 cases of intentional or inadvertent use of Entityzidovudine at differing gestations in pregnancy, there were eight Entityspontaneous first trimester abortions , eight therapeutic terminations, and eight cases of fetal abnormality occurring among a total of 88 cases where the pregnancy progressed. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9975 | Adverse-Effect | This is the first reported case of EntityBOOP associated with single - agent Entityrituximab , and along with two other patients we describe, as well as two prior reports of BOOP in NHL patients receiving rituximab - based combinations, strengthens the possibility of a causal relationship. |
| 0.9940 | Adverse-Effect | This is the first reported case of BOOP associated with single - agent rituximab, and along with two other patients we describe, as well as two prior reports of EntityBOOP in NHL patients receiving Entityrituximab - based combinations, strengthens the possibility of a causal relationship. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The patient completed a 10 - month follow - up, maintaining a complete resolution of the treated skin lesions ; however, the development of a Entitypainful hand ulcer , possibly associated with the Entityhydroxyurea , and new skin cancers were observed at the last follow - up visit. |
| 0.9987 | Adverse-Effect | The patient completed a 10 - month follow - up, maintaining a complete resolution of the treated skin lesions ; however, the development of a painful hand ulcer, possibly associated with the Entityhydroxyurea , and new Entityskin cancers were observed at the last follow - up visit. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The case is presented of a 72 - year - old man with hormone - refractory prostate cancer and weekly administration of 30 mg / m2 Entitydocetaxel who developed Entitysubacute interstitial pneumonitis - related pulmonary fibrosis after seven doses and died despite mechanical ventilation and high - dose corticosteroid treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Therefore, it is reasonable to conclude that : 1 ) 2 - CdA can induce durable complete remission in MCD patients but unfortunately it can not cure the disease ; 2 ) the possibility that Entity2 - CdA may accelerate the Entitytransformation of MCD to NHL can not be ruled out. |
| 0.9745 | Adverse-Effect | Therefore, it is reasonable to conclude that : 1 ) Entity2 - CdA can induce durable complete remission in MCD patients but unfortunately it can not cure the disease ; 2 ) the possibility that 2 - CdA may accelerate the Entitytransformation of MCD to NHL can not be ruled out. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and Entityfever up to 39 degrees C one day after the administration of Entitysalazosulfapyridine . |
| 1.0000 | Adverse-Effect | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, Entitymalaise , and fever up to 39 degrees C one day after the administration of Entitysalazosulfapyridine . |
| 0.9999 | Adverse-Effect | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and Entitypustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of Entitysalazosulfapyridine . |
| 0.9999 | Adverse-Effect | A 26 - year - old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with Entitydiffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of Entitysalazosulfapyridine . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We present a case report of a patient with alveolar hydatid disease, whose treatment with Entitymebendazole was brief due to side effects of Entityalopecia and granulocytopenia ; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia. |
| 1.0000 | Adverse-Effect | We present a case report of a patient with alveolar hydatid disease, whose treatment with Entitymebendazole was brief due to side effects of alopecia and Entitygranulocytopenia ; and review the features of this disease which, with increasing international migration, may be encountered more frequently in Australia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe 2 male patients, a 49 - year - old with psoriatic arthritis and impaired renal function and a 43 - year - old renal transplant recipient, who both sustained a marked Entitydecline in glomerular filtration rate in conjunction with a selective inhibitor of cyclooxygenase - 2 ( COX - 2 ), Entityrofecoxib . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and Entitybile stasis , demonstrated 20 days after the initiation of antithyroid therapy with 20 mg Entitymethimazole daily. |
| 1.0000 | Adverse-Effect | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with Entitygranulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg Entitymethimazole daily. |
| 1.0000 | Adverse-Effect | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and cholestasis, and biopsy features of Entityfatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg Entitymethimazole daily. |
| 0.9998 | Adverse-Effect | The main clinical features of this 58 - year - old female patient were laboratory evidence of leucopenia and Entitycholestasis , and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg Entitymethimazole daily. |
| 0.9998 | Adverse-Effect | The main clinical features of this 58 - year - old female patient were laboratory evidence of Entityleucopenia and cholestasis, and biopsy features of fatty liver parenchyma degeneration with granulocytic portal infiltration and bile stasis, demonstrated 20 days after the initiation of antithyroid therapy with 20 mg Entitymethimazole daily. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | On the fifth day after administration of a high dose of EntityARA - C ( 2 g / m2 intravenously every 12 hours ), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, Entitysepsis , and death on the 22nd day. |
| 0.9996 | Adverse-Effect | On the fifth day after administration of a high dose of EntityARA - C ( 2 g / m2 intravenously every 12 hours ), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and Entitydeath on the 22nd day. |
| 0.9999 | Adverse-Effect | On the fifth day after administration of a high dose of EntityARA - C ( 2 g / m2 intravenously every 12 hours ), she developed Entitybullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day. |
| 0.9995 | Adverse-Effect | On the fifth day after administration of a high dose of EntityARA - C ( 2 g / m2 intravenously every 12 hours ), she developed bullous lesions on the hands and soles that disseminated, evolving to Entitynecrosis , sepsis, and death on the 22nd day. |
| Adverse-Effect | On the fifth day after administration of a high dose of EntityARA - C ( 2 g / m2 intravenously every 12 hours ), she developed Entitybullous lesions on the hands and soles that disseminated, evolving to necrosis , sepsis, and death on the 22nd day. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | It is presumed that her Entityhyperchloremic metabolic acidosis was secondary to Entitycholestyramine because of the similarity to pediatric reports ; the rapid and lasting response to intravenous sodium bicarbonate ; the absence of another etiology ; normal serum potassium, chloride and bicarbonate despite continued spironolactone therapy after recovery. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Previous studies have demonstrated the interaction of EntityMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including Entityacute renal failure , pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 1.0000 | Adverse-Effect | Previous studies have demonstrated the interaction of EntityMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, Entitypancytopenia , vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 1.0000 | Adverse-Effect | Previous studies have demonstrated the interaction of EntityMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, Entitydiarrhea , elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 1.0000 | Adverse-Effect | Previous studies have demonstrated the interaction of EntityMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, Entityjaundice , mucosal ulcerations, and pyrexia. |
| 1.0000 | Adverse-Effect | Previous studies have demonstrated the interaction of EntityMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, Entityvomiting , diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and pyrexia. |
| 1.0000 | Adverse-Effect | Previous studies have demonstrated the interaction of EntityMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, mucosal ulcerations, and Entitypyrexia . |
| 0.9999 | Adverse-Effect | Previous studies have demonstrated the interaction of EntityMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, elevated liver transaminases, jaundice, Entitymucosal ulcerations , and pyrexia. |
| 0.9999 | Adverse-Effect | Previous studies have demonstrated the interaction of EntityMTX and a variety of non - steroidal, anti - inflammatory drugs ( NSAIDs ) with various clinical manifestations including acute renal failure, pancytopenia, vomiting, diarrhea, Entityelevated liver transaminases , jaundice, mucosal ulcerations, and pyrexia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, divalproex sodium, risperidone, and Entitycarbamazepine ) presenting with mixed EntitySS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 1.0000 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, divalproex sodium, risperidone, and Entitycarbamazepine ) presenting with mixed SS / EntityNMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9999 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( Entityvenlafaxine , topiramate, divalproex sodium, risperidone, and carbamazepine ) presenting with mixed SS / EntityNMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9999 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, divalproex sodium, Entityrisperidone , and carbamazepine ) presenting with mixed SS / EntityNMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9998 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, Entitytopiramate , divalproex sodium, risperidone, and carbamazepine ) presenting with mixed SS / EntityNMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9998 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( Entityvenlafaxine , topiramate, divalproex sodium, risperidone, and carbamazepine ) presenting with mixed EntitySS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9998 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, divalproex sodium, Entityrisperidone , and carbamazepine ) presenting with mixed EntitySS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9998 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, Entitytopiramate , divalproex sodium, risperidone, and carbamazepine ) presenting with mixed EntitySS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9997 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, Entitydivalproex sodium , risperidone, and carbamazepine ) presenting with mixed SS / EntityNMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| 0.9997 | Adverse-Effect | METHOD : Case analysis of a poly - drug overdose ( venlafaxine, topiramate, Entitydivalproex sodium , risperidone, and carbamazepine ) presenting with mixed EntitySS / NMS features and whose clinical management suggests a practical algorithm for treatment of undifferentiated SS / NMS in critical care settings. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9989 | Adverse-Effect | After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely Entitypegvisomant alone and not the long - acting somatostatin analog or the combination of these two drugs was responsible for this case of drug - induced Entityhepatitis . |
| 0.9956 | Adverse-Effect | After rechallenge with monotherapy pegvisomant, however, the Entityhepatic enzyme disturbances reappeared within a few weeks, indicating that most likely Entitypegvisomant alone and not the long - acting somatostatin analog or the combination of these two drugs was responsible for this case of drug - induced hepatitis. |
| 0.9999 | Adverse-Effect | After rechallenge with monotherapy pegvisomant, however, the hepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long - acting Entitysomatostatin analog or the combination of these two drugs was responsible for this case of drug - induced Entityhepatitis . |
| 0.9902 | Adverse-Effect | After rechallenge with monotherapy pegvisomant, however, the Entityhepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long - acting Entitysomatostatin analog or the combination of these two drugs was responsible for this case of drug - induced hepatitis. |
| Adverse-Effect | After rechallenge with monotherapy Entitypegvisomant , however, the Entityhepatic enzyme disturbances reappeared within a few weeks, indicating that most likely pegvisomant alone and not the long - acting somatostatin analog or the combination of these two drugs was responsible for this case of drug - induced hepatitis. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Possible pathophysiological mechanisms which may have been operative in this case include : a direct central nervous system ( CNS ) toxic effect of valproic acid ; a paradoxical epileptogenic effect secondary to the drug ; and an indirect CNS toxic effect mediated through Entityvalproic acid - induced Entityhyperammonemia . |
| 0.8683 | Adverse-Effect | Possible pathophysiological mechanisms which may have been operative in this case include : a direct central nervous system ( CNS ) toxic effect of Entityvalproic acid ; a paradoxical epileptogenic effect secondary to the drug ; and an indirect CNS toxic effect mediated through valproic acid - induced Entityhyperammonemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed Entityradiation recall to Entitygemcitabine and were discussed in the current study to 13. |
| 0.9999 | Adverse-Effect | The authors also determined that their case of Entitymyositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of radiation recall, thereby bringing the number of patients who developed radiation recall to Entitygemcitabine and were discussed in the current study to 13. |
| 0.9998 | Adverse-Effect | The authors also determined that their case of myositis developing in the rectus abdominus muscle of a patient with pancreatic adenocarcinoma was the manifestation of Entityradiation recall , thereby bringing the number of patients who developed radiation recall to Entitygemcitabine and were discussed in the current study to 13. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These findings suggest that Entityclozapine - induced Entityseizures can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of seizures and that concomitant use of a suitable mood stabilizer / anti - epileptic medication can improve the outcome of treatment - resistant schizophrenia. |
| 0.9964 | Adverse-Effect | These findings suggest that Entityclozapine - induced seizures can be successfully treated, that gradual dose titration can reduce the likelihood of further episodes of Entityseizures and that concomitant use of a suitable mood stabilizer / anti - epileptic medication can improve the outcome of treatment - resistant schizophrenia. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti - androgen therapy in the form of Entitycyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed Entityfemoral head avascular necrosis . |
| 0.9993 | Adverse-Effect | We report the case histories of two patients with histologically confirmed Entityadenocarcinoma of the prostate , both of whom had been treated with steroidal anti - androgen therapy in the form of Entitycyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Postoperatively, the first two patients treated with 1 to 2 cc of Entitythrombin were Entityslow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with intracranial hypertension. |
| 0.9999 | Adverse-Effect | Postoperatively, the first two patients treated with 1 to 2 cc of Entitythrombin were slow to awaken ; one had evidence of Entityvasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with intracranial hypertension. |
| 0.9998 | Adverse-Effect | Postoperatively, the first two patients treated with 1 to 2 cc of Entitythrombin were slow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and Entitymultiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with intracranial hypertension. |
| 0.9996 | Adverse-Effect | Postoperatively, the first two patients treated with 1 to 2 cc of Entitythrombin were slow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized frontal hematoma with Entityintracranial hypertension . |
| 0.9994 | Adverse-Effect | Postoperatively, the first two patients treated with 1 to 2 cc of Entitythrombin were slow to awaken ; one had evidence of vasospasm by transcranial Doppler ultrasound studies and multiple infarcts on cranial computerized tomography, while the other had a moderate - sized Entityfrontal hematoma with intracranial hypertension. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | RESULTS : The estimated number of EntityAccutane prescriptions for reproductive - aged women has more than doubled in the past 10 years ; it is the most widely used Entityteratogenic drug in the United States, with approximately 2. 5 per 1, 000 reproductive - aged women exposed to Accutane in 1999. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and Entityeosinophilia two weeks after receiving Entitytrimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 1.0000 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and Entityeosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( EntitySMX ) treatment. |
| 0.9999 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and Entityeosinophilia two weeks after receiving trimethoprim ( TMP ) - Entitysulfamethoxazole ( SMX ) treatment. |
| 0.9999 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and Entityeosinophilia two weeks after receiving trimethoprim ( EntityTMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9999 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, Entityatypical lymphocytosis , and eosinophilia two weeks after receiving Entitytrimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9999 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, Entitycervical lymphadenopathy , hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving Entitytrimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9998 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with Entityfever , skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving Entitytrimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9998 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, Entityhepatosplenomegaly , atypical lymphocytosis, and eosinophilia two weeks after receiving Entitytrimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9998 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, Entityskin eruptions , cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving Entitytrimethoprim ( TMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9997 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, Entityatypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( EntitySMX ) treatment. |
| 0.9997 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, Entitycervical lymphadenopathy , hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( EntitySMX ) treatment. |
| 0.9997 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with Entityfever , skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( EntitySMX ) treatment. |
| 0.9996 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, Entityhepatosplenomegaly , atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( EntitySMX ) treatment. |
| 0.9996 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, Entitycervical lymphadenopathy , hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - Entitysulfamethoxazole ( SMX ) treatment. |
| 0.9996 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with Entityfever , skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - Entitysulfamethoxazole ( SMX ) treatment. |
| 0.9996 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, Entityskin eruptions , cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - sulfamethoxazole ( EntitySMX ) treatment. |
| 0.9996 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, Entityatypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( TMP ) - Entitysulfamethoxazole ( SMX ) treatment. |
| 0.9996 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, Entityhepatosplenomegaly , atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - Entitysulfamethoxazole ( SMX ) treatment. |
| 0.9995 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, Entityskin eruptions , cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( TMP ) - Entitysulfamethoxazole ( SMX ) treatment. |
| 0.9995 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, Entitycervical lymphadenopathy , hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( EntityTMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9995 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with Entityfever , skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( EntityTMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9995 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, hepatosplenomegaly, Entityatypical lymphocytosis , and eosinophilia two weeks after receiving trimethoprim ( EntityTMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9994 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, skin eruptions, cervical lymphadenopathy, Entityhepatosplenomegaly , atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( EntityTMP ) - sulfamethoxazole ( SMX ) treatment. |
| 0.9994 | Adverse-Effect | A 27 - year - old man who had a history of bronchial asthma, eosinophilic enteritis, and eosinophilic pneumonia presented with fever, Entityskin eruptions , cervical lymphadenopathy, hepatosplenomegaly, atypical lymphocytosis, and eosinophilia two weeks after receiving trimethoprim ( EntityTMP ) - sulfamethoxazole ( SMX ) treatment. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Although it is difficult to be certain of the direct link of amiodarone on the basis of a single case, it is reasonable to presume that this histopathology is associated with Entityamiodarone - induced Entityhypothyroidism and that involution changes represent the hypofunctional status of this drug - induced disorder. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9994 | Adverse-Effect | It also highlights a current major etiologic question, that is, whether and to what degree Entitylead exposure contributes to the development of Entityhypertension , and raises the issue of whether lead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium. |
| 0.9993 | Adverse-Effect | It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether Entitylead - induced Entityhypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium. |
| 0.9481 | Adverse-Effect | It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether Entitylead - induced hypertension constitutes a subset of Entityhypertension that is especially amenable to therapy with dietary calcium. |
| Adverse-Effect | It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether Entitylead Entitylead - induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | EntityRisperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2 / 5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including tardive dyskinesia ( EntityTD ). |
| 0.9999 | Adverse-Effect | EntityRisperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2 / 5HT2 binding ratio, which results in a low incidence of extrapyramidal side effects including Entitytardive dyskinesia ( TD ). |
| 0.9999 | Adverse-Effect | EntityRisperidone is a frequently used member of a new class of atypical antipsychotics - the serotonin - dopamine antagonists ( SDAs ) - due to its comparatively high efficacy and low D2 / 5HT2 binding ratio, which results in a low incidence of Entityextrapyramidal side effects including tardive dyskinesia ( TD ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as Entitynephrotoxicity , ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 1.0000 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, Entitygastrointestinal disturbances , blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 1.0000 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, Entityototoxicity , gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 1.0000 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " Entityred man syndrome " and anaphylaxis. |
| 1.0000 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, Entityblood disorders , and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.9999 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and Entityanaphylaxis . |
| 0.9999 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of Entityhypersensitivity reactions - an anaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 0.9998 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an Entityanaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| 1.0000 | Adverse-Effect | EntityVancomycin is widely used against methicillin - resistant Staphylococcus aureus infections, but it is associated with many adverse effects such as nephrotoxicity, ototoxicity, gastrointestinal disturbances, blood disorders, and two types of hypersensitivity reactions - an Entityanaphylactoid reaction known as " red man syndrome " and anaphylaxis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Entityamiodarone for 4 years, developed Entitythyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9999 | Adverse-Effect | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Entityamiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by Entitytransiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9995 | Adverse-Effect | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Entityamiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or Entitythyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9999 | Adverse-Effect | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Entityamiodarone for 4 years, developed thyrotoxicosis with Entitysubacute onset , accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9997 | Adverse-Effect | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Entityamiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or Entitythyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9995 | Adverse-Effect | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Entityamiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or Entitythyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9994 | Adverse-Effect | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Entityamiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( TRAb ), or Entitythyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| 0.9991 | Adverse-Effect | Among 12 thyrotoxic patients, a patient with arrhythmogenic right ventricular dysplasia, who had been taking Entityamiodarone for 4 years, developed thyrotoxicosis with subacute onset, accompanied by transiently positive thyrotropin ( TSH ) receptor antibody ( EntityTRAb ), or thyrotropin - binding inhibiting immunoglobulin ( TBII ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9414 | Adverse-Effect | EntityThrombocytopenia with or without microangiopathy following Entityquinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " quinine - associated TTP / HUS. " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| 0.6825 | Adverse-Effect | Thrombocytopenia with or without microangiopathy following quinine is often referred to as Entityquinine " Entityhypersensitivity . " When schistocytes are present it is frequently termed " quinine - associated TTP / HUS. " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| 0.6060 | Adverse-Effect | Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " Entityquinine - associated TTP / EntityHUS . " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. |
| Adverse-Effect | Thrombocytopenia with or without microangiopathy following quinine is often referred to as quinine " hypersensitivity. " When schistocytes are present it is frequently termed " Entityquinine - associated EntityTTP / HUS . " A severe deficiency of the vWF - cleaving protease, ADAMTS13, is associated with idiopathic TTP. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | Intravenous Entityverapamil therapy in babies may cause Entityapnea , hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9924 | Adverse-Effect | Intravenous Entityverapamil therapy in babies may cause apnea, Entityhypotension , and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9874 | Adverse-Effect | Intravenous Entityverapamil therapy in babies may cause apnea, hypotension, and Entitybradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9707 | Adverse-Effect | Intravenous Entityverapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause Entitysudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.9533 | Adverse-Effect | Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; Entityquinidine may be related to the death ; children with " familial seizure disorders " may in fact have the Entitylong QT interval syndrome . |
| 0.8352 | Adverse-Effect | Intravenous Entityverapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of Entityatrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.5138 | Adverse-Effect | Intravenous verapamil therapy in babies may cause Entityapnea , hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; Entityquinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| 0.7548 | Adverse-Effect | Intravenous Entityverapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; quinidine may be related to the death ; children with " familial seizure disorders " may in fact have the Entitylong QT interval syndrome . |
| 0.6422 | Adverse-Effect | Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause Entitysudden death ; Entityquinidine may be related to the death ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. |
| Adverse-Effect | Intravenous verapamil therapy in babies may cause apnea, hypotension, and bradycardia ; continued episodes of atrial flutter in a child may cause sudden death ; Entityquinidine may be related to the Entitydeath ; children with " familial seizure disorders " may in fact have the long QT interval syndrome. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The pharmaceutical company producing EntityHalfan has reported 8 Entitycardiac arrests , leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.9999 | Adverse-Effect | The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 Entitydeaths , when a higher dose than recommended was used, there was recent or concomitant treatment with Entitymefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.9997 | Adverse-Effect | The pharmaceutical company producing EntityHalfan has reported 8 cardiac arrests, leading to 6 Entitydeaths , when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.9997 | Adverse-Effect | The pharmaceutical company producing Halfan has reported 8 Entitycardiac arrests , leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with Entitymefloquine , there was pre - existing prolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.9998 | Adverse-Effect | The pharmaceutical company producing Halfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with Entitymefloquine , there was pre - existing Entityprolongation of the QT interval or the patient had a thiamine deficiency. |
| 0.9983 | Adverse-Effect | The pharmaceutical company producing EntityHalfan has reported 8 cardiac arrests, leading to 6 deaths, when a higher dose than recommended was used, there was recent or concomitant treatment with mefloquine, there was pre - existing Entityprolongation of the QT interval or the patient had a thiamine deficiency. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The administration of " sweet spirits of nitre " ( Entity4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by Entityacute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.9997 | Adverse-Effect | The administration of " sweet spirits of nitre " ( Entity4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and Entitysevere anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.9995 | Adverse-Effect | The administration of " Entitysweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by Entityacute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.9987 | Adverse-Effect | The administration of " Entitysweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and Entitysevere anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.9980 | Adverse-Effect | The administration of " sweet spirits of nitre " ( Entity4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin Entitydied from the consequences of hypoxemia. |
| 0.9980 | Adverse-Effect | The administration of " Entitysweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin Entitydied from the consequences of hypoxemia. |
| 0.9946 | Adverse-Effect | The administration of " sweet spirits of nitre " ( Entity4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of Entityhypoxemia . |
| 0.9944 | Adverse-Effect | The administration of " Entitysweet spirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of Entityhypoxemia . |
| 0.9996 | Adverse-Effect | The administration of " sweet Entityspirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by Entityacute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.9988 | Adverse-Effect | The administration of " sweet Entityspirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and Entitysevere anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of hypoxemia. |
| 0.9982 | Adverse-Effect | The administration of " sweet Entityspirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin Entitydied from the consequences of hypoxemia. |
| 0.9949 | Adverse-Effect | The administration of " sweet Entityspirits of nitre " ( 4 % ethyl nitrite CH3CH2ONO in 70 % ethyl alcohol ) was followed by acute methemoglobinemia and severe anoxic metabolic acidosis in infant twins, Methylene blue administration reversed methemoglobinemia in both, but one twin died from the consequences of Entityhypoxemia . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Although the literature on the use of Entityrisperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of Entityextrapyramidal symptoms ( EPS ). |
| 0.9995 | Adverse-Effect | Although the literature on the use of Entityrisperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms ( EntityEPS ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of Entitycisplatin without complications experienced Entityhypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9998 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced Entityhypersensitivity reactions to Entitycisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9984 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to Entitycisplatin : one, involving intrahepatic artery infusion, manifested Entitygeneral erythema , dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9964 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to Entitycisplatin : one, involving intrahepatic artery infusion, manifested general erythema, Entitydyspnea , and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9951 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to Entitycisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and Entityhypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9916 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of Entitycisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, Entitydyspnea , and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9916 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to Entitycisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested Entityabdominal pain , general erythema, and fever. |
| 0.9907 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to Entitycisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and Entityfever . |
| 0.9894 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of Entitycisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and Entityhypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9857 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of Entitycisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested Entitygeneral erythema , dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and fever. |
| 0.9852 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of cisplatin without complications experienced hypersensitivity reactions to Entitycisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, Entitygeneral erythema , and fever. |
| 0.9839 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of Entitycisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested Entityabdominal pain , general erythema, and fever. |
| 0.9835 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of Entitycisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, general erythema, and Entityfever . |
| 0.9733 | Adverse-Effect | Two patients with ovarian cancer who had received multiple courses of Entitycisplatin without complications experienced hypersensitivity reactions to cisplatin : one, involving intrahepatic artery infusion, manifested general erythema, dyspnea, and hypotension ; the other, involving intravenous infusion, manifested abdominal pain, Entitygeneral erythema , and fever. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We report 5 patients ( 3 patients with chronic hepatitis C treated with pegylated interferon alfa - 2b in association with oral ribavirin and two patients with chronic myelocytic leukemia ) who developed Entitylocal cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of Entitypegylated interferon alfa - 2b at different doses. |
| 0.9990 | Adverse-Effect | We report 5 patients ( 3 patients with chronic hepatitis C treated with pegylated interferon alfa - 2b in association with oral Entityribavirin and two patients with chronic myelocytic leukemia ) who developed Entitylocal cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa - 2b at different doses. |
| 0.9968 | Adverse-Effect | We report 5 patients ( 3 patients with chronic hepatitis C treated with Entitypegylated interferon alfa - 2b in association with oral ribavirin and two patients with chronic myelocytic leukemia ) who developed Entitylocal cutaneous reactions at sites of injection after the administration of weekly subcutaneous injections of pegylated interferon alfa - 2b at different doses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9995 | Adverse-Effect | Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of Entitybleomycin - induced Entityhyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients. |
| 0.9953 | Adverse-Effect | Although this type of Entityhyperpigmentation has been previously seen in patients with cancer who are receiving Entitybleomycin , this is, to our knowledge, the first reported case of bleomycin - induced hyperpigmentation in an AIDS patient and should be added to the growing list of cutaneous eruptions seen in these patients. |
| 0.8172 | Adverse-Effect | Although this type of hyperpigmentation has been previously seen in patients with cancer who are receiving bleomycin, this is, to our knowledge, the first reported case of Entitybleomycin - induced hyperpigmentation in an AIDS patient and should be added to the growing list of Entitycutaneous eruptions seen in these patients. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | Our report suggested that EntityCBDCA Entityhypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because CBDCA hypersensitivity can occur even with low - dose CBDCA administration. |
| 0.9996 | Adverse-Effect | Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because EntityCBDCA Entityhypersensitivity can occur even with low - dose CBDCA administration. |
| 0.9995 | Adverse-Effect | Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because CBDCA Entityhypersensitivity can occur even with low - dose EntityCBDCA administration. |
| 0.5250 | Adverse-Effect | Our report suggested that CBDCA Entityhypersensitivity was correlated with the total dose of previously administered platinum agents and that CBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because EntityCBDCA hypersensitivity can occur even with low - dose CBDCA administration. |
| 0.8084 | Adverse-Effect | Our report suggested that CBDCA hypersensitivity was correlated with the total dose of previously administered platinum agents and that EntityCBDCA should be excluded in patients who have received multiple platinum - based chemotherapy, even in platinum - sensitive cases, because CBDCA Entityhypersensitivity can occur even with low - dose CBDCA administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This paper reports on a 6. 9 - year - old autistic male who developed repeated episodes of Entityacute dystonic reactions associated with Entitypimozide administration at the doses of 0. 096 mg / kg / day and 0. 032 mg / kg / day and 32 hours following pimozide withdrawal, as well as during subsequent thioridazine administration. |
| 0.9994 | Adverse-Effect | This paper reports on a 6. 9 - year - old autistic male who developed repeated episodes of Entityacute dystonic reactions associated with pimozide administration at the doses of 0. 096 mg / kg / day and 0. 032 mg / kg / day and 32 hours following pimozide withdrawal, as well as during subsequent Entitythioridazine administration. |
| 0.9992 | Adverse-Effect | This paper reports on a 6. 9 - year - old autistic male who developed repeated episodes of Entityacute dystonic reactions associated with pimozide administration at the doses of 0. 096 mg / kg / day and 0. 032 mg / kg / day and 32 hours following Entitypimozide withdrawal, as well as during subsequent thioridazine administration. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We have seen a case of terminal malignant melanoma in which clinical manifestations, indicative of Entityanterior spinal artery syndrome , developed following the injection of 0. 3 ml of 10 % Entityphenol - glycerine into the cervical subarachnoid space at the C4 - - C5 level for the control of severe right arm pain. |
| 0.9994 | Adverse-Effect | We have seen a case of Entityterminal malignant melanoma in which clinical manifestations, indicative of anterior spinal artery syndrome, developed following the injection of 0. 3 ml of 10 % Entityphenol - glycerine into the cervical subarachnoid space at the C4 - - C5 level for the control of severe right arm pain. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Contrary to previous recommendations, our experience cautions against the further use of high - dose Entitycytarabine in patients who develop EntityPPE , and is a timely reminder of the potential toxicity of this agent, which is now increasingly being used as first - line treatment in the management of haematologic malignancies. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| Adverse-Effect | Attempts were made to stop and then restart the Entitytheophylline therapy at progressively lower doses ; however, with each attempt, the patient's Entityreaction to the drug became more toxic , with serum theophylline levels ranging between 99. 9 and 149. 9 micromol / L ( 18 and 27 microg / mL ). | |
| Adverse-Effect | Attempts were made to stop and then restart the theophylline therapy at progressively lower doses ; however, with each attempt, the patient's Entityreaction to the drug became more toxic , with serum Entitytheophylline levels ranging between 99. 9 and 149. 9 micromol / L ( 18 and 27 microg / mL ). | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9991 | Adverse-Effect | Since recent studies have reported no negative interactions with concurrent use, we here report three cases ( one case of a prolonged seizure, a serotonin syndrome and a Entityfocal seizure ) of severe Entitylithium - induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. |
| 0.9990 | Adverse-Effect | Since recent studies have reported no negative interactions with concurrent use, we here report three cases ( one case of a Entityprolonged seizure , a serotonin syndrome and a focal seizure ) of severe Entitylithium - induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. |
| 0.9990 | Adverse-Effect | Since recent studies have reported no negative interactions with concurrent use, we here report three cases ( one case of a prolonged seizure, a Entityserotonin syndrome and a focal seizure ) of severe Entitylithium - induced side effects while patients underwent ECT without complications and lithium serum levels were still subtherapeutic. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Eleven patients developed Entityinfection requiring hospitalization while taking Entityleflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 1.0000 | Adverse-Effect | Eleven patients developed infection requiring hospitalization while taking Entityleflunomide including : Entitylower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9999 | Adverse-Effect | Eleven patients developed infection requiring hospitalization while taking Entityleflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), Entitydisseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9999 | Adverse-Effect | Eleven patients developed infection requiring hospitalization while taking Entityleflunomide including : lower respiratory tract infections ( 3 ), Entitycellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9999 | Adverse-Effect | Eleven patients developed infection requiring hospitalization while taking Entityleflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), Entityabdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9998 | Adverse-Effect | Eleven patients developed infection requiring hospitalization while taking Entityleflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), Entitymycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9998 | Adverse-Effect | Eleven patients developed infection requiring hospitalization while taking Entityleflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable EntityTB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and gastroenteritis ( 1 ). |
| 0.9998 | Adverse-Effect | Eleven patients developed infection requiring hospitalization while taking Entityleflunomide including : lower respiratory tract infections ( 3 ), cellulitis ( 2 ), disseminated herpes zoster ( 2 ), probable TB liver ( 1 ), abdominal sepsis ( 1 ), mycotic aneurysm ( 1 ) and Entitygastroenteritis ( 1 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | During dose - finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving Entitypantoprazole developed Entityperipheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| 0.9981 | Adverse-Effect | During dose - finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving Entityomeprazole and two young female volunteers receiving pantoprazole developed Entityperipheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| 0.9971 | Adverse-Effect | During dose - finding studies for intravenous proton pump inhibitors omeprazole and Entitypantoprazole , three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed Entityperipheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| 0.9967 | Adverse-Effect | During dose - finding studies for intravenous proton pump inhibitors Entityomeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed Entityperipheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Only two case reports of adults with allergic contact dermatitis to this chemical exist in the literature, and we describe three more cases of children with recalcitrant atopic dermatitis found to have potential Entityallergic contact dermatitis to Entitybisabolol - a component of the Aquaphor emollient they were using to treat their atopic dermatitis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9987 | Adverse-Effect | We describe the infectious toxicities experienced by the first two patients in our institution treated with dexamethasone ( 10 mg / m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of Entityinfectious complications with Entitydexamethasone . |
| 0.9954 | Adverse-Effect | We describe the Entityinfectious toxicities experienced by the first two patients in our institution treated with Entitydexamethasone ( 10 mg / m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the dexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone. |
| 0.7104 | Adverse-Effect | We describe the Entityinfectious toxicities experienced by the first two patients in our institution treated with dexamethasone ( 10 mg / m ( 2 ) / day for 4 weeks with gradual tapering ) during induction according to the Entitydexamethasone arm of BFM 2000 and review the relevant literature that suggests an increased risk of infectious complications with dexamethasone. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and Entityhydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered Entitymethotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| 0.9999 | Adverse-Effect | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed Entityleukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered Entitymethotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| 0.9998 | Adverse-Effect | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and Entityhydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered Entitymethotrexate and cranial irradiation. |
| 0.9997 | Adverse-Effect | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed Entityleukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered Entitymethotrexate and cranial irradiation. |
| 1.0000 | Adverse-Effect | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to Entitycentral nervous system prophylaxis by, in the first case intrathecally administered Entitymethotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| 0.9999 | Adverse-Effect | We report the case histories of identical twin brothers who developed Entityconcordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered Entitymethotrexate and, in the second by intrathecally administered methotrexate and cranial irradiation. |
| 0.9998 | Adverse-Effect | We report the case histories of identical twin brothers who developed concordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to Entitycentral nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered Entitymethotrexate and cranial irradiation. |
| 0.9996 | Adverse-Effect | We report the case histories of identical twin brothers who developed Entityconcordant acute lymphoblastic leukemia at the age of 4 years and who later developed leukoencephalopathy and hydrocephalus related to central nervous system prophylaxis by, in the first case intrathecally administered methotrexate and, in the second by intrathecally administered Entitymethotrexate and cranial irradiation. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) Entitycitalopram developed Entityconfusion , agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with Entityserotonin syndrome , following initiation of Entityfentanyl , and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9999 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) Entitycitalopram developed confusion, Entityagitation , tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9999 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) Entitycitalopram developed confusion, agitation, Entitytachycardia , tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9998 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) Entitycitalopram developed confusion, agitation, tachycardia, tremors, Entitymyoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9998 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) Entitycitalopram developed confusion, agitation, tachycardia, Entitytremors , myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9998 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and Entityunsteady gait , consistent with serotonin syndrome, following initiation of Entityfentanyl , and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9998 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) Entitycitalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and Entityunsteady gait , consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9997 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, Entitymyoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of Entityfentanyl , and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9997 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with Entityserotonin syndrome , following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of Entityfentanyl . |
| 0.9997 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) Entitycitalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with Entityserotonin syndrome , following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9997 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, Entitytremors , myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of Entityfentanyl , and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9997 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, Entityagitation , tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of Entityfentanyl , and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9997 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, Entitytachycardia , tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of Entityfentanyl , and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9995 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed Entityconfusion , agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of Entityfentanyl , and all symptoms and signs resolved following discontinuation of fentanyl. |
| 0.9993 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, Entitymyoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of Entityfentanyl . |
| 0.9992 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, tremors, myoclonic jerks and Entityunsteady gait , consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of Entityfentanyl . |
| 0.9991 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, Entityagitation , tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of Entityfentanyl . |
| 0.9991 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, tachycardia, Entitytremors , myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of Entityfentanyl . |
| 0.9991 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed confusion, agitation, Entitytachycardia , tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of Entityfentanyl . |
| 0.9987 | Adverse-Effect | CASE SUMMARY : A 65 - year - old patient chronically treated with the selective serotonin reuptake inhibitor ( SSRI ) citalopram developed Entityconfusion , agitation, tachycardia, tremors, myoclonic jerks and unsteady gait, consistent with serotonin syndrome, following initiation of fentanyl, and all symptoms and signs resolved following discontinuation of Entityfentanyl . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We describe longitudinal diffusion - weighted MRI findings of Entitysub - acute leukoencephalopathy following Entitymethotrexate therapy in a 24 - year - old man diagnosed with pre - B - cell acute lymphoblastic leukemia ( ALL ), presenting with right - sided paralysis and aphasia after second consolidation with intrathecal triple - drug therapy given intrathecally. |
| 0.9998 | Adverse-Effect | We describe longitudinal diffusion - weighted MRI findings of sub - acute leukoencephalopathy following Entitymethotrexate therapy in a 24 - year - old man diagnosed with pre - B - cell acute lymphoblastic leukemia ( ALL ), presenting with right - sided paralysis and Entityaphasia after second consolidation with intrathecal triple - drug therapy given intrathecally. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | This report describes an individual with mental retardation who experienced Entitybehavioral exacerbation associated with Entityclonazepam prescribed at 2 mg / day ( 0. 02 mg / kg / day ) to treat aggression, self - injurious behavior, property destruction, and screaming, which was measured with a 15 - minute partial interval recording measurement method. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | In this article lithium is not discussed, although there are a number of concerns about Entitylithium ' s potential Entityteratogenicity , and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9994 | Adverse-Effect | In this article lithium is not discussed, although there are a number of concerns about Entitylithium ' s potential teratogenicity, and it has been implicated in EntityEpstein's anomaly , a congenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9992 | Adverse-Effect | In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in EntityEpstein's anomaly , a congenital heart defect among infants born to women taking Entitylithium ; as with other medications, however, the data have specific limitations. |
| 0.9985 | Adverse-Effect | In this article lithium is not discussed, although there are a number of concerns about lithium's potential Entityteratogenicity , and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking Entitylithium ; as with other medications, however, the data have specific limitations. |
| 1.0000 | Adverse-Effect | In this article lithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a Entitycongenital heart defect among infants born to women taking Entitylithium ; as with other medications, however, the data have specific limitations. |
| 0.9992 | Adverse-Effect | In this article lithium is not discussed, although there are a number of concerns about Entitylithium ' s potential teratogenicity, and it has been implicated in Epstein's anomaly, a Entitycongenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9990 | Adverse-Effect | In this article Entitylithium is not discussed, although there are a number of concerns about lithium's potential Entityteratogenicity , and it has been implicated in Epstein's anomaly, a congenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9975 | Adverse-Effect | In this article Entitylithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in EntityEpstein's anomaly , a congenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| 0.9971 | Adverse-Effect | In this article Entitylithium is not discussed, although there are a number of concerns about lithium's potential teratogenicity, and it has been implicated in Epstein's anomaly, a Entitycongenital heart defect among infants born to women taking lithium ; as with other medications, however, the data have specific limitations. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CASE SUMMARY : A 61 - year - old woman with no apparent risk factors for liver injury developed Entityacute hepatitis one week after the final dose of a long - term course of pulse Entityitraconazole therapy ( 200 mg orally twice daily, 1 wk on, 3 wk off, for 24 wk ) for onychomycosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( EntityARA - C ) ; among them, along with myelosuppression, five experienced Entityfever , infectious complications, gastrointestinal tract symptoms and severe myalgias. |
| 0.9999 | Adverse-Effect | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( EntityARA - C ) ; among them, along with myelosuppression, five experienced fever, Entityinfectious complications , gastrointestinal tract symptoms and severe myalgias. |
| 0.9998 | Adverse-Effect | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, Entitycytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced Entityfever , infectious complications, gastrointestinal tract symptoms and severe myalgias. |
| 0.9998 | Adverse-Effect | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( EntityARA - C ) ; among them, along with myelosuppression, five experienced fever, infectious complications, Entitygastrointestinal tract symptoms and severe myalgias. |
| 0.9997 | Adverse-Effect | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, cytosine arabinoside ( EntityARA - C ) ; among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and Entitysevere myalgias . |
| 0.9995 | Adverse-Effect | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, Entitycytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced fever, Entityinfectious complications , gastrointestinal tract symptoms and severe myalgias. |
| 0.9991 | Adverse-Effect | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, Entitycytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced fever, infectious complications, Entitygastrointestinal tract symptoms and severe myalgias. |
| 0.9991 | Adverse-Effect | Thirty - six patients with AL received, in a three - month period, 51 cycles of combined chemotherapy which included, in all of them, Entitycytosine arabinoside ( ARA - C ) ; among them, along with myelosuppression, five experienced fever, infectious complications, gastrointestinal tract symptoms and Entitysevere myalgias . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | 1. EntityChanges in the plasma cortisol level were reported in a male patient with panic disorder during the period of low - dose Entityalprazolam treatment ( mean 0. 62 + / - 0. 15 mg / day ) compared with during the period of high - dose period ( mean 1. 08 + / - 0. 28 mg / day ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9979 | Adverse-Effect | DISCUSSION : After exclusion of other causes, the onset of Entitythrombocytopenia after administration of Entitylansoprazole , the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole. |
| 0.9996 | Adverse-Effect | DISCUSSION : After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an Entityidiosyncratic thrombocytopenic response to Entitylansoprazole . |
| Adverse-Effect | DISCUSSION : After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic Entitythrombocytopenic response to Entitylansoprazole . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | In a single practice during the 21 years 1971 - 1991, the incidence of Entitygestational diabetes in pregnancies in which Entitynorethisterone was prescribed was 32. 4 % ( 22 of 69 ) in comparison with 7. 1 % in pregnancies in which the women did not take norethisterone ( 137 of 1, 684 ) ( p < 0. 001 ). |
| 0.9987 | Adverse-Effect | In a single practice during the 21 years 1971 - 1991, the incidence of Entitygestational diabetes in pregnancies in which norethisterone was prescribed was 32. 4 % ( 22 of 69 ) in comparison with 7. 1 % in pregnancies in which the women did not take Entitynorethisterone ( 137 of 1, 684 ) ( p < 0. 001 ). |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These findings are consistent with an immune - complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the Entityrenal disease associated with Entitygold therapy in rheumatoid arthritis. |
| 0.9999 | Adverse-Effect | These findings are consistent with an immune - complex form of glomerulopathy in which gold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by Entitygold therapy may be a causative factor in the Entityrenal disease associated with gold therapy in rheumatoid arthritis. |
| 0.8323 | Adverse-Effect | These findings are consistent with an immune - complex form of glomerulopathy in which Entitygold is neither the antigen nor a hapten in the glomerular deposits, and they suggest the hypothesis that antibodies to tubular epithelial antigens induced by gold therapy may be a causative factor in the Entityrenal disease associated with gold therapy in rheumatoid arthritis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | The latter form ( EntityMacrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, Entityacute and chronic pulmonary reactions , peripheral neuropathy, blood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 1.0000 | Adverse-Effect | The latter form ( EntityMacrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and Entityallergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 1.0000 | Adverse-Effect | The latter form ( EntityMacrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, acute and chronic pulmonary reactions, Entityperipheral neuropathy , blood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 0.9999 | Adverse-Effect | The latter form ( EntityMacrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - Entityliver damage , acute and chronic pulmonary reactions, peripheral neuropathy, blood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| 0.9999 | Adverse-Effect | The latter form ( EntityMacrodantin ) is reported to engender less gastrointestinal intolerance but it can produce the same adverse effects as the conventional form - - liver damage, acute and chronic pulmonary reactions, peripheral neuropathy, Entityblood dyscrasias and allergic reactions - - and does so just as rapidly and floridly ; one such case is reported here. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | RESULTS : After 4 - to 14 - month period of therapy with the combination of indapamide ( 2. 5 mg / day ) and fosinopril ( 10 mg / day ) in three patients and 6 - month period of monotherapy with Entityindapamide ( 2. 5 mg / day ) in one patient, glucose levels of all patients increased and achieve criteria of Entitydiabetes diagnoses. |
| 0.9997 | Adverse-Effect | RESULTS : After 4 - to 14 - month period of therapy with the combination of indapamide ( 2. 5 mg / day ) and Entityfosinopril ( 10 mg / day ) in three patients and 6 - month period of monotherapy with indapamide ( 2. 5 mg / day ) in one patient, glucose levels of all patients increased and achieve criteria of Entitydiabetes diagnoses. |
| 0.9997 | Adverse-Effect | RESULTS : After 4 - to 14 - month period of therapy with the combination of Entityindapamide ( 2. 5 mg / day ) and fosinopril ( 10 mg / day ) in three patients and 6 - month period of monotherapy with indapamide ( 2. 5 mg / day ) in one patient, glucose levels of all patients increased and achieve criteria of Entitydiabetes diagnoses. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9994 | Adverse-Effect | This case demonstrates an occupational activity ( construction ) that has now become the dominant source of lead exposure for U. S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic Entitylead Entitylead toxicity , and the importance of preventing further exposure and using proper methods to treat acute toxicity. |
| 0.9942 | Adverse-Effect | This case demonstrates an occupational activity ( construction ) that has now become the dominant source of lead exposure for U. S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic Entitylead toxicity, and the importance of preventing further exposure and using proper methods to treat Entityacute toxicity . |
| 0.9823 | Adverse-Effect | This case demonstrates an occupational activity ( construction ) that has now become the dominant source of Entitylead exposure for U. S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic Entitylead toxicity , and the importance of preventing further exposure and using proper methods to treat acute toxicity. |
| 0.9681 | Adverse-Effect | This case demonstrates an occupational activity ( construction ) that has now become the dominant source of Entitylead exposure for U. S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic lead toxicity, and the importance of preventing further exposure and using proper methods to treat Entityacute toxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9997 | Adverse-Effect | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and EntityFraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced Entityplatelet activation with the patient's serum. |
| 0.9997 | Adverse-Effect | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins EntityFragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced Entityplatelet activation with the patient's serum. |
| 0.9992 | Adverse-Effect | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard Entityheparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced Entityplatelet activation with the patient's serum. |
| 1.0000 | Adverse-Effect | By means of the in vitro Entityheparin - induced Entityplatelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9997 | Adverse-Effect | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the Entityenoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced Entityplatelet activation with the patient's serum. |
| 0.9993 | Adverse-Effect | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( EntitySanofi Labaz , Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced Entityplatelet activation with the patient's serum. |
| 0.9863 | Adverse-Effect | By means of the in vitro heparin - induced Entityplatelet activation ( HIPA ) assay it was shown that standard Entityheparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9862 | Adverse-Effect | By means of the in vitro Entityheparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced Entityplatelet activation with the patient's serum. |
| 0.9856 | Adverse-Effect | By means of the in vitro heparin - induced Entityplatelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and EntityFraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9828 | Adverse-Effect | By means of the in vitro heparin - induced Entityplatelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins EntityFragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9641 | Adverse-Effect | By means of the in vitro heparin - induced Entityplatelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the Entityenoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| 0.9625 | Adverse-Effect | By means of the in vitro heparin - induced Entityplatelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( EntitySanofi Labaz , Munich, FRG ), as well as the enoxaparine Clexane ( Nattermann, Cologne, FRG ), all induced platelet activation with the patient's serum. |
| Adverse-Effect | By means of the in vitro heparin - induced platelet activation ( HIPA ) assay it was shown that standard heparin and the LMW heparins Fragmin and Fraxiparin ( Sanofi Labaz, Munich, FRG ), as well as the enoxaparine EntityClexane ( Nattermann, Cologne, FRG ), all induced Entityplatelet activation with the patient's serum. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9993 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral Entityleishmaniasis associated with Entitycutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.9858 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( EntityCS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with Entitycutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.9784 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with EntityCS for asthma, a severe visceral leishmaniasis associated with Entitycutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.9762 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a Entityvisceral involvement after cutaneous leishmaniasis in a man receiving EntityCS . |
| 0.9724 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in Entitycorticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with Entitycutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.9530 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a Entityvisceral involvement after cutaneous Entityleishmaniasis in a man receiving CS. |
| 0.9413 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual Entityleishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with Entitycutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.9276 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( EntityCS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a Entityvisceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.8765 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in Entitycorticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a Entityvisceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.8750 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with EntityCS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a Entityvisceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.8479 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with Entitycutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving EntityCS . |
| 0.7184 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual Entityleishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a Entityvisceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.7129 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral Entityleishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a Entityvisceral involvement after cutaneous leishmaniasis in a man receiving CS. |
| 0.6962 | Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with Entitycutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous Entityleishmaniasis in a man receiving CS. |
| Adverse-Effect | CASE PRESENTATION : Three cases of EntityLeishmania infantum leishmaniasis in Entitycorticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. | |
| Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in Entitycorticosteroid ( CS ) - treated patients are reported : an isolated Entitylingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. | |
| Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after Entitycutaneous leishmaniasis in a man receiving EntityCS . | |
| Adverse-Effect | CASE PRESENTATION : Three cases of EntityLeishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated lingual leishmaniasis in a farmer treated with EntityCS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. | |
| Adverse-Effect | CASE PRESENTATION : Three cases of Leishmania infantum leishmaniasis in corticosteroid ( CS ) - treated patients are reported : an isolated Entitylingual leishmaniasis in a farmer treated with EntityCS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a Entitytransient coronary vasoconstriction induced by the Entitydopamine infusion. |
| 0.9998 | Adverse-Effect | Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an Entityacute ischemic event , possibly related to a transient coronary vasoconstriction induced by the Entitydopamine infusion. |
| Adverse-Effect | Although the existence of an acute pericarditis or an acute myocarditis as possible causes of the ST elevation can not be fully ruled out, the sudden onset, prominent magnitude, and brief duration of the ST elevation are perhaps more indicative of an acute ischemic event, possibly related to a transient Entitycoronary vasoconstriction induced by the Entitydopamine infusion. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9861 | Adverse-Effect | Its overall Entitytoxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as " Entityretinoic acid syndrome. " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| 0.9840 | Adverse-Effect | Its overall toxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a potentially fatal symptom complex referred to as " Entityretinoic acid Entityretinoic acid syndrome . " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| 0.9809 | Adverse-Effect | Its overall toxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a Entitypotentially fatal symptom complex referred to as " Entityretinoic acid syndrome. " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| 0.9776 | Adverse-Effect | Its overall toxicity is considerably less compared to standard induction chemotherapy ; however, it is associated with a high incidence of a potentially Entityfatal symptom complex referred to as " Entityretinoic acid syndrome. " This report describes a patient with APL who developed the syndrome a few weeks after initiating induction therapy with ATRA despite being treated for hyperleukocytosis. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | We further used immunohistochemistry ( IHC ) to examine the relative role of platelet - derived growth factor - B ( PDGF - B ), insulin - like growth factor I ( IGF - I ), transforming growth factor - beta1 ( TGF - beta1 ) and cyclooxygenase - 2 ( COX - 2 ) in the pathogenesis of EntityBCNU - related Entitypulmonary fibrosis . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | CONCLUSION : The present findings suggest that : ( i ) amantadine probably exerts its anti - dyskinetic effect by acting on the " indirect " pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in EntityL - dopa induced Entitydyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. |
| 0.9310 | Adverse-Effect | CONCLUSION : The present findings suggest that : ( i ) amantadine probably exerts its anti - dyskinetic effect by acting on the " indirect " pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced Entitydyskinesias may differ from those involved in EntityL - dopa induced dyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. |
| 0.6383 | Adverse-Effect | CONCLUSION : The present findings suggest that : ( i ) Entityamantadine probably exerts its anti - dyskinetic effect by acting on the " indirect " pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced Entitydyskinesias may differ from those involved in L - dopa induced dyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. |
| 0.6129 | Adverse-Effect | CONCLUSION : The present findings suggest that : ( i ) Entityamantadine probably exerts its anti - dyskinetic effect by acting on the " indirect " pathway ; ( ii ) the pathophysiological mechanisms of subthalamotomy induced dyskinesias may differ from those involved in L - dopa induced Entitydyskinesias ; ( iii ) dyskinesias induced by STN surgery resolve spontaneously as compensatory mechanisms develop. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( EntityMTX ) ( 12 g / m2 ), and went on to develop Entityacute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9999 | Adverse-Effect | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme Entityelevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose Entitymethotrexate ( MTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9998 | Adverse-Effect | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending Entityrenal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose Entitymethotrexate ( MTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9998 | Adverse-Effect | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose Entitymethotrexate ( MTX ) ( 12 g / m2 ), and went on to develop Entityacute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9997 | Adverse-Effect | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending renal toxicity and extreme Entityelevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( EntityMTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9995 | Adverse-Effect | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of impending Entityrenal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( EntityMTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9999 | Adverse-Effect | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of Entityimpending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose Entitymethotrexate ( MTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| 0.9998 | Adverse-Effect | A 10 - year - old boy with osteosarcoma and normal renal function manifested laboratory evidence of Entityimpending renal toxicity and extreme elevation of aspartate aminotrasferase and alanine aminotransferase within 2 hours after the completion of a 4 - hour infusion of high - dose methotrexate ( EntityMTX ) ( 12 g / m2 ), and went on to develop acute renal failure with life - threatening hyperkalemia 29 hours later. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Although risk factors for EntityMTX - induced Entitypulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis. |
| 0.7323 | Adverse-Effect | Although risk factors for EntityMTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and Entitymild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis. |
| 0.5160 | Adverse-Effect | Although risk factors for EntityMTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by Entitypulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX pneumonitis. |
| 0.4001 | Adverse-Effect | Although risk factors for EntityMTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of MTX Entitypneumonitis . |
| Adverse-Effect | Although risk factors for MTX - induced pulmonary toxicity are poorly understood, the presence in 3 out of 5 of our patients of pre - existing lung disease, represented by diffuse interstitial changes on chest X - ray, and mild bronchial asthma in two RA patients and by pulmonary silicosis in the patient with PsA may account for a predisposition to the development of EntityMTX Entitypneumonitis . | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | A retrospective epidemiological study of deaths from Entityhepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( Entityvinyl chloride ,'Thorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9998 | Adverse-Effect | A retrospective epidemiological study of deaths from Entityhepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride, ' EntityThorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9997 | Adverse-Effect | A retrospective epidemiological study of deaths from Entityhepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride,'Thorotrast ', and Entityinorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9999 | Adverse-Effect | A retrospective epidemiological study of Entitydeaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( Entityvinyl chloride ,'Thorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9999 | Adverse-Effect | A retrospective epidemiological study of Entitydeaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride, ' EntityThorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9998 | Adverse-Effect | A retrospective epidemiological study of Entitydeaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride,'Thorotrast ', and Entityinorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of androgenic - anabolic steroids. |
| 0.9993 | Adverse-Effect | A retrospective epidemiological study of Entitydeaths from hepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride,'Thorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of Entityandrogenic - anabolic steroids . |
| 0.9988 | Adverse-Effect | A retrospective epidemiological study of deaths from Entityhepatic angiosarcoma ( HAS ) in the U. S. showed that during 1964 - - 74 there were 168 such cases, of which 37 ( 22 % ) were associated with previously known causes ( vinyl chloride,'Thorotrast ', and inorganic arsenic ) and 4 ( 3. 1 % ) of the remaining 131 cases with the use of Entityandrogenic - anabolic steroids . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of Entityrenal toxicity may be present as early as 2 hours after the completion of a 4 - hour EntityMTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion. |
| 0.9954 | Adverse-Effect | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of Entityrenal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion, and to suggest that monitoring for EntityMTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion. |
| 0.9935 | Adverse-Effect | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and carboxypeptidase G2, we present this case to emphasize that signs of Entityrenal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour EntityMTX infusion. |
| 0.9376 | Adverse-Effect | Although his renal function recovered completely with high - dose leucovorin, hemodialysis, charcoal hemoperfusion, and Entitycarboxypeptidase G2 , we present this case to emphasize that signs of Entityrenal toxicity may be present as early as 2 hours after the completion of a 4 - hour MTX infusion, and to suggest that monitoring for MTX toxicity should perhaps begin within a few hours after the completion of 4 - hour MTX infusion. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9999 | Adverse-Effect | We suggest that Entitynicotinic acid was the cause of his Entityliver disease , that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.9946 | Adverse-Effect | We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of Entitynicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of Entityhepatotoxicity . |
| 0.9397 | Adverse-Effect | We suggest that nicotinic acid was the cause of his Entityliver disease , that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of Entitynicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.9879 | Adverse-Effect | We suggest that Entitynicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of Entityliver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.9872 | Adverse-Effect | We suggest that Entitynicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the Entityhepatic failure , and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.9720 | Adverse-Effect | We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the Entityhepatic failure , and that the probable increased use of Entitynicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.8768 | Adverse-Effect | We suggest that nicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of Entityliver injury and the severity of the hepatic failure, and that the probable increased use of Entitynicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of hepatotoxicity. |
| 0.4252 | Adverse-Effect | We suggest that Entitynicotinic acid was the cause of his liver disease, that this case is of particular note because of the rather short period of therapy before the onset of liver injury and the severity of the hepatic failure, and that the probable increased use of nicotinic acid for serum cholesterol control makes it especially important for physicians and their patients to be alert to the signs of Entityhepatotoxicity . |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 0.9998 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, decreased MED to both UVA and UVB, and Entitypersistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Entitymequitazine . |
| 0.9994 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Entitymequitazine for 6 months, and there were strong positive photopatch test results with immediate Entityerythema reaction, cross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9989 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate Entityerythema reaction, cross - reaction to Entitypromethazine , decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9985 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Entitydecreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Entitymequitazine . |
| 0.9985 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to Entitypromethazine , decreased MED to both UVA and UVB, and Entitypersistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9972 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Entitymequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, decreased MED to both UVA and UVB, and Entitypersistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9970 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Entitymequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Entitydecreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9969 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate Entityerythema reaction, cross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Entitymequitazine . |
| 0.9962 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to Entitypromethazine , Entitydecreased MED to both UVA and UVB , and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9998 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, Entitycross - reaction to Entitypromethazine , decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9997 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Entitymequitazine for 6 months, and there were strong positive photopatch test results with immediate Entityerythema reaction , cross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9995 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate Entityerythema reaction , cross - reaction to Entitypromethazine , decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9986 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Entitymequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, Entitycross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9986 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate Entityerythema reaction , cross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Entitymequitazine . |
| 0.9965 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, Entitycross - reaction to promethazine, decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Entitymequitazine . |
| 0.9963 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Entitydecreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Entitymequitazine . |
| 0.9957 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Entitydecreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Entitymequitazine . |
| 0.9930 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Entitymequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Entitydecreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9923 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Entitymequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to promethazine, Entitydecreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9911 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to Entitypromethazine , Entitydecreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| 0.9902 | Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, cross - reaction to Entitypromethazine , Entitydecreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. |
| Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, Entitycross - reaction to promethazine , decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the Entitymequitazine . | |
| Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken mequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, Entitycross - reaction to promethazine Entitypromethazine , decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. | |
| Adverse-Effect | In case no. 2, the pathogenic mechanism seemed to be persistent light reaction preceded by systemic photoallergy, as he had taken Entitymequitazine for 6 months, and there were strong positive photopatch test results with immediate erythema reaction, Entitycross - reaction to promethazine , decreased MED to both UVA and UVB, and persistence of the photosensitivity over a 3 - year follow - up period after discontinuation of the mequitazine. | |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | Major points illustrated are, ( 1 ) occurrence of EntityHIT with any dose or form of Entityheparin ; ( 2 ) misperceptions on the diagnostic criteria ; ( 3 ) correct ( thrombin inhibitors ) and incorrect ( platelet transfusions and warfarin ) management ; ( 4 ) influence of management strategy on clinical outcomes ; ( 5 ) severity of the syndrome ; and ( 6 ) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time. |
| 0.9655 | Adverse-Effect | Major points illustrated are, ( 1 ) occurrence of EntityHIT with any dose or form of heparin ; ( 2 ) misperceptions on the diagnostic criteria ; ( 3 ) correct ( thrombin inhibitors ) and incorrect ( platelet transfusions and warfarin ) management ; ( 4 ) influence of management strategy on clinical outcomes ; ( 5 ) severity of the syndrome ; and ( 6 ) potential for both anamnestic response to Entityheparin and disappearance of HIT antibodies over time. |
| 0.9587 | Adverse-Effect | Major points illustrated are, ( 1 ) occurrence of EntityHIT with any dose or form of heparin ; ( 2 ) misperceptions on the diagnostic criteria ; ( 3 ) correct ( thrombin inhibitors ) and incorrect ( platelet transfusions and Entitywarfarin ) management ; ( 4 ) influence of management strategy on clinical outcomes ; ( 5 ) severity of the syndrome ; and ( 6 ) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time. |
| Score | Relation | Text (Head - Tail) |
|---|---|---|
| 1.0000 | Adverse-Effect | These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the EntityMP - induced Entitytransient renal failure . |
| 0.9934 | Adverse-Effect | These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an EntityMP therapy and the associated Entityrenal interstitial edema , proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the MP - induced transient renal failure. |
| 0.9868 | Adverse-Effect | These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated Entityrenal interstitial edema , proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the EntityMP - induced transient renal failure. |
| 0.9720 | Adverse-Effect | These findings mean that the effect of the EntityMP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the MP - induced Entitytransient renal failure . |
| 0.9662 | Adverse-Effect | These findings mean that the effect of the EntityMP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an MP therapy and the associated Entityrenal interstitial edema , proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the MP - induced transient renal failure. |
| 0.9527 | Adverse-Effect | These findings mean that the effect of the MP pulse therapy on renal function depends on the clinical state of the patient and that renal deterioration after the pulse therapy may be more marked in patients who are more nephrotic and more impaired in renal function and suggest that increasing sodium and water retention during an EntityMP therapy and the associated renal interstitial edema, proposed as one of the mechanisms of acute renal failure occurring in patients with minimal - change nephrotic syndrome, may be responsible for the MP - induced Entitytransient renal failure . |